
<html lang="en"     class="pb-page"  data-request-id="69296eb2-1450-407a-a773-240438ed82dd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c01467;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections" /></meta><meta name="dc.Creator" content="Rinky  Raghuvanshi" /></meta><meta name="dc.Creator" content="Sandip B.  Bharate" /></meta><meta name="dc.Description" content="Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer’s disease, and viral infections. The majority of appro..." /></meta><meta name="Description" content="Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer’s disease, and viral infections. The majority of appro..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 4, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01467" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01467" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01467" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01467" /></link>
        
    
    

<title>Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01467" /></meta><meta property="og:title" content="Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0012.jpeg" /></meta><meta property="og:description" content="Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer’s disease, and viral infections. The majority of approved antiviral agents are inhibitors of virus-specific targets that are encoded by individual viruses. These inhibitors are narrow-spectrum agents that can cause resistance development. Viruses are dependent on host cellular proteins, including kinases, for progression of their life-cycle. Thus, targeting kinases is an important therapeutic approach to discovering broad-spectrum antiviral agents. As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antiviral activity or are useful in the management of viral infections." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01467"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01467">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01467&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01467&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01467&amp;href=/doi/10.1021/acs.jmedchem.0c01467" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.0c02111" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01929" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rinky Raghuvanshi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rinky Raghuvanshi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Division,CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India</div><div class="loa-info-affiliations-info">Academy of Scientific & Innovative Research, Ghaziabad 201002, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rinky++Raghuvanshi">Rinky Raghuvanshi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator"> and </span><li><span><span class="hlFld-ContribAuthor">Sandip B. Bharate</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandip B. Bharate</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry Division,CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India</div><div class="loa-info-affiliations-info">Academy of Scientific & Innovative Research, Ghaziabad 201002, India</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +91-191-2586333, Tel: + 91-191-2585006 (Extn. 345). Email: <a href="/cdn-cgi/l/email-protection#3f4c5d575e4d5e4b5a7f56565652114d5a4c115651"><span class="__cf_email__" data-cfemail="0e7d6c666f7c6f7a6b4e67676763207c6b7d206760">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#6516040b010c15070d0417041100250208040c094b060a08"><span class="__cf_email__" data-cfemail="592a38373d30293b31382b382d3c193e34383035773a3634">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandip+B.++Bharate">Sandip B. Bharate</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6081-5787" title="Orcid link">http://orcid.org/0000-0001-6081-5787</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01467&amp;href=/doi/10.1021%2Facs.jmedchem.0c01467" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 4, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 August 2020</li><li><span class="item_label"><b>Published</b> online</span>4 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01467" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01467</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRinky%2BRaghuvanshi%252C%2BSandip%2BB.%2BBharate%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.0c01467%26title%3DRecent%2BDevelopments%2Bin%2Bthe%2BUse%2Bof%2BKinase%2BInhibitors%2Bfor%2BManagement%2Bof%2BViral%2BInfections%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D29%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01467"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1457</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01467" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rinky&quot;,&quot;last_name&quot;:&quot;Raghuvanshi&quot;},{&quot;first_name&quot;:&quot;Sandip&quot;,&quot;last_name&quot;:&quot;B. Bharate&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01467&quot;},&quot;abstract&quot;:&quot;Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer’s disease, and viral infections. The majority of approved antiviral agents are inhibitors of virus-specific targets that are encoded by individual viruses. These inhibitors are narrow-spectrum agents that can cause resistance development. Viruses are dependent on host cellular proteins, including kinases, for progression of their life-cycle. Thus, targeting kinases is an important therapeutic approach to discovering broad-spectrum antiviral agents. As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01467&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01467" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01467&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01467" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01467&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01467" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01467&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01467&amp;href=/doi/10.1021/acs.jmedchem.0c01467" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01467" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01467" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01467%26sid%3Dliteratum%253Aachs%26pmid%3D33539089%26genre%3Darticle%26aulast%3DRaghuvanshi%26date%3D2021%26atitle%3DRecent%2BDevelopments%2Bin%2Bthe%2BUse%2Bof%2BKinase%2BInhibitors%2Bfor%2BManagement%2Bof%2BViral%2BInfections%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer’s disease, and viral infections. The majority of approved antiviral agents are inhibitors of virus-specific targets that are encoded by individual viruses. These inhibitors are narrow-spectrum agents that can cause resistance development. Viruses are dependent on host cellular proteins, including kinases, for progression of their life-cycle. Thus, targeting kinases is an important therapeutic approach to discovering broad-spectrum antiviral agents. As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antiviral activity or are useful in the management of viral infections.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42365" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42365" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The majority of approved antiviral drugs directly target the proteins that are encoded by individual viruses. These directly acting antiviral drugs cover a narrow spectrum that does not meet clinical needs during the outbreak of novel viruses. Moreover, very often directly acting drugs have limited use because of the rapid emergence of drug resistance. Multiple viruses have a small genome and therefore require support from host cell machinery for efficient infection. Immediately after entry into the host cell, viruses hijack the host cellular machinery to obtain assistance for completion of the replication cycle. Among host cell resources, cellular kinases play a vital role in the progression of the life cycle of many viruses. The therapeutic approach of targeting host cellular kinases provides many advantages over conventional, direct-acting antiviral drugs.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Kinase-targeted agents provide a higher barrier to resistance compared to directly acting antiviral drugs and cover multiple viral genotypes or serotypes, thus providing a broad-spectrum range.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Alongside several advantages, the disadvantage associated with the host-targeting therapeutic approach is its nonspecificity, and therefore this strategy may result in undesired toxic effects. However, the availability of numerous selective kinase inhibitors that are expected to show a desirable therapeutic window holds great promise in repurposing for antiviral therapy.</div><div class="NLM_p">Since the past decade, host cellular kinases have started gaining attention as potential targets for developing antiviral drugs. Many research articles have demonstrated the importance of cellular kinases in the life cycle of viruses. Meertens et al.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> have shown that dengue (DENV) and Zika viruses (ZIKV) utilize the receptor tyrosine kinase AXL as an entry factor for infecting the host. Most viruses enter host cells via receptor-mediated endocytosis, which is regulated by AP2-associated protein kinase 1 (AAK1) and cyclin G-associated kinase (GAK). Downregulation of these two kinases is expected to stop the entry of the virus into host cells.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8">(5−8)</a> In addition, AAK1 and GAK are also involved in the regulation of hepatitis C virus (HCV) secretion and cell–cell spreading via post<i>trans</i>-Golgi network transport.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Epidermal growth factor receptor (EGFR) is another receptor tyrosine kinase that acts as an entry coreceptor for adeno-associated virus serotype 6 (AAV6),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and human cytomegalovirus (HCMV).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">A number of studies have shown that the activation of p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinases (JNK1/2) is essential for the replication of porcine epidemic diarrhea virus (PEDV), murine coronavirus (mCoV), and human CoV 229E (HCoV-229E);<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> however, the mechanism by which p38 MAPK participates in virus replication is unclear. A study has shown that p38 MAPK indirectly phosphorylates the translation initiation factor eIF4E, which in turn promotes viral protein synthesis and subsequent production of infectious mCoV.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Cencic et al.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> reported that targeting the eIF4F complex, which is a downstream protein of p38 MAPK, is an ideal strategy for blocking CoV infection. The MAPK/ERK pathway also regulates effective influenza A virus (IAV) production and the export of viral ribonucleoprotein complexes from the nucleus.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This pathway is also known to regulate the entry of Ebola virus (EBOV) into target cells, which is followed by the production of proinflammatory cytokines and cellular toxicity, thus ultimately contributing to disease progression.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a></div><div class="NLM_p">Coleman et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> indicated that Abelson tyrosine-protein kinase 2 (Abl2) plays a vital role in the efficient replication of severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). It was demonstrated that activation of G protein-coupled receptor kinase 2 (GRK2) enables IAV replication.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Similarly, the lipid kinases such as phosphatidylinositol 4-kinases (PI4 kinases) were also known to show a significant impact on the replication of many viruses, such as hepatitis C virus (HCV), some enteroviruses, and picornaviruses.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><div class="NLM_p last">Although several reviews describe the implications of cellular kinases in the virus life cycle and virulence,<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31">(24−31)</a> there are few reviews on small molecule kinase inhibitors as antiviral agents. The importance of cyclin-dependent kinases (Cdks)<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30">(26−30)</a> and Src tyrosine kinases<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> in the life cycle events of multiple viruses has been reviewed. Coiras et al.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and Fuente et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> discusses the possibility of using tyrosine kinase inhibitors and Cdk inhibitors for the treatment of human immunodeficiency virus-1 (HIV-1) infection. Furthermore, the roles of various kinase signaling pathways in IAV infection have been reviewed by Ludwig et al.,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Planz,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and Meineke et al.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The only review that discusses approved kinase inhibitors with broad-spectrum antiviral activity is by Schor and Einav (2018).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Schor and Einav’s review was primarily focused on FDA approved kinase inhibitors but did not discuss clinical candidates or discovery stage kinase inhibitors. Weisberg (2020)<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> specifically discusses repurposing efforts for approved kinase inhibitors against coronavirus disease-2019 (COVID-19, also called SARS-CoV-2) but has not covered other viruses or preclinical/clinical candidates. So far, there has been no comprehensive review that examines preclinical/clinical stage or approved kinase inhibitors as antiviral agents. On the other hand, a significant number of developments are occurring in this domain due to the emergence of the COVID-19 pandemic, with several repurposing efforts for kinase inhibitors underway. The present perspective precisely discusses all kinase inhibitors among the discovery-stage, clinical trial candidates, and FDA-approved drugs that are reported to have antiviral activity or are useful in the management of viral infections. The kinase inhibitors that are being investigated in antiviral clinical trials are discussed in detail. High-throughput screening (HTS) has a vital role in repurposing kinase inhibitors, and thus its contribution has been reviewed and discussed. As Janus kinase (JAK) inhibitors are the focus of many clinical trials, their potential role for repurposing has been discussed in a separate section.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  High-Throughput Screening for Repurposing Kinase Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The screening of bioactive compound libraries using HTS platforms is one of the primary steps in the repurposing of drugs. The collection of FDA-approved drugs and clinical candidates is a vital resource for repositioning and repurposing efforts. For target-based HTS platforms, the virtual screening filter helps trim down the massive databases to a small number of potential compounds (at least by 10-fold) and thereby assists in searching multiple databases with available screening resources. Therefore, the combination of computational tools with HTS platforms is one of the undoubtedly promising approaches for repositioning/repurposing. Drug discovery and development from scratch to the end requires tremendous efforts, time, and financial resources and is complicated, particularly for antiviral drugs. Numerous HTS-driven antiviral repurposing efforts have been made that have provided interesting antiviral leads, with many directly reaching late-stage clinical trials. Over the years, several kinase-focused libraries have also been tested in cell-based HTS platforms for antiviral activity against a diverse range of viruses, including chikungunya (CHIKV), DENV, ZIKV, HIV-1, IAV, MERS-CoV, and SARS-CoV-2. A group of researchers from Institut Pasteur Korea<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> screened a kinase focused chemical library (BioFocus, Belgium) of 4 000 compounds using a cell-based resazurin reduction assay in CHIKV-infected Huh7 cells. Six leads identified from the screen displayed an anticytopathic effect (anti-CPE) likely by targeting kinases involved in apoptosis. The most active lead was CND3514 (<b>1</b>), which inhibits CHIKV-induced CPE with an EC<sub>50</sub> value of 2.2 μM. The exact kinase target of compound <b>1</b> has not yet been investigated; however, the role of dsRNA-dependent protein kinase (PKR) has been hypothesized.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The CHIKV dsRNA activates PKR, which in turn, phosphorylates translation initiation factor 2A (eIF2A).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The same group of researchers also screened this kinase-focused library for the inhibition of dengue viruses DENV1, DENV2, DENV3, and DENV4 in Huh-7.5 cells using an image-based high-content assay platform. The most active compound identified from this screen is CND1201 (<b>2</b>) which inhibit the CPE of all four dengue serotypes with EC<sub>50</sub> values ranging from 0.9 to 7.6 μM. The exact kinase target is not known for the hit compounds; however, based on the structural similarity with clinical kinase inhibitors, c-Src kinase has been predicted as a possible target.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Researchers from Memorial Sloan-Kettering Cancer Center have screened a library of 5 632 compounds (a diverse set of compounds, including several natural products) in DENV infection assays in HEK293 cells. This screen identified two kinase inhibitors, BIBU1361 (<b>3</b>, EGFR inhibitor) and H-89 (<b>4</b>, PKA inhibitor, IC<sub>50</sub> 50 nM), with anti-DENV activity (IC<sub>50</sub> values 0.9 and 0.96 μM).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Abreu and co-workers from the University of Brazil<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> have identified inhibitors of herpes simplex virus-1 (HSV-1) replication via Cdk-2 structure-based virtual screening of commercially available compound libraries. Three compounds, <b>5</b>–<b>7</b>, that were identified as potential Cdk2 inhibitors by vHTS displayed anti-HSV-1 activity with EC<sub>50</sub> values of 32, 29, and 64 μM, respectively, with compound <b>6</b> having the best selectivity index of 48. Compounds <b>5</b> and <b>6</b> also show activity against acyclovir-resistant HO-1 and PAAr5 strains. Xu et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> from Florida State University conducted an HTS of six thousand small molecules (a collection of approved drugs and other biologically active compounds) in a ZIKV-based cellular HTS platform (SNB-19 glioblastoma cells). The screen provided 10 Cdk inhibitors (comprising the Cdk2 inhibitor PHA-690509, <b>8</b>) that inhibited ZIKV replication.</div><div class="NLM_p">Hematopoietic cell kinase (Hck) belongs to the Src family of tyrosine kinases that is expressed in macrophages and lymphocytes. Macrophages are a major host cell for HIV-1, in which Hck plays a crucial role in Nef-dependent HIV-1 replication.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A research group from the University of Pittsburgh screened the NIH MLSCN library of 220 000 compounds using the <i>in vitro</i> FRET-based Nef:Hck kinase assay to identify inhibitors of Nef-dependent Hck activity. The diphenylpyrazole derivative B9 (<b>9</b>) demonstrated submicromolar potency against HIV-1 replication by inhibiting Nef dimerization in cells.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">Tripp’s group from the University of Georgia performed HTS of a kinase inhibitor library (comprising several clinical candidates) against the IAV H7N9 strain in A549 cells. The study showed that three clinical-stage kinase inhibitors, dinaciclib (<b>10</b>), flavopiridol (<b>11</b>), and PIK-75 (<b>12</b>), displayed promising anti-CPE activity against H7N9 and other IAV strains.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Imatinib (<b>13</b>) is an FDA-approved drug that is currently being studied in a clinical trial in COVID-19 patients. Previously, it was identified as an inhibitor of SARS-CoV and MERS-CoV replication via cell-based screening of a library of FDA-approved drugs.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Recently, in the COVID-19 pandemic, Riva et al.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> screened a library of known drugs consisting of ∼12 000 FDA-approved or clinical-stage small molecules using a cell-based assay against the SARS-CoV-2 HKU-001a strain. The screen identified the PIKfyve kinase inhibitor apilimod (<b>14</b>) as an inhibitor of SARS-CoV-2 replication with an EC<sub>50</sub> value of 23 nM. Garcia et al.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> found three kinase inhibitors, berzosertib (VE-822, <b>15</b>), vistusertib (AZD2014, <b>16</b>), and nilotinib (<b>17</b>), with anti-SARS-CoV-2 activity (IC<sub>50</sub> values in the nanomolar range) in cell-based screening of a library of 430 protein kinase inhibitor clinical candidates. Mirabelli and co-workers<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> from the University of Michigan Medical School utilized quantitative high-content morphological profiling coupled with an AI-based machine learning strategy to identify small molecules effective against SARS-CoV-2 infection. Apart from the nonkinase inhibitor lactoferrin as one of the active substances, the screen identified three kinase inhibitors, fedratinib (<b>18</b>, JAK2 kinase inhibitor), bosutinib (<b>19</b>, BCR-Abl inhibitor), and gilteritinib (<b>20</b>, Flt3 inhibitor) as inhibitors of SARS-CoV-2 replication in Huh7 cells, with IC<sub>50</sub> values of 24, 20, and 225 nM, respectively. Chu and co-workers<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> from National University of Singapore performed HTS of FDA approved drug library (1 175 compounds) for antiviral activity in EV-A71- infected RD cells. The kinase inhibitor crizotinib (<b>21</b>) was one of the active compound that displayed >50% reduction in EV-A71 infection at 10 μM. The chemical structures of antiviral leads identified from HTS efforts are provided in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. High-throughput screening efforts to repurpose kinase inhibitors as antiviral agents. The numbers in the blue color indicate the size of compound databases used in HTS. The numbers in red color mentioned near chemical structures indicate the literature reference. The kinase target of the identified antiviral leads is mentioned in the parentheses below each structure. Screens a, b, and k used Huh-7/Huh-7.5 cells, screen c used HEK-293, screen d used HFL1 cells, screen e used SNB-19 glioblastoma cells, screen g used A549 cells, screens h–j used Vero E6 cells, and screen l used RD cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  FDA Approved Kinase Inhibitors for the Management of Viral Infections</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases have emerged as potential therapeutic targets in several diseases, including cancers, rheumatoid arthritis, and infectious diseases. The FDA has approved 65 kinase inhibitors for different therapeutic indications, of which 22 possess antiviral activity in addition to their primary biological activity. As repurposing is the dominant motive in pandemic situations, 12 of these approved kinase inhibitors are being investigated in clinical trials for viral infections. A summary of FDA-approved kinase inhibitors <i>vis-a-vis</i> antiviral kinase inhibitors is provided in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. These antiviral kinase inhibitors are discussed below in three subcategories based on the type of kinase that they inhibit. These categories include tyrosine kinase inhibitors, serine-threonine kinase inhibitors, and lipid kinase inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Complete list of FDA-approved kinase inhibitors, highlighting the drugs with antiviral effects. Five additional kinase inhibitors <i>viz</i>., apatinib, icotinib, peficitinib, delgocitinib, and leflunomide that are in clinical use are not listed here. Apatinib and icotinib are kinase inhibitors that are approved only in China. Peficitinib and delgocitinib are JAK inhibitors that are approved in Japan for rheumatoid arthritis and atopic dermatitis, respectively. Leflunomide is a FDA approved drug for rheumatoid arthritis which primarily acts via DDODH inhibition; however, it also inhibits tyrosine kinases (fyn and lck). The inhibitors mentioned in blue and green boxes are reported to possess antiviral activity at least in the <i>in vitro</i> system. The inhibitors mentioned in orange are JAK inhibitors that control the cytokine storm in viral infections and thus are potential agents for repurposing in the management of viral infections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  Tyrosine Kinase Inhibitors</h3><div class="NLM_p">All enveloped viruses have to cross the host cell membrane for entry inside the host cell. Two Abl kinases (Abl1 and Abl2) are expressed in human cells and are known to mediate viral infections. Studies have shown that the presence of Abl kinases is essential for the fusion of coronaviruses (SARS-CoV and MERS-CoV) to host cells.<a onclick="showRef(event, 'ref20 ref51'); return false;" href="javascript:void(0);" class="ref ref20 ref51">(20,51)</a> Imatinib mesylate (<b>13</b>) is an FDA-approved anticancer c-Abl inhibitor that has shown antiviral activity against MERS-CoV and SARS-CoV with EC<sub>50</sub> values of 17.6 and 9.8 μM (Vero E6 cells), respectively.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Further investigation has indicated that imatinib inhibits a step in the SARS-CoV and MERS-CoV replication cycle (before RNA production) that occurs within the first 4 h and no later than 5 h postinfection. It blocks SARS-CoV and MERS-CoV replication by inhibiting virion fusion with the endosomal membrane, preventing nucleocapsid entry into the host cell cytoplasm.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Imatinib has also shown antiviral effects in a vaccinia virus-infected mouse model. Treatment with 100 mg/kg/d imatinib was found to reduce the number of viral genomes and improve the survival rate in vaccinia-infected mice. Imatinib prevents the propagation of the virus to ovaries after intraperitoneal infection and promotes survival after lethal challenge, indicating its prophylactic as well as therapeutic potential.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Furthermore, imatinib also inhibits pathogenesis induced by Kaposi’s sarcoma herpes virus in HIV patients.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Dasatinib (<b>22</b>, BMS-354825) is another FDA-approved cAbl kinase inhibitor for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). Reeves et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> have shown that dasatinib displays strong efficacy <i>in vitro</i> against poxviruses; however, it has inadequate efficacy in a mouse model of vaccinia virus infection, which is likely due to its immunotoxic effect associated with Src inhibition.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Its dosing at 25 mg/kg, but not 15 mg/kg QD, prevents graft rejection in a murine cardiac transplant model. De Wispelaere and workers<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> have shown that Fyn, which is a Src family kinase, is essential for the replication of DENV. SiRNA-mediated depletion of Fyn causes a 10-fold reduction in viral titers. Dasatinib inhibits DENV replication (EC<sub>90</sub> 4.7 μM) via Fyn kinase inhibition<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> in Huh7 cells. Dyall et al.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> found that dasatinib also inhibits the CPE of coronaviruses MERS-CoV and SARS-CoV with EC<sub>50</sub> values of 5.46, and 2.1 μM in Vero E6 cells, respectively. The combination of dasatinib with the directly acting antiviral agent sofosbuvir displayed synergistic anti-HCV activity in cell culture as well as in a human liver-chimeric uPA/SCID mouse model.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Moreover, dasatinib also blocks CHIKV replication at the level of structural protein synthesis, but it does not block CHIKV RNA replication.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> It prevents HCV pseudoparticle (HCVpp) entry (IC<sub>50</sub> 0.53 μM) and cell culture-derived HCV (HCVcc) infection (IC<sub>50</sub> 0.50 μM) in Huh7.5.1 human hepatoma cells. It blocks HCV entry by regulating CD81–claudin-1 coreceptor associations and viral glycoprotein-dependent membrane fusion.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The aminoquinoline bosutinib (<b>19</b>, SKI-606) is an FDA approved BCR-Abl and Src kinase inhibitor for CML. It was identified as an inhibitor of SARS-CoV-2 replication via HTS conducted at the University of Michigan Medical School, showing remarkable EC<sub>50</sub> (20 nM) for inhibition of cytopathic effects in a cell-based assay.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Nilotinib (<b>17</b>, AMN-107) is another FDA approved BCR-Abl kinase inhibitor (IC<sub>50</sub>< 30 nM) that has been identified as an inhibitor of SARS-CoV-2 replication via cell-based screening of 430 protein kinase inhibitor clinical candidates at the University of California.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> It inhibits SARS-CoV-2 infectivity in cells with an EC<sub>50</sub> value of 80 nM. The pharmacokinetic data of nilotinib indicate that it is primarily distributed in blood with a very poor tissue distribution (Vd = 0.55–3.9 L/kg),<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> raising concerns over its repurposing for COVID-19. Erlotinib (<b>23</b>) is an inhibitor of epidermal growth factor receptor (EGFR) that is used in the treatment of nonsmall cell lung cancer, pancreatic cancer, and several other types of cancer. It impairs HCV entry (IC<sub>50</sub> 0.45 μM) and infectivity in Huh7 cells (IC<sub>50</sub> 0.53 μM). An <i>in vivo</i> study was performed to check the effect of erlotinib on HCV infection in the chimeric urokinase plasminogen activator-severe combined immunodeficiency (uPA-SCID) mouse model. The results show that erlotinib (50 mg/kg/day for 20 days) treatment causes a decrease in steady-state HCV RNA levels by more than 90% and a significant delay in the kinetics of HCV infection.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The vaccinia growth factor poxvirus stimulates host cells via EGFR and thereby facilitates viral spreading. Gefitinib (<b>24</b>), which is an FDA-approved EGFR inhibitor, inhibits poxvirus spreading via EGFR inhibition. It also reduces plaque formation in vaccinia virus (VACV)-infected Hep2 cells with an EC<sub>50</sub> value of 4.9 μM.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a></div><div class="NLM_p">Viral infection (HCV, for instance) of host cells may activate the Ras/Raf/MEK pathway, which in turn blocks the IFN-JAK-STAT pathway. Blocking this pathway results in the downregulation of IFN-stimulated genes and IFN-γ receptors, creating suitable conditions for virus replication.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Rapid acceleration of fibrosarcoma-1 (Raf-1) kinase binding to nonstructural protein 5A is essential for the replication of HCV. Downregulation of Raf-1 hampers HCV replication, indicating its vital role in this process.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Sorafenib (<b>25</b>, BAY43-9006) inhibits HCV replication (IC<sub>50</sub> 7.2 μM) via inhibition of c-Raf kinase.<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> It also inhibits enterovirus 71 (EV71) replication with IC<sub>50</sub> values of 1.5 and 1.3 μM in RD cells and SK-N-SH cells, respectively, by blocking postentry event(s) at both viral protein translation and genomic RNA replication levels.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Kindrachuk et al.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> demonstrated a role of c-Raf kinase early in the life cycle of MERS-CoV and not later in the replication stage. Pretreatment of cells with sorafenib strongly inhibited MERS-CoV infection (93% at 10 μM). The inhibitory activity was reduced when sorafenib was added to cells at 2 h following infection (30% inhibition at 10 μM), suggesting the role of c-Raf early in the viral life cycle. Benedict et al.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> have shown that sorafenib also inhibits Rift valley fever virus (RVFV) infection <i>in vitro</i> (EC<sub>50</sub> 3.9 μM) as well as <i>in vivo</i>. Sorafenib at 30 mg/kg (PO) resulted in a reduction in the viral burden on day 4, and thus it increased the survival rate of infected animals. Lundberg et al.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> have shown that sorafenib inhibits the replication of Venezuelan equine encephalitis virus (VEEV) with an EC<sub>50</sub> value of 3.7 μM. It also inhibits the replication of alphaviruses such as eastern and western equine encephalitis viruses (EEEV and WEEV), Sindbis virus, and CHIKV. The potency was higher toward Sindbis virus and CHIKV alphaviruses with EC<sub>50</sub> values of 1.3 and 0.16 μM, respectively. Mechanistic action studies suggested that it inhibits viral translation through dephosphorylation of several vital proteins, including eIF4E and p70S6K.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> It also inhibits rabies virus (RABV) replication (70% at 5 μM) in N2A cells. Moreover, it displayed synergistic antiviral activity when tested in combination with IFN-β.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The therapeutic combination comprising infliximab (anti-TNF-α antibody), caspase-1 (Ac-YVAD-cmk), sorafenib, and human rabies immunoglobulins (HRIG) when tested in silver-haired bat rabies virus (SHBRV)-infected C57Bl/6 mice prevented mortality almost completely after pre-exposure treatment along with producing a significant reduction in viral titers in the CNS. Postexposure treatments also greatly improved survival rates.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Sorafenib (<b>25</b>), along with another structurally similar urea-based tyrosine kinase inhibitor, regorafenib (<b>26</b>), inhibits all influenza viral strains <i>viz</i>., H1N1 (strain A/Puerto Rico/8/1934, A/Hamburg/04/2009, and A/Hamburg/04/2009), H3N2 (A/Mallard/Germany/439/2004, Victoria/3/1975, and A/Panama/2007/1999) with IC<sub>50</sub> values in the nM range. Both inhibitors interfere with the fusion of the virus with an endosomal membrane, which is a critical step in the viral replication cycle.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Midostaurin (<b>27</b>, PKC142) is a tyrosine kinase inhibitor approved in 2017 by the FDA for the treatment of AML. Midostaurin displays anti-HIV-1 activity (EC<sub>50</sub> 0.416 μM) in primary monocyte-derived macrophages by blocking the early formation of viral DNA before the integration step. Moreover, in HIV-1 latency models, midostaurin effectively reversed HIV-1 latency and was synergistic in combination with vorinostat and panobinostat.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Midostaurin is a BCS class II drug with high oral absorption and extensive metabolism. After a 50 mg midostaurin dose in 6 healthy volunteers, high oral absorption was seen, with 22% of it staying unchanged in the blood circulation. The AUC for unchanged midostaurin was 15.7 μg h/mL [27 μM h], with a half-life of 20 h for midostaurin.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Thus, its antiviral EC<sub>50</sub> of 0.416 μM is expected to be realistically achieved to exhibit an <i>in vivo</i> antiviral effect.</div><div class="NLM_p">Gilteritinib (<b>20</b>, ASP2215) is a Flt3/Axl dual kinase inhibitor that has been identified as an anti-SARS-CoV-2 compound during Huh7 cell-based HTS of FDA-approved compounds and clinical candidates.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Sunitinib (<b>28</b>), which is a multitarget tyrosine kinase inhibitor used for renal cell carcinoma, was identified as an inhibitor of HCV infection in a cell-based assay. It inhibits HCV infection with an EC<sub>50</sub> value of 1.2 μM in Huh-7.5 cells via inhibition of AAK1 kinase (IC<sub>50</sub> of 45 nM, <i>K</i><sub>d</sub> of 35 nM). Similarly, erlotinib also inhibits HCV infection with an IC<sub>50</sub> value of 0.6 μM, but its effect occurs via inhibition of GAK (IC<sub>50</sub> 38 nM, <i>K</i><sub>d</sub> 21 nM).<a onclick="showRef(event, 'ref6 ref7 ref73'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref73">(6,7,73)</a> Furthermore, the broad-spectrum antiviral activity of both drugs was explored by Bekerman et al.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Both drugs exhibited antiviral effects against CHIKV, Junín virus (JUNV), respiratory syncytial virus (RSV), and different strains of DENV, EBOV, and HIV. The combination (sunitinib/erlotinib, 30 mg/kg doses) treatment resulted in an 11-fold reduction in viral RNA, a significant reduction in the virus load in the serum, spleen, and liver of DENV-infected mice<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and suppression of systemic infection of DENV-infected IFN-α/β and IFN-γ receptor-deficient mice.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Furthermore, this combination has entered a phase I/II clinical trial for EBOV disease;<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> however, the side effects associated with sunitinib and erlotinib at the doses required to inhibit AAK1 may not be tolerated by patients infected with SARS-CoV-2.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><div class="NLM_p">Janus kinase is a nonreceptor tyrosine kinase that transduces cytokine-mediated signals via the JAK-STAT pathway. Baricitinib (<b>29</b>) is an FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. It controls cytokine signaling by modulating the JAK-STAT pathway.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> By virtue of its cytokine inhibitory activities, it is being studied in COVID-19 patients. Recently, the combination of baricitinib and the antiviral drug remdesivir has received FDA approval for emergency use in COVID-19 patients.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Another JAK inhibitor, ruxolitinib (<b>30</b>), which is being clinically used for myelofibrosis treatment, possesses antiviral activities against HIV and SARS-CoV-2 viruses. Ruxolitinib inhibits HIV-1 replication in human macrophages and inhibits the HIV-induced activation of monocytes without causing toxicity. It reduces astrogliosis in the brains of mice with HIV encephalitis when administered intravenously at 50 mg/kg (TID).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Currently, it is being investigated in SARS-CoV-2-infected patients.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Researchers from the Huazhong University of Science and Technology, Wuhan, published that in a single-blind trial of ruxolitinib (5 mg, BID) in SARS-CoV-2-infected patients, the levels of proinflammatory cytokines were significantly reduced. Ruxolitinib was well tolerated, with low toxicities and no significant safety concerns, and led to faster clinical improvement, indicating its potential to be tested in a larger trial.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In another trial from Germany in COVID-19 patients with severe systemic hyperinflammation, ruxolitinib (7.5 mg, BID) significantly reduced inflammation on day 7 with clinical improvement and without any drug-induced toxicity.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Another study conducted in Italy in COVID-19 patients with acute respiratory disease (ARD) showed that ruxolitinib (20 mg, BID) treatment resulted in full recovery of respiratory function within 7 days.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Tofacitinib (<b>31</b>), which is another JAK inhibitor, inhibits HIV-1 replication <i>in vitro</i>.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> It has been reported that oral dosing of 5 mg BID requires a longer time to achieve a desirable plasma concentration to exhibit anti-inflammatory effects.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Thus, in ongoing clinical trials in COVID-19 patients, it is being dosed at 10 mg of PO BID initially until oxygen levels normalize and then at 5 mg of PO BID until 14 days.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Fedratinib (<b>18</b>, TG-101348, SAR302503) is an orally bioavailable semiselective JAK2 inhibitor (IC<sub>50</sub> 6 nM) approved by the FDA in 2019 for myeloproliferative neoplasms that exhibits potent antiviral activity against SARS-CoV-2 with an IC<sub>50</sub> value of 24 nM (SI > 37.5).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> It also inhibits Flt3 and Ret kinases at IC<sub>50</sub> values of 15 and 48 nM, respectively. By virtue of their ability to directly control inflammation, JAK inhibitors are valuable, particularly in the management of ARD-associated viral infections.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">Leflunomide (<b>32</b>) is an immunomodulator used in the treatment of rheumatoid arthritis. The <i>in vitro</i> and <i>in vivo</i> studies by Waldmans et al.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> suggest that the active metabolite of leflunomide, i.e., A771726 (<b>33</b>), reduces the HCMV load by inhibiting protein tyrosine kinase activity. Furthermore, two different groups have shown that treatment with leflunomide reduces BK viremia and disease progression in patients with BKV nephropathy.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> A recent study<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> has shown that the active metabolite A771726 inhibits the replication of two IAV subtypes, H1N1 and H9N2 viruses, through inhibition of the activity of JAK1 and JAK3. It also inhibits JUNV replication with an EC<sub>50</sub> in the micromolar range.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Leflunomide in combination with two approved immunosuppressive mTOR inhibitors (either everolimus or sirolimus) inhibits BK virus genome replication via inhibition of large T antigen expression, phosphoinositide-dependent kinase-1 (PDK-1), the protein kinase Akt (Akt), mammalian target of rapamycin (mTOR), and 70 kDa ribosomal protein S6 kinase (p70S6K) phosphorylation.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Leflunomide is currently being studied in SARS-CoV-2-infected patients in a clinical trial.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a></div><div class="NLM_p">Bruton tyrosine kinase (BTK) plays a vital role in oncogenic signaling and regulates macrophage signaling and activation. Thus, similar to JAK inhibitors, targeting the inflammatory response in viral infections by BTK inhibitors is being investigated.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Zanubrutinib (<b>34</b>, BGB-3111) is a potent BTK inhibitor (IC<sub>50</sub> 0.3 nM) approved for mantle cell lymphoma. It is currently being investigated in COVID-19 patients.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Another FDA-approved BTK inhibitor, ibrutinib (<b>35</b>, PCI-32765), is also being investigated in COVID-19 patients.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The Guangzhou medical university China is conducting the pharmacokinetic study of seven tyrosine kinase inhibitors gefitinib, erlotinib, afatinib, osimertinib, crizotinib, apatinib, and icotinib in HBV-infected patients (NCT03680183). The chemical structures of FDA-approved tyrosine kinase inhibitors possessing antiviral activity are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. FDA approved tyrosine kinase inhibitors <b>13, 17–35</b> that exhibit antiviral activity or are used in the management of viral infections. The <i>in vitro</i> kinase inhibition, <i>in vitro</i> antiviral activity, cellular toxicity (CC<sub>50</sub> values), <i>in vivo</i> antiviral activity, and clinical trial (CT) information are shown as brown, black, green, red, and blue colored texts, respectively. All other figures follow a similar color pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">3.2.  Serine-Threonine Kinase Inhibitors</h3><div class="NLM_p">The life cycle of many viruses depend on cyclin-dependent kinases. Nemeth et al.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> and Pauls et al.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> described the importance of Cdk6 and Cdk9 in HIV-1 infection. Cdk9 is also a validated target in herpes simplex virus type 1 (HSV-1) infection.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Palbociclib (<b>36</b>) is a potent Cdk4/6 inhibitor (IC<sub>50</sub> of 11 and 16 nM) approved by the FDA in 2015 for the treatment of HR-positive, HER2-negative advanced, or metastatic breast cancer.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> It potently inhibits VSV-pseudotyped NL4-3 HIV-1 infection in monocyte-derived macrophages with an EC<sub>50</sub> value of 0.12 μM.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> It also inhibits HSV-1 with an EC<sub>50</sub> value of 0.020 μM.<a onclick="showRef(event, 'ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref102 ref103">(102,103)</a> The FDA-approved mTOR inhibitor everolimus (<b>37</b>) exhibits inhibitory activity against MERS-CoV both pre- and postinfection (56% and 59% inhibition, respectively, at 10 μM).<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Trametinib (<b>38</b>, GSK-1120212) is an FDA-approved MEK inhibitor for the treatment of patients with V600E mutated metastatic melanoma. It shows selective allosteric ATP noncompetitive inhibition of MEK1 and MEK2, with IC<sub>50</sub> values of 0.92 and 1.8 nM, respectively.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Trametinib inhibits the replication of IAV strain RB1/H1N1pdm09 with an EC<sub>50</sub> value of 0.016 μM by blocking the export of progeny vRNPs from the nucleus. In the IAV-infected mouse model, administration of trametinib at a 3 mg/kg (PO) dose resulted in a reduction in the titer of progeny vRNPs.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Selumetinib (AZD-6244, <b>39</b>) is an FDA-approved MEK inhibitor for neurofibromatosis. It exhibits a significant antiviral effect against pandemic influenza A/Regensburg/D6/2009 (H1N1pdm09) virus (EC<sub>50</sub> 0.75 μM) via modulation of the Raf/MEK/ERK signaling pathway, which is a prerequisite for IAV replication.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The chemical structures of FDA-approved serine-threonine kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. FDA-approved serine-threonine kinase inhibitors <b>36</b>–<b>39</b> that exhibit antiviral activity</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many FDA-approved kinase inhibitors are reported to possess antiviral activity <i>in vitro</i> or <i>in vivo</i>; however, only few of them have been investigated in human clinical trials in virus-infected patients (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Imatinib was tolerated in a phase II trial in AIDS-associated Kaposi’s sarcoma, and 30 percent of patients showed long-term clinical benefit.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Most of the trials are ongoing, and thus, their results are not available.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Approved Kinase Inhibitors Being Repurposed in Virus-Infected Patients</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">repositioning for virus infection<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase inhibitor</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">original indication (approval year)</th><th class="colsep0 rowsep0" align="center">viral infection</th><th class="colsep0 rowsep0" align="center">CT phase</th><th class="colsep0 rowsep0" align="center" char=".">no. of trials</th><th class="colsep0 rowsep0" align="center">trial status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">myelofibrosis (2011), polycythemia vera (2014)</td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">NSCLC (2004)</td><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib + sunitinib</td><td class="colsep0 rowsep0" align="left">Multiple RTKs</td><td class="colsep0 rowsep0" align="left">NSCLC (2004), renal cell carcinoma (2006)</td><td class="colsep0 rowsep0" align="left">EBOV</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ruxolitinib</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">myelofibrosis (2011), polycythemia vera (2014)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II/III</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leflunomide</td><td class="colsep0 rowsep0" align="left">Multiple Kinases</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis (1998)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">I/II</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">baricitinib</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis (2018)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II/III</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinib</td><td class="colsep0 rowsep0" align="left">Abl</td><td class="colsep0 rowsep0" align="left">CML, AML (2r001)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II/III</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tofacitinib</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis (2012), ulcerative colitis (2018)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">zanubrutinib</td><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma (2019)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma (2013)</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">NSCLC (2004)</td><td class="colsep0 rowsep0" align="left">HBV</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">breast, lung cancer (2003)</td><td class="colsep0 rowsep0" align="left">HBV</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apatinib</td><td class="colsep0 rowsep0" align="left">VEGFR-2</td><td class="colsep0 rowsep0" align="left">gastric cancer (2014)</td><td class="colsep0 rowsep0" align="left">HBV</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">icotinib</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">lung cancer (2011)</td><td class="colsep0 rowsep0" align="left">HBV</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Information as of December 2020.</p></div></div></div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> depicts the general schematic diagram of the virus replication cycle, showing the roles of cellular kinases at various stages of the life cycle. Sunitinib, midostaurin, baricitinib, and erlotinib interfere with the viral life cycle at the endocytosis stage by inhibiting AAK1 or GAK kinases. Imatinib inhibits the c-Abl kinase, which plays a vital role in the fusion stage of the SARS-CoV life cycle. Dasatinib inhibits the Fyn kinase that is essential for the transcription of DENV. It also shows anti-DENV activity by interfering at the fusion stage by inhibiting c-Abl kinase. Sorafenib and selumetinib target the Raf/MEK pathway in HCV replication. Several kinase inhibitors exhibit antiviral effects by inhibiting an additional or even a different kinase target than the target in the original therapeutic indication, e.g., midostaurin is a Flt3 kinase inhibitor; however, it exhibits antiviral effects via inhibition of AAK1.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. General life cycle of viruses that are taken up by host cells by endocytosis. The host kinase targets and FDA-approved kinase inhibitors engaging those targets are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">4.  Kinase Inhibitor Clinical Candidates with Antiviral Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.1.  Tyrosine Kinase Inhibitors</h3><div class="NLM_p">There are more than 500 kinase inhibitors that are under clinical investigation. Many of them are simultaneously being repurposed for viral infections. More than 25 clinical candidate kinase inhibitors are reported to have antiviral activity as an additional therapeutic effect. BIBX1382 (<b>40</b>) is an inhibitor of Erb-B kinases, including ErbB1 and epidermal growth factor receptor (EGFR) kinase, and is being investigated in clinical trials in solid tumors.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> It inhibits Lassa mammarenavirus (LASV), EBOV, and Marburg virus (MARV), with EC<sub>50</sub> values of 3.2, 1.1, and 1.8 μM, respectively. Mechanistic studies have shown that BIBX1382 inhibits EBOV glycoprotein-dependent entry of 1976 EBOV and 2014 EBOV viruses with EC<sub>50</sub> values of 1.2 and 1.6 μM, respectively.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> The EC<sub>50</sub> values for inhibition of glycoprotein-dependent entry of LASV and vesicular stomatitis virus (VSV) were 7.5 and 30.9 μM, respectively. Canertinib (<b>41</b>, CI 1033) is an EGFR inhibitor that was investigated in phase I/II clinical trials in breast cancer and NSCLC. Canertinib is a known inhibitor of ErbB-1, ErbB-2, and ErbB-4 with IC<sub>50</sub> values of 0.8, 19, and 7 nM, respectively.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Upon entry into the host cell, the EGF-like domain of variola virus (smallpox) growth factor (SPGF) targets human ErbB-1 to facilitate viral replication. Thus, given the ability of SPGF to hijack the host ErbB-1, inhibitors of this kinase were tested <i>in vitro</i> and <i>in vivo</i> in variola virus infection. Canertinib blocks the secondary viral spread of variola virus <i>in vitro</i> and has also shown strong antiviral activity at a 50 mg/kg/day dose in a vaccinia virus mouse model by promoting the survival of animals and augmenting systemic T cell immunity.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Bemcentinib (<b>42</b>, R428, BGB324) is an inhibitor of Axl tyrosine kinase (IC<sub>50</sub> 14 nM) currently being investigated in TNBC, NSCLC, lung cancer, pancreatic cancer, melanoma, and brain cancer patients.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> It has previously been reported to exhibit potent antiviral activity against ZIKV (75% inhibition at 1 μM),<a onclick="showRef(event, 'ref4 ref113'); return false;" href="javascript:void(0);" class="ref ref4 ref113">(4,113)</a> and now it is being investigated in SARS-CoV-2-infected patients in the U.K.<a onclick="showRef(event, 'ref114 ref115'); return false;" href="javascript:void(0);" class="ref ref114 ref115">(114,115)</a> Saracatinib (<b>43</b>, AZD0530) is an experimental drug (phase III in ovarian cancer) and dual selective inhibitor of Src and Abl kinases. It inhibits DENV replication with an EC<sub>50</sub> value of 12.2 μM (Huh7 cells) by blocking the infectious cycle at the step of steady-state RNA replication.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Moreover, it inhibited the cytopathic effect of MERS-CoV with an EC<sub>50</sub> of 2.9 μM in a cell-based assay. It also exhibits antiviral activity against other human coronaviruses, such as hCoV-229E and OC43, with EC<sub>50</sub> values of 2.4 and 5.1 μM, respectively. Furthermore, it also inhibited feline infectious peritonitis virus (FIPV) with an EC<sub>50</sub> of 7 μM. Mechanistic studies have shown that it directly inhibits MERS-CoV infection by reducing the production of progeny viruses, indicating its activity at an early stage of infection. Saracatinib exhibited a synergistic antiviral effect against MERS-CoV in combination with gemcitabine, which is an anticancer drug.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Since there are many similarities in terms of genetics, pathogenesis, clinical manifestation, etc. between SARS-CoV, MERS-CoV, and SARS-CoV-2 infections, it was suggested that saracatinib should be clinically tested for its antiviral effect in the early stage of SARS-CoV-2 infection, either alone or in combination with current antiviral drugs.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Saracatinib possesses immunomodulatory effects on CD8(+) T cells, which are not accompanied by Src inhibition but are associated with Akt-mToR inhibition.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Dose-dependent immune potentiation and immunosuppressive effects are associated with Src kinase inhibitors; thus, careful selection of a safe dosage is essential in preclinical/clinical settings. Pacritinib (<b>44</b>) is a JAK2 inhibitor that is in a phase III trial for myelofibrosis and phase II in AML.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Currently, it is being investigated in SARS-CoV-2-infected patients.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> AT9283 (<b>45</b>) is a potent multikinase inhibitor (JAK2/3 (IC<sub>50</sub> 1.2, 1.1 nM) that is in a clinical trial for the treatment of non-Hodgkins lymphoma.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> It reduces HSV-1 infection by 75–95% in neurons at 10 μM but is less effective in neural progenitor cells (NPCs) and Vero cells.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Filgotinib (<b>46</b>, GLPG0634) is a JAK1/2 inhibitor (IC<sub>50</sub>, 10, 28 nM) that is clinically used for psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> It has been shown to inhibit HIV-1 replication in <i>in vitro</i> assays.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Using single-cell RNA sequencing data analysis, Guo et al.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> identified several FDA-approved drugs with the potential for repurposing in SARS-CoV-2 infection. One of the potential drugs identified in this study includes lestaurtinib (<b>47</b>, CEP-701; KT-5555), which is a JAK2 inhibitor. It is currently being clinically investigated in phase III trials in cell lymphoblastic leukemia and phase II trials in AML.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> The chemical structures of clinical trial stage tyrosine kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Tyrosine kinase inhibitors <b>40</b>–<b>47</b> at the clinical trial stage exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.2.  Serine-Threonine Kinase Inhibitors</h3><div class="NLM_p">Cyclin-dependent kinases (Cdks) are primarily known to regulate the cell cycle and transcription in host cells. Flavopiridol (<b>11</b>, L86-8275, HMR1275) is a potent cyclin-dependent kinase inhibitor (Cdk-1, 2, 4, 9: IC<sub>50</sub> 10–200 nM) that is in cancer clinical trials with primary side effects such as penia, namely, neutropenia, anemia, thrombocytopenia, and lymphopenia.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> It blocks HIV-1 replication in both single-round and viral spread assays with an IC<sub>50</sub> of <10 nM.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> It also exhibits potent antiviral activity against H7N9 IAV, as well as other IAV strains, with IC<sub>50</sub> values ranging from 0.24 to 0.79 μM.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Dinaciclib (<b>10</b>, SCH 727965) blocks the activity of Cdk1, 2, 5, and 9 with IC<sub>50</sub> values between 1 and 4 nM. It was granted orphan-drug status for CLL in 2011 and is also being investigated in numerous clinical trials for cancer.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> It exhibits potent antiviral activity against H7N9 IAV, as well as other IAV strains, with IC<sub>50</sub> values in the nM range and SI > 475.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Seliciclib (<b>48</b>, aSbR-21, roscovitine, CYC202) is an inhibitor of Cdk1 and 2 (IC<sub>50</sub> 450, 100 nM) and is currently in a phase II clinical trial for Cushing’s disease.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> It exhibits potent antiviral activity against ZIKV infection with an IC<sub>50</sub> of 24 nM.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Furthermore, it also effectively inhibited wild-type and resistant HIV-1 mutants in T cells, monocytes, and PBMCs, with IC<sub>50</sub> values within the range of 0.36–1.8 μM.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> In addition, it inhibits varicella-zoster virus (VZV) replication in MoVo cells.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> It also inhibited multiple subtypes of influenza strains, including A/WSN/1933 (H1N1), A/Aichi/2/68 (H3N2), and A/FM1/47 (H1N1), with IC<sub>50</sub> values of 3.35, 7.01, and 5.99 μM, respectively. It specifically binds to the viral PB2cap protein and reduces viral polymerase activity.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In addition, the HCMV viral titers in HFF cells where reduced only when roscovitine was added at the beginning of the infection indicating the role of Cdk at the initial stages of infection. This led to inhibition of viral DNA replication and late viral gene expression.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Another extensively studied Cdk inhibitor, olomoucine (<b>49</b>), inhibits the DNA replication of human cytomegalovirus (HCMV) at 10 μM.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> FIT-039 (<b>50</b>) is a specific Cdk9 inhibitor (IC<sub>50</sub> value of 5.8 μM) and is being clinically investigated for use against common warts. It suppressed the replication of HSV and other DNA viruses, including HCMV and human adenovirus (HAdV). It also suppressed the replication of ACV-resistant HSV-1 (IC<sub>50</sub> 0.69 μM), not only <i>in vitro</i> but also in an <i>in vivo</i> model.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Moreover, FIT-039 dose-dependently reduced HBV infection with an IC<sub>50</sub> value of 0.33 μM.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> In preclinical animal studies, the topical application of FIT039 suppressed skin lesions in a murine HSV-1 infection model.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Intravenously injected FIT039 dramatically enhanced the effect of entecavir in HBV-infected mice.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> It also suppressed the proliferation of HPV in cell culture.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Recently, a phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 for use on verruca vulgaris (caused by HPV infection) or common warts on the extremities.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> PHA-767491 (<b>51</b>) is a potent ATP-competitive dual Cdc7/Cdk9 inhibitor with IC<sub>50</sub> values of 10 and 34 nM, respectively. It blocks HSV-1-induced necrosis (postvirus entry stage) in L929 cells with an IC<sub>50</sub> value of 1.86 μM. It also reduces virus titers in mouse fibroblast L929 cells, HeLa cervical cancer cells, and T98G glioblastoma cells. Studies indicated that PHA-767491 reduces the expression levels of the envelope glycoprotein gB and viral ribonucleotide reductase large subunit ICP6 in all these cell lines. It also reduces viral titers in livers and spleens in HSV-1-infected mice at a 25 mg/kg dose.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><div class="NLM_p">PD-0325901 (mirdametinib, <b>52</b>), AZD-8330 (ARRY-424704, <b>53</b>), and RDEA-119 (refametinib, <b>54</b>) are orally available MEK inhibitors that are in cancer clinical trials. These MEK inhibitors in combination with oseltamivir (approved antiviral medication) exhibit significant antiviral effects against the pandemic influenza A/Regensburg/D6/2009 (H1N1pdm09) virus. The antiviral effect of MEK inhibitors may be attributed to inactivation of the Raf/MEK/ERK signaling pathway, which is a prerequisite for IAV replication.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> PD184352 (<b>55</b>, CI-1040) is a clinically tested MEK inhibitor that significantly reduces influenza virus infection <i>in vitro</i> and <i>in vivo</i>. It suppressed the replication of H1N1pdm09IAV (A/Regensburg/D6/2009 (H1N1) in human alveolar epithelial cells (A549) with an EC<sub>50</sub> value of 0.026 μM, which is in the same range as oseltamivir for this virus. It also inhibits several IAV strains, indicating its broad activity against human IAV and IBV that cause seasonal epidemics as well as against avian IAV.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> ATR-002 (<b>56</b>) is a major active metabolite of PD184352 (<b>55</b>, CI-1040) that exhibits superior <i>in vivo</i> antiviral effects against influenza virus compared to CI-1040. As ATR-002 has a high concentration in mouse plasma, the dose of ATR-002 required to achieve the same titer reduction was 6-fold lower than that of CI-1040.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><div class="NLM_p">MK2206 (<b>57</b>) is a highly selective allosteric inhibitor of Akt (PKB) kinase, which is in phase I/II clinical trials against cancer.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> It efficiently inhibited infection with influenza pH1N1 virus <i>in vitro</i> with an EC<sub>50</sub> value of 0.79 μM. However, interestingly, it was unable to inhibit infection with H3N2, H7N9, and H5N1 viruses. Mode-of-action studies have shown that MK2206 alters Akt signaling and inhibits endocytic uptake of the virus.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> CX-6258 (<b>58</b>) is an orally bioavailable PIM-kinase inhibitor that is being investigated in cancer clinical trials.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> It has an antiviral effect on enterovirus A71 (EV-A71) infection in both RD and HeLa cells. At 2 μM, viral mRNA levels were significantly decreased (∼70–80%) in both RD and HeLa cells. In addition, the viral titer was also reduced by more than 10<sup>3</sup> after inhibiting Pim1 activity with CX-6258 in RD and HeLa cells (∼50–60%).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Berzosertib (<b>15</b>, VE-822) is an inhibitor of ataxia telangiectasia and Rad3-related protein (ATR) kinase with an IC<sub>50</sub> of 19 nM, which is being investigated in cancer clinical trials and has also displayed potent <i>in vitro</i> antiviral activity against SARS-CoV-2 with an IC<sub>50</sub> value of 4.28 nM. It limits viral infection by inhibiting the serine/threonine-protein kinase ATR needed for viral replication.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> BI-2536 (<b>59</b>) is a potent Plk1 inhibitor (IC<sub>50</sub> 0.83 nM) that has been clinically tested for cancer ailments, but clinical trials have been discontinued at the phase I stage. An <i>in vitro</i> antiviral study performed in human lung cells showed strong dose-dependent inhibition of IAV replication with an IC<sub>50</sub> value of 0.08 μM.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Screening of a kinase inhibitor library provided the mTOR inhibitor clinical candidate vistusertib (<b>16</b>, AZD2014) as an inhibitor of SARS-CoV-2 replication.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The chemical structures of serine-threonine kinase inhibitor clinical candidates that exhibit antiviral activity are shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Serine-threonine kinase inhibitors <b>10</b>, <b>11</b>, <b>15</b>, <b>16</b>, and <b>48</b>–<b>59</b> at the clinical trial stage that exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.3.  Lipid Kinase Inhibitors</h3><div class="NLM_p">Arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen. The PI3K/Akt signaling pathway plays a key role in various stages of the LCMV life cycle. Urata et al. (2012)<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> showed the role of PI3K/AKT signaling in arenavirus budding. The Novartis compound BEZ-235 (<b>60</b>, dactolisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor currently in cancer clinical trials. Treatment of cells with BEZ-235 (0.5–5 μM) was found to inhibit LCMV multiplication in cultured cells.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Campbell et al.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> showed that although BEZ-235 does not have an effect on either HIV binding or entry, BEZ-235-induced autophagy influences HIV infection and replication in primary macrophages. It decreases extracellular HIV p24 antigen accumulation by 83% at 25 μM. PIK-75 (<b>12</b>) is a PI3K inhibitor (IC<sub>50</sub> 5.8 nM) that displays potent antiviral activity against H7N9 IAV as well as other IAV strains (pdmH1N1 and H3N2) with an excellent selectivity index (SI > 250).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">In addition to PI3Ks, other lipid kinases, i.e., sphingosine kinases (Sphk 1 and 2), are also known to play a vital role in IAV infection. Both isoforms 1 and 2 of sphingosine kinase (SphK) facilitate the replication of IAV. Furthermore, IAV infection results in increased expression and phosphorylation of SphK2 in host cells. Opaganib (<b>61</b>, ABC294640) is a SphK2-specific inhibitor and investigational drug for cancer<a onclick="showRef(event, 'ref151 ref152'); return false;" href="javascript:void(0);" class="ref ref151 ref152">(151,152)</a> currently in a clinical trial stage for cholangiocarcinoma and multiple myeloma. It efficiently inhibits IAV replication <i>in vitro</i> with an EC<sub>50</sub> value of 1.78 μM. In a preclinical study, opaganib at a 75 mg/kg PO dose (daily for 2 days) protected mice against lethal IAV infection by reducing virus replication.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> It is also being investigated in a phase II/III trial in SARS-CoV-2-infected patients.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">Apilimod (<b>14</b>, STA-5326; LAM-002A), which was originally identified as an inhibitor of interleukins IL-12 and IL-23, was tested in a phase II clinical trial in Crohn’s disease, psoriasis, and rheumatoid arthritis, but it was not pursued further for these indications because of inadequate efficacy.<a onclick="showRef(event, 'ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref154 ref155">(154,155)</a> Subsequently, researchers at Novartis Institutes for Biomedical Research determined that apilimod also inhibits lipid kinase PIKfyve (IC<sub>50</sub> = 15 nM).<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Apilimod blocks EBOV and Marburg virus (MARV) infections of Huh7, Vero E6, and primary human macrophage cells, with notable potency in macrophages (IC<sub>50</sub> 10 nM).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Mode-of-action studies have suggested that apilimod blocks EBOV entry and infection through a PIKfyve-dependent pathway.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> Recently, it was found to inhibit SARS-CoV-2 replication at an EC<sub>50</sub> of 23 nM (SI > 4000),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and it has also entered a clinical trial in COVID-19 patients.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Recently, researchers from Harvard Medical School have shown that inhibition of PIKfyve prevents infection by Zaire ebolavirus (ZEBOV) and SARS-CoV-2. The inhibitors of PIKfyve, <i>viz</i>., apilimod (<b>14</b>) and vacuolin-1 (<b>62</b>) blocked the entry of ZEBOV and SARS-CoV-2 via inhibition of PIKfyve.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></div><div class="NLM_p">Phosphoinositide-dependent kinase-1 (PDK-1) plays a vital role in a variety of cellular functions, leading to the activation of the PI3K signaling pathway. The phenanthrene derivative OSU-03012 (<b>63</b>, AR-12) was reported to inhibit PDK-1<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> and LASV replication in A549 cells with an EC<sub>50</sub> of 0.5 μM. OSU-03012 also inhibits the replication of encephalitic Nipah virus (NiV-Luc), EBOV-GFP, and MARV-GFP with EC<sub>50</sub> values of ∼0.3 μM.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> It also inhibits ZIKV strains belonging to both the African and Asian/American lineages in Huh-7 and/or neuronal cells with an IC<sub>50</sub> of 2 μM.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> OSU-03012 in combination with the antifungal drug fluconazole has received orphan-drug status for treating cryptococcosis of the brain.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> The kinase inhibitor clinical candidates that are being repositioned for viral infections are tabulated in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. The chemical structures of clinical trial-stage lipid kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lipid kinase inhibitors <b>12</b>, <b>14</b>, and <b>60–63</b> at the clinical trial stage that exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Kinase Inhibitors in Clinical Trials, Being Repurposed for Viral Infections</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">details of repositioning for virus infection<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase inhibitor</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">original indication (phase of trial, status)</th><th class="colsep0 rowsep0" align="center">viral infection</th><th class="colsep0 rowsep0" align="center">CT phase</th><th class="colsep0 rowsep0" align="center" char=".">no. of trials</th><th class="colsep0 rowsep0" align="center">trial status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">opaganib</td><td class="colsep0 rowsep0" align="left">sphingosine kinase-2</td><td class="colsep0 rowsep0" align="left">phase II in cholangiocarcinoma</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II/III</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">2 ongoing, 1 completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Abivertinib</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">phase III in NSCLC</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bemcentinib</td><td class="colsep0 rowsep0" align="left">Axl</td><td class="colsep0 rowsep0" align="left">phase II in lung, pancreatic, melanoma cancers ongoing. Phase II in TNBC completed.</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pacritinib</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">phase III in myelofibrosis, phase II in AML, phase I/II in Graft-versus-host disease</td><td class="colsep0 rowsep0" align="left">COVID-19</td><td class="colsep0 rowsep0" align="left">III</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FIT039</td><td class="colsep0 rowsep0" align="left">Cdk9</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Verruca vulgaris, common warts</td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">ongoing</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Information as of December 2020.</p></div></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">5.  Discovery Stage Kinase Inhibitors with Antiviral Activity</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">5.1.  Tyrosine Kinase Inhibitors</h3><div class="NLM_p">Genistein (<b>64</b>) is a flavonoid that is a broad-spectrum tyrosine kinase inhibitor.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> It inhibits infection with viruses, such as SV40,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> HIV-1,<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> HSV,<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> and Pichinde <i>virus</i> (PICV).<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Genistein at 5–10 μg/mL completely inhibits HIV-1 virus replication and spread in macrophage cultures. Inhibition of cell fusion between macrophages and HIV-1 Ba-L Env-expressing cells and suppression of gp120-induced TNF-α secretion by primary macrophages contribute to genistein’s overall inhibitory effect on wild-type HIV-1 infection in cell culture. Moreover, it blocks infections at the level of entry and, possibly, early postentry stages.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In the case of PICV, which is an arenavirus, there was the highest degree of inhibition in pretreated target cells, while there was modest inhibition of infection when the drug was added to cultures up to 48 h after infection. Genistein at 100 μM inhibited the cytopathic effect (90% reduction in viral titer) in PICV-infected Vero cells.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Genistein treatment markedly reduces the phosphorylation of tyrosine residues in viral polypeptides, which results in a decreased HSV-1 titer. Genistein also inhibited the HSV-1-induced cytopathic effect in Vero cells (virus yield reduced to 11% at 50 μM).<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Another study showed that genistein reduces HBV production with an IC<sub>50</sub> value of 46 μM in fibroblast cells. Furthermore, it also exhibits an additive effect with the known antiviral drugs acyclovir and ganciclovir against HBV infection in cellular systems.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p">GNF-2 (<b>65</b>) is a well-established allosteric inhibitor of BCR-Abl kinase.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> It inhibits DENV2 in a viral infectivity assay with an IC<sub>90</sub> value of 15 μM. It blocks infection at two steps of the DENV life cycle by distinct mechanisms, <i>viz</i>., inhibition of DENV entry via direct binding to the virion as well as inhibition of cellular Abl kinases to block a postentry step in the DENV life cycle.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> c-Abl is also known to play a role in EEV infectivity. This kinase mediates the release of infectious EEV <i>in vitro</i>. Thus, the Abl kinase inhibitor PD-166326 (<b>66</b>) blocks the tyrosine kinase activity essential for actin motility and cell-to-cell spread of EEV virus.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Using a microscopy-based assay, Rausch et al.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> identified WAY-600 (<b>67</b>) as a tyrosine kinase inhibitor with antiviral activity against ZIKV with an EC<sub>50</sub> value of 2.28 μM. Hesperadin (<b>68</b>) is an ATP-competitive inhibitor of aurora B kinase with an IC<sub>50</sub> of 250 nM.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> It inhibits multiple human clinical isolates of IAV and IBV with submicromolar efficacy, including oseltamivir-resistant strains. It inhibits the early stage of viral replication by delaying the nuclear entry of viral ribonucleoprotein complexes, thereby inhibiting viral RNA transcription and translation as well as viral protein synthesis.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">Tyrphostin A9 (<b>69</b>) and AG879 (<b>70</b>) are two receptor tyrosine kinase inhibitors of the tyrphostin class that exhibit robust antiviral activity against IAV replication in cultured cells. Both compounds inhibit three postentry steps of the influenza virus life cycle, including blockage of Crm1-dependent nuclear export of the vRNP complex, viral RNA synthesis, and virus release. Tyrphostin A9 and AG879 inhibited influenza virus replication (∼50%) at 4 and 10 μM, respectively.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> Tyrphostin A9 at 4 μM caused an ∼3 log decrease in TGEV progeny titers. It also exhibited potent antiviral activity against the replication of various CoVs, including mCoV, porcine epidemic diarrhea virus (PEDV), and feline infectious peritonitis virus (FIPV). Mechanistic studies have shown that the inhibitory activity of tyrphostin A9 against TGEV infection is mainly mediated by the MAPK signaling pathway. Further studies have shown that it blocks the postadsorption stage of the TGEV life cycle.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><div class="NLM_p">WV970 (<b>71</b>) is a multikinase inhibitor (IC<sub>50</sub> in the nanomolar range) that displays anti-influenza activity. It inhibits multiple kinases, including JAK-2, with 61% inhibition at 50 nM. Its antiviral activity is similar to that of oseltamivir carboxylate (IC<sub>50</sub> 0.012 μM), which is a currently available antiviral drug. It exhibits potent antiviral activity against the influenza A strain A/Udorn/307/1972 (H3N2) and influenza B strains B/Yamagata/16/88 and B/Nagasaki/1/87, in addition to the highly pathogenic avian influenza virus strains A/ck/Yamaguchi/7/2004 (H5N1) and A/Anhui/1/2013 (H7N9), with IC<sub>50</sub> values ranging from 20 to 58 nM. Inhibition of vRNP-mediated viral genome replication and transcription was identified as its mode of antiviral action.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div><div class="NLM_p">C-Terminal Src kinase (Csk) is a tyrosine kinase from the Src kinase family. ASN 2324598 (structure not disclosed) is a Csk inhibitor (IC<sub>50</sub> 1.2 μM).<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a><i>In vitro</i> studies have shown that at 20 μM ASN 2324598, viral titers and viral RNA levels were significantly reduced (Huh-7 cells). The viral titers in control and ASN 2324598-treated cells were 9.2 and 1.2 log<sub>10</sub> PFU/mL, respectively.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> RO0504985 (<b>72</b>), which is an inhibitor of several CMGC-group kinase proteins, inhibits the replication of different HCMV strains, <i>viz</i>., AD169 and Merlin (RCMV1111) with EC<sub>50</sub> values of 0.01 and 1.3 μM, respectively. A mode-of-action study has shown that RO0504985 inhibits the production of immediate early viral IE2 proteins and the late viral protein pp28.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Compounds CND1201 (<b>2</b>),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> BIBU1361 (<b>3</b>),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and B9 (<b>9</b>)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were identified as antiviral compounds during HTS of a compound library. BX795 (<b>73</b>) is a potent and selective inhibitor of PDK1, with an IC<sub>50</sub> of 6 nM. BX795 is also a potent and relatively specific inhibitor of TBK1 and IKKε, with IC<sub>50</sub> values of 6 and 41 nM, respectively. It possesses anti-HSV-1 activity <i>in vitro</i> and <i>in vivo</i> via inhibition of viral protein synthesis.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> It also displays anti-HSV-2 activity <i>in vitro</i> as well as <i>in vivo</i>.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Y15 (<b>74</b>) is a potent and specific inhibitor of focal adhesion kinase (FAK) that exhibits antiviral activity against influenza virus. An <i>in vivo</i> study showed that Y15 at 5 mg/kg limits viral replication and pathogenesis.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> The chemical structures of discovery-stage tyrosine kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery-stage tyrosine kinase inhibitors <b>2</b>, <b>3</b>, <b>9</b>, <b>64</b>–<b>74</b> as antiviral agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">5.2.  Serine-Threonine Kinase Inhibitors</h3><div class="NLM_p">Several Cdk inhibitors have been reported to show antiviral activity against a wide range of viruses.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> PHA-690509 (<b>8</b>) is an ATP-competitive Cdk inhibitor with a submicromolar IC<sub>50</sub> against multiple Cdks, in particular Cdk2 (IC<sub>50</sub> 31 nM). It suppresses the production of infectious ZIKV particles at submicromolar concentrations (IC<sub>50</sub> 0.09 μM). A time-of-addition experiment in SNB-19 cells indicated that it inhibits ZIKV infection at the postentry stage, probably at the viral RNA replication step. RGB-286147 (<b>75</b>) is another pan-Cdk inhibitor that exhibits potent ZIKV antiviral activity with an IC<sub>50</sub> value of 27 nM.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Alsterpaullone (<b>76</b>) is a Cdk (and GSK-3β) inhibitor that has been selected for preclinical development in an NCI program. Alsterpaullone displays a potent inhibitory effect on HIV-1-infected cells (IC<sub>50</sub> 150 nM). Its mechanism of action has been attributed to inhibition of the Cdk2/cyclin A complex at the G1/S, as well as a few other kinases.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Purvalanol A (<b>77</b>) is a potent and cell-permeable Cdk inhibitor with IC<sub>50</sub> values of 4, 70, 35, and 850 nM for Cdk2/B, Cdk2/A, Cdk2/E, and Cdk4/D1, respectively. It exhibits antiviral activity against VZV and HIV-1 with EC<sub>50</sub> values in the micromolar range.<a onclick="showRef(event, 'ref102 ref186'); return false;" href="javascript:void(0);" class="ref ref102 ref186">(102,186)</a> LDC4297 (<b>78</b>) is an aminotriazine class of selective Cdk7 inhibitors (IC<sub>50</sub> < 5 nM) possessing antiviral activity <i>via</i> inhibition of HCMV replication.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> A vHTS-guided cell-based screening of potential Cdk2 inhibitors provided three inhibitors, <b>5</b>–<b>7</b>, of HSV-1 replication (IC<sub>50</sub> values 29–64 μM).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">There are several MEK-ERK1/2-MAP kinase signaling pathway inhibitors that are reported as antiviral agents. U0126 (<b>79</b>) is a highly selective inhibitor of both MEK1 and MEK2 with IC<sub>50</sub> values of 72 and 58 nM, respectively. U0126 inhibits Borna disease virus (BDV) foci formation at 12.5 μM. Moreover, the virus titer in U0126-treated cells was drastically reduced by 2.3 log<sub>10</sub> per cell, representing a reduction in the virus titer by 99.5% in guinea pig cell line CRL 1405 at 25 μM.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Pleschka et al.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> showed that at 50 μM, it reduced the number of infectious IAV particles by 80%. It also decreases IBV infection.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> U0126 suppresses replication of pandemic H1N1v and highly pathogenic avian influenza viruses with EC<sub>50</sub> values of 1.2 μM in A549 cells and 74.7 μM in MDCKII cells. An <i>in vivo</i> study showed that treatment with 10 mM U0126 resulted in a substantial reduction in virus titers in the lungs of IAV-infected mice 24 h after treatment (EC<sub>50</sub> 0.62 mM).<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> U0126 (at 2 μM) reduces JUNV titers by 70–75% in U937 cells.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Moreover, it displays broad-spectrum antiviral activity against yellow fever virus strain YFV-17D, dengue virus (DENV-2 and -3), and Saint-Louis encephalitis virus. The reduced levels of ERK1/2 phosphorylation may be attributed to its antiviral activities.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> An <i>in vivo</i> study by Manjunatha et al.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> showed that it significantly reduces RABV infection via inhibition of the MEK-ERK1/2-MAP kinase signaling pathway. 20(S)-Ginsenoside Rg3 (<b>80</b>), which is a MAPK inhibitor, displays <i>in vitro</i> antiviral activity against murine virus mCoV-68 (IC<sub>50</sub> 10 μM) via the suppression of p38 and/or the JNK-associated MAPK signaling pathway.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> SB203580 (<b>81</b>) is a specific p38 MAPK inhibitor (IC<sub>50</sub> 105 nM) that shows antiviral activity against human coronavirus 229E (HCoV-229E). At 4 μM, it reduced viral RNA by ∼60% in an <i>in vitro</i> study.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">In the IAV life cycle, endocytosis of viral particles appears to be controlled by the protein kinase C isoform PKCβII.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Bisindolylmaleimide (<b>82</b>) is a PKCβII inhibitor that reversibly inhibits virus entry by blocking endosomal trafficking and virion uncoating of both IAV and IBV.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> Cyclin G-associated kinase (GAK) is a serine-threonine kinase that is encoded by the GAK gene in humans. GAK inhibitor <b>83</b> (EC<sub>50</sub> 2.5 μM for inhibition of virus replication) is an isothiazolopyridine class of compounds that displays potent activity against HCV by inhibiting two distinct steps in the HCV life cycle (i.e., viral entry and assembly).<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Another group performed a slight modification on the central scaffold of the compound, which led to a decrease in antiviral activity (compound <b>84</b>).<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Further optimization was performed to enhance the antiviral activity while maintaining the GAK inhibition activity. Derivative <b>85</b> (GAK, <i>K</i><sub>d</sub> 0.089 μM) demonstrated <i>in vitro</i> activity against DENV in human primary dendritic cells with an EC<sub>50</sub> value of 3.5 μM. It also shows efficacy against unrelated EBOV and CHIKV viruses with EC<sub>50</sub> values in the micromolar range. Moreover, inhibition of GAK activity was validated as an important mechanism of the antiviral action of these compounds.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> The Martinez-Gualda group<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> discovered isothiazolo[4,3-<i>b</i>]pyridine derivative <b>86</b> with potent GAK inhibition activity (IC<sub>50</sub> 0.024 μM) and antiviral activity against DENV (EC<sub>50</sub> 1.04 μM) in Huh7 cells.</div><div class="NLM_p">Adaptor-associated protein kinase 1 (also known as AP2-associated protein kinase 1) is a serine-threonine kinase that is encoded by the AAK1 gene in humans. 3,5-Disubstituted pyrrolopyridine <b>87</b> is an AAK1 inhibitor (IC<sub>50</sub> 4 nM) that displays potent antiviral activity against DENV and EBOV viruses. It shows EC<sub>50</sub> values of 0.72 and 0.043 μM against DENV in two different cell lines. It has less antiviral activity against EBOV (EC<sub>50</sub> 1.59 μM), with no cytotoxicity up to 10 μM.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> A-443654 (<b>88</b>) is a specific inhibitor of Akt (PKB) that shows <i>in vitro</i> inhibition of HBV replication and expression. The antiviral mechanism of the compound mainly depends on the downregulation of aurora A kinase, which plays an essential role in viral replication.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Tyrphostin A9 (<b>89</b>) and rottlerin (<b>90</b>) are mammalian Ser/Thr and Tyr kinase inhibitors with anti-RABV activity with EC<sub>50</sub> values of 0.9 and 1.0 μM, respectively. Rottlerin and tyrphostin are inhibitors of PKCδ and PDGFR kinases; however, the roles of these kinases in RABV infection have not yet been established. Mechanistic studies show that both inhibitors interfere at the early step of the viral cycle and prevent viral replication. In the presence of tyrphostin A9, viral entry through endocytosis was disturbed, leading to improper delivery of nucleocapsids into the particles in the cytoplasm, whereas rottlerin was found to inhibit transcription, most likely by decreasing intracellular ATP concentration and therefore replication of the viral genome.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Screening of a kinase-focused library provided CND3514 (<b>1</b>) as an anti-CHIKV compound, likely exhibiting this effect via inhibition of PKR kinase.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Isoquinoline sulfonamide H-89 (<b>4</b>; PKA, IC<sub>50</sub> 50 nM) was identified as anti-DENV (IC<sub>50</sub> 0.9 μM)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> by screening a compound library. Recently, researchers from Taiwan have reported that benzene sulfonamide <b>91</b> displays anti-DENV and anti-ZIKV activity in human neuronal BE(2)C cells with EC<sub>50</sub> values of 1.52 and 1.91 μM, respectively. Compound <b>91</b> is a potent calcium/calmodulin-dependent kinase II (CaMKII) inhibitor with an IC<sub>50</sub> value of 0.79 μM. It significantly reduced the viremia level and increased the animal survival time in a mouse model of DENV-2 and ZIKV infection.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> The chemical structures of the discovery-stage serine-threonine kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Discovery-stage serine-threonine kinase inhibitors <b>1</b>, <b>4</b>–<b>8</b>, <b>75</b>–<b>91</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">5.3.  Lipid Kinase Inhibitors</h3><div class="NLM_p">PI3K-mediated signaling plays a vital role in virus replication. BF738735 (<b>92</b>), enviroxime (<b>93</b>), and PIK93 (<b>94</b>) are phosphatidylinositol 4-kinase III beta (PI4KB) inhibitors with IC<sub>50</sub> values in the nanomolar range. These compounds inhibit the <i>in vitro</i> replication of HCV subgenomic replicons of different genotypes (GT1a, 1b, 4a) with EC<sub>50</sub> values ranging from 0.1 to 9.3 μM.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> Furthermore, PI3K-mediated signaling also plays an essential role in regulating vesicular trafficking of the Ebola virus ZEBOV, which is necessary for virus entry into the cell. Disruption of this signaling leads to inappropriate trafficking within the cell, blocking the steps leading to membrane fusion. The PI3K inhibitor LY294002 (<b>95</b>) at 50 μM significantly reduced (10-fold) ZEBOV infection.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Cotreatment with LY294002 and quercetin has shown an additive effect against HCV.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> LY294002 at 10 μM also inhibits the JUNV titer by 5-fold in Vero- and BHK-21-infected cells.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> PIK-75 (<b>12</b>), which is a PI3K-α selective inhibitor, displays antiviral activity against H7N9 IAV, as well as other IAV strains, with IC<sub>50</sub> values from 0.04 to 0.40 μM. It inhibits the activity of PI3K and DNA-PK, and it is still in a late preclinical evaluation stage for the treatment of AML, breast cancer, pancreatic cancer, and encephalomyelitis.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> M85 (<b>96</b>) has broad-spectrum antiviral activity against IAV, IBV, HCV, and human rhinovirus (HRV) with IC<sub>50</sub> values in the micromolar range. Its antiviral activity against IAV is mediated by targeting EGFR and PIK3C2β kinases, which control the early stages of endocytosis. Moreover, M85 displays strong synergism with oseltamivir <i>in vitro</i> and protects mice from lethal influenza infection.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Mejdrová et al.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> identified pyrazolo[1,5-<i>a</i>]pyrimidine-class selective PI4KIIIβ (IC<sub>50</sub> 0.054 μM) inhibitor <b>97</b> that shows antiviral activity against viruses CVB3 and HRV and distinct genotypes of HCV (1b, 2a) with EC<sub>50</sub> values in the nanomolar range. Further structural modification has led to the synthesis of <b>98</b>, which is a selective subnanomolar inhibitor of PI4KIIIB (IC<sub>50</sub> 6.1 nM) that shows a significant antiviral effects against HCV, HRV, and coxsackievirus B3 (CVB3).<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> SKI II (<b>99</b>) is a highly selective and non-ATP-competitive SphK inhibitor (IC<sub>50</sub> 0.5 μM) that reduces the titers of measles virus MV by 1 log (90%) in primary human peripheral blood lymphocytes and by 70–80% in human BJAB B cells.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> The chemical structures of the discovery-stage lipid kinase inhibitors that possess antiviral activities are shown in <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Discovery-stage lipid kinase inhibitors <b>92</b>–<b>99</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">6.  JAK Inhibitors in the Management of Viral Infections</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">JAK is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals <i>via</i> the JAK-STAT pathway. Various cytokines activate the JAK-STAT signaling cascade to turn on its various functions, including immune regulation.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> The notorious role of IL-6 in SARS-CoV-2-infected patients has been noted, and thus, anti-IL-6 approaches have been explored and even approved for therapeutic use.<a onclick="showRef(event, 'ref213 ref214 ref215 ref216 ref217'); return false;" href="javascript:void(0);" class="ref ref213 ref214 ref215 ref216 ref217">(213−217)</a> Controlling the cytokine storm <i>via</i> JAK inhibitors is a promising approach that is being clinically investigated in COVID-19 mitigation.<a onclick="showRef(event, 'ref212 ref215 ref218 ref219'); return false;" href="javascript:void(0);" class="ref ref212 ref215 ref218 ref219">(212,215,218,219)</a></div><div class="NLM_p">The Janus kinases Tyk2 and JAK1 are also major targets of both RNA and DNA viruses. Supekova et al.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> unraveled the role of JAK1 in HCV replication. The HCV core protein is known to interact directly with JAK <i>via</i> its proline-rich JAK-binding motif, which is essential for the efficient production of infectious viruses.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> HIV replication in T-lymphocytes requires T cells to be activated with the continuous need for IL-2 stimulation that is regulated by the JAK-STAT pathway. Thus, inhibition of the JAK-STAT signaling pathway results in hampered HIV replication.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> In agreement with this, JAK inhibitors were recently reported to inhibit HIV replication in PBMCs and macrophages.<a onclick="showRef(event, 'ref79 ref83'); return false;" href="javascript:void(0);" class="ref ref79 ref83">(79,83)</a> Recently, it has been reported that the combination of JAK inhibitors with at least one antiviral agent has the potential to eliminate the presence of HIV.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p">Although the primary effect of JAK inhibitors is the regulation of cytokine levels via modulation of the JAK-STAT pathway, many drugs within this class exhibit antiviral effects by targeting host enzymes that viruses hijack for cell entry. JAK inhibitors block numb-associated kinases such as AAK1 and GAK that are responsible for clathrin-mediated viral endocytosis.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Baricitinib, ruxolitinib, and fedratinib inhibits AAK1 and GAK with IC<sub>50</sub> values ranging from 17 to 110 nM and 1–136 nM, respectively, in a cell-free assay. JAK inhibitors also inhibit these viral entry-associated kinases in a cell-based assay with IC<sub>50</sub> values ranging from 30 to 960 nM.<a onclick="showRef(event, 'ref76 ref223'); return false;" href="javascript:void(0);" class="ref ref76 ref223">(76,223)</a> Baricitinib (<b>29</b>) is the most potent AAK1 inhibitor (<i>K</i><sub>d</sub> 8.2 nM) having a potency that is within the exposure range of its approved clinical dose (2–4 mg QD) for the treatment of rheumatoid arthritis. It regulates clathrin-mediated endocytosis via inhibition of AAK1. The inhibition of JAK has also been shown to reduce the SARS-CoV-2 infectivity in primary human liver cells.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Thus, baricitinib also displays antiviral activity in primary human liver spheroids, as it reduces the SARS-CoV-2 viral load by 30–40% at 400 and 800 nM.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Its pharmacokinetics data shows that it gets rapidly absorbed from the gastrointestinal tract, attaining <i>C</i><sub>max</sub> at 1.5 h with an oral bioavailability of 79%. It showed dose-linear exposure over the dosing range of 2–20 mg. Repeated-dose administration resulted in steady-state concentrations after 2–3 days with minimal accumulation with QD dosing.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> The elimination half-life was 8–13 h, and it was well tolerated in human clinical trials with efficacy in RA patients.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> There are at least 16 clinical trials ongoing for the repurposing of baricitinib for usage against SARS-CoV-2 infection. Stebbing et al.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> suggested the combination of baricitinib with direct-acting antivirals to simultaneously reduce viral infectivity, viral replication, and the aberrant host inflammatory response in COVID-19 patients. The pilot study<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> of baricitinib in a small group of COVID-19 patients (<i>n</i> = 12) demonstrated its safety, with significant improvement in clinical parameters. Baricitinib when administered in combination with remdesivir in hospitalized patients with COVID-19 has reduced the recovery time compared to patients who received a placebo with remdesivir. Following these results, on November 19 2020, FDA has granted an emergency use approval to this combination in hospitalized COVID-19 patients needing oxygen.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> However, baricitinib as a stand-alone treatment for COVID-19 is not yet been authorized.</div><div class="NLM_p">Ruxolitinib (<b>30</b>, INCB018424) is another potent inhibitor of Janus kinases with selectivity toward JAK1 and 2 that inhibits JAK1, 2, and 3 and Tyr2 with IC<sub>50</sub> values of 3.3, 2.8, 428, and 19 nM, respectively.<a onclick="showRef(event, 'ref228 ref229'); return false;" href="javascript:void(0);" class="ref ref228 ref229">(228,229)</a> In PBMCs, it blocks IL-6-mediated STAT3 phosphorylation and the production of monocyte chemoattractant protein-1.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> The oral administration of ruxolitinib suppressed cytokine levels in animal models.<a onclick="showRef(event, 'ref228 ref231'); return false;" href="javascript:void(0);" class="ref ref228 ref231">(228,231)</a> A single oral dose (25 mg) of ruxolitinib in healthy human volunteers was rapidly absorbed attaining a peak concentration (<i>C</i><sub>max</sub> 1093 nM, AUC 3200 nM.h) within 1 h with a terminal half-life of 2.3 h.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> In another single-dose human pharmacokinetics study, ruxolitinib administered at doses of 5, 10, 25, 50, 100, and 200 mg/kg displayed a dose-dependent increase in <i>C</i><sub>max</sub> and AUC. The <i>C</i><sub>max</sub> increased from 195 to 7010 nM, whereas the AUC increased from 811 to 30 600 nM. Repeated dosing of ruxolitinib for 10 consecutive days did not result in the accumulation of the drug because of its shorter half-life. The 100 mg QD was the MTD of the repeat-dose toxicity study in healthy volunteers.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> At least 20 clinical trials are investigating the efficacy of ruxolitinib in SARS-CoV-2 infected patients. It was also clinically investigated in HIV-1 patients (phase II). The results of the few COVID-19 clinical studies that have been published indicate its effectiveness in overcoming ARD in these patients.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a></div><div class="NLM_p">Tofacitinib (<b>31</b>) is an FDA-approved JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is being investigated in patients infected with SARS-CoV-2 and psoriasis. It is a pan-JAK inhibitor with higher activity against JAK1/JAK3 with IC<sub>50</sub> values of 33 nM and 76 nM.<a onclick="showRef(event, 'ref234 ref235'); return false;" href="javascript:void(0);" class="ref ref234 ref235">(234,235)</a> Tofacitinib also displayed a good pharmacokinetic profile and linear and dose-proportional plasma exposure from 0.1 to 100 mg oral doses. The oral bioavailability of tofacitinib was 74% in healthy individuals, with <i>T</i><sub>max</sub> achieved in 0.5–1 h. Tofacitinib showed rapid elimination with a terminal half-life of 2.3–3.1 h. Steady-state plasma concentrations were attained with no accumulation after BID dosing.<a onclick="showRef(event, 'ref225 ref236'); return false;" href="javascript:void(0);" class="ref ref225 ref236">(225,236)</a> Tofacitinib (5, 10 mg BID) demonstrated a consistent safety profile (as a monotherapy or combination therapy) and sustained efficacy in rheumatoid arthritis patients.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> Thrombosis is one of the major risk factors associated with the usage of tofacitinib.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a></div><div class="NLM_p">Furthermore, Wu et al.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> proposed the use of another FDA approved JAK2 inhibitor fedratinib for reducing the mortality of COVID-19 patients with TH17 type immune profiles. Numerous clinical trials have demonstrated the tolerability of JAK inhibitors in repeated-dose administrations with decent oral exposure (steady-state concentration) throughout multiple-dose studies. Thus, JAK inhibitors hold great promise for the management of viral infections.<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a></div><div class="NLM_p">There are seven JAK kinases that are approved for therapeutic use. Ruxolitinib, tofacitinib, baricitinib, upadacitinib, and fedratinib are approved by the FDA for rheumatoid arthritis and myelofibrosis. Peficitinib and delgocitinib are approved in Japan for the treatment of rheumatoid arthritis and atopic dermatitis, respectively. In addition, there are numerous JAK inhibitors that are under clinical investigation for various indications (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). With the exception of peficitinib and fedratinib, the remaining five approved JAK inhibitors are being clinically investigated in COVID-19 patients. JAK inhibitors have inherent advantages because of their dual ability to exhibit anti-inflammatory effects by suppressing IL-6 levels and antiviral effects by interfering with the viral endocytosis step. Furthermore, the majority of them are orally bioavailable with short half-lives. Candidates with proven safety in humans have strong potential for placement in a repurposing pipeline for viral infections. The chemical structures of JAK inhibitors with antiviral activity are provided in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. The chemical structures of other JAK inhibitors that are listed in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf" class="ext-link">Figure S1</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. List of FDA Approved and Clinical Stage JAK Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">antiviral effects<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">Sr. no.</th><th class="colsep0 rowsep0" align="center">JAK inhibitor</th><th class="colsep0 rowsep0" align="center">JAK (IC<sub>50</sub>)</th><th class="colsep0 rowsep0" align="center">development status</th><th class="colsep0 rowsep0" align="center">primary indication</th><th class="colsep0 rowsep0" align="center">AAK1/GAK</th><th class="colsep0 rowsep0" align="center">antiviral activity (in vitro)</th><th class="colsep0 rowsep0" align="center">clinical trial for management of viral infection</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">1.</td><td class="colsep0 rowsep0" rowspan="2" align="left">bariticinib (<b>29</b>)</td><td class="colsep0 rowsep0" rowspan="2" align="left">JAK1/2: 5.9/5.7 nM</td><td class="colsep0 rowsep0" rowspan="2" align="left">FDA approved (2018)</td><td class="colsep0 rowsep0" rowspan="2" align="left">rheumatoid arthritis</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> 17, 136 nM<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">SARS-CoV-2<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">COVID-19 (16 studies)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub> 8.2, 120 nM<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">2.</td><td class="colsep0 rowsep0" align="left">ruxolitinib (<b>30</b>, INC424)</td><td class="colsep0 rowsep0" align="left">JAK1/2: 3.3/2.8 nM</td><td class="colsep0 rowsep0" align="left">FDA approved (2011)</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> 100, 120 nM<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td><td class="colsep0 rowsep0" align="left">HIV, SARS-CoV-2</td><td class="colsep0 rowsep0" align="left">COVID-19 (21 studies)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3.</td><td class="colsep0 rowsep0" align="left">tofacitinib (<b>31</b>, CP-690,550)</td><td class="colsep0 rowsep0" align="left">JAK3/2: 1/20 nM</td><td class="colsep0 rowsep0" align="left">FDA approved (2012)</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>d</sub> 7500 nM, 18000 nM<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td><td class="colsep0 rowsep0" align="left">HIV, SARS-CoV-2</td><td class="colsep0 rowsep0" align="left">COVID-19 (5 studies)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">4.</td><td class="colsep0 rowsep0" align="left">AZD0449 (R256)</td><td class="colsep0 rowsep0" align="left">JAK1/3: EC<sub>50</sub> 44 nM</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">asthma</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">5.</td><td class="colsep0 rowsep0" rowspan="2" align="left">AZD4205</td><td class="colsep0 rowsep0" rowspan="2" align="left">JAK1: 73 nM</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" rowspan="2" align="left">T cell lymphoma; NSCLC</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase I/II completed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">6.</td><td class="colsep0 rowsep0" rowspan="2" align="left">PF-06651600 (ritlecitinib)</td><td class="colsep0 rowsep0" align="left">JAK3</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">alopecia areata</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">33.1 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">7.</td><td class="colsep0 rowsep0" align="left">peficitinib</td><td class="colsep0 rowsep0" align="left">JAK3/1</td><td class="colsep0 rowsep0" align="left">approved in Japan</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.7/3.9 nM</td><td class="colsep0 rowsep0" align="left">phase 2 dicontinued</td><td class="colsep0 rowsep0" align="left">plaque psoriasis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="char" char=".">8.</td><td class="colsep0 rowsep0" rowspan="3" align="left">pacritinib (<b>44</b>)</td><td class="colsep0 rowsep0" rowspan="3" align="left">JAK2: 23 nM</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" rowspan="3" align="left">COVID-19 (1 study)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">graft-versus-host disease</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">9.</td><td class="colsep0 rowsep0" rowspan="2" align="left">momelotinib</td><td class="colsep0 rowsep0" align="left">JAK1/2:</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">myelofibrosis,</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11/18 nM</td><td class="colsep0 rowsep0" align="left">preclinical</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">10.</td><td class="colsep0 rowsep0" align="left">SHR0302</td><td class="colsep0 rowsep0" align="left">JAK1</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">11.</td><td class="colsep0 rowsep0" align="left">AT9283 (<b>45</b>)</td><td class="colsep0 rowsep0" align="left">JAK2/3: 1.1/1.2 nM</td><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">non-Hodgkins lymphoma</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">70–90% reduction in HSV-1 at 10 μM</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">12.</td><td class="colsep0 rowsep0" rowspan="2" align="left">cerdulatinib</td><td class="colsep0 rowsep0" align="left">JAK1/2/3</td><td class="colsep0 rowsep0" align="left">orphan drug (2018)</td><td class="colsep0 rowsep0" rowspan="2" align="left">T-cell lymphoma; CML</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12/6/8 nM</td><td class="colsep0 rowsep0" align="left">phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">13.</td><td class="colsep0 rowsep0" rowspan="2" align="left">delgocitinib</td><td class="colsep0 rowsep0" align="left">JAK1/2/3</td><td class="colsep0 rowsep0" align="left">approved in Japan</td><td class="colsep0 rowsep0" align="left">atopic dermatitis</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.8/2.6/13 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">alopecia areata</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">14.</td><td class="colsep0 rowsep0" rowspan="2" align="left">filgotinib (<b>45</b>, GLPG0634)</td><td class="colsep0 rowsep0" align="left">JAK1/2:</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">psoriatic arthritis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left">Suppress HIV-1 reactivation in cell line<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10/28 nM</td><td class="colsep0 rowsep0" align="left">Phase II</td><td class="colsep0 rowsep0" align="left">ankylosing spondylitis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">15.</td><td class="colsep0 rowsep0" align="left">fedratinib (<b>18</b>, TG-101348)</td><td class="colsep0 rowsep0" align="left">JAK2: 3 nM</td><td class="colsep0 rowsep0" align="left">approved in the U.S.</td><td class="colsep0 rowsep0" align="left">myelofibrosis and polycythemia vera</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> 32, 1 nM</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2 (IC<sub>50</sub> 24 nM)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">16.</td><td class="colsep0 rowsep0" align="left">gandotinib (LY2784544)</td><td class="colsep0 rowsep0" align="left">JAK2: 3 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">myeloproliferative disorders</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">17.</td><td class="colsep0 rowsep0" rowspan="2" align="left">gusacitinib (ASN-002)</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">atopic dermatitis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5–46 nM</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">solid tumors</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">18.</td><td class="colsep0 rowsep0" align="left">ilginatinib (NS-018)</td><td class="colsep0 rowsep0" align="left">JAK2: 0.27 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">myelofibrosis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="char" char=".">19.</td><td class="colsep0 rowsep0" rowspan="3" align="left">itacitinib (INCB039110)</td><td class="colsep0 rowsep0" rowspan="3" align="left">JAK1: 2 nM</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">graft-versus-host disease</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">Hodgkin’s disease</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">bronchiolitis obliterans</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">20.</td><td class="colsep0 rowsep0" rowspan="2" align="left">lestaurtinib (<b>46</b>, CEP-701; KT-5555)</td><td class="colsep0 rowsep0" rowspan="2" align="left">JAK2: 0.9 nM</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" rowspan="2" align="left">lymphoblastic leukemia; AML</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left">proposed for SARS-CoV-2 based on single-cell RNA sequencing data</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">21.</td><td class="colsep0 rowsep0" rowspan="2" align="left">TD-1473</td><td class="colsep0 rowsep0" align="left">JAK1/3:</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">ulcerative colitis</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">32–158 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">Crohn’s disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">22.</td><td class="colsep0 rowsep0" rowspan="2" align="left">brepocitinib (PF-06700841)</td><td class="colsep0 rowsep0" rowspan="2" align="left">JAK1/2: 17/77 nM</td><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">alopecia areata</td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td><td class="colsep0 rowsep0" rowspan="2" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase I</td><td class="colsep0 rowsep0" align="left">inflammatory bowel diseases</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">23.</td><td class="colsep0 rowsep0" align="left">SB1317</td><td class="colsep0 rowsep0" align="left">JAK2: 73 nM</td><td class="colsep0 rowsep0" align="left">phase I/II</td><td class="colsep0 rowsep0" align="left">anaplastic astrocytoma</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">24.</td><td class="colsep0 rowsep0" align="left">abrocitinib (PF-4965842)</td><td class="colsep0 rowsep0" align="left">JAK1: 29 nM</td><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">atopic dermatitis</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="char" char=".">25.</td><td class="colsep0 rowsep0" rowspan="3" align="left">upadacitinib (ABT-494)</td><td class="colsep0 rowsep0" rowspan="3" align="left">JAK1: 43 nM</td><td class="colsep0 rowsep0" align="left">approved in the U.S.</td><td class="colsep0 rowsep0" align="left">rheumatoid arthritis;</td><td class="colsep0 rowsep0" rowspan="3" align="left"><i>K</i><sub>d</sub> 9900 nM, 2200 nM<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></td><td class="colsep0 rowsep0" rowspan="3" align="left"> </td><td class="colsep0 rowsep0" rowspan="3" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase III</td><td class="colsep0 rowsep0" align="left">ankylosing spondylitis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phase II</td><td class="colsep0 rowsep0" align="left">systemic lupus erythematosus</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">26.</td><td class="colsep0 rowsep0" align="left">jakotinib HCl</td><td class="colsep0 rowsep0" align="left">JAK</td><td class="colsep0 rowsep0" align="left">not known</td><td class="colsep0 rowsep0" align="left">not known</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">COVID-19 (China)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Information as of December 2020.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Baricitinib-remdesivir combination received FDA approval for emergency use in COVID-19 patients.</p></div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">7.  Summary and Future Prospects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases are among extensively investigated targets in medicinal chemistry programs. More than 30% drug discovery efforts in major multinational companies comprise kinases as molecular targets. These efforts have already provided more than 60 drugs in the last 20 years, with the majority of them for cancers. By virtue of crucial role of kinases in post-translational modifications of variety of proteins, they are present in all tissue types, and they perform variety of cellular functions. Their role in progression of virus life cycle is also considered to be vital. The entry of virus into the host cell follows its replication cycle with the aid of host cellular machinery that consists of a variety of enzymes including number of kinases. Because of the unique functional aspects of kinases in cellular systems, such as cell cycle regulation and transcription processes, viruses take control of the cellular kinases upon entry into host cells. Thus, kinases are considered as one of the crucial antiviral drug discovery target. Kinases that appear to be promising antiviral targets include c-Abl (viral fusion stage), EGFR, AAK1 (at entry of the virus), and JAK/BTK kinases that regulate the virus-induced cytokine storm. Although the kinase-driven antiviral drug discovery efforts are sparse, numerous efforts have been made toward repurposing known kinase inhibitors as potential antiviral agents via employing HTS platforms.</div><div class="NLM_p">As the majority of the kinase-inhibitors binds to the ATP-binding site, there is always a toxicity concern associated with this class of compounds. However, an appropriate dosing regimen and the shorter duration of treatment required in antiviral therapy have limited this concern. The original therapeutic indication of the majority of kinase inhibitors is for diseases requiring chronic treatments over several months. However, the treatment of viral infections requires a few days. This makes the repurposing of kinase inhibitors for viral infections attractive. Second, several identified antiviral kinase inhibitors have displayed excellent selectivity index (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information) in cell-based assays. Finally, the correct identification of real kinase associated with their antiviral effects requires revisiting. For several compounds, the kinase target associated with their antiviral activities appears to be different than the kinase that regulates their anticancer effects. In some cases, additional second kinase is associated with its antiviral effect. Examples include (a) dasatinib exhibiting an anti-DENV effect via inhibition of Fyn and c-Abl kinase; (b) erlotinib (EGFR inhibitor) inhibiting viral entry via inhibition of EGFR, as well as by inhibition of another kinase, GAK; (c) sunitinib, which is a multikinase inhibitor that has VEGFR-1/2 as the primary target in cancer, exhibiting an antiviral effect via inhibition of AAK1 that regulates the endocytosis step; and (d) midostaurin, which is a Flt3 inhibitor, exhibiting anti-HCV activity via inhibition of AAK1 kinase. Although a large number of kinase inhibitors exhibit antiviral activity <i>in vitro</i>, in several cases, there appear to be discrepancies between their kinase inhibition potency and antiviral (anticytopathic) effects. These discrepancies could be attributed to the presence of other kinases or other unknown targets that are related to their antiviral effects.</div><div class="NLM_p">Numerous small-molecule drugs that are inhibitors of various kinases, such as EGFR (imatinib) and Janus kinases (baricitinib, ruxolitinib, and pacritinib), are being investigated directly in phase III clinical trials in the treatment of COVID-19. Many others are not yet been studied in the COVID-19 pandemic but are promising, especially those that exhibit broad-spectrum antiviral activity, including erlotinib (<b>23</b>), sorafenib (<b>25</b>), sunitinib (<b>28</b>), saracatinib (<b>43</b>), etc. There is a repertoire of kinase inhibitors (>500 candidates in clinical trials and >60 FDA approved) available for application in repurposing pipelines. However, the critical analysis and correlation of their pharmacokinetic exposure and therapeutically relevant antiviral potency is required to decide their fate toward clinical use as antivirals.</div><div class="NLM_p last">Several clinical candidates (e.g., dinaciclib, PD-0325901, AZD-8330, PIK-75), discovery-stage compounds (e.g., WV970) exhibited potent anti-influenza activity. Further investigation of these kinase inhibitors is warranted for their possible clinical use as broad-spectrum anti-influenza agents. Most importantly, the kinase-targeted medicinal chemistry programs supported by antiviral screens must also be established to discover broad-spectrum antiviral agents for future pandemics. The literature presented in this review strongly supports the promise of kinase inhibitors for repurposing as antiviral agents.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01467" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75172" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75172" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01467?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01467</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical structures of JAK inhibitor clinical candidates and in vitro antiviral activity and cellular cytotoxicity of kinase inhibitors (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf">jm0c01467_si_001.pdf (284.26 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01467" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21132" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21132" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandip B. Bharate</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division,CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu 180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, Ghaziabad 201002, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6081-5787" title="Orcid link">http://orcid.org/0000-0001-6081-5787</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84f7e6ece5f6e5f0e1c4ededede9aaf6e1f7aaedeaa4f7e5eae0edf4e6ece5f6e5f0e1c4e3e9e5ede8aae7ebe9"><span class="__cf_email__" data-cfemail="710213191003100514311818181c5f0314025f181f">[email protected]</span> <span class="__cf_email__" data-cfemail="8efdefe0eae7feece6effceffaebcee9e3efe7e2a0ede1e3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rinky Raghuvanshi</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Division,CSIR-Indian Institute
of Integrative Medicine, Canal Road, Jammu 180001, India</span>; 
    <span class="hlFld-Affiliation affiliation">Academy
of Scientific & Innovative Research, Ghaziabad 201002, India</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Rinky Raghuvanshi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=BIO-d7e4301-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Rinky Raghuvanshi</b> received her M.Sc. degree in Organic Chemistry from Kurukshetra University, Haryana, in 2014. She was then engaged in the natural products research on high-altitude plants as a Junior Research Fellow at Defence Institute of High Altitude Research, DRDO, Chandigarh. In March 2018, she joined the laboratory of Dr. Sandip B. Bharate at CSIR Indian Institute of Integrative Medicine Jammu to pursue a Ph.D. in Chemical Sciences. Her research interests are in the area of natural products driven drug discovery for oncology and CNS diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Sandip B. Bharate</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=BIO-d7e4306-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sandip B. Bharate</b> is a Principal Scientist at Indian Institute of Integrative Medicine (IIIM). He earned M.S. and Ph.D. from NIPER Mohali and subsequently worked as a Research Scientist at Piramal Life Sciences Mumbai for 1.5 years. Following the NIH postdoctoral fellowship at the University of Montana, he began his independent research career at IIIM in 2011. His laboratory focuses on the discovery and development of small-molecule kinase inhibitors and has invented a Cdk inhibitor that has recently entered a clinical trial. He is the recipient of CSIR, NASI, and OPPI young scientist awards and also received a MEDI Young Investigator Award 2020 from ACS. He has been listed among the World’s Top 2% Scientists (Medicinal Chemistry) in the list released by Stanford University in 2020.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">R. Raghuvanshi thanks UGC for the award of Junior Research Fellowship. S. B. Bharate acknowledges the financial support from CSIR for Young Scientist Award Grant (P90807). This is IIIM Publication Number CSIR-IIIM/IPR/00258.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AAV6</td><td class="NLM_def"><p class="first last">adeno-associated virus serotype 6</p></td></tr><tr><td class="NLM_term">AAK1</td><td class="NLM_def"><p class="first last">AP2-associated protein kinase 1</p></td></tr><tr><td class="NLM_term">Abl2</td><td class="NLM_def"><p class="first last">Abelson tyrosine-protein kinase 2</p></td></tr><tr><td class="NLM_term">AIDS</td><td class="NLM_def"><p class="first last">acquired immunodeficiency syndrome</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">ARD</td><td class="NLM_def"><p class="first last">acute respiratory disease</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BCS</td><td class="NLM_def"><p class="first last">biopharmaceutics classification system</p></td></tr><tr><td class="NLM_term">BDV</td><td class="NLM_def"><p class="first last">Borna disease virus</p></td></tr><tr><td class="NLM_term">BKV</td><td class="NLM_def"><p class="first last">is the virus from polyomavirus family (BK virus is an abbreviation of the name of the first patient from whom the virus was isolated from in 1971)</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CHIKV</td><td class="NLM_def"><p class="first last">chikungunya virus</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">CMV</td><td class="NLM_def"><p class="first last">cytomegalovirus</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease 2019</p></td></tr><tr><td class="NLM_term">Csk</td><td class="NLM_def"><p class="first last">c-terminal Src kinase</p></td></tr><tr><td class="NLM_term">c-Src</td><td class="NLM_def"><p class="first last">cellular sarcoma</p></td></tr><tr><td class="NLM_term">CVB3</td><td class="NLM_def"><p class="first last">Coxsackievirus B3</p></td></tr><tr><td class="NLM_term">DENV</td><td class="NLM_def"><p class="first last">dengue virus</p></td></tr><tr><td class="NLM_term">DDODH</td><td class="NLM_def"><p class="first last">dihydroorotate dehydrogenase</p></td></tr><tr><td class="NLM_term">EBOV</td><td class="NLM_def"><p class="first last">Ebola virus</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">EEEV</td><td class="NLM_def"><p class="first last">eastern equine encephalitis viruses</p></td></tr><tr><td class="NLM_term">EEV</td><td class="NLM_def"><p class="first last">equine encephalitis virus</p></td></tr><tr><td class="NLM_term">EV-A71</td><td class="NLM_def"><p class="first last">enterovirus A71</p></td></tr><tr><td class="NLM_term">FIPV</td><td class="NLM_def"><p class="first last">feline infectious peritonitis virus</p></td></tr><tr><td class="NLM_term">GAK</td><td class="NLM_def"><p class="first last">cyclin G-associated kinase</p></td></tr><tr><td class="NLM_term">GRK2</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinase 2</p></td></tr><tr><td class="NLM_term">HAdV</td><td class="NLM_def"><p class="first last">human adenovirus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HCVpp</td><td class="NLM_def"><p class="first last">hepatitis C virus pseudoparticles</p></td></tr><tr><td class="NLM_term">HCMV</td><td class="NLM_def"><p class="first last">human cytomegalovirus</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus-1</p></td></tr><tr><td class="NLM_term">HRIG</td><td class="NLM_def"><p class="first last">human rabies immunoglobulins</p></td></tr><tr><td class="NLM_term">HPV</td><td class="NLM_def"><p class="first last">human papillomavirus</p></td></tr><tr><td class="NLM_term">HSV-1</td><td class="NLM_def"><p class="first last">herpes simplex virus-1</p></td></tr><tr><td class="NLM_term">HSG</td><td class="NLM_def"><p class="first last">human salivary gland</p></td></tr><tr><td class="NLM_term">HPD</td><td class="NLM_def"><p class="first last">human primary dendritic cells</p></td></tr><tr><td class="NLM_term">HRV</td><td class="NLM_def"><p class="first last">human rhinovirus</p></td></tr><tr><td class="NLM_term">Huh7</td><td class="NLM_def"><p class="first last">human hepatoma cells</p></td></tr><tr><td class="NLM_term">IAV</td><td class="NLM_def"><p class="first last">influenza A virus</p></td></tr><tr><td class="NLM_term">JNV</td><td class="NLM_def"><p class="first last">Junin virus</p></td></tr><tr><td class="NLM_term">LASV</td><td class="NLM_def"><p class="first last">Lassa mammarena virus</p></td></tr><tr><td class="NLM_term">LCMV</td><td class="NLM_def"><p class="first last">lymphocytic choriomeningitis virus</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases</p></td></tr><tr><td class="NLM_term">MARV</td><td class="NLM_def"><p class="first last">Marburg virus</p></td></tr><tr><td class="NLM_term">mCoV</td><td class="NLM_def"><p class="first last">murine coronavirus</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin-Darby canine kidney</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">MDM</td><td class="NLM_def"><p class="first last">monocyte derived macrophages</p></td></tr><tr><td class="NLM_term">MERS-CoV</td><td class="NLM_def"><p class="first last">Middle East respiratory syndrome related coronavirus</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">MV</td><td class="NLM_def"><p class="first last">measles virus</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">NiV</td><td class="NLM_def"><p class="first last">Nipah virus</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">PDK-1</td><td class="NLM_def"><p class="first last">phosphoinositide-dependent kinase-1</p></td></tr><tr><td class="NLM_term">PEDV</td><td class="NLM_def"><p class="first last">porcine epidemic diarrhea virus</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">phosphatidylinositol</p></td></tr><tr><td class="NLM_term">PI4KB</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4-kinase III beta</p></td></tr><tr><td class="NLM_term">PIK3C2β</td><td class="NLM_def"><p class="first last">phosphoinositide 3 class II β</p></td></tr><tr><td class="NLM_term">PHH</td><td class="NLM_def"><p class="first last">primary human hepatocytes</p></td></tr><tr><td class="NLM_term">PICV</td><td class="NLM_def"><p class="first last">Pichinde virus</p></td></tr><tr><td class="NLM_term">PIKfyve</td><td class="NLM_def"><p class="first last">phosphoinositide kinase FYVE-type zinc finger containing</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">quaque die (means once a day)</p></td></tr><tr><td class="NLM_term">RABV</td><td class="NLM_def"><p class="first last">rabies virus</p></td></tr><tr><td class="NLM_term">RD cells</td><td class="NLM_def"><p class="first last">Rhabdomyosarcoma cells</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">RVFV</td><td class="NLM_def"><p class="first last">Rift valley fever virus</p></td></tr><tr><td class="NLM_term">SARS-CoV</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome-related coronavirus</p></td></tr><tr><td class="NLM_term">SerC</td><td class="NLM_def"><p class="first last">sertoli cells</p></td></tr><tr><td class="NLM_term">SphK2</td><td class="NLM_def"><p class="first last">sphongosine kinase-2</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">TID</td><td class="NLM_def"><p class="first last">thrice a day</p></td></tr><tr><td class="NLM_term">TGEV</td><td class="NLM_def"><p class="first last">transmissible gastroenteritis virus</p></td></tr><tr><td class="NLM_term">SHBRV</td><td class="NLM_def"><p class="first last">silver-haired bat rabies virus</p></td></tr><tr><td class="NLM_term">VEEV</td><td class="NLM_def"><p class="first last">Venezuelan equine encephalitis virus</p></td></tr><tr><td class="NLM_term">VSV</td><td class="NLM_def"><p class="first last">vesicular stomatitis virus</p></td></tr><tr><td class="NLM_term">VZV</td><td class="NLM_def"><p class="first last">varicella–zoster virus</p></td></tr><tr><td class="NLM_term">WNV</td><td class="NLM_def"><p class="first last">West Nile virus</p></td></tr><tr><td class="NLM_term">YFV-17D</td><td class="NLM_def"><p class="first last">yellow fever virus, 17D vaccine strain</p></td></tr><tr><td class="NLM_term">WEEV</td><td class="NLM_def"><p class="first last">western equine encephalitis virus</p></td></tr><tr><td class="NLM_term">ZIKV</td><td class="NLM_def"><p class="first last">Zika virus</p></td></tr><tr><td class="NLM_term">ZEBOV</td><td class="NLM_def"><p class="first last">Zaire Ebola virus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 240 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarah, C.</span></span> <span> </span><span class="NLM_article-title">Viral infections: Targeting host kinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnrd.2017.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1eisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=314&author=C.+Sarah&title=Viral+infections%3A+Targeting+host+kinases&doi=10.1038%2Fnrd.2017.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Viral infections Targeting host kinases</span></div><div class="casAuthors">Sarah, Crunkhorn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooBuCth4HdLrVg90H21EOLACvtfcHk0liXBLOhE2krHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1eisbs%253D&md5=d1fe20b89a9bbb5f2b2296aec1cb295c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.75%26sid%3Dliteratum%253Aachs%26aulast%3DSarah%26aufirst%3DC.%26atitle%3DViral%2520infections%253A%2520Targeting%2520host%2520kinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D314%26doi%3D10.1038%2Fnrd.2017.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Infectious disease. Combating emerging viral threats</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1126/science.aaa3778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fscience.aaa3778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25883340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=282-283&author=E.+Bekermanauthor=S.+Einav&title=Infectious+disease.+Combating+emerging+viral+threats&doi=10.1126%2Fscience.aaa3778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combating emerging viral threats</span></div><div class="casAuthors">Bekerman, Elena; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6232</span>),
    <span class="NLM_cas:pages">282-283</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDTBlEp8j0LVg90H21EOLACvtfcHk0liXBLOhE2krHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D&md5=1cf54cc0a7db0925573f96ed72c27c11</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa3778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa3778%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DInfectious%2520disease.%2520Combating%2520emerging%2520viral%2520threats%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D282%26epage%3D283%26doi%3D10.1126%2Fscience.aaa3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnec, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guivel-Benhassine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chom.2012.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=544-557&author=L.+Meertensauthor=X.+Carnecauthor=M.+P.+Lecoinauthor=R.+Ramdasiauthor=F.+Guivel-Benhassineauthor=E.+Lewauthor=G.+Lemkeauthor=O.+Schwartzauthor=A.+Amara&title=The+TIM+and+TAM+families+of+phosphatidylserine+receptors+mediate+dengue+virus+entry&doi=10.1016%2Fj.chom.2012.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry</span></div><div class="casAuthors">Meertens, Laurent; Carnec, Xavier; Lecoin, Manuel Perera; Ramdasi, Rasika; Guivel-Benhassine, Florence; Lew, Erin; Lemke, Greg; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases.  However, the mol. interactions mediating DV entry are poorly understood.  We detd. that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors.  Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors.  Conversely, DV infection of susceptible cells is inhibited by anti-TIM or anti-TAM antibodies or knockdown of TIM and TAM expression.  TIM receptors facilitate DV entry by directly interacting with virion-assocd. PtdSer.  TAM-mediated infection relies on indirect DV recognition, in which the TAM ligand Gas6 acts as a bridging mol. by binding to PtdSer within the virion.  This dual mode of virus recognition by TIM and TAM receptors reveals how DVs usurp the apoptotic cell clearance pathway for infectious entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYGMhUV8WdLVg90H21EOLACvtfcHk0liXBLOhE2krHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK&md5=7a00c7dc61dc042960aa302124140818</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DCarnec%26aufirst%3DX.%26aulast%3DLecoin%26aufirst%3DM.%2BP.%26aulast%3DRamdasi%26aufirst%3DR.%26aulast%3DGuivel-Benhassine%26aufirst%3DF.%26aulast%3DLew%26aufirst%3DE.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DThe%2520TIM%2520and%2520TAM%2520families%2520of%2520phosphatidylserine%2520receptors%2520mediate%2520dengue%2520virus%2520entry%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D12%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.chom.2012.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324-333&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.+M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0lhukDvUXkaNoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.%2BM.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26epage%3D333%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+implications+for+virus+origins+and+receptor+binding&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0lhukDvUXkaNoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520implications%2520for%2520virus%2520origins%2520and%2520receptor%2520binding%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e1002845</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002845&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0li7Qy5mXEr2zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26spage%3De1002845%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AAK1 and GAK regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AAK1+and+GAK+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the μ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0li7Qy5mXEr2zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAAK1%2520and%2520GAK%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eaFRJ31_W9z0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaescu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenbach, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Interactions between the hepatitis c virus nonstructural 2 protein and host adaptor proteins 1 and 4 orchestrate virus release</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e02233-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.02233-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FmBio.02233-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29535204" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e02233-17&author=F.+Xiaoauthor=S.+Wangauthor=R.+Barouch-Bentovauthor=G.+Neveuauthor=S.+Puauthor=M.+Beerauthor=S.+Schorauthor=S.+Kumarauthor=V.+Nicolaescuauthor=B.+D.+Lindenbachauthor=G.+Randallauthor=S.+Einav&title=Interactions+between+the+hepatitis+c+virus+nonstructural+2+protein+and+host+adaptor+proteins+1+and+4+orchestrate+virus+release&doi=10.1128%2FmBio.02233-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FmBio.02233-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02233-17%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DPu%26aufirst%3DS.%26aulast%3DBeer%26aufirst%3DM.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DNicolaescu%26aufirst%3DV.%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DInteractions%2520between%2520the%2520hepatitis%2520c%2520virus%2520nonstructural%25202%2520protein%2520and%2520host%2520adaptor%2520proteins%25201%2520and%25204%2520orchestrate%2520virus%2520release%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De02233-17%26doi%3D10.1128%2FmBio.02233-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amornphimoltham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorini, J. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1038/nm.2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.2145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20473307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=662-664&author=M.+L.+Wellerauthor=P.+Amornphimolthamauthor=M.+Schmidtauthor=P.+A.+Wilsonauthor=J.+S.+Gutkindauthor=J.+A.+Chiorini&title=Epidermal+growth+factor+receptor+is+a+co-receptor+for+adeno-associated+virus+serotype+6&doi=10.1038%2Fnm.2145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6</span></div><div class="casAuthors">Weller, Melodie L.; Amornphimoltham, Panomwat; Schmidt, Michael; Wilson, Paul A.; Gutkind, J. Silvio; Chiorini, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-664</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A key step in gene therapy is the efficient transfer of genes in a cell type- and tissue-specific manner.  To better understand the mechanism of adeno-assocd. virus serotype 6 (AAV6) transduction, we used comparative gene anal. (CGA) combined with pathway visualization software to identify a pos. correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression.  Subsequent expts. suggested that EGFR is necessary for vector internalization and probably functions as a co-receptor for AAV6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqIDkYot5n7Vg90H21EOLACvtfcHk0ljVClD_n9pBQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslyqtr4%253D&md5=627160f93b0dc03c4f73dce3e83e0b4f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm.2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2145%26sid%3Dliteratum%253Aachs%26aulast%3DWeller%26aufirst%3DM.%2BL.%26aulast%3DAmornphimoltham%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DP.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26aulast%3DChiorini%26aufirst%3DJ.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520is%2520a%2520co-receptor%2520for%2520adeno-associated%2520virus%2520serotype%25206%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D662%26epage%3D664%26doi%3D10.1038%2Fnm.2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huong, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab-Traub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.-S.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/nature01818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnature01818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12879076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1aqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2003&pages=456-461&author=X.+Wangauthor=S.-M.+Huongauthor=M.+L.+Chiuauthor=N.+Raab-Traubauthor=E.-S.+Huang&title=Epidermal+growth+factor+receptor+is+a+cellular+receptor+for+human+cytomegalovirus&doi=10.1038%2Fnature01818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus</span></div><div class="casAuthors">Wang, Xin; Huong, Shu-Mei; Chiu, Marie L.; Raab-Traub, Nancy; Huang, Eng-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue">6947</span>),
    <span class="NLM_cas:pages">456-461</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) is a widespread opportunistic herpesvirus that causes severe and fatal diseases in immune-compromised individuals, including organ transplant recipients and individuals with AIDS.  It is also a leading cause of virus-assocd. birth defects and is assocd. with atherosclerosis and coronary restenosis.  HCMV initiates infection and intracellular signalling by binding to its cognate cellular receptors and by activating several signalling pathways including those mediated by mitogen-activated protein kinase, phosphatidylinositol-3-OH kinase, interferons, and G proteins.  But a cellular receptor responsible for viral entry and HCMV-induced signalling has yet to be identified.  Here we show that HCMV infects cells by interacting with epidermal growth factor receptor (EGFR) and inducing signalling.  Transfecting EGFR-neg. cells with an EGFR complementary DNA renders non-susceptible cells susceptible to HCMV.  Ligand displacement and crosslinking analyses show that HCMV interacts with EGFR through gB, its principal envelope glycoprotein.  GB preferentially binds EGFR and EGFR-ErbB3 oligomeric mols. in Chinese hamster ovary cells transfected with erbB family cDNAs.  Taken together, these data indicate that EGFR is a necessary component for HCMV-triggered signalling and viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkR2hFJXw_C7Vg90H21EOLACvtfcHk0ljVClD_n9pBQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1aqsbk%253D&md5=d907f0bd0db76935021af259ec241795</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01818%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuong%26aufirst%3DS.-M.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DRaab-Traub%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.-S.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520is%2520a%2520cellular%2520receptor%2520for%2520human%2520cytomegalovirus%26jtitle%3DNature%26date%3D2003%26volume%3D424%26spage%3D456%26epage%3D461%26doi%3D10.1038%2Fnature01818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. H.</span></span> <span> </span><span class="NLM_article-title">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27215486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2016&pages=1-12&author=C.+Leeauthor=Y.+Kimauthor=J.+H.+Jeon&title=JNK+and+p38+mitogen-activated+protein+kinase+pathways+contribute+to+porcine+epidemic+diarrhea+virus+infection&doi=10.1016%2Fj.virusres.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span></div><div class="casAuthors">Lee, Changhee; Kim, Youngnam; Jeon, Ji Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways, which are central building blocks in the intracellular signaling network, are often manipulated by viruses of diverse families to favor their replication.  Among the MAPK family, the extracellular signal-regulated kinase (ERK) pathway is known to be modulated during the infection with porcine epidemic diarrhea virus (PEDV); however, involvement of stress-activated protein kinases (SAPKs) comprising p38 MAPK and c-Jun NH2-terminal kinase (JNK) remains to be detd.  Therefore, in the present study, we investigated whether activation of p38 MAPK and JNK cascades is required for PEDV replication.  Our results showed that PEDV activates p38 MAPK and JNK1/2 up to 24 h post-infection, whereas, thereafter their phosphorylation levels recede to baseline levels or even fall below them.  Notably, UV-irradiated inactivated PEDV, which can enter cells but cannot replicate inside them, failed to induce phosphorylation of p38 MAPK and JNK1/2 suggesting that viral biosynthesis is essential for activation of these kinases.  Treatment of cells with selective p38 or JNK inhibitors markedly impaired PEDV replication in a dose-dependent manner and these antiviral effects were found to be maximal during the early times of the infection.  Furthermore, direct pharmacol. inhibition of p38 MAPK or JNK1/2 activation resulted in a significant redn. of viral RNA synthesis, viral protein expression, and progeny release.  However, independent treatments with either SAPK inhibitor did not inhibit PEDV-induced apoptotic cell death mediated by activation of mitochondrial apoptosis-inducing factor (AIF) suggesting that SAPKs are irrelevant to the apoptosis pathway during PEDV infection.  In summary, our data demonstrated crit. roles of the p38 and JNK1/2 signaling pathways in facilitating successful viral infection during the post-entry steps of the PEDV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFU6UbPFBvXLVg90H21EOLACvtfcHk0liyy2xUbqnxrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D&md5=c0bffb5299069d3fad2a3c1123040b14</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJeon%26aufirst%3DJ.%2BH.%26atitle%3DJNK%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%2520contribute%2520to%2520porcine%2520epidemic%2520diarrhea%2520virus%2520infection%26jtitle%3DVirus%2520Res.%26date%3D2016%26volume%3D222%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.virusres.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">5937</span>– <span class="NLM_lpage">5948</span>, <span class="refDoi"> DOI: 10.1128/JVI.76.12.5937-5948.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.76.12.5937-5948.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12021326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=5937-5948&author=S.+Banerjeeauthor=K.+Narayananauthor=T.+Mizutaniauthor=S.+Makino&title=Murine+coronavirus+replication-induced+p38+mitogen-activated+protein+kinase+activation+promotes+interleukin-6+production+and+virus+replication+in+cultured+cells&doi=10.1128%2FJVI.76.12.5937-5948.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span></div><div class="casAuthors">Banerjee, Sangeeta; Narayanan, Krishna; Mizutani, Tetsuya; Makino, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5937-5948</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Analyses of mitogen-activated protein kinases (MAPKs) in a mouse hepatitis virus (MHV)-infected macrophage-derived J774.1 cell line showed activation of two MAPKs, p38 MAPK and c-Jun N-terminal kinase (JNK), but not of extracellular signal-regulated kinase (ERK).  Activation of MAPKs was evident by 6 h post-infection.  However, UV-irradiated MHV failed to activate MAPKs, which demonstrated that MHV replication was necessary for their activation.  Several other MHV-permissive cell lines also showed activation of both p38 MAPK and JNK, which indicated that the MHV-induced stress-kinase activation was not restricted to any particular cell type.  The upstream kinase responsible for activating MHV-induced p38 MAPK was the MAPK kinase 3.  Expts. with a specific inhibitor of p38 MAPK, SB 203580, demonstrated that MHV-induced p38 MAPK activation resulted in the accumulation of interleukin-6 (IL-6) mRNAs and an increase in the prodn. of IL-6, regardless of MHV-induced general host protein synthesis inhibition.  Furthermore, MHV prodn. was suppressed in SB 203580-treated cells, demonstrating that activated p38 MAPK played a role in MHV replication.  The reduced MHV prodn. in SB 203580-treated cells was, at least in part, due to a decrease in virus-specific protein synthesis and virus-specific mRNA accumulation.  Interestingly, there was a transient increase in the amt. of phosphorylation of the translation initiation factor 4E (eIF4E) in infected cells, and this eIF4E phosphorylation was p38 MAPK dependent; it is known that phosphorylated eIF4E enhances translation rates of cap-contg. mRNAs.  Furthermore, the upstream kinase responsible for eIF4E phosphorylation, MAPK-interacting kinase 1, was also phosphorylated and activated in response to MHV infection.  Our data suggested that host cells, in response to MHV replication, activated p38 MAPK, which subsequently phosphorylated eIF4E to efficiently translate certain host proteins, including IL-6, during virus-induced severe host protein synthesis inhibition.  MHV utilized this p38 MAPK-dependent increase in eIF4E phosphorylation to promote virus-specific protein synthesis and subsequent progeny virus prodn.  Enhancement of virus-specific protein synthesis through virus-induced eIF4E activation has not been reported in any other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0BvjYf6qJwrVg90H21EOLACvtfcHk0liyy2xUbqnxrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D&md5=a6bbc508aba8194d38d090363792355c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.12.5937-5948.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.12.5937-5948.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DMakino%26aufirst%3DS.%26atitle%3DMurine%2520coronavirus%2520replication-induced%2520p38%2520mitogen-activated%2520protein%2520kinase%2520activation%2520promotes%2520interleukin-6%2520production%2520and%2520virus%2520replication%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D5937%26epage%3D5948%26doi%3D10.1128%2FJVI.76.12.5937-5948.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirasawa, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2007.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18055026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=150-152&author=M.+Konoauthor=K.+Tatsumiauthor=A.+M.+Imaiauthor=K.+Saitoauthor=T.+Kuriyamaauthor=H.+Shirasawa&title=Inhibition+of+human+coronavirus+229E+infection+in+human+epithelial+lung+cells+%28L132%29+by+chloroquine%3A+involvement+of+p38+MAPK+and+ERK&doi=10.1016%2Fj.antiviral.2007.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK</span></div><div class="casAuthors">Kono, Masakazu; Tatsumi, Koichiro; Imai, Alberto M.; Saito, Kengo; Kuriyama, Takayuki; Shirasawa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-152</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The antiviral effects of chloroquine (CQ) on human coronavirus 229E (HCoV-229E) infection of human fetal lung cell line, L132 are reported.  CQ significantly decreased the viral replication at concns. lower than in clin. usage.  We demonstrated that CQ affects the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK).  Furthermore, p38 MAPK inhibitor, SB203580, inhibits CPE induced by HCoV-229E infection and viral replication.  Our findings suggest that CQ affects the activation of MAPKs, involved in the replication of HCoV-229E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCBeEC2erNLVg90H21EOLACvtfcHk0liyy2xUbqnxrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D&md5=33d4220cb47dd09c191e35275adff654</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DA.%2BM.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DKuriyama%26aufirst%3DT.%26aulast%3DShirasawa%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520human%2520coronavirus%2520229E%2520infection%2520in%2520human%2520epithelial%2520lung%2520cells%2520%2528L132%2529%2520by%2520chloroquine%253A%2520involvement%2520of%2520p38%2520MAPK%2520and%2520ERK%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D150%26epage%3D152%26doi%3D10.1016%2Fj.antiviral.2007.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1128/JVI.00078-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00078-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21507972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6381-6389&author=R.+Cencicauthor=M.+Desforgesauthor=D.+R.+Hallauthor=D.+Kozakovauthor=Y.+Duauthor=J.+Minauthor=R.+Dingledineauthor=H.+Fuauthor=S.+Vajdaauthor=P.+J.+Talbotauthor=J.+Pelletier&title=Blocking+eIF4E-eIF4G+interaction+as+a+strategy+to+impair+coronavirus+replication&doi=10.1128%2FJVI.00078-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span></div><div class="casAuthors">Cencic, Regina; Desforges, Marc; Hall, David R.; Kozakov, Dima; Du, Yuhong; Min, Jaeki; Dingledine, Raymond; Fu, Haian; Vajda, Sandor; Talbot, Pierre J.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6381-6389</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses are a family of enveloped single-stranded pos.-sense RNA viruses causing respiratory, enteric, and neurol. diseases in mammals and fowl.  Human coronaviruses are recognized to cause up to a third of common colds and are suspected to be involved in enteric and neurol. diseases.  Coronavirus replication involves the generation of nested subgenomic mRNAs (sgmRNAs) with a common capped 5' leader sequence.  The translation of most of the sgmRNAs is thought to be cap dependent and displays a requirement for eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex needed for the recruitment of 40S ribosomes.  We recently reported on an ultrahigh-throughput screen to discover compds. that inhibit eIF4F activity by blocking the interaction of two of its subunits.  Herein we describe a mol. from this screen that prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation.  This inhibitor significantly decreased human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers.  Our results support the strategy of targeting the eIF4F complex to block coronavirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmYijWiXmX5LVg90H21EOLACvtfcHk0liyy2xUbqnxrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D&md5=2825b0855928a3dbbc53ac015dd55d16</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FJVI.00078-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00078-11%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DBlocking%2520eIF4E-eIF4G%2520interaction%2520as%2520a%2520strategy%2520to%2520impair%2520coronavirus%2520replication%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D6381%26epage%3D6389%26doi%3D10.1128%2FJVI.00078-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0li2tzUegWrNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1002/ddr.20303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fddr.20303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20930947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFCnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=255-265&author=A.+A.+Kolokoltsovauthor=M.+F.+Saeedauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Identification+of+novel+cellular+targets+for+therapeutic+intervention+against+Ebola+virus+infection+by+siRNA+screening&doi=10.1002%2Fddr.20303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening</span></div><div class="casAuthors">Kolokoltsov, Andrey A.; Saeed, Mohammad F.; Freiberg, Alexander N.; Holbrook, Michael R.; Davey, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-265</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">While much progress has been made in developing drugs against a few prominent viruses such as HIV, few examples exist for emerging infectious agents.  In some cases, broad spectrum anti-viral drugs, such as ribavirin, are effective, but for some groups of viruses, these show little efficacy in animal models.  Traditional methods focus on screening small mol. libraries to identify drugs that target virus factors, with the intention that side-effects to the host can be minimized.  However, this greatly limits potential drug targets and virus genes can rapidly mutate to avoid drug action.  Recent advances in siRNA gene-targeting technologies have provided a powerful tool to specifically target and suppress the expression of cell genes.  Since viruses are completely dependent upon host cell proteins for propagation, siRNA screening promises to reveal novel cell proteins and signaling pathways that may be viable targets for drug therapy regimens.  Here, an siRNA screening approach was used to identify gene products that play crit. roles in Ebola virus infection.  By gene cluster anal., proteins in phosphatidylinositol-3-kinase and calcium/calmodulin kinase related networks were identified as important for Zaire Ebola virus infection and prioritized for further evaluation.  The key roles of each were confirmed by testing available drugs specific for members of each pathway.  Interestingly, both sets of proteins are also important in cancer and subject to intense investigation.  Thus, development of new drugs against these cancer targets may also prove useful in combating Ebola virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ERtFFAkQUbVg90H21EOLACvtfcHk0li2tzUegWrNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFCnsLg%253D&md5=2a9a5f2d61cf56c511674366144e5014</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fddr.20303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.20303%26sid%3Dliteratum%253Aachs%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520novel%2520cellular%2520targets%2520for%2520therapeutic%2520intervention%2520against%2520Ebola%2520virus%2520infection%2520by%2520siRNA%2520screening%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2009%26volume%3D70%26spage%3D255%26epage%3D265%26doi%3D10.1002%2Fddr.20303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1128/JVI.01586-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01586-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17108034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=1230-1240&author=C.+A.+Zampieriauthor=J.-F.+Fortinauthor=G.+P.+Nolanauthor=G.+J.+Nabel&title=The+ERK+mitogen-activated+protein+kinase+pathway+contributes+to+Ebola+virus+glycoprotein-induced+cytotoxicity&doi=10.1128%2FJVI.01586-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span></div><div class="casAuthors">Zampieri, Carisa A.; Fortin, Jean-Francois; Nolan, Garry P.; Nabel, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ebola virus is a highly lethal pathogen that causes hemorrhagic fever in humans and nonhuman primates.  Among the seven known viral gene products, the envelope glycoprotein (GP) alone induces cell rounding and detachment that ultimately leads to cell death.  Cellular cytotoxicity is not seen with comparable levels of expression of a mutant form of GP lacking a mucin-like domain (GPΔmuc).  GP-induced cell death is non-apoptotic and is preceded by down-modulation of cell surface mols. involved in signaling pathways, including certain integrins and epidermal growth factor receptor.  To investigate the mechanism of GP-induced cellular toxicity, we analyzed the activation of several signal transduction pathways involved in cell growth and survival.  The active form of extracellular signal-regulated kinases type 1 and 2 (ERK1/2), phospho-ERK1/2, was reduced in cells expressing GP compared to those expressing GPΔmuc as detd. by flow cytometry, in contrast to the case for several other signaling proteins.  Subsequent anal. of the activation states and kinase activities of related kinases revealed a more pronounced effect on the ERK2 kinase isoform.  Disruption of ERK2 activity by a dominant neg. ERK or by small interfering RNA-mediated ERK2 knockdown potentiated the decrease in αV integrin expression assocd. with toxicity.  Conversely, activation of the pathway through the expression of a constitutively active form of ERK2 significantly protected against this effect.  These results indicate that the ERK signaling cascade mediates GP-mediated cytotoxicity and plays a role in pathogenicity induced by this gene product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9VqOOhotUrVg90H21EOLACvtfcHk0li2tzUegWrNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D&md5=a5bd3c4731380c3ad2cda2673f9300cb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FJVI.01586-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01586-06%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DFortin%26aufirst%3DJ.-F.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520ERK%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520contributes%2520to%2520Ebola%2520virus%2520glycoprotein-induced%2520cytotoxicity%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D1230%26epage%3D1240%26doi%3D10.1128%2FJVI.01586-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+Middle+East+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0lgOpoOSenw87A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520Middle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8924</span>– <span class="NLM_lpage">8933</span>, <span class="refDoi"> DOI: 10.1128/JVI.01429-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01429-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27466418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8924-8933&author=C.+M.+Colemanauthor=J.+M.+Siskauthor=R.+M.+Mingoauthor=E.+A.+Nelsonauthor=J.+M.+Whiteauthor=M.+B.+Frieman&title=Abelson+kinase+inhibitors+are+potent+inhibitors+of+severe+acute+respiratory+syndrome+coronavirus+and+middle+east+respiratory+syndrome+coronavirus+fusion&doi=10.1128%2FJVI.01429-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span></div><div class="casAuthors">Coleman, Christopher M.; Sisk, Jeanne M.; Mingo, Rebecca M.; Nelson, Elizabeth A.; White, Judith M.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8924-8933</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.  There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.  We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro.  Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane.  We specifically identified the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro.  These data demonstrate that specific approved drugs can be characterized in vitro for their anticoronavirus activity and used to identify host proteins required for coronavirus replication.  This type of study is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJU1Zz7G1ED7Vg90H21EOLACvtfcHk0lgOpoOSenw87A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE&md5=090a5b4bb7680982944fc665dfbdc5e5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.01429-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01429-16%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DMingo%26aufirst%3DR.%2BM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DAbelson%2520kinase%2520inhibitors%2520are%2520potent%2520inhibitors%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520and%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8924%26epage%3D8933%26doi%3D10.1128%2FJVI.01429-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanguez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schading, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3679</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06119-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41467-018-06119-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30206219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3c3nvFWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3679&author=E.+Yanguezauthor=A.+Hunzikerauthor=M.+P.+Dobayauthor=S.+Yildizauthor=S.+Schadingauthor=E.+Elshinaauthor=U.+Karakusauthor=P.+Gehrigauthor=J.+Grossmannauthor=R.+Dijkmanauthor=M.+Schmolkeauthor=S.+Stertz&title=Phosphoproteomic-based+kinase+profiling+early+in+influenza+virus+infection+identifies+GRK2+as+antiviral+drug+target&doi=10.1038%2Fs41467-018-06119-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span></div><div class="casAuthors">Yanguez Emilio; Hunziker Annika; Schading Simon; Elshina Elizaveta; Karakus Umut; Stertz Silke; Dobay Maria Pamela; Yildiz Soner; Schmolke Mirco; Gehrig Peter; Grossmann Jonas; Dijkman Ronald; Dijkman Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although annual influenza epidemics affect around 10% of the global population, current treatment options are limited and development of new antivirals is needed.  Here, using quantitative phosphoproteomics, we reveal the unique phosphoproteome dynamics that occur in the host cell within minutes of influenza A virus (IAV) infection.  We uncover cellular kinases required for the observed signaling pattern and find that inhibition of selected candidates, such as the G protein-coupled receptor kinase 2 (GRK2), leads to decreased IAV replication.  As GRK2 has emerged as drug target in heart disease, we focus on its role in IAV infection and show that it is required for viral uncoating.  Replication of seasonal and pandemic IAVs is severely decreased by specific GRK2 inhibitors in primary human airway cultures and in mice.  Our study reveals the IAV-induced changes to the cellular phosphoproteome and identifies GRK2 as crucial node of the kinase network that enables IAV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF382y4lQtoQ8IxFYvehhofW6udTcc2eZ1EW8BLJoGNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3nvFWrug%253D%253D&md5=67be912cc821f73914ef448ac81356b0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06119-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06119-y%26sid%3Dliteratum%253Aachs%26aulast%3DYanguez%26aufirst%3DE.%26aulast%3DHunziker%26aufirst%3DA.%26aulast%3DDobay%26aufirst%3DM.%2BP.%26aulast%3DYildiz%26aufirst%3DS.%26aulast%3DSchading%26aufirst%3DS.%26aulast%3DElshina%26aufirst%3DE.%26aulast%3DKarakus%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DP.%26aulast%3DGrossmann%26aufirst%3DJ.%26aulast%3DDijkman%26aufirst%3DR.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DPhosphoproteomic-based%2520kinase%2520profiling%2520early%2520in%2520influenza%2520virus%2520infection%2520identifies%2520GRK2%2520as%2520antiviral%2520drug%2520target%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3679%26doi%3D10.1038%2Fs41467-018-06119-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorobantu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albulescu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kampen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strating, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Schaar, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuppeveld, F. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of the host lipid landscape to promote RNA virus replication: the picornavirus encephalomyocarditis virus converges on the pathway used by hepatitis C virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005185</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1005185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26406250" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005185&author=C.+M.+Dorobantuauthor=L.+Albulescuauthor=C.+Harakauthor=Q.+Fengauthor=M.+van+Kampenauthor=J.+R.+Stratingauthor=A.+E.+Gorbalenyaauthor=V.+Lohmannauthor=H.+M.+van+der%0ASchaarauthor=F.+J.+van+Kuppeveld&title=Modulation+of+the+host+lipid+landscape+to+promote+RNA+virus+replication%3A+the+picornavirus+encephalomyocarditis+virus+converges+on+the+pathway+used+by+hepatitis+C+virus&doi=10.1371%2Fjournal.ppat.1005185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005185%26sid%3Dliteratum%253Aachs%26aulast%3DDorobantu%26aufirst%3DC.%2BM.%26aulast%3DAlbulescu%26aufirst%3DL.%26aulast%3DHarak%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3Dvan%2BKampen%26aufirst%3DM.%26aulast%3DStrating%26aufirst%3DJ.%2BR.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3Dvan%2Bder%2BSchaar%26aufirst%3DH.%2BM.%26aulast%3Dvan%2BKuppeveld%26aufirst%3DF.%2BJ.%26atitle%3DModulation%2520of%2520the%2520host%2520lipid%2520landscape%2520to%2520promote%2520RNA%2520virus%2520replication%253A%2520the%2520picornavirus%2520encephalomyocarditis%2520virus%2520converges%2520on%2520the%2520pathway%2520used%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26spage%3De1005185%26doi%3D10.1371%2Fjournal.ppat.1005185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebhan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Brey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erfle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaderali, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poenisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenburg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiet, M.-S.</span></span> <span> </span><span class="NLM_article-title">Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2010.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chom.2010.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21238945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsV2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=32-45&author=S.+Reissauthor=I.+Rebhanauthor=P.+Backesauthor=I.+Romero-Breyauthor=H.+Erfleauthor=P.+Matulaauthor=L.+Kaderaliauthor=M.+Poenischauthor=H.+Blankenburgauthor=M.-S.+Hiet&title=Recruitment+and+activation+of+a+lipid+kinase+by+hepatitis+C+virus+NS5A+is+essential+for+integrity+of+the+membranous+replication+compartment&doi=10.1016%2Fj.chom.2010.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment</span></div><div class="casAuthors">Reiss, Simon; Rebhan, Ilka; Backes, Perdita; Romero-Brey, Ines; Erfle, Holger; Matula, Petr; Kaderali, Lars; Poenisch, Marion; Blankenburg, Hagen; Hiet, Marie-Sophie; Longerich, Thomas; Diehl, Sarah; Ramirez, Fidel; Balla, Tamas; Rohr, Karl; Kaul, Artur; Buehler, Sandra; Pepperkok, Rainer; Lengauer, Thomas; Albrecht, Mario; Eils, Roland; Schirmacher, Peter; Lohmann, Volker; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major causative agent of chronic liver disease in humans.  To gain insight into host factor requirements for HCV replication, the authors performed an siRNA screen of the human kinome and identified 13 different kinases, including phosphatidylinositol-4 kinase III alpha (PI4KIIIα), as being required for HCV replication.  Consistent with elevated levels of the PI4KIIIα product phosphatidylinositol-4-phosphate (PI4P) detected in HCV-infected cultured hepatocytes and liver tissue from chronic hepatitis C patients, the enzymic activity of PI4KIIIα was crit. for HCV replication.  Viral nonstructural protein 5A (NS5A) was found to interact with PI4KIIIα and stimulate its kinase activity.  The absence of PI4KIIIα activity induced a dramatic change in the ultrastructural morphol. of the membranous HCV replication complex.  This anal. suggests that the direct activation of a lipid kinase by HCV NS5A contributes critically to the integrity of the membranous viral replication complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z667iG5LHrVg90H21EOLACvtfcHk0lgnSghFcnAeoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsV2gtw%253D%253D&md5=3ca6a0b604c8f7379ca3d131e8755054</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2010.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2010.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DReiss%26aufirst%3DS.%26aulast%3DRebhan%26aufirst%3DI.%26aulast%3DBackes%26aufirst%3DP.%26aulast%3DRomero-Brey%26aufirst%3DI.%26aulast%3DErfle%26aufirst%3DH.%26aulast%3DMatula%26aufirst%3DP.%26aulast%3DKaderali%26aufirst%3DL.%26aulast%3DPoenisch%26aufirst%3DM.%26aulast%3DBlankenburg%26aufirst%3DH.%26aulast%3DHiet%26aufirst%3DM.-S.%26atitle%3DRecruitment%2520and%2520activation%2520of%2520a%2520lipid%2520kinase%2520by%2520hepatitis%2520C%2520virus%2520NS5A%2520is%2520essential%2520for%2520integrity%2520of%2520the%2520membranous%2520replication%2520compartment%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2011%26volume%3D9%26spage%3D32%26epage%3D45%26doi%3D10.1016%2Fj.chom.2010.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1080/14740338.2017.1313224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1080%2F14740338.2017.1313224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28387147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=547-559&author=M.+Coirasauthor=J.+Ambrosioniauthor=F.+Cervantesauthor=J.+M.+Mir%C3%B3author=J.+Alcam%C3%AD&title=Tyrosine+kinase+inhibitors%3A+potential+use+and+safety+considerations+in+HIV-1+infection&doi=10.1080%2F14740338.2017.1313224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span></div><div class="casAuthors">Coiras, Mayte; Ambrosioni, Juan; Cervantes, Francisco; Miro, Jose M.; Alcami, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-559</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism.  New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection.: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection.  These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia.  The most relevant papers have been selected and commented.: The family of TKIs are directed against the activation of tyrosine kinases from the Src family.  Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1.  During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not.  Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBdl_4AHijwrVg90H21EOLACvtfcHk0lgnSghFcnAeoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D&md5=5976725b6d26c627218be0207febd954</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F14740338.2017.1313224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2017.1313224%26sid%3Dliteratum%253Aachs%26aulast%3DCoiras%26aufirst%3DM.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520potential%2520use%2520and%2520safety%2520considerations%2520in%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2017%26volume%3D16%26spage%3D547%26epage%3D559%26doi%3D10.1080%2F14740338.2017.1313224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddukuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics</span>. <i>Curr. HIV Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.2174/1570162033485339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F1570162033485339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15043199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=131-152&author=C.+de%0Ala+Fuenteauthor=A.+Maddukuriauthor=K.+Kehnauthor=S.+Baylorauthor=L.+Dengauthor=A.+Pumferyauthor=F.+Kashanchi&title=Pharmacological+cyclin-dependent+kinase+inhibitors+as+HIV-1+antiviral+therapeutics&doi=10.2174%2F1570162033485339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics</span></div><div class="casAuthors">de la Fuente, Cynthia; Maddukuri, Anil; Kehn, Kylene; Baylor, Shanese Y.; Deng, Longwen; Pumfery, Anne; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Current HIV Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-152</span>CODEN:
                <span class="NLM_cas:coden">CHRUBF</span>;
        ISSN:<span class="NLM_cas:issn">1570-162X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human immunodeficiency virus type 1 (HIV-1) can infect quiescent cells; however, viral prodn. is restricted to actively proliferating cells.  Recent evidence has indicated that HIV-1 viral proteins, Vpr and Tat, perturb the cell cycle to optimize HIV-1 replication.  Vpr arrests the cell cycle at G2 by inactivating the cyclin B/cdk1 complex.  Tat regulates the cell cycle by altering factors involved in proliferation and differentiation (i.e. the cdk inhibitor p21/waf1) and assocg. with cyclin/cdk complexes (i.e. cyclin E/cdk2, cyclin H/cdk7, and cyclin T/cdk9).  These studies indicate the importance of host cellular factors, such as cyclin/cdk complexes, in regulating HIV-1 replication and therefore represent novel targets for antiviral therapeutics.  Recently, the efficacy of pharmalogical cdk inhibitors (PCIs) in abrogating viral replication has been under development.  To date there are 25-30 PCIs that have been synthesized against known cdks, several of which have been shown to inhibit HIV-1 and other AIDS-assocd. viruses in vitro and in vivo.  Targeting these crit. cyclin/cdk complexes needed for viral propagation may solve the problems inherent in current HAART therapy, including the emergence of drug-resistant viruses.  Thus, PCIs have the potential to become novel therapeutic antiviral drugs that can inhibit HIV-1 transcription and opens the possibility of new avenues of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTg2I_nNlevbVg90H21EOLACvtfcHk0lgzirhsKYYGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLc%253D&md5=b4adf0a50049e89da64e1d4a374031c2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1570162033485339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570162033485339%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DC.%26aulast%3DMaddukuri%26aufirst%3DA.%26aulast%3DKehn%26aufirst%3DK.%26aulast%3DBaylor%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DPharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520as%2520HIV-1%2520antiviral%2520therapeutics%26jtitle%3DCurr.%2520HIV%2520Res.%26date%3D2003%26volume%3D1%26spage%3D131%26epage%3D152%26doi%3D10.2174%2F1570162033485339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases as cellular targets for antiviral drugs</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1093/jac/dkf227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdkf227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12460995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2002&pages=779-792&author=L.+M.+Schang&title=Cyclin-dependent+kinases+as+cellular+targets+for+antiviral+drugs&doi=10.1093%2Fjac%2Fdkf227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases as cellular targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-792</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are required for replication of viruses that replicate only in dividing cells, such as adeno- and papillomaviruses.  Recently, cdks have been shown to be required also for replication of viruses that can replicate in non-dividing cells, such as HIV-1 and herpes simplex virus types 1 and 2 (HSV-1 and -2).  In these expts., pharmacol. cdk inhibitors (PCIs) were shown to have potent antiviral activity in vitro against HIV-1, HSV-1 and -2, human cytomegalovirus, varicella-zoster virus, and to inhibit specific functions of other viruses.  Since two PCIs, flavopiridol and roscovitine, are proving to be non-toxic in human clin. trials against cancer, PCIs may be useful as antivirals.  As significant advantages, PCIs are active in vitro against many viruses, including drug-resistant strains of HIV-1 and HSV-1, and mutant strains of HIV-1 or HSV-1 resistant to PCIs have not been identified in spite of intense efforts.  Furthermore, the antiviral effects of a PCI and a conventional antiviral drug are additive.  The etiopathogenesis of several diseases, such as Kaposi's sarcoma, HPV-induced cervical carcinoma and HIV-assocd. nephropathy (HIVAN), among others, includes replication or expression of proteins by viruses that require cdks.  Thus, PCIs could target both the etiol. agent (the virus) and the pathogenic mechanisms (cell replication).  Two important questions regarding the antiviral activities of PCIs are the focus of current research efforts, (i) the identity of the specific cdks that mediate the antiviral activities of PCIs, and (ii) whether PCIs have antiviral activity in vivo at non-toxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw9wi9L1YWErVg90H21EOLACvtfcHk0lgzirhsKYYGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlOisb8%253D&md5=d82217067f547370d4d3e8e692da0e43</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkf227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkf227%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DCyclin-dependent%2520kinases%2520as%2520cellular%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2002%26volume%3D50%26spage%3D779%26epage%3D792%26doi%3D10.1093%2Fjac%2Fdkf227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1697</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbapap.2003.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=197-209&author=L.+M.+Schang&title=Effects+of+pharmacological+cyclin-dependent+kinase+inhibitors+on+viral+transcription+and+replication&doi=10.1016%2Fj.bbapap.2003.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">197-209</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (CDKs) are required for replication of adeno-, papilloma- and other viruses that replicate only in dividing cells.  Surprisingly, CDKs are also required for replication of HIV-1, HSV-1, and other viruses that can replicate in nondividing cells.  Since two low-mol. wt. pharmacol. CDK inhibitors (PCIs), flavopiridol (Flavo) and roscovitine (Rosco), appear to be nontoxic in human clin. trials against cancer, these drugs have been proposed as potential antiviral drugs.  Rosco preferentially inhibits CDKs involved in cell cycle regulation (CDK1, 2, and 7) or neuronal functions (CDK5), whereas Flavo preferentially inhibits CDKs involved in cell cycle (CDK1, 2, 4, 7) or transcription (CDK7, and 9).  As potential antivirals, PCIs display several advantages: (i) they are active against many different viruses, including drug-resistant strains of HIV-1 and HSV-1; (ii) PCI-resistant mutants of HIV-1 or HSV-1 have not been identified; and (iii) the antiviral effects of PCIs and conventional antivirals appear to be additive (as expected from drugs that target independent pathways).  Moreover, PCIs target both the etiol. agents (i.e., the virus) and the pathogenic mechanisms (i.e., unrestricted cell division) of the many diseases that include both a CDK-requiring virus and unrestricted cell division (e.g., Kaposi's sarcoma, cervical carcinoma, HIV-assocd. nephropathy-HIVAN).  This is nicely illustrated in a recent study which demonstrated the efficacy of Flavo in a mouse model of HIVAN.  Herein, the authors will review the involvement of CDKs in viral replication and the antiviral properties of the most extensively characterized PCIs, with special emphasis on the mechanisms of inhibition of viral transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1qZrRElz5C7Vg90H21EOLACvtfcHk0lgzirhsKYYGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsL0%253D&md5=43453bb6646be8d728bcc767adaef5c7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DEffects%2520of%2520pharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520on%2520viral%2520transcription%2520and%2520replication%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D197%26epage%3D209%26doi%3D10.1016%2Fj.bbapap.2003.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+cyclin-dependent+kinases+%28CDKs%29+as+novel+targets+for+antiviral+drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0lgzirhsKYYGkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%2520as%2520novel%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M+Schangauthor=M.+R+St.+Vincentauthor=J.+J+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0lgvJjOkDGTfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR%26aulast%3DLacasse%26aufirst%3DJ.%2BJ%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1054/drup.2000.0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1054%2Fdrup.2000.0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11498372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlyhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2000&pages=83-88&author=L.+Meijer&title=Cyclin-dependent+kinases+inhibitors+as+potential+anticancer%2C+antineurodegenerative%2C+antiviral+and+antiparasitic+agents&doi=10.1054%2Fdrup.2000.0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents</span></div><div class="casAuthors">Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 45 refs.  Cyclin-dependent kinases (CDKs) play a key role in the cell division cycle, in neuronal functions, in transcription and in apoptosis.  Intensive screening with these kinases as targets has lead to the identification of highly selective and potent small-mol. inhibitors.  Co-crystn. with CDK2 shows that these flat heterocyclic hydrophobic compds. bind through two or three hydrogen bonds with the side chains of two amino acids located in the ATP-binding pocket of the kinase.  These inhibitors are anti-proliferative; they arrest cells in G1 and in G2/M phase.  Furthermore they facilitate or even trigger apoptosis in proliferating cells while they protect neuronal cells and thymocytes from apoptosis.  The potential use of these inhibitors is being extensively evaluated for cancer chemotherapy and also in other therapeutic areas: neurol. (Alzheimer's disease), cardiovascular (restenosis, angiogenesis), nephrol. (glomerulonephritis), parasitol. (Plasmodium, Trypanosoma, Toxoplasma, etc.) and virol. (cytomegalovirus, HIV, herpes virus).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMVv2fRjR-LVg90H21EOLACvtfcHk0lgvJjOkDGTfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlyhu70%253D&md5=bd8a547eb685d8874330ff8207581bd8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1054%2Fdrup.2000.0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.2000.0129%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DCyclin-dependent%2520kinases%2520inhibitors%2520as%2520potential%2520anticancer%252C%2520antineurodegenerative%252C%2520antiviral%2520and%2520antiparasitic%2520agents%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2000%26volume%3D3%26spage%3D83%26epage%3D88%26doi%3D10.1054%2Fdrup.2000.0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1586/14787210.4.6.953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1586%2F14787210.4.6.953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17181411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=953-956&author=L.+M.+Schang&title=First+demonstration+of+the+effectiveness+of+inhibitors+of+cellular+protein+kinases+in+antiviral+therapy&doi=10.1586%2F14787210.4.6.953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">953-956</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Viral replication and pathogenesis involves many cellular protein kinases, and many specific inhibitors of such kinase have been developed for the treatment of noninfectious diseases.  As expected, such drugs have been repeatedly demonstrated to inhibit viral replication in cultured cells.  Cellular protein kinases have thus been considered for several years as potentially valid targets for antiviral therapy.  However, until recently there was no proof of such activity in vivo.  The three papers discussed herein demonstrate that inhibitors of cellular protein kinases are indeed effective for the treatment of virus-induced disease in animal models and human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9R2Lm_fQr8bVg90H21EOLACvtfcHk0lgvJjOkDGTfXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGru78%253D&md5=6564e6af860cf5f1335917339861a78c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1586%2F14787210.4.6.953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.4.6.953%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DFirst%2520demonstration%2520of%2520the%2520effectiveness%2520of%2520inhibitors%2520of%2520cellular%2520protein%2520kinases%2520in%2520antiviral%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2006%26volume%3D4%26spage%3D953%26epage%3D956%26doi%3D10.1586%2F14787210.4.6.953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Torres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Jose, E.</span></span> <span> </span><span class="NLM_article-title">Src tyrosine kinase inhibitors: New perspectives on their immune, antiviral, and senotherapeutic potential</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1011</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffphar.2019.01011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31619990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1011&author=J.+Rivera-Torresauthor=E.+San+Jose&title=Src+tyrosine+kinase+inhibitors%3A+New+perspectives+on+their+immune%2C+antiviral%2C+and+senotherapeutic+potential&doi=10.3389%2Ffphar.2019.01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential</span></div><div class="casAuthors">Rivera-Torres Jose; San Jose Esther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1011</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Deregulated activity of the Src tyrosine kinases leads to malignant transformation.  Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has increased notably due to their beneficial effects.  Dasatinib, a second-generation STKI inhibitor widely studied, proved high efficiency in CML patients resistant to imatinib.  In the last decade STKIs have also been implicated and showed therapeutic potential for the treatment of diverse pathologies other than cancer.  In this regard, we review the properties of STKIs, dasatinib in particular, including its immunomodulatory role.  Similarly, the potential benefits, adverse effects, and safety concerns of these inhibitors regarding viral infections are considered.  Moreover, since life expectancy has increased in the last decades accompanied by age-related morbidity, the reduction of undesirable effects associated to aging has become a powerful therapeutic target.  Here, we comment on the ability of STKIs to alleviate age-associated physical dysfunction and their potential impact in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuB58-0Ghq7mQt-ICR3qNfW6udTcc2eaR1LevglARzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D&md5=abb7070b94a2328a1c01559aecbeb7d5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01011%26sid%3Dliteratum%253Aachs%26aulast%3DRivera-Torres%26aufirst%3DJ.%26aulast%3DSan%2BJose%26aufirst%3DE.%26atitle%3DSrc%2520tyrosine%2520kinase%2520inhibitors%253A%2520New%2520perspectives%2520on%2520their%2520immune%252C%2520antiviral%252C%2520and%2520senotherapeutic%2520potential%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1011%26doi%3D10.3389%2Ffphar.2019.01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span> <span> </span><span class="NLM_article-title">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/S1471-4914(02)00010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS1471-4914%2802%2900010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12615037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=46-52&author=S.+Ludwigauthor=O.+Planzauthor=S.+Pleschkaauthor=T.+Wolff&title=Influenza-virus-induced+signaling+cascades%3A+targets+for+antiviral+therapy%3F&doi=10.1016%2FS1471-4914%2802%2900010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span></div><div class="casAuthors">Ludwig, Stephan; Planz, Oliver; Pleschka, Stephan; Wolff, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">46-52</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Influenza viruses continue to pose a severe threat worldwide, causing thousands of deaths and an enormous economic loss every year.  The major problem in fighting influenza is the high genetic variability of the virus, resulting in the rapid formation of variants that escape the acquired immunity against previous virus strains, or have resistance to antiviral agents.  Every virus depends on its host cell and, hence, cellular functions that are essential for viral replication might be suitable targets for antiviral therapy.  As a result, intracellular signaling cascades induced by the virus, in particular mitogen-activated protein kinase pathways, have recently come into focus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTupjREwwibVg90H21EOLACvtfcHk0lhwYoJOLAgWeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D&md5=0824b4a81b06874f3a8e4964e4737eb8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2900010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252900010-2%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26atitle%3DInfluenza-virus-induced%2520signaling%2520cascades%253A%2520targets%2520for%2520antiviral%2520therapy%253F%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D46%26epage%3D52%26doi%3D10.1016%2FS1471-4914%2802%2900010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23603495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=457-468&author=O.+Planz&title=Development+of+cellular+signaling+pathway+inhibitors+as+new+antivirals+against+influenza&doi=10.1016%2Fj.antiviral.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span></div><div class="casAuthors">Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-468</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Influenza virus exploits a no. of cellular signaling pathways during the course of its replication, rendering them potential targets for new therapeutic interventions.  Several preclin. approaches are now focusing on cellular factors or pathways as a means of treating influenza.  By targeting host factors, rather than viral mechanisms, these novel therapies may be effective against multiple virus strains and subtypes, and are less likely to elicit viral drug resistance.  The most promising candidates are inhibitors of intracellular signaling cascades that are essential for virus replication.  This article reviews novel approaches and compds. that target the Raf/MEK/ERK signaling pathway, NF-κB signaling, the PI3K/Akt pathway and the PKC signaling cascade.  Although these new antiviral strategies are still in an early phase of preclin. development, results to date suggest they offer a new approach to the treatment of influenza, supplementing direct-acting antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk82XeTtb077Vg90H21EOLACvtfcHk0lhwYoJOLAgWeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D&md5=51b9a73e0faa5a894c7cef307cda92cd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520cellular%2520signaling%2520pathway%2520inhibitors%2520as%2520new%2520antivirals%2520against%2520influenza%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D457%26epage%3D468%26doi%3D10.1016%2Fj.antiviral.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Influenza virus infections and cellular kinases</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.3390/v11020171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv11020171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=171&author=R.+Meinekeauthor=G.+F.+Rimmelzwaanauthor=H.+Elbahesh&title=Influenza+virus+infections+and+cellular+kinases&doi=10.3390%2Fv11020171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus infections and cellular kinases</span></div><div class="casAuthors">Meineke, Robert; Rimmelzwaan, Guus F.; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Influenza A viruses (IAVs) are a major cause of respiratory illness and are responsible for yearly epidemics assocd. with more than 500,000 annual deaths globally.  Novel IAVs may cause pandemic outbreaks and zoonotic infections with, for example, highly pathogenic avian influenza virus (HPAIV) of the H5N1 and H7N9 subtypes, which pose a threat to public health.  Treatment options are limited and emergence of strains resistant to antiviral drugs jeopardize this even further.  Like all viruses, IAVs depend on host factors for every step of the virus replication cycle.  Host kinases link multiple signaling pathways in respond to a myriad of stimuli, including viral infections.  Their regulation of multiple response networks has justified actively targeting cellular kinases for anti-cancer therapies and immune modulators for decades.  There is a growing vol. of research highlighting the significant role of cellular kinases in regulating IAV infections.  Their functional role is illustrated by the required phosphorylation of several IAV proteins necessary for replication and/or evasion/suppression of the innate immune response.  Identified in the majority of host factor screens, functional studies further support the important role of kinases and their potential as host restriction factors.  PKC, ERK, PI3K and FAK, to name a few, are kinases that regulate viral entry and replication.  Addnl., kinases such as IKK, JNK and p38 MAPK are essential in mediating viral sensor signaling cascades that regulate expression of antiviral chemokines and cytokines.  The feasibility of targeting kinases is steadily moving from bench to clinic and already-approved cancer drugs could potentially be repurposed for treatments of severe IAV infections.  In this review, we will focus on the contribution of cellular kinases to IAV infections and their value as potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSc-PzlVOvnrVg90H21EOLACvtfcHk0lhwYoJOLAgWeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI&md5=7f0bed27a7c1bf8ea5c8870c7533f087</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fv11020171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11020171%26sid%3Dliteratum%253Aachs%26aulast%3DMeineke%26aufirst%3DR.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DInfluenza%2520virus%2520infections%2520and%2520cellular%2520kinases%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D171%26doi%3D10.3390%2Fv11020171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broad-spectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broad-spectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0liRvDorwxalcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0liRvDorwxalcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonotto, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas-Junior, L. H.</span></span> <span> </span><span class="NLM_article-title">Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2471</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0002471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24205414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVentbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2471&author=D.+J.+Cruzauthor=R.+M.+Bonottoauthor=R.+G.+Gomesauthor=C.+T.+da+Silvaauthor=J.+B.+Taniguchiauthor=J.+H.+Noauthor=B.+Lombardotauthor=O.+Schwartzauthor=M.+A.+Hansenauthor=L.+H.+Freitas-Junior&title=Identification+of+novel+compounds+inhibiting+chikungunya+virus-induced+cell+death+by+high+throughput+screening+of+a+kinase+inhibitor+library&doi=10.1371%2Fjournal.pntd.0002471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library</span></div><div class="casAuthors">Cruz, Deu John M.; Bonotto., Rafaela M.; Gomes, Rafael G. B.; da Silva, Camila T.; Taniguchi, Juliana B.; No, Joo Hwan; Lombardot, Benoit; Schwartz, Olivier; Hansen, Michael A. E.; Freitas, Lucio H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e2471/1-e2471/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Chikungunya virus (CHIKV) is a mosquito-borne arthrogenic alphavirus that causes acute febrile illness in humans accompanied by joint pains and in many cases, persistent arthralgia lasting weeks to years.  The re-emergence of CHIKV has resulted in numerous outbreaks in the eastern hemisphere, and threatens to expand in the foreseeable future.  Unfortunately, no effective treatment is currently available.  The present study reports the use of resazurin in a cell-based high-throughput assay, and an image-based high-content assay to identify and characterize inhibitors of CHIKV-infection in vitro.  CHIKV is a highly cytopathic virus that rapidly kills infected cells.  Thus, cell viability of HuH-7 cells infected with CHIKV in the presence of compds. was detd. by measuring metabolic redn. of resazurin to identify inhibitors of CHIKV-assocd. cell death.  A kinase inhibitor library of 4,000 compds. was screened against CHIKV infection of HuH-7 cells using the resazurin redn. assay, and the cell toxicity was also measured in non-infected cells.  Seventy-two compds. showing ≥50% inhibition property against CHIKV at 10 μM were selected as primary hits.  Four compds. having a benzofuran core scaffold (CND0335, CND0364, CND0366 and CND0415), one pyrrolopyridine (CND0545) and one thiazol-carboxamide (CND3514) inhibited CHIKV-assocd. cell death in a dose-dependent manner, with EC50 values between 2.2 μM and 7.1 μM.  Based on image anal., these 6 hit compds. did not inhibit CHIKV replication in the host cell.  However, CHIKV-infected cells manifested less prominent apoptotic blebs typical of CHIKV cytopathic effect compared with the control infection.  Moreover, treatment with these compds. reduced viral titers in the medium of CHIKV-infected cells by up to 100-fold.  In conclusion, this cell-based high-throughput screening assay using resazurin, combined with the image-based high content assay approach identified compds. against CHIKV having a novel antiviral activity - inhibition of virus-induced CPE - likely by targeting kinases involved in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa0Hv1LPscxbVg90H21EOLACvtfcHk0liRvDorwxalcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVentbc%253D&md5=c6eef7d6930dd18523ed74770fb75791</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002471%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DD.%2BJ.%26aulast%3DBonotto%26aufirst%3DR.%2BM.%26aulast%3DGomes%26aufirst%3DR.%2BG.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BT.%26aulast%3DTaniguchi%26aufirst%3DJ.%2BB.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DLombardot%26aufirst%3DB.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DHansen%26aufirst%3DM.%2BA.%26aulast%3DFreitas-Junior%26aufirst%3DL.%2BH.%26atitle%3DIdentification%2520of%2520novel%2520compounds%2520inhibiting%2520chikungunya%2520virus-induced%2520cell%2520death%2520by%2520high%2520throughput%2520screening%2520of%2520a%2520kinase%2520inhibitor%2520library%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2471%26doi%3D10.1371%2Fjournal.pntd.0002471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streblow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defilippis, V. R.</span></span> <span> </span><span class="NLM_article-title">Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1128/JVI.00767-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00767-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20962078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=606-620&author=L.+K.+Whiteauthor=T.+Saliauthor=D.+Alvaradoauthor=E.+Gattiauthor=P.+Pierreauthor=D.+Streblowauthor=V.+R.+Defilippis&title=Chikungunya+virus+induces+IPS-1-dependent+innate+immune+activation+and+protein+kinase+R-independent+translational+shutoff&doi=10.1128%2FJVI.00767-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff</span></div><div class="casAuthors">White, Laura K.; Sali, Tina; Alvarado, David; Gatti, Evelina; Pierre, Philippe; Streblow, Daniel; DeFilippis, Victor R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">606-620</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chikungunya virus (CHIKV) is an arthritogenic mosquito-transmitted alphavirus that is undergoing re-emergence in areas around the Indian Ocean.  Despite the current and potential danger posed by this virus, we know surprisingly little about the induction and evasion of CHIKV-assocd. antiviral immune responses.  With this in mind we investigated innate immune reactions to CHIKV in human fibroblasts, a demonstrable in vivo target of virus replication and spread.  We show that CHIKV infection leads to activation of the transcription factor interferon regulatory factor 3 (IRF3) and subsequent transcription of IRF3-dependent antiviral genes, including beta interferon (IFN-β).  IRF3 activation occurs by way of a virus-induced innate immune signaling pathway that includes the adaptor mol. interferon promoter stimulator 1 (IPS-1).  Despite strong transcriptional upregulation of these genes, however, translation of the corresponding proteins is not obsd.  We further demonstrate that translation of cellular (but not viral) genes is blocked during infection and that although CHIKV is found to trigger inactivation of the translational mol. eukaryotic initiation factor subunit 2α by way of the double-stranded RNA sensor protein kinase R, this response is not required for the block to protein synthesis.  Furthermore, overall diminution of cellular RNA synthesis is also obsd. in the presence of CHIKV and transcription of IRF3-dependent antiviral genes appears specifically blocked late in infection.  We hypothesize that the obsd. absence of IFN-β and antiviral proteins during infection results from an evasion mechanism exhibited by CHIKV that is dependent on widespread shutoff of cellular protein synthesis and a targeted block to late synthesis of antiviral mRNA transcripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrds1AGp9cI97Vg90H21EOLACvtfcHk0lgjLDfd69mNSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCisrw%253D&md5=dec2018815e86466c4c520b2f2c47ffd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FJVI.00767-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00767-10%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DL.%2BK.%26aulast%3DSali%26aufirst%3DT.%26aulast%3DAlvarado%26aufirst%3DD.%26aulast%3DGatti%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DStreblow%26aufirst%3DD.%26aulast%3DDefilippis%26aufirst%3DV.%2BR.%26atitle%3DChikungunya%2520virus%2520induces%2520IPS-1-dependent%2520innate%2520immune%2520activation%2520and%2520protein%2520kinase%2520R-independent%2520translational%2520shutoff%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D606%26epage%3D620%26doi%3D10.1128%2FJVI.00767-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koishi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan Bonotto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windisch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona
Mosimann, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Borba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes Duarte dos Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas-Junior, L. H.</span></span> <span> </span><span class="NLM_article-title">High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2073</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0002073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23437413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2073&author=D.+J.+M.+Cruzauthor=A.+C.+Koishiauthor=J.+B.+Taniguchiauthor=X.+Liauthor=R.+Milan+Bonottoauthor=J.+H.+Noauthor=K.+H.+Kimauthor=S.+Baekauthor=H.+Y.+Kimauthor=M.+P.+Windischauthor=A.+L.+Pamplona%0AMosimannauthor=L.+de+Borbaauthor=M.+Liuzziauthor=M.+A.+E.+Hansenauthor=C.+Nunes+Duarte+dos+Santosauthor=L.+H.+Freitas-Junior&title=High+content+screening+of+a+kinase-focused+library+reveals+compounds+broadly-active+against+dengue+viruses&doi=10.1371%2Fjournal.pntd.0002073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses</span></div><div class="casAuthors">Cruz, Deu John M.; Koishi, Andrea Cristine; Taniguchi, Juliana Bosso; Li, Xiaolan; Milan Bonotto, Rafaela; No, Joo Hwan; Kim, Keum Hyun; Baek, Sungmin; Kim, Hee Young; Windisch, Marc Peter; Mosimann, Ana Luiza Pamplona; de Borba, Luana; Liuzzi, Michel; Hansen, Michael Adsetts Edberg; Duarte dos Santos, Claudia Nunes; Freitas, Lucio Holanda, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e2073</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that has a large impact in global health.  It is considered as one of the medically important arboviruses, and developing a preventive or therapeutic soln. remains a top priority in the medical and scientific community.  Drug discovery programs for potential dengue antivirals have increased dramatically over the last decade, largely in part to the introduction of high-throughput assays.  In this study, we have developed an image-based dengue high-throughput/high-content assay (HT/HCA) using an innovative computer vision approach to screen a kinase-focused library for anti-dengue compds.  Using this dengue HT/HCA, we identified a group of compds. with a 4-(1-aminoethyl)-N-methylthiazol-2-amine as a common core structure that inhibits dengue viral infection in a human liver-derived cell line (Huh-7.5 cells).  Compds. CND1201, CND1203 and CND1243 exhibited strong antiviral activities against all four dengue serotypes.  Plaque redn. and time-of-addn. assays suggests that these compds. interfere with the late stage of viral infection cycle.  These findings demonstrate that our image-based dengue HT/HCA is a reliable tool that can be used to screen various chem. libraries for potential dengue antiviral candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRQ5DwXVJ77rVg90H21EOLACvtfcHk0lgjLDfd69mNSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSktrg%253D&md5=15cc205a49dce6b94d44d9a6ff3a5de9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002073%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DKoishi%26aufirst%3DA.%2BC.%26aulast%3DTaniguchi%26aufirst%3DJ.%2BB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMilan%2BBonotto%26aufirst%3DR.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBaek%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DWindisch%26aufirst%3DM.%2BP.%26aulast%3DPamplona%2BMosimann%26aufirst%3DA.%2BL.%26aulast%3Dde%2BBorba%26aufirst%3DL.%26aulast%3DLiuzzi%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DM.%2BA.%2BE.%26aulast%3DNunes%2BDuarte%2Bdos%2BSantos%26aufirst%3DC.%26aulast%3DFreitas-Junior%26aufirst%3DL.%2BH.%26atitle%3DHigh%2520content%2520screening%2520of%2520a%2520kinase-focused%2520library%2520reveals%2520compounds%2520broadly-active%2520against%2520dengue%2520viruses%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2073%26doi%3D10.1371%2Fjournal.pntd.0002073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhinder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Früh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaballah, H.</span></span> <span> </span><span class="NLM_article-title">High-content assay to identify inhibitors of dengue virus infection</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1089/adt.2010.0321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fadt.2010.0321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20973722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlensLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=553-570&author=D.+Shumauthor=J.+L.+Smithauthor=A.+J.+Hirschauthor=B.+Bhinderauthor=C.+Raduauthor=D.+A.+Steinauthor=J.+A.+Nelsonauthor=K.+Fr%C3%BChauthor=H.+Djaballah&title=High-content+assay+to+identify+inhibitors+of+dengue+virus+infection&doi=10.1089%2Fadt.2010.0321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">High-Content Assay to Identify Inhibitors of Dengue Virus Infection</span></div><div class="casAuthors">Shum, David; Smith, Jessica L.; Hirsch, Alec J.; Bhinder, Bhavneet; Radu, Constantin; Stein, David A.; Nelson, Jay A.; Frueh, Klaus; Djaballah, Hakim</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-570</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually.  Current treatments for DENV infections are nonspecific and largely ineffective.  In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection.  Using this high-content approach, we monitored the inhibition of test compds. on DENV protein prodn. by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells.  The adapted 384-well microtiter-based assay was validated using a small panel of compds. previously reported as having inhibitory activity against DENV infections of cell cultures, including compds. with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan).  A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S.  Food and Drug Administration-approved drugs.  Assay control statistics show an av. Z' of 0.63, indicative of a robust assay in this cell-based format.  Using a threshold of >80% DENV inhibition with <20% cellular cytotoxicity, 79 compds. were initially scored as pos. hits.  A follow-up screen confirmed 73 compds. with IC50 potencies ranging from 60 nM to 9 μM and yielding a hit rate of 1.3%.  Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections.  In summary, this assay offers the opportunity to screen libraries of chem. compds., in an effort to identify and develop novel drug candidates against DENV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4SAeXBIEKdrVg90H21EOLACvtfcHk0lgjLDfd69mNSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlensLnK&md5=12e918bb02e9660011cc03e0f170450d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0321%26sid%3Dliteratum%253Aachs%26aulast%3DShum%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DHirsch%26aufirst%3DA.%2BJ.%26aulast%3DBhinder%26aufirst%3DB.%26aulast%3DRadu%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DD.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26aulast%3DFr%25C3%25BCh%26aufirst%3DK.%26aulast%3DDjaballah%26aufirst%3DH.%26atitle%3DHigh-content%2520assay%2520to%2520identify%2520inhibitors%2520of%2520dengue%2520virus%2520infection%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D553%26epage%3D570%26doi%3D10.1089%2Fadt.2010.0321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, P. A.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">104621</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31634495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=104621&author=D.+J.+Viegasauthor=T.+G.+Edwardsauthor=D.+C.+Bloomauthor=P.+A.+Abreu&title=Virtual+screening+identified+compounds+that+bind+to+cyclin+dependent+kinase+2+and+prevent+herpes+simplex+virus+type+1+replication+and+reactivation+in+neurons&doi=10.1016%2Fj.antiviral.2019.104621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons</span></div><div class="casAuthors">Viegas, Daiane J.; Edwards, Terri G.; Bloom, David C.; Abreu, Paula A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104621</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSV-1 is one of the most prevalent viruses worldwide, and due to the limited therapies mainly with acyclovir and analogs and the emergence of acyclovir (ACV) resistant strains, the search for new drugs with different modes of action is needed.  This study identified compds. that bind in silico to cyclin dependent kinase 2 (CDK2), a cellular enzyme required for efficient HSV-1 replication, and have anti-HSV-1 activity.  Compds. obtained from virtual screening by Pharmit were filtered in FAF-Drugs4 for good pharmacokinetic and toxicol. profiles and submitted to mol. docking on CDK2 using Autodock Vina.  The six most promising compds. were evaluated for inhibiting lytic replication of HSV-1 wild-type and ACV-resistant strains on human fibroblasts.  The compds. were also assayed for cytotoxicity.  Compds. 1, 2 and 3 showed antiviral activity with EC50 (50% of effective drug concn.) of 32, 29 and 64μM and CC50 (50% of cytotoxic concn.) of 159, 1410 and 2044μM, resp.  Compds. 1 and 2 were also active against ACV resistant strains and compd. 3 inhibited the reactivation of HSV-1 in neurons, which is an important finding to guide drug design of new anti-HSV-1 antivirals with different modes of action.  These compds. are promising candidates for optimization into more potent agents to treat HSV-1 infections and recurrences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dRyfoHYEb7Vg90H21EOLACvtfcHk0ljoZiHsyGCx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrsbfP&md5=4266502f994c2a88e52581049e049cc7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104621%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DD.%2BJ.%26aulast%3DEdwards%26aufirst%3DT.%2BG.%26aulast%3DBloom%26aufirst%3DD.%2BC.%26aulast%3DAbreu%26aufirst%3DP.%2BA.%26atitle%3DVirtual%2520screening%2520identified%2520compounds%2520that%2520bind%2520to%2520cyclin%2520dependent%2520kinase%25202%2520and%2520prevent%2520herpes%2520simplex%2520virus%2520type%25201%2520replication%2520and%2520reactivation%2520in%2520neurons%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D172%26spage%3D104621%26doi%3D10.1016%2Fj.antiviral.2019.104621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.+K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.+L.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of ∼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0ljoZiHsyGCx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%2BK.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.%2BL.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emert-Sedlak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithgall, T. E.</span></span> <span> </span><span class="NLM_article-title">Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1021/cb900195c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb900195c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=939-947&author=L.+Emert-Sedlakauthor=T.+Kodamaauthor=E.+C.+Lernerauthor=W.+Daiauthor=C.+Fosterauthor=B.+W.+Dayauthor=J.+S.+Lazoauthor=T.+E.+Smithgall&title=Chemical+library+screens+targeting+an+HIV-1+accessory+factor%2Fhost+cell+kinase+complex+identify+novel+antiretroviral+compounds&doi=10.1021%2Fcb900195c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Library Screens Targeting an HIV-1 Accessory Factor/Host Cell Kinase Complex Identify Novel Antiretroviral Compounds</span></div><div class="casAuthors">Emert-Sedlak, Lori; Kodama, Toshiaki; Lerner, Edwina C.; Dai, Weixiang; Foster, Caleb; Day, Billy W.; Lazo, John S.; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">939-947</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nef is an HIV-1 accessory protein essential for AIDS progression and an attractive target for drug discovery.  Lack of a catalytic function makes Nef difficult to assay in chem. library screens.  We developed a high-throughput screening assay for inhibitors of Nef function by coupling it to one of its host cell binding partners, the Src-family kinase Hck.  Hck activation is dependent upon Nef in this assay, providing a direct readout of Nef activity in vitro.  Using this screen, a unique diphenylfuropyrimidine was identified as a strong inhibitor of Nef-dependent Hck activation.  This compd. also exhibited remarkable antiretroviral effects, blocking Nef-dependent HIV replication in cell culture.  Structurally related analogs were synthesized and shown to exhibit similar Nef-dependent antiviral activity, identifying the diphenylfuropyrimidine substructure as a new lead for antiretroviral drug development.  This study demonstrates that coupling noncatalytic HIV accessory factors with host cell target proteins addressable by high-throughput assays may afford new avenues for the discovery of anti-HIV agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YEk6ygTwPrVg90H21EOLACvtfcHk0ljoZiHsyGCx_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmurvJ&md5=53140299c379a88c02ac9c9c4a7c138b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fcb900195c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb900195c%26sid%3Dliteratum%253Aachs%26aulast%3DEmert-Sedlak%26aufirst%3DL.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DLerner%26aufirst%3DE.%2BC.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DChemical%2520library%2520screens%2520targeting%2520an%2520HIV-1%2520accessory%2520factor%252Fhost%2520cell%2520kinase%2520complex%2520identify%2520novel%2520antiretroviral%2520compounds%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D939%26epage%3D947%26doi%3D10.1021%2Fcb900195c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emert-Sedlak, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narute, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanamala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithgall, T. E.</span></span> <span> </span><span class="NLM_article-title">Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2012.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23352142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=82-91&author=L.+A.+Emert-Sedlakauthor=P.+Naruteauthor=S.+T.+Shuauthor=J.+A.+Poeauthor=H.+Shiauthor=N.+Yanamalaauthor=J.+J.+Alvaradoauthor=J.+S.+Lazoauthor=J.+I.+Yehauthor=P.+A.+Johnstonauthor=T.+E.+Smithgall&title=Effector+kinase+coupling+enables+high-throughput+screens+for+direct+HIV-1+Nef+antagonists+with+antiretroviral+activity&doi=10.1016%2Fj.chembiol.2012.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effector Kinase Coupling Enables High-Throughput Screens for Direct HIV-1 Nef Antagonists with Antiretroviral Activity</span></div><div class="casAuthors">Emert-Sedlak, Lori A.; Narute, Purushottam; Shu, Sherry T.; Poe, Jerrod A.; Shi, Haibin; Yanamala, Naveena; Alvarado, John Jeff; Lazo, John S.; Yeh, Joanne I.; Johnston, Paul A.; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">HIV-1 Nef, a crit. AIDS progression factor, represents an important target protein for antiretroviral drug discovery.  Because Nef lacks intrinsic enzymic activity, we developed an assay that couples Nef to the activation of Hck, a Src family member and .  Using this assay, we screened a large, diverse chem. library and identified small mols. that block Nef-dependent Hck activity with low micromolar potency.  Of these, a diphenylpyrazolo compd. demonstrated submicromolar potency in HIV-1 replication assays against a broad range of primary Nef variants.  This compd. binds directly to Nef via a pocket formed by the Nef dimerization interface and disrupts Nef dimerization in cells.  Coupling of nonenzymic viral accessory factors to host cell effector proteins amenable to high-throughput screening may represent a general strategy for the discovery of new antimicrobial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BIbLPKgxrLVg90H21EOLACvtfcHk0ljv0zG4w9Pgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eguro%253D&md5=5bf45fa525e60bc84cf23d1615e6be93</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DEmert-Sedlak%26aufirst%3DL.%2BA.%26aulast%3DNarute%26aufirst%3DP.%26aulast%3DShu%26aufirst%3DS.%2BT.%26aulast%3DPoe%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYanamala%26aufirst%3DN.%26aulast%3DAlvarado%26aufirst%3DJ.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DYeh%26aufirst%3DJ.%2BI.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DEffector%2520kinase%2520coupling%2520enables%2520high-throughput%2520screens%2520for%2520direct%2520HIV-1%2520Nef%2520antagonists%2520with%2520antiretroviral%2520activity%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.chembiol.2012.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+influenza+a+virus+replication&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0ljv0zG4w9Pgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520influenza%2520a%2520virus%2520replication%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Sancho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgstaller-Muehlbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pache, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesus, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Sobrido, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. K.</span></span> <span> </span><span class="NLM_article-title">A large-scale drug repositioning survey for SARS-CoV-2 antivirals</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.04.16.044016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.04.16.044016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32511357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Rivaauthor=S.+Yuanauthor=X.+Yinauthor=L.+Martin-Sanchoauthor=N.+Matsunagaauthor=S.+Burgstaller-Muehlbacherauthor=L.+Pacheauthor=P.+P.+De+Jesusauthor=M.+V.+Hullauthor=M.+Changauthor=J.+F.+Chanauthor=J.+Caoauthor=V.+K.+Poonauthor=K.+Herbertauthor=T.+T.+Nguyenauthor=Y.+Puauthor=C.+Nguyenauthor=A.+Rubanovauthor=L.+Martinez-Sobridoauthor=W.+C.+Liuauthor=L.+Miorinauthor=K.+M.+Whiteauthor=J.+R.+Johnsonauthor=C.+Bennerauthor=R.+Sunauthor=P.+G.+Schultzauthor=A.+Suauthor=A.+Garcia-Sastreauthor=A.+K.+Chatterjeeauthor=K.+Y.+Yuenauthor=S.+K.+Chanda&title=A+large-scale+drug+repositioning+survey+for+SARS-CoV-2+antivirals&doi=10.1101%2F2020.04.16.044016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1101%2F2020.04.16.044016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.16.044016%26sid%3Dliteratum%253Aachs%26aulast%3DRiva%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DMartin-Sancho%26aufirst%3DL.%26aulast%3DMatsunaga%26aufirst%3DN.%26aulast%3DBurgstaller-Muehlbacher%26aufirst%3DS.%26aulast%3DPache%26aufirst%3DL.%26aulast%3DDe%2BJesus%26aufirst%3DP.%2BP.%26aulast%3DHull%26aufirst%3DM.%2BV.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DV.%2BK.%26aulast%3DHerbert%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DRubanov%26aufirst%3DA.%26aulast%3DMartinez-Sobrido%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%2BC.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DBenner%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DSu%26aufirst%3DA.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DChanda%26aufirst%3DS.%2BK.%26atitle%3DA%2520large-scale%2520drug%2520repositioning%2520survey%2520for%2520SARS-CoV-2%2520antivirals%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.16.044016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugaswami, V.</span></span> <span> </span><span class="NLM_article-title">Antiviral drug screen of kinase inhibitors identifies cellular signaling pathways critical for SARS-COV-2 replication</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.06.24.150326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.06.24.150326" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Garciaauthor=A.+Sharmaauthor=A.+Ramaiahauthor=C.+Senauthor=D.+Kohnauthor=B.+Gompertsauthor=C.+N.+Svendsenauthor=R.+D.+Damoiseauxauthor=V.+Arumugaswami&title=Antiviral+drug+screen+of+kinase+inhibitors+identifies+cellular+signaling+pathways+critical+for+SARS-COV-2+replication&doi=10.1101%2F2020.06.24.150326"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1101%2F2020.06.24.150326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.06.24.150326%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DRamaiah%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DC.%26aulast%3DKohn%26aufirst%3DD.%26aulast%3DGomperts%26aufirst%3DB.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DDamoiseaux%26aufirst%3DR.%2BD.%26aulast%3DArumugaswami%26aufirst%3DV.%26atitle%3DAntiviral%2520drug%2520screen%2520of%2520kinase%2520inhibitors%2520identifies%2520cellular%2520signaling%2520pathways%2520critical%2520for%2520SARS-COV-2%2520replication%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.06.24.150326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirabelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotring, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fursmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadambi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretto, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alysandratos, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handelman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wobus, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherwax, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashour, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, J. Z.</span></span> <span> </span><span class="NLM_article-title">Morphological cell profiling of SARS-COV-2 infection identifies drug repurposing candidates for COVID-19</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.27.117184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.05.27.117184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32577649" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Mirabelliauthor=J.+W.+Wotringauthor=C.+J.+Zhangauthor=S.+M.+McCartyauthor=R.+Fursmidtauthor=T.+Frumauthor=N.+S.+Kadambiauthor=A.+T.+Aminauthor=T.+R.+O%E2%80%99Mearaauthor=C.+D.+Prettoauthor=J.+R.+Spenceauthor=J.+Huangauthor=K.+D.+Alysandratosauthor=D.+N.+Kottonauthor=S.+K.+Handelmanauthor=C.+E.+Wobusauthor=K.+J.+Weatherwaxauthor=G.+A.+Mashourauthor=M.+J.+O%E2%80%99Mearaauthor=J.+Z.+Sexton&title=Morphological+cell+profiling+of+SARS-COV-2+infection+identifies+drug+repurposing+candidates+for+COVID-19&doi=10.1101%2F2020.05.27.117184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1101%2F2020.05.27.117184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.27.117184%26sid%3Dliteratum%253Aachs%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DWotring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BJ.%26aulast%3DMcCarty%26aufirst%3DS.%2BM.%26aulast%3DFursmidt%26aufirst%3DR.%26aulast%3DFrum%26aufirst%3DT.%26aulast%3DKadambi%26aufirst%3DN.%2BS.%26aulast%3DAmin%26aufirst%3DA.%2BT.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DPretto%26aufirst%3DC.%2BD.%26aulast%3DSpence%26aufirst%3DJ.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DAlysandratos%26aufirst%3DK.%2BD.%26aulast%3DKotton%26aufirst%3DD.%2BN.%26aulast%3DHandelman%26aufirst%3DS.%2BK.%26aulast%3DWobus%26aufirst%3DC.%2BE.%26aulast%3DWeatherwax%26aufirst%3DK.%2BJ.%26aulast%3DMashour%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DSexton%26aufirst%3DJ.%2BZ.%26atitle%3DMorphological%2520cell%2520profiling%2520of%2520SARS-COV-2%2520infection%2520identifies%2520drug%2520repurposing%2520candidates%2520for%2520COVID-19%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.27.117184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogarajah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span> <span> </span><span class="NLM_article-title">Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8159</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-65152-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41598-020-65152-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32424333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsl2ms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=8159&author=J.+Sunauthor=T.+Yogarajahauthor=R.+C.+H.+Leeauthor=P.+Kaurauthor=M.+Inoueauthor=Y.+W.+Tanauthor=J.+J.+H.+Chu&title=Drug+repurposing+of+pyrimidine+analogs+as+potent+antiviral+compounds+against+human+enterovirus+A71+infection+with+potential+clinical+applications&doi=10.1038%2Fs41598-020-65152-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications</span></div><div class="casAuthors">Sun, Jialei; Yogarajah, Thinesshwary; Lee, Regina Ching Hua; Kaur, Parveen; Inoue, Masafumi; Tan, Yong Wah; Chu, Justin Jang Hann</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8159</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: EV-A71 is one of the etiol. agents for the HFMD in young children and a potential cause of neurol. complications in afflicted patients.  Since its discovery in 1969, there remains no approved antiviral for EV-A71 and other HFMD-causing enteroviruses.  Gemcitabine and other nucleoside analogs, LY2334737 and sofosbuvir inhibition of EV-A71 infection were disclosed using mol. and proteomic quantification, and in vitro and in vivo efficacy evaluation.  Gemcitabine displayed a significant redn. of infectious EV-A71 titers by 2.5 logs PFU/mL and was shown to target the early stage of EV-A71 viral RNA and viral protein synthesis process esp. via inhibition of the RNA dependent RNA polymerase.  In addn., the drug combination study of gemcitabine's synergistic effects with interferon-β at 1:1 and 1:2 ratio enhanced inhibition against EV-A71 replication.  Since gemcitabine is known to metabolize rapidly in vivo, other nucleoside analogs, LY2334737 and sofosbuvir conferred protection in mice against lethal EV-A71 challenge by potentially reducing the death rate, viral titers as well on virus-induced pathol. in the limb muscle tissue of mice.  Addnl., we found that gemcitabine is competent to inhibit other pos.-sense RNA viruses of the Flaviviridae family.  Overall, these drugs provide new insights into targeting viral factors as a broad-spectrum antiviral strategy with potential therapeutic value for future development and are worthy of potential clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfyTG5b8CO7Vg90H21EOLACvtfcHk0ljYAKAb-eyzLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsl2ms7k%253D&md5=8b84654e33a7450db30468b4013f5d87</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-65152-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-65152-4%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYogarajah%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DR.%2BC.%2BH.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BW.%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26atitle%3DDrug%2520repurposing%2520of%2520pyrimidine%2520analogs%2520as%2520potent%2520antiviral%2520compounds%2520against%2520human%2520enterovirus%2520A71%2520infection%2520with%2520potential%2520clinical%2520applications%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D8159%26doi%3D10.1038%2Fs41598-020-65152-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machamer, C. E.</span></span> <span> </span><span class="NLM_article-title">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1099/jgv.0.001047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2Fjgv.0.001047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29557770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=619-630&author=J.+M.+Siskauthor=M.+B.+Friemanauthor=C.+E.+Machamer&title=Coronavirus+S+protein-induced+fusion+is+blocked+prior+to+hemifusion+by+Abl+kinase+inhibitors&doi=10.1099%2Fjgv.0.001047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span></div><div class="casAuthors">Sisk, Jeanne M.; Frieman, Matthew B.; Machamer, Carolyn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-630</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">1465-2099</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication.  The virus spike (S) protein mediates fusion with the host cell membrane.  We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titers and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions.  SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging.  Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection.  We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titers by blocking the first round of virus infection.  Addnl., all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step.  Our results indicate that membrane fusion (both virus-cell and cell-cell) is blocked in the presence of Abl kinase inhibitors.  Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection.  This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3OXSytq77rVg90H21EOLACvtfcHk0ljYAKAb-eyzLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF&md5=af00456c0177a52a04764bcaeb717cdb</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.001047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.001047%26sid%3Dliteratum%253Aachs%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DMachamer%26aufirst%3DC.%2BE.%26atitle%3DCoronavirus%2520S%2520protein-induced%2520fusion%2520is%2520blocked%2520prior%2520to%2520hemifusion%2520by%2520Abl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2018%26volume%3D99%26spage%3D619%26epage%3D630%26doi%3D10.1099%2Fjgv.0.001047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bommarius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebeis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chahroudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nm1265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm1265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15980865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1ajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=731-739&author=P.+M.+Reevesauthor=B.+Bommariusauthor=S.+Lebeisauthor=S.+McNultyauthor=J.+Christensenauthor=A.+Swimmauthor=A.+Chahroudiauthor=R.+Chavanauthor=M.+B.+Feinbergauthor=D.+Veachauthor=W.+Bornmannauthor=M.+Shermanauthor=D.+Kalman&title=Disabling+poxvirus+pathogenesis+by+inhibition+of+Abl-family+tyrosine+kinases&doi=10.1038%2Fnm1265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Bommarius, Bettina; Lebeis, Sarah; McNulty, Shannon; Christensen, Jens; Swimm, Alyson; Chahroudi, Ann; Chavan, Rahul; Feinberg, Mark B.; Veach, Darren; Bornmann, William; Sherman, Melanie; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Poxviridae family members vaccinia and variola virus enter mammalian cells, replicate outside the nucleus and produce virions that travel to the cell surface along microtubules, fuse with the plasma membrane and egress from infected cells toward apposing cells on actin-filled membranous protrusions.  The authors show that cell-assocd. enveloped virions (CEV) use Abl- and Src- family tyrosine kinases for actin motility, and that these kinases act in a redundant fashion, perhaps permitting motility in a greater range of cell types.  Addnl., release of CEV from the cell requires Abl- but not Src-family tyrosine kinases, and is blocked by STI-571 (Gleevec), an Abl-family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Finally, the authors show that STI-571 reduces viral dissemination by five orders of magnitude and promotes survival in infected mice, suggesting possible use for this drug in treating smallpox or complications assocd. with vaccination.  This therapeutic approach may prove generally efficacious in treating microbial infections that rely on host tyrosine kinases, and, because the drug targets host but not viral mols., this strategy is much less likely to engender resistance compared to conventional antimicrobial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoToBZlyMnm_rVg90H21EOLACvtfcHk0lj2gYB83ms52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1ajtb4%253D&md5=199db4a44332be99b624c8de944321f9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnm1265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1265%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DBommarius%26aufirst%3DB.%26aulast%3DLebeis%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSwimm%26aufirst%3DA.%26aulast%3DChahroudi%26aufirst%3DA.%26aulast%3DChavan%26aufirst%3DR.%26aulast%3DFeinberg%26aufirst%3DM.%2BB.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DDisabling%2520poxvirus%2520pathogenesis%2520by%2520inhibition%2520of%2520Abl-family%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D731%26epage%3D739%26doi%3D10.1038%2Fnm1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubley, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantanowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiello, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib-induced regression of AIDS-related Kaposi’s sarcoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.06.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1200%2FJCO.2005.06.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15572730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Gnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=982-989&author=H.+B.+Koonauthor=G.+J.+Bubleyauthor=L.+Pantanowitzauthor=D.+Masielloauthor=B.+Smithauthor=K.+Crosbyauthor=J.+Properauthor=W.+Weedenauthor=T.+E.+Millerauthor=P.+Chatisauthor=M.+J.+Egorinauthor=S.+R.+Tahanauthor=B.+J.+Dezube&title=Imatinib-induced+regression+of+AIDS-related+Kaposi%E2%80%99s+sarcoma&doi=10.1200%2FJCO.2005.06.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib-induced regression of AIDS-related Kaposi's sarcoma</span></div><div class="casAuthors">Koon, Henry B.; Bubley, Glenn J.; Pantanowitz, Liron; Masiello, David; Smith, Brad; Crosby, Katherine; Proper, JoAnn; Weeden, Will; Miller, Thomas E.; Chatis, Pamela; Egorin, Merrill J.; Tahan, Steven R.; Dezube, Bruce J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">982-989</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Activation of the platelet-derived growth factor (PDGF) and c-kit receptors has been proposed as important in mediating the growth of AIDS-related Kaposi's sarcoma (KS).  We investigated the response of KS to the PDGF receptor (PDGFR)/c-kit inhibitor, imatinib mesylate, and investigated the effect of this therapy on crit. signal transduction intermediates.  Ten male patients with AIDS-related cutaneous KS, which progressed despite chemotherapy and/or highly active antiretroviral therapy, received imatinib mesylate administered orally, 300 mg twice daily.  Clin. response was detd. by serial tumor measurements.  To det. biol. and histol. response, skin lesion biopsies were obtained at baseline and following 4 wk of therapy.  Five of 10 participants had a partial response by tumor measurements.  Biopsies after 4 wk of therapy demonstrated histol. regression in four of six patients.  Four patients' tumor biopsies were assessable for immunohistochem. end points pre- and post-therapy.  These demonstrated inhibition of PDGFR and its downstream effector, extracellular receptor kinase, which is a member of the mitogen-activated protein kinase family.  The most common adverse event was diarrhea, which led to dose redn. in six patients.  Imatinib mesylate administered orally twice daily for AIDS-related KS results in clin. and histol. regression of cutaneous KS lesions within 4 wk.  These promising results demonstrate that inhibition of the c-kit and/or PDGF receptors may represent an effective strategy for treating KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89CLQq2rDcLVg90H21EOLACvtfcHk0lj2gYB83ms52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Gnsr8%253D&md5=41d4e985c212ef785ecdf39b2cb89949</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.06.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.06.079%26sid%3Dliteratum%253Aachs%26aulast%3DKoon%26aufirst%3DH.%2BB.%26aulast%3DBubley%26aufirst%3DG.%2BJ.%26aulast%3DPantanowitz%26aufirst%3DL.%26aulast%3DMasiello%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DProper%26aufirst%3DJ.%26aulast%3DWeeden%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DT.%2BE.%26aulast%3DChatis%26aufirst%3DP.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DTahan%26aufirst%3DS.%2BR.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26atitle%3DImatinib-induced%2520regression%2520of%2520AIDS-related%2520Kaposi%25E2%2580%2599s%2520sarcoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D982%26epage%3D989%26doi%3D10.1200%2FJCO.2005.06.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1128/JVI.01814-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01814-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20962097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=21-31&author=P.+M.+Reevesauthor=S.+K.+Smithauthor=V.+A.+Olsonauthor=S.+H.+Thorneauthor=W.+Bornmannauthor=I.+K.+Damonauthor=D.+Kalman&title=Variola+and+monkeypox+viruses+utilize+conserved+mechanisms+of+virion+motility+and+release+that+depend+on+abl+and+SRC+family+tyrosine+kinases&doi=10.1128%2FJVI.01814-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on Abl and Src family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Smith, Scott K.; Olson, Victoria A.; Thorne, Steve H.; Bornmann, William; Damon, Inger K.; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Vaccinia virus (VacV) enters mammalian cells, replicates extranuclearly, and produces virions that move to the cell surface along microtubules, fuse with the plasma membrane, and move from infected cells toward apposing cells on actin-filled membranous protrusions or actin tails.  To form actin tails, cell-assocd. enveloped virions (CEV) required Abl and Src family tyrosine kinases.  Furthermore, release of CEV from the cell requires Abl but not Src family tyrosine kinases and is blocked by imatinib mesylate (STI-571; Gleevec), an Abl family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Here we demonstrate that the Poxviridae family members monkeypox virus (MPX) and variola virus (VarV) use conserved mechanisms for actin motility and extracellular enveloped virion (EEV) release.  Furthermore, we show that imatinib mesylate is effective in a mouse model of infection with VacV, whether delivered prophylactically or postinfection, and restricts spread of virions from the site of inoculation.  While inhibitors of both Src and Abl family kinases, such as dasatinib (BMS-354825; Sprycel), are effective in limiting dissemination of VacV, VarV, and MPX in vitro, members of this class of drugs appear to have immunosuppressive effects in vivo that preclude their use as anti-infectives.  Together, these data suggest a possible utility for imatinib mesylate in treating smallpox or MPX infections or complications assocd. with vaccination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp110ZF6U0WXbVg90H21EOLACvtfcHk0lj2gYB83ms52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D&md5=587e7600337ba2d6169ea9c9c0ab2f5d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FJVI.01814-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01814-10%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BK.%26aulast%3DOlson%26aufirst%3DV.%2BA.%26aulast%3DThorne%26aufirst%3DS.%2BH.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DVariola%2520and%2520monkeypox%2520viruses%2520utilize%2520conserved%2520mechanisms%2520of%2520virion%2520motility%2520and%2520release%2520that%2520depend%2520on%2520abl%2520and%2520SRC%2520family%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D21%26epage%3D31%26doi%3D10.1128%2FJVI.01814-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>– <span class="NLM_lpage">7381</span>, <span class="refDoi"> DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+de%0AWispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0liLbRdChjBAOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2013-306155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fgutjnl-2013-306155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24848265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=483-494&author=F.+Xiaoauthor=I.+Fofanaauthor=C.+Thumannauthor=L.+Maillyauthor=R.+Allesauthor=E.+Robinetauthor=N.+Meyerauthor=M.+Schaefferauthor=F.+Habersetzerauthor=M.+Doffo%C3%ABlauthor=P.+Leyssenauthor=J.+Neytsauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Synergy+of+entry+inhibitors+with+direct-acting+antivirals+uncovers+novel+combinations+for+prevention+and+treatment+of+hepatitis+C&doi=10.1136%2Fgutjnl-2013-306155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span></div><div class="casAuthors">Xiao, Fei; Fofana, Isabel; Thumann, Christine; Mailly, Laurent; Alies, Roxane; Robinet, Eric; Meyer, Nicolas; Schaeffer, Mickael; Habersetzer, Francois; Doffoel, Michel; Leyssen, Pieter; Neyts, Johan; Zeisel, Mirjam B.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection.  Viral entry is a promising target for antiviral therapy.  Design Aiming to explore the role of entry inhibitors for future clin. development, we investigated the antiviral efficacy and toxicity of entry inhibitors in combination with DAAs or other host-targeting agents (HTAs).  Screening a large series of combinations of entry inhibitors with DAAs or other HTAs, we uncovered novel combinations of antivirals for prevention and treatment of HCV infection.  Results Combinations of DAAs or HTAs and entry inhibitors including CD81-, scavenger receptor class B type I (SR-BI)- or claudin-1 (CLDN1)-specific antibodies or small-mol. inhibitors erlotinib and dasatinib were characterised by a marked and synergistic inhibition of HCV infection over a broad range of concns. with undetectable toxicity in exptl. designs for prevention and treatment both in cell culture models and in human liver-chimeric uPA/SCID mice.  Conclusions Our results provide a rationale for the development of antiviral strategies combining entry inhibitors with DAAs or HTAs by taking advantage of synergy.  The uncovered combinations provide perspectives for efficient strategies to prevent liver graft infection and novel interferon-free regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEKArTUoU-LVg90H21EOLACvtfcHk0liLbRdChjBAOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D&md5=553f99c08b810f3a9058ed71124ee7c9</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2013-306155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2013-306155%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DAlles%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DSynergy%2520of%2520entry%2520inhibitors%2520with%2520direct-acting%2520antivirals%2520uncovers%2520novel%2520combinations%2520for%2520prevention%2520and%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D483%26epage%3D494%26doi%3D10.1136%2Fgutjnl-2013-306155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broeckel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totonchy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreklywich, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streblow, D. N.</span></span> <span> </span><span class="NLM_article-title">Src family kinase inhibitors block translation of alphavirus subgenomic mRNAs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e02325-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02325-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02325-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30917980" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02325-18&author=R.+Broeckelauthor=S.+Sarkarauthor=N.+A.+Mayauthor=J.+Totonchyauthor=C.+N.+Kreklywichauthor=P.+Smithauthor=L.+Gravesauthor=V.+R.+DeFilippisauthor=M.+T.+Heiseauthor=T.+E.+Morrisonauthor=N.+Moormanauthor=D.+N.+Streblow&title=Src+family+kinase+inhibitors+block+translation+of+alphavirus+subgenomic+mRNAs&doi=10.1128%2FAAC.02325-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FAAC.02325-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02325-18%26sid%3Dliteratum%253Aachs%26aulast%3DBroeckel%26aufirst%3DR.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DMay%26aufirst%3DN.%2BA.%26aulast%3DTotonchy%26aufirst%3DJ.%26aulast%3DKreklywich%26aufirst%3DC.%2BN.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DGraves%26aufirst%3DL.%26aulast%3DDeFilippis%26aufirst%3DV.%2BR.%26aulast%3DHeise%26aufirst%3DM.%2BT.%26aulast%3DMorrison%26aufirst%3DT.%2BE.%26aulast%3DMoorman%26aufirst%3DN.%26aulast%3DStreblow%26aufirst%3DD.%2BN.%26atitle%3DSrc%2520family%2520kinase%2520inhibitors%2520block%2520translation%2520of%2520alphavirus%2520subgenomic%2520mRNAs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De02325-18%26doi%3D10.1128%2FAAC.02325-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavillette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffelsberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/nm.2341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.2341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21516087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=589-595&author=J.+Lupbergerauthor=M.+B.+Zeiselauthor=F.+Xiaoauthor=C.+Thumannauthor=I.+Fofanaauthor=L.+Zonaauthor=C.+Davisauthor=C.+J.+Meeauthor=M.+Turekauthor=S.+Gorkeauthor=C.+Royerauthor=B.+Fischerauthor=M.+N.+Zahidauthor=D.+Lavilletteauthor=J.+Fresquetauthor=F.+L.+Cossetauthor=S.+M.+Rothenbergauthor=T.+Pietschmannauthor=A.+H.+Patelauthor=P.+Pessauxauthor=M.+Doffo%C3%ABlauthor=W.+Raffelsbergerauthor=O.+Pochauthor=J.+A.+McKeatingauthor=L.+Brinoauthor=T.+F.+Baumert&title=EGFR+and+EphA2+are+host+factors+for+hepatitis+C+virus+entry+and+possible+targets+for+antiviral+therapy&doi=10.1038%2Fnm.2341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span></div><div class="casAuthors">Lupberger, Joachim; Zeisel, Mirjam B.; Xiao, Fei; Thumann, Christine; Fofana, Isabel; Zona, Laetitia; Davis, Christopher; Mee, Christopher J.; Turek, Marine; Gorke, Sebastian; Royer, Cathy; Fischer, Benoit; Zahid, Muhammad N.; Lavillette, Dimitri; Fresquet, Judith; Cosset, Francois-Loic; Rothenberg, S. Michael; Pietschmann, Thomas; Patel, Arvind H.; Pessaux, Patrick; Doffoel, Michel; Raffelsberger, Wolfgang; Poch, Olivier; McKeating, Jane A.; Brino, Laurent; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies.  Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors.  Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry.  Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo.  The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor assocns. and viral glycoprotein-dependent membrane fusion.  These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity.  Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNZcMOXBl57Vg90H21EOLACvtfcHk0liLbRdChjBAOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D&md5=9a772f9cb03077335c7e7f5918a6e1ef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnm.2341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2341%26sid%3Dliteratum%253Aachs%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DZona%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DMee%26aufirst%3DC.%2BJ.%26aulast%3DTurek%26aufirst%3DM.%26aulast%3DGorke%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DZahid%26aufirst%3DM.%2BN.%26aulast%3DLavillette%26aufirst%3DD.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DPessaux%26aufirst%3DP.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DRaffelsberger%26aufirst%3DW.%26aulast%3DPoch%26aufirst%3DO.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DBrino%26aufirst%3DL.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DEGFR%2520and%2520EphA2%2520are%2520host%2520factors%2520for%2520hepatitis%2520C%2520virus%2520entry%2520and%2520possible%2520targets%2520for%2520antiviral%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D589%26epage%3D595%26doi%3D10.1038%2Fnm.2341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span> <span> </span><span class="NLM_article-title">Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1002/bdd.1821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fbdd.1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23097199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12iurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=536-549&author=B.+Xiaauthor=T.+Heimbachauthor=H.+Heauthor=T.+H.+Lin&title=Nilotinib+preclinical+pharmacokinetics+and+practical+application+toward+clinical+projections+of+oral+absorption+and+systemic+availability&doi=10.1002%2Fbdd.1821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availabilityNilotinib Preclinical PharmacokineticsB. Xia et al.</span></div><div class="casAuthors">Xia, Binfeng; Heimbach, Tycho; He, Handan; Lin, Tsu-han</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">536-549</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Nilotinib is a highly potent and selective bcr-abl tyrosine kinase inhibitor used for the treatment of patients who are in the chronic and accelerated phases of Philadelphia chromosome-pos. (Ph+) chronic myeloid leukemia (CML).  Nilotinib preclin. data and its use for practical predictions of systemic exposure profiles and oral absorption are described.  The systemic clearance (CL) of nilotinib was relatively low in rodents with a value of less than 25% of hepatic blood flow (QH), while it was moderate in monkeys and dogs (CL /QH = 32-35%).  The steady state vol. of distribution (Vss) ranged from 0.55 to 3.9 l/kg across the species tested.  The max. concn. (Cmax) of nilotinib occurred at 0.5-4 h and the bioavailability was moderate (17-44%).  The plasma protein binding was high (> 97.5%) in preclin. species and humans.  The human CL (∼ 0.1 l/h/kg) and Vss (∼2.0 l/kg) were best predicted by the rat-dog-human proportionality method and allometric scaling method, resp.  The human i.v. pharmacokinetic profile was projected by the Wajima Css-MRT' method.  The predicted micro-consts. from human i.v. profiles were incorporated into the advanced compartmental absorption and transit model within the GastroPlus program to simulate the oral concn.-time curves in humans.  Overall, the simulated oral human pharmacokinetic profiles showed good agreement with obsd. clin. data, and the model predicted that the Cmax, AUC, t1/2, Vz/F and CL/F values were within 1.3-fold of the obsd. values.  The abs. oral bioavailability of nilotinib in healthy humans was predicted to be low (< 25%).  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdZ39wDv4LXLVg90H21EOLACvtfcHk0lipZYmjxcYUGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12iurbN&md5=f7f9af2214fe33b980ff7d516ee58d63</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1821%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DB.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DT.%2BH.%26atitle%3DNilotinib%2520preclinical%2520pharmacokinetics%2520and%2520practical%2520application%2520toward%2520clinical%2520projections%2520of%2520oral%2520absorption%2520and%2520systemic%2520availability%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2012%26volume%3D33%26spage%3D536%26epage%3D549%26doi%3D10.1002%2Fbdd.1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langhammer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellerbrok, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa)</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2010.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2010.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21094187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=64-70&author=S.+Langhammerauthor=R.+Kobanauthor=C.+Yueauthor=H.+Ellerbrok&title=Inhibition+of+poxvirus+spreading+by+the+anti-tumor+drug+Gefitinib+%28Iressa%29&doi=10.1016%2Fj.antiviral.2010.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa)</span></div><div class="casAuthors">Langhammer, Stefan; Koban, Robert; Yue, Constanze; Ellerbrok, Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-70</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The threat of smallpox virus as a bioterrorist weapon is raising international concerns again since the anthrax attacks in the USA in 2001.  The medical readiness of treating patients suffering from such infections is a prerequisite of an effective civil defense system.  Currently the only therapeutic option for the treatment of poxvirus infections relies on the virostatic nulceosid analog cidofovir, although severe side effects and drug resistant strains have been described.  A growing understanding of poxvirus pathogenesis raises the possibility to explore other appropriate targets involved in the viral replication cycle.  Poxvirus encoded growth factors such as the Vaccinia Growth Factor (VGF) stimulate host cells via the Epidermal Growth Factor Receptor (EGFR) and thereby facilitate viral spreading.  In this study we could visualize for the first time the paracrine priming of uninfected cells for subsequent infection by orthopoxviruses directly linked to EGFR phosphorylation.  Since EGFR is a well known target for anti-tumor therapy small mols. for inhibition of its tyrosine kinase (TK) activity are readily available and clin. evaluated.  In this study we analyzed three different EGFR receptor tyrosine kinase inhibitors for inhibition of orthopoxvirus infection in epithelial cells.  The inhibitor shown to be most effective was Gefitinib (Iressa) which is already approved as a drug for anti-tumor medication in the USA and in Europe.  Thus Gefitnib may provide a new therapeutic option for single or combination therapy of acute poxvirus infections, acting on a cellular target and thus reducing the risk of viral resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzuSF4zOBfbVg90H21EOLACvtfcHk0liRk2gnmLaMwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Sltw%253D%253D&md5=fd3e7ad641fc95e0a438d1fdad64ad05</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2010.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2010.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DLanghammer%26aufirst%3DS.%26aulast%3DKoban%26aufirst%3DR.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DEllerbrok%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520poxvirus%2520spreading%2520by%2520the%2520anti-tumor%2520drug%2520Gefitinib%2520%2528Iressa%2529%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D89%26spage%3D64%26epage%3D70%26doi%3D10.1016%2Fj.antiviral.2010.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1128/JVI.00688-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00688-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22114332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=1544-1554&author=Q.+Zhangauthor=R.+Gongauthor=J.+Quauthor=Y.+Zhouauthor=W.+Liuauthor=M.+Chenauthor=Y.+Liuauthor=Y.+Zhuauthor=J.+Wu&title=Activation+of+the+Ras%2FRaf%2FMEK+pathway+facilitates+hepatitis+C+virus+replication+via+attenuation+of+the+interferon-JAK-STAT+pathway&doi=10.1128%2FJVI.00688-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway</span></div><div class="casAuthors">Zhang, Qi; Gong, Rui; Qu, Jing; Zhou, Yijing; Liu, Weiyong; Chen, Mingzhou; Liu, Yingle; Zhu, Ying; Wu, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1544-1554</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of chronic liver diseases worldwide, often leading to the development of hepatocellular carcinoma (HCC).  Constitutive activation of the Ras/Raf/MEK pathway is responsible for approx. 30% of cancers.  Here we attempted to address the correlation between activation of this pathway and HCV replication.  We showed that knockdown of Raf1 inhibits HCV replication, while activation of the Ras/Raf/MEK pathway by V12, a constitutively active form of Ras, stimulates HCV replication.  We further demonstrated that this effect is regulated through attenuation of the interferon (IFN)-JAK-STAT pathway.  Activation of the Ras/Raf/MEK pathway downregulates the expression of IFN-stimulated genes (ISGs), attenuates the phosphorylation of STAT1/2, and inhibits the expression of interferon (alpha, beta, and omega) receptors 1 and 2 (IFNAR1/2).  Furthermore, we obsd. that HCV infection activates the Ras/Raf/MEK pathway.  Thus, we propose that during HCV infection, the Ras/Raf/MEK pathway is activated, which in turn attenuates the IFN-JAK-STAT pathway, resulting in stimulation of HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqpQJ8ts-X7Vg90H21EOLACvtfcHk0liRk2gnmLaMwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2ntro%253D&md5=1a952d338ca0b80fa67c1794cd5eb34a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FJVI.00688-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00688-11%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520the%2520Ras%252FRaf%252FMEK%2520pathway%2520facilitates%2520hepatitis%2520C%2520virus%2520replication%2520via%2520attenuation%2520of%2520the%2520interferon-JAK-STAT%2520pathway%26jtitle%3DJ.%2520Virol%26date%3D2012%26volume%3D86%26spage%3D1544%26epage%3D1554%26doi%3D10.1128%2FJVI.00688-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bürckstümmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span> <span> </span><span class="NLM_article-title">Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>580</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2005.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.febslet.2005.12.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=16405965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2006&pages=575-580&author=T.+B%C3%BCrckst%C3%BCmmerauthor=M.+Kriegsauthor=J.+Lupbergerauthor=E.+K.+Pauliauthor=S.+Schmittelauthor=E.+Hildt&title=Raf-1+kinase+associates+with+Hepatitis+C+virus+NS5A+and+regulates+viral+replication&doi=10.1016%2Fj.febslet.2005.12.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication</span></div><div class="casAuthors">Buerckstuemmer, T.; Kriegs, M.; Lupberger, J.; Pauli, E. K.; Schmittel, S.; Hildt, E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">580</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a pos.-strand RNA virus that frequently causes persistent infection assocd. with severe liver disease.  HCV nonstructural protein 5A (NS5A) is essential for viral replication.  Here, the kinase Raf-1 was identified as a novel cellular binding partner of NS5A, binding to the C-terminal domain of NS5A.  Raf-1 colocalizes with NS5A in the HCV replication complex.  The interaction of NS5A with Raf-1 results in increased Raf-1 phosphorylation at serine 338.  Integrity of Raf-1 is crucial for HCV replication: inhibition of Raf-1 by the small-mol. inhibitor BAY43-9006 or downregulation of Raf-1 by siRNA attenuates viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxz1OpOmSPrbVg90H21EOLACvtfcHk0liRk2gnmLaMwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslWksQ%253D%253D&md5=8e5cc137a67f7cb905b9ec74d85861aa</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCrckst%25C3%25BCmmer%26aufirst%3DT.%26aulast%3DKriegs%26aufirst%3DM.%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DPauli%26aufirst%3DE.%2BK.%26aulast%3DSchmittel%26aufirst%3DS.%26aulast%3DHildt%26aufirst%3DE.%26atitle%3DRaf-1%2520kinase%2520associates%2520with%2520Hepatitis%2520C%2520virus%2520NS5A%2520and%2520regulates%2520viral%2520replication%26jtitle%3DFEBS%2520Lett.%26date%3D2006%26volume%3D580%26spage%3D575%26epage%3D580%26doi%3D10.1016%2Fj.febslet.2005.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span> <span> </span><span class="NLM_article-title">New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.1136/gut.2009.182212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fgut.2009.182212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19710032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SjtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=1644-1653&author=K.+Himmelsbachauthor=D.+Sauterauthor=T.+F.+Baumertauthor=L.+Ludwigauthor=H.+E.+Blumauthor=E.+Hildt&title=New+aspects+of+an+anti-tumour+drug%3A+sorafenib+efficiently+inhibits+HCV+replication&doi=10.1136%2Fgut.2009.182212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication</span></div><div class="casAuthors">Himmelsbach, K.; Sauter, D.; Baumert, T. F.; Ludwig, L.; Blum, H. E.; Hildt, E.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1644-1653</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background and aims: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and is assocd. with significant morbidity and mortality.  Since there is evidence for an interaction of NS5A with c-Raf we studied whether the c-Raf inhibitor sorafenib affects HCV replication.  Methods: HCV replicating HuH7.5 cells were treated with sorafenib and examd. for HCV RNA titers by northern blotting or real time polymerase chain reaction (PCR), for core, NS3 and NS5A expression by immunostaining, and for replication by luciferase reporter assays.  Results: Here we demonstrate that in cells replicating infectious HCV particles, NS5A recruits c-Raf to the replicon complex resulting in the activation of c-Raf.  Therefore, we studied the effect of inhibition of c-Raf on HCV replication using the anti-tumor drug sorafenib that is known to inhibit c-Raf with high specificity.  Sorafenib efficiently blocks HCV replication and viral gene expression.  In addn., in HCV-replicating cells sorafenib decreased the hyperphosphory-lated form of NS5A and resulted in the formation of addnl. hypophosphorylated forms.  Further, sorafenib caused a rapid dissocn. of lipid droplets.  We provide evidence that the antiviral effect of sorafenib indeed is caused by inhibition of c-Raf.  By contrast, inhibition of targets downstream of c-Raf or inhibition of tyrosine kinases by sunitinib did not affect HCV replication.  Conclusion: Our data demonstrate that the well-characterized anti-tumor drug sorafenib efficiently blocks HCV replication in vitro.  This novel effect of sorafenib should be further explored as an antiviral strategy for patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZBHiHeSMlbVg90H21EOLACvtfcHk0ljKvi6Yq7WdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SjtbnM&md5=60b5b4873a0d5baa3bdb843fb8bf4444</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1136%2Fgut.2009.182212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2009.182212%26sid%3Dliteratum%253Aachs%26aulast%3DHimmelsbach%26aufirst%3DK.%26aulast%3DSauter%26aufirst%3DD.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DLudwig%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DH.%2BE.%26aulast%3DHildt%26aufirst%3DE.%26atitle%3DNew%2520aspects%2520of%2520an%2520anti-tumour%2520drug%253A%2520sorafenib%2520efficiently%2520inhibits%2520HCV%2520replication%26jtitle%3DGut%26date%3D2009%26volume%3D58%26spage%3D1644%26epage%3D1653%26doi%3D10.1136%2Fgut.2009.182212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span> <span> </span><span class="NLM_article-title">The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2014.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24680956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=80-85&author=M.+Gaoauthor=H.+Duanauthor=J.+Liuauthor=H.+Zhangauthor=X.+Wangauthor=M.+Zhuauthor=J.+Guoauthor=Z.+Zhaoauthor=L.+Mengauthor=Y.+Peng&title=The+multi-targeted+kinase+inhibitor+sorafenib+inhibits+enterovirus+71+replication+by+regulating+IRES-dependent+translation+of+viral+proteins&doi=10.1016%2Fj.antiviral.2014.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins</span></div><div class="casAuthors">Gao, Meng; Duan, Hao; Liu, Jing; Zhang, Hao; Wang, Xin; Zhu, Meng; Guo, Jitao; Zhao, Zhenlong; Meng, Lirong; Peng, Yihong</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activation of ERK and p38 signal cascade in host cells has been demonstrated to be essential for picornavirus enterovirus 71 (EV71) replication and up-regulation of virus-induced cyclooxygenase-2 (COX-2)/prostaglandins E2 (PGE2) expression.  The aim of this study was to examine the effects of sorafenib, a clin. approved anti-cancer multi-targeted kinase inhibitor, on the propagation and pathogenesis of EV71, with a view to its possible mechanism and potential use in the design of therapy regimes for Hand foot and mouth disease (HFMD) patients with life threatening neurol. complications.  In this study, non-toxic concns. of sorafenib were shown to inhibit the yield of infectious progeny EV71 (clin. BC08 strain) by about 90% in three different cell types.  A similar inhibitory effect of sorafenib was obsd. on the synthesis of both viral genomic RNA and the VP1 protein.  Interestingly, sorafenib exerted obvious inhibition of the EV71 internal ribosomal entry site (IRES)-mediated translation, the first step in picornavirus replication, by linking it to a firefly luciferase reporter gene.  Sorafenib was also able to prevent both EV71-induced CPE and the activation of ERK and p38, which contributes to up-regulation COX-2/PGE2 expression induced by the virus.  Overall, this study shows that sorafenib strongly inhibits EV71 replication at least in part by regulating viral IRES-dependent translation of viral proteins, indicating a novel potential strategy for the treatment of HFMD patients with severe neurol. complications.  To our knowledge, this is the first report that investigates the mechanism by which sorafenib inhibits EV71 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBqZdOAF8ji7Vg90H21EOLACvtfcHk0ljKvi6Yq7WdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrs7s%253D&md5=1b496803359f9c0ca4fea70aaad5bc2d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DY.%26atitle%3DThe%2520multi-targeted%2520kinase%2520inhibitor%2520sorafenib%2520inhibits%2520enterovirus%252071%2520replication%2520by%2520regulating%2520IRES-dependent%2520translation%2520of%2520viral%2520proteins%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D80%26epage%3D85%26doi%3D10.1016%2Fj.antiviral.2014.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2FmTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0ljKvi6Yq7WdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252FmTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benedict, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span> <span> </span><span class="NLM_article-title">Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">676</span>, <span class="refDoi"> DOI: 10.3389/fmicb.2015.00676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffmicb.2015.00676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26217313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FnsVyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=676&author=A.+Benedictauthor=N.+Bansalauthor=S.+Seninaauthor=I.+Hooperauthor=L.+Lundbergauthor=C.+de+la+Fuenteauthor=A.+Narayananauthor=B.+Guttingauthor=K.+Kehn-Hall&title=Repurposing+FDA-approved+drugs+as+therapeutics+to+treat+Rift+Valley+fever+virus+infection&doi=10.3389%2Ffmicb.2015.00676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection</span></div><div class="casAuthors">Benedict Ashwini; Bansal Neha; Senina Svetlana; Hooper Idris; Lundberg Lindsay; de la Fuente Cynthia; Narayanan Aarthi; Kehn-Hall Kylene; Gutting Bradford</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">676</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">There are currently no FDA-approved therapeutics available to treat Rift Valley fever virus (RVFV) infection.  In an effort to repurpose drugs for RVFV treatment, a library of FDA-approved drugs was screened to determine their ability to inhibit RVFV.  Several drugs from varying compound classes, including inhibitors of growth factor receptors, microtubule assembly/disassembly, and DNA synthesis, were found to reduce RVFV replication.  The hepatocellular and renal cell carcinoma drug, sorafenib, was the most effective inhibitor, being non-toxic and demonstrating inhibition of RVFV in a cell-type and virus strain independent manner.  Mechanism of action studies indicated that sorafenib targets at least two stages in the virus infectious cycle, RNA synthesis and viral egress.  Computational modeling studies also support this conclusion. siRNA knockdown of Raf proteins indicated that non-classical targets of sorafenib are likely important for the replication of RVFV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRL1yZE_XXes9FxYDaSSP8XfW6udTcc2eayaOsZp8L7f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FnsVyhug%253D%253D&md5=8fb3dab4164aa5dd4b7d716c8c4ab2c1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.00676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.00676%26sid%3Dliteratum%253Aachs%26aulast%3DBenedict%26aufirst%3DA.%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DSenina%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DI.%26aulast%3DLundberg%26aufirst%3DL.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DC.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DGutting%26aufirst%3DB.%26aulast%3DKehn-Hall%26aufirst%3DK.%26atitle%3DRepurposing%2520FDA-approved%2520drugs%2520as%2520therapeutics%2520to%2520treat%2520Rift%2520Valley%2520fever%2520virus%2520infection%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D676%26doi%3D10.3389%2Ffmicb.2015.00676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span> <span> </span><span class="NLM_article-title">Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29981794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=57-67&author=L.+Lundbergauthor=A.+Brahmsauthor=I.+Hooperauthor=B.+Careyauthor=S.+C.+Linauthor=B.+Dahalauthor=A.+Narayananauthor=K.+Kehn-Hall&title=Repurposed+FDA-Approved+drug+sorafenib+reduces+replication+of+Venezuelan+equine+encephalitis+virus+and+other+alphaviruses&doi=10.1016%2Fj.antiviral.2018.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses</span></div><div class="casAuthors">Lundberg, Lindsay; Brahms, Ashwini; Hooper, Idris; Carey, Brian; Lin, Shih-Chao; Dahal, Bibha; Narayanan, Aarthi; Kehn-Hall, Kylene</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The New World alphaviruses -Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, and WEEV resp.) - cause a febrile disease that is often lethal in equines and children and leads to long-term neurol. sequelae in survivors.  Endemic to the Americas, epizootic outbreaks of the three viruses occur sporadically in the continental United States.  All three viruses aerosolize readily, replicate to high titers in cell culture, and have low infectious doses.  Addnl., there are no FDA-approved vaccines or therapeutics for human use.  To address the therapeutic gap, a high throughput assay utilizing a luciferase reporter virus, TC83-luc, was performed to screen a library of com. available, FDA-approved drugs for antiviral activity.  From a group of twenty compds. found to significantly decrease luminescence, the carcinoma therapeutic sorafenib inhibited replication of VEEV-TC83 and TrD in vitro.  Addnl., sorafenib inhibited replication of EEEV and two Old World alphaviruses, Sindbis virus and chikungunya virus, at 8 and 16h post-infection.  Sorafenib caused no toxicity in Vero cells, and coupled with a low EC50 value, yielded a selectivity index of >19.  Mechanism of actions studies suggest that sorafenib inhibited viral translation through dephosphorylation of several key proteins, including eIF4E and p70S6K, leading to a redn. in viral protein prodn. and overall viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw7dHEEGsA3rVg90H21EOLACvtfcHk0lgZZ4O8WCXwEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsb3L&md5=9e3cdad60e9ee6a10ae9ae816ffbf3b6</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DLundberg%26aufirst%3DL.%26aulast%3DBrahms%26aufirst%3DA.%26aulast%3DHooper%26aufirst%3DI.%26aulast%3DCarey%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DS.%2BC.%26aulast%3DDahal%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DKehn-Hall%26aufirst%3DK.%26atitle%3DRepurposed%2520FDA-Approved%2520drug%2520sorafenib%2520reduces%2520replication%2520of%2520Venezuelan%2520equine%2520encephalitis%2520virus%2520and%2520other%2520alphaviruses%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D157%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.antiviral.2018.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgách, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuranecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakonyi, T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4663</span>– <span class="NLM_lpage">4672</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2018.01.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.vaccine.2018.01.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29459063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4663-4672&author=A.+Marosiauthor=P.+Forg%C3%A1chauthor=M.+Gyuraneczauthor=K.+M.+Sulyokauthor=T.+Bakonyi&title=Evaluation+of+in+vitro+inhibitory+potential+of+type-I+interferons+and+different+antiviral+compounds+on+rabies+virus+replication&doi=10.1016%2Fj.vaccine.2018.01.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication</span></div><div class="casAuthors">Marosi, Andras; Forgach, Petra; Gyuranecz, Miklos; Sulyok, Kinga M.; Bakonyi, Tamas</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4663-4672</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Five different compds. were tested for their in vitro inhibitory effect against RABV multiplication in mouse neuroblastoma (N2A) cell line.  N2A cells were infected with the fixed RABV strain CVS-11 one hour prior to adding antivirals or their resp. combinations.  The infectious titer of RABV as well as the quantity of viral RNA was detd. in the cell culturing medium after 48 h.  All five tested compds. (mouse interferon (IFN)-α and -β, ribavirin, favipiravir (T-705) and sorafenib) reduced viral replication in a concn.-dependent manner: IFN-β and sorafenib both provided 73.71% relative inhibition of viral replication in the highest non-cytotoxic concn., while ribavirin caused 48.07%, IFN-α caused 44.87% and favipiravir caused 35.25% relative inhibition, resp.  When applied in combination, their antiviral activity was not synergistic, but a pronounced inhibition was detected when IFN-β was combined with sorafenib, ribavirin, or favipiravir.  The highest antiviral effect was caused by the combination of IFN-β and sorafenib (77.19% relative inhibition).  In other combinations there was an antagonistic effect detected in the redn. of viral replication.  The results demonstrate that these compds. can be promising candidates for a potential combination treatment of rabies, noting that some combinations are not favorable in vitro, which makes thorough in vivo studies necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfijIQR_IdJ7Vg90H21EOLACvtfcHk0lgZZ4O8WCXwEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSks7g%253D&md5=4809c6a269a2eb0786403bc888d0a8d6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2018.01.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2018.01.082%26sid%3Dliteratum%253Aachs%26aulast%3DMarosi%26aufirst%3DA.%26aulast%3DForg%25C3%25A1ch%26aufirst%3DP.%26aulast%3DGyuranecz%26aufirst%3DM.%26aulast%3DSulyok%26aufirst%3DK.%2BM.%26aulast%3DBakonyi%26aufirst%3DT.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520inhibitory%2520potential%2520of%2520type-I%2520interferons%2520and%2520different%2520antiviral%2520compounds%2520on%2520rabies%2520virus%2520replication%26jtitle%3DVaccine%26date%3D2019%26volume%3D37%26spage%3D4663%26epage%3D4672%26doi%3D10.1016%2Fj.vaccine.2018.01.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forró, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felde, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdélyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Širmarová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salát, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuranecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ružek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koraka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakonyi, T.</span></span> <span> </span><span class="NLM_article-title">Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4724</span>– <span class="NLM_lpage">4735</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2018.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.vaccine.2018.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29805091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVeitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4724-4735&author=A.+Marosiauthor=L.+Dufkovaauthor=B.+Forr%C3%B3author=O.+Feldeauthor=K.+Erd%C3%A9lyiauthor=J.+%C5%A0irmarov%C3%A1author=M.+Palusauthor=V.+H%C3%B6nigauthor=J.+Sal%C3%A1tauthor=R.+Tikosauthor=M.+Gyuraneczauthor=D.+Ru%C5%BEekauthor=B.+Martinaauthor=P.+Korakaauthor=A.+Osterhausauthor=T.+Bakonyi&title=Combination+therapy+of+rabies-infected+mice+with+inhibitors+of+pro-inflammatory+host+response%2C+antiviral+compounds+and+human+rabies+immunoglobulin&doi=10.1016%2Fj.vaccine.2018.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin</span></div><div class="casAuthors">Marosi, Andras; Dufkova, Lucie; Forro, Barbara; Felde, Orsolya; Erdelyi, Karoly; Sirmarova, Jana; Palus, Martin; Honig, Vaclav; Salat, Jiri; Tikos, Reka; Gyuranecz, Miklos; Ruzek, Daniel; Martina, Byron; Koraka, Penelope; Osterhaus, Albert D. M. E.; Bakonyi, Tamas</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4724-4735</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent studies demonstrated that inhibitors of pro-inflammatory mol. cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compds. interfere with rabies virus replication in vitro.  In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS.  C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100.  In one exptl. group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge.  In the first expt. therapeutic combination contained inhibitors of tumor necrosis factor-a (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib).  In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice.  The addn. of human rabies Igs (HRIG) to the combination in the second expt. almost completely prevented mortality in the pre-exposure treatment group along with a significant redn. of viral titers in the CNS.  Post-exposure treatments also greatly improved survival rates.  As part of the combination with immunomodulatory compds., HRIG had a higher impact on survival than alone.  In the third expt. the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705).  As a blood-brain barrier opener, mannitol was also administered.  This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components.  In all expts., viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment.  According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreJov-4zSJ37Vg90H21EOLACvtfcHk0lgZZ4O8WCXwEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVeitrzK&md5=16c726359643c6db95b7978a39ab9062</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2018.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2018.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DMarosi%26aufirst%3DA.%26aulast%3DDufkova%26aufirst%3DL.%26aulast%3DForr%25C3%25B3%26aufirst%3DB.%26aulast%3DFelde%26aufirst%3DO.%26aulast%3DErd%25C3%25A9lyi%26aufirst%3DK.%26aulast%3D%25C5%25A0irmarov%25C3%25A1%26aufirst%3DJ.%26aulast%3DPalus%26aufirst%3DM.%26aulast%3DH%25C3%25B6nig%26aufirst%3DV.%26aulast%3DSal%25C3%25A1t%26aufirst%3DJ.%26aulast%3DTikos%26aufirst%3DR.%26aulast%3DGyuranecz%26aufirst%3DM.%26aulast%3DRu%25C5%25BEek%26aufirst%3DD.%26aulast%3DMartina%26aufirst%3DB.%26aulast%3DKoraka%26aufirst%3DP.%26aulast%3DOsterhaus%26aufirst%3DA.%26aulast%3DBakonyi%26aufirst%3DT.%26atitle%3DCombination%2520therapy%2520of%2520rabies-infected%2520mice%2520with%2520inhibitors%2520of%2520pro-inflammatory%2520host%2520response%252C%2520antiviral%2520compounds%2520and%2520human%2520rabies%2520immunoglobulin%26jtitle%3DVaccine%26date%3D2019%26volume%3D37%26spage%3D4724%26epage%3D4735%26doi%3D10.1016%2Fj.vaccine.2018.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weege, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravenstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieben, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Sancho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai-Matsushima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welke, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlas, A.</span></span> <span> </span><span class="NLM_article-title">RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e1007601</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1007601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1007601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30883607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=e1007601&author=M.+Leschauthor=M.+Lucknerauthor=M.+Meyerauthor=F.+Weegeauthor=I.+Gravensteinauthor=M.+Rafteryauthor=C.+Siebenauthor=L.+Martin-Sanchoauthor=A.+Imai-Matsushimaauthor=R.+W.+Welkeauthor=R.+Friseauthor=W.+Barclayauthor=G.+Sch%C3%B6nrichauthor=A.+Herrmannauthor=T.+F.+Meyerauthor=A.+Karlas&title=RNAi-based+small+molecule+repositioning+reveals+clinically+approved+urea-based+kinase+inhibitors+as+broadly+active+antivirals&doi=10.1371%2Fjournal.ppat.1007601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals</span></div><div class="casAuthors">Lesch, Markus; Luckner, Madlen; Meyer, Michael; Weege, Friderike; Gravenstein, Isabella; Raftery, Martin; Sieben, Christian; Martin-Sancho, Laura; Imai-Matsushima, Aki; Welke, Robert-William; Frise, Rebecca; Barclay, Wendy; Schonrich, Gunther; Herrmann, Andreas; Meyer, Thomas F.; Karlas, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1007601/1-e1007601/34</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Influenza viruses (IVs) tend to rapidly develop resistance to virus-directed vaccines and common antivirals targeting pathogen determinants, but novel host-directed approaches might preclude resistance development.  To identify the most promising cellular targets for a host directed approach against influenza, we performed a comparative small interfering RNA (siRNA) loss-of-function screen of IV replication in A549 cells.  Anal. of four different IV strains including a highly pathogenic avian H5N1 strain, an influenza B virus (IBV) and two human influenza A viruses (IAVs) revealed 133 genes required by all four IV strains.  According to gene enrichment analyses, these strain-independent host genes were particularly enriched for nucleocytoplasmic trafficking.  In addn., 360 strain-specific genes were identified with distinct patterns of usage for IAVs vs. IBV and human vs. avian IVs.  The strain-independent host genes served to define 43 exptl. and otherwise clin. approved drugs, targeting reportedly fourteen of the encoded host factors.  Amongst the approved drugs, the urea-based kinase inhibitors (UBKIs) regorafenib and sorafenib exhibited a superior therapeutic window of high IV antiviral activity and low cytotoxicity.  Both UBKIs appeared to block a cell signaling pathway involved in IV replication after internalization, yet prior to vRNP uncoating.  Interestingly, both compds. were active also against unrelated viruses including cowpox virus (CPXV), hantavirus (HTV), herpes simplex virus 1 (HSV1) and vesicular stomatitis virus (VSV) and showed antiviral efficacy in human primary respiratory cells.  An in vitro resistance development anal. for regorafenib failed to detect IV resistance development against this drug.  Taken together, the otherwise clin. approved UBKIs regorafenib and sorafenib possess high and broad-spectrum antiviral activity along with substantial robustness against resistance development and thus constitute attractive host directed drug candidates against a range of viral infections including influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpvRg2BQf47Vg90H21EOLACvtfcHk0ljlbrKFD_FbiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7zJ&md5=52e175766a8f5ed3073186eb6ecba371</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1007601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1007601%26sid%3Dliteratum%253Aachs%26aulast%3DLesch%26aufirst%3DM.%26aulast%3DLuckner%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DWeege%26aufirst%3DF.%26aulast%3DGravenstein%26aufirst%3DI.%26aulast%3DRaftery%26aufirst%3DM.%26aulast%3DSieben%26aufirst%3DC.%26aulast%3DMartin-Sancho%26aufirst%3DL.%26aulast%3DImai-Matsushima%26aufirst%3DA.%26aulast%3DWelke%26aufirst%3DR.%2BW.%26aulast%3DFrise%26aufirst%3DR.%26aulast%3DBarclay%26aufirst%3DW.%26aulast%3DSch%25C3%25B6nrich%26aufirst%3DG.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DT.%2BF.%26aulast%3DKarlas%26aufirst%3DA.%26atitle%3DRNAi-based%2520small%2520molecule%2520repositioning%2520reveals%2520clinically%2520approved%2520urea-based%2520kinase%2520inhibitors%2520as%2520broadly%2520active%2520antivirals%26jtitle%3DPLoS%2520Pathog.%26date%3D2019%26volume%3D15%26spage%3De1007601%26doi%3D10.1371%2Fjournal.ppat.1007601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Vidal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellví, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31077767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=18-27&author=E.+Garcia-Vidalauthor=R.+Badiaauthor=M.+Pujantellauthor=M.+Castellv%C3%ADauthor=E.+Felipauthor=B.+Clotetauthor=E.+Riveira-Mu%C3%B1ozauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Dual+effect+of+the+broad+spectrum+kinase+inhibitor+midostaurin+in+acute+and+latent+HIV-1+infection&doi=10.1016%2Fj.antiviral.2019.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection</span></div><div class="casAuthors">Garcia-Vidal, Edurne; Badia, Roger; Pujantell, Maria; Castellvi, Marc; Felip, Eudald; Clotet, Bonaventura; Riveira-Munoz, Eva; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-27</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Midostaurin is a multi-kinase inhibitor with antineoplastic activity.  We assessed the capacity of midostaurin to affect early and late steps of HIV-1 infection and to reactivate HIV-1 latently infected cells, alone or in combination with histone deacetylase inhibitors (HDACi) known to act as latency-reversing agents (LRA).  Acute HIV-1 infection was assessed by flow cytometry in three cell types treated with midostaurin in the presence or absence of SAMHD1.  Non-infected cells were treated with midostaurin and harvested for Western blot anal.  Macrophage infections were also measured by quant. RT-PCR.  HIV-1 latency reactivation was assessed in several latency models.  Midostaurin induced G2/M arrest and inhibited CDK2, preventing the phosphorylation of SAMHD1 assocd. to inhibition of its dNTPase activity.  In the presence of SAMHD1, midostaurin blocked HIV-1 DNA formation and viral replication.  However, following Vpx-mediated SAMHD1 degrdn., midostaurin increased viral transcripts and virus replication.  In three out of four HIV-1 latency models, including primary CD4+ T cells, midostaurin effectively reversed HIV-1 latency and was synergistic in combination with LRA vorinostat and panobinostat.  Our study describes a dual effect for midostaurin in HIV-1 infection, antiviral or proviral depending on SAMHD1 activation, and highlights a role for active SAMHD1 in regulating the activity of potential HIV-1 latency reversal agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ptaEF-fUsbVg90H21EOLACvtfcHk0ljlbrKFD_FbiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVyhs7s%253D&md5=e1dedd467d87aec7be0e02af385ed652</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Vidal%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DCastellv%25C3%25AD%26aufirst%3DM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DDual%2520effect%2520of%2520the%2520broad%2520spectrum%2520kinase%2520inhibitor%2520midostaurin%2520in%2520acute%2520and%2520latent%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D18%26epage%3D27%26doi%3D10.1016%2Fj.antiviral.2019.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: Insights from human absorption, metabolism, and excretion studies of a BDDCS II drug</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fdmd.116.072744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28270565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=540-555&author=H.+Heauthor=P.+Tranauthor=H.+Guauthor=V.+Tedescoauthor=J.+Zhangauthor=W.+Linauthor=E.+Gatlikauthor=K.+Kleinauthor=T.+Heimbach&title=Midostaurin%2C+a+novel+protein+kinase+inhibitor+for+the+treatment+of+acute+myelogenous+leukemia%3A+Insights+from+human+absorption%2C+metabolism%2C+and+excretion+studies+of+a+BDDCS+II+drug&doi=10.1124%2Fdmd.116.072744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug</span></div><div class="casAuthors">He, Handan; Tran, Phi; Gu, Helen; Tedesco, Vivienne; Zhang, Jin; Lin, Wen; Gatlik, Ewa; Klein, Kai; Heimbach, Tycho</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">540-555</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The absorption, metab., and excretion of midostaurin, a potent class III tyrosine protein kinase inhibitor for acute myelogenous leukemia, were evaluated in healthy subjects.  A microemulsion formulation was chosen to optimize absorption.  After a 50-mg [14C]-midostaurin dose, oral absorption was high (>90%) and relatively rapid.  In plasma, the major circulating components were midostaurin (22%), CGP52421 (32.7%), and CGP62221 (27.7%).  Long plasma half-lives were obsd. for midostaurin (20.3 h), CGP52421 (495 h), and CGP62221 (33.4 h).  Through careful mass-balance study design, the recovery achieved was good (81.6%), despite the long radioactivity half-lives.  Most of the radioactive dose was recovered in feces (77.6%) mainly as metabolites, because only 3.43% was unchanged, suggesting mainly hepatic metab.  Renal elimination was minor (4%).  Midostaurin metab. pathways involved hydroxylation, O-demethylation, amide hydrolysis, and N-demethylation.  High plasma CGP52421 and CGP62221 exposures in humans, along with relatively potent cell-based IC50 for FMS-like tyrosine kinase 3-internal tandem duplications inhibition, suggested that the antileukemic activity in AML patients may also be maintained by the metabolites.  Very high plasma protein binding (>99%) required equil. gel filtration to identify differences between humans and animals.  Because midostaurin, CGP52421, and CGP62221 are metabolized mainly by CYP3A4 and are inhibitors/inducers for CYP3A, potential drug-drug interactions with mainly CYP3A4 modulators/CYP3A substrates could be expected.  Given its low aq. soly., high oral absorption and extensive metab. (>90%), midostaurin is a Biopharmaceutics Classification System/Biopharmaceutics Drug Disposition Classification System (BDDCS) class II drug in human, consistent with rat BDDCS in vivo data showing high absorption (>90%) and extensive metab. (>90%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGj-4CfyRJrVg90H21EOLACvtfcHk0lguId0wN7rpAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvJ&md5=2b65e7c63b30c3cf4499efc41a3223f1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072744%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DTedesco%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DGatlik%26aufirst%3DE.%26aulast%3DKlein%26aufirst%3DK.%26aulast%3DHeimbach%26aufirst%3DT.%26atitle%3DMidostaurin%252C%2520a%2520novel%2520protein%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%253A%2520Insights%2520from%2520human%2520absorption%252C%2520metabolism%252C%2520and%2520excretion%2520studies%2520of%2520a%2520BDDCS%2520II%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D540%26epage%3D555%26doi%3D10.1124%2Fdmd.116.072744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e12697</span>, <span class="refDoi"> DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=e12697&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J+Richardsonauthor=V.+Monteilauthor=V.+M+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A+R.+Terresauthor=B.+J+Nickoloffauthor=R.+E+Higgsauthor=G.+Rochaauthor=N.+L+Byersauthor=D.+E+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellino&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0lguId0wN7rpAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ%26aulast%3DHiggs%26aufirst%3DR.%2BE%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL%26aulast%3DSchlichting%26aufirst%3DD.%2BE%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26spage%3De12697%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29753658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=67-75&author=S.+Y.+Puauthor=F.+Xiaoauthor=S.+Schorauthor=E.+Bekermanauthor=F.+Zaniniauthor=R.+Barouch-Bentovauthor=C.+M.+Nagamineauthor=S.+Einav&title=Feasibility+and+biological+rationale+of+repurposing+sunitinib+and+erlotinib+for+dengue+treatment&doi=10.1016%2Fj.antiviral.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span></div><div class="casAuthors">Pu, Szu-Yuan; Xiao, Fei; Schor, Stanford; Bekerman, Elena; Zanini, Fabio; Barouch-Bentov, Rina; Nagamine, Claude M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue virus (DENV) infection; a major global threat.  We reported that the cellular kinases AAK1 and GAK regulate intracellular trafficking of multiple viruses and that sunitinib and erlotinib, approved anticancer drugs with potent activity against these kinases, protect DENV-infected mice from mortality.  Nevertheless, further characterization of the therapeutic potential and underlying mechanism of this approach is required prior to clin. evaluation.  Here, we demonstrate that sunitinib/erlotinib combination achieves sustained suppression of systemic infection at approved dose in DENV-infected IFN-α/β and IFN-γ receptor-deficient mice.  Nevertheless, treatment with these blood-brain barrier impermeable drugs delays, yet does not prevent, late-onset paralysis; a common manifestation in this immunodeficient mouse model but not in humans.  Sunitinib and erlotinib treatment also demonstrates efficacy in human primary monocyte-derived dendritic cells.  Addnl., DENV infection induces expression of AAK1 transcripts, but not GAK, via single-cell transcriptomics, and these kinases are important mol. targets underlying the anti-DENV effect of sunitinib and erlotinib.  Lastly, sunitinib/erlotinib combination alters inflammatory cytokine responses in DENV-infected mice.  These findings support feasibility of repurposing sunitinib/erlotinib combination as a host-targeted antiviral approach and contribute to understanding its mechanism of antiviral action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cs8UpuoykLVg90H21EOLACvtfcHk0lguId0wN7rpAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D&md5=acde697b6e3c6d9f42a2011be6091e83</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DFeasibility%2520and%2520biological%2520rationale%2520of%2520repurposing%2520sunitinib%2520and%2520erlotinib%2520for%2520dengue%2520treatment%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D155%26spage%3D67%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Multiple
treatments for ebola virus disease (EVD)</i>, NCT02380625, Clinical
Research Management, Inc., <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Multiple%0Atreatments+for+ebola+virus+disease+%28EVD%29%2C+NCT02380625%2C+Clinical%0AResearch+Management%2C+Inc.%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DMultiple%250Atreatments%2520for%2520ebola%2520virus%2520disease%2520%2528EVD%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span> <span> </span><span class="NLM_article-title">COVID-19: combining antiviral and anti-inflammatory treatments</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(20)30132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS1473-3099%2820%2930132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32113509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=400-402&author=J.+Stebbingauthor=A.+Phelanauthor=I.+Griffinauthor=C.+Tuckerauthor=O.+Oechsleauthor=D.+Smithauthor=P.+Richardson&title=COVID-19%3A+combining+antiviral+and+anti-inflammatory+treatments&doi=10.1016%2FS1473-3099%2820%2930132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: combining antiviral and anti-inflammatory treatments</span></div><div class="casAuthors">Stebbing, Justin; Phelan, Anne; Griffin, Ivan; Tucker, Catherine; Oechsle, Olly; Smith, Dan; Richardson, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-402</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential for combination therapy of the anti-inflammatory baricitinib with the direct-acting antivirals (lopinavir or ritonavir and remdesivir) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drug-metabolizing enzymes.  Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzcjx8n9u2irVg90H21EOLACvtfcHk0ljKglRcyYw9uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFCitb4%253D&md5=c311166386f148d130f49b72f3c0b381</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930132-8%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DCOVID-19%253A%2520combining%2520antiviral%2520and%2520anti-inflammatory%2520treatments%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D400%26epage%3D402%26doi%3D10.1016%2FS1473-3099%2820%2930132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriques, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djabali, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1276</span>, <span class="refDoi"> DOI: 10.3390/cells8101276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fcells8101276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVygtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1276&author=C.+Liuauthor=R.+Arnoldauthor=G.+Henriquesauthor=K.+Djabali&title=Inhibition+of+JAK-STAT+signaling+with+baricitinib+reduces+inflammation+and+improves+cellular+homeostasis+in+progeria+cells&doi=10.3390%2Fcells8101276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells</span></div><div class="casAuthors">Liu, Chang; Arnold, Rouven; Henriques, Goncalo; Djabali, Karima</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1276</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hutchinson-Gilford progeria syndrome (HGPS), a rare premature aging disorder that leads to death at an av. age of 14.7 years due to myocardial infarction or stroke, is caused by mutations in the LMNA gene.  Nearly 90% of HGPS cases carry the G608G mutation within exon 11 that generates a truncated prelamin A protein "progerin".  Progerin accumulates in HGPS cells and induces premature senescence at the cellular and organismal levels.  Children suffering from HGPS develop numerous clin. features that overlap with normal aging, including atherosclerosis, arthritis, hair loss and lipodystrophy.  To det. whether an aberrant signaling pathway might underliethedevelopmentofthesefourdiseases(atherosclerosis, arthritis, hairlossandlipodystrophy), we performed a text mining anal. of scientific literature and databases.  We found a total of 17 genes assocd. with all four pathologies, 14 of which were linked to the JAK1/2-STAT1/3 signaling pathway.  We report that the inhibition of the JAK-STAT pathway with baricitinib, a Food and Drug Administration-approved JAK1/2 inhibitor, restored cellular homeostasis, delayed senescence and decreased proinflammatory markers in HGPS cells.  Our ex vivo data using human cell models indicate that the overactivation of JAK-STAT signaling mediates premature senescence and that the inhibition of this pathway could show promise for the treatment of HGPS and age-related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppgM8ThAvADbVg90H21EOLACvtfcHk0ljKglRcyYw9uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVygtbo%253D&md5=63739aa82503a5bc04e44c886b781779</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3390%2Fcells8101276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8101276%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DHenriques%26aufirst%3DG.%26aulast%3DDjabali%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520JAK-STAT%2520signaling%2520with%2520baricitinib%2520reduces%2520inflammation%2520and%2520improves%2520cellular%2520homeostasis%2520in%2520progeria%2520cells%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D1276%26doi%3D10.3390%2Fcells8101276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span>FDA News
Release,  <i>Coronavirus (COVID-19) Update: FDA authorizes drug
combination for treatment of COVID-19</i>, November 19, <span class="NLM_year">2020</span>, <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed 2020-11-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News%0ARelease%2C+Coronavirus+%28COVID-19%29+Update%3A+FDA+authorizes+drug%0Acombination+for+treatment+of+COVID-19%2C+November+19%2C+2020%2C+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+2020-11-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Update%253A%2520FDA%2520authorizes%2520drug%250Acombination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haile, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyor, W. R.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.nbd.2016.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26851503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=137-143&author=W.+B.+Haileauthor=C.+Gavegnanoauthor=S.+Taoauthor=Y.+Jiangauthor=R.+F.+Schinaziauthor=W.+R.+Tyor&title=The+Janus+kinase+inhibitor+ruxolitinib+reduces+HIV+replication+in+human+macrophages+and+ameliorates+HIV+encephalitis+in+a+murine+model&doi=10.1016%2Fj.nbd.2016.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model</span></div><div class="casAuthors">Haile, Woldeab B.; Gavegnano, Christina; Tao, Sijia; Jiang, Yong; Schinazi, Raymond F.; Tyor, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A hallmark of persistent HIV-1 infection in the central nervous system is increased activation of mononuclear phagocytes and surrounding astrogliosis, conferring persistent HIV-induced inflammation.  This inflammation is believed to result in neuronal dysfunction and the clin. manifestations of HIV-assocd. neurocognitive disorders (HAND).  The Jak/STAT pathway is activated in macrophages/myeloid cells upon HIV-1 infection, modulating many pro-inflammatory pathways that result in HAND, thereby representing an attractive cellular target.  Thus, the impact of ruxolitinib, a Janus Kinase (Jak) 1/2 inhibitor that is FDA approved for myelofibrosis and polycythemia vera, was assessed for its potential to inhibit HIV-1 replication in macrophages and HIV-induced activation in monocytes/macrophages in culture.  In addn., a murine model of HIV encephalitis (HIVE) was used to assess the impact of ruxolitinib on histopathol. features of HIVE, brain viral load, as well as its ability to penetrate the blood-brain-barrier (BBB).  Ruxolitinib was found to inhibit HIV-1 replication in macrophages, HIV-induced activation of monocytes (CD14/CD16) and macrophages (HLA-DR, CCR5, and CD163) without apparent toxicity.  In vivo, systemically administered ruxolitinib was detected in the brain during HIVE in SCID mice and markedly inhibited astrogliosis.  Together, these data indicate that ruxolitinib reduces HIV-induced activation and infiltration of monocytes/macrophages in vitro, reduces the replication of HIV in vitro, penetrates the BBB when systemically administered in mice and reduces astrogliosis in the brains of mice with HIVE.  These data suggest that ruxolitinib will be useful as a novel therapeutic to treat humans with HAND.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXOQeIdU_kbVg90H21EOLACvtfcHk0ljKglRcyYw9uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFyisrk%253D&md5=dbf6e2d9858d543e04ff66cef9d2c808</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaile%26aufirst%3DW.%2BB.%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DTyor%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Janus%2520kinase%2520inhibitor%2520ruxolitinib%2520reduces%2520HIV%2520replication%2520in%2520human%2520macrophages%2520and%2520ameliorates%2520HIV%2520encephalitis%2520in%2520a%2520murine%2520model%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2016%26volume%3D92%26spage%3D137%26epage%3D143%26doi%3D10.1016%2Fj.nbd.2016.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La
Rosee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birndt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, P.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0891-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41375-020-0891-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32518419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1805-1815&author=F.+La%0ARoseeauthor=H.+C.+Bremerauthor=I.+Gehrkeauthor=A.+Kehrauthor=A.+Hochhausauthor=S.+Birndtauthor=M.+Fellhauerauthor=M.+Henkesauthor=B.+Kumleauthor=S.+G.+Russoauthor=P.+La+Rosee&title=The+Janus+kinase+1%2F2+inhibitor+ruxolitinib+in+COVID-19+with+severe+systemic+hyperinflammation&doi=10.1038%2Fs41375-020-0891-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span></div><div class="casAuthors">La Rosee, F.; Bremer, H. C.; Gehrke, I.; Kehr, A.; Hochhaus, A.; Birndt, S.; Fellhauer, M.; Henkes, M.; Kumle, B.; Russo, S. G.; La Rosee, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1805-1815</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure.  These patients present with progressive hyperinflammation governed by proinflammatory cytokines.  An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation.  Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux).  Patients were treated with efficacy/toxicity guided step up dosing up to 14 days.  Retrospective anal. of CIS redn. and clin. outcome was performed.  Out of 105 patients treated between March 30th and Apr. 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg.  A total of 12/14 patients achieved significant redn. of CIS by ≥25% on day 7 with sustained clin. improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity.  Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure.  A multicenter phase-II clin. trial has been initiated (NCT04338958).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLEoRYA18u7Vg90H21EOLACvtfcHk0liPZJmJykMhkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K&md5=801ce3cc74a405a334ca0d380aa53333</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0891-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0891-0%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosee%26aufirst%3DF.%26aulast%3DBremer%26aufirst%3DH.%2BC.%26aulast%3DGehrke%26aufirst%3DI.%26aulast%3DKehr%26aufirst%3DA.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DBirndt%26aufirst%3DS.%26aulast%3DFellhauer%26aufirst%3DM.%26aulast%3DHenkes%26aufirst%3DM.%26aulast%3DKumle%26aufirst%3DB.%26aulast%3DRusso%26aufirst%3DS.%2BG.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26atitle%3DThe%2520Janus%2520kinase%25201%252F2%2520inhibitor%2520ruxolitinib%2520in%2520COVID-19%2520with%2520severe%2520systemic%2520hyperinflammation%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1805%26epage%3D1815%26doi%3D10.1038%2Fs41375-020-0891-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2020.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaci.2020.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32470486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=137-146&author=Y.+Caoauthor=J.+Weiauthor=L.+Zouauthor=T.+Jiangauthor=G.+Wangauthor=L.+Chenauthor=L.+Huangauthor=F.+Mengauthor=L.+Huangauthor=N.+Wangauthor=X.+Zhouauthor=H.+Luoauthor=Z.+Maoauthor=X.+Chenauthor=J.+Xieauthor=J.+Liuauthor=H.+Chengauthor=J.+Zhaoauthor=G.+Huangauthor=W.+Wangauthor=J.+Zhou&title=Ruxolitinib+in+treatment+of+severe+coronavirus+disease+2019+%28COVID-19%29%3A+A+multicenter%2C+single-blind%2C+randomized+controlled+trial&doi=10.1016%2Fj.jaci.2020.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span></div><div class="casAuthors">Cao, Yang; Wei, Jia; Zou, Liang; Jiang, Tiebin; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Xie, Jungang; Liu, Jing; Cheng, Hui; Zhao, Jianping; Huang, Gang; Wang, Wei; Zhou, Jianfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-146.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Accumulating evidence proposed Janus-assocd. kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.  This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019.  We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019.  Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus std.-of-care treatment (22 patients) or placebo based on std.-of-care treatment (21 patients).  After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study.  Treatment with ruxolitinib plus std.-of-care was not assocd. with significantly accelerated clin. improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clin. improvement.  Eighteen (90%) patients from the ruxolitinib group showed computed tomog. improvement at day 14 compared with 13 (61.9%) patients from the control group (P =.0495).  Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group.  Ruxolitinib was well tolerated with low toxicities and no new safety signals.  Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.  Although no statistical difference was obsd., ruxolitinib recipients had a numerically faster clin. improvement.  Significant chest computed tomog. improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsWKI4tj6YcLVg90H21EOLACvtfcHk0liPZJmJykMhkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ&md5=b758d7ebcb2a43a00d91009ad4787240</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2020.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2020.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520in%2520treatment%2520of%2520severe%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%253A%2520A%2520multicenter%252C%2520single-blind%252C%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2020%26volume%3D146%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.jaci.2020.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capochiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frediani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iervasi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolicchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuccaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertaggia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccioni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conticini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozzetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchia, M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib rapidly reduces acute respiratory distress syndrome in covid-19 disease. Analysis of data collection from RESPIRE protocol</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.3389/fmed.2020.00466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffmed.2020.00466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB38bgvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=466&author=E.+Capochianiauthor=B.+Fredianiauthor=G.+Iervasiauthor=A.+Paolicchiauthor=S.+Saniauthor=P.+Roncucciauthor=A.+Cuccaroauthor=F.+Franchiauthor=F.+Simonettiauthor=D.+Carraraauthor=I.+Bertaggiaauthor=D.+Nassoauthor=R.+Riccioniauthor=S.+Scollettaauthor=S.+Valenteauthor=E.+Conticiniauthor=A.+Gozzettiauthor=M.+Bocchia&title=Ruxolitinib+rapidly+reduces+acute+respiratory+distress+syndrome+in+covid-19+disease.+Analysis+of+data+collection+from+RESPIRE+protocol&doi=10.3389%2Ffmed.2020.00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol</span></div><div class="casAuthors">Capochiani Enrico; Cuccaro Annarosa; Simonetti Federico; Bertaggia Ilaria; Nasso Daniela; Riccioni Rossella; Frediani Bruno; Conticini Edoardo; Iervasi Giorgio; Paolicchi Aldo; Sani Spartaco; Roncucci Paolo; Franchi Federico; Scolletta Sabino; Carrara Davide; Valente Serafina; Gozzetti Alessandro; Bocchia Monica</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">466</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">Background: The Coronavirus disease (COVID-19) pandemic is causing millions of infections and hundreds of thousands of deaths worldwide.  Cumulative clinical and laboratory evidence suggest that a subset of patients with severe COVID-19 may develop a cytokine storm syndrome during the course of the disease, with severe respiratory impairment requiring ventilatory support.  One field of research nowadays is to identify and treat viral-induced hyperinflammation with drugs used in other clinical conditions characterized by an hyperinflammation status.  These drugs might help to reduce COVID19 mortality.  Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis.  We used ruxolitinib in 18 patients with clinically progressive COVID-19 related acute respiratory distress syndrome, with a primary endpoint to rapidly reduce the degree of respiratory impairment and as a secondary endpoint to rapidly restore the PaO2/FiO2 ratio, as an evaluation of clinical status, and monitoring of drug related Adverse Events.  Parameters of inflammation responses and organ functions were assessed and monitored.  The treatment plan was ruxolitinib 20 mg bid for the first 48 h and subsequent two-step de-escalation at 10 mg bid and 5 mg bid for a maximum of 14 days of treatment.  Results: Our data collection shows a rapid clinical response with no evolution from non-invasive ventilation to mechanical ventilation in 16/18 patients and no response in two patients (overall response rate-ORR 89%).  Already after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement, and after 7 days of treatment 11/18 patients showed fully recovered respiratory function (pO2 > 98% in spontaneous breathing), 4/18 patients had minimal oxygen requirement (2-4 L/m), 1/18 patient showed stable disease, and 2/18 patient showed progressive disease.  After 14 days, 16/18 patients showed complete recovery of respiratory function (ORR 89%).  Compliance to ruxolitinib planned treatment was 100% and no serious adverse event was recorded.  In our case series of 18 critically ill patients with COVID-19 and ARDS, administration of ruxolitinib resulted in a clinical improvement that concurred to modify the standard course of disease.  Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.  RESPIRE Study (Ruxolitinib for the treatment of acute rESPIratory distREss syndrome, ClinicalTrials.gov Identifier: NCT04361903).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfIW9Qi75uwYNpW7w2tapOfW6udTcc2eaPHmG9WNfu37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bgvFymtA%253D%253D&md5=69c99afcd5fa34a1d449bbba4267461c</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2020.00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2020.00466%26sid%3Dliteratum%253Aachs%26aulast%3DCapochiani%26aufirst%3DE.%26aulast%3DFrediani%26aufirst%3DB.%26aulast%3DIervasi%26aufirst%3DG.%26aulast%3DPaolicchi%26aufirst%3DA.%26aulast%3DSani%26aufirst%3DS.%26aulast%3DRoncucci%26aufirst%3DP.%26aulast%3DCuccaro%26aufirst%3DA.%26aulast%3DFranchi%26aufirst%3DF.%26aulast%3DSimonetti%26aufirst%3DF.%26aulast%3DCarrara%26aufirst%3DD.%26aulast%3DBertaggia%26aufirst%3DI.%26aulast%3DNasso%26aufirst%3DD.%26aulast%3DRiccioni%26aufirst%3DR.%26aulast%3DScolletta%26aufirst%3DS.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DConticini%26aufirst%3DE.%26aulast%3DGozzetti%26aufirst%3DA.%26aulast%3DBocchia%26aufirst%3DM.%26atitle%3DRuxolitinib%2520rapidly%2520reduces%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520covid-19%2520disease.%2520Analysis%2520of%2520data%2520collection%2520from%2520RESPIRE%2520protocol%26jtitle%3DFront.%2520Med.%26date%3D2020%26volume%3D7%26spage%3D466%26doi%3D10.3389%2Ffmed.2020.00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detorio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1128/AAC.02496-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02496-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24419350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1977-1986&author=C.+Gavegnanoauthor=M.+Detorioauthor=C.+Monteroauthor=A.+Bosqueauthor=V.+Planellesauthor=R.+F.+Schinazi&title=Ruxolitinib+and+tofacitinib+are+potent+and+selective+inhibitors+of+HIV-1+replication+and+virus+reactivation+in+vitro&doi=10.1128%2FAAC.02496-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span></div><div class="casAuthors">Gavegnano, Christina; Detorio, Mervi; Montero, Catherine; Bosque, Alberto; Planelles, Vicente; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1977-1986, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The JAK-STAT pathway is activated in both macrophages and lymphocytes upon human immunodeficiency virus type 1 (HIV-1) infection and thus represents an attractive cellular target to achieve HIV suppression and reduced inflammation, which may impact virus sanctuaries.  Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, resp., but their therapeutic application for treatment of HIV infection was unexplored.  Both drugs demonstrated submicromolar inhibition of infection with HIV-1, HIV-2, and a simian-human immunodeficiency virus, RT-SHIV, across primary human or rhesus macaque lymphocytes and macrophages, with no apparent significant cytotoxicity at 2 to 3 logs above the median effective antiviral concn.  Combination of tofacitinib and ruxolitinib increased the efficacy by 53- to 161-fold vs. that obsd. for monotherapy, resp., and each drug applied alone to primary human lymphocytes displayed similar efficacy against HIV-1 contg. various polymerase substitutions.  Both drugs inhibited virus replication in lymphocytes stimulated with phytohemagglutinin (PHA) plus interleukin-2 (IL-2), but not PHA alone, and inhibited reactivation of latent HIV-1 at low-micromolar concns. across the J-Lat T cell latency model and in primary human central memory lymphocytes.  Thus, targeted inhibition of JAK provided a selective, potent, and novel mechanism to inhibit HIV-1 replication in lymphocytes and macrophages, replication of drug-resistant HIV-1, and reactivation of latent HIV-1 and has the potential to reset the immunol. milieu in HIV-infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3eFMp64h4bVg90H21EOLACvtfcHk0lgeRjOT-wT0YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D&md5=85566414304fc2f381e99bca472b8691</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FAAC.02496-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02496-13%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DDetorio%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DRuxolitinib%2520and%2520tofacitinib%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520HIV-1%2520replication%2520and%2520virus%2520reactivation%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1977%26epage%3D1986%26doi%3D10.1128%2FAAC.02496-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Tofacitinib
in SARS-COV2 pneumonia</i> (NCT04332042);  <i>tofacitinib
plus hydroxycloroquine vs hydroxycloroquine in patients with COVID-19
interstitial pneumonia</i> (NCT04390061);  <i>tofacitinib
in hospitalized patients with COVID-19 pneumonia</i> (NCT04469114);  <i>tofacitinib for treatment of moderate COVID-19</i> (NCT04415151), <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Tofacitinib%0Ain+SARS-COV2+pneumonia+%28NCT04332042%29%3B+tofacitinib%0Aplus+hydroxycloroquine+vs+hydroxycloroquine+in+patients+with+COVID-19%0Ainterstitial+pneumonia+%28NCT04390061%29%3B+tofacitinib%0Ain+hospitalized+patients+with+COVID-19+pneumonia+%28NCT04469114%29%3B+tofacitinib+for+treatment+of+moderate+COVID-19+%28NCT04415151%29%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTofacitinib%250Ain%2520SARS-COV2%2520pneumonia%26jtitle%3Dtofacitinib%250Aplus%2520hydroxycloroquine%2520vs%2520hydroxycloroquine%2520in%2520patients%2520with%2520COVID-19%250Ainterstitial%2520pneumonia%26jtitle%3Dtofacitinib%250Ain%2520hospitalized%2520patients%2520with%2520COVID-19%2520pneumonia%26jtitle%3Dtofacitinib%2520for%2520treatment%2520of%2520moderate%2520COVID-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span>; <span class="NLM_string-name">Schinazi, R. F.</span></span> <i>Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections</i>. U.S. Patent <span class="NLM_patent">10022378 B2</span>, May 15, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Gavegnano&author=R.+F.+Schinazi&title=Antiviral+JAK+inhibitors+useful+in+treating+or+preventing+retroviral+and+other+viral+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26jtitle%3DAntiviral%2520JAK%2520inhibitors%2520useful%2520in%2520treating%2520or%2520preventing%2520retroviral%2520and%2520other%2520viral%2520infections%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedmak, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span>. <i>Intervirology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1159/000053979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1159%2F000053979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=412-418&author=W.+J.+Waldmanauthor=D.+A.+Knightauthor=L.+Blinderauthor=J.+Shenauthor=N.+S.+Lurainauthor=D.+M.+Millerauthor=D.+D.+Sedmakauthor=J.+W.+Williamsauthor=A.+S.+Chong&title=Inhibition+of+cytomegalovirus+in+vitro+and+in+vivo+by+the+experimental+immunosuppressive+agent+leflunomide&doi=10.1159%2F000053979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span></div><div class="casAuthors">Waldman, W. James; Knight, Deborah A.; Blinder, Leonard; Shen, JiKun; Lurain, Nell S.; Miller, Daniel M.; Sedmak, Daniel D.; Williams, James W.; Chong, Anita S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Intervirology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">412-418</span>CODEN:
                <span class="NLM_cas:coden">IVRYAK</span>;
        ISSN:<span class="NLM_cas:issn">0300-5526</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Despite progress in antiviral chemotherapy, cytomegalovirus (CMV) remains a major cause of morbidity and mortality among pharmacol. immunosuppressed transplant recipients, frequently engaging the clinician in a struggle to balance graft preservation with control of CMV disease.  Leflunomide, an inhibitor of protein kinase activity and pyrimidine synthesis, is an exptl. immunosuppressive agent effective against acute and chronic rejection in animal models.  Herein we summarize our recent studies demonstrating that leflunomide inhibits the prodn. of multiple clin. CMV isolates (including multi-drug-resistant virus) in both human fibroblasts and endothelial cells.  In contrast to all other anti-CMV drugs currently in use, leflunomide does not inhibit viral DNA synthesis, but rather appears to interfere with virion assembly.  Finally, preliminary studies in a rat model suggest that this agent reduces viral load in vivo.  These findings imply that leflunomide, an effective immunosuppressive agent, shows potential to concurrently attenuate a major complication of immunosuppression, CMV disease, by a novel mechanism of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolSzgyco_QqrVg90H21EOLACvtfcHk0lgeRjOT-wT0YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D&md5=e2fa6f422349ef0f74d13194a944c239</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1159%2F000053979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000053979%26sid%3Dliteratum%253Aachs%26aulast%3DWaldman%26aufirst%3DW.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DBlinder%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLurain%26aufirst%3DN.%2BS.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DSedmak%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DA.%2BS.%26atitle%3DInhibition%2520of%2520cytomegalovirus%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520the%2520experimental%2520immunosuppressive%2520agent%2520leflunomide%26jtitle%3DIntervirology%26date%3D2000%26volume%3D42%26spage%3D412%26epage%3D418%26doi%3D10.1159%2F000053979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadambi, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thistlewaite, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfinkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, M. A.</span></span> <span> </span><span class="NLM_article-title">Leflunomide for polyomavirus type BK nephropathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1056/NEJM200503173521125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1056%2FNEJM200503173521125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15784677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1yhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1157-1158&author=J.+W.+Williamsauthor=B.+Javaidauthor=P.+V.+Kadambiauthor=D.+Gillenauthor=R.+Harlandauthor=J.+R.+Thistlewaiteauthor=M.+Garfinkelauthor=P.+Fosterauthor=W.+Atwoodauthor=J.+M.+Millisauthor=S.+M.+Meehanauthor=M.+A.+Josephson&title=Leflunomide+for+polyomavirus+type+BK+nephropathy&doi=10.1056%2FNEJM200503173521125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Leflunomide for polyomavirus type BK nephropathy</span></div><div class="casAuthors">Williams, James W.; Javaid, Basit; Kadambi, Predeep V.; Gillen, Daniel; Harland, Robert; Thistlewaite, J. Richard; Garfinkel, Marc; Foster, Preston; Atwood, Walter; Millis, J. Michael; Meehan, Shane M.; Josephson, Michelle A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1157-1158</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4PplEiwJ6LVg90H21EOLACvtfcHk0lh1oaTpdL57RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1yhur4%253D&md5=bcbfe6cac3b6ad7f1755eceb2fe94280</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1056%2FNEJM200503173521125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200503173521125%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DJavaid%26aufirst%3DB.%26aulast%3DKadambi%26aufirst%3DP.%2BV.%26aulast%3DGillen%26aufirst%3DD.%26aulast%3DHarland%26aufirst%3DR.%26aulast%3DThistlewaite%26aufirst%3DJ.%2BR.%26aulast%3DGarfinkel%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DP.%26aulast%3DAtwood%26aufirst%3DW.%26aulast%3DMillis%26aufirst%3DJ.%2BM.%26aulast%3DMeehan%26aufirst%3DS.%2BM.%26aulast%3DJosephson%26aufirst%3DM.%2BA.%26atitle%3DLeflunomide%2520for%2520polyomavirus%2520type%2520BK%2520nephropathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1157%26epage%3D1158%26doi%3D10.1056%2FNEJM200503173521125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. G.</span></span> <span> </span><span class="NLM_article-title">Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation</span>. <i>Pediatr. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">E50</span>– <span class="NLM_lpage">E54</span>, <span class="refDoi"> DOI: 10.1111/petr.12029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fpetr.12029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23210794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=E50-E54&author=Y.+H.+Jungauthor=K.+C.+Moonauthor=J.+W.+Haauthor=S.+J.+Kimauthor=I.+S.+Haauthor=H.+I.+Cheongauthor=H.+G.+Kang&title=Leflunomide+therapy+for+BK+virus+allograft+nephropathy+after+pediatric+kidney+transplantation&doi=10.1111%2Fpetr.12029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1111%2Fpetr.12029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpetr.12029%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DMoon%26aufirst%3DK.%2BC.%26aulast%3DHa%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHa%26aufirst%3DI.%2BS.%26aulast%3DCheong%26aufirst%3DH.%2BI.%26aulast%3DKang%26aufirst%3DH.%2BG.%26atitle%3DLeflunomide%2520therapy%2520for%2520BK%2520virus%2520allograft%2520nephropathy%2520after%2520pediatric%2520kidney%2520transplantation%26jtitle%3DPediatr.%2520Transplant.%26date%3D2013%26volume%3D17%26spage%3DE50%26epage%3DE54%26doi%3D10.1111%2Fpetr.12029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10145</span>, <span class="refDoi"> DOI: 10.1096/fj.201902793RR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1096%2Ffj.201902793RR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32598086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Gnu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=10132-10145&author=J.+Wangauthor=J.+Sunauthor=J.+Huauthor=C.+Wangauthor=R.+A.+Prinzauthor=D.+Pengauthor=X.+Liuauthor=X.+Xu&title=A77+1726%2C+the+active+metabolite+of+the+anti-rheumatoid+arthritis+drug+leflunomide%2C+inhibits+influenza+A+virus+replication+in+vitro+and+in+vivo+by+inhibiting+the+activity+of+Janus+kinases&doi=10.1096%2Ffj.201902793RR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases</span></div><div class="casAuthors">Wang, Jiongjiong; Sun, Jing; Hu, Jiao; Wang, Chengming; Prinz, Richard A.; Peng, Daxin; Liu, Xiufan; Xu, Xiulong</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">10132-10145</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">1530-6860</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The newly reassorted IAV subtypes from zoonotic reservoirs respond poorly to current vaccines and antiviral therapy.  There is an unmet need in developing novel antiviral drugs for better control of IAV infection.  The cellular factors that are crucial for virus replication have been sought as novel mol. targets for antiviral therapy.  Recent studies have shown that Janus kinases (JAK), JAK1, and JAK2, play an important role in IAV replication.  Leflunomide is an anti-inflammatory drug primarily used for treating rheumatoid arthritis (RA).  Prior studies suggest that A77 1726, the active metabolite of leflunomide, inhibits the activity of JAK1 and JAK3.  Our current study aims to det. if A77 1726 can function as a JAK inhibitor to control IAV infection.  Here, we report that A77 1726 inhibited the replication of three IAV subtypes(H5N1, H1N1, H9N2)in three cell types (chicken embryonic fibroblasts, A549, and MDCK).  A77 1726 inhibited JAK1, JAK2, and STAT3 tyrosine phosphorylation.  Similar observations were made with Ruxolitinib (Rux), a JAK-specific inhibitor.  JAK2 overexpression enhanced H5N1 virus replication and compromised the antiviral activity of A77 1726.  Leflunomide inhibited virus replication in the lungs of IAV-infected mice, alleviated their body wt. loss, and prolonged their survival.  Our study demonstrates for the first time the ability of A77 1726 to inhibit JAK2 activity and suggests that inhibition of JAK activity contributes to its antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRh9AnI4C2i7Vg90H21EOLACvtfcHk0lh1oaTpdL57RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Gnu7zO&md5=274979fb4412e68c2805196c6bc0aee7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1096%2Ffj.201902793RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201902793RR%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPrinz%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DA77%25201726%252C%2520the%2520active%2520metabolite%2520of%2520the%2520anti-rheumatoid%2520arthritis%2520drug%2520leflunomide%252C%2520inhibits%2520influenza%2520A%2520virus%2520replication%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520inhibiting%2520the%2520activity%2520of%2520Janus%2520kinases%26jtitle%3DFASEB%2520J.%26date%3D2020%26volume%3D34%26spage%3D10132%26epage%3D10145%26doi%3D10.1096%2Ffj.201902793RR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damonte, E. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of A771726, the active metabolite of leflunomide, against Junin virus</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1002/jmv.25024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fjmv.25024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29315647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslertb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=819-827&author=C.+S.+Sepulvedaauthor=C.+C.+Garciaauthor=E.+B.+Damonte&title=Antiviral+activity+of+A771726%2C+the+active+metabolite+of+leflunomide%2C+against+Junin+virus&doi=10.1002%2Fjmv.25024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of A771726, the active metabolite of leflunomide, against Junin virus</span></div><div class="casAuthors">Sepulveda, Claudia S.; Garcia, Cybele C.; Damonte, Elsa B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-827</span>CODEN:
                <span class="NLM_cas:coden">JMVIDB</span>;
        ISSN:<span class="NLM_cas:issn">0146-6615</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the effect of A771726, the active metabolite of leflunomide, (CONICET-UBA), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad against the infection with Junin virus (JUNV), agent of Argentine hemorrhagic fever (AHF).  The treatment with non-cytotoxic concns. of A771726 of Vero and A549 cells infected with JUNV inhibited virus replication in a dose-dependent manner, as detd. by virus yield redn. assay.  The antiviral effectiveness of A771726 was not importantly affected by the multiplicity of infection and the virus strain.  Moreover, the combination of A771726 and ribavirin had a significantly more potent antiviral activity than each single drug treatment.  Mechanistic studies showed that the main action of A771726 is exerted before 6 h of JUNV infection.  Accordingly, inhibition of viral RNA synthesis was detected in treated infected cells by real time RT-PCR.  The exogenous addn. of uridine or orotic acid produced a partial reversal of the inhibitory effect of A771726 on infective virus prodn. whereas a total reversion was detected on JUNV RNA synthesis, probably by restoration of the enzymic activity of dihydroorotate dehydrogenase (DHODH) and the intracellular pyrimidine pools.  In conclusion, these results suggest that the antiviral target would be viral RNA synthesis through pyrimidine depletion, but any other effect of the compd. on JUNV infection cannot be excluded.  This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compd. alone or in combination with ribavirin to combat AHF as well as other human pathogenic arena viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKcSOjtURN5bVg90H21EOLACvtfcHk0lh1oaTpdL57RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslertb4%253D&md5=c54bf5daa9659353503eb8d009616e7d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fjmv.25024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.25024%26sid%3Dliteratum%253Aachs%26aulast%3DSepulveda%26aufirst%3DC.%2BS.%26aulast%3DGarcia%26aufirst%3DC.%2BC.%26aulast%3DDamonte%26aufirst%3DE.%2BB.%26atitle%3DAntiviral%2520activity%2520of%2520A771726%252C%2520the%2520active%2520metabolite%2520of%2520leflunomide%252C%2520against%2520Junin%2520virus%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2018%26volume%3D90%26spage%3D819%26epage%3D827%26doi%3D10.1002%2Fjmv.25024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liacini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seamone, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muruve, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbles, L. A.</span></span> <span> </span><span class="NLM_article-title">Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1097/TP.0b013e3182007be2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1097%2FTP.0b013e3182007be2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21079551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=1450-1457&author=A.+Liaciniauthor=M.+E.+Seamoneauthor=D.+A.+Muruveauthor=L.+A.+Tibbles&title=Anti-BK+virus+mechanisms+of+sirolimus+and+leflunomide+alone+and+in+combination%3A+toward+a+new+therapy+for+BK+virus+infection&doi=10.1097%2FTP.0b013e3182007be2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection</span></div><div class="casAuthors">Liacini, Abdelhamid; Seamone, Mark E.; Muruve, Daniel A.; Tibbles, Lee Anne</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1450-1457</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Human BK polyomavirus is the causative agent of BK nephropathy which is now the leading cause of early renal graft loss.  Although no randomized clin. trials have supported this therapy, redn. of immunosuppressive drugs is the current BK nephropathy treatment.  We hypothesized that inhibition of the intracellular protein kinase pathways activated by BK virus may be a more effective therapeutic strategy than redn. of immunosuppression.  Four days after infection of renal epithelial cells lines CCD1103, CCD1105 and human primary tubular epithelial cells with BK virus, we found increased phosphorylation of 3'-phosphoinositide-dependent kinase-1 (PDK-1), the protein kinase Akt (Akt), mammalian target of rapamycin (mTOR), and 70 kDa ribosomal protein S6 kinase (p70S6K).  To inhibit this pathway, we used sirolimus, which repressed p70S6K phosphorylation and reduced BK virus large T antigen expression in a dose-dependent manner.  We then used the tyrosine kinase inhibitor leflunomide (using the active metabolite A77 1726), which decreased PDK1 and Akt phosphorylation and inhibited BK virus genome replication and early gene expression.  The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.  On the basis of these results, we suggest that inhibition of protein kinase pathways with a combination of sirolimus and leflunomide may be an effective therapy for BK virus reactivation.  Because both sirolimus and leflunomide possess immunosuppressive activity, combination therapy may reduce BK pathogenesis while maintaining appropriate transplant immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtBRM8dTYrxbVg90H21EOLACvtfcHk0ljV5uRZ4oevhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrtrnO&md5=ae9aa5e1c961a5ebe3351e578bb9e7ec</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1097%2FTP.0b013e3182007be2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FTP.0b013e3182007be2%26sid%3Dliteratum%253Aachs%26aulast%3DLiacini%26aufirst%3DA.%26aulast%3DSeamone%26aufirst%3DM.%2BE.%26aulast%3DMuruve%26aufirst%3DD.%2BA.%26aulast%3DTibbles%26aufirst%3DL.%2BA.%26atitle%3DAnti-BK%2520virus%2520mechanisms%2520of%2520sirolimus%2520and%2520leflunomide%2520alone%2520and%2520in%2520combination%253A%2520toward%2520a%2520new%2520therapy%2520for%2520BK%2520virus%2520infection%26jtitle%3DTransplantation%26date%3D2010%26volume%3D90%26spage%3D1450%26epage%3D1457%26doi%3D10.1097%2FTP.0b013e3182007be2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, D.</span></span> <span> </span><span class="NLM_article-title">Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy</span>. <i>Nephrology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1111/nep.12948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fnep.12948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28247521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVOksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=326-329&author=J.+Jawauthor=P.+Hillauthor=D.+Goodman&title=Combination+of+Leflunomide+and+Everolimus+for+treatment+of+BK+virus+nephropathy&doi=10.1111%2Fnep.12948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy</span></div><div class="casAuthors">Jaw, Juli; Hill, Prue; Goodman, David</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326-329</span>CODEN:
                <span class="NLM_cas:coden">NEPHF2</span>;
        ISSN:<span class="NLM_cas:issn">1320-5358</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BK nephropathy (BKN) is a common cause of graft dysfunction following kidney transplantation.  Minimization of immunosuppressive therapy remains the first line of therapy, but this may lead to rejection and graft loss.  In some cases, despite lowering immunosuppression, BK infection can persist, leading to chronic damage and kidney failure.  Currently, there is no specific anti-BK viral therapy.  Recent in vitro expts. have demonstrated a redn. in BK viral replication when infected cells are treated with the combination of Leflunomide and Everolimus.  This study aims to explore the effect of this drugs combination on viral clearance and graft function in patients with persistent disease despite redn. in immunosuppression.  We treated three patients with combination Leflunomide and Everolimus.  Data on medical history, biochem. parameters and viral loads were collected.  Significant improvement in viral loads was obsd. in two cases with resoln. of viremia in another (Table 1).  Two recipients had preserved allograft function.  The remaining graft was lost because of combination of obstruction and BKN.  No adverse reactions such as bone marrow toxicity were obsd.  Combination of Leflunomide and Everolimus is safe and should be considered as a rescue therapy in treatment of BKN, esp. in those who fail to clear this infection despite redn. of immunosuppressive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9HcDHiE52SbVg90H21EOLACvtfcHk0ljV5uRZ4oevhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVOksb0%253D&md5=95aec43e62f5617065f3fd070c4cae4a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fnep.12948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.12948%26sid%3Dliteratum%253Aachs%26aulast%3DJaw%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DP.%26aulast%3DGoodman%26aufirst%3DD.%26atitle%3DCombination%2520of%2520Leflunomide%2520and%2520Everolimus%2520for%2520treatment%2520of%2520BK%2520virus%2520nephropathy%26jtitle%3DNephrology%26date%3D2017%26volume%3D22%26spage%3D326%26epage%3D329%26doi%3D10.1111%2Fnep.12948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of leflunomide for refractory COVID-19: An open-label controlled study</span>. <i>MedRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.29.20114223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.05.29.20114223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Q.+Wangauthor=H.+Guoauthor=Y.+Liauthor=X.+Jianauthor=X.+Houauthor=N.+Zhongauthor=J.+Feiauthor=D.+Suauthor=Z.+Bianauthor=Y.+Zhangauthor=Y.+Huauthor=Y.+Sunauthor=X.+Yuauthor=Y.+Liauthor=B.+Jiangauthor=Y.+Liauthor=F.+Qinauthor=Y.+Wuauthor=Y.+Gaoauthor=Z.+Hu&title=Efficacy+and+safety+of+leflunomide+for+refractory+COVID-19%3A+An+open-label+controlled+study&doi=10.1101%2F2020.05.29.20114223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1101%2F2020.05.29.20114223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.29.20114223%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJian%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DFei%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DBian%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DZ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520leflunomide%2520for%2520refractory%2520COVID-19%253A%2520An%2520open-label%2520controlled%2520study%26jtitle%3DMedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.29.20114223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">NIH U.S. National
Library of Medicine</span>.  <i>Leflunomide
in Mild COVID-19 Patients</i>, NCT04361214, University of Chicago, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National%0ALibrary+of+Medicine.+Leflunomide%0Ain+Mild+COVID-19+Patients%2C+NCT04361214%2C+University+of+Chicago%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLeflunomide%250Ain%2520Mild%2520COVID-19%2520Patients" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionakis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roswarski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monticelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roshon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrzesinski, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarakas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bruton tyrosine kinase in patients with severe COVID-19</span>. <i>Sci. Immunol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">eabd0110</span>, <span class="refDoi"> DOI: 10.1126/sciimmunol.abd0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fsciimmunol.abd0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32503877" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=eabd0110&author=M.+Roschewskiauthor=M.+S.+Lionakisauthor=J.+P.+Sharmanauthor=J.+Roswarskiauthor=A.+Goyauthor=M.+A.+Monticelliauthor=M.+Roshonauthor=S.+H.+Wrzesinskiauthor=J.+V.+Desaiauthor=M.+A.+Zarakasauthor=J.+Collenauthor=K.+Roseauthor=A.+Hamdyauthor=R.+Izumiauthor=G.+W.+Wrightauthor=K.+K.+Chungauthor=J.+Baselgaauthor=L.+M.+Staudtauthor=W.+H.+Wilson&title=Inhibition+of+Bruton+tyrosine+kinase+in+patients+with+severe+COVID-19&doi=10.1126%2Fsciimmunol.abd0110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.abd0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.abd0110%26sid%3Dliteratum%253Aachs%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DLionakis%26aufirst%3DM.%2BS.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DRoswarski%26aufirst%3DJ.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DMonticelli%26aufirst%3DM.%2BA.%26aulast%3DRoshon%26aufirst%3DM.%26aulast%3DWrzesinski%26aufirst%3DS.%2BH.%26aulast%3DDesai%26aufirst%3DJ.%2BV.%26aulast%3DZarakas%26aufirst%3DM.%2BA.%26aulast%3DCollen%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DK.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DG.%2BW.%26aulast%3DChung%26aufirst%3DK.%2BK.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26atitle%3DInhibition%2520of%2520Bruton%2520tyrosine%2520kinase%2520in%2520patients%2520with%2520severe%2520COVID-19%26jtitle%3DSci.%2520Immunol%26date%3D2020%26volume%3D5%26spage%3Deabd0110%26doi%3D10.1126%2Fsciimmunol.abd0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeker, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shadman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, A. R.</span></span> <span> </span><span class="NLM_article-title">BTK inhibitors in cancer patients with COVID-19: ″The winner will be the one who controls that chaos″ (napoleon bonaparte)</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3514</span>– <span class="NLM_lpage">3516</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-20-1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-20-1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32345646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKrtrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=3514-3516&author=E.+A.+Chongauthor=L.+E.+Roekerauthor=M.+Shadmanauthor=M.+S.+Davidsauthor=S.+J.+Schusterauthor=A.+R.+Mato&title=BTK+inhibitors+in+cancer+patients+with+COVID-19%3A+%E2%80%B3The+winner+will+be+the+one+who+controls+that+chaos%E2%80%B3+%28napoleon+bonaparte%29&doi=10.1158%2F1078-0432.CCR-20-1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">BTK inhibitors in cancer patients with COVID-19: "the winner will be the one who controls that chaos" (Napoleon Bonaparte)</span></div><div class="casAuthors">Chong, Elise A.; Roeker, Lindsey E.; Shadman, Mazyar; Davids, Matthew S.; Schuster, Stephen J.; Mato, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3514-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  As the SARS-CoV-2 (COVID-19) pandemic spreads and the no. of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID-19-affected patients grows, the authors must consider the pros and cons of BTKi discontinuation for the authors' patients.  In favor of BTKi continuation, BTK plays an active role in macrophage polarization.  By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state assocd. with COVID-19.  In favor of BTKi discontinuation, the authors note a potentially increased risk of secondary infections and impaired humoral immunity.  The authors hypothesize that the potential benefit of blunting a hyperinflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption.  On the basis of this, the authors suggest continuing BTKi in patients with COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNi9sKn8QYnLVg90H21EOLACvtfcHk0lgqSMGtjNcIpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKrtrjF&md5=ae51304398c87b4c35d5e1038eb65b97</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-1427%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DE.%2BA.%26aulast%3DRoeker%26aufirst%3DL.%2BE.%26aulast%3DShadman%26aufirst%3DM.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMato%26aufirst%3DA.%2BR.%26atitle%3DBTK%2520inhibitors%2520in%2520cancer%2520patients%2520with%2520COVID-19%253A%2520%25E2%2580%25B3The%2520winner%2520will%2520be%2520the%2520one%2520who%2520controls%2520that%2520chaos%25E2%2580%25B3%2520%2528napoleon%2520bonaparte%2529%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D3514%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-20-1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skarbnik, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumerai, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span> <span> </span><span class="NLM_article-title">The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1182/blood.2020006288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood.2020006288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32302379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1SjtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=1912-1915&author=S.+P.+Treonauthor=J.+J.+Castilloauthor=A.+P.+Skarbnikauthor=J.+D.+Soumeraiauthor=I.+M.+Ghobrialauthor=M.+L.+Guerreraauthor=K.+Meidauthor=G.+Yang&title=The+BTK+inhibitor+ibrutinib+may+protect+against+pulmonary+injury+in+COVID-19-infected+patients&doi=10.1182%2Fblood.2020006288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients</span></div><div class="casAuthors">Treon, Steven P.; Castillo, Jorge J.; Skarbnik, Alan P.; Soumerai, Jacob D.; Ghobrial, Irene M.; Guerrera, Maria Luisa; Meid, Kirsten; Yang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1912-1915</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-vs.-host disease (cGVHD).  The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model.  Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.  We care for 600 to 800 Waldenstrom macroglobulinemia (WM) patients each year, ~ 300 of whom are on a BTK inhibitor.  We identified 6 patients receiving ibrutinib for WM who were diagnosed with COVID-19; these patients consented to the use of their data.  Their clin. characteristics appear in Table 1.  Their median age was 66 years, and 5 were on the recommended treatment dose of 420 mg/d; the sixth patient was on a reduced dose of 140 mg/d because of arthralgias.  For all patients, the median time on ibrutinib was 52 mo.  Their median time with COVID-19-related symptoms prior to diagnostic testing was 5 days, and the median time since diagnosis of COVID-19 was 22 days.  All 6 patients experienced cough and fever as prodromal symptoms.  The 5 patients on ibrutinib, 420 mg/d, did not experience dyspnea and did not require hospitalization.  Their course was marked by steady improvement, and resoln. or near resoln. of COVID-19-related symptoms during the follow-up period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ANuw-HJegbVg90H21EOLACvtfcHk0lgqSMGtjNcIpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1SjtbzF&md5=702770337b78a2c6f22d1f22080695e5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1182%2Fblood.2020006288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2020006288%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DSkarbnik%26aufirst%3DA.%2BP.%26aulast%3DSoumerai%26aufirst%3DJ.%2BD.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DGuerrera%26aufirst%3DM.%2BL.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DG.%26atitle%3DThe%2520BTK%2520inhibitor%2520ibrutinib%2520may%2520protect%2520against%2520pulmonary%2520injury%2520in%2520COVID-19-infected%2520patients%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26spage%3D1912%26epage%3D1915%26doi%3D10.1182%2Fblood.2020006288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greff, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szantai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemenics, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szathmary, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span> <span> </span><span class="NLM_article-title">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.2174/092986711794839188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+Nemethauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Szantai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathmaryauthor=J.+Minarovitsauthor=G.+Keriauthor=L.+Orfi&title=Novel%2C+selective+CDK9+inhibitors+for+the+treatment+of+HIV+infection&doi=10.2174%2F092986711794839188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0lgqSMGtjNcIpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSzantai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathmary%26aufirst%3DZ.%26aulast%3DMinarovits%26aufirst%3DJ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520selective%2520CDK9%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358%26doi%3D10.2174%2F092986711794839188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez-Arias, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control and HIV-1 susceptibility are linked by cdk6-dependent cdk2 phosphorylation of samhd1 in myeloid and lymphoid cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">1988</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1400873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1400873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25015816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1988-1997&author=E.+Paulsauthor=A.+Ruizauthor=R.+Badiaauthor=M.+Permanyerauthor=A.+Gubernauthor=E.+Riveira-Mu%C3%B1ozauthor=J.+Torres-Torronterasauthor=M.+%C3%81lvarezauthor=B.+Motheauthor=C.+Branderauthor=M.+Crespoauthor=L.+Men%C3%A9ndez-Ariasauthor=B.+Clotetauthor=O.+T.+Kepplerauthor=R.+Mart%C3%ADauthor=F.+Posasauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Cell+cycle+control+and+HIV-1+susceptibility+are+linked+by+cdk6-dependent+cdk2+phosphorylation+of+samhd1+in+myeloid+and+lymphoid+cells&doi=10.4049%2Fjimmunol.1400873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells</span></div><div class="casAuthors">Pauls, Eduardo; Ruiz, Alba; Badia, Roger; Permanyer, Marc; Gubern, Albert; Riveira-Munoz, Eva; Torres-Torronteras, Javier; Alvarez, Mar; Mothe, Beatriz; Brander, Christian; Crespo, Manel; Menendez-Arias, Luis; Clotet, Bonaventura; Keppler, Oliver T.; Marti, Ramon; Posas, Francesc; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1988-1997</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Proliferating cells are preferentially susceptible to infection by retroviruses.  Sterile α motif and HD domain-contg. protein-1 (SAMHD1) is a recently described deoxynucleotide phosphohydrolase controlling the size of the intracellular deoxynucleotide triphosphate (dNTP) pool, a limiting factor for retroviral reverse transcription in noncycling cells.  Proliferating (Ki67+) primary CD4+ T cells or macrophages express a phosphorylated form of SAMHD1 that corresponds with susceptibility to infection in cell culture.  We identified cyclin-dependent kinase (CDK) 6 as an upstream regulator of CDK2 controlling SAMHD1 phosphorylation in primary T cells and macrophages susceptible to infection by HIV-1.  In turn, CDK2 was strongly linked to cell cycle progression and coordinated SAMHD1 phosphorylation and inactivation.  CDK inhibitors specifically blocked HIV-1 infection at the reverse transcription step in a SAMHD1-dependent manner, reducing the intracellular dNTP pool.  Our findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is important for replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-LI-z2ggFCbVg90H21EOLACvtfcHk0liUEbUszuRmkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM&md5=5c1c895a20f64ad71e0578ea2fca74bf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400873%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DGubern%26aufirst%3DA.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3D%25C3%2581lvarez%26aufirst%3DM.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DMen%25C3%25A9ndez-Arias%26aufirst%3DL.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DKeppler%26aufirst%3DO.%2BT.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPosas%26aufirst%3DF.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520control%2520and%2520HIV-1%2520susceptibility%2520are%2520linked%2520by%2520cdk6-dependent%2520cdk2%2520phosphorylation%2520of%2520samhd1%2520in%2520myeloid%2520and%2520lymphoid%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D1988%26epage%3D1997%26doi%3D10.4049%2Fjimmunol.1400873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roizman, B.</span></span> <span> </span><span class="NLM_article-title">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">10591</span>– <span class="NLM_lpage">10599</span>, <span class="refDoi"> DOI: 10.1128/JVI.01242-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01242-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18753202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=10591-10599&author=L.+O.+Durandauthor=B.+Roizman&title=Role+of+cdk9+in+the+optimization+of+expression+of+the+genes+regulated+by+ICP22+of+herpes+simplex+virus+1&doi=10.1128%2FJVI.01242-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span></div><div class="casAuthors">Durand, Lizette Olga; Roizman, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10591-10599</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ICP22 is a multi-functional herpes simplex virus 1 (HSV-1) regulatory protein that regulates the accumulation of a subset of late (γ2) proteins exemplified by UL38, UL41, and US11.  ICP22 binds the cyclin-dependent kinase 9 (cdk9) but not cdk7, and this complex in conjunction with viral protein kinases phosphorylates the carboxyl terminus of RNA polymerase II (Pol II) in vitro.  The primary function of cdk9 and its partners, the cyclin T variants, is in the elongation of RNA transcripts, although functions related to the initiation and processing of transcripts have also been reported.  We report two series of expts. designed to probe the role of cdk9 in infected cells.  In the first, infected cells were treated with 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), a specific inhibitor of cdk9.  In cells treated with DRB, the major effect was in the accumulation of viral RNAs and proteins regulated by ICP22.  The accumulation of α, β, or γ proteins not regulated by ICP22 was not affected by the drug.  The results obtained with DRB were duplicated in cells transfected with small interfering RNA (siRNA) targeting cdk9 mRNAs.  Interestingly, DRB and siRNA reduced the levels of ICP22 but not those of other α gene products.  In addn., cdk9 and ICP22 appeared to colocalize with RNA Pol II in wild-type-virus-infected cells but not in ΔUL13-infected cells.  We conclude that cdk9 plays a crit. role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXb1W_R979rVg90H21EOLACvtfcHk0liUEbUszuRmkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF&md5=7a494e43fe778e3ad849facc21b13143</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1128%2FJVI.01242-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01242-08%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DL.%2BO.%26aulast%3DRoizman%26aufirst%3DB.%26atitle%3DRole%2520of%2520cdk9%2520in%2520the%2520optimization%2520of%2520expression%2520of%2520the%2520genes%2520regulated%2520by%2520ICP22%2520of%2520herpes%2520simplex%2520virus%25201%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D10591%26epage%3D10599%26doi%3D10.1128%2FJVI.01242-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Palbociclib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0379-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs40265-015-0379-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25792301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=543-551&author=S.+Dhillon&title=Palbociclib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0379-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-551</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Palbociclib (Ibrance) is an oral, reversible, selective, small-mol. inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6 developed by Pfizer for the treatment of cancer.  CDKs are important modulators of cell cycle entry and progression in response to growth signals, and inhibition of these kinases with palbociclib could enhance the activity of other anticancer drugs in tolerable regimens.  Palbociclib, in combination with letrozole, was recently approved in the US for the first-line treatment of advanced breast cancer.  Phase III development is underway worldwide investigating its use as first-line treatment in advanced breast cancer, as well as treatment of recurrent or advanced breast cancer and high-risk, early-stage breast cancer.  A phase II trial is underway in the USA for non-small cell lung cancer under a US National Cancer Institute-funded research collaboration, and several phase I and II investigations are being conducted for various other solid tumor types and haematol. malignancies.  This article summarizes the milestones in the development of palbociclib leading to this first approval for use in postmenopausal women with estrogen-pos., human epidermal growth factor receptor (HER) 2-neg. advanced breast cancer as initial endocrine-based therapy for their metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_I2Tzeff7_7Vg90H21EOLACvtfcHk0liUEbUszuRmkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCrsrs%253D&md5=cd4f6d1160c06397c51e4b30222cb3d4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0379-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0379-9%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DPalbociclib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D543%26epage%3D551%26doi%3D10.1007%2Fs40265-015-0379-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1097/QAD.0000000000000399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1097%2FQAD.0000000000000399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25036183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2213-2222&author=E.+Paulsauthor=R.+Badiaauthor=J.+Torres-Torronterasauthor=A.+Ruizauthor=M.+Permanyerauthor=E.+Riveira-Mu%C3%B1ozauthor=B.+Clotetauthor=R.+Martiauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Palbociclib%2C+a+selective+inhibitor+of+cyclin-dependent+kinase4%2F6%2C+blocks+HIV-1+reverse+transcription+through+the+control+of+sterile+%CE%B1+motif+and+HD+domain-containing+protein-1+%28SAMHD1%29+activity&doi=10.1097%2FQAD.0000000000000399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span></div><div class="casAuthors">Pauls, Eduardo; Badia, Roger; Torres-Torronteras, Javier; Ruiz, Alba; Permanyer, Marc; Riveira-Munoz, Eva; Clotet, Bonaventura; Marti, Ramon; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2213-2222</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Sterile α motif and HD domain-contg. protein-1 (SAMHD1) inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides.  SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation.  However, the exact mechanism of SAMHD1 regulation in primary cells is unclear.  We explore the effect of palbociclib, a CDK6 inhibitor, in HIV-1 replication.  Methods: Human primary monocytes were differentiated into macrophages with monocyte-colony stimulating factor and CD4 T lymphocytes stimulated with phytohaemagglutinin (PHA)/interleukin-2.  Cells were treated with palbociclib and then infected with a Green fluorescent protein-expressing HIV-1 or R5 HIV-1 BaL.  Viral DNA was measured by quant. PCR and infection assessed by flow cytometry.  Deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation.  HIV-1 replication was blocked by AT7519 (66.4±3.8%; n=4), roscovitine (47.3±3.9%; n=4) and purvalanol A (55.7±15.7%; n=4) at subtoxic concns.  Palbociclib, a potent and selective CDK6 inhibitor, blocked SAMHD1 phosphorylation, intracellular dNTP levels, HIV-1 reverse transcription and HIV-1 replication in primary macrophages and CD4 T lymphocytes.  Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160.  The antiviral effect was lost when SAMHD1 was degraded by Vpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect.  Conclusions: Our results indicate that SAMHD1-mediated HIV-1 restriction is controlled by CDK as previously suggested but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation.  Our study provides a new signaling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnbJDONasm7Vg90H21EOLACvtfcHk0lhLjSXIjpeC2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM&md5=68935096ca65c2f15a2b24423c006302</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2FQAD.0000000000000399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0000000000000399%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DMarti%26aufirst%3DR.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DPalbociclib%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase4%252F6%252C%2520blocks%2520HIV-1%2520reverse%2520transcription%2520through%2520the%2520control%2520of%2520sterile%2520%25CE%25B1%2520motif%2520and%2520HD%2520domain-containing%2520protein-1%2520%2528SAMHD1%2529%2520activity%26jtitle%3DAIDS%26date%3D2014%26volume%3D28%26spage%3D2213%26epage%3D2222%26doi%3D10.1097%2FQAD.0000000000000399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile α motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0lhLjSXIjpeC2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrlova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiss, F.</span></span> <span> </span><span class="NLM_article-title">Trametinib (GSK1120212)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-91442-8_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2F978-3-319-91442-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30069762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVSgtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=91-100&author=R.+Zeiserauthor=H.+Andrlovaauthor=F.+Meiss&title=Trametinib+%28GSK1120212%29&doi=10.1007%2F978-3-319-91442-8_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Trametinib (GSK1120212)</span></div><div class="casAuthors">Zeiser, Robert; Andrlova, Hana; Meiss, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a crit. role in the regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis.  Therefore, MEK inhibition was recognized as a promising target for antineo-plastic therapy.  Trametinib (GSK1120212), an oral MEK inhibitor which is selective for MEK1 and MEK2, has been approved by the FDA for the treatment of metastatic melanoma in a combination with a BRAF inhibitor.  In this overview, preclin. and clin. data for trametinib are presented including mechanisms based on in vitro studies as well as findings from different clin. studies.  The future clin. trial in different solid tumor entities will define the therapeutic role of this targeted therapy approach, possibly as a combination with other targeted therapies such as BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7cKn7vicfELVg90H21EOLACvtfcHk0lhLjSXIjpeC2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVSgtrjP&md5=c9255082da16be6f208cfb3e8334a74f</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DZeiser%26aufirst%3DR.%26aulast%3DAndrlova%26aufirst%3DH.%26aulast%3DMeiss%26aufirst%3DF.%26atitle%3DTrametinib%2520%2528GSK1120212%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D91%26epage%3D100%26doi%3D10.1007%2F978-3-319-91442-8_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schräder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29990517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmsFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=80-92&author=T.+Schr%C3%A4derauthor=S.+E.+Dudekauthor=A.+Schreiberauthor=C.+Ehrhardtauthor=O.+Planzauthor=S.+Ludwig&title=The+clinically+approved+MEK+inhibitor+Trametinib+efficiently+blocks+influenza+A+virus+propagation+and+cytokine+expression&doi=10.1016%2Fj.antiviral.2018.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression</span></div><div class="casAuthors">Schrader Tobias; Ehrhardt Christina; Dudek Sabine E; Schreiber Andre; Planz Oliver; Ludwig Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Influenza A virus (IAV) infections are still a major global threat for humans, especially for the risk groups of young children and the elderly.  Annual epidemics and sporadically occurring pandemics highlight the necessity of effective antivirals that can limit viral replication.  The currently licensed antiviral drugs target viral factors and are prone to provoke viral resistance.  In infected host cells IAV induces various cellular signaling cascades.  The Raf/MEK/ERK signaling cascade is indispensable for IAV replication because it triggers the nuclear export of newly assembled viral ribonucleoproteins (vRNPs).  Inhibition of this cascade limits viral replication.  Thus, next to their potential in anti-tumor therapy, inhibitors targeting the Raf/MEK/ERK signaling cascade came into focus as potential antiviral drugs.  The first licensed MEK inhibitor Trametinib (GSK-1120212) is used for treatment of malignant melanoma, being highly selective and having a promising side effect profile.  Since Trametinib may be qualified for a repurposing approach that would significantly shorten development time for an anti-flu use, we evaluated its antiviral potency and mode of action.  In this study, we describe that Trametinib efficiently blocks replication of different IAV subtypes in vitro and in vivo.  The broad antiviral activity against various IAV strains was due to its ability to interfere with export of progeny vRNPs from the nucleus.  The compound also limited hyper-expression of several cytokines.  Thus, we show for the first time that a clinically approved MEK inhibitor acts as a potent anti-influenza agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMPUw-TFMkJp6t8nS6Nc3fW6udTcc2ebu9F5JwnixMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmsFOrsA%253D%253D&md5=5857631999e5b7b65ac64ab8d3767182</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25A4der%26aufirst%3DT.%26aulast%3DDudek%26aufirst%3DS.%2BE.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DThe%2520clinically%2520approved%2520MEK%2520inhibitor%2520Trametinib%2520efficiently%2520blocks%2520influenza%2520A%2520virus%2520propagation%2520and%2520cytokine%2520expression%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D157%26spage%3D80%26epage%3D92%26doi%3D10.1016%2Fj.antiviral.2018.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haasbach, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmayer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2013.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2013.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23523553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=319-324&author=E.+Haasbachauthor=C.+Hartmayerauthor=O.+Planz&title=Combination+of+MEK+inhibitors+and+oseltamivir+leads+to+synergistic+antiviral+effects+after+influenza+A+virus+infection+in+vitro&doi=10.1016%2Fj.antiviral.2013.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro</span></div><div class="casAuthors">Haasbach, Emanuel; Hartmayer, Carmen; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">MEK inhibitors are very potent and promising compds. in cancer therapy.  Earlier investigations have demonstrated that they also possess antiviral properties against influenza virus.  This is due to the fact that activation of the Raf/MEK/ERK signaling pathway is a prerequisite for influenza virus replication.  As an alternative to vaccination, antiviral therapy is a means to control influenza.  The appearance of influenza virus strains that are resistant to current treatment options demonstrates the need for new antiviral strategies.  The aim of the presented study was to investigate whether the combination of MEK inhibitors with oseltamivir, an inhibitor of viral neuraminidase activity, would result in a synergistic antiviral effect against pandemic influenza A/Regensburg/D6/2009 (H1N1pdm09) virus.  Here we show that 4 different MEK inhibitors, PD-0325901, AZD-6244, AZD-8330, and RDEA-119 that are orally available and at least in a phase I clin. trial against cancer demonstrate antiviral activity as single agents or in combination with oseltamivir.  Combination treatment increased the antiviral activity of oseltamivir significantly and resulted in a synergistic antiviral effect as detd. by the Chou-Talalay method.  Taken together, the results demonstrate increased antiviral activity of oseltamivir after combination with MEK inhibitors.  These data are promising for further preclin. in vitro and in vivo investigations on the way to developing new antiviral regimens against influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA5--RW746VLVg90H21EOLACvtfcHk0ljMXhSOdL7vcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlSmtbs%253D&md5=9723a5424927948bb7f18904f34a56b4</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DHaasbach%26aufirst%3DE.%26aulast%3DHartmayer%26aufirst%3DC.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DCombination%2520of%2520MEK%2520inhibitors%2520and%2520oseltamivir%2520leads%2520to%2520synergistic%2520antiviral%2520effects%2520after%2520influenza%2520A%2520virus%2520infection%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D319%26epage%3D324%26doi%3D10.1016%2Fj.antiviral.2013.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krown, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapisuwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboulafia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS malignancy consortium protocol 042</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.48.6365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1200%2FJCO.2012.48.6365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24378417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Wiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=402-408&author=H.+B.+Koonauthor=S.+E.+Krownauthor=J.+Y.+Leeauthor=K.+Hondaauthor=S.+Rapisuwonauthor=Z.+Wangauthor=D.+Aboulafiaauthor=E.+G.+Reidauthor=M.+A.+Rudekauthor=B.+J.+Dezubeauthor=A.+Noy&title=Phase+II+trial+of+imatinib+in+AIDS-associated+Kaposi%E2%80%99s+sarcoma%3A+AIDS+malignancy+consortium+protocol+042&doi=10.1200%2FJCO.2012.48.6365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042</span></div><div class="casAuthors">Koon, Henry B.; Krown, Susan E.; Lee, Jeannette Y.; Honda, Kord; Rapisuwon, Suthee; Wang, Zhenghe; Aboulafia, David; Reid, Erin G.; Rudek, Michelle A.; Dezube, Bruce J.; Noy, Ariela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8).  Activation of the c-kit and platelet-derived growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell KSHV infection.  In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial regression of AIDS-assocd. KS (AIDS-KS) in five of 10 patients.  Patients and Methods This multicenter phase II study was designed to est. the response rate to imatinib in AIDS-KS.  Secondary objectives included investigation of predictors of response and imatinib pharmacokinetics in patients on antiretrovirals.  Patients received imatinib 400 mg/day by mouth for up to 12 mo with dose escalation up to 600 mg/day at 3 mo if their disease was stable.  Results Thirty patients were treated at 12 AIDS Malignancy Consortium sites.  Ten patients (33.3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progression.  Nine patients completed 52 wk of imatinib therapy.  The median treatment duration was 22.5 wk.  Only five patients (16.7%) discontinued therapy owing to adverse events.  Antiretroviral regimens did not significantly alter imatinib metab.  Activating mutations in PDGF-R and c-kit were not found at baseline or at disease progression.  We found no correlation with response with changes in any of the candidate cytokines.  Conclusion Imatinib has activity in AIDS-KS.  Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity.  Thirty percent of patients showed long-term clin. benefit and remained on imatinib for the entire year.  These results suggest imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1h992cqFsm7Vg90H21EOLACvtfcHk0ljMXhSOdL7vcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Wiu7s%253D&md5=a58c653acc5f45e76011a6942934c172</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.6365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.6365%26sid%3Dliteratum%253Aachs%26aulast%3DKoon%26aufirst%3DH.%2BB.%26aulast%3DKrown%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DRapisuwon%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DAboulafia%26aufirst%3DD.%26aulast%3DReid%26aufirst%3DE.%2BG.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DNoy%26aufirst%3DA.%26atitle%3DPhase%2520II%2520trial%2520of%2520imatinib%2520in%2520AIDS-associated%2520Kaposi%25E2%2580%2599s%2520sarcoma%253A%2520AIDS%2520malignancy%2520consortium%2520protocol%2520042%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D402%26epage%3D408%26doi%3D10.1200%2FJCO.2012.48.6365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egeblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kempen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1006/bbrc.2001.4302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1006%2Fbbrc.2001.4302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11178955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFemsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2001&pages=25-31&author=M.+Egebladauthor=O.+H.+Mortensenauthor=L.+C.+van+Kempenauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=BIBX1382BS%2C+but+not+AG1478+or+PD153035%2C+inhibits+the+ErbB+kinases+at+different+concentrations+in+intact+cells&doi=10.1006%2Fbbrc.2001.4302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">BIBX1382BS, but Not AG1478 or PD153035, Inhibits the ErbB Kinases at Different Concentrations in Intact Cells</span></div><div class="casAuthors">Egeblad, Mikala; Mortensen, Ole H.; van Kempen, Leon C. L. T.; Jaattela, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The activation of ErbB tyrosine kinase receptors (ErbB1, -2, -3, and -4) by ligand-induced homo- or heterodimerization regulates cell growth, death, and differentiation.  AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays.  The authors compared their ability to inhibit ErbB receptor signaling in intact cells to that of a novel ErbB receptor kinase inhibitor, BIBX1382BS.  Neither AG1478 nor PD153035 displayed any specificity for ErbB1-mediated signaling induced by transforming growth factor α (TGF-α) as compared to signaling initiated through the other ErbB kinases.  In contrast, BIBX1382BS was more potent at inhibiting signaling induced by TGF-α than that induced by neuregulin1-β1 or anti-ErbB2 agonist antibodies.  Interestingly, this compd. blocked antibody-induced ErbB4 homodimer activation at even lower concns. than ErbB1-triggered signaling.  Thus, BIBX1382BS, but not AG1478 and PD153035, can be employed to differentiate between the ErbB kinases in intact cells when used at appropriate concns.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT-5Grd1YMP7Vg90H21EOLACvtfcHk0ljMXhSOdL7vcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFemsL0%253D&md5=a93b3d75bf3ef5dac851f284cd7cb39f</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2001.4302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2001.4302%26sid%3Dliteratum%253Aachs%26aulast%3DEgeblad%26aufirst%3DM.%26aulast%3DMortensen%26aufirst%3DO.%2BH.%26aulast%3Dvan%2BKempen%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DBIBX1382BS%252C%2520but%2520not%2520AG1478%2520or%2520PD153035%252C%2520inhibits%2520the%2520ErbB%2520kinases%2520at%2520different%2520concentrations%2520in%2520intact%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D281%26spage%3D25%26epage%3D31%26doi%3D10.1006%2Fbbrc.2001.4302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albariño, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava-Ranjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2015.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25986249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXos1eltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2015&pages=40-47&author=E.+L.+Mohrauthor=L.+K.+McMullanauthor=M.+K.+Loauthor=J.+R.+Spenglerauthor=%C3%89.+Bergeronauthor=C.+G.+Albari%C3%B1oauthor=P.+Shrivastava-Ranjanauthor=C.+F.+Chiangauthor=S.+T.+Nicholauthor=C.+F.+Spiropoulouauthor=M.+Flint&title=Inhibitors+of+cellular+kinases+with+broad-spectrum+antiviral+activity+for+hemorrhagic+fever+viruses&doi=10.1016%2Fj.antiviral.2015.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses</span></div><div class="casAuthors">Mohr, Emma L.; McMullan, Laura K.; Lo, Michael K.; Spengler, Jessica R.; Bergeron, Eric; Albarino, Cesar G.; Shrivastava-Ranjan, Punya; Chiang, Cheng-Feng; Nichol, Stuart T.; Spiropoulou, Christina F.; Flint, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Host cell kinases are important for the replication of a no. of hemorrhagic fever viruses.  We tested a panel of kinase inhibitors for their ability to block the replication of multiple hemorrhagic fever viruses.  OSU-03012 inhibited the replication of Lassa, Ebola, Marburg and Nipah viruses, whereas BIBX 1382 dihydrochloride inhibited Lassa, Ebola and Marburg viruses.  BIBX 1382 blocked both Lassa and Ebola virus glycoprotein-dependent cell entry.  These compds. may be used as tools to understand conserved virus-host interactions, and implicate host cell kinases that may be targets for broad spectrum therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMf48R5EzygbVg90H21EOLACvtfcHk0lje1G7s0Z2F4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXos1eltrk%253D&md5=8475f940789e99dff0ecb80bbd248b24</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DMohr%26aufirst%3DE.%2BL.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DSpengler%26aufirst%3DJ.%2BR.%26aulast%3DBergeron%26aufirst%3D%25C3%2589.%26aulast%3DAlbari%25C3%25B1o%26aufirst%3DC.%2BG.%26aulast%3DShrivastava-Ranjan%26aufirst%3DP.%26aulast%3DChiang%26aufirst%3DC.%2BF.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DFlint%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520cellular%2520kinases%2520with%2520broad-spectrum%2520antiviral%2520activity%2520for%2520hemorrhagic%2520fever%2520viruses%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D120%26spage%3D40%26epage%3D47%26doi%3D10.1016%2Fj.antiviral.2015.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Canertinib pfizer</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=14730468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=58-63&author=C.+M.+Galmarini&title=Canertinib+pfizer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Canertinib (Pfizer)</span></div><div class="casAuthors">Galmarini, Carlos Maria</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-63</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review. Canertinib, a water-sol., orally available analog of PD-169414, is an epidermal growth factor tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.  This article describes the synthesis and structure-activity relations of the compd., its preclin. development, metab. and pharmacokinetics, toxicity, clin. development, and side effects and contraindications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB89fHpFtThrVg90H21EOLACvtfcHk0lje1G7s0Z2F4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFOgsL4%253D&md5=16edbe74a518e9eb2143a02ab48af1ec</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DCanertinib%2520pfizer%26jtitle%3DIDrugs%26date%3D2004%26volume%3D7%26spage%3D58%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reche, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morehead, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinherz, E. L.</span></span> <span> </span><span class="NLM_article-title">Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1172/JCI200523220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI200523220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15690085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=379-387&author=H.+Yangauthor=S.+K.+Kimauthor=M.+Kimauthor=P.+A.+Recheauthor=T.+J.+Moreheadauthor=I.+K.+Damonauthor=R.+M.+Welshauthor=E.+L.+Reinherz&title=Antiviral+chemotherapy+facilitates+control+of+poxvirus+infections+through+inhibition+of+cellular+signal+transduction&doi=10.1172%2FJCI200523220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction</span></div><div class="casAuthors">Yang, Hailin; Kim, Sung-Kwon; Kim, Mikyung; Reche, Pedro A.; Morehead, Tiara J.; Damon, Inger K.; Welsh, Raymond M.; Reinherz, Ellis L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-387</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The EGF-like domain of smallpox growth factor (SPGF) targets human ErbB-1, inducing tyrosine phosphorylation of certain host cellular substrates via activation of the receptor's kinase domain and thereby facilitating viral replication.  Given these findings, low mol. wt. org. inhibitors of ErbB-1 kinases might function as antiviral agents against smallpox.  Here the authors show that CI-1033 and related 4-anilinoquinazolines inhibit SPGF-induced human cellular DNA synthesis, protein tyrosine kinase activation, and c-Cbl assocn. with ErbB-1 and resultant internalization.  Infection of monkey kidney BSC-40 and VERO-E6 cells in vitro by variola strain Solaimen is blocked by CI-1033, primarily at the level of secondary viral spreading.  In an in vivo lethal vaccinia virus pneumonia model, CI-1033 alone promotes survival of animals, augments systemic T cell immunity and, in conjunction with a single dose of anti-L1R intracellular mature virus particle-specific mAb, fosters virtually complete viral clearance of the lungs of infected mice by the eighth day after infection.  Collectively, these findings show that chem. inhibitors of host-signaling pathways exploited by viral pathogens may represent potent antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWVtv6p3y8lrVg90H21EOLACvtfcHk0lje1G7s0Z2F4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsb0%253D&md5=c1b511e39b6762c0db4ccc081e0bf850</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI200523220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200523220%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DReche%26aufirst%3DP.%2BA.%26aulast%3DMorehead%26aufirst%3DT.%2BJ.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DWelsh%26aufirst%3DR.%2BM.%26aulast%3DReinherz%26aufirst%3DE.%2BL.%26atitle%3DAntiviral%2520chemotherapy%2520facilitates%2520control%2520of%2520poxvirus%2520infections%2520through%2520inhibition%2520of%2520cellular%2520signal%2520transduction%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D379%26epage%3D387%26doi%3D10.1172%2FJCI200523220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargill, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della
Corte, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-20-0414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1541-7786.MCR-20-0414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=33172976" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+Ramkumarauthor=C.+A.+Stewartauthor=K.+R.+Cargillauthor=C.+M.+Della%0ACorteauthor=Q.+Wangauthor=L.+Shenauthor=L.+Diaoauthor=R.+J.+Cardnellauthor=D.+H.+Pengauthor=B.+L.+Rodriguezauthor=Y.+H.+Fanauthor=J.+V.+Heymachauthor=J.+Wangauthor=C.+M.+Gayauthor=D.+L.+Gibbonsauthor=L.+A.+Byers&title=AXL+inhibition+induces+DNA+damage+and+replication+stress+in+non-small+cell+lung+cancer+cells+and+promotes+sensitivity+to+ATR+inhibitors&doi=10.1158%2F1541-7786.MCR-20-0414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-20-0414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-20-0414%26sid%3Dliteratum%253Aachs%26aulast%3DRamkumar%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DC.%2BA.%26aulast%3DCargill%26aufirst%3DK.%2BR.%26aulast%3DDella%2BCorte%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DPeng%26aufirst%3DD.%2BH.%26aulast%3DRodriguez%26aufirst%3DB.%2BL.%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DAXL%2520inhibition%2520induces%2520DNA%2520damage%2520and%2520replication%2520stress%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520and%2520promotes%2520sensitivity%2520to%2520ATR%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F1541-7786.MCR-20-0414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strange, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiyarom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourhabibi
Zarandi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadri-Ardekani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span> <span> </span><span class="NLM_article-title">Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e01372-19</span>, <span class="refDoi"> DOI: 10.1128/mBio.01372-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FmBio.01372-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31311882" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=e01372-19&author=D.+P.+Strangeauthor=B.+Jiyaromauthor=N.+Pourhabibi%0AZarandiauthor=X.+Xieauthor=C.+Bakerauthor=H.+Sadri-Ardekaniauthor=P.+Y.+Shiauthor=S.+Verma&title=Axl+promotes+zika+virus+entry+and+modulates+the+antiviral+state+of+human+sertoli+cells&doi=10.1128%2FmBio.01372-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FmBio.01372-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.01372-19%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DD.%2BP.%26aulast%3DJiyarom%26aufirst%3DB.%26aulast%3DPourhabibi%2BZarandi%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DSadri-Ardekani%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DVerma%26aufirst%3DS.%26atitle%3DAxl%2520promotes%2520zika%2520virus%2520entry%2520and%2520modulates%2520the%2520antiviral%2520state%2520of%2520human%2520sertoli%2520cells%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26spage%3De01372-19%26doi%3D10.1128%2FmBio.01372-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Soyza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phekoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar-Hari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">Accord Collaborators. ACCORD: A multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of covid-19 in hospitalised patients: A structured summary of a study protocol for a randomised controlled trial</span>. <i>Trials</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">691</span>, <span class="refDoi"> DOI: 10.1186/s13063-020-04584-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13063-020-04584-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32736596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFaisrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=691&author=T.+Wilkinsonauthor=R.+Dixonauthor=C.+Pageauthor=M.+Carrollauthor=G.+Griffithsauthor=L.+P.+Hoauthor=A.+De+Soyzaauthor=T.+Feltonauthor=K.+E.+Lewisauthor=K.+Phekooauthor=J.+D.+Chalmersauthor=A.+Gordonauthor=L.+McGarveyauthor=J.+Dohertyauthor=R.+C.+Readauthor=M.+Shankar-Hariauthor=N.+Martinez-Alierauthor=M.+O%E2%80%99Kellyauthor=G.+Duncanauthor=R.+Wallesauthor=J.+Sykesauthor=C.+Summersauthor=D.+Singh&title=Accord+Collaborators.+ACCORD%3A+A+multicentre%2C+seamless%2C+phase+2+adaptive+randomisation+platform+study+to+assess+the+efficacy+and+safety+of+multiple+candidate+agents+for+the+treatment+of+covid-19+in+hospitalised+patients%3A+A+structured+summary+of+a+study+protocol+for+a+randomised+controlled+trial&doi=10.1186%2Fs13063-020-04584-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial</span></div><div class="casAuthors">Wilkinson, Tom; Dixon, Rupert; Page, Clive; Carroll, Miles; Griffiths, Gareth; Ho, Ling-Pei; De Soyza, Anthony; Felton, Timothy; Lewis, Keir E.; Phekoo, Karen; Chalmers, James D.; Gordon, Anthony; McGarvey, Lorcan; Doherty, Jillian; Read, Robert C.; Shankar-Hari, Manu; Martinez-Alier, Nuria; O'Kelly, Michael; Duncan, Graeme; Walles, Roelize; Sykes, James; Summers, Charlotte; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Trials</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">691</span>CODEN:
                <span class="NLM_cas:coden">TRIACW</span>;
        ISSN:<span class="NLM_cas:issn">1745-6215</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In Stage 1 we will evaluate the safety and efficacy of candidate agents as add-on therapies to std. of care (SoC) in patients hospitalized with COVID-19 in a screening stage.  Stage 2 is to confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalized with COVID-19 in an expansion stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEl0Zg6TU-5rVg90H21EOLACvtfcHk0lhPh0jxIoGVQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFaisrrP&md5=5ceb30e9e8319c31831d2987f4a68172</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1186%2Fs13063-020-04584-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13063-020-04584-9%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DDixon%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DL.%2BP.%26aulast%3DDe%2BSoyza%26aufirst%3DA.%26aulast%3DFelton%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DK.%2BE.%26aulast%3DPhekoo%26aufirst%3DK.%26aulast%3DChalmers%26aufirst%3DJ.%2BD.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMcGarvey%26aufirst%3DL.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DRead%26aufirst%3DR.%2BC.%26aulast%3DShankar-Hari%26aufirst%3DM.%26aulast%3DMartinez-Alier%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Kelly%26aufirst%3DM.%26aulast%3DDuncan%26aufirst%3DG.%26aulast%3DWalles%26aufirst%3DR.%26aulast%3DSykes%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DAccord%2520Collaborators.%2520ACCORD%253A%2520A%2520multicentre%252C%2520seamless%252C%2520phase%25202%2520adaptive%2520randomisation%2520platform%2520study%2520to%2520assess%2520the%2520efficacy%2520and%2520safety%2520of%2520multiple%2520candidate%2520agents%2520for%2520the%2520treatment%2520of%2520covid-19%2520in%2520hospitalised%2520patients%253A%2520A%2520structured%2520summary%2520of%2520a%2520study%2520protocol%2520for%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DTrials%26date%3D2020%26volume%3D21%26spage%3D691%26doi%3D10.1186%2Fs13063-020-04584-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Encinar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, J. A.</span></span> <span> </span><span class="NLM_article-title">Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2’-O-methylation of viral RNA</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">525</span>, <span class="refDoi"> DOI: 10.3390/v12050525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv12050525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2gtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=525&author=J.+A.+Encinarauthor=J.+A.+Menendez&title=Potential+drugs+targeting+early+innate+immune+evasion+of+SARS-coronavirus+2+via+2%E2%80%99-O-methylation+of+viral+RNA&doi=10.3390%2Fv12050525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2'-O-methylation of viral RNA</span></div><div class="casAuthors">Encinar, Jose Antonio; Menendez, Javier A.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition.  The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap.  Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermol. interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-L-methionine-binding pocket of nsp16, (2) the unique "activating surface" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16.  We employed ≈9000 U.S. Food and Drug Administration (FDA)-approved investigational and exptl. drugs from the DrugBank repository for docking virtual screening.  After mol. dynamics calcns. of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacol. overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clin. features of COVID-19.  Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacol. reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0mO1fQpoAxrVg90H21EOLACvtfcHk0lhPh0jxIoGVQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2gtbzM&md5=48d6a5c7ce6aef4e099bd9e6256d2952</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3390%2Fv12050525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv12050525%26sid%3Dliteratum%253Aachs%26aulast%3DEncinar%26aufirst%3DJ.%2BA.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DPotential%2520drugs%2520targeting%2520early%2520innate%2520immune%2520evasion%2520of%2520SARS-coronavirus%25202%2520via%25202%25E2%2580%2599-O-methylation%2520of%2520viral%2520RNA%26jtitle%3DViruses%26date%3D2020%26volume%3D12%26spage%3D525%26doi%3D10.3390%2Fv12050525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi"> DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+middle+east+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0lgwvw2IcZfj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520middle%2520east%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabavi, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berindan-Neagoe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cismaru, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasekhian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabavi, S. M.</span></span> <span> </span><span class="NLM_article-title">Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.5114/aoms.2020.94504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.5114%2Faoms.2020.94504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32399097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWqsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=519-521&author=S.+F.+Nabaviauthor=S.+Habtemariamauthor=E.+Clementiauthor=I.+Berindan-Neagoeauthor=C.+A.+Cismaruauthor=M.+Rasekhianauthor=M.+Banachauthor=M.+Izadiauthor=M.+Bagheriauthor=M.+S.+Bagheriauthor=S.+M.+Nabavi&title=Lessons+learned+from+SARS-CoV+and+MERS-CoV%3A+FDA-approved+Abelson+tyrosine-protein+kinase+2+inhibitors+may+help+us+combat+SARS-CoV-2&doi=10.5114%2Faoms.2020.94504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2</span></div><div class="casAuthors">Nabavi, Seyed Fazel; Habtemariam, Solomon; Clementi, Emilio; Berindan-Neagoe, Ioana; Cismaru, Cosmin Andrei; Rasekhian, Mahsa; Banach, Maciej; Izadi, Morteza; Bagheri, Mahdi; Bagheri, Mohammad Sadegh; Nabavi, Seyed Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-521</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1896-9151</span>.
    
            (<span class="NLM_cas:orgname">Termedia sp. z o.o.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZzKZM7zwe7Vg90H21EOLACvtfcHk0lgwvw2IcZfj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWqsrzO&md5=78aabe527a681c3e4232446e06f4e5c9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.5114%2Faoms.2020.94504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2020.94504%26sid%3Dliteratum%253Aachs%26aulast%3DNabavi%26aufirst%3DS.%2BF.%26aulast%3DHabtemariam%26aufirst%3DS.%26aulast%3DClementi%26aufirst%3DE.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26aulast%3DCismaru%26aufirst%3DC.%2BA.%26aulast%3DRasekhian%26aufirst%3DM.%26aulast%3DBanach%26aufirst%3DM.%26aulast%3DIzadi%26aufirst%3DM.%26aulast%3DBagheri%26aufirst%3DM.%26aulast%3DBagheri%26aufirst%3DM.%2BS.%26aulast%3DNabavi%26aufirst%3DS.%2BM.%26atitle%3DLessons%2520learned%2520from%2520SARS-CoV%2520and%2520MERS-CoV%253A%2520FDA-approved%2520Abelson%2520tyrosine-protein%2520kinase%25202%2520inhibitors%2520may%2520help%2520us%2520combat%2520SARS-CoV-2%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2020%26volume%3D16%26spage%3D519%26epage%3D521%26doi%3D10.5114%2Faoms.2020.94504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabzevari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsaci, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J. W.</span></span> <span> </span><span class="NLM_article-title">Distinct effects of saracatinib on memory CD8+ T cell differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">4323</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1101439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22450814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVKis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=4323-4333&author=S.+Takaiauthor=H.+Sabzevariauthor=B.+Farsaciauthor=J.+Schlomauthor=J.+W.+Greiner&title=Distinct+effects+of+saracatinib+on+memory+CD8%2B+T+cell+differentiation&doi=10.4049%2Fjimmunol.1101439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation</span></div><div class="casAuthors">Takai, Shinji; Sabzevari, Helen; Farsaci, Benedetto; Schlom, Jeffrey; Greiner, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4323-4333</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunol. memory involving CD8+ T cells is a hallmark of an adaptive Ag-specific immune response and constitutes a crit. component of protective immunity.  Designing approaches that enhance long-term T cell memory would, for the most part, fortify vaccines and enhance host protection against infectious diseases and, perhaps, cancer immunotherapy.  A better understanding of the cellular programs involved in the Ag-specific T cell response has led to new approaches that target the magnitude and quality of the memory T cell response.  In this article, we show that T cells from TCR transgenic mice for the nucleoprotein of influenza virus NP68 exhibit the distinct phases-priming, expansion, contraction, and memory-of an Ag-specific T cell response when exposed in vitro to the cognate peptide.  Saracatinib, a specific inhibitor of Src family kinases, administered at low doses during the expansion or contraction phases, increased CD62Lhigh/CD44high central memory CD8+ T cells and IFN-γ prodn. but suppressed immunity when added during the priming phase.  These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.  Increased central memory cells by saracatinib were recapitulated in mice using a poxvirus-based influenza vaccine, thus underscoring the importance of dose and timing of the inhibitor in the context of memory T cell differentiation.  Finally, vaccine plus saracatinib treatment showed better protection against tumor challenge.  The immune-potentiating effects on CD8+ T cells by a low dose of saracatinib might afford better protection from pathogens or cancer when combined with vaccine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0R8mdTuUVi7Vg90H21EOLACvtfcHk0lgwvw2IcZfj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVKis7c%253D&md5=d7a00d74cb4bc6fb075f4b1ad3c2ae27</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101439%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DS.%26aulast%3DSabzevari%26aufirst%3DH.%26aulast%3DFarsaci%26aufirst%3DB.%26aulast%3DSchlom%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DJ.%2BW.%26atitle%3DDistinct%2520effects%2520of%2520saracatinib%2520on%2520memory%2520CD8%252B%2520T%2520cell%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D4323%26epage%3D4333%26doi%3D10.4049%2Fjimmunol.1101439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e44</span>, <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=e44&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2011%26volume%3D1%26spage%3De44%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>PRE-VENT
study in hospitalized patients with severe COVID-19 with or without
cancer</i>, NCT04404361, CTI BioPharma, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+PRE-VENT%0Astudy+in+hospitalized+patients+with+severe+COVID-19+with+or+without%0Acancer%2C+NCT04404361%2C+CTI+BioPharma%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPRE-VENT%250Astudy%2520in%2520hospitalized%2520patients%2520with%2520severe%2520COVID-19%2520with%2520or%2520without%250Acancer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persky, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3005</span>, <span class="refDoi"> DOI: 10.1002/ijc.26324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fijc.26324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21796626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=2997-3005&author=W.+Qiauthor=X.+Liuauthor=L.+S.+Cookeauthor=D.+O.+Perskyauthor=T.+P.+Millerauthor=M.+Squiresauthor=D.+Mahadevan&title=AT9283%2C+a+novel+aurora+kinase+inhibitor%2C+suppresses+tumor+growth+in+aggressive+B-cell+lymphomas&doi=10.1002%2Fijc.26324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas</span></div><div class="casAuthors">Qi, Wenqing; Liu, Xiaobing; Cooke, Laurence S.; Persky, Daniel O.; Miller, Thomas P.; Squires, Matthew; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2997-3005</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Aurora kinases are oncogenic serine/threonine kinases that play key roles in regulating the mitotic phase of the eukaryotic cell cycle.  Auroras are overexpressed in numerous tumors including B-cell non-Hodgkin's lymphomas and are validated oncol. targets.  AT9283, a pan-aurora inhibitor inhibited growth and survival of multiple solid tumors in vitro and in vivo.  In this study, we demonstrated that AT9283 had potent activity against Aurora B in a variety of aggressive B-(non-Hodgkin lymphoma) B-NHL cell lines.  Cells treated with AT9283 exhibited endoreduplication confirming the mechanism of action of an Aurora B inhibitor.  Also, treatment of B-NHL cell lines with AT9283 induced apoptosis in a dose and time dependent manner and inhibited cell proliferation with an IC50 < 1 μM.  It is well known that inhibition of auroras (A or B) synergistically enhances the effects of microtubule targeting agents such as taxanes and vinca alkaloids to induce antiproliferation and apoptosis.  We evaluated whether AT9283 in combination with docetaxel is more efficient in inducing apoptosis than AT9283 or docetaxel alone.  At very low doses (5 nM) apoptosis was doubled in the combination (23%) compared to AT9283 or docetaxel alone (10%).  A mouse xenograft model of mantle cell lymphoma demonstrated that AT9283 at 15 mg/kg and docetaxel (10 mg/kg) alone had modest anti-tumor activity.  However, AT9283 at 20 mg/kg and AT9283 (15 or 20 mg/kg) plus docetaxel (10 mg/kg) demonstrated a statistically significant tumor growth inhibition and enhanced survival.  Together, our results suggest that AT9283 plus docetaxel may represent a novel therapeutic strategy in B-cell NHL and warrant early phase clin. trial evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrGCnYS1skLVg90H21EOLACvtfcHk0lgei6nhRq5iiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyru77P&md5=97924eef001b0646fffe26b56ef4ad1b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fijc.26324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26324%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCooke%26aufirst%3DL.%2BS.%26aulast%3DPersky%26aufirst%3DD.%2BO.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DAT9283%252C%2520a%2520novel%2520aurora%2520kinase%2520inhibitor%252C%2520suppresses%2520tumor%2520growth%2520in%2520aggressive%2520B-cell%2520lymphomas%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D2997%26epage%3D3005%26doi%3D10.1002%2Fijc.26324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Aiuto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokuburra, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yolken, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinchington, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimgaonkar, V. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of three cell-based drug screening platforms for HSV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28342892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsV2jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=136-140&author=L.+D%E2%80%99Aiutoauthor=K.+Williamsonauthor=P.+Dimitrionauthor=J.+McNultyauthor=C.+E.+Brownauthor=C.+B.+Dokuburraauthor=A.+J.+Nielsenauthor=W.+J.+Linauthor=P.+Piazzaauthor=M.+E.+Schurdakauthor=J.+Woodauthor=R.+H.+Yolkenauthor=P.+R.+Kinchingtonauthor=D.+C.+Bloomauthor=V.+L.+Nimgaonkar&title=Comparison+of+three+cell-based+drug+screening+platforms+for+HSV-1+infection&doi=10.1016%2Fj.antiviral.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of three cell-based drug screening platforms for HSV-1 infection</span></div><div class="casAuthors">D'Aiuto, Leonardo; Williamson, Kelly; Dimitrion, Peter; McNulty, James; Brown, Carla E.; Dokuburra, Chanti Babu; Nielsen, Alexander J.; Lin, Wen Jing; Piazza, Paolo; Schurdak, Mark E.; Wood, Joel; Yolken, Robert H.; Kinchington, Paul R.; Bloom, David C.; Nimgaonkar, Vishwajit L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">136-140</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acyclovir (ACV) and its derivs. have been highly effective for treating recurrent, lytic infections with Herpes Simplex Virus, type 1 (HSV-1), but searches for addnl. antiviral drugs are motivated by recent reports of resistance to ACV, particularly among immunocompromised patients.  In addn., the relative neurotoxicity of ACV and its inability to prevent neurol. sequelae among HSV-1 encephalitis survivors compel searches for new drugs to treat HSV-1 infections of the central nervous system (CNS).  Primary drug screens for neurotropic viruses like HSV-1 typically utilize non-neuronal cell lines, but they may miss drugs that have neuron specific antiviral effects.  Therefore, we compared the effects of a panel of conventional and novel anti-herpetic compds. in monkey epithelial (Vero) cells, human induced pluripotent stem cells (hiPSCs)-derived neural progenitor cells (NPCs) and hiPSC-derived neurons (N = 73 drugs).  While the profiles of activity for the majority of the drugs were similar in all three tissues, Vero cells were less likely than NPCs to identify drugs with substantial inhibitory activity in hiPSC-derived neurons.  We discuss the relative merits of each cell type for antiviral drug screens against neuronal infections with HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI5Pecgdd87LVg90H21EOLACvtfcHk0lgei6nhRq5iiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsV2jtLc%253D&md5=bbea0d9c8ea4c33dad8fc482d62088e0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Aiuto%26aufirst%3DL.%26aulast%3DWilliamson%26aufirst%3DK.%26aulast%3DDimitrion%26aufirst%3DP.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26aulast%3DDokuburra%26aufirst%3DC.%2BB.%26aulast%3DNielsen%26aufirst%3DA.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BJ.%26aulast%3DPiazza%26aufirst%3DP.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DYolken%26aufirst%3DR.%2BH.%26aulast%3DKinchington%26aufirst%3DP.%2BR.%26aulast%3DBloom%26aufirst%3DD.%2BC.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DComparison%2520of%2520three%2520cell-based%2520drug%2520screening%2520platforms%2520for%2520HSV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D142%26spage%3D136%26epage%3D140%26doi%3D10.1016%2Fj.antiviral.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span> <span> </span><span class="NLM_article-title">Filgotinib, a JAK1 inhibitor, for treatment-resistant rheumatoid arthritis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.9056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1001%2Fjama.2019.9056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31334773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvgt1CnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2019&pages=309-311&author=J.+A.+Singh&title=Filgotinib%2C+a+JAK1+inhibitor%2C+for+treatment-resistant+rheumatoid+arthritis&doi=10.1001%2Fjama.2019.9056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis</span></div><div class="casAuthors">Singh Jasvinder A; Singh Jasvinder A; Singh Jasvinder A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_PfUXIyzcJXwOGIfWJ7-GfW6udTcc2eaYOsJHLuBQQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvgt1CnsQ%253D%253D&md5=fc8f96d49b28c96593bac1d649e10a47</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.9056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.9056%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26atitle%3DFilgotinib%252C%2520a%2520JAK1%2520inhibitor%252C%2520for%2520treatment-resistant%2520rheumatoid%2520arthritis%26jtitle%3DJAMA%26date%3D2019%26volume%3D322%26spage%3D309%26epage%3D311%26doi%3D10.1001%2Fjama.2019.9056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenike, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. C.</span></span> <span> </span><span class="NLM_article-title">Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">4969</span>– <span class="NLM_lpage">4984</span>, <span class="refDoi"> DOI: 10.1172/JCI137371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI137371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32573496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVejsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2020&pages=4969-4984&author=Y.+J.+Yehauthor=K.+M.+Jenikeauthor=R.+M.+Calviauthor=J.+Chiarellaauthor=R.+Hohauthor=S.+G.+Deeksauthor=Y.+C.+Ho&title=Filgotinib+suppresses+HIV-1-driven+gene+transcription+by+inhibiting+HIV-1+splicing+and+T+cell+activation&doi=10.1172%2FJCI137371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation</span></div><div class="casAuthors">Yeh, Yang-Hui Jimmy; Jenike, Katharine M.; Calvi, Rachela M.; Chiarella, Jennifer; Hoh, Rebecca; Deeks, Steven G.; Ho, Ya-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4969-4984</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">1558-8238</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Despite effective antiretroviral therapy, HIV-1-infected cells continue to produce viral antigens and induce chronic immune exhaustion.  We propose to identify HIV-1-suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1-induced immune activation.  Using a newly developed dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed HIV-1-infected individuals.  We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets.  Using differential expression anal., gene set enrichment anal., and exon-intron landscape anal., we examd. the impact of drug treatment on the cellular environment at a genome-wide level.  We identified what we believe to be a new function of a JAK inhibitor, filgotinib, that suppresses HIV-1 splicing.  First, filgotinib preferentially suppresses spliced HIV-1 RNA transcription.  Second, filgotinib suppresses HIV-1-driven aberrant cancer-related gene expression at the integration site.  Third, we found that filgotinib suppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing.  Finally, we found that filgotinib treatment reduces the proliferation of HIV-1-infected cells.  Overall, the combination of a drug screen and transcriptome anal. provides systematic understanding of cellular targets required for HIV-1 reactivation and drug candidates that may reduce HIV-1-related immune activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVirccEf0HLVg90H21EOLACvtfcHk0liDH3GcqQnMcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVejsbnI&md5=976532f9a28d0910ab5ed80f8b646eaa</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1172%2FJCI137371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI137371%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BJ.%26aulast%3DJenike%26aufirst%3DK.%2BM.%26aulast%3DCalvi%26aufirst%3DR.%2BM.%26aulast%3DChiarella%26aufirst%3DJ.%26aulast%3DHoh%26aufirst%3DR.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DHo%26aufirst%3DY.%2BC.%26atitle%3DFilgotinib%2520suppresses%2520HIV-1-driven%2520gene%2520transcription%2520by%2520inhibiting%2520HIV-1%2520splicing%2520and%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2020%26volume%3D130%26spage%3D4969%26epage%3D4984%26doi%3D10.1172%2FJCI137371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, J.</span></span> <span> </span><span class="NLM_article-title">Identification of repurposal drugs and adverse drug reactions for various courses of coronavirus disease 2019 (COVID-19) based on single-cell rna sequencing data</span>. <i>arXiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">arXiv:2005.07856</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=arXiv%3A2005.07856&author=K.+Guoauthor=Z.+Wangauthor=P.+Gaoauthor=Q.+Puauthor=M.+Wuauthor=C.+Huangauthor=J.+Hur&title=Identification+of+repurposal+drugs+and+adverse+drug+reactions+for+various+courses+of+coronavirus+disease+2019+%28COVID-19%29+based+on+single-cell+rna+sequencing+data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DHur%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520repurposal%2520drugs%2520and%2520adverse%2520drug%2520reactions%2520for%2520various%2520courses%2520of%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%2520based%2520on%2520single-cell%2520rna%2520sequencing%2520data%26jtitle%3DarXiv%26date%3D2020%26spage%3DarXiv%253A2005.07856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">133</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0675-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13045-018-0675-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30514344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=133&author=M.+Wuauthor=C.+Liauthor=X.+Zhu&title=FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1186%2Fs13045-018-0675-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors in acute myeloid leukemia</span></div><div class="casAuthors">Wu, Mei; Li, Chuntuan; Zhu, Xiongpeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML).  FLT3 inhibitors have been in active clin. development.  Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML.  In this review, we summarized the preclin. and clin. studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101.  New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopXLTxxmAs07Vg90H21EOLACvtfcHk0liDH3GcqQnMcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisrrF&md5=f7de5205add8f1f94c531d44a6b1ba16</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0675-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0675-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D133%26doi%3D10.1186%2Fs13045-018-0675-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamo, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2647</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-11-3203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22374332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2638-2647&author=J.+J.+Lukeauthor=D.+R.+D%E2%80%99Adamoauthor=M.+A.+Dicksonauthor=M.+L.+Keohanauthor=R.+D.+Carvajalauthor=R.+G.+Makiauthor=E.+de+Stanchinaauthor=E.+Musiauthor=S.+Singerauthor=G.+K.+Schwartz&title=The+cyclin-dependent+kinase+inhibitor+flavopiridol+potentiates+doxorubicin+efficacy+in+advanced+sarcomas%3A+preclinical+investigations+and+results+of+a+phase+I+dose-escalation+clinical+trial&doi=10.1158%2F1078-0432.CCR-11-3203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial</span></div><div class="casAuthors">Luke, Jason J.; D'Adamo, David R.; Dickson, Mark A.; Keohan, Mary Louise; Carvajal, Richard D.; Maki, Robert G.; de Stanchina, Elisa; Musi, Elgilda; Singer, Samuel; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2647</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dysregulated cyclin-dependent kinases are important to the growth of some sarcomas.  Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate chemotherapy.  As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas.  Exptl. Design: Sarcoma cell lines and xenografts were treated with flavopiridol alone and in combination with doxorubicin.  In the phase I study, doxorubicin and flavopiridol were administered on two flavopiridol schedules; a 1-h bolus and split dosing as a 30-min bolus followed by a 4-h infusion.  RESULTS: Preclinically, flavopiridol potentiated doxorubicin.  In vivo, doxorubicin administered 1 h before flavopiridol was more active than doxorubicin alone.  Clin., 31 patients were enrolled on protocol and flavopiridol was escalated to target dose in two schedules (90 mg/m2 bolus; 50 mg/m2 bolus + 40 mg/m2 infusion) both in combination with doxorubicin (60 mg/m2).  Dose-limiting toxicities were neutropenia, leukopenia, and febrile neutropenia but no max. tolerated dose was defined.  Flavopiridol pharmacokinetics showed increasing Cmax with increasing dose.  Response Evaluation Criteria in Solid Tumors (RECIST) responses included two partial responses, however, stable disease was seen in 16 patients.  Of 12 evaluable patients with progressive well- and dedifferentiated liposarcoma, eight had stable disease greater than 12 wk.  CONCLUSIONS: The sequential combination of doxorubicin followed by flavopiridol is well tolerated on both schedules.  Disease control was obsd. in well- and dedifferentiated liposarcoma specifically, a disease in which CDK4 is known to be amplified.  Clin Cancer Res; 18(9); 2638-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFrDRUWsiTA7Vg90H21EOLACvtfcHk0liDH3GcqQnMcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeisLw%253D&md5=e001bd1f9f9146ad388734a6d7416e7f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3203%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%2BR.%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DKeohan%26aufirst%3DM.%2BL.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMusi%26aufirst%3DE.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DThe%2520cyclin-dependent%2520kinase%2520inhibitor%2520flavopiridol%2520potentiates%2520doxorubicin%2520efficacy%2520in%2520advanced%2520sarcomas%253A%2520preclinical%2520investigations%2520and%2520results%2520of%2520a%2520phase%2520I%2520dose-escalation%2520clinical%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2638%26epage%3D2647%26doi%3D10.1158%2F1078-0432.CCR-11-3203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>– <span class="NLM_lpage">28348</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.+H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0lgveJaS0unbyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.%2BH.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib for the treatment of breast cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.948152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1517%2F13543784.2014.948152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25107301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlansr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1305-1312&author=C.+Criscitielloauthor=G.+Vialeauthor=A.+Espositoauthor=G.+Curigliano&title=Dinaciclib+for+the+treatment+of+breast+cancer&doi=10.1517%2F13543784.2014.948152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">for the treatment of breast cancer</span></div><div class="casAuthors">Criscitiello, Carmen; Viale, Giulia; Esposito, Angela; Curigliano, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1305-1312</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncol. due to their key role in controlling gene transcription and cell cycle progression. (MK-7965, formerly SCH727965) is a relatively novel CDK 1/2/5/9 inhibitor that has shown promising results in preclin. studies and an acceptable safety profile in Phase I clin. trials.  It is currently under clin. evaluation for the treatment of hematol. and solid malignancies, including breast cancer.  Areas covered: This review summarizes the current understanding of CDK's role in physiol. and cancer, and the therapeutic value of blocking their pathways in breast cancer.  Particularly, the article reviews the preclin. and clin. data for dinaciclib in its use for the treatment of breast cancer.  Expert opinion: A better understanding of the mol. mechanisms underlying cell cycle dysregulation in cancer is needed in order to develop novel CDK inhibitors.  Addnl., further efforts are needed to identify potential biomarkers of dinaciclib efficacy, which could allow a better selection of patients enrolled in clin. trials.  Moreover, combination therapies with dinaciclib or other CDK and chemotherapy, endocrine therapy or targeted therapies might be further evaluated in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFvTeT7jtBW7Vg90H21EOLACvtfcHk0lgveJaS0unbyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlansr3N&md5=7fb3eea033dba57830aa9afa6876f4c2</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.948152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.948152%26sid%3Dliteratum%253Aachs%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DEsposito%26aufirst%3DA.%26aulast%3DCurigliano%26aufirst%3DG.%26atitle%3DDinaciclib%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D1305%26epage%3D1312%26doi%3D10.1517%2F13543784.2014.948152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldoss, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, A. K.</span></span> <span> </span><span class="NLM_article-title">Seliciclib in malignancies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1957</span>– <span class="NLM_lpage">1965</span>, <span class="refDoi"> DOI: 10.1517/13543780903418445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1517%2F13543780903418445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19938906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOhtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1957-1965&author=I.+T.+Aldossauthor=T.+Tashiauthor=A.+K.+Ganti&title=Seliciclib+in+malignancies&doi=10.1517%2F13543780903418445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Seliciclib in malignancies</span></div><div class="casAuthors">Aldoss, Ibrahim T.; Tashi, Tsewang; Ganti, Apar Kishor</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1957-1965</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Cyclins and cyclin-dependent kinases (CDK) form a key part of the regulatory proteins that govern the cell cycle.  Aberrancy in their function can lead to uncontrolled growth and proliferation of the cells which forms the basis of many human diseases, esp. cancers.  Seliciclib (CYC202, R-roscovitine) is a second-generation CDK inhibitor that competes for ATP binding sites on these kinases, reducing tumor growth and inducing cell death.  It is a direct inhibitor of cyclin E/CDK2 and also has inhibitory effects on cyclin H/CDK7 and cyclin T/CDK9.  Seliciclib leads to growth arrest and apoptosis of cell lines through activation of the p53 gene, inhibition of RNA processing and blockage of the RNA polymerase II-dependent transcription, and redn. of anti-apoptotic proteins.  Seliciclib has good oral bioavailability, although its absorption is slowed by food.  It is distributed rapidly to the body tissues and metabolized rapidly to a carboxylated deriv. that is excreted by the kidneys.  The major adverse effects of seliciclib are electrolyte disturbances (hypokalemia, hyponatremia), gastrointestinal side effects (nausea, emesis, anorexia), fatigue, transient hyperglycemia, elevation of liver enzymes and reversible elevation of serum creatinine.  At present, it is in Phase II trials for non-small cell lung cancer and nasopharyngeal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4qaWdA4zynrVg90H21EOLACvtfcHk0lgveJaS0unbyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOhtrbO&md5=73e7949fca2fa087f93f0d028449269c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1517%2F13543780903418445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903418445%26sid%3Dliteratum%253Aachs%26aulast%3DAldoss%26aufirst%3DI.%2BT.%26aulast%3DTashi%26aufirst%3DT.%26aulast%3DGanti%26aufirst%3DA.%2BK.%26atitle%3DSeliciclib%2520in%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1957%26epage%3D1965%26doi%3D10.1517%2F13543780903418445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Opaganib,
a sphingosine kinase-2 (sk2) inhibitor in covid-19 pneumonia</i>, NCT04467840, RedHill Biopharma Limited, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Opaganib%2C%0Aa+sphingosine+kinase-2+%28sk2%29+inhibitor+in+covid-19+pneumonia%2C+NCT04467840%2C+RedHill+Biopharma+Limited%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DOpaganib%252C%250Aa%2520sphingosine%2520kinase-2%2520%2528sk2%2529%2520inhibitor%2520in%2520covid-19%2520pneumonia" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de La Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianella-Borradori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of CYC202 in HIV-1-infected cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">3029</span>– <span class="NLM_lpage">3042</span>, <span class="refDoi"> DOI: 10.1074/jbc.M406435200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.M406435200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15531588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=3029-3042&author=E.+Agbottahauthor=C.+de+La+Fuenteauthor=S.+Nekhaiauthor=A.+Barnettauthor=A.+Gianella-Borradoriauthor=A.+Pumferyauthor=F.+Kashanchi&title=Antiviral+activity+of+CYC202+in+HIV-1-infected+cells&doi=10.1074%2Fjbc.M406435200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of CYC202 in HIV-1-infected Cells</span></div><div class="casAuthors">Agbottah, Emmanuel; de La Fuente, Cynthia; Nekhai, Sergie; Barnett, Anna; Gianella-Borradori, Athos; Pumfery, Anne; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3029-3042</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">There are currently 40 million individuals in the world infected with human immunodeficiency virus (HIV).  The introduction of highly active antiretroviral therapy (HAART) has led to a significant redn. in AIDS-related morbidity and mortality.  Unfortunately, up to 25% of patients discontinue their initial HAART regimen.  Current HIV-1 inhibitors target the fusion of the virus to the cell and two viral proteins, reverse transcriptase and protease.  Here, we examd. whether other targets, such as an activated transcription factor, could be targeted to block HIV-1 replication.  We specifically asked whether we could target a cellular kinase needed for HIV-1 transcription using CYC202 (R-roscovitine), a pharmacol. cyclin-dependent kinase inhibitor.  We targeted the cdk2-cyclin E complex in HIV-1-infected cells because both cdk2 and cyclin E are nonessential during mammalian development and are likely replaced by other kinases.  We found that CYC202 effectively inhibits wild type and resistant HIV-1 mutants in T-cells, monocytes, and peripheral blood mononuclear cells at a low IC50 and sensitizes these cells to enhanced apoptosis resulting in a dramatic drop in viral titers.  Interestingly, the effect of CYC202 is independent of cell cycle stage and more specific for the cdk2-cyclin E complex.  Finally, we show that cdk2-cyclin E is loaded onto the HIV-1 genome in vivo and that CYC202 is able to inhibit the uploading of this cdk-cyclin complex onto HIV-1 DNA.  Therefore, targeting cellular enzymes necessary for HIV-1 transcription, which are not needed for cell survival, is a compelling strategy to inhibit wild type and mutant HIV-1 strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVxunqZ3T3lLVg90H21EOLACvtfcHk0lieSOTwVIYBXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12itg%253D%253D&md5=af4003d6df64a8d3773940ab69a15d77</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M406435200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M406435200%26sid%3Dliteratum%253Aachs%26aulast%3DAgbottah%26aufirst%3DE.%26aulast%3Dde%2BLa%2BFuente%26aufirst%3DC.%26aulast%3DNekhai%26aufirst%3DS.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DGianella-Borradori%26aufirst%3DA.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DAntiviral%2520activity%2520of%2520CYC202%2520in%2520HIV-1-infected%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D3029%26epage%3D3042%26doi%3D10.1074%2Fjbc.M406435200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinchington, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. F.</span></span> <span> </span><span class="NLM_article-title">Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">2853</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.6.2853-2862.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.78.6.2853-2862.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=14990704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlSntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=2853-2862&author=S.+L.+Taylorauthor=P.+R.+Kinchingtonauthor=A.+Brooksauthor=J.+F.+Moffat&title=Roscovitine%2C+a+cyclin-dependent+kinase+inhibitor%2C+prevents+replication+of+varicella-zoster+virus&doi=10.1128%2FJVI.78.6.2853-2862.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus</span></div><div class="casAuthors">Taylor, Shannon L.; Kinchington, Paul R.; Brooks, Andrew; Moffat, Jennifer F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2853-2862</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Understanding the interactions between varicella-zoster virus (VZV) and host cells can be addressed by using small mol. inhibitors of cellular enzymes.  Roscovitine (Rosco) is a purine deriv. that inhibits cyclindependent kinase 1 (cdk1), cdk2, cdk5, cdk7, and cdk9, which are key regulators of the cell cycle and transcription.  Herpesviruses are known to interact with cell cycle proteins; thus, the antiviral effects of Rosco on VZV growth were evaluated.  In a plaque redn. assay, 25 μM Rosco prevented VZV replication, and the antiviral effect was reversible for at least up to 24 h posttreatment.  Rosco also reduced expression of the major transactivator, IE62, over 48 h.  Confocal microscopy studies indicated that Rosco caused the immediate-early proteins ORF4 and IE62 to abnormally localize in infected cells and prevented cell-cell spread of VZV over 48 h.  Rosco was found to inhibit VZV DNA synthesis as measured by real-time PCR, and this technique was used to est. the 50% effective concn. (EC50) of 14 μM.  This value was close to the EC50 est. of 12 μM detd. from plaque redn. assays.  At 25 μM, Rosco was not cytotoxic over 48 h in a neutral red uptake assay, and proliferation was slowed as the cells accumulated in a G2-like state.  These results demonstrate the importance of cdk's in VZV replication and suggest that cdk inhibitors could serve as useful VZV antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjl83l5YV547Vg90H21EOLACvtfcHk0lieSOTwVIYBXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlSntLo%253D&md5=f03716ff4cc2afc925ddc10c87a2a8bd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.6.2853-2862.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.6.2853-2862.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BL.%26aulast%3DKinchington%26aufirst%3DP.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DMoffat%26aufirst%3DJ.%2BF.%26atitle%3DRoscovitine%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520prevents%2520replication%2520of%2520varicella-zoster%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D2853%26epage%3D2862%26doi%3D10.1128%2FJVI.78.6.2853-2862.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>526</i></span>,  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2020.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbrc.2020.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32327257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2020&pages=1143-1149&author=Q.+Huangauthor=Y.+Zhongauthor=J.+Liauthor=Y.+Yeauthor=W.+Wuauthor=L.+Chenauthor=M.+Fengauthor=J.+Yangauthor=S.+Liu&title=Kinase+inhibitor+roscovitine+as+a+PB2+cap-binding+inhibitor+against+influenza+a+virus+replication&doi=10.1016%2Fj.bbrc.2020.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication</span></div><div class="casAuthors">Huang, Qi; Zhong, Yingyuan; Li, Jingyan; Ye, Yilu; Wu, Wenjiao; Chen, Lizhu; Feng, Mingkai; Yang, Jie; Liu, Shuwen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study, we examd. the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clin. trials, on influenza A viruses (IAVs) and its antiviral mechanism.  The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC50 value of 3.35 ± 0.39, 7.01 ± 1.84 and 5.99 ± 1.89μM, resp.  Moreover, roscovitine suppressed the gene transcription and genome replication steps in the viral life cycle.  Further mechanistic studies indicated that roscovitine reduced viral polymerase activity and bound specifically to the viral PB2cap protein by fluorescence polarization assay (FP) and surface plasmon resonance (SPR).  Therefore, we believed roscovitine, as a PB2cap inhibitor, was a prospective antiviral agent to be developed as therapeutic treatment against influenza A virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv4xhVjCGNgbVg90H21EOLACvtfcHk0lieSOTwVIYBXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeiu70%253D&md5=663e0a6a4109d3fc00f6cc56a249ac92</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2020.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2020.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DKinase%2520inhibitor%2520roscovitine%2520as%2520a%2520PB2%2520cap-binding%2520inhibitor%2520against%2520influenza%2520a%2520virus%2520replication%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2020%26volume%3D526%26spage%3D1143%26epage%3D1149%26doi%3D10.1016%2Fj.bbrc.2020.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamrakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, D. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus ul122–123 and ul37 immediate-early transcripts and at later times for virus production</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">11219</span>– <span class="NLM_lpage">11232</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.20.11219-11232.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.78.20.11219-11232.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15452241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=11219-11232&author=V.+Sanchezauthor=A.+K.+McElroyauthor=J.+Yenauthor=S.+Tamrakarauthor=C.+L.+Clarkauthor=R.+A.+Schwartzauthor=D.+H.+Spector&title=Cyclin-dependent+kinase+activity+is+required+at+early+times+for+accurate+processing+and+accumulation+of+the+human+cytomegalovirus+ul122%E2%80%93123+and+ul37+immediate-early+transcripts+and+at+later+times+for+virus+production&doi=10.1128%2FJVI.78.20.11219-11232.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production</span></div><div class="casAuthors">Sanchez, Veronica; McElroy, Anita K.; Yen, Judy; Tamrakar, Sama; Clark, Charles L.; Schwartz, Rachel A.; Spector, Deborah H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11219-11232</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) infection leads to dysregulation of multiple cell cycle-regulatory proteins.  In this study, we examd. the effects of inhibition of cyclin-dependent kinase (cdk) activity on viral replication.  With the drug Roscovitine, a specific inhibitor of cyclin-dependent kinases 1, 2, 5, 7, and 9, we have shown that during the first 6 h of infection, cyclin-dependent kinase-dependent events occurred that included the regulated processing and accumulation of the immediate-early (IE) UL122-123 transcripts and UL36-37 transcripts.  Altered processing of UL122-123 led to a loss of IE1-72 and an increase in IE2-86.  The ratio of spliced to unspliced UL37 transcripts also changed.  These effects did not require de novo protein synthesis or degrdn. of proteins by the proteasome.  Addn. of Roscovitine at the beginning of the infection was also assocd. with inhibition of expression of selected viral early gene products, viral DNA replication, and late viral gene expression.  When Roscovitine was added after the first 6 h of infection, the effects on IE gene expression were no longer obsd. and viral replication proceeded through the late phase, but viral titers were reduced.  The redn. in viral titer was obsd. even when Roscovitine was first added at 48 h postinfection, indicating that cyclin-dependent kinase activity is required at both IE and late times.  Flavopiridol, another specific inhibitor of cyclin-dependent kinases, had similar effects on IE and early gene expression.  These results underscore the importance of accurate RNA processing and reiterate the significant role of cell cycle-regulatory factors in HCMV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoErcDAXG9aarVg90H21EOLACvtfcHk0li22vDH3ZCI-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlKis70%253D&md5=1af7de712f5b08ef39b60dafce06ac9f</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.20.11219-11232.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.20.11219-11232.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DMcElroy%26aufirst%3DA.%2BK.%26aulast%3DYen%26aufirst%3DJ.%26aulast%3DTamrakar%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DC.%2BL.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DSpector%26aufirst%3DD.%2BH.%26atitle%3DCyclin-dependent%2520kinase%2520activity%2520is%2520required%2520at%2520early%2520times%2520for%2520accurate%2520processing%2520and%2520accumulation%2520of%2520the%2520human%2520cytomegalovirus%2520ul122%25E2%2580%2593123%2520and%2520ul37%2520immediate-early%2520transcripts%2520and%2520at%2520later%2520times%2520for%2520virus%2520production%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D11219%26epage%3D11232%26doi%3D10.1128%2FJVI.78.20.11219-11232.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresnahan, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldogh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1006/viro.1997.8489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1006%2Fviro.1997.8489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=9168886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1997&pages=239-247&author=W.+A.+Bresnahanauthor=I.+Boldoghauthor=P.+Chiauthor=E.+A.+Thompsonauthor=T.+Albrecht&title=Inhibition+of+cellular+Cdk2+activity+blocks+human+cytomegalovirus+replication&doi=10.1006%2Fviro.1997.8489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span></div><div class="casAuthors">Bresnahan, Wade A.; Boldough, Istvan; Chi, Ping; Thompson, E. Aubrey; Albrecht, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Human cytomegalovirus is a herpesvirus that induces numerous cellular processes upon infection.  Among these are activation of cyclin-dependent kinase 2, which regulates cell cycle progression in G1 and S phase.  We report here that inhibition of cellular Cdk2 activity blocks HCMV replication.  Inhibition of Cdk2 activity by roscovitine inhibits HCMV DNA synthesis, prodn. of infectious progeny, and late antigen expression in infected cells in a dose-dependent manner.  HCMV replication is also inhibited by the expression of a Cdk2 dominant neg. mutant, whereas expression of wild-type Cdk2 has no effect on viral replication.  These data indicate that activation of cellular Cdk2 is necessary for HCMV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3AKL3CzS17Vg90H21EOLACvtfcHk0li22vDH3ZCI-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D&md5=ae27d67b0473636f85e5a292eb5db347</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1006%2Fviro.1997.8489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1997.8489%26sid%3Dliteratum%253Aachs%26aulast%3DBresnahan%26aufirst%3DW.%2BA.%26aulast%3DBoldogh%26aufirst%3DI.%26aulast%3DChi%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26aulast%3DAlbrecht%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cellular%2520Cdk2%2520activity%2520blocks%2520human%2520cytomegalovirus%2520replication%26jtitle%3DVirology%26date%3D1997%26volume%3D231%26spage%3D239%26epage%3D247%26doi%3D10.1006%2Fviro.1997.8489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1172/JCI73805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI73805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25003190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3479-3488&author=M.+Yamamotoauthor=H.+Onogiauthor=I.+Kiiauthor=S.+Yoshidaauthor=K.+Iidaauthor=H.+Sakaiauthor=M.+Abeauthor=T.+Tsubotaauthor=N.+Itoauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+prevents+replication+of+multiple+DNA+viruses&doi=10.1172%2FJCI73805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span></div><div class="casAuthors">Yamamoto, Makoto; Onogi, Hiroshi; Kii, Isao; Yoshida, Suguru; Iida, Kei; Sakai, Hiroyuki; Abe, Minako; Tsubota, Toshiaki; Ito, Nobutoshi; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3479-3488</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk.  Here, we explored the use of compds. that inhibit or interfere with the action of essential host factors to prevent virus replication.  In particular, we focused on the cyclin-dependent kinase 9 (CDK9) inhibitor, FIT-039, which suppressed replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.  Specifically, FIT-039 inhibited replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells, and topical application of FIT-039 ointment suppressed skin legion formation in a murine HSV-1 infection model.  FIT-039 did not affect cell cycle progression or cellular proliferation in host cells.  Compared with the general CDK inhibitor flavopiridol, transcriptome analyses of FIT-039-treated cells revealed that FIT-039 specifically inhibited CDK9.  Given at concns. above the inhibitory concn., FIT-039 did not have a cytotoxic effect on mammalian cells.  Importantly, administration of FIT-039 ameliorated the severity of skin lesion formation in mice infected with an acydovir-resistant HSV-1, without noticeable adverse effects.  Together, these data indicate that FIT-039 has potential as an antiviral agent for clin. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_l0ZnQV7lWLVg90H21EOLACvtfcHk0li22vDH3ZCI-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I&md5=f5e7516ba1e29c56f33530b2cd2f6811</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1172%2FJCI73805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI73805%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DTsubota%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520prevents%2520replication%2520of%2520multiple%2520DNA%2520viruses%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D3479%26epage%3D3488%26doi%3D10.1172%2FJCI73805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama-Dobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriishi, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27515132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=156-164&author=T.+Tanakaauthor=K.+Okuyama-Dobashiauthor=S.+Murakamiauthor=W.+Chenauthor=T.+Okamotoauthor=K.+Uedaauthor=T.+Hosoyaauthor=Y.+Matsuuraauthor=A.+Ryoauthor=Y.+Tanakaauthor=M.+Hagiwaraauthor=K.+Moriishi&title=Inhibitory+effect+of+CDK9+inhibitor+FIT-039+on+hepatitis+B+virus+propagation&doi=10.1016%2Fj.antiviral.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span></div><div class="casAuthors">Tanaka, Tomohisa; Okuyama-Dobashi, Kaori; Murakami, Shuko; Chen, Wenjia; Okamoto, Toru; Ueda, Keiji; Hosoya, Takamitsu; Matsuura, Yoshiharu; Ryo, Akihide; Tanaka, Yasuhito; Hagiwara, Masatoshi; Moriishi, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current therapies for hepatitis B virus (HBV) cannot completely eliminate the HBV genome because of the stable population of covalently closed circular DNA (cccDNA) and so on.  FIT-039, which is a cyclin-dependent kinase (CDK) 9 inhibitor, is known to suppress the replication of several DNA viruses including HSV, HPV and human adenovirus.  In this study, we investigated the antiviral effect of FIT-039 on HBV infection.  HepG2 cells expressing human sodium taurocholate cotransporting polypeptide (HepG2/NTCP cells) were infected with HBV in the presence of FIT-039.  FIT-039 dose-dependently reduced intracellular viral RNA, nucleocapsid-assocd. viral DNA, and supernatant viral antigens without cytotoxicity in the infected cells (IC50 = 0.33 μM, CC50 > 50 μM).  The antiviral activity of FIT-039 was prominent at an early phase of viral infection, although the compd. did not inhibit preS1-binding to HepG2/NTCP cells.  FIT-039 reduced cccDNA in HBV-replicating or HBV-infected cells.  Furthermore, the antiviral activity of entecavir was significantly enhanced by the combination with FIT-039 in the chimeric mice having human hepatocytes infected with HBV.  None of the mice had significant drug-related body wt. or serum human-albumin concn. changes.  These data suggest that CDK9 inhibitor FIT-039 is a promising antiviral candidate for HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWi-qx6kiD2rVg90H21EOLACvtfcHk0li22vDH3ZCI-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL&md5=1ab41f68b2a0645ce4d1031798e281d0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOkuyama-Dobashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DMoriishi%26aufirst%3DK.%26atitle%3DInhibitory%2520effect%2520of%2520CDK9%2520inhibitor%2520FIT-039%2520on%2520hepatitis%2520B%2520virus%2520propagation%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D133%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.antiviral.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 suppresses viral oncogenes e6 and e7 and has a therapeutic effect on Hpv-induced neoplasia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4518</span>– <span class="NLM_lpage">4528</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-17-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29712686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1ejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4518-4528&author=M.+Ajiroauthor=H.+Sakaiauthor=H.+Onogiauthor=M.+Yamamotoauthor=E.+Sumiauthor=T.+Sawadaauthor=T.+Nomuraauthor=K.+Kabashimaauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+suppresses+viral+oncogenes+e6+and+e7+and+has+a+therapeutic+effect+on+Hpv-induced+neoplasia&doi=10.1158%2F1078-0432.CCR-17-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has a therapeutic effect on HPV-induced neoplasia</span></div><div class="casAuthors">Ajiro, Masahiko; Sakai, Hiroyuki; Onogi, Hiroshi; Yamamoto, Makoto; Sumi, Eriko; Sawada, Teruo; Nomura, Takashi; Kabashima, Kenji; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4518-4528</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide.  The purpose of this study is to assess the therapeutic effect of the newly developed cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on cervical neoplasia induced by human papillomavirus (HPV) infection.  Exptl. Design: We examd. FIT-039 for its effect on HPV gene expression in HPV+ cervical cancer cells.  Primary keratinocytes monolayer and organotypic raft culture models were used to evaluate HPV viral replication and cervical intraepithelial neoplasia (CIN) phenotypes.  Preclin. pharmacokinetics and toxicity tests for FIT-039 were also conducted.  Finally, the anti-HPV effect of FIT-039 was further examd. in vivo, using HPV+ cervical cancer xenografts.  Results: FIT-039 inhibits HPV replication and expression of E6 and E7 viral oncogenes, restoring tumor suppressors p53 and pRb in HPV+ cervical cancer cells.  The therapeutic effect of FIT-039 was demonstrated in CIN model of an organotypic raft culture, where FIT-039 suppressed HPV18-induced dysplasia/hyperproliferation with redn. in viral load.  FIT-039 also repressed growth of HPV16+, but not HPV- cervical cancer xenografts without any significant adverse effects.  Safety and pharmacokinetics of FIT-039 were confirmed for systemic and topical routes.  Conclusions: The CDK9 inhibitor FIT-039 showed potent anti-HPV activity without significant toxicity in preclin. studies.  Thus, FIT-039 is expected to be a novel therapeutic for CIN to prevent cervical cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaMGDFeOIC7bVg90H21EOLACvtfcHk0lgM9Urn30NWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1ejt7s%253D&md5=b352ae15eefe61c3480c6c619c249060</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3119%26sid%3Dliteratum%253Aachs%26aulast%3DAjiro%26aufirst%3DM.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSumi%26aufirst%3DE.%26aulast%3DSawada%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520suppresses%2520viral%2520oncogenes%2520e6%2520and%2520e7%2520and%2520has%2520a%2520therapeutic%2520effect%2520on%2520Hpv-induced%2520neoplasia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4518%26epage%3D4528%26doi%3D10.1158%2F1078-0432.CCR-17-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toichi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uozumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial</span>. <i>Trials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">489</span>, <span class="refDoi"> DOI: 10.1186/s13063-019-3570-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13063-019-3570-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31399147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=489&author=T.+Nomuraauthor=E.+Sumiauthor=G.+Egawaauthor=S.+Nakajimaauthor=E.+Toichiauthor=R.+Uozumiauthor=H.+Tadaauthor=T.+Nakagawaauthor=M.+Hagiwaraauthor=K.+Kabashima&title=The+efficacy+of+a+cyclin+dependent+kinase+9+%28CDK9%29+inhibitor%2C+FIT039%2C+on+verruca+vulgaris%3A+study+protocol+for+a+randomized+controlled+trial&doi=10.1186%2Fs13063-019-3570-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial</span></div><div class="casAuthors">Nomura Takashi; Egawa Gyohei; Nakajima Saeko; Kabashima Kenji; Sumi Eriko; Uozumi Ryuji; Tada Harue; Toichi Eiko; Nakagawa Takayuki; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Trials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">489</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Human papilloma viruses (HPVs) infect squamous epithelial cells and form verrucous lesions, or warts.  Besides the psychosocial problems caused by the disfiguring warts, a subset of HPVs can be the primary etiologic agent for malignancies such as cervical cancer.  However, there is no curative antiviral therapy for HPV infection.  We recently found that the viral RNA transcription of DNA viruses requires cyclin dependent kinase 9 (CDK9) in the host cells, and that FIT039, a specific inhibitor of CDK9, suppressed the proliferation of DNA viruses such as herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, human cytomegalovirus, hepatitis virus B, and HPVs.  Here, we describe a protocol to evaluate the safety and antiviral effect of FIT039 on common warts in human skin.  METHODS AND DESIGN:  A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 on common warts on the extremities.  A total of 44 adults with a primary diagnosis of verruca vulgaris on the extremities without serious comorbidities will be randomized into either the intervention group with an FIT039-releasing transdermal patch or a control group for a duration of 14 days.  Outcomes will be assessed at baseline and postintervention.  Participants will be further assessed at 2 months follow-up.  The primary endpoint for efficacy is the resolution of the warts.  The safety endpoint is the incidence of adverse events and adverse drug reactions.  The secondary endpoints are changes in the dimensions of the wart, the cross-sectional area of the wart, and the number of clots within the area of the wart.  DISCUSSION:  This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients.  TRIAL REGISTRATION:  UMIN Clinical Trials, UMIN000029695 .  Registered on 1 November 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGFM6SumS6DFHFYivNCdPRfW6udTcc2ebDeBcsNvm8Zrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvms1enug%253D%253D&md5=b5d65de2c1048cf410ee94eb0015d91b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1186%2Fs13063-019-3570-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13063-019-3570-6%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DSumi%26aufirst%3DE.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DToichi%26aufirst%3DE.%26aulast%3DUozumi%26aufirst%3DR.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DThe%2520efficacy%2520of%2520a%2520cyclin%2520dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%252C%2520FIT039%252C%2520on%2520verruca%2520vulgaris%253A%2520study%2520protocol%2520for%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DTrials%26date%3D2019%26volume%3D20%26spage%3D489%26doi%3D10.1186%2Fs13063-019-3570-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo</span>. <i>BMC Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">217</span>, <span class="refDoi"> DOI: 10.1186/s12879-017-2305-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs12879-017-2305-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28320320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFags73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=217&author=J.+Houauthor=Z.+Zhangauthor=Q.+Huangauthor=J.+Yanauthor=X.+Zhangauthor=X.+Yuauthor=G.+Tanauthor=C.+Zhengauthor=F.+Xuauthor=S.+He&title=Antiviral+activity+of+PHA767491+against+human+herpes+simplex+virus+in+vitro+and+in+vivo&doi=10.1186%2Fs12879-017-2305-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo</span></div><div class="casAuthors">Hou, Jue; Zhang, Zili; Huang, Qiang; Yan, Jun; Zhang, Xiaohu; Yu, Xiaoliang; Tan, Guihua; Zheng, Chunfu; Xu, Feng; He, Sudan</div><div class="citationInfo"><span class="NLM_cas:title">BMC Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">217/1-217/9</span>CODEN:
                <span class="NLM_cas:coden">BIDMBJ</span>;
        ISSN:<span class="NLM_cas:issn">1471-2334</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Herpes simplex virus (HSV) is a common human pathogen that causes a variety of diseases, including oral-labial, genital lesions and life-threatening encephalitis.  The antiviral nucleoside analogs such as acyclovir are currently used in anti-HSV therapies; however, clin. overuse of these drugs has led to the emergence of drug-resistant viral strains.  Hence, there is an urgent need to develop new anti-HSV agents.  Methods: To identify novel anti-HSV-1 compds., we screened the LOPAC small scale library of 1280 bioactive compds. to identify inhibitors of HSV-1-induced necroptosis.  Further expts. including western blot anal., Q-PCR anal. and immunohistochem. were performed to explore the antiviral mechanism of the compds.  Results: Here, we identified PHA767491 as a new inhibitor of HSV.  PHA767491 potently blocked the proliferation of HSV in cells, as well as HSV induced cell death.  Further, we found that PHA767491 strongly inhibited HSV infection post viral entry.  Moreover, PHA767491 reduced the expression of viral genes required for DNA synthesis including UL30/42 DNA polymerase and UL5/8/52 helicase-primase complex.  The essential immediate early (IE) genes such as ICP4 and ICP27 are crit. for the expression of the early and late genes.  Of note, PHA767491 inhibited the expression of all IE genes of both HSV-1 and HSV-2.  Importantly, PHA767491 reduced viral titers in the tissues from the mice infected with HSV-1.  Consistently, immunohistochem. anal. showed that PHA767491 dramatically attenuated expression of viral protein gB in the livers.  Conclusions: Taken together, PHA767491 has potent anti-HSV activity by inhibiting viral replication both in vitro and in mouse model.  Thus, PHA767491 could be a promising agent for the development of new anti-HSV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kctOsqvqqLVg90H21EOLACvtfcHk0lgM9Urn30NWnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFags73O&md5=b58b795a9b799dde25b63f01ff7a5a58</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1186%2Fs12879-017-2305-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12879-017-2305-0%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DS.%26atitle%3DAntiviral%2520activity%2520of%2520PHA767491%2520against%2520human%2520herpes%2520simplex%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBMC%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D217%26doi%3D10.1186%2Fs12879-017-2305-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haasbach, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28377100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=178-184&author=E.+Haasbachauthor=C.+M%C3%BCllerauthor=C.+Ehrhardtauthor=A.+Schreiberauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=The+MEK-inhibitor+CI-1040+displays+a+broad+anti-influenza+virus+activity+in+vitro+and+provides+a+prolonged+treatment+window+compared+to+standard+of+care+in+vivo&doi=10.1016%2Fj.antiviral.2017.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo</span></div><div class="casAuthors">Haasbach, Emanuel; Mueller, Christin; Ehrhardt, Christina; Schreiber, Andre; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178-184</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza viruses (IV) continue to pose an imminent threat to human welfare.  Yearly re-occurring seasonal epidemic outbreaks and pandemics with high mortality can occur.  Besides vaccination against a limited no. of viral strains only a few antiviral drugs are available, which are losing their effectiveness as more and more IV strains become resistant.  Thus, new antiviral approaches that omit IV resistance are urgently needed.  Here, the dependency on the cellular Raf/MEK/ERK signaling pathway for IV replication opens a new perspective.  In consequence, we studied the antiviral potential of the MEK inhibitor Cl-1040 (PD184352).  We show that Cl-1040 significantly reduces virus titers in vitro via retention of viral RNP complexes in the cell nucleus.  Furthermore, Cl-1040 is effective against a broad range of IV strains, including highly pathogenic avian IV, as well as against a Tamiflu-resistant IV strain. Using a mouse model, we demonstrate that Cl-1040 can reduce IV lung titers in vivo. Importantly, the treatment window for Cl-1040 expands up to 48 h post infection when Tamiflu treatment has no effect.  In conclusion, Cl-1040 offers an interesting perspective for anti-IV approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz9V8putsbXLVg90H21EOLACvtfcHk0lgwAirLnlNB2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrurc%253D&md5=f4025799c292f98eb4eea6f9765a77bc</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DHaasbach%26aufirst%3DE.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DThe%2520MEK-inhibitor%2520CI-1040%2520displays%2520a%2520broad%2520anti-influenza%2520virus%2520activity%2520in%2520vitro%2520and%2520provides%2520a%2520prolonged%2520treatment%2520window%2520compared%2520to%2520standard%2520of%2520care%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D142%26spage%3D178%26epage%3D184%26doi%3D10.1016%2Fj.antiviral.2017.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Heier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quernheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104806</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2020.104806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32304723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104806&author=M.+Laureauthor=H.+Hamzaauthor=J.+Koch-Heierauthor=M.+Quernheimauthor=C.+M%C3%BCllerauthor=A.+Schreiberauthor=G.+M%C3%BCllerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+efficacy+against+influenza+virus+and+pharmacokinetic+analysis+of+a+novel+MEK-inhibitor%2C+ATR-002%2C+in+cell+culture+and+in+the+mouse+model&doi=10.1016%2Fj.antiviral.2020.104806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span></div><div class="casAuthors">Laure, Martin; Hamza, Hazem; Koch-Heier, Julia; Quernheim, Martin; Mueller, Christin; Schreiber, Andre; Mueller, Gerhard; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104806</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiviral therapies against influenza are required, esp. for high-risk patients, severe influenza and in case of highly pathogenic influenza virus (IV) strains.  This may be overcome by targeting host cell factors that are required for IV propagation.  IV induces a variety of host cell signaling cascades, such as the Raf/MEK/ERK kinase pathway.  MEK-inhibitors block the activation of the pathway on the bottleneck of the signaling cascade leading to impaired virus propagation.  In the present study, we aimed to compare the antiviral potency and bioavailability of the MEK-inhibitor CI-1040 vs. its major active metabolite ATR-002, in vitro as well as in the mouse model.  In cell culture assays, an approx. 10-fold higher concn. of ATR-002 is required to generate the same antiviral activity as for CI-1040.  Interestingly, we obsd. that considerably lower concns. of ATR-002 were required to achieve a redn. of the viral load in vivo.  Pharmacokinetic studies with ATR-002 and CI-1040 in mice have found the Cmax and AUC to be far higher for ATR-002 than for CI-1040.  Our results thereby demonstrate the in vivo superiority of the active metabolite ATR-002 over CI-1040 as an antiviral agent despite its weaker cell membrane permeability.  Therefore, ATR-002 is an attractive candidate for development as an efficient antiviral agent, esp. given the fact that a treatment based on cellular pathway inhibition would be far less likely to lead to viral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCdKB75g1RNbVg90H21EOLACvtfcHk0lgwAirLnlNB2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D&md5=9d7774956ebbe323b85b719653716ef4</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104806%26sid%3Dliteratum%253Aachs%26aulast%3DLaure%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DH.%26aulast%3DKoch-Heier%26aufirst%3DJ.%26aulast%3DQuernheim%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520efficacy%2520against%2520influenza%2520virus%2520and%2520pharmacokinetic%2520analysis%2520of%2520a%2520novel%2520MEK-inhibitor%252C%2520ATR-002%252C%2520in%2520cell%2520culture%2520and%2520in%2520the%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104806%26doi%3D10.1016%2Fj.antiviral.2020.104806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bimbo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkilä, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaasalainen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, H. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6884</span>– <span class="NLM_lpage">6893</span>, <span class="refDoi"> DOI: 10.1021/nn402062f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn402062f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOqu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=6884-6893&author=L.+M.+Bimboauthor=O.+V.+Denisovaauthor=E.+M%C3%A4kil%C3%A4author=M.+Kaasalainenauthor=J.+K.+De+Brabanderauthor=J.+Hirvonenauthor=J.+Salonenauthor=L.+Kakkolaauthor=D.+Kainovauthor=H.+A.+Santos&title=Inhibition+of+influenza+A+virus+infection+in+vitro+by+saliphenylhalamide-loaded+porous+silicon+nanoparticles&doi=10.1021%2Fnn402062f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles</span></div><div class="casAuthors">Bimbo, Luis M.; Denisova, Oxana V.; Makila, Ermei; Kaasalainen, Martti; De Brabander, Jef K.; Hirvonen, Jouni; Salonen, Jarno; Kakkola, Laura; Kainov, Denis; Santos, Helder A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6884-6893</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Influenza A viruses (IAVs) cause recurrent epidemics in humans, with serious threat of lethal worldwide pandemics.  The occurrence of antiviral-resistant virus strains and the emergence of highly pathogenic influenza viruses have triggered an urgent need to develop new anti-IAV treatments.  One compd. found to inhibit IAV, and other virus infections, is saliphenylhalamide (SaliPhe).  SaliPhe targets host vacuolar-ATPase and inhibits acidification of endosomes, a process needed for productive virus infection.  The major obstacle for the further development of SaliPhe as antiviral drug has been its poor soly.  Here, we investigated the possibility to increase SaliPhe soly. by loading the compd. in thermally hydrocarbonized porous silicon (THCPSi) nanoparticles.  SaliPhe-loaded nanoparticles were further investigated for the ability to inhibit influenza A infection in human retinal pigment epithelium and Madin-Darby canine kidney cells, and we show that upon release from THCPSi, SaliPhe inhibited IAV infection in vitro and reduced the amt. of progeny virus in IAV-infected cells.  Overall, the PSi-based nanosystem exhibited increased dissoln. of the investigated anti-IAV drug SaliPhe and displayed excellent in vitro stability, low cytotoxicity, and remarkable redn. of viral load in the absence of org. solvents.  This proof-of-principle study indicates that PSi nanoparticles could be used for efficient delivery of antivirals to infected cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0XrUI2NFPO7Vg90H21EOLACvtfcHk0lgwAirLnlNB2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOqu77N&md5=16612b7ec5369e80370940a9bedb0059</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fnn402062f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn402062f%26sid%3Dliteratum%253Aachs%26aulast%3DBimbo%26aufirst%3DL.%2BM.%26aulast%3DDenisova%26aufirst%3DO.%2BV.%26aulast%3DM%25C3%25A4kil%25C3%25A4%26aufirst%3DE.%26aulast%3DKaasalainen%26aufirst%3DM.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DSalonen%26aufirst%3DJ.%26aulast%3DKakkola%26aufirst%3DL.%26aulast%3DKainov%26aufirst%3DD.%26aulast%3DSantos%26aufirst%3DH.%2BA.%26atitle%3DInhibition%2520of%2520influenza%2520A%2520virus%2520infection%2520in%2520vitro%2520by%2520saliphenylhalamide-loaded%2520porous%2520silicon%2520nanoparticles%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D6884%26epage%3D6893%26doi%3D10.1021%2Fnn402062f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denisova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Söderholm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Schantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bychkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashchinkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desloovere, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikonen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theisen, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyman, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matikainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julkunen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelens, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkhusha, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3696</span>, <span class="refDoi"> DOI: 10.1128/AAC.02798-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02798-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24752266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3689-3696&author=O.+V.+Denisovaauthor=S.+S%C3%B6derholmauthor=S.+Virtanenauthor=C.+Von+Schantzauthor=D.+Bychkovauthor=E.+Vashchinkinaauthor=J.+Desloovereauthor=J.+Tynellauthor=N.+Ikonenauthor=L.+L.+Theisenauthor=T.+A.+Nymanauthor=S.+Matikainenauthor=O.+Kallioniemiauthor=I.+Julkunenauthor=C.+P.+Mullerauthor=X.+Saelensauthor=V.+V.+Verkhushaauthor=D.+E.+Kainov&title=Akt+inhibitor+MK2206+prevents+influenza+pH1N1+virus+infection+in+vitro&doi=10.1128%2FAAC.02798-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro</span></div><div class="casAuthors">Denisova, Oxana V.; Soderholm, Sandra; Virtanen, Salla; Von Schantz, Carina; Bychkov, Dmitrii; Vashchinkina, Elena; Desloovere, Jens; Tynell, Janne; Ikonen, Niina; Theisen, Linda L.; Nyman, Tuula A.; Matikainen, Sampsa; Kallioniemi, Olli; Julkunen, Ilkka; Muller, Claude P.; Saelens, Xavier; Verkhusha, Vladislav V.; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3689-3696, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The influenza pH1N1 virus caused a global flu pandemic in 2009 and continues manifestation as a seasonal virus.  Better understanding of the virus-host cell interaction could result in development of better prevention and treatment options.  Here we show that the Akt inhibitor MK2206 blocks influenza pH1N1 virus infection in vitro.  In particular, at noncytotoxic concns., MK2206 alters Akt signaling and inhibits endocytic uptake of the virus.  Interestingly, MK2206 is unable to inhibit H3N2, H7N9, and H5N1 viruses, indicating that pH1N1 evolved specific requirements for efficient infection.  Thus, Akt signaling could be exploited further for development of better therapeutics against pH1N1 virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0gFAt6524vbVg90H21EOLACvtfcHk0lg7sWzf1958xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7jJ&md5=dd78e965b377f1f1748089b78c367297</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FAAC.02798-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02798-13%26sid%3Dliteratum%253Aachs%26aulast%3DDenisova%26aufirst%3DO.%2BV.%26aulast%3DS%25C3%25B6derholm%26aufirst%3DS.%26aulast%3DVirtanen%26aufirst%3DS.%26aulast%3DVon%2BSchantz%26aufirst%3DC.%26aulast%3DBychkov%26aufirst%3DD.%26aulast%3DVashchinkina%26aufirst%3DE.%26aulast%3DDesloovere%26aufirst%3DJ.%26aulast%3DTynell%26aufirst%3DJ.%26aulast%3DIkonen%26aufirst%3DN.%26aulast%3DTheisen%26aufirst%3DL.%2BL.%26aulast%3DNyman%26aufirst%3DT.%2BA.%26aulast%3DMatikainen%26aufirst%3DS.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DJulkunen%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DC.%2BP.%26aulast%3DSaelens%26aufirst%3DX.%26aulast%3DVerkhusha%26aufirst%3DV.%2BV.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DAkt%2520inhibitor%2520MK2206%2520prevents%2520influenza%2520pH1N1%2520virus%2520infection%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3689%26epage%3D3696%26doi%3D10.1128%2FAAC.02798-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffaele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macalino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of CX-6258. A potent, selective, and orally efficacious pan-PIM kinases inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1021/ml200259q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200259q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OjurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=135-139&author=M.+Haddachauthor=J.+Michauxauthor=M.+K.+Schwaebeauthor=F.+Pierreauthor=S.+E.+O%E2%80%99Brienauthor=C.+Borsanauthor=J.+Tranauthor=N.+Raffaeleauthor=S.+Ravulaauthor=D.+Dryginauthor=A.+Siddiqui-Jainauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=C.+Proffittauthor=D.+Macalinoauthor=N.+Streinerauthor=J.+Bliesathauthor=M.+Omoriauthor=J.+P.+Whittenauthor=K.+Anderesauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+of+CX-6258.+A+potent%2C+selective%2C+and+orally+efficacious+pan-PIM+kinases+inhibitor&doi=10.1021%2Fml200259q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor</span></div><div class="casAuthors">Haddach, Mustapha; Michaux, Jerome; Schwaebe, Michael K.; Pierre, Fabrice; O'Brien, Sean E.; Borsan, Cosmin; Tran, Joe; Raffaele, Nicholas; Ravula, Suchitra; Drygin, Denis; Siddiqui-Jain, Adam; Darjania, Levan; Stansfield, Ryan; Proffitt, Chris; Macalino, Diwata; Streiner, Nicole; Bliesath, Joshua; Omori, May; Whitten, Jeffrey P.; Anderes, Kenna; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-139</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship anal. in a series of 3-(5-((2-oxoindolin-3-ylidene)methyl)furan-2-yl)amides identified I, a pan-Pim kinases inhibitor with excellent biochem. potency and kinase selectivity.  I exhibited in vitro synergy with chemotherapeutics and robust in vivo efficacy in two Pim kinases driven tumor models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5-aB3Tu-gDrVg90H21EOLACvtfcHk0lg7sWzf1958xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OjurjP&md5=a8c9dc11c9d192d1276e3c05161a40cb</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fml200259q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200259q%26sid%3Dliteratum%253Aachs%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DBorsan%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DJ.%26aulast%3DRaffaele%26aufirst%3DN.%26aulast%3DRavula%26aufirst%3DS.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DMacalino%26aufirst%3DD.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520of%2520CX-6258.%2520A%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520pan-PIM%2520kinases%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D135%26epage%3D139%26doi%3D10.1021%2Fml200259q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. L.</span></span> <span> </span><span class="NLM_article-title">Pim1 impacts enterovirus A71 replication and represents a potential target in antiviral therapy</span>. <i>iScience</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/j.isci.2019.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.isci.2019.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31476618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCnt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=715-727&author=F.+Zhouauthor=Q.+Wanauthor=J.+Luauthor=Y.+Chenauthor=G.+Luauthor=M.+L.+He&title=Pim1+impacts+enterovirus+A71+replication+and+represents+a+potential+target+in+antiviral+therapy&doi=10.1016%2Fj.isci.2019.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Pim1 Impacts Enterovirus A71 Replication and Represents a Potential Target in Antiviral Therapy</span></div><div class="casAuthors">Zhou, Fanghang; Wan, Qianya; Lu, Jing; Chen, Ying; Lu, Gui; He, Ming-Liang</div><div class="citationInfo"><span class="NLM_cas:title">iScience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">ISCICE</span>;
        ISSN:<span class="NLM_cas:issn">2589-0042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Enterovirus A71 (EV-A71) infection causes hand-foot-and-mouth disease (HFMD) and fatal neurol. diseases, and there are no effective treatments.  Host factors play key roles in establishing viral infection and detg. the disease progression and outcome of antiviral therapies.  In this study, we found that the expression of Pim1 was significantly upregulated in EV-A71 infection.  Ectopic expression or silencing of Pim1 promoted or inhibited EV-A71 replication through two distinct mechanisms.  Pim1 enhanced viral IRES activity by increasing viral 2A protease-mediated eIF4G cleavage and blocked AUF1, a suppressor of IRES, translocation from the nucleus to cytosol.  More importantly, we discovered that Pim1 inhibitors (SGI-1776, AZD-1208, and CX-6258) reduced EV-A71 reprodn.  Particularly, CX-6258 remarkably reduced EV-A71 reprodn. more than 1,000 times, providing a potential therapeutic agent for EV-A71 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPKRxeFryZj7Vg90H21EOLACvtfcHk0lgr0Kc3D-XHvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCnt7bN&md5=2e7d7a4025e39099af92fc3095f90cf5</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.isci.2019.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.isci.2019.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DM.%2BL.%26atitle%3DPim1%2520impacts%2520enterovirus%2520A71%2520replication%2520and%2520represents%2520a%2520potential%2520target%2520in%2520antiviral%2520therapy%26jtitle%3DiScience%26date%3D2019%26volume%3D19%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.isci.2019.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Recum-Knepper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Frandsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yángüez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soonthornvacharin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Identification of Polo-like kinases as potential novel drug targets for influenza A virus</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">8629</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-08942-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41598-017-08942-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28819179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC1cfpsVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=8629&author=M.+O.+Pohlauthor=J.+von+Recum-Knepperauthor=A.+Rodriguez-Frandsenauthor=C.+Lanzauthor=E.+Y%C3%A1ng%C3%BCezauthor=S.+Soonthornvacharinauthor=T.+Wolffauthor=S.+K.+Chandaauthor=S.+Stertz&title=Identification+of+Polo-like+kinases+as+potential+novel+drug+targets+for+influenza+A+virus&doi=10.1038%2Fs41598-017-08942-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Polo-like kinases as potential novel drug targets for influenza A virus</span></div><div class="casAuthors">Pohl Marie O; Lanz Caroline; Yanguez Emilio; Stertz Silke; Pohl Marie O; Lanz Caroline; von Recum-Knepper Jessica; Rodriguez-Frandsen Ariel; Soonthornvacharin Stephen; Chanda Sumit K; Wolff Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8629</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In recent years genome-wide RNAi screens have revealed hundreds of cellular factors required for influenza virus infections in human cells.  The long-term goal is to establish some of them as drug targets for the development of the next generation of antivirals against influenza.  We found that several members of the polo-like kinases (PLK), a family of serine/threonine kinases with well-known roles in cell cycle regulation, were identified as hits in four different RNAi screens and we therefore studied their potential as drug target for influenza.  We show that knockdown of PLK1, PLK3, and PLK4, as well as inhibition of PLK kinase activity by four different compounds, leads to reduced influenza virus replication, and we map the requirement of PLK activity to early stages of the viral replication cycle.  We also tested the impact of the PLK inhibitor BI2536 on influenza virus replication in a human lung tissue culture model and observed strong inhibition of virus replication with no measurable toxicity.  This study establishes the PLKs as potential drug targets for influenza and contributes to a more detailed understanding of the intricate interactions between influenza viruses and their host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiV1UTYqDlf1f1XRtfYM0dfW6udTcc2eYkRBcGRjh41bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfpsVKrsQ%253D%253D&md5=72b66e333c4bf7f57dcb8793b7c70f93</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-08942-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-08942-7%26sid%3Dliteratum%253Aachs%26aulast%3DPohl%26aufirst%3DM.%2BO.%26aulast%3Dvon%2BRecum-Knepper%26aufirst%3DJ.%26aulast%3DRodriguez-Frandsen%26aufirst%3DA.%26aulast%3DLanz%26aufirst%3DC.%26aulast%3DY%25C3%25A1ng%25C3%25BCez%26aufirst%3DE.%26aulast%3DSoonthornvacharin%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DChanda%26aufirst%3DS.%2BK.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520Polo-like%2520kinases%2520as%2520potential%2520novel%2520drug%2520targets%2520for%2520influenza%2520A%2520virus%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D8629%26doi%3D10.1038%2Fs41598-017-08942-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, J. C.</span></span> <span> </span><span class="NLM_article-title">The PI3K/Akt pathway contributes to arenavirus budding</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">4578</span>– <span class="NLM_lpage">4585</span>, <span class="refDoi"> DOI: 10.1128/JVI.06604-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.06604-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22345463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsVCgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=4578-4585&author=S.+Urataauthor=N.+Ngoauthor=J.+C.+de+la+Torre&title=The+PI3K%2FAkt+pathway+contributes+to+arenavirus+budding&doi=10.1128%2FJVI.06604-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/Akt pathway contributes to arenavirus budding</span></div><div class="casAuthors">Urata, Shuzo; Ngo, Nhi; Carlos de la Torre, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4578-4585</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose a significant public health concern in regions where they are endemic.  On the other hand, evidence indicates that the globally distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen.  The phosphatidylinositol 3-kinase (PI3K)/Akt pathway participates in many cellular processes, including cell survival and differentiation, and also has been shown to play important roles in different steps of the life cycles of a variety of viruses.  Here we report that the inhibition of the PI3K/Akt pathway inhibited budding and to a lesser extent RNA synthesis, but not cell entry, of LCMV.  Accordingly, BEZ-235, a PI3K inhibitor currently in cancer clin. trials, inhibited LCMV multiplication in cultured cells.  These findings, together with those previously reported for Junin virus (JUNV), indicate that targeting the PI3K/Akt pathway could represent a novel antiviral strategy to combat human-pathogenic arenaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhC88x3storVg90H21EOLACvtfcHk0lgr0Kc3D-XHvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsVCgtr0%253D&md5=298878f4dd1ed84f7175f85a8673aada</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FJVI.06604-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.06604-11%26sid%3Dliteratum%253Aachs%26aulast%3DUrata%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DN.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520PI3K%252FAkt%2520pathway%2520contributes%2520to%2520arenavirus%2520budding%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D4578%26epage%3D4585%26doi%3D10.1128%2FJVI.06604-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herns, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, S. A.</span></span> <span> </span><span class="NLM_article-title">Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">5808</span>– <span class="NLM_lpage">5820</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.002353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.RA118.002353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29475942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFSqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=5808-5820&author=G.+R.+Campbellauthor=R.+S.+Bruckmanauthor=S.+D.+Hernsauthor=S.+Joshiauthor=D.+L.+Durdenauthor=S.+A.+Spector&title=Induction+of+autophagy+by+PI3K%2FMTOR+and+PI3K%2FMTOR%2FBRD4+inhibitors+suppresses+HIV-1+replication&doi=10.1074%2Fjbc.RA118.002353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication</span></div><div class="casAuthors">Campbell, Grant R.; Bruckman, Rachel S.; Herns, Shayna D.; Joshi, Shweta; Durden, Donald L.; Spector, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5808-5820</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In this study, we investigated the effects of the dual phosphatidylinositol 3-kinase/mechanistic target of rapamycin (PI3K/MTOR) inhibitor dactolisib (NVP-BEZ235), the PI3K/MTOR/bromodomain-contg. protein 4 (BRD4) inhibitor SF2523, and the bromodomain and extra terminal domain inhibitor JQ1 on the productive infection of primary macrophages with human immunodeficiency type-1 (HIV).  These inhibitors did not alter the initial susceptibility of macrophages to HIV infection.  However, dactolisib, JQ1, and SF2523 all decreased HIV replication in macrophages in a dose-dependent manner via degrdn. of intracellular HIV through autophagy.  Macrophages treated with dactolisib, JQ1, or SF2523 displayed an increase in LC3B lipidation combined with SQSTM1 degrdn. without inducing increased cell death.  LC3B-II levels were further increased in the presence of pepstatin A suggesting that these inhibitors induce autophagic flux.  RNA interference for ATG5 and ATG7 and pharmacol. inhibitors of autophagosome-lysosome fusion and of lysosomal hydrolases all blocked the inhibition of HIV.  Thus, we demonstrate that the mechanism of PI3K/MTOR and PI3K/MTOR/BRD4 inhibitor suppression of HIV requires the formation of autophagosomes, as well as their subsequent maturation into autolysosomes.  These data provide further evidence in support of a role for autophagy in the control of HIV infection and open new avenues for the use of this class of drugs in HIV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-D9wUfaylbVg90H21EOLACvtfcHk0lgvBv6Vt8MRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFSqu74%253D&md5=06a414ed7a31e34ed7cfd9bb28b48fdd</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.002353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.002353%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DG.%2BR.%26aulast%3DBruckman%26aufirst%3DR.%2BS.%26aulast%3DHerns%26aufirst%3DS.%2BD.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26aulast%3DSpector%26aufirst%3DS.%2BA.%26atitle%3DInduction%2520of%2520autophagy%2520by%2520PI3K%252FMTOR%2520and%2520PI3K%252FMTOR%252FBRD4%2520inhibitors%2520suppresses%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D5808%26epage%3D5820%26doi%3D10.1074%2Fjbc.RA118.002353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett-Mayer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogretmen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisendine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maines, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. B.</span></span> <span> </span><span class="NLM_article-title">A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4642</span>– <span class="NLM_lpage">4650</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-16-2363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28420720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4642-4650&author=C.+D.+Brittenauthor=E.+Garrett-Mayerauthor=S.+H.+Chinauthor=K.+Shiraiauthor=B.+Ogretmenauthor=T.+A.+Bentzauthor=A.+Brisendineauthor=K.+Andertonauthor=S.+L.+Cusackauthor=L.+W.+Mainesauthor=Y.+Zhuangauthor=C.+D.+Smithauthor=M.+B.+Thomas&title=A+phase+I+study+of+ABC294640%2C+a+first-in-class+sphingosine+kinase-2+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-16-2363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Britten, Carolyn D.; Garrett-Mayer, Elizabeth; Chin, Steven H.; Shirai, Keisuke; Ogretmen, Besim; Bentz, Tricia A.; Brisendine, Alan; Anderton, Kate; Cusack, Susan L.; Maines, Lynn W.; Zhuang, Yan; Smith, Charles D.; Thomas, Melanie B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4642-4650</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Sphingosine kinases (SK1 and SK2) regulate tumor growth by generating the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P).  This phase I study investigated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABC294640, a first-in-class orally available inhibitor of SK2.  Exptl. Design: Escalating doses of ABC294640 were administered orally to patients with advanced solid tumors in sequential cohorts at the following dose levels: 250 mg qd, 250 mg bid, 500 mg bid, and 750 mg bid, continuously in cycles of 28 days.  Serial blood samples were obtained to measure ABC294640 concns. and sphingolipid profiles.  Results: Twenty-two patients were enrolled, and 21 received ABC294640.  The most common drug-related toxicities were nausea, vomiting, and fatigue.  Among the 4 patients at 750 mg bid, one had dose-limiting grade 3 nausea and vomiting, and 2 were unable to complete cycle 1 due to diverse drug-related toxicities.  The 500 mg bid dose level was established as the recommended phase II dose.  ABC294640 administration resulted in decreases in S1P levels over the first 12 h, with return to baseline at 24 h.  The best response was a partial response in a patient with cholangiocarcinoma at 250 mg qd, and stable disease was obsd. in 6 patients with various solid tumors across dose levels.  Conclusions: At 500 mg bid, ABC294640 is well tolerated and achieves biol. relevant plasma concns.  Changes in plasma sphingolipid levels may provide a useful pharmacodynamic biomarker for ABC294640.  Clin Cancer Res; 23(16); 4642-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccHLDVdNAnrVg90H21EOLACvtfcHk0lgvBv6Vt8MRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu7rF&md5=036326983052de4e17377dee55052098</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2363%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DChin%26aufirst%3DS.%2BH.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOgretmen%26aufirst%3DB.%26aulast%3DBentz%26aufirst%3DT.%2BA.%26aulast%3DBrisendine%26aufirst%3DA.%26aulast%3DAnderton%26aufirst%3DK.%26aulast%3DCusack%26aufirst%3DS.%2BL.%26aulast%3DMaines%26aufirst%3DL.%2BW.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26aulast%3DThomas%26aufirst%3DM.%2BB.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520ABC294640%252C%2520a%2520first-in-class%2520sphingosine%2520kinase-2%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4642%26epage%3D4650%26doi%3D10.1158%2F1078-0432.CCR-16-2363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1111/bjh.16530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fbjh.16530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32124438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFaqtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=405-417&author=F.+R.+LeBlancauthor=J.+M.+Pearsonauthor=S.+F.+Tanauthor=H.+Cheonauthor=J.+C.+Xingauthor=W.+Duntonauthor=D.+J.+Feithauthor=T.+P.+Loughran&title=Sphingosine+kinase-2+is+overexpressed+in+large+granular+lymphocyte+leukaemia+and+promotes+survival+through+Mcl-1&doi=10.1111%2Fbjh.16530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1</span></div><div class="casAuthors">LeBlanc, Francis R.; Pearson, Jennifer M.; Tan, Su-Fern; Cheon, HeeJin; Xing, Jeffrey C.; Dunton, Wendy; Feith, David J.; Loughran, Thomas P., Jr</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-417</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sphingolipid metab. is increasingly recognized as a therapeutic target in cancer due to its regulation of cell proliferation and apoptosis.  The sphingolipid rheostat is proposed to control cell fate through maintaining balance between pro-apoptotic and pro-survival sphingolipids.  This balance is regulated by metabolising enzymes involved in sphingolipid prodn.  One such enzyme, sphingosine kinase-2 (SPHK2), produces pro-survival sphingosine 1-phosphate (S1P) by phosphorylation of pro-apoptotic sphingosine.  Elevated SPHK2 has been found in multiple cancer types and contributes to cell survival, chemotherapeutic resistance and apoptosis resistance.  We have previously shown elevation of S1P in large granular lymphocyte (LGL) leukemia serum and cells isolated from patients.  Here, we examd. SPHK2 expression in LGL leukemia and found SPHK2 mRNA and protein upregulation in a majority of LGL leukemia patient samples.  Knockdown of SPHK2 with siRNA in LGL leukemia cell lines decreased proliferation.  Addnl., the use of ABC294640 or K145, both SPHK2-specific inhibitors, decreased viability of LGL leukemia cell lines.  ABC294640 selectively induced apoptosis in LGL cell lines and freshly isolated LGL leukemia patient cells compared to normal controls.  Mechanistically, SPHK2 inhibition downregulated pro-survival myeloid cell leukemia-1 (Mcl-1) protein through proteasomal degrdn.  Targeting of SPHK2 therefore provides a novel therapeutic approach for the treatment of LGL leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5UKhTZsBXlrVg90H21EOLACvtfcHk0lgvBv6Vt8MRQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFaqtL3J&md5=4cf5aef2342b639b2d9af4cee8f9c596</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fbjh.16530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.16530%26sid%3Dliteratum%253Aachs%26aulast%3DLeBlanc%26aufirst%3DF.%2BR.%26aulast%3DPearson%26aufirst%3DJ.%2BM.%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DCheon%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DJ.%2BC.%26aulast%3DDunton%26aufirst%3DW.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26atitle%3DSphingosine%2520kinase-2%2520is%2520overexpressed%2520in%2520large%2520granular%2520lymphocyte%2520leukaemia%2520and%2520promotes%2520survival%2520through%2520Mcl-1%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2020%26volume%3D190%26spage%3D405%26epage%3D417%26doi%3D10.1111%2Fbjh.16530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studstill, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahm, B.</span></span> <span> </span><span class="NLM_article-title">Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30125617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=171-177&author=C.+Xiaauthor=Y.+J.+Seoauthor=C.+J.+Studstillauthor=M.+Vijayanauthor=J.+J.+Wolfauthor=B.+Hahm&title=Transient+inhibition+of+sphingosine+kinases+confers+protection+to+influenza+A+virus+infected+mice&doi=10.1016%2Fj.antiviral.2018.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</span></div><div class="casAuthors">Xia, Chuan; Seo, Young-Jin; Studstill, Caleb J.; Vijayan, Madhuvanthi; Wolf, Jennifer J.; Hahm, Bumsuk</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza continues to pose a threat to public health by causing illness and mortality in humans.  Discovering host factors that regulate influenza virus propagation is vital for the development of novel drugs.  We have previously reported that sphingosine kinase (SphK) 1 promotes influenza A virus (IAV) replication in vitro.  Here we demonstrate that the other isoform of SphK, SphK2 promotes the replication of influenza A virus (IAV) in cultured cells, and temporary inhibition of SphK1 or SphK2 enhances the host defense against influenza in mice.  IAV infection led to an increased expression and phosphorylation of SphK2 in host cells.  Furthermore, pharmacol. inhibition or siRNA-based knockdown of SphK2 attenuated IAV replication in vitro.  Notably, oral administration of an SphK2-specific inhibitor substantially improved the viability of mice following IAV infection.  In addn., the local instillation of an SphK1-specific inhibitor or an inhibitor that globally blocks SphK1 and SphK2 provided protection to IAV-infected mice.  Collectively, our results indicate that both SphK1 and SphK2 function as proviral factors during IAV infection in vivo.  Therefore, SphK1 and SphK2 represent potential host targets for therapeutics against influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGortAJwhk2uhbVg90H21EOLACvtfcHk0lhbPFwkZDkp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyrs7zN&md5=917faf2ff203854730479084e4db5808</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DC.%26aulast%3DSeo%26aufirst%3DY.%2BJ.%26aulast%3DStudstill%26aufirst%3DC.%2BJ.%26aulast%3DVijayan%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DJ.%2BJ.%26aulast%3DHahm%26aufirst%3DB.%26atitle%3DTransient%2520inhibition%2520of%2520sphingosine%2520kinases%2520confers%2520protection%2520to%2520influenza%2520A%2520virus%2520infected%2520mice%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D158%26spage%3D171%26epage%3D177%26doi%3D10.1016%2Fj.antiviral.2018.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krausz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlag, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lufkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuijk, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodde, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedquist, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span> <span> </span><span class="NLM_article-title">Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1755</span>, <span class="refDoi"> DOI: 10.1002/art.34339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fart.34339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22170479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=1750-1755&author=S.+Krauszauthor=M.+J.+Boumansauthor=D.+M.+Gerlagauthor=J.+Lufkinauthor=A.+W.+van+Kuijkauthor=A.+Bakkerauthor=M.+de+Boerauthor=B.+M.+Loddeauthor=K.+A.+Reedquistauthor=E.+W.+Jacobsonauthor=M.+O%E2%80%99Mearaauthor=P.+P.+Tak&title=Brief+report%3A+a+phase+IIa%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+apilimod+mesylate%2C+an+interleukin-12%2Finterleukin-23+inhibitor%2C+in+patients+with+rheumatoid+arthritis&doi=10.1002%2Fart.34339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis</span></div><div class="casAuthors">Krausz, Sarah; Boumans, Maria J. H.; Gerlag, Danielle M.; Lufkin, Joelle; van Kuijk, Arno W. R.; Bakker, Alian; de Boer, Maarten; Lodde, Beatrijs M.; Reedquist, Kris A.; Jacobson, Eric W.; O'Meara, Michael; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1750-1755</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin-12 (IL-12)/IL-23 inhibitor, in patients with rheumatoid arthritis (RA).  Methods : We performed a phase IIa, randomized, double-blind, placebo-controlled proof-of-concept study of apilimod, in combination with methotrexate, in 29 patients with active RA (3:1 ratio of apilimod-treated to placebo-treated patients) in 3 stages.  Patients received apilimod 100 mg/day or placebo for 4 wk (stage 1) or 8 wk (stage 2).  In stage 3, patients received apilimod 100 mg twice a day or placebo for 8 wk, with an optional extension of 4 wk.  Clin. response (Disease Activity Score in 28 joints [DAS28] and American College of Rheumatol. [ACR] criteria) was assessed throughout; synovial tissue samples collected at baseline and on day 29 (stages 1 and 2) or day 57 (stage 3) were stained for cellular markers and cytokines for immunohistochem. anal.  Results : While only mild adverse events were obsd. in stages 1 and 2, in stage 3, all patients experienced headache and/or nausea.  Among apilimod-treated patients (100 mg/day), there was a small, but significant, redn. in the DAS28 on day 29 and day 57 compared with baseline.  ACR20 response was reached in only 6% of patients on day 29 and 25% of patients on day 57, similar to the percentage of responders in the placebo group.  Increasing the dosage (100 mg twice a day) did not improve clin. efficacy.  Consistent with clin. results, apilimod did not have an effect on expression of synovial biomarkers.  Of importance, we also did not observe an effect of apilimod on synovial IL-12 and IL-23 expression.  Conclusion : Our results do not support the notion that IL-12/IL-23 inhibition by apilimod is able to induce robust clin. improvement in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDSYFKciwGeLVg90H21EOLACvtfcHk0lhbPFwkZDkp8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOltL0%253D&md5=962eb0fb499e40cc7de36f41adfef49f</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fart.34339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.34339%26sid%3Dliteratum%253Aachs%26aulast%3DKrausz%26aufirst%3DS.%26aulast%3DBoumans%26aufirst%3DM.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DLufkin%26aufirst%3DJ.%26aulast%3Dvan%2BKuijk%26aufirst%3DA.%2BW.%26aulast%3DBakker%26aufirst%3DA.%26aulast%3Dde%2BBoer%26aufirst%3DM.%26aulast%3DLodde%26aufirst%3DB.%2BM.%26aulast%3DReedquist%26aufirst%3DK.%2BA.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DBrief%2520report%253A%2520a%2520phase%2520IIa%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520apilimod%2520mesylate%252C%2520an%2520interleukin-12%252Finterleukin-23%2520inhibitor%252C%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D1750%26epage%3D1755%26doi%3D10.1002%2Fart.34339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbloom, S.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease</span>. <i>Inflamm Bowel Dis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/ibd.21159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fibd.21159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19918967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1209-1218&author=B.+E.+Sandsauthor=E.+W.+Jacobsonauthor=T.+Sylwestrowiczauthor=Z.+Younesauthor=G.+Drydenauthor=R.+Fedorakauthor=S.+Greenbloom&title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+oral+interleukin-12%2F23+inhibitor+apilimod+mesylate+for+treatment+of+active+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease</span></div><div class="casAuthors">Sands Bruce E; Jacobson Eric W; Sylwestrowicz Thomas; Younes Ziad; Dryden Gerald; Fedorak Richard; Greenbloom Susan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1209-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD).  We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD.  METHODS:  We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450).  Patients were stratified according to C-reactive protein (CRP) levels and corticosteroid use and were randomly assigned to receive placebo or apilimod mesylate 50 mg daily or 100 mg daily.  The study was divided into an induction phase (43 days) and a maintenance phase (125 days).  The primary analysis involved a comparison of the proportion of patients experiencing clinical response, defined as at least a 100-point decrease in CDAI score from baseline at day 29.  Data on adverse events were also collected.  RESULTS:  In all, 220 of the planned 282 patients were enrolled when the Data Monitoring Committee determined that the drug was not efficacious as a treatment and closed enrollment.  A clinical response was experienced by 18 patients (24.7%) in the 50-mg daily (QD) group (n = 73) and 19 patients (25.7%) in the 100 mg QD group (n = 74), as compared with 21 patients (28.8%) in the placebo group (n = 73) on day 29 (P = 0.71 for each comparison).  No significant adverse safety signal was observed.  CONCLUSIONS:  Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKP1Ngip31hrrIbt-tGZmxfW6udTcc2eYR7XD-_EYYQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D&md5=4e87fe88e4b06cb7a47d7554a6597a4a</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fibd.21159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21159%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DDryden%26aufirst%3DG.%26aulast%3DFedorak%26aufirst%3DR.%26aulast%3DGreenbloom%26aufirst%3DS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520oral%2520interleukin-12%252F23%2520inhibitor%2520apilimod%2520mesylate%2520for%2520treatment%2520of%2520active%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm%2520Bowel%2520Dis%26date%3D2010%26volume%3D16%26spage%3D1209%26epage%3D1218%26doi%3D10.1002%2Fibd.21159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar-Roman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Camilli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span> <span> </span><span class="NLM_article-title">PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23890009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=912-921&author=X.+Caiauthor=Y.+Xuauthor=A.+K.+Cheungauthor=R.+C.+Tomlinsonauthor=A.+Alcazar-Romanauthor=L.+Murphyauthor=A.+Billichauthor=B.+Zhangauthor=Y.+Fengauthor=M.+Klumppauthor=J.+M.+Rondeauauthor=A.+N.+Fazalauthor=C.+J.+Wilsonauthor=V.+Myerauthor=G.+Jobertyauthor=T.+Bouwmeesterauthor=M.+A.+Labowauthor=P.+M.+Finanauthor=J.+A.+Porterauthor=H.+L.+Ploeghauthor=D.+Bairdauthor=P.+De+Camilliauthor=J.+A.+Tallaricoauthor=Q.+Huang&title=PIKfyve%2C+a+class+III+PI+kinase%2C+is+the+target+of+the+small+molecular+IL-12%2FIL-23+inhibitor+apilimod+and+a+player+in+Toll-like+receptor+signaling&doi=10.1016%2Fj.chembiol.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling</span></div><div class="casAuthors">Cai, Xinming; Xu, Yongyao; Cheung, Atwood K.; Tomlinson, Ronald C.; Alcazar-Roman, Abel; Murphy, Leon; Billich, Andreas; Zhang, Bailin; Feng, Yan; Klumpp, Martin; Rondeau, Jean-Michel; Fazal, Aleem N.; Wilson, Christopher J.; Myer, Vic; Joberty, Gerard; Bouwmeester, Tewis; Labow, Mark A.; Finan, Peter M.; Porter, Jeffrey A.; Ploegh, Hidde L.; Baird, Daniel; De Camilli, Pietro; Tallarico, John A.; Huang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">912-921</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) signaling is a key component of innate immunity.  Aberrant TLR activation leads to immune disorders via dysregulation of cytokine prodn., such as IL-12/IL-23.  Herein, we identify and characterize PIKfyve, a lipid kinase, as a crit. player in TLR signaling using apilimod as an affinity tool.  Apilimod is a potent small mol. inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clin. trials for patients with Crohn's disease or rheumatoid arthritis.  Using a chem. genetic approach, we show that it binds to PIKfyve and blocks its phosphotransferase activity, leading to selective inhibition of IL-12/IL-23p40.  Pharmacol. or genetic inactivation of PIKfyve is necessary and sufficient for suppression of IL-12/IL-23p40 expression.  Thus, we have uncovered a phosphoinositide-mediated regulatory mechanism that controls TLR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpALdejwmIR_rVg90H21EOLACvtfcHk0lhrTY6jGcKuIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE&md5=9b296c00beb17b95ec9a17c1750a1862</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCheung%26aufirst%3DA.%2BK.%26aulast%3DTomlinson%26aufirst%3DR.%2BC.%26aulast%3DAlcazar-Roman%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DKlumpp%26aufirst%3DM.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DFazal%26aufirst%3DA.%2BN.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%2BA.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DBaird%26aufirst%3DD.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DPIKfyve%252C%2520a%2520class%2520III%2520PI%2520kinase%252C%2520is%2520the%2520target%2520of%2520the%2520small%2520molecular%2520IL-12%252FIL-23%2520inhibitor%2520apilimod%2520and%2520a%2520player%2520in%2520Toll-like%2520receptor%2520signaling%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D912%26epage%3D921%26doi%3D10.1016%2Fj.chembiol.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0005540</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=e0005540&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0lhrTY6jGcKuIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26spage%3De0005540%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warkentin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salambanga, F. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobasa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, M.</span></span> <span> </span><span class="NLM_article-title">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2017.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virol.2017.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29031163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=17-28&author=S.+Qiuauthor=A.+Leungauthor=Y.+Boauthor=R.+A.+Kozakauthor=S.+P.+Anandauthor=C.+Warkentinauthor=F.+D.+R.+Salambangaauthor=J.+Cuiauthor=G.+Kobingerauthor=D.+Kobasaauthor=M.+C%C3%B4t%C3%A9&title=Ebola+virus+requires+phosphatidylinositol+%283%2C5%29+bisphosphate+production+for+efficient+viral+entry&doi=10.1016%2Fj.virol.2017.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span></div><div class="casAuthors">Qiu, Shirley; Leung, Anders; Bo, Yuxia; Kozak, Robert A.; Anand, Sai Priya; Warkentin, Corina; Salambanga, Fabiola D. R.; Cui, Jennifer; Kobinger, Gary; Kobasa, Darwyn; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For entry, Ebola virus (EBOV) requires the interaction of its viral glycoprotein with the cellular protein Niemann-Pick C1 (NPC1) which resides in late endosomes and lysosomes.  How EBOV is trafficked and delivered to NPC1 and whether this is pos. regulated during entry remain unclear.  Here, we show that the PIKfyve-ArPIKfyve-Sac3 cellular complex, which is involved in the metab. of phosphatidylinositol (3,5) bisphosphate (PtdIns(3,5)P2), is crit. for EBOV infection.  Although the expression of all subunits of the complex was required for efficient entry, PIKfyve kinase activity was specifically crit. for entry by all pathogenic filoviruses.  Inhibition of PIKfyve prevented colocalization of EBOV with NPC1 and led to virus accumulation in intracellular vesicles with characteristics of early endosomes.  Importantly, genetically-encoded phosphoinositide probes revealed an increase in PtdIns(3,5)P2-pos. vesicles in cells during EBOV entry.  Taken together, our studies suggest that EBOV requires PtdIns(3,5)P2 prodn. in cells to promote efficient delivery to NPC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBj4bGDkDZELVg90H21EOLACvtfcHk0ljle7U5IO10cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI&md5=1a0bed541a6186ca937abcc2cabc4bb6</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2017.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2017.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAnand%26aufirst%3DS.%2BP.%26aulast%3DWarkentin%26aufirst%3DC.%26aulast%3DSalambanga%26aufirst%3DF.%2BD.%2BR.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DKobinger%26aufirst%3DG.%26aulast%3DKobasa%26aufirst%3DD.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.%26atitle%3DEbola%2520virus%2520requires%2520phosphatidylinositol%2520%25283%252C5%2529%2520bisphosphate%2520production%2520for%2520efficient%2520viral%2520entry%26jtitle%3DVirology%26date%3D2018%26volume%3D513%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fj.virol.2017.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>A
study of
LAM-002A for the prevention of progression of COVID-19</i>, NCT04446377,
AI Therapeutics, Inc., <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+A%0Astudy+of%0ALAM-002A+for+the+prevention+of+progression+of+COVID-19%2C+NCT04446377%2C%0AAI+Therapeutics%2C+Inc.%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DA%250Astudy%2520of%250ALAM-002A%2520for%2520the%2520prevention%2520of%2520progression%2520of%2520COVID-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlauf, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cureton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">20803</span>– <span class="NLM_lpage">20813</span>, <span class="refDoi"> DOI: 10.1073/pnas.2007837117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1073%2Fpnas.2007837117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32764148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=20803-20813&author=Y.-L.+Kangauthor=Y.-Y.+Chouauthor=P.+W.+Rothlaufauthor=Z.+Liuauthor=T.+K.+Sohauthor=D.+Curetonauthor=J.+B.+Caseauthor=R.+E.+Chenauthor=M.+S.+Diamondauthor=S.+P.+J.+Whelanauthor=T.+Kirchhausen&title=Inhibition+of+PIKfyve+kinase+prevents+infection+by+Zaire+ebolavirus+and+SARS-CoV-2&doi=10.1073%2Fpnas.2007837117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span></div><div class="casAuthors">Kang, Yuan-Lin; Chou, Yi-ying; Rothlauf, Paul W.; Liu, Zhuoming; Soh, Timothy K.; Cureton, David; Case, James Brett; Chen, Rita E.; Diamond, Michael S.; Whelan, Sean P. J.; Kirchhausen, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20803-20813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Virus entry is a multistep process.  It initiates when the virus attaches to the host cell and ends when the viral contents reach the cytosol.  Genetically unrelated viruses can subvert analogous subcellular mechanisms and use similar trafficking pathways for successful entry.  Antiviral strategies targeting early steps of infection are therefore appealing, particularly when the probability for successful interference through a common step is highest.  We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) contg. the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small-mol. inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.  We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.  These results define tools for studying the intracellular trafficking of pathogens elicited by inhibition of PIKfyve kinase and suggest the potential for targeting this kinase in developing small-mol. antivirals against SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYcbVh--KCN7Vg90H21EOLACvtfcHk0ljle7U5IO10cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP&md5=a7e1b43b16edffb6dabc91258b88ab7c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2007837117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2007837117%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.-L.%26aulast%3DChou%26aufirst%3DY.-Y.%26aulast%3DRothlauf%26aufirst%3DP.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSoh%26aufirst%3DT.%2BK.%26aulast%3DCureton%26aufirst%3DD.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DR.%2BE.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DWhelan%26aufirst%3DS.%2BP.%2BJ.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520PIKfyve%2520kinase%2520prevents%2520infection%2520by%2520Zaire%2520ebolavirus%2520and%2520SARS-CoV-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D20803%26epage%3D20813%26doi%3D10.1073%2Fpnas.2007837117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulp, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4309</span>– <span class="NLM_lpage">4318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-4063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F0008-5472.CAN-03-4063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15205346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFWlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4309-4318&author=J.+Zhuauthor=J.+W.+Huangauthor=P.+H.+Tsengauthor=Y.+T.+Yangauthor=J.+Fowbleauthor=C.+W.+Shiauauthor=Y.+J.+Shawauthor=S.+K.+Kulpauthor=C.+S.+Chen&title=From+the+cyclooxygenase-2+inhibitor+celecoxib+to+a+novel+class+of+3-phosphoinositide-dependent+protein+kinase-1+inhibitors&doi=10.1158%2F0008-5472.CAN-03-4063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors</span></div><div class="casAuthors">Zhu, Jiuxiang; Huang, Jui-Wen; Tseng, Ping-Hui; Yang, Ya-Ting; Fowble, Joseph; Shiau, Chung-Wai; Shaw, Yeng-Jeng; Kulp, Samuel K.; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4309-4318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The blockade of Akt activation through the inhibition of 3-phosphoinositide-dependent kinase-1 (PDK-1) represents a major signaling mechanism whereby celecoxib mediates apoptosis.  Celecoxib, however, is a weak PDK-1 inhibitor (IC50, 48 μM), requiring at least 30 μM to exhibit discernable effects on the growth of tumor cells in vitro.  Here, we report the structure-based optimization of celecoxib to develop PDK-1 inhibitors with greater potency in enzyme inhibition and growth inhibition.  Kinetics of PDK-1 inhibition by celecoxib with respect to ATP suggest that celecoxib derivs. inhibit PDK-1 by competing with ATP for binding, a mechanism reminiscent to that of many kinase inhibitors.  Structure-activity anal. together with mol. modeling was used to generate compds. that were tested for their potency in inhibiting PDK-1 kinase activity and in inducing apoptosis in PC-3 prostate cancer cells.  Docking of potent compds. into the ATP-binding site of PDK-1 was performed for lead optimization, leading to two compds., OSU-03012 and OSU-03013, with IC50 values in PDK-1 inhibition and apoptosis induction in the low μM range.  Exposure of PC-3 cells to these agents led to Akt dephosphorylation and inhibition of p70 S6 kinase activity.  Moreover, overexpression of constitutively active forms of PDK-1 and Akt partially protected OSU-03012-induced apoptosis.  Screening in a panel of 60 cell lines and more extensive testing in PC-3 cells indicated that the mean concn. for total growth inhibition was ∼3 μM for both agents.  Considering the conserved role of PDK-1/Akt signaling in promoting tumorigenesis, these celecoxib analogs are of translational relevance for cancer prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrSQXLNmChLVg90H21EOLACvtfcHk0ljle7U5IO10cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFWlsbg%253D&md5=41dd9332d38a19283709719a7e3cb574</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-4063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-4063%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%2BW.%26aulast%3DTseng%26aufirst%3DP.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DFowble%26aufirst%3DJ.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DShaw%26aufirst%3DY.%2BJ.%26aulast%3DKulp%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DFrom%2520the%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520to%2520a%2520novel%2520class%2520of%25203-phosphoinositide-dependent%2520protein%2520kinase-1%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4309%26epage%3D4318%26doi%3D10.1158%2F0008-5472.CAN-03-4063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chik, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span> <span> </span><span class="NLM_article-title">The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30326204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGhsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2018&pages=38-47&author=J.+F.+Chanauthor=Z.+Zhuauthor=H.+Chuauthor=S.+Yuanauthor=K.+K.+Chikauthor=C.+C.+Chanauthor=V.+K.+Poonauthor=C.+C.+Yipauthor=X.+Zhangauthor=J.+O.+Tsangauthor=Z.+Zouauthor=K.+M.+Teeauthor=H.+Shuaiauthor=G.+Luauthor=K.+Y.+Yuen&title=The+celecoxib+derivative+kinase+inhibitor+AR-12+%28OSU-03012%29+inhibits+Zika+virus+via+down-regulation+of+the+PI3K%2FAkt+pathway+and+protects+Zika+virus-infected+A129+mice%3A+A+host-targeting+treatment+strategy&doi=10.1016%2Fj.antiviral.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</span></div><div class="casAuthors">Chan, Jasper Fuk-Woo; Zhu, Zheng; Chu, Hin; Yuan, Shuofeng; Chik, Kenn Ka-Heng; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Yip, Cyril Chik-Yan; Zhang, Xi; Tsang, Jessica Oi-Ling; Zou, Zijiao; Tee, Kah-Meng; Shuai, Huiping; Lu, Gang; Yuen, Kwok-Yung</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Zika virus (ZIKV) is a human-pathogenic flavivirus that has recently emerged as a global public health threat.  ZIKV infection may be assocd. with congenital malformations in infected fetuses and severe neurol. and systemic complications in infected adults.  There are currently limited treatment options for ZIKV infection.  AR-12 (OSU-03012) is a celecoxib deriv. cellular kinase inhibitor that has broad-spectrum antiviral activities.  In this study, we investigated the antiviral activity and mechanism of AR-12 against ZIKV.  We evaluated the in vitro anti-ZIKV activity of AR-12, using cell protection and virus yield redn. assays, in multiple clin. relevant cell lines, and the in vivo treatment effects of AR-12 in a lethal mouse model using type I interferon receptor-deficient A129 mice.  AR-12 inhibited ZIKV strains belonging to both the African and Asian/American lineages in Huh-7 and/or neuronal cells.  AR12 IC50 against ZIKV was consistently <2 μM in these cells.  ZIKV-infected A129 mice treated with i.p. or orally administered AR-12 had significantly higher survival rate (50.0%-83.3% vs 0%, P < 0.05), less body wt. loss, and lower blood and tissue ZIKV RNA loads than untreated control A129 mice.  These anti-ZIKV effects were likely the results of down-regulation of the PI3K/Akt pathway by AR-12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Ds4v9pBb07Vg90H21EOLACvtfcHk0lgiQds3O33fTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGhsL%252FO&md5=05baf975452e24ce11ac163b47937a97</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChik%26aufirst%3DK.%2BK.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DPoon%26aufirst%3DV.%2BK.%26aulast%3DYip%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTsang%26aufirst%3DJ.%2BO.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DTee%26aufirst%3DK.%2BM.%26aulast%3DShuai%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26atitle%3DThe%2520celecoxib%2520derivative%2520kinase%2520inhibitor%2520AR-12%2520%2528OSU-03012%2529%2520inhibits%2520Zika%2520virus%2520via%2520down-regulation%2520of%2520the%2520PI3K%252FAkt%2520pathway%2520and%2520protects%2520Zika%2520virus-infected%2520A129%2520mice%253A%2520A%2520host-targeting%2520treatment%2520strategy%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D160%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.antiviral.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koselny, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halterman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fothergill, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederhold, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushion, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappelye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span> <span> </span><span class="NLM_article-title">The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7115</span>– <span class="NLM_lpage">7127</span>, <span class="refDoi"> DOI: 10.1128/AAC.01061-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.01061-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27645246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7115-7127&author=K.+Koselnyauthor=J.+Greenauthor=L.+DiDoneauthor=J.+P.+Haltermanauthor=A.+W.+Fothergillauthor=N.+P.+Wiederholdauthor=T.+F.+Pattersonauthor=M.+T.+Cushionauthor=C.+Rappelyeauthor=M.+Wellingtonauthor=D.+J.+Krysan&title=The+celecoxib+derivative+AR-12+has+broad-spectrum+antifungal+activity+in+vitro+and+improves+the+activity+of+fluconazole+in+a+murine+model+of+cryptococcosis&doi=10.1128%2FAAC.01061-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis</span></div><div class="casAuthors">Koselny, Kristy; Green, Julianne; Di Done, Louis; Halterman, Justin P.; Fothergill, Annette W.; Wiederhold, Nathan P.; Patterson, Thomas F.; Cushion, Melanie T.; Rappelye, Chad; Wellington, Melanie; Krysan, Damian J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7115-7127</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Only one new class of antifungal drugs has been introduced into clin. practice in the last 30 years, and thus the identification of small mols. with novel mechanisms of action is an important goal of current anti-infective research.  Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib deriv. which has been tested in a phase I clin. trial as an anticancer agent.  AR-12 inhibits fungal acetyl CoA (acetyl-CoA) synthetase in vitro and is fungicidal at concns. similar to those achieved in human plasma.  AR-12 has a broad spectrum of activity, including activity against yeasts (e.g., Candida albicans, non-albicans Candida spp., Cryptococcus neoformans), molds (e.g., Fusarium, Mucor), and dimorphic fungi (Blastomyces, Histoplasma, and Coccidioides) with MICs of 2 to 4 μg/mL.  AR-12 is also active against azole- and echinocandin-resistant Candida isolates, and subinhibitory AR-12 concns. increase the susceptibility of fluconazole- and echinocandin-resistant Candida isolates.  Finally, AR-12 also increases the activity of fluconazole in a murine model of cryptococcosis.  Taken together, these data indicate that AR-12 represents a promising class of small mols. with broad-spectrum antifungal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQ4IgzvpGPLVg90H21EOLACvtfcHk0lgiQds3O33fTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjsLc%253D&md5=2e9f2e77742e265c5cfbb4f43bb63b2f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1128%2FAAC.01061-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01061-16%26sid%3Dliteratum%253Aachs%26aulast%3DKoselny%26aufirst%3DK.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DDiDone%26aufirst%3DL.%26aulast%3DHalterman%26aufirst%3DJ.%2BP.%26aulast%3DFothergill%26aufirst%3DA.%2BW.%26aulast%3DWiederhold%26aufirst%3DN.%2BP.%26aulast%3DPatterson%26aufirst%3DT.%2BF.%26aulast%3DCushion%26aufirst%3DM.%2BT.%26aulast%3DRappelye%26aufirst%3DC.%26aulast%3DWellington%26aufirst%3DM.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520celecoxib%2520derivative%2520AR-12%2520has%2520broad-spectrum%2520antifungal%2520activity%2520in%2520vitro%2520and%2520improves%2520the%2520activity%2520of%2520fluconazole%2520in%2520a%2520murine%2520model%2520of%2520cryptococcosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7115%26epage%3D7127%26doi%3D10.1128%2FAAC.01061-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, Y.</span></span> <span> </span><span class="NLM_article-title">Genistein, a specific inhibitor of tyrosine-specific protein kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">5592</span>– <span class="NLM_lpage">5595</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)45614-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0021-9258%2818%2945614-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=3106339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaL2sXktF2rurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=5592-5595&author=T.+Akiyamaauthor=J.+Ishidaauthor=S.+Nakagawaauthor=H.+Ogawaraauthor=S.+Watanabeauthor=N.+Itohauthor=M.+Shibuyaauthor=Y.+Fukami&title=Genistein%2C+a+specific+inhibitor+of+tyrosine-specific+protein+kinases&doi=10.1016%2FS0021-9258%2818%2945614-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein, a specific inhibitor of tyrosine-specific protein kinases</span></div><div class="casAuthors">Akiyama, Tetsu; Ishida, Junko; Nakagawa, Suguru; Ogawara, Hiroshi; Watanabe, Shunichi; Itoh, Noriki; Shibuya, Masabumi; Fukami, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5592-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Tyrosine-specific protein kinase activity of the EGF receptor, pp60v-src, and pp110gag-fes was inhibited in vitro by an isoflavone, genistein.  The inhibition was competitive with respect to ATP and noncompetitive to a phosphate acceptor, histone H2B.  By contrast, genistein scarcely inhibited the enzyme activities of serine- and threonine-specific protein kinases, such as cAMP-dependent protein kinase, phosphorylase kinase, and the Ca2+/phospholipid-dependent enzyme protein kinase C.  When the effect of genistein on the phosphorylation of the EGF receptor was examd. in cultured A431 cells, EGF-stimulated serine, threonine, and tyrosine phosphorylation was decreased.  Phosphoamino acid anal. of total cell proteins revealed that genistein inhibited EGF-stimulated increase in phosphotyrosine level in A431 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrl4yNfRolrVg90H21EOLACvtfcHk0lgiQds3O33fTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktF2rurk%253D&md5=a5166857ec7cf5aaf80118fcca1f254a</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2945614-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252945614-1%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DNakagawa%26aufirst%3DS.%26aulast%3DOgawara%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DItoh%26aufirst%3DN.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DFukami%26aufirst%3DY.%26atitle%3DGenistein%252C%2520a%2520specific%2520inhibitor%2520of%2520tyrosine-specific%2520protein%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D5592%26epage%3D5595%26doi%3D10.1016%2FS0021-9258%2818%2945614-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damm, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartenbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezzacasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzchalia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helenius, A.</span></span> <span> </span><span class="NLM_article-title">Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1083/jcb.200407113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1083%2Fjcb.200407113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15668298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2005&pages=477-488&author=E.+M.+Dammauthor=L.+Pelkmansauthor=J.+Kartenbeckauthor=A.+Mezzacasaauthor=T.+Kurzchaliaauthor=A.+Helenius&title=Clathrin-+and+caveolin-1-independent+endocytosis%3A+entry+of+simian+virus+40+into+cells+devoid+of+caveolae&doi=10.1083%2Fjcb.200407113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Clathrin- and caveolin-1-independent endocytosis: Entry of simian virus 40 into cells devoid of caveolae</span></div><div class="casAuthors">Damm, Eva-Maria; Pelkmans, Lucas; Kartenbeck, Juergen; Mezzacasa, Anna; Kurzchalia, Teymuras; Helenius, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-488</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Simian Virus 40 (SV40) has been shown to enter host cells by caveolar endocytosis followed by transport via caveosomes to the endoplasmic reticulum (ER).  Using a caveolin-1 (cav-1)-deficient cell line (human hepatoma 7) and embryonic fibroblasts from a cav-1 knockout mouse, we found that in the absence of caveolae, but also in wild-type embryonic fibroblasts, the virus exploits an alternative, cav-1-independent pathway.  Internalization was rapid (t1/2 = 20 min) and cholesterol- and tyrosine kinase- dependent but independent of clathrin, dynamin II, and ARF6.  The viruses were internalized in small, tight-fitting vesicles and transported to membrane-bounded, pH-neutral organelles similar to caveosomes but devoid of cav-1 and -2.  The viruses were next transferred by microtubule-dependent vesicular transport to the ER, a step that was required for infectivity.  Our results revealed the existence of a virus-activated endocytic pathway from the plasma membrane to the ER that involves neither clathrin nor caveolae and that can be activated also in the presence of cav-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGr1Y1-7CiqLVg90H21EOLACvtfcHk0lhW5r7wot53xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktbw%253D&md5=07724bccee68642067ef720e8e66f4ef</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200407113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200407113%26sid%3Dliteratum%253Aachs%26aulast%3DDamm%26aufirst%3DE.%2BM.%26aulast%3DPelkmans%26aufirst%3DL.%26aulast%3DKartenbeck%26aufirst%3DJ.%26aulast%3DMezzacasa%26aufirst%3DA.%26aulast%3DKurzchalia%26aufirst%3DT.%26aulast%3DHelenius%26aufirst%3DA.%26atitle%3DClathrin-%2520and%2520caveolin-1-independent%2520endocytosis%253A%2520entry%2520of%2520simian%2520virus%252040%2520into%2520cells%2520devoid%2520of%2520caveolae%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2005%26volume%3D168%26spage%3D477%26epage%3D488%26doi%3D10.1083%2Fjcb.200407113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stantchev, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, C. C.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2006.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2006.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17030448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2007&pages=178-189&author=T.+S.+Stantchevauthor=I.+Markovicauthor=W.+G.+Telfordauthor=K.+A.+Clouseauthor=C.+C.+Broder&title=The+tyrosine+kinase+inhibitor+genistein+blocks+HIV-1+infection+in+primary+human+macrophages&doi=10.1016%2Fj.virusres.2006.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span></div><div class="casAuthors">Stantchev, Tzanko S.; Markovic, Ingrid; Telford, William G.; Clouse, Kathleen A.; Broder, Christopher C.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Binding of HIV-1 envelope glycoprotein (Env) to its cellular receptors elicits a variety of signaling events, including the activation of select tyrosine kinases.  To evaluate the potential role of such signaling, we examd. the effects of the tyrosine kinase inhibitor, genistein, on HIV-1 entry and infection of human macrophages using a variety of assays.  Without altering cell viability, cell surface expression of CD4 and CCR5 or their abilities to interact with Env, genistein inhibited infection of macrophages by reporter gene-encoding, β-lactamase contg., or wild type virions, as well as Env-mediated cell-fusion.  The observation that genistein blocked virus infection if applied before, during or immediately after the infection period, but not 24 h later; coupled with a more pronounced inhibition of infection in the reporter gene assays as compared to both β-lactamase and p24 particle entry assays, imply that genistein exerts its inhibitory effects on both entry and early post-entry steps.  These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as addnl. opportunities for the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOAvO4kSxB7Vg90H21EOLACvtfcHk0lhW5r7wot53xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D&md5=310c85933553074029e094e7d3a1bdb8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2006.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2006.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DStantchev%26aufirst%3DT.%2BS.%26aulast%3DMarkovic%26aufirst%3DI.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26aulast%3DClouse%26aufirst%3DK.%2BA.%26aulast%3DBroder%26aufirst%3DC.%2BC.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520genistein%2520blocks%2520HIV-1%2520infection%2520in%2520primary%2520human%2520macrophages%26jtitle%3DVirus%2520Res.%26date%3D2007%26volume%3D123%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.virusres.2006.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1007/BF01309554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2FBF01309554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=8397505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1993&pages=451-461&author=Y.+Yuraauthor=H.+Yoshidaauthor=M.+Sato&title=Inhibition+of+herpes+simplex+virus+replication+by+genistein%2C+an+inhibitor+of+protein-tyrosine+kinase&doi=10.1007%2FBF01309554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span></div><div class="casAuthors">Yura, Y.; Yoshida, H.; Sato, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">451-61</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    </div><div class="casAbstract">Genistein, an inhibitor of protein-tyrosine kinase, inhibited the replication of herpes simplex virus type 1 (HSV-1) at genistein concns. of more than 25 μM, whereas the related compds., which do not inhibit protein-tyrosine kinases, did not affect the replication of HSV-1.  In the presence of genistein, the phosphorylation of tyrosine residues in specific viral polypeptides was markedly reduced.  These results indicate that the phosphorylation of tyrosine residues in viral polypeptides may be essential for the replication of HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPTvlkqS9JUbVg90H21EOLACvtfcHk0lhW5r7wot53xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D&md5=ddabba9625d89206daf303e7f4739274</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2FBF01309554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01309554%26sid%3Dliteratum%253Aachs%26aulast%3DYura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520replication%2520by%2520genistein%252C%2520an%2520inhibitor%2520of%2520protein-tyrosine%2520kinase%26jtitle%3DArch.%2520Virol.%26date%3D1993%26volume%3D132%26spage%3D451%26epage%3D461%26doi%3D10.1007%2FBF01309554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowick, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. F.</span></span> <span> </span><span class="NLM_article-title">Genistein treatment of cells inhibits arenavirus infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2007.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17961732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=153-156&author=E.+M.+Velaauthor=G.+C.+Bowickauthor=N.+K.+Herzogauthor=J.+F.+Aronson&title=Genistein+treatment+of+cells+inhibits+arenavirus+infection&doi=10.1016%2Fj.antiviral.2007.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein treatment of cells inhibits arenavirus infection</span></div><div class="casAuthors">Vela, Eric M.; Bowick, Gavin C.; Herzog, Norbert K.; Aronson, Judith F.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arenaviridae is a family of enveloped viruses some of which are capable of causing hemorrhagic fever syndromes in humans.  In this report, we demonstrate that treatment of host cells with the tyrosine kinase inhibitor genistein inhibits infection of cells with the New World arenavirus Pichinde (PICV).  The greatest degree of inhibition was obsd. in pre-treated target cells, but modest inhibition of infection was also seen when drug was added to cultures up to 48 h after infection.  We show that PICV-induced phosphorylation of the activating transcription factor-2 protein (ATF-2) and cAMP response element binding protein (CREB) is inhibited following genistein treatment.  Lastly, genistein treatment also inhibited transduction of cells with pseudotyped retrovirus particles expressing envelope proteins of the Old World arenavirus Lassa virus.  These results demonstrate that kinase activity is required for arenavirus infection and that therapeutics designed to inhibit kinase activity should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxt-7U7F05bVg90H21EOLACvtfcHk0lgz24aZ2HBuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D&md5=ed23a98d1235f071148053c4620f5594</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DE.%2BM.%26aulast%3DBowick%26aufirst%3DG.%2BC.%26aulast%3DHerzog%26aufirst%3DN.%2BK.%26aulast%3DAronson%26aufirst%3DJ.%2BF.%26atitle%3DGenistein%2520treatment%2520of%2520cells%2520inhibits%2520arenavirus%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.antiviral.2007.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeCher, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diep, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, J. K.</span></span> <span> </span><span class="NLM_article-title">Genistein has antiviral activity against herpes B virus and acts synergistically with antiviral treatments to reduce effective dose</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">499</span>, <span class="refDoi"> DOI: 10.3390/v11060499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv11060499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=499&author=J.+C.+LeCherauthor=N.+Diepauthor=P.+W.+Krugauthor=J.+K.+Hilliard&title=Genistein+has+antiviral+activity+against+herpes+B+virus+and+acts+synergistically+with+antiviral+treatments+to+reduce+effective+dose&doi=10.3390%2Fv11060499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3390%2Fv11060499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11060499%26sid%3Dliteratum%253Aachs%26aulast%3DLeCher%26aufirst%3DJ.%2BC.%26aulast%3DDiep%26aufirst%3DN.%26aulast%3DKrug%26aufirst%3DP.%2BW.%26aulast%3DHilliard%26aufirst%3DJ.%2BK.%26atitle%3DGenistein%2520has%2520antiviral%2520activity%2520against%2520herpes%2520B%2520virus%2520and%2520acts%2520synergistically%2520with%2520antiviral%2520treatments%2520to%2520reduce%2520effective%2520dose%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D499%26doi%3D10.3390%2Fv11060499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20072125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&author=J.+Zhangauthor=F.+J.+Adrianauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.+R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr-Abl+by+combining+allosteric+with+ATP-binding-site+inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Adrian, Francisco J.; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Li, Allen G.; Iacob, Roxana E.; Sim, Taebo; Powers, John; Dierks, Christine; Sun, Fangxian; Guo, Gui-Rong; Ding, Qiang; Okram, Barun; Choi, Yongmun; Wojciechowski, Amy; Deng, Xianming; Liu, Guoxun; Fendrich, Gabriele; Strauss, Andre; Vajpai, Navratna; Grzesiek, Stephan; Tuntland, Tove; Liu, Yi; Bursulaya, Badry; Azam, Mohammad; Manley, Paul W.; Engen, John R.; Daley, George Q.; Warmuth, Markus; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">501-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an effort to find new pharmacol. modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor.  Here, using soln. NMR, X-ray crystallog., mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site.  GNF-5, an analog of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochem. and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model.  These results show that therapeutically relevant inhibition of Bcr-Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtkKFuTQx1LVg90H21EOLACvtfcHk0lgz24aZ2HBuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D&md5=46c122384fa004d27865c77f4a9165b7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.%2BR.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr-Abl%2520by%2520combining%2520allosteric%2520with%2520ATP-binding-site%2520inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potisopon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann Chu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">GNF-2 inhibits dengue virus by targeting abl kinases and the viral e protein</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27105280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=443-452&author=M.+J.+Clarkauthor=C.+Miduturuauthor=A.+G.+Schmidtauthor=X.+Zhuauthor=J.+D.+Pittsauthor=J.+Wangauthor=S.+Potisoponauthor=J.+Zhangauthor=A.+Wojciechowskiauthor=J.+J.+Hann+Chuauthor=N.+S.+Grayauthor=P.+L.+Yang&title=GNF-2+inhibits+dengue+virus+by+targeting+abl+kinases+and+the+viral+e+protein&doi=10.1016%2Fj.chembiol.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein</span></div><div class="casAuthors">Clark, Margaret J.; Miduturu, Chandra; Schmidt, Aaron G.; Zhu, Xuling; Pitts, Jared D.; Wang, Jinhua; Potisopon, Supanee; Zhang, Jianming; Wojciechowski, Amy; Chu, Justin Jang Hann; Gray, Nathanael S.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-452</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus.  Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yielded drugs that have advanced to the clinic.  Here, we show that the allosteric Abl kinase inhibitor GNF-2 interferes with dengue virus replication via activity mediated by cellular Abl kinases but addnl. blocks viral entry via an Abl-independent mechanism.  To characterize this newly discovered antiviral activity, we developed disubstituted pyrimidines that block dengue virus entry with structure-activity relationships distinct from those driving kinase inhibition.  We demonstrate that biotin- and fluorophore-conjugated derivs. of GNF-2 interact with the dengue glycoprotein, E, in the pre-fusion conformation that exists on the virion surface, and that this interaction inhibits viral entry.  This study establishes GNF-2 as an antiviral compd. with polypharmacol. activity and provides "lead" compds. for further optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-_Dumc6V_A7Vg90H21EOLACvtfcHk0lgz24aZ2HBuAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D&md5=d5bd0ad159a7df03b992ecb96a7d231f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPitts%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPotisopon%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DHann%2BChu%26aufirst%3DJ.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DGNF-2%2520inhibits%2520dengue%2520virus%2520by%2520targeting%2520abl%2520kinases%2520and%2520the%2520viral%2520e%2520protein%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D443%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinbren, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, S.</span></span> <span> </span><span class="NLM_article-title">Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against zika virus</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.celrep.2016.12.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28099856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Chs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=804-815&author=K.+Rauschauthor=B.+A.+Hackettauthor=N.+L.+Weinbrenauthor=S.+M.+Reederauthor=Y.+Sadovskyauthor=C.+A.+Hunterauthor=D.+C.+Schultzauthor=C.+B.+Coyneauthor=S.+Cherry&title=Screening+bioactives+reveals+nanchangmycin+as+a+broad+spectrum+antiviral+active+against+zika+virus&doi=10.1016%2Fj.celrep.2016.12.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus</span></div><div class="casAuthors">Rausch, Keiko; Hackett, Brent A.; Weinbren, Nathan L.; Reeder, Sophia M.; Sadovsky, Yoel; Hunter, Christopher A.; Schultz, David C.; Coyne, Carolyn B.; Cherry, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">804-815</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Zika virus is an emerging arthropod-borne flavivirus for which there are no vaccines or specific therapeutics.  We screened a library of 2,000 bioactive compds. for their ability to block Zika virus infection in three distinct cell types with two different strains of Zika virus.  Using a microscopy-based assay, we validated 38 drugs that inhibited Zika virus infection, including FDA-approved nucleoside analogs.  Cells expressing high levels of the attachment factor AXL can be protected from infection with receptor tyrosine kinase inhibitors, while placental-derived cells that lack AXL expression are insensitive to this inhibition.  Importantly, we identified nanchangmycin as a potent inhibitor of Zika virus entry across all cell types tested, including physiol. relevant primary cells.  Nanchangmycin also was active against other medically relevant viruses, including West Nile, dengue, and chikungunya viruses that use a similar route of entry.  This study provides a resource of small mols. to study Zika virus pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuIFZmaMBHLVg90H21EOLACvtfcHk0ljii1GaJIjEXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Chs7g%253D&md5=6f64daa643f3c4dd4f98a090e1e3e056</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DRausch%26aufirst%3DK.%26aulast%3DHackett%26aufirst%3DB.%2BA.%26aulast%3DWeinbren%26aufirst%3DN.%2BL.%26aulast%3DReeder%26aufirst%3DS.%2BM.%26aulast%3DSadovsky%26aufirst%3DY.%26aulast%3DHunter%26aufirst%3DC.%2BA.%26aulast%3DSchultz%26aufirst%3DD.%2BC.%26aulast%3DCoyne%26aufirst%3DC.%2BB.%26aulast%3DCherry%26aufirst%3DS.%26atitle%3DScreening%2520bioactives%2520reveals%2520nanchangmycin%2520as%2520a%2520broad%2520spectrum%2520antiviral%2520active%2520against%2520zika%2520virus%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D804%26epage%3D815%26doi%3D10.1016%2Fj.celrep.2016.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaTerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieder, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. M.</span></span> <span> </span><span class="NLM_article-title">The small molecule hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1083/jcb.200208092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1083%2Fjcb.200208092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12707311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtl2isb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2003&pages=281-294&author=S.+Haufauthor=R.+W.+Coleauthor=S.+LaTerraauthor=C.+Zimmerauthor=G.+Schnappauthor=R.+Walterauthor=A.+Heckelauthor=J.+van+Meelauthor=C.+L.+Riederauthor=J.+M.+Peters&title=The+small+molecule+hesperadin+reveals+a+role+for+Aurora+B+in+correcting+kinetochore-microtubule+attachment+and+in+maintaining+the+spindle+assembly+checkpoint&doi=10.1083%2Fjcb.200208092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint</span></div><div class="casAuthors">Hauf, Silke; Cole, Richard W.; LaTerra, Sabrina; Zimmer, Christine; Schnapp, Gisela; Walter, Rainer; Heckel, Armin; van Meel, Jacques; Rieder, Conly L.; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-294</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The proper segregation of sister chromatids in mitosis depends on bipolar attachment of all chromosomes to the mitotic spindle.  We have identified the small mol. Hesperadin as an inhibitor of chromosome alignment and segregation.  Our data imply that Hesperadin causes this phenotype by inhibiting the function of the mitotic kinase Aurora B.  Mammalian cells treated with Hesperadin enter anaphase in the presence of numerous monooriented chromosomes, many of which may have both sister kinetochores attached to one spindle pole (syntelic attachment).  Hesperadin also causes cells arrested by taxol or monastrol to enter anaphase within <1 h, whereas cells in nocodazole stay arrested for 3-5 h.  Together, our data suggest that Aurora B is required to generate unattached kinetochores on monooriented chromosomes, which in turn could promote bipolar attachment as well as maintain checkpoint signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-9s78ZbJorVg90H21EOLACvtfcHk0ljii1GaJIjEXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtl2isb8%253D&md5=a79851e7d015a1530340a38e86b1943f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200208092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200208092%26sid%3Dliteratum%253Aachs%26aulast%3DHauf%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DR.%2BW.%26aulast%3DLaTerra%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DSchnapp%26aufirst%3DG.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3Dvan%2BMeel%26aufirst%3DJ.%26aulast%3DRieder%26aufirst%3DC.%2BL.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520small%2520molecule%2520hesperadin%2520reveals%2520a%2520role%2520for%2520Aurora%2520B%2520in%2520correcting%2520kinetochore-microtubule%2520attachment%2520and%2520in%2520maintaining%2520the%2520spindle%2520assembly%2520checkpoint%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D161%26spage%3D281%26epage%3D294%26doi%3D10.1083%2Fjcb.200208092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musharrafieh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1929</span>, <span class="refDoi"> DOI: 10.3390/ijms18091929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fijms18091929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOlsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1929&author=Y.+Huauthor=J.+Zhangauthor=R.+Musharrafiehauthor=R.+Hauauthor=C.+Maauthor=J.+Wang&title=Chemical+genomics+approach+leads+to+the+identification+of+hesperadin%2C+an+aurora+B+kinase+inhibitor%2C+as+a+broad-spectrum+influenza+antiviral&doi=10.3390%2Fijms18091929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral</span></div><div class="casAuthors">Hu, Yanmei; Zhang, Jiantao; Musharrafieh, Rami; Hau, Raymond; Ma, Chunlong; Wang, Jun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1929/1-1929/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Influenza viruses are respiratory pathogens that are responsible for annual influenza epidemics and sporadic influenza pandemics.  Oseltamivir (Tamiflu) is currently the only FDAapproved oral drug that is available for the prevention and treatment of influenza virus infection.  However, its narrow therapeutic window, coupled with the increasing incidence of drug resistance, calls for the next generation of influenza antivirals.  In this study, we discovered hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral through forward chem. genomics screening.  Hesperadin inhibits multiple human clin. isolates of influenza A and B viruses with single to submicromolar efficacy, including oseltamivir-resistant strains.  Mechanistic studies revealed that hesperadin inhibits the early stage of viral replication by delaying the nuclear entry of viral ribonucleoprotein complex, thereby inhibiting viral RNA transcription and translation as well as viral protein synthesis.  Moreover, a combination of hesperadin with oseltamivir shows synergistic antiviral activity, therefore hesperadin can be used either alone to treat infections by oseltamivir-resistant influenza viruses or used in combination with oseltamivir to delay resistance evolution among oseltamivir-sensitive strains.  In summary, the discovery of hesperadin as a broad-spectrum influenza antiviral offers an alternative to combat future influenza epidemics and pandemics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxC84q0qSarVg90H21EOLACvtfcHk0ljii1GaJIjEXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOlsrzJ&md5=06792c248e23e339c22a3f0be405ef2f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.3390%2Fijms18091929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18091929%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMusharrafieh%26aufirst%3DR.%26aulast%3DHau%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DChemical%2520genomics%2520approach%2520leads%2520to%2520the%2520identification%2520of%2520hesperadin%252C%2520an%2520aurora%2520B%2520kinase%2520inhibitor%252C%2520as%2520a%2520broad-spectrum%2520influenza%2520antiviral%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1929%26doi%3D10.3390%2Fijms18091929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2827</span>, <span class="refDoi"> DOI: 10.1128/JVI.01969-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01969-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21209112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=2818-2827&author=N.+Kumarauthor=Y.+Liangauthor=T.+G.+Parslowauthor=Y.+Liang&title=Receptor+tyrosine+kinase+inhibitors+block+multiple+steps+of+influenza+a+virus+replication&doi=10.1128%2FJVI.01969-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span></div><div class="casAuthors">Kumar, Naveen; Liang, Yuhong; Parslow, Tristram G.; Liang, Yuying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2818-2827</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host signaling pathways play important roles in the replication of influenza virus, but their functional effects remain to be characterized at the mol. level.  Here we identify two receptor tyrosine kinase inhibitors (RTKIs) of the tyrphostin class that exhibit robust antiviral activity against influenza A virus replication in cultured cells.  One of these (AG879) is a selective inhibitor of the nerve growth factor receptor and human epidermal growth factor receptor 2 (TrkA/HER2) signaling; the other, tyrphostin A9 (A9), inhibits the platelet-derived growth factor receptor (PDGFR) pathway.  We find that each inhibits at least three postentry steps of the influenza virus life cycle: AG879 and A9 both strongly inhibit the synthesis of all three influenza virus RNA species, block Crm1-dependent nuclear export, and also prevent the release of viral particles through a pathway that is modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).  Tests of short hairpin RNA (shRNA) knockdown and addnl. small-mol. inhibitors confirmed that interventions targeting TrkA can suppress influenza virus replication.  Our study suggests that host cell receptor tyrosine kinase signaling is required for maximal influenza virus RNA synthesis, viral ribonucleoprotein (vRNP) nuclear export, and virus release and that specific RTKIs hold promise as novel anti-influenza virus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDOKlH_iMWLVg90H21EOLACvtfcHk0lhpDG-lcruZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM&md5=5b0e29955db6cd71e6d371db771138d0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1128%2FJVI.01969-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01969-10%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DParslow%26aufirst%3DT.%2BG.%26aulast%3DLiang%26aufirst%3DY.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520multiple%2520steps%2520of%2520influenza%2520a%2520virus%2520replication%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D2818%26epage%3D2827%26doi%3D10.1128%2FJVI.01969-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">104651</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31751591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2020&pages=104651&author=W.+Dongauthor=W.+Xieauthor=Y.+Liuauthor=B.+Suiauthor=H.+Zhangauthor=L.+Liuauthor=Y.+Tanauthor=X.+Tongauthor=Z.+F.+Fuauthor=P.+Yinauthor=L.+Fangauthor=G.+Peng&title=Receptor+tyrosine+kinase+inhibitors+block+proliferation+of+TGEV+mainly+through+p38+mitogen-activated+protein+kinase+pathways&doi=10.1016%2Fj.antiviral.2019.104651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Dong, Wanyu; Xie, Wenting; Liu, Yunbo; Sui, Baokun; Zhang, Hao; Liu, Liran; Tan, Yubei; Tong, Xiaohan; Fu, Zhen F.; Yin, Ping; Fang, Liurong; Peng, Guiqing</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104651</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available.  Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays.  Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV) and feline infectious peritonitis virus (FIPV).  We further performed a comparative phosphoproteomic anal. to investigate the mechanism of action of A9 against TGEV infection in vitro.  We specifically identified p38 and JNK1, which are the downstream mols. of receptor tyrosine kinases (RTKs) required for efficient TGEV replication, as A9 targets through plaque assays, qRT-PCR and Western blotting assays. p38 and JNK1 inhibitors and RNA interference further showed that the inhibitory activity of A9 against TGEV infection was mainly mediated by the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  All these findings indicated that the RTKI A9 directly inhibits TGEV replication and that its inhibitory activity against TGEV replication mainly occurs by targeting p38, which provides vital clues to the design of novel drugs against CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnYnZ9MxD37Vg90H21EOLACvtfcHk0lhpDG-lcruZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO&md5=d0b78e75caf0d2932528e2ff6706d961</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104651%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DG.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520proliferation%2520of%2520TGEV%2520mainly%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D173%26spage%3D104651%26doi%3D10.1016%2Fj.antiviral.2019.104651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakisaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutiwitoonchai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbrc.2014.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24858693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslaitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=49-54&author=Y.+Sasakiauthor=M.+Kakisakaauthor=N.+Chutiwitoonchaiauthor=S.+Tajimaauthor=H.+Hikonoauthor=T.+Saitoauthor=Y.+Aida&title=Identification+of+a+novel+multiple+kinase+inhibitor+with+potent+antiviral+activity+against+influenza+virus+by+reducing+viral+polymerase+activity&doi=10.1016%2Fj.bbrc.2014.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity</span></div><div class="casAuthors">Sasaki, Yutaka; Kakisaka, Michinori; Chutiwitoonchai, Nopporn; Tajima, Shigeru; Hikono, Hirokazu; Saito, Takehiko; Aida, Yoko</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuraminidase inhibitors are the only currently available influenza treatment, although resistant viruses to these drugs have already been reported.  Thus, new antiviral drugs with novel mechanisms of action are urgently required.  In this study, we identified a novel antiviral compd., WV970, through cell-based screening of a 50,000 compd. library and subsequent lead optimization.  This compd. exhibited potent antiviral activity with nanomolar IC50 values against both influenza A and B viruses but not non-influenza RNA viruses.  Time-of-addn. and indirect immunofluorescence assays indicated that WV970 acted at an early stage of the influenza life cycle, but likely after nuclear entry of viral ribonucleoprotein (vRNP).  Further analyses of viral RNA expression and viral polymerase activity indicated that WV970 inhibited vRNP-mediated viral genome replication and transcription.  Finally, structure-based virtual screening and comprehensive human kinome screening were used to demonstrate that WV970 acts as a multiple kinase inhibitor, many of which are assocd. with influenza virus replication.  Collectively, these results strongly suggest that WV970 is a promising anti-influenza drug candidate and that several kinases assocd. with viral replication are promising drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVOZMxWNbCLVg90H21EOLACvtfcHk0lhpDG-lcruZFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslaitbk%253D&md5=e8cc148a987f9dcddc59e2bbf43b045e</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DKakisaka%26aufirst%3DM.%26aulast%3DChutiwitoonchai%26aufirst%3DN.%26aulast%3DTajima%26aufirst%3DS.%26aulast%3DHikono%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DAida%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520a%2520novel%2520multiple%2520kinase%2520inhibitor%2520with%2520potent%2520antiviral%2520activity%2520against%2520influenza%2520virus%2520by%2520reducing%2520viral%2520polymerase%2520activity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.bbrc.2014.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunte, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koetsier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostjukova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilimnik, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyatkin, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelnikova, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, H. K.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">3497</span>– <span class="NLM_lpage">3502</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2005.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.febslet.2005.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15961079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2005&pages=3497-3502&author=D.+P.+Kunteauthor=R.+K.+Waliauthor=J.+L.+Koetsierauthor=J.+Hartauthor=M.+N.+Kostjukovaauthor=A.+Y.+Kilimnikauthor=I.+G.+Pyatkinauthor=S.+R.+Strelnikovaauthor=H.+K.+Roy&title=Down-regulation+of+the+tumor+suppressor+gene+C-terminal+Src+kinase%3A+an+early+event+during+premalignant+colonic+epithelial+hyperproliferation&doi=10.1016%2Fj.febslet.2005.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of the tumor suppressor gene C-terminal Src kinase: An early event during premalignant colonic epithelial hyperproliferation</span></div><div class="casAuthors">Kunte, Dhananjay P.; Wali, Ramesh K.; Koetsier, Jennifer L.; Hart, John; Kostjukova, Maria N.; Kilimnik, Anna Y.; Pyatkin, Ilia G.; Strelnikova, Svetlana R.; Roy, Hemant K.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3497-3502</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyperproliferation of the premalignant epithelium is crit. for colonic carcinogenesis; however the mechanisms remain largely unexplored.  We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity.  Furthermore, pharmacol. or genetic (RNA interference) inhibition of Csk resulted in increased proliferation in colon cancer cell lines through the mitogen-activated protein kinase dependent pathway.  Thus, we demonstrate, for the first time, that Csk suppression is an important early event in colorectal cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFkbrFw5VpbVg90H21EOLACvtfcHk0lh_L_iJvnyZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWrtrs%253D&md5=8bba93e1ce1da827af8fb57622242dad</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DKunte%26aufirst%3DD.%2BP.%26aulast%3DWali%26aufirst%3DR.%2BK.%26aulast%3DKoetsier%26aufirst%3DJ.%2BL.%26aulast%3DHart%26aufirst%3DJ.%26aulast%3DKostjukova%26aufirst%3DM.%2BN.%26aulast%3DKilimnik%26aufirst%3DA.%2BY.%26aulast%3DPyatkin%26aufirst%3DI.%2BG.%26aulast%3DStrelnikova%26aufirst%3DS.%2BR.%26aulast%3DRoy%26aufirst%3DH.%2BK.%26atitle%3DDown-regulation%2520of%2520the%2520tumor%2520suppressor%2520gene%2520C-terminal%2520Src%2520kinase%253A%2520an%2520early%2520event%2520during%2520premalignant%2520colonic%2520epithelial%2520hyperproliferation%26jtitle%3DFEBS%2520Lett.%26date%3D2005%26volume%3D579%26spage%3D3497%26epage%3D3502%26doi%3D10.1016%2Fj.febslet.2005.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30490</span>, <span class="refDoi"> DOI: 10.1038/srep30490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fsrep30490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27457684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=30490&author=R.+Kumarauthor=T.+Agrawalauthor=N.+A.+Khanauthor=Y.+Nakayamaauthor=G.+R.+Medigeshi&title=Identification+and+characterization+of+the+role+of+c-terminal+Src+kinase+in+dengue+virus+replication&doi=10.1038%2Fsrep30490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span></div><div class="casAuthors">Kumar, Rinki; Agrawal, Tanvi; Khan, Naseem Ahmed; Nakayama, Yuji; Medigeshi, Guruprasad R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30490</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We screened a siRNA library targeting human tyrosine kinases in Huh-7 cells and identified c-terminal Src kinase (Csk) as one of the kinases involved in dengue virus replication.  Knock-down of Csk expression by siRNAs or inhibition of Csk by an inhibitor reduced dengue virus RNA levels but did not affect viral entry.  Csk partially colocalized with viral replication compartments.  Dengue infection was drastically reduced in cells lacking the three ubiquitous src family kinases, Src, Fyn and Yes.  Csk knock-down in these cells failed to block dengue virus replication suggesting that the effect of Csk is via regulation of Src family kinases.  Csk was found to be hyper-phosphorylated during dengue infection and inhibition of protein kinase A led to a block in Csk phosphorylation and dengue virus replication.  Overexpression studies suggest an important role for the kinase and SH3 domains in this process.  Our results identified a novel role for Csk as a host tyrosine kinase involved in dengue virus replication and provide further insights into the role of host factors in dengue replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVlEp-nx5hb7Vg90H21EOLACvtfcHk0lh_L_iJvnyZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ&md5=91a61fd24e54e8517cd5bd07bf27bb74</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fsrep30490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep30490%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520role%2520of%2520c-terminal%2520Src%2520kinase%2520in%2520dengue%2520virus%2520replication%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D30490%26doi%3D10.1038%2Fsrep30490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strang, B. L.</span></span> <span> </span><span class="NLM_article-title">RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28501424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2017&pages=21-26&author=B.+L.+Strang&title=RO0504985+is+an+inhibitor+of+CMGC+kinase+proteins+and+has+anti-human+cytomegalovirus+activity&doi=10.1016%2Fj.antiviral.2017.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity</span></div><div class="casAuthors">Strang, Blair L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Public-private partnerships allow many previously unavailable compds. to be screened for antiviral activity.  Here a screening method was used to identify an oxindole compd., RO0504985, from a Roche kinase inhibitor library that inhibited human cytomegalovirus (HCMV) protein prodn.  RO0504985 was previously described as an inhibitor of cyclin-dependent kinase 2 (CDK2).  However, using kinase selectivity assays it was found that RO0504985 was an inhibitor of several CMGC group kinase proteins, including CDK2.  Using virus yield redn. assays it was obsd. that RO0504985 inhibited replication of different HCMV strains at low micromolar concns.  Western blotting was used to investigate how RO0504985 inhibited HCMV replication.  Treatment of HCMV infected cells with RO0504985 inhibited prodn. of the immediate early viral IE2 proteins and the late viral protein pp28.  Thus, RO0504985 inhibited HCMV replication by preventing prodn. of specific HCMV proteins necessary for virus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo519ED6ixmbVg90H21EOLACvtfcHk0lh_L_iJvnyZwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCqurs%253D&md5=9758b92eed458cc7743842d50b228f3f</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DStrang%26aufirst%3DB.%2BL.%26atitle%3DRO0504985%2520is%2520an%2520inhibitor%2520of%2520CMGC%2520kinase%2520proteins%2520and%2520has%2520anti-human%2520cytomegalovirus%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D144%26spage%3D21%26epage%3D26%26doi%3D10.1016%2Fj.antiviral.2017.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavalli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volety, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">BX795 demonstrates potent antiviral benefits against herpes simplex virus-1 infection of human cell lines</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">104814</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2020.104814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32380150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOjurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=104814&author=A.+Iqbalauthor=R.+Suryawanshiauthor=T.+Yadavalliauthor=I.+Voletyauthor=D.+Shukla&title=BX795+demonstrates+potent+antiviral+benefits+against+herpes+simplex+virus-1+infection+of+human+cell+lines&doi=10.1016%2Fj.antiviral.2020.104814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines</span></div><div class="casAuthors">Iqbal, Aqsa; Suryawanshi, Rahul; Yadavalli, Tejabhiram; Volety, Ipsita; Shukla, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104814</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herpes simplex virus-1 (HSV-1) infection is known to cause skin blisters, keratitis as well as deadly cases of encephalitis in some situations.  Only a few therapeutic modalities are available for this globally prevalent infection.  Very recently, a small mol. BX795 was identified as an inhibitor of HSV-1 protein synthesis in an ocular model of infection.  In order to demonstrate its broader antiviral benefits, this study was aimed at evaluating the antiviral efficacy, mode-of-action, and toxicity of BX795 against HSV-1 infection of three human cell lines: HeLa, HEK, and HCE.  Several different assays, including cell survival anal., imaging, plaque anal., Immunoblotting, and qRT-PCR, were performed.  In all cases, BX795 demonstrated low toxicity at therapeutic concn. and showed strong antiviral benefits.  Quite interestingly, cell line-dependent differences in the mechanism of antiviral action and cytokine response to infection were seen upon BX795 treatment.  Taken together, our results suggest that BX795 may exert its antiviral benefits via cell-line specific mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJfeQoc1x97Vg90H21EOLACvtfcHk0lgPMj9sYXFrsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOjurrK&md5=27947db17288ceec13c1cf5f92eb0284</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104814%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DSuryawanshi%26aufirst%3DR.%26aulast%3DYadavalli%26aufirst%3DT.%26aulast%3DVolety%26aufirst%3DI.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DBX795%2520demonstrates%2520potent%2520antiviral%2520benefits%2520against%2520herpes%2520simplex%2520virus-1%2520infection%2520of%2520human%2520cell%2520lines%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D180%26spage%3D104814%26doi%3D10.1016%2Fj.antiviral.2020.104814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavalli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qatanani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volety, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activity, tolerability, and mechanism of action of BX795 as an antiviral against herpes simplex virus 2 genital infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">e00245-20</span>, <span class="refDoi"> DOI: 10.1128/AAC.00245-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.00245-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32601167" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=e00245-20&author=J.+Hopkinsauthor=T.+Yadavalliauthor=R.+Suryawanshiauthor=F.+Qatananiauthor=I.+Voletyauthor=R.+Kogantiauthor=A.+Iqbalauthor=D.+Shukla&title=In+vitro+and+in+vivo+activity%2C+tolerability%2C+and+mechanism+of+action+of+BX795+as+an+antiviral+against+herpes+simplex+virus+2+genital+infection&doi=10.1128%2FAAC.00245-20"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FAAC.00245-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00245-20%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DYadavalli%26aufirst%3DT.%26aulast%3DSuryawanshi%26aufirst%3DR.%26aulast%3DQatanani%26aufirst%3DF.%26aulast%3DVolety%26aufirst%3DI.%26aulast%3DKoganti%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%252C%2520tolerability%252C%2520and%2520mechanism%2520of%2520action%2520of%2520BX795%2520as%2520an%2520antiviral%2520against%2520herpes%2520simplex%2520virus%25202%2520genital%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26spage%3De00245-20%26doi%3D10.1128%2FAAC.00245-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virol.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31176924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFensLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2019&pages=54-63&author=S.+Bergmannauthor=H.+Elbahesh&title=Targeting+the+proviral+host+kinase%2C+FAK%2C+limits+influenza+a+virus+pathogenesis+and+NFkB-regulated+pro-inflammatory+responses&doi=10.1016%2Fj.virol.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the proviral host kinase, FAK, limits influenza A virus pathogenesis and NFκB-regulated pro-inflammatory responses</span></div><div class="casAuthors">Bergmann, Silke; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infections result in ∼500,000 global deaths annually.  Host kinases link multiple signaling pathways at various stages of infection and are attractive therapeutic target.  Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, regulates several cellular processes including NFκB and antiviral responses.  We investigated how FAK kinase activity regulates IAV pathogenesis.  Using a severe infection model, we infected IAV-susceptible DBA/2 J mice with a LD of H1N1 IAV.  We obsd. reduced viral load and pro-inflammatory cytokines, delayed mortality, and increased survival in FAK inhibitor (Y15) treated mice.  In vitro IAV-induced NFκB-promoter activity was reduced by Y15 or a dominant neg. kinase-dead FAK mutant (FAK-KD) independently of the viral immune modulator, NS1.  Finally, we obsd. reduced IAV-induced nuclear localization of NFkB in FAK-KD expressing cells.  Our data suggest a novel mechanism where IAV hijacks FAK to promote viral replication and limit its ability to contribute to innate immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJjWpvNXcU7bVg90H21EOLACvtfcHk0lgPMj9sYXFrsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFensLrE&md5=1cdb026d95d30541bc34a640b204e437</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DS.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520proviral%2520host%2520kinase%252C%2520FAK%252C%2520limits%2520influenza%2520a%2520virus%2520pathogenesis%2520and%2520NFkB-regulated%2520pro-inflammatory%2520responses%26jtitle%3DVirology%26date%3D2019%26volume%3D534%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.virol.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockaert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7882</span>, <span class="refDoi"> DOI: 10.1128/JVI.76.15.7874-7882.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.76.15.7874-7882.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12097601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=7874-7882&author=L.+M.+Schangauthor=A.+Bantlyauthor=M.+Knockaertauthor=F.+Shaheenauthor=L.+Meijerauthor=M.+H.+Malimauthor=N.+S.+Grayauthor=P.+A.+Schaffer&title=Pharmacological+cyclin-dependent+kinase+inhibitors+inhibit+replication+of+wild-type+and+drug-resistant+strains+of+herpes+simplex+virus+and+human+immunodeficiency+virus+type+1+by+targeting+cellular%2C+not+viral%2C+proteins&doi=10.1128%2FJVI.76.15.7874-7882.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins</span></div><div class="casAuthors">Schang, Luis M.; Bantly, Andrew; Knockaert, Marie; Shaheen, Farida; Meijer, Laurent; Malim, Michael H.; Gray, Nathanael S.; Schaffer, Priscilla A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7874-7882</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Pharmacol. cyclin-dependent kinase (cdk) inhibitors (PCIs) block replication of several viruses, including herpes simplex virus type 1 (HSV-1) and human immunodeficiency virus type 1 (HIV-1).  Yet, these antiviral effects could result from inhibition of either cellular cdks or viral enzymes.  For example, in addn. to cellular cdks, PCIs could inhibit any of the herpesvirus-encoded kinases, DNA replication proteins, or proteins involved in nucleotide metab.  To address this issue, we asked whether purine-derived PCIs (P-PCIs) inhibit HSV and HIV-1 replication by targeting cellular or viral proteins.  P-PCIs inhibited replication of HSV-1 and -2 and HIV-1, which require cellular cdks to replicate, but not vaccinia virus or lymphocytic choriomeningitis virus, which are not known to require cdks to replicate.  P-PCIs also inhibited strains of HSV-1 and HIV-1 that are resistant to conventional antiviral drugs, which target viral proteins.  In addn., the anti-HSV effects of P-PCIs and a conventional antiherpesvirus drug, acyclovir, were additive, demonstrating that the two drugs act by distinct mechanisms.  Lastly, the spectrum of proteins that bound to P-PCIs in exts. of mock- and HSV-infected cells was the same.  Based on these observations, we conclude that P-PCIs inhibit virus replication by targeting cellular, not viral, proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlu88p4K_ArVg90H21EOLACvtfcHk0lg2XojeCLzR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlKqsbY%253D&md5=ef81912af20cae0a92208b81dc7405de</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.15.7874-7882.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.15.7874-7882.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26aulast%3DBantly%26aufirst%3DA.%26aulast%3DKnockaert%26aufirst%3DM.%26aulast%3DShaheen%26aufirst%3DF.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DMalim%26aufirst%3DM.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchaffer%26aufirst%3DP.%2BA.%26atitle%3DPharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520drug-resistant%2520strains%2520of%2520herpes%2520simplex%2520virus%2520and%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520targeting%2520cellular%252C%2520not%2520viral%252C%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D7874%26epage%3D7882%26doi%3D10.1128%2FJVI.76.15.7874-7882.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2eZ4cW68IOQuxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisenfelder, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. L.</span></span> <span> </span><span class="NLM_article-title">Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1697</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbapap.2003.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15023363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=225-231&author=J.+F.+Moffatauthor=M.+A.+McMichaelauthor=S.+A.+Leisenfelderauthor=S.+L.+Taylor&title=Viral+and+cellular+kinases+are+potential+antiviral+targets+and+have+a+central+role+in+varicella+zoster+virus+pathogenesis&doi=10.1016%2Fj.bbapap.2003.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis</span></div><div class="casAuthors">Moffat, Jennifer F.; McMichael, Michelle A.; Leisenfelder, Stacey A.; Taylor, Shannon L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Herpesviruses utilize viral and cellular kinases for replication, and these mediate essential functions that are important for viral pathogenesis.  Elucidating the roles of kinases in herpesvirus infections may highlight virus-host interactions that are possible targets for kinase inhibitors with antiviral activity.  Varicella zoster virus (VZV) encodes two kinases that phosphorylate viral proteins involved in regulation, assembly, and virulence.  VZV infection also induces the activity of host cell cyclin-dependent kinases (cdk4 and cdk2) in nondividing cells, causing a dysregulation of the cell cycle.  Roscovitine and purvalanol, kinase inhibitors that target cdks, prevent VZV replication at concns. with few cytotoxic effects.  Cdk inhibitors therefore have potential as antivirals that may extend to a broad range of viruses and have the added advantage that resistance does not arise easily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWqyA-ur1aprVg90H21EOLACvtfcHk0lg2XojeCLzR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLs%253D&md5=5fe3d869f6987f54e5bd81700503074e</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BF.%26aulast%3DMcMichael%26aufirst%3DM.%2BA.%26aulast%3DLeisenfelder%26aufirst%3DS.%2BA.%26aulast%3DTaylor%26aufirst%3DS.%2BL.%26atitle%3DViral%2520and%2520cellular%2520kinases%2520are%2520potential%2520antiviral%2520targets%2520and%2520have%2520a%2520central%2520role%2520in%2520varicella%2520zoster%2520virus%2520pathogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D225%26epage%3D231%26doi%3D10.1016%2Fj.bbapap.2003.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutterer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milbradt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeittrager, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zischinsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, M.</span></span> <span> </span><span class="NLM_article-title">A novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1128/AAC.04534-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.04534-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25624324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=2062-2071&author=C.+Huttererauthor=J.+Eickhoffauthor=J.+Milbradtauthor=K.+Kornauthor=I.+Zeittragerauthor=H.+Bahsiauthor=S.+Wagnerauthor=G.+Zischinskyauthor=A.+Wolfauthor=C.+Degenhartauthor=A.+Ungerauthor=M.+Baumannauthor=B.+Kleblauthor=M.+Marschall&title=A+novel+CDK7+inhibitor+of+the+pyrazolotriazine+class+exerts+broad-spectrum+antiviral+activity+at+nanomolar+concentrations&doi=10.1128%2FAAC.04534-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span></div><div class="casAuthors">Hutterer Corina; Milbradt Jens; Korn Klaus; Zeittrager Isabel; Bahsi Hanife; Wagner Sabrina; Marschall Manfred; Eickhoff Jan; Zischinsky Gunther; Wolf Alexander; Degenhart Carsten; Unger Anke; Baumann Matthias; Klebl Bert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2062-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases represent central and multifunctional regulators of a balanced virus-host interaction.  Cyclin-dependent protein kinase 7 (CDK7) plays crucial regulatory roles in cell cycle and transcription, both connected with the replication of many viruses.  Previously, we developed a CDK7 inhibitor, LDC4297, that inhibits CDK7 in vitro in the nano-picomolar range.  Novel data from a kinome-wide evaluation (>330 kinases profiled in vitro) demonstrate a kinase selectivity.  Importantly, we provide first evidence for the antiviral potential of the CDK7 inhibitor LDC4297, i.e., in exerting a block of the replication of human cytomegalovirus (HCMV) in primary human fibroblasts at nanomolar concentrations (50% effective concentration, 24.5 ± 1.3 nM).  As a unique feature compared to approved antiherpesviral drugs, inhibition occurred already at the immediate-early level of HCMV gene expression.  The mode of antiviral action was considered multifaceted since CDK7-regulated cellular factors that are supportive of HCMV replication were substantially affected by the inhibitors.  An effect of LDC4297 was identified in the interference with HCMV-driven inactivation of retinoblastoma protein (Rb), a regulatory step generally considered a hallmark of herpesviral replication.  In line with this finding, a broad inhibitory activity of the drug could be demonstrated against a selection of human and animal herpesviruses and adenoviruses, whereas other viruses only showed intermediate drug sensitivity.  Summarized, the CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFOdfST00W0BcfW6udTcc2eazW6z3dn2yw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D&md5=57c36db4aa7415d9023016868151ba3f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1128%2FAAC.04534-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04534-14%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMilbradt%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DK.%26aulast%3DZeittrager%26aufirst%3DI.%26aulast%3DBahsi%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DZischinsky%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DDegenhart%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMarschall%26aufirst%3DM.%26atitle%3DA%2520novel%2520CDK7%2520inhibitor%2520of%2520the%2520pyrazolotriazine%2520class%2520exerts%2520broad-spectrum%2520antiviral%2520activity%2520at%2520nanomolar%2520concentrations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D2062%26epage%3D2071%26doi%3D10.1128%2FAAC.04534-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4871</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1128/JVI.75.10.4871-4877.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.75.10.4871-4877.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11312358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD3M3it1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2001&pages=4871-4877&author=O.+Planzauthor=S.+Pleschkaauthor=S.+Ludwig&title=MEK-specific+inhibitor+U0126+blocks+spread+of+Borna+disease+virus+in+cultured+cells&doi=10.1128%2FJVI.75.10.4871-4877.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells</span></div><div class="casAuthors">Planz O; Pleschka S; Ludwig S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4871-7</span>
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Borna disease virus (BDV) is a highly neurotropic virus that causes Borna disease, a virus-induced immune-mediated encephalomyelitis, in a variety of warm-blooded animals.  Recent studies reported that BDV can be detected in patients with psychiatric disorders.  BDV is noncytopathic, replicates in the nucleus of infected cells, and spreads intraaxonally in vivo.  Upon infection of susceptible cultured cells, virus can be detected in foci.  Little is known about the cellular components required for BDV replication.  Here, we show that the cellular Raf/MEK/ERK signaling cascade is activated upon infection with BDV.  In the presence of the MEK-specific inhibitor U0126, cells get infected with BDV; however, there is a block in virus spread to neighboring cells.  The effect of the inhibitor on virus spread was still observed when the compound was added 2 h postinfection but not if treatment was initiated as late as 4 h after infection.  Our results provide new insights into the BDV-host cell interaction and show that virus infection can be controlled with drugs interfering with a cellular signaling pathway.  Since concentrations of the MEK inhibitor required to block BDV focus formation are not toxic for the host cells, our finding may be important with respect to antiviral drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbDfTsMtEqSHy-c-E1v-fmfW6udTcc2eazW6z3dn2yw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3it1ensg%253D%253D&md5=71a4536e48840bf1a13302f744b36696</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1128%2FJVI.75.10.4871-4877.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.75.10.4871-4877.2001%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DMEK-specific%2520inhibitor%2520U0126%2520blocks%2520spread%2520of%2520Borna%2520disease%2520virus%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2001%26volume%3D75%26spage%3D4871%26epage%3D4877%26doi%3D10.1128%2FJVI.75.10.4871-4877.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span> <span> </span><span class="NLM_article-title">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(04)00108-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0014-5793%2804%2900108-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15013748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2004&pages=37-43&author=S.+Ludwigauthor=T.+Wolffauthor=C.+Ehrhardtauthor=W.+J.+Wurzerauthor=J.+Reinhardtauthor=O.+Planzauthor=S.+Pleschka&title=MEK+inhibition+impairs+influenza+B+virus+propagation+without+emergence+of+resistant+variants&doi=10.1016%2FS0014-5793%2804%2900108-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span></div><div class="casAuthors">Ludwig, Stephan; Wolff, Thorsten; Ehrhardt, Christina; Wurzer, Walter Jurgen; Reinhardt, Jens; Planz, Oliver; Pleschka, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Influenza A and B viruses are still a major worldwide threat.  We demonstrate that influenza B virus infection induces signaling via the Raf/MEK/ERK cascade, a process required for efficient virus prodn.  Expression of dominant-neg. Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers.  MEK inhibition appears to interfere with a distinct viral nuclear export process.  Most importantly, no resistant virus variants emerged in the presence of U0126 demonstrating that influenza viruses cannot easily adapt to the missing cellular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH2SOtrmGyrbVg90H21EOLACvtfcHk0lg9x5P1IXzG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D&md5=30a70331cb39e18f1db14f415063ba91</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2804%2900108-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252804%252900108-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DWurzer%26aufirst%3DW.%2BJ.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26atitle%3DMEK%2520inhibition%2520impairs%2520influenza%2520B%2520virus%2520propagation%2520without%2520emergence%2520of%2520resistant%2520variants%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D561%26spage%3D37%26epage%3D43%26doi%3D10.1016%2FS0014-5793%2804%2900108-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Droebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21854809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2011&pages=195-203&author=K.+Droebnerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+activity+of+the+MEK-inhibitor+U0126+against+pandemic+H1N1v+and+highly+pathogenic+avian+influenza+virus+in+vitro+and+in+vivo&doi=10.1016%2Fj.antiviral.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span></div><div class="casAuthors">Droebner, Karoline; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of the 2009 H1N1 pandemic swine influenza A virus is a good example of how this viral infection can impact health systems around the world in a very short time.  The continuous zoonotic circulation and reassortment potential of influenza A viruses (IAV) in nature represents an enormous public health threat to humans.  Beside vaccination antivirals are needed to efficiently control spreading of the disease.  In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v = variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.  U0126 showed antiviral activity in cell culture against all tested IAV strains including oseltamivir resistant variants.  Furthermore, we were able to demonstrate that treatment of mice with U0126 via the aerosol route led to (i) inhibition of MEK activation in the lung (ii) redn. of progeny IAV titers compared to untreated controls (iii) protection of IAV infected mice against a 100× lethal viral challenge.  Moreover, no adverse effects of U0126 were found in cell culture or in the mouse.  Thus, we conclude that U0126, by inhibiting the cellular target MEK, has an antiviral potential not only in vitro in cell culture, but also in vivo in the mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6szZdpUCJ_bVg90H21EOLACvtfcHk0lg9x5P1IXzG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI&md5=2818e18e307a3cda653b302d30857638</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDroebner%26aufirst%3DK.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520activity%2520of%2520the%2520MEK-inhibitor%2520U0126%2520against%2520pandemic%2520H1N1v%2520and%2520highly%2520pathogenic%2520avian%2520influenza%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D92%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.antiviral.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castilla, V.</span></span> <span> </span><span class="NLM_article-title">Raf/MEK/ERK pathway activation is required for Junín virus replication</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1099/vir.0.061242-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2Fvir.0.061242-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24421112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyms7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=799-805&author=M.+E.+Rodr%C3%ADguezauthor=J.+E.+Brunettiauthor=M.+B.+Wachsmanauthor=L.+A.+Scolaroauthor=V.+Castilla&title=Raf%2FMEK%2FERK+pathway+activation+is+required+for+Jun%C3%ADn+virus+replication&doi=10.1099%2Fvir.0.061242-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Raf/MEK/ERK pathway activation is required for Junin virus replication</span></div><div class="casAuthors">Rodriguez, Maria Eugenia; Brunetti, Jesus Emanuel; Wachsman, Monica Beatriz; Scolaro, Luis Alberto; Castilla, Viviana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">799-805</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">In the present work we investigated the importance of the Raf/MEK/ERK signalling pathway in the multiplication of the arenavirus Junin (JUNV) in monkey and human cell cultures.  We established that JUNV induces a biphasic activation of ERK and we proved that a specific inhibitor of the ERK pathway, U0126, impairs viral replication.  Furthermore, U0126 exerted inhibitory action against the arenaviruses Tacaribe and Pichinde.  Moreover, treatment with known ERK activators such as phorbol 12-myristate 13-acetate and serum increased viral yields whereas ERK silencing by small interfering RNAs caused the inhibition of viral multiplication.  Therefore, activation of the Raf/MEK/ERK signalling pathway is required to ensure efficient JUNV replication and may constitute a host target for the development of novel effective therapeutic strategies to deal with arenavirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4QqvKAiMrerVg90H21EOLACvtfcHk0liV30uiHUbS5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyms7rM&md5=8be371d05a5c15534f003376291e76fc</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.061242-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.061242-0%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%2BE.%26aulast%3DBrunetti%26aufirst%3DJ.%2BE.%26aulast%3DWachsman%26aufirst%3DM.%2BB.%26aulast%3DScolaro%26aufirst%3DL.%2BA.%26aulast%3DCastilla%26aufirst%3DV.%26atitle%3DRaf%252FMEK%252FERK%2520pathway%2520activation%2520is%2520required%2520for%2520Jun%25C3%25ADn%2520virus%2520replication%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2014%26volume%3D95%26spage%3D799%26epage%3D805%26doi%3D10.1099%2Fvir.0.061242-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albarnaz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveira, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palhares, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteluber, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacca, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroon, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonjardim, C. A.</span></span> <span> </span><span class="NLM_article-title">MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2014.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25241249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFylu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=82-92&author=J.+D.+Albarnazauthor=L.+C.+De+Oliveiraauthor=A.+A.+Torresauthor=R.+M.+Palharesauthor=M.+C.+Casteluberauthor=C.+M.+Rodriguesauthor=P.+L.+Cardozoauthor=A.+M.+De+Souzaauthor=C.+C.+Paccaauthor=P.+C.+Ferreiraauthor=E.+G.+Kroonauthor=M.+L.+Nogueiraauthor=C.+A.+Bonjardim&title=MEK%2FERK+activation+plays+a+decisive+role+in+yellow+fever+virus+replication%3A+implication+as+an+antiviral+therapeutic+target&doi=10.1016%2Fj.antiviral.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">MEK/ERK activation plays a decisive role in yellow fever virus replication: Implication as an antiviral therapeutic target</span></div><div class="casAuthors">Albarnaz, Jonas D.; De Oliveira, Leonardo C.; Torres, Alice A.; Palhares, Rafael M.; Casteluber, Marisa C.; Rodrigues, Claudiney M.; Cardozo, Pablo L.; De Souza, Aryadina M. R.; Pacca, Carolina C.; Ferreira, Paulo C. P.; Kroon, Erna G.; Nogueira, Mauricio L.; Bonjardim, Claudio A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-92</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exploiting the inhibition of host signaling pathways aiming for discovery of potential antiflaviviral compds. is clearly a beneficial strategy for the control of life-threatening diseases caused by flaviviruses.  Here we describe the antiviral activity of the MEK1/2 inhibitor U0126 against Yellow fever virus 17D vaccine strain (YFV-17D).  Infection of VERO cells with YFV-17D stimulates ERK1/2 phosphorylation early during infection.  Pharmacol. inhibition of MEK1/2 through U0126 treatment of VERO cells blockades not only the YFV-stimulated ERK1/2 phosphorylation, but also inhibits YFV replication by ∼99%.  U0126 was also effective against dengue virus (DENV-2 and -3) and Saint-Louis encephalitis virus (SLEV).  Levels of NS4AB, as detected by immunofluorescence, are diminished upon treatment with the inhibitor, as well as the characteristic endoplasmic reticulum membrane invagination stimulated during the infection.  Though not protective, treatment of YFV-infected, adult BALB/c mice with U0126 resulted in significant redn. of virus titers in brains.  Collectively, our data suggest the potential targeting of the MEK1/2 kinase as a therapeutic tool against diseases caused by flaviviruses such as yellow fever, adverse events assocd. with yellow fever vaccination and dengue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhqYp9UV497Vg90H21EOLACvtfcHk0liV30uiHUbS5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFylu77N&md5=ea466efa138d26eb89b490b23d2b8792</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlbarnaz%26aufirst%3DJ.%2BD.%26aulast%3DDe%2BOliveira%26aufirst%3DL.%2BC.%26aulast%3DTorres%26aufirst%3DA.%2BA.%26aulast%3DPalhares%26aufirst%3DR.%2BM.%26aulast%3DCasteluber%26aufirst%3DM.%2BC.%26aulast%3DRodrigues%26aufirst%3DC.%2BM.%26aulast%3DCardozo%26aufirst%3DP.%2BL.%26aulast%3DDe%2BSouza%26aufirst%3DA.%2BM.%26aulast%3DPacca%26aufirst%3DC.%2BC.%26aulast%3DFerreira%26aufirst%3DP.%2BC.%26aulast%3DKroon%26aufirst%3DE.%2BG.%26aulast%3DNogueira%26aufirst%3DM.%2BL.%26aulast%3DBonjardim%26aufirst%3DC.%2BA.%26atitle%3DMEK%252FERK%2520activation%2520plays%2520a%2520decisive%2520role%2520in%2520yellow%2520fever%2520virus%2520replication%253A%2520implication%2520as%2520an%2520antiviral%2520therapeutic%2520target%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D111%26spage%3D82%26epage%3D92%26doi%3D10.1016%2Fj.antiviral.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saminathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivasharanappa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeshappa, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunathareddy, G. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model</span>. <i>Microb. Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.micpath.2017.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.micpath.2017.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28939254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=38-49&author=V.+Manjunathaauthor=K.+P.+Singhauthor=M.+Saminathanauthor=R.+Singhauthor=N.+Shivasharanappaauthor=C.+S.+Umeshappaauthor=K.+Dhamaauthor=G.+B.+Manjunathareddy&title=Inhibition+of+MEK-ERK1%2F2-MAP+kinase+signalling+pathway+reduces+rabies+virus+induced+pathologies+in+mouse+model&doi=10.1016%2Fj.micpath.2017.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model</span></div><div class="casAuthors">Manjunatha, Venkataravanappa; Singh, Karam Pal; Saminathan, Mani; Singh, Rajendra; Shivasharanappa, Nayakwadi; Umeshappa, Channakeshava Sokke; Dhama, Kuldeep; Manjunathareddy, Gundallahalli Bayyappa</div><div class="citationInfo"><span class="NLM_cas:title">Microbial Pathogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-49</span>CODEN:
                <span class="NLM_cas:coden">MIPAEV</span>;
        ISSN:<span class="NLM_cas:issn">0882-4010</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The extracellular signal-regulated kinase (ERK) pathway has been shown to regulate pathogenesis of many viral infections, but its role during rabies virus (RV) infection in vivo is not clear.  In the present study, we investigated the potential role of MEK-ERK1/2 signalling pathway in the pathogenesis of rabies in mouse model and its regulatory effects on pro-inflammatory cytokines and other mediators of immunity, and kinetics of immune cells.  Mice were infected with 25 LD50 of challenge virus std. (CVS) strain of RV by intracerebral (i.c.) inoculation and were treated i.c. with U0126 (specific inhibitor of MEK1/2) at 10 μM/mouse at 0, 2, 4 and 6 days post-infection.  Treatment with U0126 resulted in delayed disease development and clin. signs, increased survival time with lesser mortality than untreated mice.  The better survival of inhibitor-treated and RV infected mice was pos. correlated with reduced viral load and reduced viral spread in the brain as quantified by real-time PCR, direct fluorescent antibody test and immunohistochem.  CVS-infected/mock-treated mice developed severe histopathol. lesions with increased Fluoro-Jade B pos. degenerating neurons in brain, which were assocd. with higher levels of serum nitric oxide, iNOS, TNF-α, and CXCL10 mRNA.  Also CVS-infected/U0126-treated mice revealed significant decrease in caspase 3 but increase in Bcl-2 mRNA levels and less TUNEL pos. apoptotic cells.  CVS-infected/U0126-treated group also showed significant increase in CD4+, CD8+ T lymphocytes and NK cells in blood and spleen possibly due to less apoptosis of these cells.  In conclusion, these data suggest that MEK-ERK1/2 signalling pathway play crit. role in the pathogenesis of RV infection in vivo and opens up new avenues of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3QpjKTwJj7Vg90H21EOLACvtfcHk0liV30uiHUbS5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntbjM&md5=0be81b1f8e34f6be6d74cc7c5d366599</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.micpath.2017.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.micpath.2017.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DK.%2BP.%26aulast%3DSaminathan%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DShivasharanappa%26aufirst%3DN.%26aulast%3DUmeshappa%26aufirst%3DC.%2BS.%26aulast%3DDhama%26aufirst%3DK.%26aulast%3DManjunathareddy%26aufirst%3DG.%2BB.%26atitle%3DInhibition%2520of%2520MEK-ERK1%252F2-MAP%2520kinase%2520signalling%2520pathway%2520reduces%2520rabies%2520virus%2520induced%2520pathologies%2520in%2520mouse%2520model%26jtitle%3DMicrob.%2520Pathog.%26date%3D2017%26volume%3D112%26spage%3D38%26epage%3D49%26doi%3D10.1016%2Fj.micpath.2017.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span>. <i>J. Funct. Foods</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.jff.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jff.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=219-228&author=S.+Kangauthor=M.+J.+Songauthor=H.+Min&title=Antiviral+activity+of+ginsenoside+Rg3+isomers+against+gammaherpesvirus+through+inhibition+of+p38-+and+JNK-associated+pathways&doi=10.1016%2Fj.jff.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span></div><div class="casAuthors">Kang, Soowon; Song, Moon Jung; Min, Hyeyoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Functional Foods</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JFFOAX</span>;
        ISSN:<span class="NLM_cas:issn">1756-4646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural compds. from functional foods targeting viruses are considered to have important role for regulating virus-related diseases.  Ginsenoside Rg3 is one of the active pharmaceutical components found in Panax ginseng C.  A. Meyer which is widely used as a functional food in East Asia.  In our present study, we have characterized the antiviral activities of the ginsenoside Rg3 isomers, 20(R)- and 20(S)-ginsenoside Rg3, against murine gammaherpesvirus 68 (MHV-68), a mouse model of human gammaherpesvirus which can cause various malignancies including cancer.  We found that both 20(R)- and 20(S)-ginsenoside Rg3 inhibited lytic replication and viral proliferation of MHV-68, although 20(S)-ginsenoside Rg3 was more effective than 20(R)-ginsenoside Rg3.  Furthermore, ginsenoside Rg3 isomers efficiently repressed chem.-induced lytic replication of human gammaherpesviruses in EBV-pos. BC-3 and KSHV-pos. Raji cell lines.  Finally, our data showed that ginsenoside Rg3 isomers suppressed the p38 and/or the JNK-assocd. MAPK signaling pathways, thereby inhibiting viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_oaZOyBy4jLVg90H21EOLACvtfcHk0lg4__HB00skCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM&md5=10a34e872f4bf9805190044b8f8eec71</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.jff.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jff.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DMin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520ginsenoside%2520Rg3%2520isomers%2520against%2520gammaherpesvirus%2520through%2520inhibition%2520of%2520p38-%2520and%2520JNK-associated%2520pathways%26jtitle%3DJ.%2520Funct.%2520Foods%26date%3D2018%26volume%3D40%26spage%3D219%26epage%3D228%26doi%3D10.1016%2Fj.jff.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Root, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNair, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Entry of influenza viruses into cells is inhibited by a highly specific protein kinase c inhibitor</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2705</span>, <span class="refDoi"> DOI: 10.1099/0022-1317-81-11-2697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2F0022-1317-81-11-2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11038382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFWgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2000&pages=2697-2705&author=C.+N.+Rootauthor=E.+G.+Willsauthor=L.+L.+McNairauthor=G.+R.+Whittaker&title=Entry+of+influenza+viruses+into+cells+is+inhibited+by+a+highly+specific+protein+kinase+c+inhibitor&doi=10.1099%2F0022-1317-81-11-2697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor</span></div><div class="casAuthors">Root, Christiana N.; Wills, Elizabeth G.; McNair, LaShonn L.; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2697-2705</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Following binding to cell surface sialic acid, entry of influenza viruses into cells is mediated by endocytosis.  Productive entry of influenza virus requires the low-pH environment of the late endosome for fusion and release of the virus into the cytoplasm and transport of the virus genome into the nucleus.  We investigated novel mechanisms to inhibit influenza virus infection using highly specific inhibitors of protein kinase C.  We found that one inhibitor, bisindolylmaleimide I, prevented replication of influenza A virus in a dose-dependent manner when added at the time of infection, but had little specific effect when added 2 h after infection had commenced.  Virus yields dropped by more than 3 log units in the presence of micromolar levels of bisindolylmaleimide I.  Influenza B virus replication was also inhibited by bisindolylmaleimide at micromolar concns.  We carried out expts. to det. the point in infection that was blocked by bisindolylmaleimide I, and detd. that entry of viral ribonucleoproteins (vRNPs) into the nucleus was prevented.  Upon drug washout vRNP nuclear entry resumed, showing that bisindolylmaleimide I is reversible.  Bisindolylmaleimide I did not affect virus binding and was apparently not acting as a weak base, because its effects were independent of the pH of the external growth medium.  These expts. show that bisindolylmaleimide I blocks replication of different types of influenza virus in a dose-dependent and reversible manner, and that virus entry into the cell is inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGqK6tlaJrrVg90H21EOLACvtfcHk0lg4__HB00skCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFWgurY%253D&md5=3f37c83d7f771e05f8e926429de56603</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-81-11-2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-81-11-2697%26sid%3Dliteratum%253Aachs%26aulast%3DRoot%26aufirst%3DC.%2BN.%26aulast%3DWills%26aufirst%3DE.%2BG.%26aulast%3DMcNair%26aufirst%3DL.%2BL.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DEntry%2520of%2520influenza%2520viruses%2520into%2520cells%2520is%2520inhibited%2520by%2520a%2520highly%2520specific%2520protein%2520kinase%2520c%2520inhibitor%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2000%26volume%3D81%26spage%3D2697%26epage%3D2705%26doi%3D10.1099%2F0022-1317-81-11-2697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis c agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3410</span>, <span class="refDoi"> DOI: 10.1021/jm501759m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501759m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3393-3410&author=S.+Kovackovaauthor=L.+Changauthor=E.+Bekermanauthor=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Chaikuadauthor=C.+Herovenauthor=M.+%C5%A0%C3%A1laauthor=S.+De+Jongheauthor=S.+Knappauthor=S.+Einavauthor=P.+Herdewijn&title=Selective+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+as+anti-hepatitis+c+agents&doi=10.1021%2Fjm501759m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents</span></div><div class="casAuthors">Kovackova, Sona; Chang, Lei; Bekerman, Elena; Neveu, Gregory; Barouch-Bentov, Rina; Chaikuad, Apirat; Heroven, Christina; Sala, Michal; De Jonghe, Steven; Knapp, Stefan; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3393-3410</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin G assocd. kinase (GAK) emerged as a promising drug target for the treatment of viral infections.  However, no potent and selective GAK inhibitors have been reported in the literature to date.  This paper describes the discovery of isothiazolo[5,4-b]pyridines as selective GAK inhibitors, with the most potent congeners displaying low nanomolar binding affinity for GAK.  Cocrystn. expts. revealed that these compds. behaved as classic type I ATP-competitive kinase inhibitors.  In addn., the authors have demonstrated that these compds. exhibit a potent activity against hepatitis C virus (HCV) by inhibiting two temporally distinct steps in the HCV life cycle (i.e., viral entry and assembly).  Hence, these GAK inhibitors represent chem. probes to study GAK function in different disease areas where GAK has been implicated (including viral infection, cancer, and Parkinson's disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjwEtUi0av7Vg90H21EOLACvtfcHk0lg4__HB00skCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D&md5=ed7f93eb3d49f6c7265dd2c0da880b43</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm501759m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501759m%26sid%3Dliteratum%253Aachs%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DSelective%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520as%2520anti-hepatitis%2520c%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3393%26epage%3D3410%26doi%3D10.1021%2Fjm501759m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure-activity relationship studies and antiviral activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1666</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1039/C5MD00229J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1039%2FC5MD00229J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26925208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12mu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1666-1672&author=J.+Liauthor=S.+Kovackovaauthor=S.+Puauthor=J.+Rozenskiauthor=S.+De+Jongheauthor=S.+Einavauthor=P.+Herdewijn&title=Isothiazolo%5B4%2C3-b%5Dpyridines+as+inhibitors+of+cyclin+G+associated+kinase%3A+synthesis%2C+structure-activity+relationship+studies+and+antiviral+activity&doi=10.1039%2FC5MD00229J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure-activity relationship studies and antiviral activity</span></div><div class="casAuthors">Li, Jiahong; Kovackova, Sona; Pu, Szuyuan; Rozenski, Jef; De Jonghe, Steven; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1666-1672</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Isothiazolo[4,3-b]pyridines were known to be endowed with potent affinity for cyclin G assocd. kinase (GAK).  Structure-activity relationship studied by broadening the structural variety at position 3 of the isothiazolo[4,3-b]pyridine scaffold.  The most potent GAK ligands (displaying Kd values of less than 100 nM) within this series carry an alkoxy group at position 3 of the central scaffold.  Unfortunately, these ligands display only modest antiviral activity against the hepatitis C virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXoI1_7VbSrVg90H21EOLACvtfcHk0lgJSdwze29eAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12mu7vM&md5=d9232d534cf6597819798e33b9b8cc0c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1039%2FC5MD00229J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00229J%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DIsothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%253A%2520synthesis%252C%2520structure-activity%2520relationship%2520studies%2520and%2520antiviral%2520activity%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1666%26epage%3D1672%26doi%3D10.1039%2FC5MD00229J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of isothiazolo[4,3- b]pyridine-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6178</span>– <span class="NLM_lpage">6192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6178-6192&author=S.+Y.+Puauthor=R.+Woutersauthor=S.+Schorauthor=J.+Rozenskiauthor=R.+Barouch-Bentovauthor=L.+I.+Prugarauthor=C.+M.+O%E2%80%99Brienauthor=J.+M.+Brannanauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+De+Jongheauthor=S.+Einav&title=Optimization+of+isothiazolo%5B4%2C3-+b%5Dpyridine-based+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+with+broad-spectrum+antiviral+activity&doi=10.1021%2Facs.jmedchem.8b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Isothiazolo[4,3-b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">Pu, Szu-Yuan; Wouters, Randy; Schor, Stanford; Rozenski, Jef; Barouch-Bentov, Rina; Prugar, Laura I.; O'Brien, Cecilia M.; Brannan, Jennifer M.; Dye, John M.; Herdewijn, Piet; De Jonghe, Steven; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6178-6192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue and other emerging viral infections.  We reported that cyclin G-assocd. kinase (GAK), a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle.  We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity.  Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity.  These compds. demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses.  Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compds.  These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDe8aVxkBtKLVg90H21EOLACvtfcHk0lgJSdwze29eAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP&md5=fe33e256835ea01c5e1932c3ccea7eac</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00613%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BM.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520isothiazolo%255B4%252C3-%2520b%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6178%26epage%3D6192%26doi%3D10.1021%2Facs.jmedchem.8b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115188</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bmc.2019.115188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31757682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115188&author=B.+Martinez-Gualdaauthor=S.+Y.+Puauthor=M.+Froeyenauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Structure-activity+relationship+study+of+the+pyridine+moiety+of+isothiazolo%5B4%2C3-b%5Dpyridines+as+antiviral+agents+targeting+cyclin+G-associated+kinase&doi=10.1016%2Fj.bmc.2019.115188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Pu, Szu-Yuan; Froeyen, Mathy; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115188</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 3,6-disubstituted isothiazolo[4,3-b]pyridines as potent and selective cyclin G-assocd. kinase (GAK) inhibitors with promising antiviral activity was reported.  In this manuscript, the structure-activity relationship study was expanded to synthesis of isothiazolo[4,3-b]pyridines with modifications of the pyridine moiety.  This effort led to the discovery of an isothiazolo[4,3-b]pyridine deriv. with a 3,4-dimethoxyphenyl residue at position 5 that displayed low nanomolar GAK binding affinity and antiviral activity against dengue virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqu1a3iqS1i7Vg90H21EOLACvtfcHk0lgJSdwze29eAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM&md5=cf709736ad37cfcda6e2310a243c55d4</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115188%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520the%2520pyridine%2520moiety%2520of%2520isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520antiviral%2520agents%2520targeting%2520cyclin%2520G-associated%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115188%26doi%3D10.1016%2Fj.bmc.2019.115188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3, 5-disubstituted-pyrrolo [2, 3-b] pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.-Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.-J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C+5-disubstituted-pyrrolo+%5B2%2C+3-b%5D+pyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0lhFpJavKDM7FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.-Y.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.-J.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C%25205-disubstituted-pyrrolo%2520%255B2%252C%25203-b%255D%2520pyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, B. Y.</span></span> <span> </span><span class="NLM_article-title">Aurora kinase A promotes hepatitis B virus replication and expression</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">104572</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31376425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=104572&author=G.+U.+Jeongauthor=B.+Y.+Ahn&title=Aurora+kinase+A+promotes+hepatitis+B+virus+replication+and+expression&doi=10.1016%2Fj.antiviral.2019.104572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora kinase A promotes hepatitis B virus replication and expression</span></div><div class="casAuthors">Jeong, Gi Uk; Ahn, Byung-Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104572</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cellular protein kinases play crit. roles in various steps of the hepatitis B virus life cycle.  We found that viral replication in infected or transfected hepatoma cell was markedly inhibited by treatment with A-443654, a specific inhibitor of Akt.  The antiviral mechanism of the drug mainly depended on the downregulation of Aurora A, a protein kinase that plays an essential role in mitosis but has not been implicated in the viral life cycle.  Our data indicated that Aurora kinase A enhances viral replication and expression independently of its kinase activity required for mitotic function.  Our findings suggest that mitotic kinases, considered to be an attractive target of antitumor agents, also provide a novel target for the development of antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHCW4eApXK7Vg90H21EOLACvtfcHk0lhFpJavKDM7FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsL3N&md5=150d43535f9213a117af884cd600c1dd</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104572%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DG.%2BU.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26atitle%3DAurora%2520kinase%2520A%2520promotes%2520hepatitis%2520B%2520virus%2520replication%2520and%2520expression%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D170%26spage%3D104572%26doi%3D10.1016%2Fj.antiviral.2019.104572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lama, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagaudrière-Gesbert, C.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies virus cycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31071352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVers7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=51-60&author=Z.+Lamaauthor=Y.+Gaudinauthor=D.+Blondelauthor=C.+Lagaudri%C3%A8re-Gesbert&title=Kinase+inhibitors+tyrphostin+9+and+rottlerin+block+early+steps+of+rabies+virus+cycle&doi=10.1016%2Fj.antiviral.2019.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies virus cycle</span></div><div class="casAuthors">Lama, Zoe; Gaudin, Yves; Blondel, Danielle; Lagaudriere-Gesbert, Cecile</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rabies virus (RABV) is a neurotropic virus that causes fatal encephalitis in humans and animals and still kills up to 59,000 people worldwide every year.  To date, only preventive or post-exposure vaccination protects against the disease but therapeutics are missing.  After screening a library of 80 kinases inhibitors, we identified two compds. as potent inhibitors of RABV infection: tyrphostin 9 and rottlerin.  Mechanism of action studies show that both inhibitors interfere with an early step of viral cycle and can prevent viral replication.  In presence of tyrphostin 9, the viral entry through endocytosis is disturbed leading to improper delivery of viral particles in cytoplasm, whereas rottlerin is inhibiting the transcription, most likely by decreasing intracellular ATP concn., and therefore the replication of the viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDmpE09EIyCrVg90H21EOLACvtfcHk0lhFpJavKDM7FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVers7nE&md5=b477b4d4dc4ab9a1e7fe34d3beff3f99</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLama%26aufirst%3DZ.%26aulast%3DGaudin%26aufirst%3DY.%26aulast%3DBlondel%26aufirst%3DD.%26aulast%3DLagaudri%25C3%25A8re-Gesbert%26aufirst%3DC.%26atitle%3DKinase%2520inhibitors%2520tyrphostin%25209%2520and%2520rottlerin%2520block%2520early%2520steps%2520of%2520rabies%2520virus%2520cycle%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D51%26epage%3D60%26doi%3D10.1016%2Fj.antiviral.2019.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simanjuntak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. S.</span></span> <span> </span><span class="NLM_article-title">Benzenesulfonamide derivatives as calcium/calmodulin-dependent protein kinase inhibitors and antiviral agents against dengue and zika virus infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1313-1327&author=W.+C.+Chenauthor=Y.+Simanjuntakauthor=L.+W.+Chuauthor=Y.+H.+Pingauthor=Y.+L.+Leeauthor=Y.+L.+Linauthor=W.+S.+Li&title=Benzenesulfonamide+derivatives+as+calcium%2Fcalmodulin-dependent+protein+kinase+inhibitors+and+antiviral+agents+against+dengue+and+zika+virus+infections&doi=10.1021%2Facs.jmedchem.9b01779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections</span></div><div class="casAuthors">Chen, Wei-Chia; Simanjuntak, Yogy; Chu, Li-Wei; Ping, Yueh-Hsin; Lee, Yi-Ling; Lin, Yi-Ling; Li, Wen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1313-1327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging and resurging mosquito-borne flaviviruses are an important public health challenge.  The increased prevalence of dengue virus (DENV) infection has had a significant socioeconomic impact on epidemic countries.  The recent outbreak of Zika virus (ZIKV) has created an international public health emergency because ZIKV infection has been linked to congenital defects and Guillain-Barr´e syndrome.  To develop potentially prophylactic antiviral drugs for combating these acute infectious diseases, we have targeted the host calcium/calmodulin-dependent kinase II (CaMKII) for inhibition.  By using CaMKII structure-guided inhibitor design, we generated four families of benzenesulfonamide (BSA) derivs. for SAR anal.  Among these substances, N-(4-cycloheptyl-4-oxobutyl)-4-methoxy-N-phenylbenzenesulfonamide (9) showed superior properties as a lead CaMKII inhibitor and antiviral agent.  BSA 9 inhibited CaMKII activity with an IC50 value of 0.79 μM and displayed EC50 values of 1.52 μM and 1.91 μM against DENV and ZIKV infections of human neuronal BE(2)C cells, resp.  Notably, 9 significantly reduced the viremia level and increased animal survival time in mouse-challenge models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPIVcnOOQM9LVg90H21EOLACvtfcHk0lh5JN0RNQNJzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D&md5=4222b9a25616a59243c22bfd57b223e7</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01779%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DSimanjuntak%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DL.%2BW.%26aulast%3DPing%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DLi%26aufirst%3DW.%2BS.%26atitle%3DBenzenesulfonamide%2520derivatives%2520as%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520antiviral%2520agents%2520against%2520dengue%2520and%2520zika%2520virus%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1313%26epage%3D1327%26doi%3D10.1021%2Facs.jmedchem.9b01779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span> <span> </span><span class="NLM_article-title">PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3375</span>– <span class="NLM_lpage">3384</span>, <span class="refDoi"> DOI: 10.1093/jac/dky327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdky327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30219827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlChsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=3375-3384&author=L.+Delangauthor=C.+Harakauthor=M.+Benkheilauthor=H.+Khanauthor=P.+Leyssenauthor=M.+Andrewsauthor=V.+Lohmannauthor=J.+Neyts&title=PI4KIII+inhibitor+enviroxime+impedes+the+replication+of+the+hepatitis+C+virus+by+inhibiting+PI3+kinases&doi=10.1093%2Fjac%2Fdky327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases</span></div><div class="casAuthors">Delang, Leen; Harak, Christian; Benkheil, Mohammed; Khan, Hayat; Leyssen, Pieter; Andrews, Martin; Lohmann, Volker; Neyts, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3375-3384</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Many pos.-stranded RNA viruses, including HCV, drastically remodel intracellular membranes to generate specialized environments for RNA replication.  Phosphatidylinositol 4-kinase III (PI4KIII)α plays an essential role in the formation of HCV replication complexes and has therefore been explored as a potential drug target.  Here, the authors characterized the anti-HCV activity of the PI4KIII inhibitors enviroxime and BF738735 and elucidated their mechanism of action.  Methods: Antiviral assays were performed using HCV subgenomic replicons and infectious HCV.  Enviroxime- and BF738735-resistant HCV replicons were generated by long-term culture with increasing compd. concns.  Intracellular localization of phosphatidylinositol 4-phosphate (PI4P) lipids was analyzed by confocal microscopy.  Results: HCV subgenomic replicons resistant to either enviroxime or BF738735 proved cross-resistant and carried mutations in the NS3, NS4B and NS5A genes.  Knockdown of PI4KIIIβ by small interfering RNA (siRNA) did not affect the replication of the HCV subgenomic replicon in this study.  Furthermore, the compds. did not affect PI4P lipid levels at the replication complexes nor the phosphorylation status of NS5A, activities attributed to PI4KIIIα.  Interestingly, the broad-spectrum phosphoinositide 3-kinase (PI3K) inhibitor LY294002 proved to be 10-fold less effective against the resistant replicons.  In addn., enviroxime and BF738735 inhibited several PI3Ks in enzymic assays.  Conclusions: Contrary to assumptions, the data indicate that PI4KIIIα and PI4KIIIβ are not the main targets for the anti-HCV activity of enviroxime and BF738735.  Instead, the authors demonstrated that both mols. impede HCV replication at least partially by an inhibitory effect on PI3Ks.  Moreover, HCV is able to bypass PI3K inhibition by acquiring mutations in its genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWRZRxsOCf-bVg90H21EOLACvtfcHk0lh5JN0RNQNJzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlChsr0%253D&md5=fc2f79b4735519f87682bccdd43acb63</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky327%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DHarak%26aufirst%3DC.%26aulast%3DBenkheil%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DH.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DPI4KIII%2520inhibitor%2520enviroxime%2520impedes%2520the%2520replication%2520of%2520the%2520hepatitis%2520C%2520virus%2520by%2520inhibiting%2520PI3%2520kinases%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D3375%26epage%3D3384%26doi%3D10.1093%2Fjac%2Fdky327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3 kinase-AKT pathway controls cellular entry of ebola virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e1000141</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1000141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1000141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18769720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000141&author=M.+F.+Saeedauthor=A.+A.+Kolokoltsovauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Phosphoinositide-3+kinase-AKT+pathway+controls+cellular+entry+of+ebola+virus&doi=10.1371%2Fjournal.ppat.1000141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span></div><div class="casAuthors">Saeed Mohammad F; Kolokoltsov Andrey A; Freiberg Alexander N; Holbrook Michael R; Davey Robert A</div><div class="citationInfo"><span class="NLM_cas:title">PLoS pathogens</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1000141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide-3 kinase (PI3K) pathway regulates diverse cellular activities related to cell growth, migration, survival, and vesicular trafficking.  It is known that Ebola virus requires endocytosis to establish an infection.  However, the cellular signals that mediate this uptake were unknown for Ebola virus as well as many other viruses.  Here, the involvement of PI3K in Ebola virus entry was studied.  A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of Zaire Ebola virus (ZEBOV).  Inhibitors of PI3K and Akt significantly reduced infection by ZEBOV at an early step during the replication cycle.  Furthermore, phosphorylation of Akt-1 was induced shortly after exposure of cells to radiation-inactivated ZEBOV, indicating that the virus actively induces the PI3K pathway and that replication was not required for this induction.  Subsequent use of pseudotyped Ebola virus and/or Ebola virus-like particles, in a novel virus entry assay, provided evidence that activity of PI3K/Akt is required at the virus entry step.  Class 1A PI3Ks appear to play a predominant role in regulating ZEBOV entry, and Rac1 is a key downstream effector in this regulatory cascade.  Confocal imaging of fluorescently labeled ZEBOV indicated that inhibition of PI3K, Akt, or Rac1 disrupted normal uptake of virus particles into cells and resulted in aberrant accumulation of virus into a cytosolic compartment that was non-permissive for membrane fusion.  We conclude that PI3K-mediated signaling plays an important role in regulating vesicular trafficking of ZEBOV necessary for cell entry.  Disruption of this signaling leads to inappropriate trafficking within the cell and a block in steps leading to membrane fusion.  These findings extend our current understanding of Ebola virus entry mechanism and may help in devising useful new strategies for treatment of Ebola virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVYOnEFnn8xZVVjGoY74BafW6udTcc2eZLhxSrqbirWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D&md5=337fa485785e2a091d392f6ff1dcc1a4</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000141%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide-3%2520kinase-AKT%2520pathway%2520controls%2520cellular%2520entry%2520of%2520ebola%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000141%26doi%3D10.1371%2Fjournal.ppat.1000141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisonero-Vaquero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Mediavilla, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorquera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majano, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jover, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Gallego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Campos, S.</span></span> <span> </span><span class="NLM_article-title">Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2013.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Flabinvest.2013.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24492281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=262-274&author=S.+Pisonero-Vaqueroauthor=M.+V.+Garc%C3%ADa-Mediavillaauthor=F.+Jorqueraauthor=P.+L.+Majanoauthor=M.+Benetauthor=R.+Joverauthor=J.+Gonz%C3%A1lez-Gallegoauthor=S.+S%C3%A1nchez-Campos&title=Modulation+of+PI3K-LXR%CE%B1-dependent+lipogenesis+mediated+by+oxidative%2Fnitrosative+stress+contributes+to+inhibition+of+HCV+replication+by+quercetin&doi=10.1038%2Flabinvest.2013.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin</span></div><div class="casAuthors">Pisonero-Vaquero, Sandra; Garcia-Mediavilla, Maria V.; Jorquera, Francisco; Majano, Pedro L.; Benet, Marta; Jover, Ramiro; Gonzalez-Gallego, Javier; Sanchez-Campos, Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-274</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is exptl. evidence that some antioxidant flavonoids show therapeutic potential in the treatment of hepatitis C through inhibition of hepatitis C virus (HCV) replication.  We examd. the effect of treatment with the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin on HCV replication efficiency in an in vitro model.  While all flavonoids studied were able to reduce viral replication at very low concns. (ranging from 0.1 to 5 μM), quercetin appeared to be the most effective inhibitor of HCV replication, showing a marked anti-HCV activity in replicon-contg. cells when combined with interferon (IFN)α.  The contribution of oxidative/nitrosative stress and lipogenesis modulation to inhibition of HCV replication by quercetin was also examd.  As expected, quercetin decreased HCV-induced reactive oxygen and nitrogen species (ROS/RNS) generation and lipoperoxidn. in replicating cells.  Quercetin also inhibited liver X receptor (LXR)α-induced lipid accumulation in LXRα-overexpressing and replicon-contg. Huh7 cells.  The mechanism underlying the LXRα-dependent lipogenesis modulatory effect of quercetin in HCV-replicating cells seems to involve phosphatidylinositol 3-kinase (PI3K)/AKT pathway inactivation.  Thus, inhibition of the PI3K pathway by LY294002 attenuated LXRα upregulation and HCV replication mediated by lipid accumulation, showing an additive effect when combined with quercetin.  Inactivation of the PI3K pathway by quercetin may contribute to the repression of LXRα-dependent lipogenesis and to the inhibition of viral replication induced by the flavonol.  Combined, our data suggest that oxidative/nitrosative stress blockage and subsequent modulation of PI3K-LXRα-mediated lipogenesis might contribute to the inhibitory effect of quercetin on HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJq5yDphNBrbVg90H21EOLACvtfcHk0lgUkjITCD3VGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFals78%253D&md5=37339fa28d0ec07ead34883327f0b4ec</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2013.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2013.156%26sid%3Dliteratum%253Aachs%26aulast%3DPisonero-Vaquero%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Mediavilla%26aufirst%3DM.%2BV.%26aulast%3DJorquera%26aufirst%3DF.%26aulast%3DMajano%26aufirst%3DP.%2BL.%26aulast%3DBenet%26aufirst%3DM.%26aulast%3DJover%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-Gallego%26aufirst%3DJ.%26aulast%3DS%25C3%25A1nchez-Campos%26aufirst%3DS.%26atitle%3DModulation%2520of%2520PI3K-LXR%25CE%25B1-dependent%2520lipogenesis%2520mediated%2520by%2520oxidative%252Fnitrosative%2520stress%2520contributes%2520to%2520inhibition%2520of%2520HCV%2520replication%2520by%2520quercetin%26jtitle%3DLab.%2520Invest.%26date%3D2014%26volume%3D94%26spage%3D262%26epage%3D274%26doi%3D10.1038%2Flabinvest.2013.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linero, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, L. A.</span></span> <span> </span><span class="NLM_article-title">Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2009.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19595723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2009&pages=166-170&author=F.+N.+Lineroauthor=L.+A.+Scolaro&title=Participation+of+the+phosphatidylinositol+3-kinase%2FAkt+pathway+in+Jun%C3%ADn+virus+replication+in+vitro&doi=10.1016%2Fj.virusres.2009.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junin virus replication in vitro</span></div><div class="casAuthors">Linero, F. N.; Scolaro, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">166-170</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors show that infection of cell cultures with the arenavirus Junin (JUNV), agent of the argentine hemorrhagic fever, leads to the activation of PI3K/Akt signalling pathway.  Phosphorylation of Akt occurs early during JUNV infection of Vero cells and is blocked by the PI3K inhibitor, Ly294002.  Infection of cells with UV-irradiated JUNV redeemed the pattern of stimulation obsd. for infectious virus indicating that an early stage of multiplication cycle would be enough to trigger activation.  Treatment of cells with chlorpromazine abrogated phosphorylation of Akt upon JUNV infection suggesting virus internalization as responsible for activation.  Inhibition of Akt phosphorylation by Ly294002 impaired viral protein synthesis and expression leading to a reduced infectious virus yield without blocking the onset of persistent stage of infection.  This impairment is linked to a reduced amt. of virus bound to cells probably due to a blockage on the recycling of transferrin cell-receptor, employed by the virus to adsorb to the cell surface.  Early Akt activation was also obsd. in BHK-21 and A549 JUNV infected cells suggesting an important role of PI3K/Akt signalling in JUNV multiplication in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodcaY729bbdLVg90H21EOLACvtfcHk0lgUkjITCD3VGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsr%252FK&md5=436b56d4d6f8c239cea2ecec81f5252b</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DLinero%26aufirst%3DF.%2BN.%26aulast%3DScolaro%26aufirst%3DL.%2BA.%26atitle%3DParticipation%2520of%2520the%2520phosphatidylinositol%25203-kinase%252FAkt%2520pathway%2520in%2520Jun%25C3%25ADn%2520virus%2520replication%2520in%2520vitro%26jtitle%3DVirus%2520Res.%26date%3D2009%26volume%3D145%26spage%3D166%26epage%3D170%26doi%3D10.1016%2Fj.virusres.2009.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hanlon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyva-Grado, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sourisseau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, M. L.</span></span> <span> </span><span class="NLM_article-title">An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.9b00230</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00230" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1779-1793&author=R.+O%E2%80%99Hanlonauthor=V.+H.+Leyva-Gradoauthor=M.+Sourisseauauthor=M.+J.+Evansauthor=M.+L.+Shaw&title=An+influenza+virus+entry+inhibitor+targets+class+II+PI3+kinase+and+synergizes+with+oseltamivir&doi=10.1021%2Facsinfecdis.9b00230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir</span></div><div class="casAuthors">O'Hanlon, Ryan; Leyva-Grado, Victor H.; Sourisseau, Marion; Evans, Matthew J.; Shaw, Megan L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1779-1793</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two classes of antivirals targeting the viral neuraminidase (NA) and endonuclease are currently the only clin. useful drugs for the treatment of influenza.  However, resistance to both antivirals has been obsd. in clin. isolates, and there was widespread resistance to oseltamivir (an NA inhibitor) among H1N1 viruses prior to 2009.  This potential for resistance and lack of diversity for antiviral targets highlights the need for new influenza antivirals with a higher barrier to resistance.  In this study, we identified an antiviral compd., M85, that targets host kinases, epidermal growth factor receptor (EGFR), and phosphoinositide 3 class II β (PIK3C2β) and is not susceptible to resistance by viral mutations.  M85 blocks endocytosis of influenza viruses and inhibits a broad-spectrum of viruses with minimal cytotoxicity.  In vitro, we found that combinations of M85 and oseltamivir have strong synergism.  In the mouse model for influenza, treatment with the combination therapy was more protective against a lethal viral challenge than oseltamivir alone, indicating that development of M85 could lead to combination therapies for influenza.  Finally, through this discovery of M85 and its antiviral mechanism, we present the first description of PIK3C2β as a necessary host factor for influenza virus entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zpIDqdoe5bVg90H21EOLACvtfcHk0lgUkjITCD3VGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensrrI&md5=04c3472d6f3bb26c5a7aaa39a9a38ae9</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00230%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hanlon%26aufirst%3DR.%26aulast%3DLeyva-Grado%26aufirst%3DV.%2BH.%26aulast%3DSourisseau%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DShaw%26aufirst%3DM.%2BL.%26atitle%3DAn%2520influenza%2520virus%2520entry%2520inhibitor%2520targets%2520class%2520II%2520PI3%2520kinase%2520and%2520synergizes%2520with%2520oseltamivir%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D1779%26epage%3D1793%26doi%3D10.1021%2Facsinfecdis.9b00230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mejdrová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalupská, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plačková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumlová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hřebabecký, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procházková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejmek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertlíková-Kaiserová, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencka, R.</span></span> <span> </span><span class="NLM_article-title">Highly selective phosphatidylinositol 4-kinase IIIΒ inhibitors and structural insight into their mode of action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3767</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3767-3793&author=I.+Mejdrov%C3%A1author=D.+Chalupsk%C3%A1author=M.+K%C3%B6glerauthor=M.+%C5%A0%C3%A1laauthor=P.+Pla%C4%8Dkov%C3%A1author=A.+Baumlov%C3%A1author=H.+H%C5%99ebabeck%C3%BDauthor=E.+Proch%C3%A1zkov%C3%A1author=M.+Dejmekauthor=R.+Guillonauthor=D.+Struninauthor=J.+Weberauthor=G.+Leeauthor=G.+Birkusauthor=H.+Mertl%C3%ADkov%C3%A1-Kaiserov%C3%A1author=E.+Bouraauthor=R.+Nencka&title=Highly+selective+phosphatidylinositol+4-kinase+III%CE%92+inhibitors+and+structural+insight+into+their+mode+of+action&doi=10.1021%2Facs.jmedchem.5b00499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action</span></div><div class="casAuthors">Mejdrova, Ivana; Chalupska, Dominika; Kogler, Martin; Sala, Michal; Plackova, Pavla; Baumlova, Adriana; Hrebabecky, Hubert; Prochazkova, Eliska; Dejmek, Milan; Guillon, Remi; Strunin, Dmytro; Weber, Jan; Lee, Gary; Birkus, Gabriel; Mertlikova-Kaiserova, Helena; Boura, Evzen; Nencka, Radim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3767-3793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 4-kinase IIIβ is a cellular lipid kinase pivotal to pathogenesis of various RNA viruses.  These viruses hijack the enzyme to modify the structure of intracellular membranes and use them for the construction of functional replication machinery.  Selective inhibitors of this enzyme are potential broad-spectrum antiviral agents, as inhibition of this enzyme results in the arrest of replication of PI4K IIIβ-dependent viruses.  Herein, we report a detailed study of novel selective inhibitors of PI4K IIIβ, which exert antiviral activity against a panel of single-stranded pos.-sense RNA viruses.  Our crystallog. data show that the inhibitors occupy the binding site for the adenine ring of the ATP mol. and therefore prevent the phosphorylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojwEoKXCJFnbVg90H21EOLACvtfcHk0liM-ebMJ9fDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOit7k%253D&md5=0f1e2c86236783ded33bfe529fafe5f1</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00499%26sid%3Dliteratum%253Aachs%26aulast%3DMejdrov%25C3%25A1%26aufirst%3DI.%26aulast%3DChalupsk%25C3%25A1%26aufirst%3DD.%26aulast%3DK%25C3%25B6gler%26aufirst%3DM.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DPla%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DBaumlov%25C3%25A1%26aufirst%3DA.%26aulast%3DH%25C5%2599ebabeck%25C3%25BD%26aufirst%3DH.%26aulast%3DProch%25C3%25A1zkov%25C3%25A1%26aufirst%3DE.%26aulast%3DDejmek%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DR.%26aulast%3DStrunin%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DMertl%25C3%25ADkov%25C3%25A1-Kaiserov%25C3%25A1%26aufirst%3DH.%26aulast%3DBoura%26aufirst%3DE.%26aulast%3DNencka%26aufirst%3DR.%26atitle%3DHighly%2520selective%2520phosphatidylinositol%25204-kinase%2520III%25CE%2592%2520inhibitors%2520and%2520structural%2520insight%2520into%2520their%2520mode%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3767%26epage%3D3793%26doi%3D10.1021%2Facs.jmedchem.5b00499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mejdrová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalupská, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plačková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klíma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumlová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hřebabecký, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procházková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejmek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matoušová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertlíková-Kaiserová, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencka, R.</span></span> <span> </span><span class="NLM_article-title">Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIΒ (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGitbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=100-118&author=I.+Mejdrov%C3%A1author=D.+Chalupsk%C3%A1author=P.+Pla%C4%8Dkov%C3%A1author=C.+M%C3%BCllerauthor=M.+%C5%A0%C3%A1laauthor=M.+Kl%C3%ADmaauthor=A.+Baumlov%C3%A1author=H.+H%C5%99ebabeck%C3%BDauthor=E.+Proch%C3%A1zkov%C3%A1author=M.+Dejmekauthor=D.+Struninauthor=J.+Weberauthor=G.+Leeauthor=M.+Matou%C5%A1ov%C3%A1author=H.+Mertl%C3%ADkov%C3%A1-Kaiserov%C3%A1author=J.+Ziebuhrauthor=G.+Birkusauthor=E.+Bouraauthor=R.+Nencka&title=Rational+design+of+novel+highly+potent+and+selective+phosphatidylinositol+4-kinase+III%CE%92+%28PI4KB%29+inhibitors+as+broad-spectrum+antiviral+agents+and+tools+for+chemical+biology&doi=10.1021%2Facs.jmedchem.6b01465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIβ (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology</span></div><div class="casAuthors">Mejdrova, Ivana; Chalupska, Dominika; Plackova, Pavla; Muller, Christin; Sala, Michal; Klima, Martin; Baumlova, Adriana; Hrebabecky, Hubert; Prochazkova, Eliska; Dejmek, Milan; Strunin, Dmytro; Weber, Jan; Lee, Gary; Matousova, Marika; Mertlikova-Kaiserova, Helena; Ziebuhr, John; Birkus, Gabriel; Boura, Evzen; Nencka, Radim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 4-kinase IIIβ (PI4KB) is indispensable for the replication of various pos.-sense single stranded RNA viruses, which hijack this cellular enzyme to remodel intracellular membranes of infected cells to set up the functional replication machinery.  Therefore, the inhibition of this PI4K isoform leads to the arrest of viral replication.  Here, the authors report on the synthesis of novel PI4KB inhibitors, which were rationally designed based on two distinct structural types of inhibitors that bind in the ATP binding side of PI4KB.  These "hybrids" not only excel in outstanding inhibitory activity but also show high selectivity to PI4KB compared to other kinases.  Thus, these compds. exert selective nanomolar or even subnanomolar activity against PI4KB as well as profound antiviral effect against hepatitis C virus, human rhinovirus, and coxsackievirus B3.  The authors' crystallog. anal. unveiled the exact position of the side chains and explains their extensive contribution to the inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG7GOmo2xaL7Vg90H21EOLACvtfcHk0liM-ebMJ9fDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGitbbM&md5=d0cc3a744b59313677b10454012c495b</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01465%26sid%3Dliteratum%253Aachs%26aulast%3DMejdrov%25C3%25A1%26aufirst%3DI.%26aulast%3DChalupsk%25C3%25A1%26aufirst%3DD.%26aulast%3DPla%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DKl%25C3%25ADma%26aufirst%3DM.%26aulast%3DBaumlov%25C3%25A1%26aufirst%3DA.%26aulast%3DH%25C5%2599ebabeck%25C3%25BD%26aufirst%3DH.%26aulast%3DProch%25C3%25A1zkov%25C3%25A1%26aufirst%3DE.%26aulast%3DDejmek%26aufirst%3DM.%26aulast%3DStrunin%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DMatou%25C5%25A1ov%25C3%25A1%26aufirst%3DM.%26aulast%3DMertl%25C3%25ADkov%25C3%25A1-Kaiserov%25C3%25A1%26aufirst%3DH.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DBoura%26aufirst%3DE.%26aulast%3DNencka%26aufirst%3DR.%26atitle%3DRational%2520design%2520of%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphatidylinositol%25204-kinase%2520III%25CE%2592%2520%2528PI4KB%2529%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520agents%2520and%2520tools%2520for%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D100%26epage%3D118%26doi%3D10.1021%2Facs.jmedchem.6b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grafen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chithelen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyersdorf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Schaulies, J.</span></span> <span> </span><span class="NLM_article-title">Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">218</span>, <span class="refDoi"> DOI: 10.3389/fcell.2019.00218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffcell.2019.00218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31632969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpvFSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=218&author=A.+Grafenauthor=F.+Schumacherauthor=J.+Chithelenauthor=B.+Kleuserauthor=N.+Beyersdorfauthor=J.+Schneider-Schaulies&title=Use+of+acid+ceramidase+and+sphingosine+kinase+inhibitors+as+antiviral+compounds+against+measles+virus+infection+of+lymphocytes+in+vitro&doi=10.3389%2Ffcell.2019.00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Acid Ceramidase and Sphingosine Kinase Inhibitors as Antiviral Compounds Against Measles Virus Infection of Lymphocytes in vitro</span></div><div class="casAuthors">Grafen Anika; Chithelen Janice; Beyersdorf Niklas; Schneider-Schaulies Jurgen; Schumacher Fabian; Kleuser Burkhard; Schumacher Fabian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses.  Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication.  Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70-80% in BJAB cells.  Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides.  SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells.  Furthermore, we found that MV infection of lymphocytes induced a transient (0.5-6 h) increase in S1P, which was prevented by SKI-II.  Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells.  As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism.  In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication.  Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL.  Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5BYysmWirH-Lt9HypzAgQfW6udTcc2eaQ5Cwq6XMY_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpvFSmsQ%253D%253D&md5=5d4eceb052e8201acd32b5c17bd00f61</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2019.00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2019.00218%26sid%3Dliteratum%253Aachs%26aulast%3DGrafen%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%26aulast%3DChithelen%26aufirst%3DJ.%26aulast%3DKleuser%26aufirst%3DB.%26aulast%3DBeyersdorf%26aufirst%3DN.%26aulast%3DSchneider-Schaulies%26aufirst%3DJ.%26atitle%3DUse%2520of%2520acid%2520ceramidase%2520and%2520sphingosine%2520kinase%2520inhibitors%2520as%2520antiviral%2520compounds%2520against%2520measles%2520virus%2520infection%2520of%2520lymphocytes%2520in%2520vitro%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2019%26volume%3D7%26spage%3D218%26doi%3D10.3389%2Ffcell.2019.00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.tips.2020.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32580895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=531-543&author=W.+Luoauthor=Y.+X.+Liauthor=L.+J.+Jiangauthor=Q.+Chenauthor=T.+Wangauthor=D.+W.+Ye&title=Targeting+JAK-STAT+signaling+to+control+cytokine+release+syndrome+in+COVID-19&doi=10.1016%2Fj.tips.2020.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19</span></div><div class="casAuthors">Luo, Wei; Li, Yi-Xin; Jiang, Li-Jun; Chen, Qian; Wang, Tao; Ye, Da-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent advances in the pathophysiol. understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc.  Therefore, the treatment of cytokine storm has been proposed as a crit. part of rescuing severe COVID-19.  Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs).  JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clin. outcomes in COVID-19.  Below, we review the possibilities and challenges of targeting the pathway in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D2HH09CZ3LVg90H21EOLACvtfcHk0lj1aKfIImYsvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF&md5=4812456ab95bfb61bef7bb78f13b8229</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520JAK-STAT%2520signaling%2520to%2520control%2520cytokine%2520release%2520syndrome%2520in%2520COVID-19%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.tips.2020.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31986264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=497-506&author=C.+Huangauthor=Y.+Wangauthor=X.+Liauthor=L.+Renauthor=J.+Zhaoauthor=Y.+Huauthor=L.+Zhangauthor=G.+Fanauthor=J.+Xuauthor=X.+Guauthor=Z.+Chengauthor=T.+Yuauthor=J.+Xiaauthor=Y.+Weiauthor=W.+Wuauthor=X.+Xieauthor=W.+Yinauthor=H.+Liauthor=M.+Liuauthor=Y.+Xiaoauthor=H.+Gaoauthor=L.+Guoauthor=J.+Xieauthor=G.+Wangauthor=R.+Jiangauthor=Z.+Gaoauthor=Q.+Jinauthor=J.+Wangauthor=B.+Cao&title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China&doi=10.1016%2FS0140-6736%2820%2930183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span></div><div class="casAuthors">Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV).  We report the epidemiol., clin., lab., and radiol. characteristics and treatment and clin. outcomes of these patients.  All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan.  We prospectively collected and analyzed data on patients with lab.-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing.  Data were obtained with standardised data collection forms shared by the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records.  Researchers also directly communicated with patients or their families to ascertain epidemiol. and symptom data.  Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.  By Jan 2, 2020, 41 admitted hospital patients had been identified as having lab.-confirmed 2019-nCoV infection.  Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]).  Median age was 49·0 years (IQR 41·0-58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market.  One family cluster was found.  Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum prodn. (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38).  Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0-13·0]).  26 (63%) Of 41 patients had lymphopenia.  All 41 patients had pneumonia with abnormal findings on chest CT.  Complications included acute respiratory distress syndrome (12 [29%]), RNAemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died.  Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα.  The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was assocd. with ICU admission and high mortality.  Major gaps in our knowledge of the origin, epidemiol., duration of human transmission, and clin. spectrum of disease need fulfilment by future studies.  Ministry of Science and Technol., Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technol. Commission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VbprmL3SvLVg90H21EOLACvtfcHk0lj1aKfIImYsvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D&md5=b279b965c1054d99e60f673859c03b49</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930183-5%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520features%2520of%2520patients%2520infected%2520with%25202019%2520novel%2520coronavirus%2520in%2520Wuhan%252C%2520China%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D497%26epage%3D506%26doi%3D10.1016%2FS0140-6736%2820%2930183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span> <span> </span><span class="NLM_article-title">The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">e223</span>– <span class="NLM_lpage">e226</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2020.03.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaad.2020.03.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32278797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2020&pages=e223-e226&author=D.+Petersonauthor=W.+Damskyauthor=B.+King&title=The+use+of+Janus+kinase+inhibitors+in+the+time+of+severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29&doi=10.1016%2Fj.jaad.2020.03.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span></div><div class="casAuthors">Peterson, Danielle; Damsky, William; King, Brett</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e223-e226</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The rates of infections, including upper respiratory infection, nasopharyngitis, and influenza, are only mildly increased in the Janus kinase inhibitor-treated group than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8yia9ReS_rVg90H21EOLACvtfcHk0lj1aKfIImYsvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyrt7s%253D&md5=31825b69099e79685654661ed72ebf3c</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2020.03.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2020.03.099%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DDamsky%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DB.%26atitle%3DThe%2520use%2520of%2520Janus%2520kinase%2520inhibitors%2520in%2520the%2520time%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520%2528SARS-CoV-2%2529%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D82%26spage%3De223%26epage%3De226%26doi%3D10.1016%2Fj.jaad.2020.03.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfi-Emran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Techar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tignanelli, C. J.</span></span> <span> </span><span class="NLM_article-title">Immunomodulation in COVID-19</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(20)30226-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS2213-2600%2820%2930226-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32380023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=544-546&author=N.+E.+Ingrahamauthor=S.+Lotfi-Emranauthor=B.+K.+Thielenauthor=K.+Techarauthor=R.+S.+Morrisauthor=S.+G.+Holtanauthor=R.+A.+Dudleyauthor=C.+J.+Tignanelli&title=Immunomodulation+in+COVID-19&doi=10.1016%2FS2213-2600%2820%2930226-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulation in COVID-19</span></div><div class="casAuthors">Ingraham, Nicholas E.; Lotfi-Emran, Sahar; Thielen, Beth K.; Techar, Kristina; Morris, Rachel S.; Holtan, Shernan G.; Dudley, R. Adams; Tignanelli, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-546</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite unprecedented social isolation and restrictions resulting in widespread economic decline.  More than 3.2 million people have been infected and more than 230,000 of them have died.  To date, no treatments have been definitively shown to be effective; however, a multipronged approach to mitigate transmission, morbidity, and mortality is ongoing.  While upstream prevention strategies such as vaccination are ideal, these strategies are unlikely to be available in time to address current clin. need.  Instead, fast-tracking of drug development and repurposing of approved drugs has facilitated and expedited clin. trials that might hasten effective therapeutics.  Many of these drugs act, at least in part, to directly limit viral replication.  By contrast, the use of interleukin-6 (IL-6) inhibition might have benefits by controlling the pathol. immune response to the virus.  Here, we expand on the theor. basis of IL-6 inhibition and propose potential benefits from other immunomodulators that could, in theory, prove more efficacious.  While IL-6 inhibition attenuates key aspects of the cytokine cascade, we posit other immune targets of inhibition to be considered and their potential to be more efficacious in the setting of COVID-19, specifically IL-1 inhibitors and Janus kinase (JAK) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vsPO8PNStLVg90H21EOLACvtfcHk0lhitL8zh2qEmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D&md5=f46765c8f803136d15684c23ab0c73bb</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930226-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930226-5%26sid%3Dliteratum%253Aachs%26aulast%3DIngraham%26aufirst%3DN.%2BE.%26aulast%3DLotfi-Emran%26aufirst%3DS.%26aulast%3DThielen%26aufirst%3DB.%2BK.%26aulast%3DTechar%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DR.%2BS.%26aulast%3DHoltan%26aufirst%3DS.%2BG.%26aulast%3DDudley%26aufirst%3DR.%2BA.%26aulast%3DTignanelli%26aufirst%3DC.%2BJ.%26atitle%3DImmunomodulation%2520in%2520COVID-19%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D544%26epage%3D546%26doi%3D10.1016%2FS2213-2600%2820%2930226-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, J. J.</span></span> <span> </span><span class="NLM_article-title">COVID-19: consider cytokine storm syndromes and immunosuppression</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30628-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930628-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32192578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFCjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1033-1034&author=P.+Mehtaauthor=D.+F.+McAuleyauthor=M.+Brownauthor=E.+Sanchezauthor=R.+S.+Tattersallauthor=J.+J.+Manson&title=COVID-19%3A+consider+cytokine+storm+syndromes+and+immunosuppression&doi=10.1016%2FS0140-6736%2820%2930628-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: consider cytokine storm syndromes and immunosuppression</span></div><div class="casAuthors">Mehta, Puja; McAuley, Daniel F.; Brown, Michael; Sanchez, Emilie; Tattersall, Rachel S.; Manson, Jessica J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10229</span>),
    <span class="NLM_cas:pages">1033-1034</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">All patients with severe COVID-19 should be screened for hyper-inflammation using lab. trends (e.g. increasing ferritin, decreasing platelet counts, or erythrocyte sedimentation rate) and the HScore to identify the subgroup of patients for whom immunosuppression could improve mortality.  Therapeutic options include steroids, i.v. Ig, selective cytokine blockade (e.g. anakinra or tocilizumab) and JAK kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmddXCLdaAZLVg90H21EOLACvtfcHk0lhitL8zh2qEmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFCjsb8%253D&md5=bd1ede3e6234aafcecf0547a3d768bfb</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930628-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930628-0%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMcAuley%26aufirst%3DD.%2BF.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DTattersall%26aufirst%3DR.%2BS.%26aulast%3DManson%26aufirst%3DJ.%2BJ.%26atitle%3DCOVID-19%253A%2520consider%2520cytokine%2520storm%2520syndromes%2520and%2520immunosuppression%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1033%26epage%3D1034%26doi%3D10.1016%2FS0140-6736%2820%2930628-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbrocini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patruno, C.</span></span> <span> </span><span class="NLM_article-title">Reply: Potential role of Janus kinase inhibitors in COVID-19</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">e65</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2020.04.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaad.2020.04.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32339701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=e65&author=M.+Napolitanoauthor=G.+Fabbrociniauthor=C.+Patruno&title=Reply%3A+Potential+role+of+Janus+kinase+inhibitors+in+COVID-19&doi=10.1016%2Fj.jaad.2020.04.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Reply: Potential role of Janus kinase inhibitors in COVID-19</span></div><div class="casAuthors">Napolitano, Maddalena; Fabbrocini, Gabriella; Patruno, Cataldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e65</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We read with interest the letter ofPeterson et al1 about the use of Janus kinase (JAK)inhibitors in the time of severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2).  The authors reported that discontinuation of JAK inhibitors in th esetting of the initial infection, such as with SARSCoV-2, maybe beneficial given the role of JAK-signal transducer and activator of transcription (STAT) dependent type I (α/β) and type II (γ) interferons in antiviral immunity.  However, data in the literature regarding the possible use of JAK inhibitors in COVID 19 patients is growing.  All of these preclin. data seem to suggest that treatment with both baricitinib and upatacitinib should not be stopped during the COVID-19 pandemic.  Obviously, a careful assessment is mandatory for each individual patient reporting any adverse effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2YX4Z-s-O7Vg90H21EOLACvtfcHk0lhitL8zh2qEmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCns7s%253D&md5=4abc528aaa7ee6fe277e035161652a1a</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2020.04.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2020.04.098%26sid%3Dliteratum%253Aachs%26aulast%3DNapolitano%26aufirst%3DM.%26aulast%3DFabbrocini%26aufirst%3DG.%26aulast%3DPatruno%26aufirst%3DC.%26atitle%3DReply%253A%2520Potential%2520role%2520of%2520Janus%2520kinase%2520inhibitors%2520in%2520COVID-19%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D83%26spage%3De65%26doi%3D10.1016%2Fj.jaad.2020.04.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seif, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aazami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshmirsafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsenzadegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pornour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a new treatment strategy for patients with COVID-19</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1159/000508247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1159%2F000508247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32392562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=467-475&author=F.+Seifauthor=H.+Aazamiauthor=M.+Khoshmirsafaauthor=M.+Kamaliauthor=M.+Mohsenzadeganauthor=M.+Pornourauthor=D.+Mansouri&title=JAK+inhibition+as+a+new+treatment+strategy+for+patients+with+COVID-19&doi=10.1159%2F000508247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibition as a New Treatment Strategy for Patients with COVID-19</span></div><div class="casAuthors">Seif, Farhad; Aazami, Hossein; Khoshmirsafa, Majid; Kamali, Monireh; Mohsenzadegan, Monireh; Pornour, Majid; Mansouri, Davood</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world.  Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed.  In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease.  Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries.  However, more studies are needed to clarify the efficacy of these therapeutics.  Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.  In addn. to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19.  Since the combination of MTX and baricitinib leads to outstanding clin. outcomes, the addn. of baricitinib to MTX might be a potential strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeDIB1cKJRLVg90H21EOLACvtfcHk0ljDHqerVdKckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL&md5=dc9d52d82a5d090166752a684d100942</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1159%2F000508247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000508247%26sid%3Dliteratum%253Aachs%26aulast%3DSeif%26aufirst%3DF.%26aulast%3DAazami%26aufirst%3DH.%26aulast%3DKhoshmirsafa%26aufirst%3DM.%26aulast%3DKamali%26aufirst%3DM.%26aulast%3DMohsenzadegan%26aufirst%3DM.%26aulast%3DPornour%26aufirst%3DM.%26aulast%3DMansouri%26aufirst%3DD.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520new%2520treatment%2520strategy%2520for%2520patients%2520with%2520COVID-19%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2020%26volume%3D181%26spage%3D467%26epage%3D475%26doi%3D10.1159%2F000508247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Convertino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiserra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span>. <i>Crit Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi"> DOI: 10.1186/s13054-020-03020-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13054-020-03020-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32527304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=331&author=I.+Convertinoauthor=M.+Tuccoriauthor=S.+Ferraroauthor=G.+Valdiserraauthor=E.+Cappelloauthor=D.+Focosiauthor=C.+Blandizzi&title=Exploring+pharmacological+approaches+for+managing+cytokine+storm+associated+with+pneumonia+and+acute+respiratory+distress+syndrome+in+COVID-19+patients&doi=10.1186%2Fs13054-020-03020-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span></div><div class="casAuthors">Convertino Irma; Tuccori Marco; Ferraro Sara; Valdiserra Giulia; Cappello Emiliano; Blandizzi Corrado; Tuccori Marco; Blandizzi Corrado; Focosi Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Critical care (London, England)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">331</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.  These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality.  Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure.  Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising.  Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied.  In this article, we discuss the potential advantages of the most promising pharmacological approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrt2z806QLEuxsqfvU0ziafW6udTcc2ebyHceRYa8KV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D&md5=338f561d1c6796524ffedbcd9b6f8df3</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1186%2Fs13054-020-03020-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13054-020-03020-3%26sid%3Dliteratum%253Aachs%26aulast%3DConvertino%26aufirst%3DI.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DFerraro%26aufirst%3DS.%26aulast%3DValdiserra%26aufirst%3DG.%26aulast%3DCappello%26aufirst%3DE.%26aulast%3DFocosi%26aufirst%3DD.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DExploring%2520pharmacological%2520approaches%2520for%2520managing%2520cytokine%2520storm%2520associated%2520with%2520pneumonia%2520and%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520COVID-19%2520patients%26jtitle%3DCrit%2520Care%26date%3D2020%26volume%3D24%26spage%3D331%26doi%3D10.1186%2Fs13054-020-03020-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Supekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezacki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlapbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1074/jbc.M703988200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.M703988200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17951261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=29-36&author=L.+Supekovaauthor=F.+Supekauthor=J.+Leeauthor=S.+Chenauthor=N.+Grayauthor=J.+P.+Pezackiauthor=A.+Schlapbachauthor=P.+G.+Schultz&title=Identification+of+human+kinases+involved+in+hepatitis+C+virus+replication+by+small+interference+RNA+library+screening&doi=10.1074%2Fjbc.M703988200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human kinases involved in Hepatitis C virus replication by small interference RNA library screening</span></div><div class="casAuthors">Supekova, Lubica; Supek, Frantisek; Lee, Jongkook; Chen, Shawn; Gray, Nathanael; Pezacki, John P.; Schlapbach, Achim; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The propagation of the hepatitis C virus (HCV) is a complex process that requires both host and viral proteins.  To facilitate identification of host cell factors that are required for HCV replication, we screened a panel of small interference RNAs that preferentially target human protein kinases using an HCV replicon expressing the firefly luciferase gene as a genetic reporter.  Small interference RNAs specific for three human kinases, Csk, Jak1, and Vrk1, were identified that reproducibly reduce viral RNA and viral protein levels in HCV replicon-bearing cells.  Treatment of replicon cells with a small mol. inhibitor of Csk also resulted in a significant redn. in HCV RNA and proteins, further supporting a role for Csk in HCV replication.  The effects of siRNAs targeting eight kinases known to be neg. regulated by Csk were then examd.; knock down of one of these kinases, Fyn, resulted in up-regulation of the HCV replicon, suggesting that Csk mediates its effect on HCV replication through Fyn.  This conclusion was further corroborated by demonstration that replicon cells treated with Csk inhibitor contained lower levels of the phosphorylated form of Fyn than control cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2twHkVKI2sLVg90H21EOLACvtfcHk0ljDHqerVdKckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D&md5=a78cc4bfc82aeb94e0f3a7cdf7641200</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703988200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703988200%26sid%3Dliteratum%253Aachs%26aulast%3DSupekova%26aufirst%3DL.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DPezacki%26aufirst%3DJ.%2BP.%26aulast%3DSchlapbach%26aufirst%3DA.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520human%2520kinases%2520involved%2520in%2520hepatitis%2520C%2520virus%2520replication%2520by%2520small%2520interference%2520RNA%2520library%2520screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D29%26epage%3D36%26doi%3D10.1074%2Fjbc.M703988200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2013.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4062%2Fbiomolther.2013.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=97-106&author=C.+Lee&title=Interaction+of+hepatitis+C+virus+core+protein+with+janus+kinase+is+required+for+efficient+production+of+infectious+viruses&doi=10.4062%2Fbiomolther.2013.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of hepatits C virus core protein with Janus kinase is required for efficient production of infectious viruses</span></div><div class="casAuthors">Lee, Choongho</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.  HCV core protein plays not only a structural role in the virion morphogenesis by encapsidating a virus RNA genome but also a nonstructural role in HCV-induced pathogenesis by blocking innate immunity.  Esp., it has been shown to regulate JAK-STAT signaling pathway through its direct interaction with Janus kinase (JAK) via its proline-rich JAK-binding motif (79PGYPWP84).  However, little is known about the physiol. significance of this HCV core-JAK assocn. in the context of the virus life cycle.  In order to gain an insight, a mutant HCV genome (J6/JFH1-79A82A) was constructed to express the mutant core with a defective JAK-binding motif (79AGYAWP84) using an HCV genotype 2a infectious clone (J6/JFH1).  When this mutant HCV genome was introduced into hepatocarcinoma cells, it was found to be severely impaired in its ability to produce infectious viruses in spite of its robust RNA genome replication.  Taken together, all these results suggest an essential requirement of HCV core-JAK protein interaction for efficient prodn. of infectious viruses and the potential of using core-JAK blockers as a new anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6PBOORRDBbVg90H21EOLACvtfcHk0lhLP8-y8Jd7QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D&md5=01b53d8d5f7d333ae663f7b21e29f509</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2013.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2013.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26atitle%3DInteraction%2520of%2520hepatitis%2520C%2520virus%2520core%2520protein%2520with%2520janus%2520kinase%2520is%2520required%2520for%2520efficient%2520production%2520of%2520infectious%2520viruses%26jtitle%3DBiomol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D97%26epage%3D106%26doi%3D10.4062%2Fbiomolther.2013.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehm, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulpa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sékaly, R. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e1006740</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1006740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1006740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29267399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1006740&author=C.+Gavegnanoauthor=J.+H.+Brehmauthor=F.+P.+Dupuyauthor=A.+Tallaauthor=S.+P.+Ribeiroauthor=D.+A.+Kulpaauthor=C.+Cameronauthor=S.+Santosauthor=S.+J.+Hurwitzauthor=V.+C.+Marconiauthor=J.+P.+Routyauthor=L.+Sabbaghauthor=R.+F.+Schinaziauthor=R.+P.+S%C3%A9kaly&title=Novel+mechanisms+to+inhibit+HIV+reservoir+seeding+using+Jak+inhibitors&doi=10.1371%2Fjournal.ppat.1006740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span></div><div class="casAuthors">Gavegnano, Christina; Brehm, Jessica H.; Dupuy, Franck P.; Talla, Aarthi; Ribeiro, Susan Pereira; Kulpa, Deanna A.; Cameron, Cheryl; Santos, Stephanie; Hurwitz, Selwyn J.; Marconi, Vincent C.; Routy, Jean-Pierre; Sabbagh, Laurent; Schinazi, Raymond F.; Sekaly, Rafick Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006740/1-e1006740/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite advances in the treatment of HIV infection with ART, elucidating strategies to overcome HIV persistence, including blockade of viral reservoir establishment, maintenance, and expansion, remains a challenge.  T cell homeostasis is a major driver of HIV persistence.  Cytokines involved in regulating homeostasis of memory T cells, the major hub of the HIV reservoir, trigger the Jak-STAT pathway.  We evaluated the ability of tofacitinib and ruxolitinib, two FDA-approved Jak inhibitors, to block seeding and maintenance of the HIV reservoir in vitro.  We provide direct demonstration for involvement of the Jak-STAT pathway in HIV persistence in vivo, ex vivo, and in vitro; pSTAT5 strongly correlates with increased levels of integrated viral DNA in vivo, and in vitro Jak inhibitors reduce the frequency of CD4+ T cells harboring integrated HIV DNA.  We show that Jak inhibitors block viral prodn. from infected cells, inhibit γ-C receptor cytokine (IL-15)-induced viral reactivation from latent stores thereby preventing transmission of infectious particles to bystander activated T cells.  These results show that dysregulation of the Jak-STAT pathway is assocd. with viral persistence in vivo, and that Jak inhibitors target key events downstream of γ-C cytokine (IL-2, IL-7 and IL-15) ligation to their receptors, impacting the magnitude of the HIV reservoir in all memory CD4 T cell subsets in vitro and ex vivo.  Jak inhibitors represent a therapeutic modality to prevent key events of T cell activation that regulate HIV persistence and together, specific, potent blockade of these events may be integrated to future curative strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUxFHplJKULVg90H21EOLACvtfcHk0lhLP8-y8Jd7QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N&md5=b311dec0f2c603fcf337df2b3b2a1e56</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006740%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DBrehm%26aufirst%3DJ.%2BH.%26aulast%3DDupuy%26aufirst%3DF.%2BP.%26aulast%3DTalla%26aufirst%3DA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DKulpa%26aufirst%3DD.%2BA.%26aulast%3DCameron%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DS.%26aulast%3DHurwitz%26aufirst%3DS.%2BJ.%26aulast%3DMarconi%26aufirst%3DV.%2BC.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DSabbagh%26aufirst%3DL.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DS%25C3%25A9kaly%26aufirst%3DR.%2BP.%26atitle%3DNovel%2520mechanisms%2520to%2520inhibit%2520HIV%2520reservoir%2520seeding%2520using%2520Jak%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2017%26volume%3D13%26spage%3De1006740%26doi%3D10.1371%2Fjournal.ppat.1006740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">e30</span>– <span class="NLM_lpage">e31</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=e30-e31&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0lhLP8-y8Jd7QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3De30%26epage%3De31%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Nievas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiadoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monzani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizos, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forfori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avendano Cespedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrozzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Jurado, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerenza, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldevilla Bernardo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranitsaris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farcomeni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres Pretel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon-Talero, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Molina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felce, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizami, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklosi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abizanda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">eabe4724</span>, <span class="refDoi"> DOI: 10.1126/sciadv.abe4724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fsciadv.abe4724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=33187978" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2021&pages=eabe4724&author=J.+Stebbingauthor=G.+Sanchez+Nievasauthor=M.+Falconeauthor=S.+Youhannaauthor=P.+Richardsonauthor=S.+Ottavianiauthor=J.+X.+Shenauthor=C.+Sommerauerauthor=G.+Tiseoauthor=L.+Ghiadoniauthor=A.+Virdisauthor=F.+Monzaniauthor=L.+R.+Rizosauthor=F.+Forforiauthor=A.+Avendano+Cespedesauthor=S.+De+Marcoauthor=L.+Carrozziauthor=F.+Lenaauthor=P.+M.+Sanchez-Juradoauthor=L.+G.+Lacerenzaauthor=N.+Cesiraauthor=D.+Caldevilla+Bernardoauthor=A.+Perrellaauthor=L.+Niccoliauthor=L.+S.+Mendezauthor=D.+Matarreseauthor=D.+Golettiauthor=Y.-J.+Tanauthor=V.+Monteilauthor=G.+Dranitsarisauthor=F.+Cantiniauthor=A.+Farcomeniauthor=S.+Duttaauthor=S.+K.+Burleyauthor=H.+Zhangauthor=M.+Pistelloauthor=W.+Liauthor=M.+M.+Romeroauthor=F.+Andres+Pretelauthor=R.+S.+Simon-Taleroauthor=R.+Garcia-Molinaauthor=C.+Kutterauthor=J.+H.+Felceauthor=Z.+F.+Nizamiauthor=A.+G.+Miklosiauthor=J.+M.+Penningerauthor=F.+Menichettiauthor=A.+Mirazimiauthor=P.+Abizandaauthor=V.+M.+Lauschke&title=JAK+inhibition+reduces+SARS-CoV-2+liver+infectivity+and+modulates+inflammatory+responses+to+reduce+morbidity+and+mortality&doi=10.1126%2Fsciadv.abe4724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.abe4724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.abe4724%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DSanchez%2BNievas%26aufirst%3DG.%26aulast%3DFalcone%26aufirst%3DM.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DJ.%2BX.%26aulast%3DSommerauer%26aufirst%3DC.%26aulast%3DTiseo%26aufirst%3DG.%26aulast%3DGhiadoni%26aufirst%3DL.%26aulast%3DVirdis%26aufirst%3DA.%26aulast%3DMonzani%26aufirst%3DF.%26aulast%3DRizos%26aufirst%3DL.%2BR.%26aulast%3DForfori%26aufirst%3DF.%26aulast%3DAvendano%2BCespedes%26aufirst%3DA.%26aulast%3DDe%2BMarco%26aufirst%3DS.%26aulast%3DCarrozzi%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DF.%26aulast%3DSanchez-Jurado%26aufirst%3DP.%2BM.%26aulast%3DLacerenza%26aufirst%3DL.%2BG.%26aulast%3DCesira%26aufirst%3DN.%26aulast%3DCaldevilla%2BBernardo%26aufirst%3DD.%26aulast%3DPerrella%26aufirst%3DA.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMendez%26aufirst%3DL.%2BS.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DDranitsaris%26aufirst%3DG.%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DFarcomeni%26aufirst%3DA.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPistello%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRomero%26aufirst%3DM.%2BM.%26aulast%3DAndres%2BPretel%26aufirst%3DF.%26aulast%3DSimon-Talero%26aufirst%3DR.%2BS.%26aulast%3DGarcia-Molina%26aufirst%3DR.%26aulast%3DKutter%26aufirst%3DC.%26aulast%3DFelce%26aufirst%3DJ.%2BH.%26aulast%3DNizami%26aufirst%3DZ.%2BF.%26aulast%3DMiklosi%26aufirst%3DA.%2BG.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DMenichetti%26aufirst%3DF.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DAbizanda%26aufirst%3DP.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DJAK%2520inhibition%2520reduces%2520SARS-CoV-2%2520liver%2520infectivity%2520and%2520modulates%2520inflammatory%2520responses%2520to%2520reduce%2520morbidity%2520and%2520mortality%26jtitle%3DSci.%2520Adv.%26date%3D2021%26volume%3D7%26spage%3Deabe4724%26doi%3D10.1126%2Fsciadv.abe4724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veeravalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madgula, L. M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Critical assessment of pharmacokinetic drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1007/s40264-020-00938-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs40264-020-00938-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32367507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2020&pages=711-725&author=V.+Veeravalliauthor=R.+P.+Dashauthor=J.+A.+Thomasauthor=R.+J.+Babuauthor=L.+M.+V.+Madgulaauthor=N.+R.+Srinivas&title=Critical+assessment+of+pharmacokinetic+drug%E2%80%93drug+interaction+potential+of+tofacitinib%2C+baricitinib+and+upadacitinib%2C+the+three+approved+janus+kinase+inhibitors+for+rheumatoid+arthritis+treatment&doi=10.1007%2Fs40264-020-00938-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment</span></div><div class="casAuthors">Veeravalli, Vijayabhaskar; Dash, Ranjeet P.; Thomas, Jennifer A.; Babu, R. Jayachandra; Madgula, Lakshmi Mohan Vamsi; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-725</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: The introduction of novel, small-mol. Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics.  This review aimed to critically assess the drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib and provide a balanced perspective for choosing the most appropriate Janus kinase inhibitor based on the needs of patients with rheumatoid arthritis including co-medications and renal/hepatic impairment status.  Based on the crit. assessment, all three approved Janus kinase inhibitors generally provide a favorable opportunity for co-prescription with a plethora of drugs.  While cytochrome P 450 3A4-related inhibition or induction altered the exposures (area under the curve) of tofacitinib and upadacitinib, it did not impact the exposure of baricitinib.  Transporter drug-drug interaction studies revealed that the disposition of baricitinib was altered with certain transporter inhibitors as compared with either tofacitinib or upadacitinib.  Adjustment of tofacitinib or baricitinib dosages but not that of upadacitinib is required with the progression of renal impairment from a mild to a severe condition.  While the dosage of tofacitinib needs to be adjusted for patients with moderate hepatic impairment status, it is not the case for either baricitinib or upadacitinib.  Assessment of the drug-drug interaction potential suggests that tofacitinib, baricitinib and upadacitinib generally show a favorable disposition with no perpetrator activity; however, as victim drugs, they show subtle pharmacokinetic differences that may be considered during polypharmacy.  Moreover, careful choice of the three drugs could be made in patients with rheumatoid arthritis with varying degrees of renal/hepatic impairments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKv0ESe477rVg90H21EOLACvtfcHk0lgHd_KQDAEuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1SnsLc%253D&md5=a4e4054c400620cf07cdd5a3a6d2651d</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1007%2Fs40264-020-00938-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-020-00938-z%26sid%3Dliteratum%253Aachs%26aulast%3DVeeravalli%26aufirst%3DV.%26aulast%3DDash%26aufirst%3DR.%2BP.%26aulast%3DThomas%26aufirst%3DJ.%2BA.%26aulast%3DBabu%26aufirst%3DR.%2BJ.%26aulast%3DMadgula%26aufirst%3DL.%2BM.%2BV.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DCritical%2520assessment%2520of%2520pharmacokinetic%2520drug%25E2%2580%2593drug%2520interaction%2520potential%2520of%2520tofacitinib%252C%2520baricitinib%2520and%2520upadacitinib%252C%2520the%2520three%2520approved%2520janus%2520kinase%2520inhibitors%2520for%2520rheumatoid%2520arthritis%2520treatment%26jtitle%3DDrug%2520Saf.%26date%3D2020%26volume%3D43%26spage%3D711%26epage%3D725%26doi%3D10.1007%2Fs40264-020-00938-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyslop, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle Camp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span> <span> </span><span class="NLM_article-title">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.3899/jrheum.171361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3899%2Fjrheum.171361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30219772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=7-18&author=J.+S.+Smolenauthor=M.+C.+Genoveseauthor=T.+Takeuchiauthor=D.+L.+Hyslopauthor=W.+L.+Maciasauthor=T.+Rooneyauthor=L.+Chenauthor=C.+L.+Dicksonauthor=J.+Riddle+Campauthor=T.+E.+Cardilloauthor=T.+Ishiiauthor=K.+L.+Winthrop&title=Safety+profile+of+baricitinib+in+patients+with+active+rheumatoid+arthritis+with+over+2+years+median+time+in+treatment&doi=10.3899%2Fjrheum.171361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span></div><div class="casAuthors">Smolen, Josef S.; Genovese, Mark C.; Takeuchi, Tsutomu; Hyslop, David L.; Macias, William L.; Rooney, Terence; Chen, Lei; Dickson, Christina L.; Camp, Jennifer Riddle; Cardillo, Tracy E.; Ishii, Taeko; Winthrop, Kevin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective.  Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).  We evaluated baricitinib's safety profile through 288 wk (up to Sept. 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].  The "all-bari-RA" group included patients who received any baricitinib dose.  Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset).  Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg - extended").  The uncommon events description used the non-controlled all-bari-RA.  There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, max. 5.5 yrs).  No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg vs. placebo or for 4 mg vs. 2 mg.  Infections including herpes zoster were significantly more frequent for 4 mg vs. placebo.  Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, resp.) or compared to published RA rates.  All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY).  IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.  Conclusion.  In this integrated anal. of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.  Trial registration nos.: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtLt3TTbQXrVg90H21EOLACvtfcHk0lgHd_KQDAEuYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL&md5=65e80ff8290c092f167e04f6505ca261</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.171361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.171361%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DHyslop%26aufirst%3DD.%2BL.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDickson%26aufirst%3DC.%2BL.%26aulast%3DRiddle%2BCamp%26aufirst%3DJ.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26atitle%3DSafety%2520profile%2520of%2520baricitinib%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520over%25202%2520years%2520median%2520time%2520in%2520treatment%26jtitle%3DJ.%2520Rheumatol.%26date%3D2019%26volume%3D46%26spage%3D7%26epage%3D18%26doi%3D10.3899%2Fjrheum.171361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicastri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobbione, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span> <span> </span><span class="NLM_article-title">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.jinf.2020.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jinf.2020.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32333918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=318-356&author=F.+Cantiniauthor=L.+Niccoliauthor=D.+Matarreseauthor=E.+Nicastriauthor=P.+Stobbioneauthor=D.+Goletti&title=Baricitinib+therapy+in+COVID-19%3A+A+pilot+study+on+safety+and+clinical+impact&doi=10.1016%2Fj.jinf.2020.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span></div><div class="casAuthors">Cantini, Fabrizio; Niccoli, Laura; Matarrese, Daniela; Nicastri, Emanuele; Stobbione, Paolo; Goletti, Delia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-356</span>CODEN:
                <span class="NLM_cas:coden">JINFD2</span>;
        ISSN:<span class="NLM_cas:issn">1532-2742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preliminary results on 12 patients with moderate COVID-19 pneumonia confirmed the safety of baricitinib therapy in a clin. context.  In the baricitinib-treated group, all clin. characteristics and respiratory function parameters improved both at wk 1 and 2 compared to baseline.  C-reactive protein values significantly decreased in the same timeframes.  No infections, cardiovascular, and hematol. adverse events occurred after a 2 wk treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0f8W8UmI8rVg90H21EOLACvtfcHk0lgepYtjzqAgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO&md5=d47bb194919c10f50d24312f137ec88d</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.jinf.2020.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinf.2020.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DNicastri%26aufirst%3DE.%26aulast%3DStobbione%26aufirst%3DP.%26aulast%3DGoletti%26aufirst%3DD.%26atitle%3DBaricitinib%2520therapy%2520in%2520COVID-19%253A%2520A%2520pilot%2520study%2520on%2520safety%2520and%2520clinical%2520impact%26jtitle%3DJ.%2520Infect.%26date%3D2020%26volume%3D81%26spage%3D318%26epage%3D356%26doi%3D10.1016%2Fj.jinf.2020.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lgepYtjzqAgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0lgepYtjzqAgzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span> <span> </span><span class="NLM_article-title">Inflammation research association-15th international conference advances in asthma and COPD and other inflammatory diseases</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19051144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=863-865&author=K.+Walker&title=Inflammation+research+association-15th+international+conference+advances+in+asthma+and+COPD+and+other+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation Research Association--15th international conference advances in asthma and COPD and other inflammatory diseases</span></div><div class="casAuthors">Walker Karen</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs : the investigational drugs journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-5</span>
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgMoQJbY8mfRBrI9DTGjC0fW6udTcc2eYfFGrZ_GUdNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D&md5=45aa68e772177ff24bf3fd91cfd0557b</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26atitle%3DInflammation%2520research%2520association-15th%2520international%2520conference%2520advances%2520in%2520asthma%2520and%2520COPD%2520and%2520other%2520inflammatory%2520diseases%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26spage%3D863%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzveig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3538</span>, <span class="refDoi"> DOI: 10.1182/blood.V110.11.3538.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood.V110.11.3538.3538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3538&author=J.+Fridmanauthor=R.+Nussenzveigauthor=P.+Liuauthor=J.+Rodgersauthor=T.+Burnauthor=P.+Haleyauthor=P.+Scherleauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=S.+Verstovsekauthor=K.+Vaddi&title=Discovery+and+preclinical+characterization+of+INCB018424%2C+a+selective+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+disorders&doi=10.1182%2Fblood.V110.11.3538.3538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1182%2Fblood.V110.11.3538.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V110.11.3538.3538%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DNussenzveig%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520INCB018424%252C%2520a%2520selective%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3538%26doi%3D10.1182%2Fblood.V110.11.3538.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shilling, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedza, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galya, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2023</span>– <span class="NLM_lpage">2031</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fdmd.110.033787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20699411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=2023-2031&author=A.+D.+Shillingauthor=F.+M.+Nedzaauthor=T.+Emmauthor=S.+Diamondauthor=E.+McKeeverauthor=N.+Punwaniauthor=W.+Williamsauthor=A.+Arvanitisauthor=L.+G.+Galyaauthor=M.+Liauthor=S.+Shepardauthor=J.+Rodgersauthor=T.-Y.+Yueauthor=S.+Yeleswaram&title=Metabolism%2C+excretion%2C+and+pharmacokinetics+of+%5B14C%5D+INCB018424%2C+a+selective+Janus+tyrosine+kinase+1%2F2+inhibitor%2C+in+humans&doi=10.1124%2Fdmd.110.033787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans</span></div><div class="casAuthors">Shilling, Adam D.; Nedza, Frank M.; Emm, Thomas; Diamond, Sharon; McKeever, Edward; Punwani, Naresh; Williams, William; Arvanitis, Argyrios; Galya, Laurine G.; Li, Mei; Shepard, Stacey; Rodgers, James; Yue, Tai-Yuen; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2023-2031</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab., excretion, and pharmacokinetics of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (INCB018424), a potent, selective inhibitor of Janus tyrosine kinase 1/2 and the first investigational drug of its class in phase III studies for the treatment of myelofibrosis, were investigated in healthy human subjects given a single oral 25-mg dose of [14C]INCB018424 as an oral soln.  INCB018424 and total radio-activity were absorbed rapidly (mean time to reach the maximal drug concn. <1 h), declining in a monophasic or biphasic fashion (mean t1/2 of 2.32 and 5.81 h, resp.).  Recovery of administered radioactivity was fairly rapid (>70% within 24 h post-dose) with 74 and 22% recovered in urine and feces, resp.  Parent compd. was the predominant entity in the circulation, representing 58 to 74% of the total radioactivity up to 6 h postdose, indicating that the overall circulating metabolite burden was low (<50% of parent).  Two metabolite peaks in plasma (M18 and a peak contg. M16/M27, both hydroxylations on the cyclopentyl moiety) were identified as major (30 and 14% of parent based on area under the curve from 0 to 24 h).  The exposures of other circulating INCB018424-related peaks were <10% of parent, consisting of mono- and dihydroxylated metabolites.  The profiles in urine and feces consisted of hydroxyl and oxo metabolites and subsequent glucuronide conjugates with parent drug accounting for <1% of the excreted dose, strongly suggesting that after an oral dose, INCB018424 was >95% absorbed.  In healthy subjects administered daily oral doses of unlabeled INCB018424, there were minimal differences in parent and metabolite concns. between day 1 and day 10, indicating a lack of accumulation of parent or metabolites between single and multiple dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVzg3TxNAT7Vg90H21EOLACvtfcHk0lgklE1utFGdpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurvI&md5=4d3e77d36b51f557e2825d90a4ad9696</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033787%26sid%3Dliteratum%253Aachs%26aulast%3DShilling%26aufirst%3DA.%2BD.%26aulast%3DNedza%26aufirst%3DF.%2BM.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DMcKeever%26aufirst%3DE.%26aulast%3DPunwani%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DArvanitis%26aufirst%3DA.%26aulast%3DGalya%26aufirst%3DL.%2BG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DYue%26aufirst%3DT.-Y.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DMetabolism%252C%2520excretion%252C%2520and%2520pharmacokinetics%2520of%2520%255B14C%255D%2520INCB018424%252C%2520a%2520selective%2520Janus%2520tyrosine%2520kinase%25201%252F2%2520inhibitor%252C%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D2023%26epage%3D2031%26doi%3D10.1124%2Fdmd.110.033787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punwani, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1177/0091270010389469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1177%2F0091270010389469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21257798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Gks7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1644-1654&author=J.+G.+Shiauthor=X.+Chenauthor=R.+F.+McGeeauthor=R.+R.+Landmanauthor=T.+Emmauthor=Y.+Loauthor=P.+A.+Scherleauthor=N.+G.+Punwaniauthor=W.+V.+Williamsauthor=S.+Yeleswaram&title=The+pharmacokinetics%2C+pharmacodynamics%2C+and+safety+of+orally+dosed+INCB018424+phosphate+in+healthy+volunteers&doi=10.1177%2F0091270010389469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers</span></div><div class="casAuthors">Shi, Jack G.; Chen, Xuejun; McGee, Ryan F.; Landman, Robert R.; Emm, Thomas; Lo, Yvonne; Scherle, Peggy A.; Punwani, Naresh G.; Williams, William V.; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1644-1654</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF).  The oral dose pharmacokinetics, pharmacodynamics, safety, and tolerability of INCB018424 were evaluated in healthy volunteers in 2 double-blind, randomized, and placebo-controlled studies.  The first study evaluated single ascending doses of 5 to 200 mg INCB018424 and the effect of food, whereas the second study evaluated multiple ascending doses, including both once- and twice-daily dosing for 10 days.  As a Biopharma-ceutical Classification System class I drug, INCB018424 exhibited good oral bioavailability and dose-proportional systemic exposures.  INCB018424 showed low oral dose clearance and a small vol. of distribution, with an approx. 3-h plasma half-life and insignificant accumulation following repeat dosing.  A high-fat meal reduced INCB018424 Cmax by 24% but had little effect on INCB018424 AUC.  INCB018424 was cleared primarily by metab. with negligible renal excretion.  The pharmacodynamics of INCB018424, evaluated by the inhibition of phosphorylated STAT3 following cytokine stimulation in whole blood, showed good correlation with INCB018424 plasma concns.  INCB018424 was generally safe and well tolerated, with 25 mg bid and 100 mg qd established as the max. tolerated doses in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9sAcu1yiNf7Vg90H21EOLACvtfcHk0lgklE1utFGdpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Gks7%252FJ&md5=b400dc074ce6a7ffd45b716ba145995e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1177%2F0091270010389469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010389469%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcGee%26aufirst%3DR.%2BF.%26aulast%3DLandman%26aufirst%3DR.%2BR.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DPunwani%26aufirst%3DN.%2BG.%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DThe%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520and%2520safety%2520of%2520orally%2520dosed%2520INCB018424%2520phosphate%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D51%26spage%3D1644%26epage%3D1654%26doi%3D10.1177%2F0091270010389469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+M.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0lhQCJ0rOwVkvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span> <span> </span><span class="NLM_article-title">Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">183</span>, <span class="refDoi"> DOI: 10.1186/s13075-019-1964-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13075-019-1964-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31375130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvkt1GitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=183&author=I.+B.+McInnesauthor=N.+L.+Byersauthor=R.+E.+Higgsauthor=J.+Leeauthor=W.+L.+Maciasauthor=S.+Naauthor=R.+A.+Ortmannauthor=G.+Rochaauthor=T.+P.+Rooneyauthor=T.+Wehrmanauthor=X.+Zhangauthor=S.+H.+Zuckermanauthor=P.+C.+Taylor&title=Comparison+of+baricitinib%2C+upadacitinib%2C+and+tofacitinib+mediated+regulation+of+cytokine+signaling+in+human+leukocyte+subpopulations&doi=10.1186%2Fs13075-019-1964-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations</span></div><div class="casAuthors">McInnes Iain B; Byers Nicole L; Higgs Richard E; Lee Jonathan; Macias William L; Na Songqing; Ortmann Robert A; Rocha Guilherme; Rooney Terence P; Zhang Xin; Zuckerman Steven H; Wehrman Thomas; Taylor Peter C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level.  METHODS:  Peripheral blood mononuclear cells from healthy donors were incubated with different JAKis, levels of phosphorylated signal transducer and activator of transcription (pSTAT) were measured following cytokine stimulation, and half maximum inhibitory concentration (IC50) values were calculated in phenotypically gated leukocyte subpopulations.  Therapeutic dose relevance of the in vitro analysis was assessed using calculated mean concentration-time profiles over 24 h obtained from JAKi-treated subjects.  Time above IC50 and average daily percent inhibition of pSTAT formation were calculated for each JAKi, cytokine, and cell type.  RESULTS:  Distinct JAKis displayed different in vitro pharmacologic profiles.  For example, tofacitinib and upadacitinib were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21) with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling during the dosing interval.  All JAKis tested inhibited JAK1/2-dependent cytokines (e.g., IL-6 and interferon [IFN]-γ), the JAK1/tyrosine kinase 2 (TYK2)-dependent cytokines IL-10 and IFN-α, the JAK2/2-dependent cytokines IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), and the JAK2/TYK2-dependent cytokine granulocyte colony-stimulating factor (G-CSF), but often to significantly differing degrees.  CONCLUSIONS:  Different JAKis modulated distinct cytokine pathways to varying degrees, and no agent potently or continuously inhibited an individual cytokine signaling pathway throughout the dosing interval.  Notably, baricitinib inhibited JAK1/3 signaling to a lesser extent than upadacitinib and tofacitinib, while upadacitinib, baricitinib, and tofacitinib inhibited the signaling of JAK2/2-dependent cytokines, including GM-CSF and IL-3, as well as the signaling of the JAK2/TYK2-dependent cytokine G-CSF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXxM4ksZxDYUNHe_gFldTbfW6udTcc2eaiSABvp-XaJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvkt1GitQ%253D%253D&md5=cd8854ced4361fefab9972a1e19a5d0d</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1964-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1964-1%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DNa%26aufirst%3DS.%26aulast%3DOrtmann%26aufirst%3DR.%2BA.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DWehrman%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZuckerman%26aufirst%3DS.%2BH.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26atitle%3DComparison%2520of%2520baricitinib%252C%2520upadacitinib%252C%2520and%2520tofacitinib%2520mediated%2520regulation%2520of%2520cytokine%2520signaling%2520in%2520human%2520leukocyte%2520subpopulations%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D183%26doi%3D10.1186%2Fs13075-019-1964-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lg3ZbrazndHPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojcik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strengholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazariciu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13075-019-1866-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13075-019-1866-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30953540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=89&author=J.+Wollenhauptauthor=E.-B.+Leeauthor=J.+R.+Curtisauthor=J.+Silverfieldauthor=K.+Terryauthor=K.+Somaauthor=C.+Mojcikauthor=R.+DeMasiauthor=S.+Strengholtauthor=K.+Kwokauthor=I.+Lazariciuauthor=L.+Wangauthor=S.+Cohen&title=Safety+and+efficacy+of+tofacitinib+for+up+to+9.5+years+in+the+treatment+of+rheumatoid+arthritis%3A+final+results+of+a+global%2C+open-label%2C+long-term+extension+study&doi=10.1186%2Fs13075-019-1866-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span></div><div class="casAuthors">Wollenhaupt Jurgen; Lee Eun-Bong; Curtis Jeffrey R; Silverfield Joel; Terry Ketti; Wang Lisy; Soma Koshika; Mojcik Chris; Kwok Kenneth; DeMasi Ryan; Strengholt Sander; Lazariciu Irina; Cohen Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA).  METHODS:  Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID.  Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion.  Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose.  The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy.  RESULTS:  Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled.  Total tofacitinib exposure was 16,291 patient-years.  Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points).  Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies.  The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8.  For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality.  Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained.  CONCLUSIONS:  Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA.  Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions.  TRIAL REGISTRATION:  NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQry7CBP_Rh3thwrmtH4OBfW6udTcc2eaiSABvp-XaJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D&md5=15c33765e0ca5ffa5772fe872ede2a8a</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1866-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1866-2%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.-B.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DMojcik%26aufirst%3DC.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DStrengholt%26aufirst%3DS.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DLazariciu%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%2520for%2520up%2520to%25209.5%2520years%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520final%2520results%2520of%2520a%2520global%252C%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D89%26doi%3D10.1186%2Fs13075-019-1866-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span> <span> </span><span class="NLM_article-title">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-216761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fannrheumdis-2019-216761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32759265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=1400-1413&author=P.+Measeauthor=C.+Charles-Schoemanauthor=S.+Cohenauthor=L.+Fallonauthor=J.+Woolcottauthor=H.+Yunauthor=J.+Kremerauthor=J.+Greenbergauthor=W.+Malleyauthor=A.+Onofreiauthor=K.+S.+Kanikauthor=D.+Grahamauthor=C.+Wangauthor=C.+Connellauthor=H.+Valdezauthor=M.+Haubenauthor=E.+Hungauthor=A.+Madsenauthor=T.+V.+Jonesauthor=J.+R.+Curtis&title=Incidence+of+venous+and+arterial+thromboembolic+events+reported+in+the+tofacitinib+rheumatoid+arthritis%2C+psoriasis+and+psoriatic+arthritis+development+programmes+and+from+real-world+data&doi=10.1136%2Fannrheumdis-2019-216761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span></div><div class="casAuthors">Mease, Philip; Charles-Schoeman, Christina; Cohen, Stanley; Fallon, Lara; Woolcott, John; Yun, Huifeng; Kremer, Joel; Greenberg, Jeffrey; Malley, Wendi; Onofrei, Alina; Kanik, Keith S.; Graham, Daniela; Wang, Cunshan; Connell, Carol; Valdez, Hernan; Hauben, Manfred; Hung, Eric; Madsen, Ann; Jones, Thomas V.; Curtis, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1400-1413</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO).  Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily vs. those receiving tumor necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib.  Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programs and observational studies.  Data from an ad hoc safety anal. of Study A3921133 are reported sep within.  Methods This post-hoc anal. used data from sep tofacitinib RA, PsO and PsA programs.  Incidence rates (IRs; patients with events per 100 patient-years exposure) were calcd. for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors.  Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analyzed.  Results 12 410 tofacitinib-treated patients from the development programs (RA: n = 7964; PsO: n = 3663; PsA: n = 783) were included.  IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts av. tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectivley, were: DVT (0.17 (0.09-0.27) and 0.15 (0.09-0.22)); PE (0.12 (0.06-0.22) and 0.13 (0.08-0.21)); ATE (0.32 (0.22-0.46) and 0.38 (0.28-0.49)).  IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors.  IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naive/biol. disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs obsd. among the corresponding patients in the tofacitinib development program.  No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.  Conclusions DVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programs were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments.  As expected, IRs of thromboembolic events were elevated in patients with vs without baseline cardiovascular or VTE risk factors, and were broadly consistent with those obsd. in the Study A3921133 ad hoc safety anal. data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32-0.87)), vs patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA program (0.24 (0.13-0.41)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXpWehht-WfbVg90H21EOLACvtfcHk0lgKxnVXOMVyWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN&md5=dc3bb7d3c470a51e397502b1f5a31d28</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216761%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DFallon%26aufirst%3DL.%26aulast%3DWoolcott%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DJ.%26aulast%3DMalley%26aufirst%3DW.%26aulast%3DOnofrei%26aufirst%3DA.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DHauben%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DMadsen%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DT.%2BV.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26atitle%3DIncidence%2520of%2520venous%2520and%2520arterial%2520thromboembolic%2520events%2520reported%2520in%2520the%2520tofacitinib%2520rheumatoid%2520arthritis%252C%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520development%2520programmes%2520and%2520from%2520real-world%2520data%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D1400%26epage%3D1413%26doi%3D10.1136%2Fannrheumdis-2019-216761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol Immunol Infect</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+An+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0lgKxnVXOMVyWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520An%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol%2520Immunol%2520Infect%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebaza, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanchieri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slade, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L.</span></span> <span> </span><span class="NLM_article-title">Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: A systematic review and meta-analysis</span>. <i>medRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.08.10.20172189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.08.10.20172189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32817985" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Walzauthor=A.+J.+Cohenauthor=A.+P.+Rebazaauthor=J.+Vanchieriauthor=M.+D.+Sladeauthor=C.+S.+D.+Cruzauthor=L.+Sharma&title=Janus+kinase-inhibitor+and+type+I+interferon+ability+to+produce+favorable+clinical+outcomes+in+COVID-19+patients%3A+A+systematic+review+and+meta-analysis&doi=10.1101%2F2020.08.10.20172189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1101%2F2020.08.10.20172189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.08.10.20172189%26sid%3Dliteratum%253Aachs%26aulast%3DWalz%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DA.%2BJ.%26aulast%3DRebaza%26aufirst%3DA.%2BP.%26aulast%3DVanchieri%26aufirst%3DJ.%26aulast%3DSlade%26aufirst%3DM.%2BD.%26aulast%3DCruz%26aufirst%3DC.%2BS.%2BD.%26aulast%3DSharma%26aufirst%3DL.%26atitle%3DJanus%2520kinase-inhibitor%2520and%2520type%2520I%2520interferon%2520ability%2520to%2520produce%2520favorable%2520clinical%2520outcomes%2520in%2520COVID-19%2520patients%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DmedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.08.10.20172189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Thanigaimalai Pillaiyar, <span class="NLM_string-name hlFld-ContribAuthor">Stefan Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinases%252Bas%252BPotential%252BTherapeutic%252BTargets%252Bfor%252BAnti-coronaviral%252BTherapy%26aulast%3DPillaiyar%26aufirst%3DThanigaimalai%26date%3D2021%26date%3D2021%26date%3D23022021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. High-throughput screening efforts to repurpose kinase inhibitors as antiviral agents. The numbers in the blue color indicate the size of compound databases used in HTS. The numbers in red color mentioned near chemical structures indicate the literature reference. The kinase target of the identified antiviral leads is mentioned in the parentheses below each structure. Screens a, b, and k used Huh-7/Huh-7.5 cells, screen c used HEK-293, screen d used HFL1 cells, screen e used SNB-19 glioblastoma cells, screen g used A549 cells, screens h–j used Vero E6 cells, and screen l used RD cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Complete list of FDA-approved kinase inhibitors, highlighting the drugs with antiviral effects. Five additional kinase inhibitors <i>viz</i>., apatinib, icotinib, peficitinib, delgocitinib, and leflunomide that are in clinical use are not listed here. Apatinib and icotinib are kinase inhibitors that are approved only in China. Peficitinib and delgocitinib are JAK inhibitors that are approved in Japan for rheumatoid arthritis and atopic dermatitis, respectively. Leflunomide is a FDA approved drug for rheumatoid arthritis which primarily acts via DDODH inhibition; however, it also inhibits tyrosine kinases (fyn and lck). The inhibitors mentioned in blue and green boxes are reported to possess antiviral activity at least in the <i>in vitro</i> system. The inhibitors mentioned in orange are JAK inhibitors that control the cytokine storm in viral infections and thus are potential agents for repurposing in the management of viral infections.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. FDA approved tyrosine kinase inhibitors <b>13, 17–35</b> that exhibit antiviral activity or are used in the management of viral infections. The <i>in vitro</i> kinase inhibition, <i>in vitro</i> antiviral activity, cellular toxicity (CC<sub>50</sub> values), <i>in vivo</i> antiviral activity, and clinical trial (CT) information are shown as brown, black, green, red, and blue colored texts, respectively. All other figures follow a similar color pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. FDA-approved serine-threonine kinase inhibitors <b>36</b>–<b>39</b> that exhibit antiviral activity</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. General life cycle of viruses that are taken up by host cells by endocytosis. The host kinase targets and FDA-approved kinase inhibitors engaging those targets are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Tyrosine kinase inhibitors <b>40</b>–<b>47</b> at the clinical trial stage exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Serine-threonine kinase inhibitors <b>10</b>, <b>11</b>, <b>15</b>, <b>16</b>, and <b>48</b>–<b>59</b> at the clinical trial stage that exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lipid kinase inhibitors <b>12</b>, <b>14</b>, and <b>60–63</b> at the clinical trial stage that exhibit antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Discovery-stage tyrosine kinase inhibitors <b>2</b>, <b>3</b>, <b>9</b>, <b>64</b>–<b>74</b> as antiviral agents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Discovery-stage serine-threonine kinase inhibitors <b>1</b>, <b>4</b>–<b>8</b>, <b>75</b>–<b>91</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/medium/jm0c01467_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Discovery-stage lipid kinase inhibitors <b>92</b>–<b>99</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01467/20210204/images/large/jm0c01467_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01467&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00375" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00375" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 240 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarah, C.</span></span> <span> </span><span class="NLM_article-title">Viral infections: Targeting host kinases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnrd.2017.75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1eisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=314&author=C.+Sarah&title=Viral+infections%3A+Targeting+host+kinases&doi=10.1038%2Fnrd.2017.75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Viral infections Targeting host kinases</span></div><div class="casAuthors">Sarah, Crunkhorn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooBuCth4HdLrVg90H21EOLACvtfcHk0li1iNIVmK4qlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1eisbs%253D&md5=d1fe20b89a9bbb5f2b2296aec1cb295c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.75%26sid%3Dliteratum%253Aachs%26aulast%3DSarah%26aufirst%3DC.%26atitle%3DViral%2520infections%253A%2520Targeting%2520host%2520kinases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D314%26doi%3D10.1038%2Fnrd.2017.75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Infectious disease. Combating emerging viral threats</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1126/science.aaa3778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fscience.aaa3778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25883340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=282-283&author=E.+Bekermanauthor=S.+Einav&title=Infectious+disease.+Combating+emerging+viral+threats&doi=10.1126%2Fscience.aaa3778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Combating emerging viral threats</span></div><div class="casAuthors">Bekerman, Elena; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6232</span>),
    <span class="NLM_cas:pages">282-283</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriDTBlEp8j0LVg90H21EOLACvtfcHk0li1iNIVmK4qlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVKjt7Y%253D&md5=1cf54cc0a7db0925573f96ed72c27c11</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa3778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa3778%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DInfectious%2520disease.%2520Combating%2520emerging%2520viral%2520threats%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D282%26epage%3D283%26doi%3D10.1126%2Fscience.aaa3778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnec, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guivel-Benhassine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chom.2012.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=544-557&author=L.+Meertensauthor=X.+Carnecauthor=M.+P.+Lecoinauthor=R.+Ramdasiauthor=F.+Guivel-Benhassineauthor=E.+Lewauthor=G.+Lemkeauthor=O.+Schwartzauthor=A.+Amara&title=The+TIM+and+TAM+families+of+phosphatidylserine+receptors+mediate+dengue+virus+entry&doi=10.1016%2Fj.chom.2012.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry</span></div><div class="casAuthors">Meertens, Laurent; Carnec, Xavier; Lecoin, Manuel Perera; Ramdasi, Rasika; Guivel-Benhassine, Florence; Lew, Erin; Lemke, Greg; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases.  However, the mol. interactions mediating DV entry are poorly understood.  We detd. that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors.  Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors.  Conversely, DV infection of susceptible cells is inhibited by anti-TIM or anti-TAM antibodies or knockdown of TIM and TAM expression.  TIM receptors facilitate DV entry by directly interacting with virion-assocd. PtdSer.  TAM-mediated infection relies on indirect DV recognition, in which the TAM ligand Gas6 acts as a bridging mol. by binding to PtdSer within the virion.  This dual mode of virus recognition by TIM and TAM receptors reveals how DVs usurp the apoptotic cell clearance pathway for infectious entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYGMhUV8WdLVg90H21EOLACvtfcHk0li1iNIVmK4qlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK&md5=7a00c7dc61dc042960aa302124140818</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DCarnec%26aufirst%3DX.%26aulast%3DLecoin%26aufirst%3DM.%2BP.%26aulast%3DRamdasi%26aufirst%3DR.%26aulast%3DGuivel-Benhassine%26aufirst%3DF.%26aulast%3DLew%26aufirst%3DE.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DThe%2520TIM%2520and%2520TAM%2520families%2520of%2520phosphatidylserine%2520receptors%2520mediate%2520dengue%2520virus%2520entry%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D12%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.chom.2012.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324-333&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.+M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0lj3zM3m2Eo5Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.%2BM.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26epage%3D333%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+implications+for+virus+origins+and+receptor+binding&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0lj3zM3m2Eo5Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520implications%2520for%2520virus%2520origins%2520and%2520receptor%2520binding%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">e1002845</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=e1002845&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0lj3zM3m2Eo5Pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26spage%3De1002845%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AAK1 and GAK regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AAK1+and+GAK+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the μ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0lj8FYikwAywmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAAK1%2520and%2520GAK%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eaXAsXzv7SMNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaescu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenbach, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Interactions between the hepatitis c virus nonstructural 2 protein and host adaptor proteins 1 and 4 orchestrate virus release</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e02233-17</span>, <span class="refDoi"> DOI: 10.1128/mBio.02233-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FmBio.02233-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29535204" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e02233-17&author=F.+Xiaoauthor=S.+Wangauthor=R.+Barouch-Bentovauthor=G.+Neveuauthor=S.+Puauthor=M.+Beerauthor=S.+Schorauthor=S.+Kumarauthor=V.+Nicolaescuauthor=B.+D.+Lindenbachauthor=G.+Randallauthor=S.+Einav&title=Interactions+between+the+hepatitis+c+virus+nonstructural+2+protein+and+host+adaptor+proteins+1+and+4+orchestrate+virus+release&doi=10.1128%2FmBio.02233-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FmBio.02233-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.02233-17%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DPu%26aufirst%3DS.%26aulast%3DBeer%26aufirst%3DM.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DNicolaescu%26aufirst%3DV.%26aulast%3DLindenbach%26aufirst%3DB.%2BD.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DInteractions%2520between%2520the%2520hepatitis%2520c%2520virus%2520nonstructural%25202%2520protein%2520and%2520host%2520adaptor%2520proteins%25201%2520and%25204%2520orchestrate%2520virus%2520release%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De02233-17%26doi%3D10.1128%2FmBio.02233-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amornphimoltham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutkind, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiorini, J. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1038/nm.2145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.2145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20473307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslyqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=662-664&author=M.+L.+Wellerauthor=P.+Amornphimolthamauthor=M.+Schmidtauthor=P.+A.+Wilsonauthor=J.+S.+Gutkindauthor=J.+A.+Chiorini&title=Epidermal+growth+factor+receptor+is+a+co-receptor+for+adeno-associated+virus+serotype+6&doi=10.1038%2Fnm.2145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6</span></div><div class="casAuthors">Weller, Melodie L.; Amornphimoltham, Panomwat; Schmidt, Michael; Wilson, Paul A.; Gutkind, J. Silvio; Chiorini, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-664</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A key step in gene therapy is the efficient transfer of genes in a cell type- and tissue-specific manner.  To better understand the mechanism of adeno-assocd. virus serotype 6 (AAV6) transduction, we used comparative gene anal. (CGA) combined with pathway visualization software to identify a pos. correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression.  Subsequent expts. suggested that EGFR is necessary for vector internalization and probably functions as a co-receptor for AAV6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqIDkYot5n7Vg90H21EOLACvtfcHk0ljfMPnrYYJpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslyqtr4%253D&md5=627160f93b0dc03c4f73dce3e83e0b4f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnm.2145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2145%26sid%3Dliteratum%253Aachs%26aulast%3DWeller%26aufirst%3DM.%2BL.%26aulast%3DAmornphimoltham%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DP.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26aulast%3DChiorini%26aufirst%3DJ.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520is%2520a%2520co-receptor%2520for%2520adeno-associated%2520virus%2520serotype%25206%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D662%26epage%3D664%26doi%3D10.1038%2Fnm.2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huong, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raab-Traub, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.-S.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>424</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1038/nature01818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnature01818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12879076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1aqsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=424&publication_year=2003&pages=456-461&author=X.+Wangauthor=S.-M.+Huongauthor=M.+L.+Chiuauthor=N.+Raab-Traubauthor=E.-S.+Huang&title=Epidermal+growth+factor+receptor+is+a+cellular+receptor+for+human+cytomegalovirus&doi=10.1038%2Fnature01818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus</span></div><div class="casAuthors">Wang, Xin; Huong, Shu-Mei; Chiu, Marie L.; Raab-Traub, Nancy; Huang, Eng-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">424</span>
        (<span class="NLM_cas:issue">6947</span>),
    <span class="NLM_cas:pages">456-461</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) is a widespread opportunistic herpesvirus that causes severe and fatal diseases in immune-compromised individuals, including organ transplant recipients and individuals with AIDS.  It is also a leading cause of virus-assocd. birth defects and is assocd. with atherosclerosis and coronary restenosis.  HCMV initiates infection and intracellular signalling by binding to its cognate cellular receptors and by activating several signalling pathways including those mediated by mitogen-activated protein kinase, phosphatidylinositol-3-OH kinase, interferons, and G proteins.  But a cellular receptor responsible for viral entry and HCMV-induced signalling has yet to be identified.  Here we show that HCMV infects cells by interacting with epidermal growth factor receptor (EGFR) and inducing signalling.  Transfecting EGFR-neg. cells with an EGFR complementary DNA renders non-susceptible cells susceptible to HCMV.  Ligand displacement and crosslinking analyses show that HCMV interacts with EGFR through gB, its principal envelope glycoprotein.  GB preferentially binds EGFR and EGFR-ErbB3 oligomeric mols. in Chinese hamster ovary cells transfected with erbB family cDNAs.  Taken together, these data indicate that EGFR is a necessary component for HCMV-triggered signalling and viral entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkR2hFJXw_C7Vg90H21EOLACvtfcHk0ljfMPnrYYJpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1aqsbk%253D&md5=d907f0bd0db76935021af259ec241795</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnature01818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01818%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DHuong%26aufirst%3DS.-M.%26aulast%3DChiu%26aufirst%3DM.%2BL.%26aulast%3DRaab-Traub%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.-S.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520is%2520a%2520cellular%2520receptor%2520for%2520human%2520cytomegalovirus%26jtitle%3DNature%26date%3D2003%26volume%3D424%26spage%3D456%26epage%3D461%26doi%3D10.1038%2Fnature01818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, J. H.</span></span> <span> </span><span class="NLM_article-title">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2016.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2016.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27215486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=2016&pages=1-12&author=C.+Leeauthor=Y.+Kimauthor=J.+H.+Jeon&title=JNK+and+p38+mitogen-activated+protein+kinase+pathways+contribute+to+porcine+epidemic+diarrhea+virus+infection&doi=10.1016%2Fj.virusres.2016.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">JNK and p38 mitogen-activated protein kinase pathways contribute to porcine epidemic diarrhea virus infection</span></div><div class="casAuthors">Lee, Changhee; Kim, Youngnam; Jeon, Ji Hyun</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways, which are central building blocks in the intracellular signaling network, are often manipulated by viruses of diverse families to favor their replication.  Among the MAPK family, the extracellular signal-regulated kinase (ERK) pathway is known to be modulated during the infection with porcine epidemic diarrhea virus (PEDV); however, involvement of stress-activated protein kinases (SAPKs) comprising p38 MAPK and c-Jun NH2-terminal kinase (JNK) remains to be detd.  Therefore, in the present study, we investigated whether activation of p38 MAPK and JNK cascades is required for PEDV replication.  Our results showed that PEDV activates p38 MAPK and JNK1/2 up to 24 h post-infection, whereas, thereafter their phosphorylation levels recede to baseline levels or even fall below them.  Notably, UV-irradiated inactivated PEDV, which can enter cells but cannot replicate inside them, failed to induce phosphorylation of p38 MAPK and JNK1/2 suggesting that viral biosynthesis is essential for activation of these kinases.  Treatment of cells with selective p38 or JNK inhibitors markedly impaired PEDV replication in a dose-dependent manner and these antiviral effects were found to be maximal during the early times of the infection.  Furthermore, direct pharmacol. inhibition of p38 MAPK or JNK1/2 activation resulted in a significant redn. of viral RNA synthesis, viral protein expression, and progeny release.  However, independent treatments with either SAPK inhibitor did not inhibit PEDV-induced apoptotic cell death mediated by activation of mitochondrial apoptosis-inducing factor (AIF) suggesting that SAPKs are irrelevant to the apoptosis pathway during PEDV infection.  In summary, our data demonstrated crit. roles of the p38 and JNK1/2 signaling pathways in facilitating successful viral infection during the post-entry steps of the PEDV life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFU6UbPFBvXLVg90H21EOLACvtfcHk0ljfMPnrYYJpwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1Shtr4%253D&md5=c0bffb5299069d3fad2a3c1123040b14</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2016.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2016.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DJeon%26aufirst%3DJ.%2BH.%26atitle%3DJNK%2520and%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%2520contribute%2520to%2520porcine%2520epidemic%2520diarrhea%2520virus%2520infection%26jtitle%3DVirus%2520Res.%26date%3D2016%26volume%3D222%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.virusres.2016.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">5937</span>– <span class="NLM_lpage">5948</span>, <span class="refDoi"> DOI: 10.1128/JVI.76.12.5937-5948.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.76.12.5937-5948.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12021326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=5937-5948&author=S.+Banerjeeauthor=K.+Narayananauthor=T.+Mizutaniauthor=S.+Makino&title=Murine+coronavirus+replication-induced+p38+mitogen-activated+protein+kinase+activation+promotes+interleukin-6+production+and+virus+replication+in+cultured+cells&doi=10.1128%2FJVI.76.12.5937-5948.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells</span></div><div class="casAuthors">Banerjee, Sangeeta; Narayanan, Krishna; Mizutani, Tetsuya; Makino, Shinji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5937-5948</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Analyses of mitogen-activated protein kinases (MAPKs) in a mouse hepatitis virus (MHV)-infected macrophage-derived J774.1 cell line showed activation of two MAPKs, p38 MAPK and c-Jun N-terminal kinase (JNK), but not of extracellular signal-regulated kinase (ERK).  Activation of MAPKs was evident by 6 h post-infection.  However, UV-irradiated MHV failed to activate MAPKs, which demonstrated that MHV replication was necessary for their activation.  Several other MHV-permissive cell lines also showed activation of both p38 MAPK and JNK, which indicated that the MHV-induced stress-kinase activation was not restricted to any particular cell type.  The upstream kinase responsible for activating MHV-induced p38 MAPK was the MAPK kinase 3.  Expts. with a specific inhibitor of p38 MAPK, SB 203580, demonstrated that MHV-induced p38 MAPK activation resulted in the accumulation of interleukin-6 (IL-6) mRNAs and an increase in the prodn. of IL-6, regardless of MHV-induced general host protein synthesis inhibition.  Furthermore, MHV prodn. was suppressed in SB 203580-treated cells, demonstrating that activated p38 MAPK played a role in MHV replication.  The reduced MHV prodn. in SB 203580-treated cells was, at least in part, due to a decrease in virus-specific protein synthesis and virus-specific mRNA accumulation.  Interestingly, there was a transient increase in the amt. of phosphorylation of the translation initiation factor 4E (eIF4E) in infected cells, and this eIF4E phosphorylation was p38 MAPK dependent; it is known that phosphorylated eIF4E enhances translation rates of cap-contg. mRNAs.  Furthermore, the upstream kinase responsible for eIF4E phosphorylation, MAPK-interacting kinase 1, was also phosphorylated and activated in response to MHV infection.  Our data suggested that host cells, in response to MHV replication, activated p38 MAPK, which subsequently phosphorylated eIF4E to efficiently translate certain host proteins, including IL-6, during virus-induced severe host protein synthesis inhibition.  MHV utilized this p38 MAPK-dependent increase in eIF4E phosphorylation to promote virus-specific protein synthesis and subsequent progeny virus prodn.  Enhancement of virus-specific protein synthesis through virus-induced eIF4E activation has not been reported in any other viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0BvjYf6qJwrVg90H21EOLACvtfcHk0lhjs0itC5Uu_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlSru7g%253D&md5=a6bbc508aba8194d38d090363792355c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.12.5937-5948.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.12.5937-5948.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DNarayanan%26aufirst%3DK.%26aulast%3DMizutani%26aufirst%3DT.%26aulast%3DMakino%26aufirst%3DS.%26atitle%3DMurine%2520coronavirus%2520replication-induced%2520p38%2520mitogen-activated%2520protein%2520kinase%2520activation%2520promotes%2520interleukin-6%2520production%2520and%2520virus%2520replication%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D5937%26epage%3D5948%26doi%3D10.1128%2FJVI.76.12.5937-5948.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kono, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirasawa, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.10.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2007.10.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18055026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=150-152&author=M.+Konoauthor=K.+Tatsumiauthor=A.+M.+Imaiauthor=K.+Saitoauthor=T.+Kuriyamaauthor=H.+Shirasawa&title=Inhibition+of+human+coronavirus+229E+infection+in+human+epithelial+lung+cells+%28L132%29+by+chloroquine%3A+involvement+of+p38+MAPK+and+ERK&doi=10.1016%2Fj.antiviral.2007.10.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK</span></div><div class="casAuthors">Kono, Masakazu; Tatsumi, Koichiro; Imai, Alberto M.; Saito, Kengo; Kuriyama, Takayuki; Shirasawa, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">150-152</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The antiviral effects of chloroquine (CQ) on human coronavirus 229E (HCoV-229E) infection of human fetal lung cell line, L132 are reported.  CQ significantly decreased the viral replication at concns. lower than in clin. usage.  We demonstrated that CQ affects the activation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK).  Furthermore, p38 MAPK inhibitor, SB203580, inhibits CPE induced by HCoV-229E infection and viral replication.  Our findings suggest that CQ affects the activation of MAPKs, involved in the replication of HCoV-229E.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtCBeEC2erNLVg90H21EOLACvtfcHk0lhjs0itC5Uu_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOlug%253D%253D&md5=33d4220cb47dd09c191e35275adff654</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.10.011%26sid%3Dliteratum%253Aachs%26aulast%3DKono%26aufirst%3DM.%26aulast%3DTatsumi%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DA.%2BM.%26aulast%3DSaito%26aufirst%3DK.%26aulast%3DKuriyama%26aufirst%3DT.%26aulast%3DShirasawa%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520human%2520coronavirus%2520229E%2520infection%2520in%2520human%2520epithelial%2520lung%2520cells%2520%2528L132%2529%2520by%2520chloroquine%253A%2520involvement%2520of%2520p38%2520MAPK%2520and%2520ERK%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D150%26epage%3D152%26doi%3D10.1016%2Fj.antiviral.2007.10.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desforges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozakov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingledine, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6381</span>– <span class="NLM_lpage">6389</span>, <span class="refDoi"> DOI: 10.1128/JVI.00078-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00078-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21507972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6381-6389&author=R.+Cencicauthor=M.+Desforgesauthor=D.+R.+Hallauthor=D.+Kozakovauthor=Y.+Duauthor=J.+Minauthor=R.+Dingledineauthor=H.+Fuauthor=S.+Vajdaauthor=P.+J.+Talbotauthor=J.+Pelletier&title=Blocking+eIF4E-eIF4G+interaction+as+a+strategy+to+impair+coronavirus+replication&doi=10.1128%2FJVI.00078-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication</span></div><div class="casAuthors">Cencic, Regina; Desforges, Marc; Hall, David R.; Kozakov, Dima; Du, Yuhong; Min, Jaeki; Dingledine, Raymond; Fu, Haian; Vajda, Sandor; Talbot, Pierre J.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6381-6389</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses are a family of enveloped single-stranded pos.-sense RNA viruses causing respiratory, enteric, and neurol. diseases in mammals and fowl.  Human coronaviruses are recognized to cause up to a third of common colds and are suspected to be involved in enteric and neurol. diseases.  Coronavirus replication involves the generation of nested subgenomic mRNAs (sgmRNAs) with a common capped 5' leader sequence.  The translation of most of the sgmRNAs is thought to be cap dependent and displays a requirement for eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex needed for the recruitment of 40S ribosomes.  We recently reported on an ultrahigh-throughput screen to discover compds. that inhibit eIF4F activity by blocking the interaction of two of its subunits.  Herein we describe a mol. from this screen that prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation.  This inhibitor significantly decreased human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers.  Our results support the strategy of targeting the eIF4F complex to block coronavirus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmYijWiXmX5LVg90H21EOLACvtfcHk0lhjs0itC5Uu_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbY%253D&md5=2825b0855928a3dbbc53ac015dd55d16</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1128%2FJVI.00078-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00078-11%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DDesforges%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DD.%2BR.%26aulast%3DKozakov%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DVajda%26aufirst%3DS.%26aulast%3DTalbot%26aufirst%3DP.%2BJ.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DBlocking%2520eIF4E-eIF4G%2520interaction%2520as%2520a%2520strategy%2520to%2520impair%2520coronavirus%2520replication%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D6381%26epage%3D6389%26doi%3D10.1128%2FJVI.00078-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0ljU9lAoPVzHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening</span>. <i>Drug Dev. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1002/ddr.20303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fddr.20303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20930947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFCnsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=255-265&author=A.+A.+Kolokoltsovauthor=M.+F.+Saeedauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Identification+of+novel+cellular+targets+for+therapeutic+intervention+against+Ebola+virus+infection+by+siRNA+screening&doi=10.1002%2Fddr.20303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening</span></div><div class="casAuthors">Kolokoltsov, Andrey A.; Saeed, Mohammad F.; Freiberg, Alexander N.; Holbrook, Michael R.; Davey, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">255-265</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">While much progress has been made in developing drugs against a few prominent viruses such as HIV, few examples exist for emerging infectious agents.  In some cases, broad spectrum anti-viral drugs, such as ribavirin, are effective, but for some groups of viruses, these show little efficacy in animal models.  Traditional methods focus on screening small mol. libraries to identify drugs that target virus factors, with the intention that side-effects to the host can be minimized.  However, this greatly limits potential drug targets and virus genes can rapidly mutate to avoid drug action.  Recent advances in siRNA gene-targeting technologies have provided a powerful tool to specifically target and suppress the expression of cell genes.  Since viruses are completely dependent upon host cell proteins for propagation, siRNA screening promises to reveal novel cell proteins and signaling pathways that may be viable targets for drug therapy regimens.  Here, an siRNA screening approach was used to identify gene products that play crit. roles in Ebola virus infection.  By gene cluster anal., proteins in phosphatidylinositol-3-kinase and calcium/calmodulin kinase related networks were identified as important for Zaire Ebola virus infection and prioritized for further evaluation.  The key roles of each were confirmed by testing available drugs specific for members of each pathway.  Interestingly, both sets of proteins are also important in cancer and subject to intense investigation.  Thus, development of new drugs against these cancer targets may also prove useful in combating Ebola virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ERtFFAkQUbVg90H21EOLACvtfcHk0ljU9lAoPVzHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFCnsLg%253D&md5=2a9a5f2d61cf56c511674366144e5014</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fddr.20303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.20303%26sid%3Dliteratum%253Aachs%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DIdentification%2520of%2520novel%2520cellular%2520targets%2520for%2520therapeutic%2520intervention%2520against%2520Ebola%2520virus%2520infection%2520by%2520siRNA%2520screening%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2009%26volume%3D70%26spage%3D255%26epage%3D265%26doi%3D10.1002%2Fddr.20303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabel, G. J.</span></span> <span> </span><span class="NLM_article-title">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1240</span>, <span class="refDoi"> DOI: 10.1128/JVI.01586-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01586-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17108034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2007&pages=1230-1240&author=C.+A.+Zampieriauthor=J.-F.+Fortinauthor=G.+P.+Nolanauthor=G.+J.+Nabel&title=The+ERK+mitogen-activated+protein+kinase+pathway+contributes+to+Ebola+virus+glycoprotein-induced+cytotoxicity&doi=10.1128%2FJVI.01586-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity</span></div><div class="casAuthors">Zampieri, Carisa A.; Fortin, Jean-Francois; Nolan, Garry P.; Nabel, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1230-1240</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Ebola virus is a highly lethal pathogen that causes hemorrhagic fever in humans and nonhuman primates.  Among the seven known viral gene products, the envelope glycoprotein (GP) alone induces cell rounding and detachment that ultimately leads to cell death.  Cellular cytotoxicity is not seen with comparable levels of expression of a mutant form of GP lacking a mucin-like domain (GPΔmuc).  GP-induced cell death is non-apoptotic and is preceded by down-modulation of cell surface mols. involved in signaling pathways, including certain integrins and epidermal growth factor receptor.  To investigate the mechanism of GP-induced cellular toxicity, we analyzed the activation of several signal transduction pathways involved in cell growth and survival.  The active form of extracellular signal-regulated kinases type 1 and 2 (ERK1/2), phospho-ERK1/2, was reduced in cells expressing GP compared to those expressing GPΔmuc as detd. by flow cytometry, in contrast to the case for several other signaling proteins.  Subsequent anal. of the activation states and kinase activities of related kinases revealed a more pronounced effect on the ERK2 kinase isoform.  Disruption of ERK2 activity by a dominant neg. ERK or by small interfering RNA-mediated ERK2 knockdown potentiated the decrease in αV integrin expression assocd. with toxicity.  Conversely, activation of the pathway through the expression of a constitutively active form of ERK2 significantly protected against this effect.  These results indicate that the ERK signaling cascade mediates GP-mediated cytotoxicity and plays a role in pathogenicity induced by this gene product.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb9VqOOhotUrVg90H21EOLACvtfcHk0ljU9lAoPVzHVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCgurs%253D&md5=a5bd3c4731380c3ad2cda2673f9300cb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1128%2FJVI.01586-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01586-06%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DC.%2BA.%26aulast%3DFortin%26aufirst%3DJ.-F.%26aulast%3DNolan%26aufirst%3DG.%2BP.%26aulast%3DNabel%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520ERK%2520mitogen-activated%2520protein%2520kinase%2520pathway%2520contributes%2520to%2520Ebola%2520virus%2520glycoprotein-induced%2520cytotoxicity%26jtitle%3DJ.%2520Virol.%26date%3D2007%26volume%3D81%26spage%3D1230%26epage%3D1240%26doi%3D10.1128%2FJVI.01586-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+Middle+East+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0ljA8pQTkNAbgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520Middle%2520East%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mingo, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">8924</span>– <span class="NLM_lpage">8933</span>, <span class="refDoi"> DOI: 10.1128/JVI.01429-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01429-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27466418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2016&pages=8924-8933&author=C.+M.+Colemanauthor=J.+M.+Siskauthor=R.+M.+Mingoauthor=E.+A.+Nelsonauthor=J.+M.+Whiteauthor=M.+B.+Frieman&title=Abelson+kinase+inhibitors+are+potent+inhibitors+of+severe+acute+respiratory+syndrome+coronavirus+and+middle+east+respiratory+syndrome+coronavirus+fusion&doi=10.1128%2FJVI.01429-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion</span></div><div class="casAuthors">Coleman, Christopher M.; Sisk, Jeanne M.; Mingo, Rebecca M.; Nelson, Elizabeth A.; White, Judith M.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8924-8933</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality.  There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East.  We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro.  Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane.  We specifically identified the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro.  These data demonstrate that specific approved drugs can be characterized in vitro for their anticoronavirus activity and used to identify host proteins required for coronavirus replication.  This type of study is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJU1Zz7G1ED7Vg90H21EOLACvtfcHk0ljA8pQTkNAbgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2lu7fE&md5=090a5b4bb7680982944fc665dfbdc5e5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1128%2FJVI.01429-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01429-16%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DMingo%26aufirst%3DR.%2BM.%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DAbelson%2520kinase%2520inhibitors%2520are%2520potent%2520inhibitors%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%2520and%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520fusion%26jtitle%3DJ.%2520Virol.%26date%3D2016%26volume%3D90%26spage%3D8924%26epage%3D8933%26doi%3D10.1128%2FJVI.01429-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanguez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schading, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3679</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06119-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41467-018-06119-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30206219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3c3nvFWrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3679&author=E.+Yanguezauthor=A.+Hunzikerauthor=M.+P.+Dobayauthor=S.+Yildizauthor=S.+Schadingauthor=E.+Elshinaauthor=U.+Karakusauthor=P.+Gehrigauthor=J.+Grossmannauthor=R.+Dijkmanauthor=M.+Schmolkeauthor=S.+Stertz&title=Phosphoproteomic-based+kinase+profiling+early+in+influenza+virus+infection+identifies+GRK2+as+antiviral+drug+target&doi=10.1038%2Fs41467-018-06119-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span></div><div class="casAuthors">Yanguez Emilio; Hunziker Annika; Schading Simon; Elshina Elizaveta; Karakus Umut; Stertz Silke; Dobay Maria Pamela; Yildiz Soner; Schmolke Mirco; Gehrig Peter; Grossmann Jonas; Dijkman Ronald; Dijkman Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although annual influenza epidemics affect around 10% of the global population, current treatment options are limited and development of new antivirals is needed.  Here, using quantitative phosphoproteomics, we reveal the unique phosphoproteome dynamics that occur in the host cell within minutes of influenza A virus (IAV) infection.  We uncover cellular kinases required for the observed signaling pattern and find that inhibition of selected candidates, such as the G protein-coupled receptor kinase 2 (GRK2), leads to decreased IAV replication.  As GRK2 has emerged as drug target in heart disease, we focus on its role in IAV infection and show that it is required for viral uncoating.  Replication of seasonal and pandemic IAVs is severely decreased by specific GRK2 inhibitors in primary human airway cultures and in mice.  Our study reveals the IAV-induced changes to the cellular phosphoproteome and identifies GRK2 as crucial node of the kinase network that enables IAV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQF382y4lQtoQ8IxFYvehhofW6udTcc2ebEkxnMNMol-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3nvFWrug%253D%253D&md5=67be912cc821f73914ef448ac81356b0</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06119-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06119-y%26sid%3Dliteratum%253Aachs%26aulast%3DYanguez%26aufirst%3DE.%26aulast%3DHunziker%26aufirst%3DA.%26aulast%3DDobay%26aufirst%3DM.%2BP.%26aulast%3DYildiz%26aufirst%3DS.%26aulast%3DSchading%26aufirst%3DS.%26aulast%3DElshina%26aufirst%3DE.%26aulast%3DKarakus%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DP.%26aulast%3DGrossmann%26aufirst%3DJ.%26aulast%3DDijkman%26aufirst%3DR.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DPhosphoproteomic-based%2520kinase%2520profiling%2520early%2520in%2520influenza%2520virus%2520infection%2520identifies%2520GRK2%2520as%2520antiviral%2520drug%2520target%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3679%26doi%3D10.1038%2Fs41467-018-06119-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dorobantu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albulescu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kampen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strating, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Schaar, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuppeveld, F. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of the host lipid landscape to promote RNA virus replication: the picornavirus encephalomyocarditis virus converges on the pathway used by hepatitis C virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e1005185</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1005185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1005185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26406250" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1005185&author=C.+M.+Dorobantuauthor=L.+Albulescuauthor=C.+Harakauthor=Q.+Fengauthor=M.+van+Kampenauthor=J.+R.+Stratingauthor=A.+E.+Gorbalenyaauthor=V.+Lohmannauthor=H.+M.+van+der%0ASchaarauthor=F.+J.+van+Kuppeveld&title=Modulation+of+the+host+lipid+landscape+to+promote+RNA+virus+replication%3A+the+picornavirus+encephalomyocarditis+virus+converges+on+the+pathway+used+by+hepatitis+C+virus&doi=10.1371%2Fjournal.ppat.1005185"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005185%26sid%3Dliteratum%253Aachs%26aulast%3DDorobantu%26aufirst%3DC.%2BM.%26aulast%3DAlbulescu%26aufirst%3DL.%26aulast%3DHarak%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3Dvan%2BKampen%26aufirst%3DM.%26aulast%3DStrating%26aufirst%3DJ.%2BR.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3Dvan%2Bder%2BSchaar%26aufirst%3DH.%2BM.%26aulast%3Dvan%2BKuppeveld%26aufirst%3DF.%2BJ.%26atitle%3DModulation%2520of%2520the%2520host%2520lipid%2520landscape%2520to%2520promote%2520RNA%2520virus%2520replication%253A%2520the%2520picornavirus%2520encephalomyocarditis%2520virus%2520converges%2520on%2520the%2520pathway%2520used%2520by%2520hepatitis%2520C%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2015%26volume%3D11%26spage%3De1005185%26doi%3D10.1371%2Fjournal.ppat.1005185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebhan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Brey, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erfle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaderali, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poenisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankenburg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiet, M.-S.</span></span> <span> </span><span class="NLM_article-title">Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2010.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chom.2010.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21238945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsV2gtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=32-45&author=S.+Reissauthor=I.+Rebhanauthor=P.+Backesauthor=I.+Romero-Breyauthor=H.+Erfleauthor=P.+Matulaauthor=L.+Kaderaliauthor=M.+Poenischauthor=H.+Blankenburgauthor=M.-S.+Hiet&title=Recruitment+and+activation+of+a+lipid+kinase+by+hepatitis+C+virus+NS5A+is+essential+for+integrity+of+the+membranous+replication+compartment&doi=10.1016%2Fj.chom.2010.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment</span></div><div class="casAuthors">Reiss, Simon; Rebhan, Ilka; Backes, Perdita; Romero-Brey, Ines; Erfle, Holger; Matula, Petr; Kaderali, Lars; Poenisch, Marion; Blankenburg, Hagen; Hiet, Marie-Sophie; Longerich, Thomas; Diehl, Sarah; Ramirez, Fidel; Balla, Tamas; Rohr, Karl; Kaul, Artur; Buehler, Sandra; Pepperkok, Rainer; Lengauer, Thomas; Albrecht, Mario; Eils, Roland; Schirmacher, Peter; Lohmann, Volker; Bartenschlager, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major causative agent of chronic liver disease in humans.  To gain insight into host factor requirements for HCV replication, the authors performed an siRNA screen of the human kinome and identified 13 different kinases, including phosphatidylinositol-4 kinase III alpha (PI4KIIIα), as being required for HCV replication.  Consistent with elevated levels of the PI4KIIIα product phosphatidylinositol-4-phosphate (PI4P) detected in HCV-infected cultured hepatocytes and liver tissue from chronic hepatitis C patients, the enzymic activity of PI4KIIIα was crit. for HCV replication.  Viral nonstructural protein 5A (NS5A) was found to interact with PI4KIIIα and stimulate its kinase activity.  The absence of PI4KIIIα activity induced a dramatic change in the ultrastructural morphol. of the membranous HCV replication complex.  This anal. suggests that the direct activation of a lipid kinase by HCV NS5A contributes critically to the integrity of the membranous viral replication complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9z667iG5LHrVg90H21EOLACvtfcHk0lj_3__GjvHu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsV2gtw%253D%253D&md5=3ca6a0b604c8f7379ca3d131e8755054</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2010.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2010.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DReiss%26aufirst%3DS.%26aulast%3DRebhan%26aufirst%3DI.%26aulast%3DBackes%26aufirst%3DP.%26aulast%3DRomero-Brey%26aufirst%3DI.%26aulast%3DErfle%26aufirst%3DH.%26aulast%3DMatula%26aufirst%3DP.%26aulast%3DKaderali%26aufirst%3DL.%26aulast%3DPoenisch%26aufirst%3DM.%26aulast%3DBlankenburg%26aufirst%3DH.%26aulast%3DHiet%26aufirst%3DM.-S.%26atitle%3DRecruitment%2520and%2520activation%2520of%2520a%2520lipid%2520kinase%2520by%2520hepatitis%2520C%2520virus%2520NS5A%2520is%2520essential%2520for%2520integrity%2520of%2520the%2520membranous%2520replication%2520compartment%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2011%26volume%3D9%26spage%3D32%26epage%3D45%26doi%3D10.1016%2Fj.chom.2010.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1080/14740338.2017.1313224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1080%2F14740338.2017.1313224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28387147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=547-559&author=M.+Coirasauthor=J.+Ambrosioniauthor=F.+Cervantesauthor=J.+M.+Mir%C3%B3author=J.+Alcam%C3%AD&title=Tyrosine+kinase+inhibitors%3A+potential+use+and+safety+considerations+in+HIV-1+infection&doi=10.1080%2F14740338.2017.1313224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span></div><div class="casAuthors">Coiras, Mayte; Ambrosioni, Juan; Cervantes, Francisco; Miro, Jose M.; Alcami, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-559</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism.  New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection.: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection.  These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia.  The most relevant papers have been selected and commented.: The family of TKIs are directed against the activation of tyrosine kinases from the Src family.  Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1.  During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not.  Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBdl_4AHijwrVg90H21EOLACvtfcHk0lj_3__GjvHu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D&md5=5976725b6d26c627218be0207febd954</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1080%2F14740338.2017.1313224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2017.1313224%26sid%3Dliteratum%253Aachs%26aulast%3DCoiras%26aufirst%3DM.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520potential%2520use%2520and%2520safety%2520considerations%2520in%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2017%26volume%3D16%26spage%3D547%26epage%3D559%26doi%3D10.1080%2F14740338.2017.1313224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddukuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics</span>. <i>Curr. HIV Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.2174/1570162033485339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F1570162033485339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15043199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2003&pages=131-152&author=C.+de%0Ala+Fuenteauthor=A.+Maddukuriauthor=K.+Kehnauthor=S.+Baylorauthor=L.+Dengauthor=A.+Pumferyauthor=F.+Kashanchi&title=Pharmacological+cyclin-dependent+kinase+inhibitors+as+HIV-1+antiviral+therapeutics&doi=10.2174%2F1570162033485339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics</span></div><div class="casAuthors">de la Fuente, Cynthia; Maddukuri, Anil; Kehn, Kylene; Baylor, Shanese Y.; Deng, Longwen; Pumfery, Anne; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Current HIV Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-152</span>CODEN:
                <span class="NLM_cas:coden">CHRUBF</span>;
        ISSN:<span class="NLM_cas:issn">1570-162X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human immunodeficiency virus type 1 (HIV-1) can infect quiescent cells; however, viral prodn. is restricted to actively proliferating cells.  Recent evidence has indicated that HIV-1 viral proteins, Vpr and Tat, perturb the cell cycle to optimize HIV-1 replication.  Vpr arrests the cell cycle at G2 by inactivating the cyclin B/cdk1 complex.  Tat regulates the cell cycle by altering factors involved in proliferation and differentiation (i.e. the cdk inhibitor p21/waf1) and assocg. with cyclin/cdk complexes (i.e. cyclin E/cdk2, cyclin H/cdk7, and cyclin T/cdk9).  These studies indicate the importance of host cellular factors, such as cyclin/cdk complexes, in regulating HIV-1 replication and therefore represent novel targets for antiviral therapeutics.  Recently, the efficacy of pharmalogical cdk inhibitors (PCIs) in abrogating viral replication has been under development.  To date there are 25-30 PCIs that have been synthesized against known cdks, several of which have been shown to inhibit HIV-1 and other AIDS-assocd. viruses in vitro and in vivo.  Targeting these crit. cyclin/cdk complexes needed for viral propagation may solve the problems inherent in current HAART therapy, including the emergence of drug-resistant viruses.  Thus, PCIs have the potential to become novel therapeutic antiviral drugs that can inhibit HIV-1 transcription and opens the possibility of new avenues of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTg2I_nNlevbVg90H21EOLACvtfcHk0lj_3__GjvHu9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit1WgsLc%253D&md5=b4adf0a50049e89da64e1d4a374031c2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F1570162033485339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570162033485339%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DC.%26aulast%3DMaddukuri%26aufirst%3DA.%26aulast%3DKehn%26aufirst%3DK.%26aulast%3DBaylor%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DPharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520as%2520HIV-1%2520antiviral%2520therapeutics%26jtitle%3DCurr.%2520HIV%2520Res.%26date%3D2003%26volume%3D1%26spage%3D131%26epage%3D152%26doi%3D10.2174%2F1570162033485339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases as cellular targets for antiviral drugs</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1093/jac/dkf227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdkf227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12460995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2002&pages=779-792&author=L.+M.+Schang&title=Cyclin-dependent+kinases+as+cellular+targets+for+antiviral+drugs&doi=10.1093%2Fjac%2Fdkf227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases as cellular targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-792</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (cdks) are required for replication of viruses that replicate only in dividing cells, such as adeno- and papillomaviruses.  Recently, cdks have been shown to be required also for replication of viruses that can replicate in non-dividing cells, such as HIV-1 and herpes simplex virus types 1 and 2 (HSV-1 and -2).  In these expts., pharmacol. cdk inhibitors (PCIs) were shown to have potent antiviral activity in vitro against HIV-1, HSV-1 and -2, human cytomegalovirus, varicella-zoster virus, and to inhibit specific functions of other viruses.  Since two PCIs, flavopiridol and roscovitine, are proving to be non-toxic in human clin. trials against cancer, PCIs may be useful as antivirals.  As significant advantages, PCIs are active in vitro against many viruses, including drug-resistant strains of HIV-1 and HSV-1, and mutant strains of HIV-1 or HSV-1 resistant to PCIs have not been identified in spite of intense efforts.  Furthermore, the antiviral effects of a PCI and a conventional antiviral drug are additive.  The etiopathogenesis of several diseases, such as Kaposi's sarcoma, HPV-induced cervical carcinoma and HIV-assocd. nephropathy (HIVAN), among others, includes replication or expression of proteins by viruses that require cdks.  Thus, PCIs could target both the etiol. agent (the virus) and the pathogenic mechanisms (cell replication).  Two important questions regarding the antiviral activities of PCIs are the focus of current research efforts, (i) the identity of the specific cdks that mediate the antiviral activities of PCIs, and (ii) whether PCIs have antiviral activity in vivo at non-toxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw9wi9L1YWErVg90H21EOLACvtfcHk0ljXNMot-dPNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptlOisb8%253D&md5=d82217067f547370d4d3e8e692da0e43</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkf227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkf227%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DCyclin-dependent%2520kinases%2520as%2520cellular%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2002%26volume%3D50%26spage%3D779%26epage%3D792%26doi%3D10.1093%2Fjac%2Fdkf227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1697</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbapap.2003.11.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15023361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=197-209&author=L.+M.+Schang&title=Effects+of+pharmacological+cyclin-dependent+kinase+inhibitors+on+viral+transcription+and+replication&doi=10.1016%2Fj.bbapap.2003.11.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">197-209</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Cyclin-dependent kinases (CDKs) are required for replication of adeno-, papilloma- and other viruses that replicate only in dividing cells.  Surprisingly, CDKs are also required for replication of HIV-1, HSV-1, and other viruses that can replicate in nondividing cells.  Since two low-mol. wt. pharmacol. CDK inhibitors (PCIs), flavopiridol (Flavo) and roscovitine (Rosco), appear to be nontoxic in human clin. trials against cancer, these drugs have been proposed as potential antiviral drugs.  Rosco preferentially inhibits CDKs involved in cell cycle regulation (CDK1, 2, and 7) or neuronal functions (CDK5), whereas Flavo preferentially inhibits CDKs involved in cell cycle (CDK1, 2, 4, 7) or transcription (CDK7, and 9).  As potential antivirals, PCIs display several advantages: (i) they are active against many different viruses, including drug-resistant strains of HIV-1 and HSV-1; (ii) PCI-resistant mutants of HIV-1 or HSV-1 have not been identified; and (iii) the antiviral effects of PCIs and conventional antivirals appear to be additive (as expected from drugs that target independent pathways).  Moreover, PCIs target both the etiol. agents (i.e., the virus) and the pathogenic mechanisms (i.e., unrestricted cell division) of the many diseases that include both a CDK-requiring virus and unrestricted cell division (e.g., Kaposi's sarcoma, cervical carcinoma, HIV-assocd. nephropathy-HIVAN).  This is nicely illustrated in a recent study which demonstrated the efficacy of Flavo in a mouse model of HIVAN.  Herein, the authors will review the involvement of CDKs in viral replication and the antiviral properties of the most extensively characterized PCIs, with special emphasis on the mechanisms of inhibition of viral transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1qZrRElz5C7Vg90H21EOLACvtfcHk0ljXNMot-dPNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsL0%253D&md5=43453bb6646be8d728bcc767adaef5c7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.024%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DEffects%2520of%2520pharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520on%2520viral%2520transcription%2520and%2520replication%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D197%26epage%3D209%26doi%3D10.1016%2Fj.bbapap.2003.11.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+cyclin-dependent+kinases+%28CDKs%29+as+novel+targets+for+antiviral+drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0ljXNMot-dPNIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%2520as%2520novel%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M+Schangauthor=M.+R+St.+Vincentauthor=J.+J+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0lhApBaCN8r2eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR%26aulast%3DLacasse%26aufirst%3DJ.%2BJ%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1054/drup.2000.0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1054%2Fdrup.2000.0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11498372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlyhu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2000&pages=83-88&author=L.+Meijer&title=Cyclin-dependent+kinases+inhibitors+as+potential+anticancer%2C+antineurodegenerative%2C+antiviral+and+antiparasitic+agents&doi=10.1054%2Fdrup.2000.0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents</span></div><div class="casAuthors">Meijer, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 45 refs.  Cyclin-dependent kinases (CDKs) play a key role in the cell division cycle, in neuronal functions, in transcription and in apoptosis.  Intensive screening with these kinases as targets has lead to the identification of highly selective and potent small-mol. inhibitors.  Co-crystn. with CDK2 shows that these flat heterocyclic hydrophobic compds. bind through two or three hydrogen bonds with the side chains of two amino acids located in the ATP-binding pocket of the kinase.  These inhibitors are anti-proliferative; they arrest cells in G1 and in G2/M phase.  Furthermore they facilitate or even trigger apoptosis in proliferating cells while they protect neuronal cells and thymocytes from apoptosis.  The potential use of these inhibitors is being extensively evaluated for cancer chemotherapy and also in other therapeutic areas: neurol. (Alzheimer's disease), cardiovascular (restenosis, angiogenesis), nephrol. (glomerulonephritis), parasitol. (Plasmodium, Trypanosoma, Toxoplasma, etc.) and virol. (cytomegalovirus, HIV, herpes virus).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZMVv2fRjR-LVg90H21EOLACvtfcHk0lhApBaCN8r2eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlyhu70%253D&md5=bd8a547eb685d8874330ff8207581bd8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1054%2Fdrup.2000.0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fdrup.2000.0129%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26atitle%3DCyclin-dependent%2520kinases%2520inhibitors%2520as%2520potential%2520anticancer%252C%2520antineurodegenerative%252C%2520antiviral%2520and%2520antiparasitic%2520agents%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2000%26volume%3D3%26spage%3D83%26epage%3D88%26doi%3D10.1054%2Fdrup.2000.0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1586/14787210.4.6.953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1586%2F14787210.4.6.953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17181411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvFGru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=953-956&author=L.+M.+Schang&title=First+demonstration+of+the+effectiveness+of+inhibitors+of+cellular+protein+kinases+in+antiviral+therapy&doi=10.1586%2F14787210.4.6.953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy</span></div><div class="casAuthors">Schang, Luis M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">953-956</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Viral replication and pathogenesis involves many cellular protein kinases, and many specific inhibitors of such kinase have been developed for the treatment of noninfectious diseases.  As expected, such drugs have been repeatedly demonstrated to inhibit viral replication in cultured cells.  Cellular protein kinases have thus been considered for several years as potentially valid targets for antiviral therapy.  However, until recently there was no proof of such activity in vivo.  The three papers discussed herein demonstrate that inhibitors of cellular protein kinases are indeed effective for the treatment of virus-induced disease in animal models and human clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9R2Lm_fQr8bVg90H21EOLACvtfcHk0lhApBaCN8r2eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvFGru78%253D&md5=6564e6af860cf5f1335917339861a78c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1586%2F14787210.4.6.953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14787210.4.6.953%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DFirst%2520demonstration%2520of%2520the%2520effectiveness%2520of%2520inhibitors%2520of%2520cellular%2520protein%2520kinases%2520in%2520antiviral%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2006%26volume%3D4%26spage%3D953%26epage%3D956%26doi%3D10.1586%2F14787210.4.6.953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Torres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Jose, E.</span></span> <span> </span><span class="NLM_article-title">Src tyrosine kinase inhibitors: New perspectives on their immune, antiviral, and senotherapeutic potential</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1011</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffphar.2019.01011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31619990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1011&author=J.+Rivera-Torresauthor=E.+San+Jose&title=Src+tyrosine+kinase+inhibitors%3A+New+perspectives+on+their+immune%2C+antiviral%2C+and+senotherapeutic+potential&doi=10.3389%2Ffphar.2019.01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential</span></div><div class="casAuthors">Rivera-Torres Jose; San Jose Esther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1011</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Deregulated activity of the Src tyrosine kinases leads to malignant transformation.  Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has increased notably due to their beneficial effects.  Dasatinib, a second-generation STKI inhibitor widely studied, proved high efficiency in CML patients resistant to imatinib.  In the last decade STKIs have also been implicated and showed therapeutic potential for the treatment of diverse pathologies other than cancer.  In this regard, we review the properties of STKIs, dasatinib in particular, including its immunomodulatory role.  Similarly, the potential benefits, adverse effects, and safety concerns of these inhibitors regarding viral infections are considered.  Moreover, since life expectancy has increased in the last decades accompanied by age-related morbidity, the reduction of undesirable effects associated to aging has become a powerful therapeutic target.  Here, we comment on the ability of STKIs to alleviate age-associated physical dysfunction and their potential impact in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuB58-0Ghq7mQt-ICR3qNfW6udTcc2ebDuL2n_Rm_eLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D&md5=abb7070b94a2328a1c01559aecbeb7d5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01011%26sid%3Dliteratum%253Aachs%26aulast%3DRivera-Torres%26aufirst%3DJ.%26aulast%3DSan%2BJose%26aufirst%3DE.%26atitle%3DSrc%2520tyrosine%2520kinase%2520inhibitors%253A%2520New%2520perspectives%2520on%2520their%2520immune%252C%2520antiviral%252C%2520and%2520senotherapeutic%2520potential%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1011%26doi%3D10.3389%2Ffphar.2019.01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span> <span> </span><span class="NLM_article-title">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span>. <i>Trends Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">52</span>, <span class="refDoi"> DOI: 10.1016/S1471-4914(02)00010-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS1471-4914%2802%2900010-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12615037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=46-52&author=S.+Ludwigauthor=O.+Planzauthor=S.+Pleschkaauthor=T.+Wolff&title=Influenza-virus-induced+signaling+cascades%3A+targets+for+antiviral+therapy%3F&doi=10.1016%2FS1471-4914%2802%2900010-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza-virus-induced signaling cascades: targets for antiviral therapy?</span></div><div class="casAuthors">Ludwig, Stephan; Planz, Oliver; Pleschka, Stephan; Wolff, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">46-52</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Influenza viruses continue to pose a severe threat worldwide, causing thousands of deaths and an enormous economic loss every year.  The major problem in fighting influenza is the high genetic variability of the virus, resulting in the rapid formation of variants that escape the acquired immunity against previous virus strains, or have resistance to antiviral agents.  Every virus depends on its host cell and, hence, cellular functions that are essential for viral replication might be suitable targets for antiviral therapy.  As a result, intracellular signaling cascades induced by the virus, in particular mitogen-activated protein kinase pathways, have recently come into focus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTupjREwwibVg90H21EOLACvtfcHk0li1Zcp41hc-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhsVWqsrg%253D&md5=0824b4a81b06874f3a8e4964e4737eb8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS1471-4914%2802%2900010-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1471-4914%252802%252900010-2%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26atitle%3DInfluenza-virus-induced%2520signaling%2520cascades%253A%2520targets%2520for%2520antiviral%2520therapy%253F%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D46%26epage%3D52%26doi%3D10.1016%2FS1471-4914%2802%2900010-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2013.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2013.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23603495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=457-468&author=O.+Planz&title=Development+of+cellular+signaling+pathway+inhibitors+as+new+antivirals+against+influenza&doi=10.1016%2Fj.antiviral.2013.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cellular signaling pathway inhibitors as new antivirals against influenza</span></div><div class="casAuthors">Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">457-468</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Influenza virus exploits a no. of cellular signaling pathways during the course of its replication, rendering them potential targets for new therapeutic interventions.  Several preclin. approaches are now focusing on cellular factors or pathways as a means of treating influenza.  By targeting host factors, rather than viral mechanisms, these novel therapies may be effective against multiple virus strains and subtypes, and are less likely to elicit viral drug resistance.  The most promising candidates are inhibitors of intracellular signaling cascades that are essential for virus replication.  This article reviews novel approaches and compds. that target the Raf/MEK/ERK signaling pathway, NF-κB signaling, the PI3K/Akt pathway and the PKC signaling cascade.  Although these new antiviral strategies are still in an early phase of preclin. development, results to date suggest they offer a new approach to the treatment of influenza, supplementing direct-acting antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk82XeTtb077Vg90H21EOLACvtfcHk0li1Zcp41hc-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotlGntbk%253D&md5=51b9a73e0faa5a894c7cef307cda92cd</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520cellular%2520signaling%2520pathway%2520inhibitors%2520as%2520new%2520antivirals%2520against%2520influenza%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D457%26epage%3D468%26doi%3D10.1016%2Fj.antiviral.2013.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meineke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimmelzwaan, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Influenza virus infections and cellular kinases</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">171</span>, <span class="refDoi"> DOI: 10.3390/v11020171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv11020171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=171&author=R.+Meinekeauthor=G.+F.+Rimmelzwaanauthor=H.+Elbahesh&title=Influenza+virus+infections+and+cellular+kinases&doi=10.3390%2Fv11020171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus infections and cellular kinases</span></div><div class="casAuthors">Meineke, Robert; Rimmelzwaan, Guus F.; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Influenza A viruses (IAVs) are a major cause of respiratory illness and are responsible for yearly epidemics assocd. with more than 500,000 annual deaths globally.  Novel IAVs may cause pandemic outbreaks and zoonotic infections with, for example, highly pathogenic avian influenza virus (HPAIV) of the H5N1 and H7N9 subtypes, which pose a threat to public health.  Treatment options are limited and emergence of strains resistant to antiviral drugs jeopardize this even further.  Like all viruses, IAVs depend on host factors for every step of the virus replication cycle.  Host kinases link multiple signaling pathways in respond to a myriad of stimuli, including viral infections.  Their regulation of multiple response networks has justified actively targeting cellular kinases for anti-cancer therapies and immune modulators for decades.  There is a growing vol. of research highlighting the significant role of cellular kinases in regulating IAV infections.  Their functional role is illustrated by the required phosphorylation of several IAV proteins necessary for replication and/or evasion/suppression of the innate immune response.  Identified in the majority of host factor screens, functional studies further support the important role of kinases and their potential as host restriction factors.  PKC, ERK, PI3K and FAK, to name a few, are kinases that regulate viral entry and replication.  Addnl., kinases such as IKK, JNK and p38 MAPK are essential in mediating viral sensor signaling cascades that regulate expression of antiviral chemokines and cytokines.  The feasibility of targeting kinases is steadily moving from bench to clinic and already-approved cancer drugs could potentially be repurposed for treatments of severe IAV infections.  In this review, we will focus on the contribution of cellular kinases to IAV infections and their value as potential therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSc-PzlVOvnrVg90H21EOLACvtfcHk0li1Zcp41hc-YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymtbjI&md5=7f0bed27a7c1bf8ea5c8870c7533f087</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.3390%2Fv11020171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11020171%26sid%3Dliteratum%253Aachs%26aulast%3DMeineke%26aufirst%3DR.%26aulast%3DRimmelzwaan%26aufirst%3DG.%2BF.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DInfluenza%2520virus%2520infections%2520and%2520cellular%2520kinases%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D171%26doi%3D10.3390%2Fv11020171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broad-spectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broad-spectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0lgTApdNrI_R6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0lgTApdNrI_R6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonotto, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardot, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas-Junior, L. H.</span></span> <span> </span><span class="NLM_article-title">Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2471</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002471</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0002471" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24205414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsVentbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2471&author=D.+J.+Cruzauthor=R.+M.+Bonottoauthor=R.+G.+Gomesauthor=C.+T.+da+Silvaauthor=J.+B.+Taniguchiauthor=J.+H.+Noauthor=B.+Lombardotauthor=O.+Schwartzauthor=M.+A.+Hansenauthor=L.+H.+Freitas-Junior&title=Identification+of+novel+compounds+inhibiting+chikungunya+virus-induced+cell+death+by+high+throughput+screening+of+a+kinase+inhibitor+library&doi=10.1371%2Fjournal.pntd.0002471"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library</span></div><div class="casAuthors">Cruz, Deu John M.; Bonotto., Rafaela M.; Gomes, Rafael G. B.; da Silva, Camila T.; Taniguchi, Juliana B.; No, Joo Hwan; Lombardot, Benoit; Schwartz, Olivier; Hansen, Michael A. E.; Freitas, Lucio H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e2471/1-e2471/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Chikungunya virus (CHIKV) is a mosquito-borne arthrogenic alphavirus that causes acute febrile illness in humans accompanied by joint pains and in many cases, persistent arthralgia lasting weeks to years.  The re-emergence of CHIKV has resulted in numerous outbreaks in the eastern hemisphere, and threatens to expand in the foreseeable future.  Unfortunately, no effective treatment is currently available.  The present study reports the use of resazurin in a cell-based high-throughput assay, and an image-based high-content assay to identify and characterize inhibitors of CHIKV-infection in vitro.  CHIKV is a highly cytopathic virus that rapidly kills infected cells.  Thus, cell viability of HuH-7 cells infected with CHIKV in the presence of compds. was detd. by measuring metabolic redn. of resazurin to identify inhibitors of CHIKV-assocd. cell death.  A kinase inhibitor library of 4,000 compds. was screened against CHIKV infection of HuH-7 cells using the resazurin redn. assay, and the cell toxicity was also measured in non-infected cells.  Seventy-two compds. showing ≥50% inhibition property against CHIKV at 10 μM were selected as primary hits.  Four compds. having a benzofuran core scaffold (CND0335, CND0364, CND0366 and CND0415), one pyrrolopyridine (CND0545) and one thiazol-carboxamide (CND3514) inhibited CHIKV-assocd. cell death in a dose-dependent manner, with EC50 values between 2.2 μM and 7.1 μM.  Based on image anal., these 6 hit compds. did not inhibit CHIKV replication in the host cell.  However, CHIKV-infected cells manifested less prominent apoptotic blebs typical of CHIKV cytopathic effect compared with the control infection.  Moreover, treatment with these compds. reduced viral titers in the medium of CHIKV-infected cells by up to 100-fold.  In conclusion, this cell-based high-throughput screening assay using resazurin, combined with the image-based high content assay approach identified compds. against CHIKV having a novel antiviral activity - inhibition of virus-induced CPE - likely by targeting kinases involved in apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa0Hv1LPscxbVg90H21EOLACvtfcHk0lgTApdNrI_R6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsVentbc%253D&md5=c6eef7d6930dd18523ed74770fb75791</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002471&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002471%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DD.%2BJ.%26aulast%3DBonotto%26aufirst%3DR.%2BM.%26aulast%3DGomes%26aufirst%3DR.%2BG.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BT.%26aulast%3DTaniguchi%26aufirst%3DJ.%2BB.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DLombardot%26aufirst%3DB.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DHansen%26aufirst%3DM.%2BA.%26aulast%3DFreitas-Junior%26aufirst%3DL.%2BH.%26atitle%3DIdentification%2520of%2520novel%2520compounds%2520inhibiting%2520chikungunya%2520virus-induced%2520cell%2520death%2520by%2520high%2520throughput%2520screening%2520of%2520a%2520kinase%2520inhibitor%2520library%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2471%26doi%3D10.1371%2Fjournal.pntd.0002471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streblow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defilippis, V. R.</span></span> <span> </span><span class="NLM_article-title">Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1128/JVI.00767-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00767-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20962078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=606-620&author=L.+K.+Whiteauthor=T.+Saliauthor=D.+Alvaradoauthor=E.+Gattiauthor=P.+Pierreauthor=D.+Streblowauthor=V.+R.+Defilippis&title=Chikungunya+virus+induces+IPS-1-dependent+innate+immune+activation+and+protein+kinase+R-independent+translational+shutoff&doi=10.1128%2FJVI.00767-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff</span></div><div class="casAuthors">White, Laura K.; Sali, Tina; Alvarado, David; Gatti, Evelina; Pierre, Philippe; Streblow, Daniel; DeFilippis, Victor R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">606-620</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chikungunya virus (CHIKV) is an arthritogenic mosquito-transmitted alphavirus that is undergoing re-emergence in areas around the Indian Ocean.  Despite the current and potential danger posed by this virus, we know surprisingly little about the induction and evasion of CHIKV-assocd. antiviral immune responses.  With this in mind we investigated innate immune reactions to CHIKV in human fibroblasts, a demonstrable in vivo target of virus replication and spread.  We show that CHIKV infection leads to activation of the transcription factor interferon regulatory factor 3 (IRF3) and subsequent transcription of IRF3-dependent antiviral genes, including beta interferon (IFN-β).  IRF3 activation occurs by way of a virus-induced innate immune signaling pathway that includes the adaptor mol. interferon promoter stimulator 1 (IPS-1).  Despite strong transcriptional upregulation of these genes, however, translation of the corresponding proteins is not obsd.  We further demonstrate that translation of cellular (but not viral) genes is blocked during infection and that although CHIKV is found to trigger inactivation of the translational mol. eukaryotic initiation factor subunit 2α by way of the double-stranded RNA sensor protein kinase R, this response is not required for the block to protein synthesis.  Furthermore, overall diminution of cellular RNA synthesis is also obsd. in the presence of CHIKV and transcription of IRF3-dependent antiviral genes appears specifically blocked late in infection.  We hypothesize that the obsd. absence of IFN-β and antiviral proteins during infection results from an evasion mechanism exhibited by CHIKV that is dependent on widespread shutoff of cellular protein synthesis and a targeted block to late synthesis of antiviral mRNA transcripts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrds1AGp9cI97Vg90H21EOLACvtfcHk0lihmqvwl9jwjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCisrw%253D&md5=dec2018815e86466c4c520b2f2c47ffd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1128%2FJVI.00767-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00767-10%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DL.%2BK.%26aulast%3DSali%26aufirst%3DT.%26aulast%3DAlvarado%26aufirst%3DD.%26aulast%3DGatti%26aufirst%3DE.%26aulast%3DPierre%26aufirst%3DP.%26aulast%3DStreblow%26aufirst%3DD.%26aulast%3DDefilippis%26aufirst%3DV.%2BR.%26atitle%3DChikungunya%2520virus%2520induces%2520IPS-1-dependent%2520innate%2520immune%2520activation%2520and%2520protein%2520kinase%2520R-independent%2520translational%2520shutoff%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D606%26epage%3D620%26doi%3D10.1128%2FJVI.00767-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koishi, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milan Bonotto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">No, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windisch, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona
Mosimann, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Borba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes Duarte dos Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freitas-Junior, L. H.</span></span> <span> </span><span class="NLM_article-title">High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e2073</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0002073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0002073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23437413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlSktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=e2073&author=D.+J.+M.+Cruzauthor=A.+C.+Koishiauthor=J.+B.+Taniguchiauthor=X.+Liauthor=R.+Milan+Bonottoauthor=J.+H.+Noauthor=K.+H.+Kimauthor=S.+Baekauthor=H.+Y.+Kimauthor=M.+P.+Windischauthor=A.+L.+Pamplona%0AMosimannauthor=L.+de+Borbaauthor=M.+Liuzziauthor=M.+A.+E.+Hansenauthor=C.+Nunes+Duarte+dos+Santosauthor=L.+H.+Freitas-Junior&title=High+content+screening+of+a+kinase-focused+library+reveals+compounds+broadly-active+against+dengue+viruses&doi=10.1371%2Fjournal.pntd.0002073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">High content screening of a kinase-focused library reveals compounds broadly-active against dengue viruses</span></div><div class="casAuthors">Cruz, Deu John M.; Koishi, Andrea Cristine; Taniguchi, Juliana Bosso; Li, Xiaolan; Milan Bonotto, Rafaela; No, Joo Hwan; Kim, Keum Hyun; Baek, Sungmin; Kim, Hee Young; Windisch, Marc Peter; Mosimann, Ana Luiza Pamplona; de Borba, Luana; Liuzzi, Michel; Hansen, Michael Adsetts Edberg; Duarte dos Santos, Claudia Nunes; Freitas, Lucio Holanda, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e2073</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that has a large impact in global health.  It is considered as one of the medically important arboviruses, and developing a preventive or therapeutic soln. remains a top priority in the medical and scientific community.  Drug discovery programs for potential dengue antivirals have increased dramatically over the last decade, largely in part to the introduction of high-throughput assays.  In this study, we have developed an image-based dengue high-throughput/high-content assay (HT/HCA) using an innovative computer vision approach to screen a kinase-focused library for anti-dengue compds.  Using this dengue HT/HCA, we identified a group of compds. with a 4-(1-aminoethyl)-N-methylthiazol-2-amine as a common core structure that inhibits dengue viral infection in a human liver-derived cell line (Huh-7.5 cells).  Compds. CND1201, CND1203 and CND1243 exhibited strong antiviral activities against all four dengue serotypes.  Plaque redn. and time-of-addn. assays suggests that these compds. interfere with the late stage of viral infection cycle.  These findings demonstrate that our image-based dengue HT/HCA is a reliable tool that can be used to screen various chem. libraries for potential dengue antiviral candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRQ5DwXVJ77rVg90H21EOLACvtfcHk0lihmqvwl9jwjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlSktrg%253D&md5=15cc205a49dce6b94d44d9a6ff3a5de9</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0002073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0002073%26sid%3Dliteratum%253Aachs%26aulast%3DCruz%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DKoishi%26aufirst%3DA.%2BC.%26aulast%3DTaniguchi%26aufirst%3DJ.%2BB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMilan%2BBonotto%26aufirst%3DR.%26aulast%3DNo%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBaek%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DWindisch%26aufirst%3DM.%2BP.%26aulast%3DPamplona%2BMosimann%26aufirst%3DA.%2BL.%26aulast%3Dde%2BBorba%26aufirst%3DL.%26aulast%3DLiuzzi%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DM.%2BA.%2BE.%26aulast%3DNunes%2BDuarte%2Bdos%2BSantos%26aufirst%3DC.%26aulast%3DFreitas-Junior%26aufirst%3DL.%2BH.%26atitle%3DHigh%2520content%2520screening%2520of%2520a%2520kinase-focused%2520library%2520reveals%2520compounds%2520broadly-active%2520against%2520dengue%2520viruses%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2013%26volume%3D7%26spage%3De2073%26doi%3D10.1371%2Fjournal.pntd.0002073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhinder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Früh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djaballah, H.</span></span> <span> </span><span class="NLM_article-title">High-content assay to identify inhibitors of dengue virus infection</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1089/adt.2010.0321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fadt.2010.0321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20973722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlensLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=553-570&author=D.+Shumauthor=J.+L.+Smithauthor=A.+J.+Hirschauthor=B.+Bhinderauthor=C.+Raduauthor=D.+A.+Steinauthor=J.+A.+Nelsonauthor=K.+Fr%C3%BChauthor=H.+Djaballah&title=High-content+assay+to+identify+inhibitors+of+dengue+virus+infection&doi=10.1089%2Fadt.2010.0321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">High-Content Assay to Identify Inhibitors of Dengue Virus Infection</span></div><div class="casAuthors">Shum, David; Smith, Jessica L.; Hirsch, Alec J.; Bhinder, Bhavneet; Radu, Constantin; Stein, David A.; Nelson, Jay A.; Frueh, Klaus; Djaballah, Hakim</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-570</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Dengue virus (DENV) infections are vectored by mosquitoes and constitute one of the most prevalent infectious diseases in many parts of the world, affecting millions of people annually.  Current treatments for DENV infections are nonspecific and largely ineffective.  In this study, we describe the adaptation of a high-content cell-based assay for screening against DENV-infected cells to identify inhibitors and modulators of DENV infection.  Using this high-content approach, we monitored the inhibition of test compds. on DENV protein prodn. by means of immunofluorescence staining of DENV glycoprotein envelope, simultaneously evaluating cytotoxicity in HEK293 cells.  The adapted 384-well microtiter-based assay was validated using a small panel of compds. previously reported as having inhibitory activity against DENV infections of cell cultures, including compds. with antiviral activity (ribavirin), inhibitors of cellular signaling pathways (U0126), and polysaccharides that are presumed to interfere with virus attachment (carrageenan).  A screen was performed against a collection of 5,632 well-characterized bioactives, including U.S.  Food and Drug Administration-approved drugs.  Assay control statistics show an av. Z' of 0.63, indicative of a robust assay in this cell-based format.  Using a threshold of >80% DENV inhibition with <20% cellular cytotoxicity, 79 compds. were initially scored as pos. hits.  A follow-up screen confirmed 73 compds. with IC50 potencies ranging from 60 nM to 9 μM and yielding a hit rate of 1.3%.  Over half of the confirmed hits are known to target transporters, receptors, and protein kinases, providing potential opportunity for drug repurposing to treat DENV infections.  In summary, this assay offers the opportunity to screen libraries of chem. compds., in an effort to identify and develop novel drug candidates against DENV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4SAeXBIEKdrVg90H21EOLACvtfcHk0lihmqvwl9jwjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlensLnK&md5=12e918bb02e9660011cc03e0f170450d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1089%2Fadt.2010.0321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2010.0321%26sid%3Dliteratum%253Aachs%26aulast%3DShum%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26aulast%3DHirsch%26aufirst%3DA.%2BJ.%26aulast%3DBhinder%26aufirst%3DB.%26aulast%3DRadu%26aufirst%3DC.%26aulast%3DStein%26aufirst%3DD.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26aulast%3DFr%25C3%25BCh%26aufirst%3DK.%26aulast%3DDjaballah%26aufirst%3DH.%26atitle%3DHigh-content%2520assay%2520to%2520identify%2520inhibitors%2520of%2520dengue%2520virus%2520infection%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2010%26volume%3D8%26spage%3D553%26epage%3D570%26doi%3D10.1089%2Fadt.2010.0321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viegas, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abreu, P. A.</span></span> <span> </span><span class="NLM_article-title">Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">104621</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104621</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104621" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31634495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrsbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2019&pages=104621&author=D.+J.+Viegasauthor=T.+G.+Edwardsauthor=D.+C.+Bloomauthor=P.+A.+Abreu&title=Virtual+screening+identified+compounds+that+bind+to+cyclin+dependent+kinase+2+and+prevent+herpes+simplex+virus+type+1+replication+and+reactivation+in+neurons&doi=10.1016%2Fj.antiviral.2019.104621"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons</span></div><div class="casAuthors">Viegas, Daiane J.; Edwards, Terri G.; Bloom, David C.; Abreu, Paula A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104621</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HSV-1 is one of the most prevalent viruses worldwide, and due to the limited therapies mainly with acyclovir and analogs and the emergence of acyclovir (ACV) resistant strains, the search for new drugs with different modes of action is needed.  This study identified compds. that bind in silico to cyclin dependent kinase 2 (CDK2), a cellular enzyme required for efficient HSV-1 replication, and have anti-HSV-1 activity.  Compds. obtained from virtual screening by Pharmit were filtered in FAF-Drugs4 for good pharmacokinetic and toxicol. profiles and submitted to mol. docking on CDK2 using Autodock Vina.  The six most promising compds. were evaluated for inhibiting lytic replication of HSV-1 wild-type and ACV-resistant strains on human fibroblasts.  The compds. were also assayed for cytotoxicity.  Compds. 1, 2 and 3 showed antiviral activity with EC50 (50% of effective drug concn.) of 32, 29 and 64μM and CC50 (50% of cytotoxic concn.) of 159, 1410 and 2044μM, resp.  Compds. 1 and 2 were also active against ACV resistant strains and compd. 3 inhibited the reactivation of HSV-1 in neurons, which is an important finding to guide drug design of new anti-HSV-1 antivirals with different modes of action.  These compds. are promising candidates for optimization into more potent agents to treat HSV-1 infections and recurrences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dRyfoHYEb7Vg90H21EOLACvtfcHk0lihC44n_aBxQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrsbfP&md5=4266502f994c2a88e52581049e049cc7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104621%26sid%3Dliteratum%253Aachs%26aulast%3DViegas%26aufirst%3DD.%2BJ.%26aulast%3DEdwards%26aufirst%3DT.%2BG.%26aulast%3DBloom%26aufirst%3DD.%2BC.%26aulast%3DAbreu%26aufirst%3DP.%2BA.%26atitle%3DVirtual%2520screening%2520identified%2520compounds%2520that%2520bind%2520to%2520cyclin%2520dependent%2520kinase%25202%2520and%2520prevent%2520herpes%2520simplex%2520virus%2520type%25201%2520replication%2520and%2520reactivation%2520in%2520neurons%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D172%26spage%3D104621%26doi%3D10.1016%2Fj.antiviral.2019.104621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.+K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.+L.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of ∼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0lihC44n_aBxQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%2BK.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.%2BL.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emert-Sedlak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithgall, T. E.</span></span> <span> </span><span class="NLM_article-title">Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1021/cb900195c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb900195c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlWmurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=939-947&author=L.+Emert-Sedlakauthor=T.+Kodamaauthor=E.+C.+Lernerauthor=W.+Daiauthor=C.+Fosterauthor=B.+W.+Dayauthor=J.+S.+Lazoauthor=T.+E.+Smithgall&title=Chemical+library+screens+targeting+an+HIV-1+accessory+factor%2Fhost+cell+kinase+complex+identify+novel+antiretroviral+compounds&doi=10.1021%2Fcb900195c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Library Screens Targeting an HIV-1 Accessory Factor/Host Cell Kinase Complex Identify Novel Antiretroviral Compounds</span></div><div class="casAuthors">Emert-Sedlak, Lori; Kodama, Toshiaki; Lerner, Edwina C.; Dai, Weixiang; Foster, Caleb; Day, Billy W.; Lazo, John S.; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">939-947</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nef is an HIV-1 accessory protein essential for AIDS progression and an attractive target for drug discovery.  Lack of a catalytic function makes Nef difficult to assay in chem. library screens.  We developed a high-throughput screening assay for inhibitors of Nef function by coupling it to one of its host cell binding partners, the Src-family kinase Hck.  Hck activation is dependent upon Nef in this assay, providing a direct readout of Nef activity in vitro.  Using this screen, a unique diphenylfuropyrimidine was identified as a strong inhibitor of Nef-dependent Hck activation.  This compd. also exhibited remarkable antiretroviral effects, blocking Nef-dependent HIV replication in cell culture.  Structurally related analogs were synthesized and shown to exhibit similar Nef-dependent antiviral activity, identifying the diphenylfuropyrimidine substructure as a new lead for antiretroviral drug development.  This study demonstrates that coupling noncatalytic HIV accessory factors with host cell target proteins addressable by high-throughput assays may afford new avenues for the discovery of anti-HIV agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2YEk6ygTwPrVg90H21EOLACvtfcHk0lihC44n_aBxQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlWmurvJ&md5=53140299c379a88c02ac9c9c4a7c138b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fcb900195c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb900195c%26sid%3Dliteratum%253Aachs%26aulast%3DEmert-Sedlak%26aufirst%3DL.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DLerner%26aufirst%3DE.%2BC.%26aulast%3DDai%26aufirst%3DW.%26aulast%3DFoster%26aufirst%3DC.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DChemical%2520library%2520screens%2520targeting%2520an%2520HIV-1%2520accessory%2520factor%252Fhost%2520cell%2520kinase%2520complex%2520identify%2520novel%2520antiretroviral%2520compounds%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2009%26volume%3D4%26spage%3D939%26epage%3D947%26doi%3D10.1021%2Fcb900195c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emert-Sedlak, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narute, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanamala, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithgall, T. E.</span></span> <span> </span><span class="NLM_article-title">Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2012.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23352142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=82-91&author=L.+A.+Emert-Sedlakauthor=P.+Naruteauthor=S.+T.+Shuauthor=J.+A.+Poeauthor=H.+Shiauthor=N.+Yanamalaauthor=J.+J.+Alvaradoauthor=J.+S.+Lazoauthor=J.+I.+Yehauthor=P.+A.+Johnstonauthor=T.+E.+Smithgall&title=Effector+kinase+coupling+enables+high-throughput+screens+for+direct+HIV-1+Nef+antagonists+with+antiretroviral+activity&doi=10.1016%2Fj.chembiol.2012.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effector Kinase Coupling Enables High-Throughput Screens for Direct HIV-1 Nef Antagonists with Antiretroviral Activity</span></div><div class="casAuthors">Emert-Sedlak, Lori A.; Narute, Purushottam; Shu, Sherry T.; Poe, Jerrod A.; Shi, Haibin; Yanamala, Naveena; Alvarado, John Jeff; Lazo, John S.; Yeh, Joanne I.; Johnston, Paul A.; Smithgall, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">HIV-1 Nef, a crit. AIDS progression factor, represents an important target protein for antiretroviral drug discovery.  Because Nef lacks intrinsic enzymic activity, we developed an assay that couples Nef to the activation of Hck, a Src family member and .  Using this assay, we screened a large, diverse chem. library and identified small mols. that block Nef-dependent Hck activity with low micromolar potency.  Of these, a diphenylpyrazolo compd. demonstrated submicromolar potency in HIV-1 replication assays against a broad range of primary Nef variants.  This compd. binds directly to Nef via a pocket formed by the Nef dimerization interface and disrupts Nef dimerization in cells.  Coupling of nonenzymic viral accessory factors to host cell effector proteins amenable to high-throughput screening may represent a general strategy for the discovery of new antimicrobial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BIbLPKgxrLVg90H21EOLACvtfcHk0lghjhgipyGc_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eguro%253D&md5=5bf45fa525e60bc84cf23d1615e6be93</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DEmert-Sedlak%26aufirst%3DL.%2BA.%26aulast%3DNarute%26aufirst%3DP.%26aulast%3DShu%26aufirst%3DS.%2BT.%26aulast%3DPoe%26aufirst%3DJ.%2BA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYanamala%26aufirst%3DN.%26aulast%3DAlvarado%26aufirst%3DJ.%2BJ.%26aulast%3DLazo%26aufirst%3DJ.%2BS.%26aulast%3DYeh%26aufirst%3DJ.%2BI.%26aulast%3DJohnston%26aufirst%3DP.%2BA.%26aulast%3DSmithgall%26aufirst%3DT.%2BE.%26atitle%3DEffector%2520kinase%2520coupling%2520enables%2520high-throughput%2520screens%2520for%2520direct%2520HIV-1%2520Nef%2520antagonists%2520with%2520antiretroviral%2520activity%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.chembiol.2012.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+influenza+a+virus+replication&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0lghjhgipyGc_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520influenza%2520a%2520virus%2520replication%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Sancho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgstaller-Muehlbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pache, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesus, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Sobrido, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. K.</span></span> <span> </span><span class="NLM_article-title">A large-scale drug repositioning survey for SARS-CoV-2 antivirals</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.04.16.044016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.04.16.044016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32511357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Rivaauthor=S.+Yuanauthor=X.+Yinauthor=L.+Martin-Sanchoauthor=N.+Matsunagaauthor=S.+Burgstaller-Muehlbacherauthor=L.+Pacheauthor=P.+P.+De+Jesusauthor=M.+V.+Hullauthor=M.+Changauthor=J.+F.+Chanauthor=J.+Caoauthor=V.+K.+Poonauthor=K.+Herbertauthor=T.+T.+Nguyenauthor=Y.+Puauthor=C.+Nguyenauthor=A.+Rubanovauthor=L.+Martinez-Sobridoauthor=W.+C.+Liuauthor=L.+Miorinauthor=K.+M.+Whiteauthor=J.+R.+Johnsonauthor=C.+Bennerauthor=R.+Sunauthor=P.+G.+Schultzauthor=A.+Suauthor=A.+Garcia-Sastreauthor=A.+K.+Chatterjeeauthor=K.+Y.+Yuenauthor=S.+K.+Chanda&title=A+large-scale+drug+repositioning+survey+for+SARS-CoV-2+antivirals&doi=10.1101%2F2020.04.16.044016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1101%2F2020.04.16.044016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.16.044016%26sid%3Dliteratum%253Aachs%26aulast%3DRiva%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DMartin-Sancho%26aufirst%3DL.%26aulast%3DMatsunaga%26aufirst%3DN.%26aulast%3DBurgstaller-Muehlbacher%26aufirst%3DS.%26aulast%3DPache%26aufirst%3DL.%26aulast%3DDe%2BJesus%26aufirst%3DP.%2BP.%26aulast%3DHull%26aufirst%3DM.%2BV.%26aulast%3DChang%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DJ.%2BF.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DV.%2BK.%26aulast%3DHerbert%26aufirst%3DK.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPu%26aufirst%3DY.%26aulast%3DNguyen%26aufirst%3DC.%26aulast%3DRubanov%26aufirst%3DA.%26aulast%3DMartinez-Sobrido%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%2BC.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DBenner%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26aulast%3DSu%26aufirst%3DA.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DChanda%26aufirst%3DS.%2BK.%26atitle%3DA%2520large-scale%2520drug%2520repositioning%2520survey%2520for%2520SARS-CoV-2%2520antivirals%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.16.044016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugaswami, V.</span></span> <span> </span><span class="NLM_article-title">Antiviral drug screen of kinase inhibitors identifies cellular signaling pathways critical for SARS-COV-2 replication</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.06.24.150326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.06.24.150326" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Garciaauthor=A.+Sharmaauthor=A.+Ramaiahauthor=C.+Senauthor=D.+Kohnauthor=B.+Gompertsauthor=C.+N.+Svendsenauthor=R.+D.+Damoiseauxauthor=V.+Arumugaswami&title=Antiviral+drug+screen+of+kinase+inhibitors+identifies+cellular+signaling+pathways+critical+for+SARS-COV-2+replication&doi=10.1101%2F2020.06.24.150326"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1101%2F2020.06.24.150326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.06.24.150326%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DRamaiah%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DC.%26aulast%3DKohn%26aufirst%3DD.%26aulast%3DGomperts%26aufirst%3DB.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DDamoiseaux%26aufirst%3DR.%2BD.%26aulast%3DArumugaswami%26aufirst%3DV.%26atitle%3DAntiviral%2520drug%2520screen%2520of%2520kinase%2520inhibitors%2520identifies%2520cellular%2520signaling%2520pathways%2520critical%2520for%2520SARS-COV-2%2520replication%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.06.24.150326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirabelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotring, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarty, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fursmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadambi, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pretto, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alysandratos, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handelman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wobus, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherwax, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mashour, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, J. Z.</span></span> <span> </span><span class="NLM_article-title">Morphological cell profiling of SARS-COV-2 infection identifies drug repurposing candidates for COVID-19</span>. <i>BioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.27.117184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.05.27.117184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32577649" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Mirabelliauthor=J.+W.+Wotringauthor=C.+J.+Zhangauthor=S.+M.+McCartyauthor=R.+Fursmidtauthor=T.+Frumauthor=N.+S.+Kadambiauthor=A.+T.+Aminauthor=T.+R.+O%E2%80%99Mearaauthor=C.+D.+Prettoauthor=J.+R.+Spenceauthor=J.+Huangauthor=K.+D.+Alysandratosauthor=D.+N.+Kottonauthor=S.+K.+Handelmanauthor=C.+E.+Wobusauthor=K.+J.+Weatherwaxauthor=G.+A.+Mashourauthor=M.+J.+O%E2%80%99Mearaauthor=J.+Z.+Sexton&title=Morphological+cell+profiling+of+SARS-COV-2+infection+identifies+drug+repurposing+candidates+for+COVID-19&doi=10.1101%2F2020.05.27.117184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1101%2F2020.05.27.117184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.27.117184%26sid%3Dliteratum%253Aachs%26aulast%3DMirabelli%26aufirst%3DC.%26aulast%3DWotring%26aufirst%3DJ.%2BW.%26aulast%3DZhang%26aufirst%3DC.%2BJ.%26aulast%3DMcCarty%26aufirst%3DS.%2BM.%26aulast%3DFursmidt%26aufirst%3DR.%26aulast%3DFrum%26aufirst%3DT.%26aulast%3DKadambi%26aufirst%3DN.%2BS.%26aulast%3DAmin%26aufirst%3DA.%2BT.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DT.%2BR.%26aulast%3DPretto%26aufirst%3DC.%2BD.%26aulast%3DSpence%26aufirst%3DJ.%2BR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DAlysandratos%26aufirst%3DK.%2BD.%26aulast%3DKotton%26aufirst%3DD.%2BN.%26aulast%3DHandelman%26aufirst%3DS.%2BK.%26aulast%3DWobus%26aufirst%3DC.%2BE.%26aulast%3DWeatherwax%26aufirst%3DK.%2BJ.%26aulast%3DMashour%26aufirst%3DG.%2BA.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DSexton%26aufirst%3DJ.%2BZ.%26atitle%3DMorphological%2520cell%2520profiling%2520of%2520SARS-COV-2%2520infection%2520identifies%2520drug%2520repurposing%2520candidates%2520for%2520COVID-19%26jtitle%3DBioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.27.117184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yogarajah, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span> <span> </span><span class="NLM_article-title">Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8159</span>, <span class="refDoi"> DOI: 10.1038/s41598-020-65152-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41598-020-65152-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32424333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsl2ms7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=8159&author=J.+Sunauthor=T.+Yogarajahauthor=R.+C.+H.+Leeauthor=P.+Kaurauthor=M.+Inoueauthor=Y.+W.+Tanauthor=J.+J.+H.+Chu&title=Drug+repurposing+of+pyrimidine+analogs+as+potent+antiviral+compounds+against+human+enterovirus+A71+infection+with+potential+clinical+applications&doi=10.1038%2Fs41598-020-65152-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications</span></div><div class="casAuthors">Sun, Jialei; Yogarajah, Thinesshwary; Lee, Regina Ching Hua; Kaur, Parveen; Inoue, Masafumi; Tan, Yong Wah; Chu, Justin Jang Hann</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8159</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: EV-A71 is one of the etiol. agents for the HFMD in young children and a potential cause of neurol. complications in afflicted patients.  Since its discovery in 1969, there remains no approved antiviral for EV-A71 and other HFMD-causing enteroviruses.  Gemcitabine and other nucleoside analogs, LY2334737 and sofosbuvir inhibition of EV-A71 infection were disclosed using mol. and proteomic quantification, and in vitro and in vivo efficacy evaluation.  Gemcitabine displayed a significant redn. of infectious EV-A71 titers by 2.5 logs PFU/mL and was shown to target the early stage of EV-A71 viral RNA and viral protein synthesis process esp. via inhibition of the RNA dependent RNA polymerase.  In addn., the drug combination study of gemcitabine's synergistic effects with interferon-β at 1:1 and 1:2 ratio enhanced inhibition against EV-A71 replication.  Since gemcitabine is known to metabolize rapidly in vivo, other nucleoside analogs, LY2334737 and sofosbuvir conferred protection in mice against lethal EV-A71 challenge by potentially reducing the death rate, viral titers as well on virus-induced pathol. in the limb muscle tissue of mice.  Addnl., we found that gemcitabine is competent to inhibit other pos.-sense RNA viruses of the Flaviviridae family.  Overall, these drugs provide new insights into targeting viral factors as a broad-spectrum antiviral strategy with potential therapeutic value for future development and are worthy of potential clin. application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSfyTG5b8CO7Vg90H21EOLACvtfcHk0lgtruv68VFb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsl2ms7k%253D&md5=8b84654e33a7450db30468b4013f5d87</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fs41598-020-65152-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-020-65152-4%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DYogarajah%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DR.%2BC.%2BH.%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DInoue%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DY.%2BW.%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26atitle%3DDrug%2520repurposing%2520of%2520pyrimidine%2520analogs%2520as%2520potent%2520antiviral%2520compounds%2520against%2520human%2520enterovirus%2520A71%2520infection%2520with%2520potential%2520clinical%2520applications%26jtitle%3DSci.%2520Rep.%26date%3D2020%26volume%3D10%26spage%3D8159%26doi%3D10.1038%2Fs41598-020-65152-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sisk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machamer, C. E.</span></span> <span> </span><span class="NLM_article-title">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1099/jgv.0.001047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2Fjgv.0.001047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29557770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2018&pages=619-630&author=J.+M.+Siskauthor=M.+B.+Friemanauthor=C.+E.+Machamer&title=Coronavirus+S+protein-induced+fusion+is+blocked+prior+to+hemifusion+by+Abl+kinase+inhibitors&doi=10.1099%2Fjgv.0.001047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors</span></div><div class="casAuthors">Sisk, Jeanne M.; Frieman, Matthew B.; Machamer, Carolyn E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">619-630</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">1465-2099</span>.
    
            (<span class="NLM_cas:orgname">Microbiology Society</span>)
        </div><div class="casAbstract">Enveloped viruses gain entry into host cells by fusing with cellular membranes, a step that is required for virus replication.  The virus spike (S) protein mediates fusion with the host cell membrane.  We have shown previously that an Abelson (Abl) kinase inhibitor, imatinib, significantly reduces SARS-CoV and MERS-CoV viral titers and prevents endosomal entry by HIV SARS S and MERS S pseudotyped virions.  SARS-CoV and MERS-CoV are classified as BSL-3 viruses, which makes experimentation into the cellular mechanisms involved in infection more challenging.  Here, we use IBV, a BSL-2 virus, as a model for studying the role of Abl kinase activity during coronavirus infection.  We found that imatinib and two specific Abl kinase inhibitors, GNF2 and GNF5, reduce IBV titers by blocking the first round of virus infection.  Addnl., all three drugs prevented IBV S-induced syncytia formation prior to the hemifusion step.  Our results indicate that membrane fusion (both virus-cell and cell-cell) is blocked in the presence of Abl kinase inhibitors.  Studying the effects of Abl kinase inhibitors on IBV will be useful in identifying the host cell pathways required for coronavirus infection.  This will provide an insight into possible therapeutic targets to treat infections by current as well as newly emerging coronaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3OXSytq77rVg90H21EOLACvtfcHk0lgtruv68VFb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVahtLjF&md5=af00456c0177a52a04764bcaeb717cdb</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1099%2Fjgv.0.001047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fjgv.0.001047%26sid%3Dliteratum%253Aachs%26aulast%3DSisk%26aufirst%3DJ.%2BM.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DMachamer%26aufirst%3DC.%2BE.%26atitle%3DCoronavirus%2520S%2520protein-induced%2520fusion%2520is%2520blocked%2520prior%2520to%2520hemifusion%2520by%2520Abl%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2018%26volume%3D99%26spage%3D619%26epage%3D630%26doi%3D10.1099%2Fjgv.0.001047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bommarius, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebeis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chahroudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinberg, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nm1265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm1265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15980865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt1ajtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=731-739&author=P.+M.+Reevesauthor=B.+Bommariusauthor=S.+Lebeisauthor=S.+McNultyauthor=J.+Christensenauthor=A.+Swimmauthor=A.+Chahroudiauthor=R.+Chavanauthor=M.+B.+Feinbergauthor=D.+Veachauthor=W.+Bornmannauthor=M.+Shermanauthor=D.+Kalman&title=Disabling+poxvirus+pathogenesis+by+inhibition+of+Abl-family+tyrosine+kinases&doi=10.1038%2Fnm1265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Bommarius, Bettina; Lebeis, Sarah; McNulty, Shannon; Christensen, Jens; Swimm, Alyson; Chahroudi, Ann; Chavan, Rahul; Feinberg, Mark B.; Veach, Darren; Bornmann, William; Sherman, Melanie; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">731-739</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Poxviridae family members vaccinia and variola virus enter mammalian cells, replicate outside the nucleus and produce virions that travel to the cell surface along microtubules, fuse with the plasma membrane and egress from infected cells toward apposing cells on actin-filled membranous protrusions.  The authors show that cell-assocd. enveloped virions (CEV) use Abl- and Src- family tyrosine kinases for actin motility, and that these kinases act in a redundant fashion, perhaps permitting motility in a greater range of cell types.  Addnl., release of CEV from the cell requires Abl- but not Src-family tyrosine kinases, and is blocked by STI-571 (Gleevec), an Abl-family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Finally, the authors show that STI-571 reduces viral dissemination by five orders of magnitude and promotes survival in infected mice, suggesting possible use for this drug in treating smallpox or complications assocd. with vaccination.  This therapeutic approach may prove generally efficacious in treating microbial infections that rely on host tyrosine kinases, and, because the drug targets host but not viral mols., this strategy is much less likely to engender resistance compared to conventional antimicrobial therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoToBZlyMnm_rVg90H21EOLACvtfcHk0libbSwW4xNVuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt1ajtb4%253D&md5=199db4a44332be99b624c8de944321f9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnm1265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1265%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DBommarius%26aufirst%3DB.%26aulast%3DLebeis%26aufirst%3DS.%26aulast%3DMcNulty%26aufirst%3DS.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DSwimm%26aufirst%3DA.%26aulast%3DChahroudi%26aufirst%3DA.%26aulast%3DChavan%26aufirst%3DR.%26aulast%3DFeinberg%26aufirst%3DM.%2BB.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DSherman%26aufirst%3DM.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DDisabling%2520poxvirus%2520pathogenesis%2520by%2520inhibition%2520of%2520Abl-family%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D731%26epage%3D739%26doi%3D10.1038%2Fnm1265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubley, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantanowitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masiello, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeden, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahan, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span> <span> </span><span class="NLM_article-title">Imatinib-induced regression of AIDS-related Kaposi’s sarcoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">982</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.06.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1200%2FJCO.2005.06.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15572730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1Gnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=982-989&author=H.+B.+Koonauthor=G.+J.+Bubleyauthor=L.+Pantanowitzauthor=D.+Masielloauthor=B.+Smithauthor=K.+Crosbyauthor=J.+Properauthor=W.+Weedenauthor=T.+E.+Millerauthor=P.+Chatisauthor=M.+J.+Egorinauthor=S.+R.+Tahanauthor=B.+J.+Dezube&title=Imatinib-induced+regression+of+AIDS-related+Kaposi%E2%80%99s+sarcoma&doi=10.1200%2FJCO.2005.06.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib-induced regression of AIDS-related Kaposi's sarcoma</span></div><div class="casAuthors">Koon, Henry B.; Bubley, Glenn J.; Pantanowitz, Liron; Masiello, David; Smith, Brad; Crosby, Katherine; Proper, JoAnn; Weeden, Will; Miller, Thomas E.; Chatis, Pamela; Egorin, Merrill J.; Tahan, Steven R.; Dezube, Bruce J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">982-989</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Activation of the platelet-derived growth factor (PDGF) and c-kit receptors has been proposed as important in mediating the growth of AIDS-related Kaposi's sarcoma (KS).  We investigated the response of KS to the PDGF receptor (PDGFR)/c-kit inhibitor, imatinib mesylate, and investigated the effect of this therapy on crit. signal transduction intermediates.  Ten male patients with AIDS-related cutaneous KS, which progressed despite chemotherapy and/or highly active antiretroviral therapy, received imatinib mesylate administered orally, 300 mg twice daily.  Clin. response was detd. by serial tumor measurements.  To det. biol. and histol. response, skin lesion biopsies were obtained at baseline and following 4 wk of therapy.  Five of 10 participants had a partial response by tumor measurements.  Biopsies after 4 wk of therapy demonstrated histol. regression in four of six patients.  Four patients' tumor biopsies were assessable for immunohistochem. end points pre- and post-therapy.  These demonstrated inhibition of PDGFR and its downstream effector, extracellular receptor kinase, which is a member of the mitogen-activated protein kinase family.  The most common adverse event was diarrhea, which led to dose redn. in six patients.  Imatinib mesylate administered orally twice daily for AIDS-related KS results in clin. and histol. regression of cutaneous KS lesions within 4 wk.  These promising results demonstrate that inhibition of the c-kit and/or PDGF receptors may represent an effective strategy for treating KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr89CLQq2rDcLVg90H21EOLACvtfcHk0ljVpandSwNEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1Gnsr8%253D&md5=41d4e985c212ef785ecdf39b2cb89949</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.06.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.06.079%26sid%3Dliteratum%253Aachs%26aulast%3DKoon%26aufirst%3DH.%2BB.%26aulast%3DBubley%26aufirst%3DG.%2BJ.%26aulast%3DPantanowitz%26aufirst%3DL.%26aulast%3DMasiello%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DCrosby%26aufirst%3DK.%26aulast%3DProper%26aufirst%3DJ.%26aulast%3DWeeden%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DT.%2BE.%26aulast%3DChatis%26aufirst%3DP.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26aulast%3DTahan%26aufirst%3DS.%2BR.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26atitle%3DImatinib-induced%2520regression%2520of%2520AIDS-related%2520Kaposi%25E2%2580%2599s%2520sarcoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D982%26epage%3D989%26doi%3D10.1200%2FJCO.2005.06.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorne, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalman, D.</span></span> <span> </span><span class="NLM_article-title">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1128/JVI.01814-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01814-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20962097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=21-31&author=P.+M.+Reevesauthor=S.+K.+Smithauthor=V.+A.+Olsonauthor=S.+H.+Thorneauthor=W.+Bornmannauthor=I.+K.+Damonauthor=D.+Kalman&title=Variola+and+monkeypox+viruses+utilize+conserved+mechanisms+of+virion+motility+and+release+that+depend+on+abl+and+SRC+family+tyrosine+kinases&doi=10.1128%2FJVI.01814-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on Abl and Src family tyrosine kinases</span></div><div class="casAuthors">Reeves, Patrick M.; Smith, Scott K.; Olson, Victoria A.; Thorne, Steve H.; Bornmann, William; Damon, Inger K.; Kalman, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-31</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Vaccinia virus (VacV) enters mammalian cells, replicates extranuclearly, and produces virions that move to the cell surface along microtubules, fuse with the plasma membrane, and move from infected cells toward apposing cells on actin-filled membranous protrusions or actin tails.  To form actin tails, cell-assocd. enveloped virions (CEV) required Abl and Src family tyrosine kinases.  Furthermore, release of CEV from the cell requires Abl but not Src family tyrosine kinases and is blocked by imatinib mesylate (STI-571; Gleevec), an Abl family kinase inhibitor used to treat chronic myelogenous leukemia in humans.  Here we demonstrate that the Poxviridae family members monkeypox virus (MPX) and variola virus (VarV) use conserved mechanisms for actin motility and extracellular enveloped virion (EEV) release.  Furthermore, we show that imatinib mesylate is effective in a mouse model of infection with VacV, whether delivered prophylactically or postinfection, and restricts spread of virions from the site of inoculation.  While inhibitors of both Src and Abl family kinases, such as dasatinib (BMS-354825; Sprycel), are effective in limiting dissemination of VacV, VarV, and MPX in vitro, members of this class of drugs appear to have immunosuppressive effects in vivo that preclude their use as anti-infectives.  Together, these data suggest a possible utility for imatinib mesylate in treating smallpox or MPX infections or complications assocd. with vaccination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp110ZF6U0WXbVg90H21EOLACvtfcHk0ljVpandSwNEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlCjtrc%253D&md5=587e7600337ba2d6169ea9c9c0ab2f5d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FJVI.01814-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01814-10%26sid%3Dliteratum%253Aachs%26aulast%3DReeves%26aufirst%3DP.%2BM.%26aulast%3DSmith%26aufirst%3DS.%2BK.%26aulast%3DOlson%26aufirst%3DV.%2BA.%26aulast%3DThorne%26aufirst%3DS.%2BH.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DKalman%26aufirst%3DD.%26atitle%3DVariola%2520and%2520monkeypox%2520viruses%2520utilize%2520conserved%2520mechanisms%2520of%2520virion%2520motility%2520and%2520release%2520that%2520depend%2520on%2520abl%2520and%2520SRC%2520family%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D21%26epage%3D31%26doi%3D10.1128%2FJVI.01814-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>– <span class="NLM_lpage">7381</span>, <span class="refDoi"> DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+de%0AWispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0ljVpandSwNEbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2013-306155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fgutjnl-2013-306155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24848265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=483-494&author=F.+Xiaoauthor=I.+Fofanaauthor=C.+Thumannauthor=L.+Maillyauthor=R.+Allesauthor=E.+Robinetauthor=N.+Meyerauthor=M.+Schaefferauthor=F.+Habersetzerauthor=M.+Doffo%C3%ABlauthor=P.+Leyssenauthor=J.+Neytsauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Synergy+of+entry+inhibitors+with+direct-acting+antivirals+uncovers+novel+combinations+for+prevention+and+treatment+of+hepatitis+C&doi=10.1136%2Fgutjnl-2013-306155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span></div><div class="casAuthors">Xiao, Fei; Fofana, Isabel; Thumann, Christine; Mailly, Laurent; Alies, Roxane; Robinet, Eric; Meyer, Nicolas; Schaeffer, Mickael; Habersetzer, Francois; Doffoel, Michel; Leyssen, Pieter; Neyts, Johan; Zeisel, Mirjam B.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection.  Viral entry is a promising target for antiviral therapy.  Design Aiming to explore the role of entry inhibitors for future clin. development, we investigated the antiviral efficacy and toxicity of entry inhibitors in combination with DAAs or other host-targeting agents (HTAs).  Screening a large series of combinations of entry inhibitors with DAAs or other HTAs, we uncovered novel combinations of antivirals for prevention and treatment of HCV infection.  Results Combinations of DAAs or HTAs and entry inhibitors including CD81-, scavenger receptor class B type I (SR-BI)- or claudin-1 (CLDN1)-specific antibodies or small-mol. inhibitors erlotinib and dasatinib were characterised by a marked and synergistic inhibition of HCV infection over a broad range of concns. with undetectable toxicity in exptl. designs for prevention and treatment both in cell culture models and in human liver-chimeric uPA/SCID mice.  Conclusions Our results provide a rationale for the development of antiviral strategies combining entry inhibitors with DAAs or HTAs by taking advantage of synergy.  The uncovered combinations provide perspectives for efficient strategies to prevent liver graft infection and novel interferon-free regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEKArTUoU-LVg90H21EOLACvtfcHk0lguCnBf6KX0QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D&md5=553f99c08b810f3a9058ed71124ee7c9</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2013-306155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2013-306155%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DAlles%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DSynergy%2520of%2520entry%2520inhibitors%2520with%2520direct-acting%2520antivirals%2520uncovers%2520novel%2520combinations%2520for%2520prevention%2520and%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D483%26epage%3D494%26doi%3D10.1136%2Fgutjnl-2013-306155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broeckel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totonchy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreklywich, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeFilippis, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streblow, D. N.</span></span> <span> </span><span class="NLM_article-title">Src family kinase inhibitors block translation of alphavirus subgenomic mRNAs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e02325-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02325-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02325-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30917980" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02325-18&author=R.+Broeckelauthor=S.+Sarkarauthor=N.+A.+Mayauthor=J.+Totonchyauthor=C.+N.+Kreklywichauthor=P.+Smithauthor=L.+Gravesauthor=V.+R.+DeFilippisauthor=M.+T.+Heiseauthor=T.+E.+Morrisonauthor=N.+Moormanauthor=D.+N.+Streblow&title=Src+family+kinase+inhibitors+block+translation+of+alphavirus+subgenomic+mRNAs&doi=10.1128%2FAAC.02325-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1128%2FAAC.02325-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02325-18%26sid%3Dliteratum%253Aachs%26aulast%3DBroeckel%26aufirst%3DR.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DMay%26aufirst%3DN.%2BA.%26aulast%3DTotonchy%26aufirst%3DJ.%26aulast%3DKreklywich%26aufirst%3DC.%2BN.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DGraves%26aufirst%3DL.%26aulast%3DDeFilippis%26aufirst%3DV.%2BR.%26aulast%3DHeise%26aufirst%3DM.%2BT.%26aulast%3DMorrison%26aufirst%3DT.%2BE.%26aulast%3DMoorman%26aufirst%3DN.%26aulast%3DStreblow%26aufirst%3DD.%2BN.%26atitle%3DSrc%2520family%2520kinase%2520inhibitors%2520block%2520translation%2520of%2520alphavirus%2520subgenomic%2520mRNAs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De02325-18%26doi%3D10.1128%2FAAC.02325-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zona, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mee, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Royer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavillette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fresquet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosset, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietschmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffelsberger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/nm.2341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnm.2341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21516087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=589-595&author=J.+Lupbergerauthor=M.+B.+Zeiselauthor=F.+Xiaoauthor=C.+Thumannauthor=I.+Fofanaauthor=L.+Zonaauthor=C.+Davisauthor=C.+J.+Meeauthor=M.+Turekauthor=S.+Gorkeauthor=C.+Royerauthor=B.+Fischerauthor=M.+N.+Zahidauthor=D.+Lavilletteauthor=J.+Fresquetauthor=F.+L.+Cossetauthor=S.+M.+Rothenbergauthor=T.+Pietschmannauthor=A.+H.+Patelauthor=P.+Pessauxauthor=M.+Doffo%C3%ABlauthor=W.+Raffelsbergerauthor=O.+Pochauthor=J.+A.+McKeatingauthor=L.+Brinoauthor=T.+F.+Baumert&title=EGFR+and+EphA2+are+host+factors+for+hepatitis+C+virus+entry+and+possible+targets+for+antiviral+therapy&doi=10.1038%2Fnm.2341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy</span></div><div class="casAuthors">Lupberger, Joachim; Zeisel, Mirjam B.; Xiao, Fei; Thumann, Christine; Fofana, Isabel; Zona, Laetitia; Davis, Christopher; Mee, Christopher J.; Turek, Marine; Gorke, Sebastian; Royer, Cathy; Fischer, Benoit; Zahid, Muhammad N.; Lavillette, Dimitri; Fresquet, Judith; Cosset, Francois-Loic; Rothenberg, S. Michael; Pietschmann, Thomas; Patel, Arvind H.; Pessaux, Patrick; Doffoel, Michel; Raffelsberger, Wolfgang; Poch, Olivier; McKeating, Jane A.; Brino, Laurent; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">589-595</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies.  Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors.  Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry.  Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo.  The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor assocns. and viral glycoprotein-dependent membrane fusion.  These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity.  Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPNZcMOXBl57Vg90H21EOLACvtfcHk0lguCnBf6KX0QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltFyqtL4%253D&md5=9a772f9cb03077335c7e7f5918a6e1ef</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fnm.2341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2341%26sid%3Dliteratum%253Aachs%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DZona%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DC.%26aulast%3DMee%26aufirst%3DC.%2BJ.%26aulast%3DTurek%26aufirst%3DM.%26aulast%3DGorke%26aufirst%3DS.%26aulast%3DRoyer%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DZahid%26aufirst%3DM.%2BN.%26aulast%3DLavillette%26aufirst%3DD.%26aulast%3DFresquet%26aufirst%3DJ.%26aulast%3DCosset%26aufirst%3DF.%2BL.%26aulast%3DRothenberg%26aufirst%3DS.%2BM.%26aulast%3DPietschmann%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DA.%2BH.%26aulast%3DPessaux%26aufirst%3DP.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DRaffelsberger%26aufirst%3DW.%26aulast%3DPoch%26aufirst%3DO.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DBrino%26aufirst%3DL.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DEGFR%2520and%2520EphA2%2520are%2520host%2520factors%2520for%2520hepatitis%2520C%2520virus%2520entry%2520and%2520possible%2520targets%2520for%2520antiviral%2520therapy%26jtitle%3DNat.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D589%26epage%3D595%26doi%3D10.1038%2Fnm.2341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span> <span> </span><span class="NLM_article-title">Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">536</span>– <span class="NLM_lpage">549</span>, <span class="refDoi"> DOI: 10.1002/bdd.1821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fbdd.1821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23097199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs12iurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=536-549&author=B.+Xiaauthor=T.+Heimbachauthor=H.+Heauthor=T.+H.+Lin&title=Nilotinib+preclinical+pharmacokinetics+and+practical+application+toward+clinical+projections+of+oral+absorption+and+systemic+availability&doi=10.1002%2Fbdd.1821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availabilityNilotinib Preclinical PharmacokineticsB. Xia et al.</span></div><div class="casAuthors">Xia, Binfeng; Heimbach, Tycho; He, Handan; Lin, Tsu-han</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">536-549</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Nilotinib is a highly potent and selective bcr-abl tyrosine kinase inhibitor used for the treatment of patients who are in the chronic and accelerated phases of Philadelphia chromosome-pos. (Ph+) chronic myeloid leukemia (CML).  Nilotinib preclin. data and its use for practical predictions of systemic exposure profiles and oral absorption are described.  The systemic clearance (CL) of nilotinib was relatively low in rodents with a value of less than 25% of hepatic blood flow (QH), while it was moderate in monkeys and dogs (CL /QH = 32-35%).  The steady state vol. of distribution (Vss) ranged from 0.55 to 3.9 l/kg across the species tested.  The max. concn. (Cmax) of nilotinib occurred at 0.5-4 h and the bioavailability was moderate (17-44%).  The plasma protein binding was high (> 97.5%) in preclin. species and humans.  The human CL (∼ 0.1 l/h/kg) and Vss (∼2.0 l/kg) were best predicted by the rat-dog-human proportionality method and allometric scaling method, resp.  The human i.v. pharmacokinetic profile was projected by the Wajima Css-MRT' method.  The predicted micro-consts. from human i.v. profiles were incorporated into the advanced compartmental absorption and transit model within the GastroPlus program to simulate the oral concn.-time curves in humans.  Overall, the simulated oral human pharmacokinetic profiles showed good agreement with obsd. clin. data, and the model predicted that the Cmax, AUC, t1/2, Vz/F and CL/F values were within 1.3-fold of the obsd. values.  The abs. oral bioavailability of nilotinib in healthy humans was predicted to be low (< 25%).  Copyright © 2012 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdZ39wDv4LXLVg90H21EOLACvtfcHk0lj-AfNIqJplwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs12iurbN&md5=f7f9af2214fe33b980ff7d516ee58d63</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fbdd.1821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.1821%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DB.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DT.%2BH.%26atitle%3DNilotinib%2520preclinical%2520pharmacokinetics%2520and%2520practical%2520application%2520toward%2520clinical%2520projections%2520of%2520oral%2520absorption%2520and%2520systemic%2520availability%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2012%26volume%3D33%26spage%3D536%26epage%3D549%26doi%3D10.1002%2Fbdd.1821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langhammer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellerbrok, H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa)</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2010.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2010.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21094187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=64-70&author=S.+Langhammerauthor=R.+Kobanauthor=C.+Yueauthor=H.+Ellerbrok&title=Inhibition+of+poxvirus+spreading+by+the+anti-tumor+drug+Gefitinib+%28Iressa%29&doi=10.1016%2Fj.antiviral.2010.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa)</span></div><div class="casAuthors">Langhammer, Stefan; Koban, Robert; Yue, Constanze; Ellerbrok, Heinz</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-70</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The threat of smallpox virus as a bioterrorist weapon is raising international concerns again since the anthrax attacks in the USA in 2001.  The medical readiness of treating patients suffering from such infections is a prerequisite of an effective civil defense system.  Currently the only therapeutic option for the treatment of poxvirus infections relies on the virostatic nulceosid analog cidofovir, although severe side effects and drug resistant strains have been described.  A growing understanding of poxvirus pathogenesis raises the possibility to explore other appropriate targets involved in the viral replication cycle.  Poxvirus encoded growth factors such as the Vaccinia Growth Factor (VGF) stimulate host cells via the Epidermal Growth Factor Receptor (EGFR) and thereby facilitate viral spreading.  In this study we could visualize for the first time the paracrine priming of uninfected cells for subsequent infection by orthopoxviruses directly linked to EGFR phosphorylation.  Since EGFR is a well known target for anti-tumor therapy small mols. for inhibition of its tyrosine kinase (TK) activity are readily available and clin. evaluated.  In this study we analyzed three different EGFR receptor tyrosine kinase inhibitors for inhibition of orthopoxvirus infection in epithelial cells.  The inhibitor shown to be most effective was Gefitinib (Iressa) which is already approved as a drug for anti-tumor medication in the USA and in Europe.  Thus Gefitnib may provide a new therapeutic option for single or combination therapy of acute poxvirus infections, acting on a cellular target and thus reducing the risk of viral resistance to treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzuSF4zOBfbVg90H21EOLACvtfcHk0lj-AfNIqJplwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Sltw%253D%253D&md5=fd3e7ad641fc95e0a438d1fdad64ad05</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2010.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2010.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DLanghammer%26aufirst%3DS.%26aulast%3DKoban%26aufirst%3DR.%26aulast%3DYue%26aufirst%3DC.%26aulast%3DEllerbrok%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520poxvirus%2520spreading%2520by%2520the%2520anti-tumor%2520drug%2520Gefitinib%2520%2528Iressa%2529%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D89%26spage%3D64%26epage%3D70%26doi%3D10.1016%2Fj.antiviral.2010.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span> <span> </span><span class="NLM_article-title">Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1544</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1128/JVI.00688-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.00688-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22114332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2ntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=1544-1554&author=Q.+Zhangauthor=R.+Gongauthor=J.+Quauthor=Y.+Zhouauthor=W.+Liuauthor=M.+Chenauthor=Y.+Liuauthor=Y.+Zhuauthor=J.+Wu&title=Activation+of+the+Ras%2FRaf%2FMEK+pathway+facilitates+hepatitis+C+virus+replication+via+attenuation+of+the+interferon-JAK-STAT+pathway&doi=10.1128%2FJVI.00688-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway</span></div><div class="casAuthors">Zhang, Qi; Gong, Rui; Qu, Jing; Zhou, Yijing; Liu, Weiyong; Chen, Mingzhou; Liu, Yingle; Zhu, Ying; Wu, Jianguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1544-1554</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a major cause of chronic liver diseases worldwide, often leading to the development of hepatocellular carcinoma (HCC).  Constitutive activation of the Ras/Raf/MEK pathway is responsible for approx. 30% of cancers.  Here we attempted to address the correlation between activation of this pathway and HCV replication.  We showed that knockdown of Raf1 inhibits HCV replication, while activation of the Ras/Raf/MEK pathway by V12, a constitutively active form of Ras, stimulates HCV replication.  We further demonstrated that this effect is regulated through attenuation of the interferon (IFN)-JAK-STAT pathway.  Activation of the Ras/Raf/MEK pathway downregulates the expression of IFN-stimulated genes (ISGs), attenuates the phosphorylation of STAT1/2, and inhibits the expression of interferon (alpha, beta, and omega) receptors 1 and 2 (IFNAR1/2).  Furthermore, we obsd. that HCV infection activates the Ras/Raf/MEK pathway.  Thus, we propose that during HCV infection, the Ras/Raf/MEK pathway is activated, which in turn attenuates the IFN-JAK-STAT pathway, resulting in stimulation of HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqqpQJ8ts-X7Vg90H21EOLACvtfcHk0lj-AfNIqJplwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2ntro%253D&md5=1a952d338ca0b80fa67c1794cd5eb34a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FJVI.00688-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00688-11%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGong%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520the%2520Ras%252FRaf%252FMEK%2520pathway%2520facilitates%2520hepatitis%2520C%2520virus%2520replication%2520via%2520attenuation%2520of%2520the%2520interferon-JAK-STAT%2520pathway%26jtitle%3DJ.%2520Virol%26date%3D2012%26volume%3D86%26spage%3D1544%26epage%3D1554%26doi%3D10.1128%2FJVI.00688-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bürckstümmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmittel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span> <span> </span><span class="NLM_article-title">Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>580</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2005.12.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.febslet.2005.12.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=16405965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=580&publication_year=2006&pages=575-580&author=T.+B%C3%BCrckst%C3%BCmmerauthor=M.+Kriegsauthor=J.+Lupbergerauthor=E.+K.+Pauliauthor=S.+Schmittelauthor=E.+Hildt&title=Raf-1+kinase+associates+with+Hepatitis+C+virus+NS5A+and+regulates+viral+replication&doi=10.1016%2Fj.febslet.2005.12.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication</span></div><div class="casAuthors">Buerckstuemmer, T.; Kriegs, M.; Lupberger, J.; Pauli, E. K.; Schmittel, S.; Hildt, E.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">580</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a pos.-strand RNA virus that frequently causes persistent infection assocd. with severe liver disease.  HCV nonstructural protein 5A (NS5A) is essential for viral replication.  Here, the kinase Raf-1 was identified as a novel cellular binding partner of NS5A, binding to the C-terminal domain of NS5A.  Raf-1 colocalizes with NS5A in the HCV replication complex.  The interaction of NS5A with Raf-1 results in increased Raf-1 phosphorylation at serine 338.  Integrity of Raf-1 is crucial for HCV replication: inhibition of Raf-1 by the small-mol. inhibitor BAY43-9006 or downregulation of Raf-1 by siRNA attenuates viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxz1OpOmSPrbVg90H21EOLACvtfcHk0lgWL_JM_x0xtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslWksQ%253D%253D&md5=8e5cc137a67f7cb905b9ec74d85861aa</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.12.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.12.071%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25BCrckst%25C3%25BCmmer%26aufirst%3DT.%26aulast%3DKriegs%26aufirst%3DM.%26aulast%3DLupberger%26aufirst%3DJ.%26aulast%3DPauli%26aufirst%3DE.%2BK.%26aulast%3DSchmittel%26aufirst%3DS.%26aulast%3DHildt%26aufirst%3DE.%26atitle%3DRaf-1%2520kinase%2520associates%2520with%2520Hepatitis%2520C%2520virus%2520NS5A%2520and%2520regulates%2520viral%2520replication%26jtitle%3DFEBS%2520Lett.%26date%3D2006%26volume%3D580%26spage%3D575%26epage%3D580%26doi%3D10.1016%2Fj.febslet.2005.12.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildt, E.</span></span> <span> </span><span class="NLM_article-title">New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1653</span>, <span class="refDoi"> DOI: 10.1136/gut.2009.182212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fgut.2009.182212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19710032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SjtbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2009&pages=1644-1653&author=K.+Himmelsbachauthor=D.+Sauterauthor=T.+F.+Baumertauthor=L.+Ludwigauthor=H.+E.+Blumauthor=E.+Hildt&title=New+aspects+of+an+anti-tumour+drug%3A+sorafenib+efficiently+inhibits+HCV+replication&doi=10.1136%2Fgut.2009.182212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication</span></div><div class="casAuthors">Himmelsbach, K.; Sauter, D.; Baumert, T. F.; Ludwig, L.; Blum, H. E.; Hildt, E.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1644-1653</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background and aims: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and is assocd. with significant morbidity and mortality.  Since there is evidence for an interaction of NS5A with c-Raf we studied whether the c-Raf inhibitor sorafenib affects HCV replication.  Methods: HCV replicating HuH7.5 cells were treated with sorafenib and examd. for HCV RNA titers by northern blotting or real time polymerase chain reaction (PCR), for core, NS3 and NS5A expression by immunostaining, and for replication by luciferase reporter assays.  Results: Here we demonstrate that in cells replicating infectious HCV particles, NS5A recruits c-Raf to the replicon complex resulting in the activation of c-Raf.  Therefore, we studied the effect of inhibition of c-Raf on HCV replication using the anti-tumor drug sorafenib that is known to inhibit c-Raf with high specificity.  Sorafenib efficiently blocks HCV replication and viral gene expression.  In addn., in HCV-replicating cells sorafenib decreased the hyperphosphory-lated form of NS5A and resulted in the formation of addnl. hypophosphorylated forms.  Further, sorafenib caused a rapid dissocn. of lipid droplets.  We provide evidence that the antiviral effect of sorafenib indeed is caused by inhibition of c-Raf.  By contrast, inhibition of targets downstream of c-Raf or inhibition of tyrosine kinases by sunitinib did not affect HCV replication.  Conclusion: Our data demonstrate that the well-characterized anti-tumor drug sorafenib efficiently blocks HCV replication in vitro.  This novel effect of sorafenib should be further explored as an antiviral strategy for patients with chronic HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmZBHiHeSMlbVg90H21EOLACvtfcHk0lgWL_JM_x0xtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SjtbnM&md5=60b5b4873a0d5baa3bdb843fb8bf4444</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1136%2Fgut.2009.182212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.2009.182212%26sid%3Dliteratum%253Aachs%26aulast%3DHimmelsbach%26aufirst%3DK.%26aulast%3DSauter%26aufirst%3DD.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26aulast%3DLudwig%26aufirst%3DL.%26aulast%3DBlum%26aufirst%3DH.%2BE.%26aulast%3DHildt%26aufirst%3DE.%26atitle%3DNew%2520aspects%2520of%2520an%2520anti-tumour%2520drug%253A%2520sorafenib%2520efficiently%2520inhibits%2520HCV%2520replication%26jtitle%3DGut%26date%3D2009%26volume%3D58%26spage%3D1644%26epage%3D1653%26doi%3D10.1136%2Fgut.2009.182212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span> <span> </span><span class="NLM_article-title">The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2014.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24680956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnvFSrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2014&pages=80-85&author=M.+Gaoauthor=H.+Duanauthor=J.+Liuauthor=H.+Zhangauthor=X.+Wangauthor=M.+Zhuauthor=J.+Guoauthor=Z.+Zhaoauthor=L.+Mengauthor=Y.+Peng&title=The+multi-targeted+kinase+inhibitor+sorafenib+inhibits+enterovirus+71+replication+by+regulating+IRES-dependent+translation+of+viral+proteins&doi=10.1016%2Fj.antiviral.2014.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins</span></div><div class="casAuthors">Gao, Meng; Duan, Hao; Liu, Jing; Zhang, Hao; Wang, Xin; Zhu, Meng; Guo, Jitao; Zhao, Zhenlong; Meng, Lirong; Peng, Yihong</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-85</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activation of ERK and p38 signal cascade in host cells has been demonstrated to be essential for picornavirus enterovirus 71 (EV71) replication and up-regulation of virus-induced cyclooxygenase-2 (COX-2)/prostaglandins E2 (PGE2) expression.  The aim of this study was to examine the effects of sorafenib, a clin. approved anti-cancer multi-targeted kinase inhibitor, on the propagation and pathogenesis of EV71, with a view to its possible mechanism and potential use in the design of therapy regimes for Hand foot and mouth disease (HFMD) patients with life threatening neurol. complications.  In this study, non-toxic concns. of sorafenib were shown to inhibit the yield of infectious progeny EV71 (clin. BC08 strain) by about 90% in three different cell types.  A similar inhibitory effect of sorafenib was obsd. on the synthesis of both viral genomic RNA and the VP1 protein.  Interestingly, sorafenib exerted obvious inhibition of the EV71 internal ribosomal entry site (IRES)-mediated translation, the first step in picornavirus replication, by linking it to a firefly luciferase reporter gene.  Sorafenib was also able to prevent both EV71-induced CPE and the activation of ERK and p38, which contributes to up-regulation COX-2/PGE2 expression induced by the virus.  Overall, this study shows that sorafenib strongly inhibits EV71 replication at least in part by regulating viral IRES-dependent translation of viral proteins, indicating a novel potential strategy for the treatment of HFMD patients with severe neurol. complications.  To our knowledge, this is the first report that investigates the mechanism by which sorafenib inhibits EV71 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBqZdOAF8ji7Vg90H21EOLACvtfcHk0lgWL_JM_x0xtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnvFSrs7s%253D&md5=1b496803359f9c0ca4fea70aaad5bc2d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DDuan%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DY.%26atitle%3DThe%2520multi-targeted%2520kinase%2520inhibitor%2520sorafenib%2520inhibits%2520enterovirus%252071%2520replication%2520by%2520regulating%2520IRES-dependent%2520translation%2520of%2520viral%2520proteins%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D106%26spage%3D80%26epage%3D85%26doi%3D10.1016%2Fj.antiviral.2014.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2FmTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0lgWL_JM_x0xtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252FmTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benedict, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutting, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span> <span> </span><span class="NLM_article-title">Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection</span>. <i>Front. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">676</span>, <span class="refDoi"> DOI: 10.3389/fmicb.2015.00676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffmicb.2015.00676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26217313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FnsVyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=676&author=A.+Benedictauthor=N.+Bansalauthor=S.+Seninaauthor=I.+Hooperauthor=L.+Lundbergauthor=C.+de+la+Fuenteauthor=A.+Narayananauthor=B.+Guttingauthor=K.+Kehn-Hall&title=Repurposing+FDA-approved+drugs+as+therapeutics+to+treat+Rift+Valley+fever+virus+infection&doi=10.3389%2Ffmicb.2015.00676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection</span></div><div class="casAuthors">Benedict Ashwini; Bansal Neha; Senina Svetlana; Hooper Idris; Lundberg Lindsay; de la Fuente Cynthia; Narayanan Aarthi; Kehn-Hall Kylene; Gutting Bradford</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in microbiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">676</span>
        ISSN:<span class="NLM_cas:issn">1664-302X</span>.
    </div><div class="casAbstract">There are currently no FDA-approved therapeutics available to treat Rift Valley fever virus (RVFV) infection.  In an effort to repurpose drugs for RVFV treatment, a library of FDA-approved drugs was screened to determine their ability to inhibit RVFV.  Several drugs from varying compound classes, including inhibitors of growth factor receptors, microtubule assembly/disassembly, and DNA synthesis, were found to reduce RVFV replication.  The hepatocellular and renal cell carcinoma drug, sorafenib, was the most effective inhibitor, being non-toxic and demonstrating inhibition of RVFV in a cell-type and virus strain independent manner.  Mechanism of action studies indicated that sorafenib targets at least two stages in the virus infectious cycle, RNA synthesis and viral egress.  Computational modeling studies also support this conclusion. siRNA knockdown of Raf proteins indicated that non-classical targets of sorafenib are likely important for the replication of RVFV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRL1yZE_XXes9FxYDaSSP8XfW6udTcc2eZ37__lQbHpyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FnsVyhug%253D%253D&md5=8fb3dab4164aa5dd4b7d716c8c4ab2c1</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.3389%2Ffmicb.2015.00676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmicb.2015.00676%26sid%3Dliteratum%253Aachs%26aulast%3DBenedict%26aufirst%3DA.%26aulast%3DBansal%26aufirst%3DN.%26aulast%3DSenina%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DI.%26aulast%3DLundberg%26aufirst%3DL.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DC.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DGutting%26aufirst%3DB.%26aulast%3DKehn-Hall%26aufirst%3DK.%26atitle%3DRepurposing%2520FDA-approved%2520drugs%2520as%2520therapeutics%2520to%2520treat%2520Rift%2520Valley%2520fever%2520virus%2520infection%26jtitle%3DFront.%2520Microbiol.%26date%3D2015%26volume%3D6%26spage%3D676%26doi%3D10.3389%2Ffmicb.2015.00676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahms, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span> <span> </span><span class="NLM_article-title">Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29981794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=57-67&author=L.+Lundbergauthor=A.+Brahmsauthor=I.+Hooperauthor=B.+Careyauthor=S.+C.+Linauthor=B.+Dahalauthor=A.+Narayananauthor=K.+Kehn-Hall&title=Repurposed+FDA-Approved+drug+sorafenib+reduces+replication+of+Venezuelan+equine+encephalitis+virus+and+other+alphaviruses&doi=10.1016%2Fj.antiviral.2018.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposed FDA-Approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses</span></div><div class="casAuthors">Lundberg, Lindsay; Brahms, Ashwini; Hooper, Idris; Carey, Brian; Lin, Shih-Chao; Dahal, Bibha; Narayanan, Aarthi; Kehn-Hall, Kylene</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-67</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The New World alphaviruses -Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV, and WEEV resp.) - cause a febrile disease that is often lethal in equines and children and leads to long-term neurol. sequelae in survivors.  Endemic to the Americas, epizootic outbreaks of the three viruses occur sporadically in the continental United States.  All three viruses aerosolize readily, replicate to high titers in cell culture, and have low infectious doses.  Addnl., there are no FDA-approved vaccines or therapeutics for human use.  To address the therapeutic gap, a high throughput assay utilizing a luciferase reporter virus, TC83-luc, was performed to screen a library of com. available, FDA-approved drugs for antiviral activity.  From a group of twenty compds. found to significantly decrease luminescence, the carcinoma therapeutic sorafenib inhibited replication of VEEV-TC83 and TrD in vitro.  Addnl., sorafenib inhibited replication of EEEV and two Old World alphaviruses, Sindbis virus and chikungunya virus, at 8 and 16h post-infection.  Sorafenib caused no toxicity in Vero cells, and coupled with a low EC50 value, yielded a selectivity index of >19.  Mechanism of actions studies suggest that sorafenib inhibited viral translation through dephosphorylation of several key proteins, including eIF4E and p70S6K, leading to a redn. in viral protein prodn. and overall viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw7dHEEGsA3rVg90H21EOLACvtfcHk0lhWCIPS0VIdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsb3L&md5=9e3cdad60e9ee6a10ae9ae816ffbf3b6</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DLundberg%26aufirst%3DL.%26aulast%3DBrahms%26aufirst%3DA.%26aulast%3DHooper%26aufirst%3DI.%26aulast%3DCarey%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DS.%2BC.%26aulast%3DDahal%26aufirst%3DB.%26aulast%3DNarayanan%26aufirst%3DA.%26aulast%3DKehn-Hall%26aufirst%3DK.%26atitle%3DRepurposed%2520FDA-Approved%2520drug%2520sorafenib%2520reduces%2520replication%2520of%2520Venezuelan%2520equine%2520encephalitis%2520virus%2520and%2520other%2520alphaviruses%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D157%26spage%3D57%26epage%3D67%26doi%3D10.1016%2Fj.antiviral.2018.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forgách, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuranecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulyok, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakonyi, T.</span></span> <span> </span><span class="NLM_article-title">Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4663</span>– <span class="NLM_lpage">4672</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2018.01.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.vaccine.2018.01.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29459063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFSks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4663-4672&author=A.+Marosiauthor=P.+Forg%C3%A1chauthor=M.+Gyuraneczauthor=K.+M.+Sulyokauthor=T.+Bakonyi&title=Evaluation+of+in+vitro+inhibitory+potential+of+type-I+interferons+and+different+antiviral+compounds+on+rabies+virus+replication&doi=10.1016%2Fj.vaccine.2018.01.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication</span></div><div class="casAuthors">Marosi, Andras; Forgach, Petra; Gyuranecz, Miklos; Sulyok, Kinga M.; Bakonyi, Tamas</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4663-4672</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Five different compds. were tested for their in vitro inhibitory effect against RABV multiplication in mouse neuroblastoma (N2A) cell line.  N2A cells were infected with the fixed RABV strain CVS-11 one hour prior to adding antivirals or their resp. combinations.  The infectious titer of RABV as well as the quantity of viral RNA was detd. in the cell culturing medium after 48 h.  All five tested compds. (mouse interferon (IFN)-α and -β, ribavirin, favipiravir (T-705) and sorafenib) reduced viral replication in a concn.-dependent manner: IFN-β and sorafenib both provided 73.71% relative inhibition of viral replication in the highest non-cytotoxic concn., while ribavirin caused 48.07%, IFN-α caused 44.87% and favipiravir caused 35.25% relative inhibition, resp.  When applied in combination, their antiviral activity was not synergistic, but a pronounced inhibition was detected when IFN-β was combined with sorafenib, ribavirin, or favipiravir.  The highest antiviral effect was caused by the combination of IFN-β and sorafenib (77.19% relative inhibition).  In other combinations there was an antagonistic effect detected in the redn. of viral replication.  The results demonstrate that these compds. can be promising candidates for a potential combination treatment of rabies, noting that some combinations are not favorable in vitro, which makes thorough in vivo studies necessary.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfijIQR_IdJ7Vg90H21EOLACvtfcHk0lhWCIPS0VIdYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFSks7g%253D&md5=4809c6a269a2eb0786403bc888d0a8d6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2018.01.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2018.01.082%26sid%3Dliteratum%253Aachs%26aulast%3DMarosi%26aufirst%3DA.%26aulast%3DForg%25C3%25A1ch%26aufirst%3DP.%26aulast%3DGyuranecz%26aufirst%3DM.%26aulast%3DSulyok%26aufirst%3DK.%2BM.%26aulast%3DBakonyi%26aufirst%3DT.%26atitle%3DEvaluation%2520of%2520in%2520vitro%2520inhibitory%2520potential%2520of%2520type-I%2520interferons%2520and%2520different%2520antiviral%2520compounds%2520on%2520rabies%2520virus%2520replication%26jtitle%3DVaccine%26date%3D2019%26volume%3D37%26spage%3D4663%26epage%3D4672%26doi%3D10.1016%2Fj.vaccine.2018.01.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marosi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufkova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forró, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felde, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdélyi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Širmarová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hönig, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salát, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tikos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuranecz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ružek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koraka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakonyi, T.</span></span> <span> </span><span class="NLM_article-title">Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin</span>. <i>Vaccine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4724</span>– <span class="NLM_lpage">4735</span>, <span class="refDoi"> DOI: 10.1016/j.vaccine.2018.05.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.vaccine.2018.05.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29805091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVeitrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4724-4735&author=A.+Marosiauthor=L.+Dufkovaauthor=B.+Forr%C3%B3author=O.+Feldeauthor=K.+Erd%C3%A9lyiauthor=J.+%C5%A0irmarov%C3%A1author=M.+Palusauthor=V.+H%C3%B6nigauthor=J.+Sal%C3%A1tauthor=R.+Tikosauthor=M.+Gyuraneczauthor=D.+Ru%C5%BEekauthor=B.+Martinaauthor=P.+Korakaauthor=A.+Osterhausauthor=T.+Bakonyi&title=Combination+therapy+of+rabies-infected+mice+with+inhibitors+of+pro-inflammatory+host+response%2C+antiviral+compounds+and+human+rabies+immunoglobulin&doi=10.1016%2Fj.vaccine.2018.05.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin</span></div><div class="casAuthors">Marosi, Andras; Dufkova, Lucie; Forro, Barbara; Felde, Orsolya; Erdelyi, Karoly; Sirmarova, Jana; Palus, Martin; Honig, Vaclav; Salat, Jiri; Tikos, Reka; Gyuranecz, Miklos; Ruzek, Daniel; Martina, Byron; Koraka, Penelope; Osterhaus, Albert D. M. E.; Bakonyi, Tamas</div><div class="citationInfo"><span class="NLM_cas:title">Vaccine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4724-4735</span>CODEN:
                <span class="NLM_cas:coden">VACCDE</span>;
        ISSN:<span class="NLM_cas:issn">0264-410X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent studies demonstrated that inhibitors of pro-inflammatory mol. cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compds. interfere with rabies virus replication in vitro.  In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS.  C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100.  In one exptl. group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge.  In the first expt. therapeutic combination contained inhibitors of tumor necrosis factor-a (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib).  In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice.  The addn. of human rabies Igs (HRIG) to the combination in the second expt. almost completely prevented mortality in the pre-exposure treatment group along with a significant redn. of viral titers in the CNS.  Post-exposure treatments also greatly improved survival rates.  As part of the combination with immunomodulatory compds., HRIG had a higher impact on survival than alone.  In the third expt. the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705).  As a blood-brain barrier opener, mannitol was also administered.  This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components.  In all expts., viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment.  According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreJov-4zSJ37Vg90H21EOLACvtfcHk0lhr5hCg6avOpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVeitrzK&md5=16c726359643c6db95b7978a39ab9062</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.vaccine.2018.05.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vaccine.2018.05.066%26sid%3Dliteratum%253Aachs%26aulast%3DMarosi%26aufirst%3DA.%26aulast%3DDufkova%26aufirst%3DL.%26aulast%3DForr%25C3%25B3%26aufirst%3DB.%26aulast%3DFelde%26aufirst%3DO.%26aulast%3DErd%25C3%25A9lyi%26aufirst%3DK.%26aulast%3D%25C5%25A0irmarov%25C3%25A1%26aufirst%3DJ.%26aulast%3DPalus%26aufirst%3DM.%26aulast%3DH%25C3%25B6nig%26aufirst%3DV.%26aulast%3DSal%25C3%25A1t%26aufirst%3DJ.%26aulast%3DTikos%26aufirst%3DR.%26aulast%3DGyuranecz%26aufirst%3DM.%26aulast%3DRu%25C5%25BEek%26aufirst%3DD.%26aulast%3DMartina%26aufirst%3DB.%26aulast%3DKoraka%26aufirst%3DP.%26aulast%3DOsterhaus%26aufirst%3DA.%26aulast%3DBakonyi%26aufirst%3DT.%26atitle%3DCombination%2520therapy%2520of%2520rabies-infected%2520mice%2520with%2520inhibitors%2520of%2520pro-inflammatory%2520host%2520response%252C%2520antiviral%2520compounds%2520and%2520human%2520rabies%2520immunoglobulin%26jtitle%3DVaccine%26date%3D2019%26volume%3D37%26spage%3D4724%26epage%3D4735%26doi%3D10.1016%2Fj.vaccine.2018.05.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weege, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravenstein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raftery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieben, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Sancho, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai-Matsushima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welke, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlas, A.</span></span> <span> </span><span class="NLM_article-title">RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e1007601</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1007601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1007601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30883607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=e1007601&author=M.+Leschauthor=M.+Lucknerauthor=M.+Meyerauthor=F.+Weegeauthor=I.+Gravensteinauthor=M.+Rafteryauthor=C.+Siebenauthor=L.+Martin-Sanchoauthor=A.+Imai-Matsushimaauthor=R.+W.+Welkeauthor=R.+Friseauthor=W.+Barclayauthor=G.+Sch%C3%B6nrichauthor=A.+Herrmannauthor=T.+F.+Meyerauthor=A.+Karlas&title=RNAi-based+small+molecule+repositioning+reveals+clinically+approved+urea-based+kinase+inhibitors+as+broadly+active+antivirals&doi=10.1371%2Fjournal.ppat.1007601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals</span></div><div class="casAuthors">Lesch, Markus; Luckner, Madlen; Meyer, Michael; Weege, Friderike; Gravenstein, Isabella; Raftery, Martin; Sieben, Christian; Martin-Sancho, Laura; Imai-Matsushima, Aki; Welke, Robert-William; Frise, Rebecca; Barclay, Wendy; Schonrich, Gunther; Herrmann, Andreas; Meyer, Thomas F.; Karlas, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1007601/1-e1007601/34</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Influenza viruses (IVs) tend to rapidly develop resistance to virus-directed vaccines and common antivirals targeting pathogen determinants, but novel host-directed approaches might preclude resistance development.  To identify the most promising cellular targets for a host directed approach against influenza, we performed a comparative small interfering RNA (siRNA) loss-of-function screen of IV replication in A549 cells.  Anal. of four different IV strains including a highly pathogenic avian H5N1 strain, an influenza B virus (IBV) and two human influenza A viruses (IAVs) revealed 133 genes required by all four IV strains.  According to gene enrichment analyses, these strain-independent host genes were particularly enriched for nucleocytoplasmic trafficking.  In addn., 360 strain-specific genes were identified with distinct patterns of usage for IAVs vs. IBV and human vs. avian IVs.  The strain-independent host genes served to define 43 exptl. and otherwise clin. approved drugs, targeting reportedly fourteen of the encoded host factors.  Amongst the approved drugs, the urea-based kinase inhibitors (UBKIs) regorafenib and sorafenib exhibited a superior therapeutic window of high IV antiviral activity and low cytotoxicity.  Both UBKIs appeared to block a cell signaling pathway involved in IV replication after internalization, yet prior to vRNP uncoating.  Interestingly, both compds. were active also against unrelated viruses including cowpox virus (CPXV), hantavirus (HTV), herpes simplex virus 1 (HSV1) and vesicular stomatitis virus (VSV) and showed antiviral efficacy in human primary respiratory cells.  An in vitro resistance development anal. for regorafenib failed to detect IV resistance development against this drug.  Taken together, the otherwise clin. approved UBKIs regorafenib and sorafenib possess high and broad-spectrum antiviral activity along with substantial robustness against resistance development and thus constitute attractive host directed drug candidates against a range of viral infections including influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpvRg2BQf47Vg90H21EOLACvtfcHk0lhr5hCg6avOpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSis7zJ&md5=52e175766a8f5ed3073186eb6ecba371</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1007601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1007601%26sid%3Dliteratum%253Aachs%26aulast%3DLesch%26aufirst%3DM.%26aulast%3DLuckner%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DWeege%26aufirst%3DF.%26aulast%3DGravenstein%26aufirst%3DI.%26aulast%3DRaftery%26aufirst%3DM.%26aulast%3DSieben%26aufirst%3DC.%26aulast%3DMartin-Sancho%26aufirst%3DL.%26aulast%3DImai-Matsushima%26aufirst%3DA.%26aulast%3DWelke%26aufirst%3DR.%2BW.%26aulast%3DFrise%26aufirst%3DR.%26aulast%3DBarclay%26aufirst%3DW.%26aulast%3DSch%25C3%25B6nrich%26aufirst%3DG.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DT.%2BF.%26aulast%3DKarlas%26aufirst%3DA.%26atitle%3DRNAi-based%2520small%2520molecule%2520repositioning%2520reveals%2520clinically%2520approved%2520urea-based%2520kinase%2520inhibitors%2520as%2520broadly%2520active%2520antivirals%26jtitle%3DPLoS%2520Pathog.%26date%3D2019%26volume%3D15%26spage%3De1007601%26doi%3D10.1371%2Fjournal.ppat.1007601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Vidal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellví, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31077767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVyhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=18-27&author=E.+Garcia-Vidalauthor=R.+Badiaauthor=M.+Pujantellauthor=M.+Castellv%C3%ADauthor=E.+Felipauthor=B.+Clotetauthor=E.+Riveira-Mu%C3%B1ozauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Dual+effect+of+the+broad+spectrum+kinase+inhibitor+midostaurin+in+acute+and+latent+HIV-1+infection&doi=10.1016%2Fj.antiviral.2019.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection</span></div><div class="casAuthors">Garcia-Vidal, Edurne; Badia, Roger; Pujantell, Maria; Castellvi, Marc; Felip, Eudald; Clotet, Bonaventura; Riveira-Munoz, Eva; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-27</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Midostaurin is a multi-kinase inhibitor with antineoplastic activity.  We assessed the capacity of midostaurin to affect early and late steps of HIV-1 infection and to reactivate HIV-1 latently infected cells, alone or in combination with histone deacetylase inhibitors (HDACi) known to act as latency-reversing agents (LRA).  Acute HIV-1 infection was assessed by flow cytometry in three cell types treated with midostaurin in the presence or absence of SAMHD1.  Non-infected cells were treated with midostaurin and harvested for Western blot anal.  Macrophage infections were also measured by quant. RT-PCR.  HIV-1 latency reactivation was assessed in several latency models.  Midostaurin induced G2/M arrest and inhibited CDK2, preventing the phosphorylation of SAMHD1 assocd. to inhibition of its dNTPase activity.  In the presence of SAMHD1, midostaurin blocked HIV-1 DNA formation and viral replication.  However, following Vpx-mediated SAMHD1 degrdn., midostaurin increased viral transcripts and virus replication.  In three out of four HIV-1 latency models, including primary CD4+ T cells, midostaurin effectively reversed HIV-1 latency and was synergistic in combination with LRA vorinostat and panobinostat.  Our study describes a dual effect for midostaurin in HIV-1 infection, antiviral or proviral depending on SAMHD1 activation, and highlights a role for active SAMHD1 in regulating the activity of potential HIV-1 latency reversal agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ptaEF-fUsbVg90H21EOLACvtfcHk0lgTVFCWveB3UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVyhs7s%253D&md5=e1dedd467d87aec7be0e02af385ed652</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Vidal%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DCastellv%25C3%25AD%26aufirst%3DM.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DDual%2520effect%2520of%2520the%2520broad%2520spectrum%2520kinase%2520inhibitor%2520midostaurin%2520in%2520acute%2520and%2520latent%2520HIV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D18%26epage%3D27%26doi%3D10.1016%2Fj.antiviral.2019.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedesco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatlik, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span> <span> </span><span class="NLM_article-title">Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: Insights from human absorption, metabolism, and excretion studies of a BDDCS II drug</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.072744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fdmd.116.072744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28270565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=540-555&author=H.+Heauthor=P.+Tranauthor=H.+Guauthor=V.+Tedescoauthor=J.+Zhangauthor=W.+Linauthor=E.+Gatlikauthor=K.+Kleinauthor=T.+Heimbach&title=Midostaurin%2C+a+novel+protein+kinase+inhibitor+for+the+treatment+of+acute+myelogenous+leukemia%3A+Insights+from+human+absorption%2C+metabolism%2C+and+excretion+studies+of+a+BDDCS+II+drug&doi=10.1124%2Fdmd.116.072744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug</span></div><div class="casAuthors">He, Handan; Tran, Phi; Gu, Helen; Tedesco, Vivienne; Zhang, Jin; Lin, Wen; Gatlik, Ewa; Klein, Kai; Heimbach, Tycho</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">540-555</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The absorption, metab., and excretion of midostaurin, a potent class III tyrosine protein kinase inhibitor for acute myelogenous leukemia, were evaluated in healthy subjects.  A microemulsion formulation was chosen to optimize absorption.  After a 50-mg [14C]-midostaurin dose, oral absorption was high (>90%) and relatively rapid.  In plasma, the major circulating components were midostaurin (22%), CGP52421 (32.7%), and CGP62221 (27.7%).  Long plasma half-lives were obsd. for midostaurin (20.3 h), CGP52421 (495 h), and CGP62221 (33.4 h).  Through careful mass-balance study design, the recovery achieved was good (81.6%), despite the long radioactivity half-lives.  Most of the radioactive dose was recovered in feces (77.6%) mainly as metabolites, because only 3.43% was unchanged, suggesting mainly hepatic metab.  Renal elimination was minor (4%).  Midostaurin metab. pathways involved hydroxylation, O-demethylation, amide hydrolysis, and N-demethylation.  High plasma CGP52421 and CGP62221 exposures in humans, along with relatively potent cell-based IC50 for FMS-like tyrosine kinase 3-internal tandem duplications inhibition, suggested that the antileukemic activity in AML patients may also be maintained by the metabolites.  Very high plasma protein binding (>99%) required equil. gel filtration to identify differences between humans and animals.  Because midostaurin, CGP52421, and CGP62221 are metabolized mainly by CYP3A4 and are inhibitors/inducers for CYP3A, potential drug-drug interactions with mainly CYP3A4 modulators/CYP3A substrates could be expected.  Given its low aq. soly., high oral absorption and extensive metab. (>90%), midostaurin is a Biopharmaceutics Classification System/Biopharmaceutics Drug Disposition Classification System (BDDCS) class II drug in human, consistent with rat BDDCS in vivo data showing high absorption (>90%) and extensive metab. (>90%).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGj-4CfyRJrVg90H21EOLACvtfcHk0lgTVFCWveB3UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGltLvJ&md5=2b65e7c63b30c3cf4499efc41a3223f1</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.072744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.072744%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DH.%26aulast%3DTran%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%26aulast%3DTedesco%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DGatlik%26aufirst%3DE.%26aulast%3DKlein%26aufirst%3DK.%26aulast%3DHeimbach%26aufirst%3DT.%26atitle%3DMidostaurin%252C%2520a%2520novel%2520protein%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%253A%2520Insights%2520from%2520human%2520absorption%252C%2520metabolism%252C%2520and%2520excretion%2520studies%2520of%2520a%2520BDDCS%2520II%2520drug%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D540%26epage%3D555%26doi%3D10.1124%2Fdmd.116.072744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e12697</span>, <span class="refDoi"> DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=e12697&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J+Richardsonauthor=V.+Monteilauthor=V.+M+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A+R.+Terresauthor=B.+J+Nickoloffauthor=R.+E+Higgsauthor=G.+Rochaauthor=N.+L+Byersauthor=D.+E+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellino&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0lgTVFCWveB3UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ%26aulast%3DHiggs%26aufirst%3DR.%2BE%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL%26aulast%3DSchlichting%26aufirst%3DD.%2BE%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26spage%3De12697%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">75</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29753658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=67-75&author=S.+Y.+Puauthor=F.+Xiaoauthor=S.+Schorauthor=E.+Bekermanauthor=F.+Zaniniauthor=R.+Barouch-Bentovauthor=C.+M.+Nagamineauthor=S.+Einav&title=Feasibility+and+biological+rationale+of+repurposing+sunitinib+and+erlotinib+for+dengue+treatment&doi=10.1016%2Fj.antiviral.2018.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment</span></div><div class="casAuthors">Pu, Szu-Yuan; Xiao, Fei; Schor, Stanford; Bekerman, Elena; Zanini, Fabio; Barouch-Bentov, Rina; Nagamine, Claude M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-75</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue virus (DENV) infection; a major global threat.  We reported that the cellular kinases AAK1 and GAK regulate intracellular trafficking of multiple viruses and that sunitinib and erlotinib, approved anticancer drugs with potent activity against these kinases, protect DENV-infected mice from mortality.  Nevertheless, further characterization of the therapeutic potential and underlying mechanism of this approach is required prior to clin. evaluation.  Here, we demonstrate that sunitinib/erlotinib combination achieves sustained suppression of systemic infection at approved dose in DENV-infected IFN-α/β and IFN-γ receptor-deficient mice.  Nevertheless, treatment with these blood-brain barrier impermeable drugs delays, yet does not prevent, late-onset paralysis; a common manifestation in this immunodeficient mouse model but not in humans.  Sunitinib and erlotinib treatment also demonstrates efficacy in human primary monocyte-derived dendritic cells.  Addnl., DENV infection induces expression of AAK1 transcripts, but not GAK, via single-cell transcriptomics, and these kinases are important mol. targets underlying the anti-DENV effect of sunitinib and erlotinib.  Lastly, sunitinib/erlotinib combination alters inflammatory cytokine responses in DENV-infected mice.  These findings support feasibility of repurposing sunitinib/erlotinib combination as a host-targeted antiviral approach and contribute to understanding its mechanism of antiviral action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2cs8UpuoykLVg90H21EOLACvtfcHk0lgqwJAhUjguFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslaqtbk%253D&md5=acde697b6e3c6d9f42a2011be6091e83</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DZanini%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DFeasibility%2520and%2520biological%2520rationale%2520of%2520repurposing%2520sunitinib%2520and%2520erlotinib%2520for%2520dengue%2520treatment%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D155%26spage%3D67%26epage%3D75%26doi%3D10.1016%2Fj.antiviral.2018.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Multiple
treatments for ebola virus disease (EVD)</i>, NCT02380625, Clinical
Research Management, Inc., <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Multiple%0Atreatments+for+ebola+virus+disease+%28EVD%29%2C+NCT02380625%2C+Clinical%0AResearch+Management%2C+Inc.%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DMultiple%250Atreatments%2520for%2520ebola%2520virus%2520disease%2520%2528EVD%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span> <span> </span><span class="NLM_article-title">COVID-19: combining antiviral and anti-inflammatory treatments</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">400</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(20)30132-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS1473-3099%2820%2930132-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32113509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=400-402&author=J.+Stebbingauthor=A.+Phelanauthor=I.+Griffinauthor=C.+Tuckerauthor=O.+Oechsleauthor=D.+Smithauthor=P.+Richardson&title=COVID-19%3A+combining+antiviral+and+anti-inflammatory+treatments&doi=10.1016%2FS1473-3099%2820%2930132-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: combining antiviral and anti-inflammatory treatments</span></div><div class="casAuthors">Stebbing, Justin; Phelan, Anne; Griffin, Ivan; Tucker, Catherine; Oechsle, Olly; Smith, Dan; Richardson, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">400-402</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The potential for combination therapy of the anti-inflammatory baricitinib with the direct-acting antivirals (lopinavir or ritonavir and remdesivir) currently being used in the COVID-19 outbreak, since it has a minimal interaction with the relevant CYP drug-metabolizing enzymes.  Combinations of baricitinib with these direct-acting antivirals could reduce viral infectivity, viral replication, and the aberrant host inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzcjx8n9u2irVg90H21EOLACvtfcHk0lgqwJAhUjguFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFCitb4%253D&md5=c311166386f148d130f49b72f3c0b381</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930132-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930132-8%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRichardson%26aufirst%3DP.%26atitle%3DCOVID-19%253A%2520combining%2520antiviral%2520and%2520anti-inflammatory%2520treatments%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D400%26epage%3D402%26doi%3D10.1016%2FS1473-3099%2820%2930132-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriques, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djabali, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells</span>. <i>Cells</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1276</span>, <span class="refDoi"> DOI: 10.3390/cells8101276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fcells8101276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVygtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=1276&author=C.+Liuauthor=R.+Arnoldauthor=G.+Henriquesauthor=K.+Djabali&title=Inhibition+of+JAK-STAT+signaling+with+baricitinib+reduces+inflammation+and+improves+cellular+homeostasis+in+progeria+cells&doi=10.3390%2Fcells8101276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of JAK-STAT signaling with baricitinib reduces inflammation and improves cellular homeostasis in progeria cells</span></div><div class="casAuthors">Liu, Chang; Arnold, Rouven; Henriques, Goncalo; Djabali, Karima</div><div class="citationInfo"><span class="NLM_cas:title">Cells</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1276</span>CODEN:
                <span class="NLM_cas:coden">CELLC6</span>;
        ISSN:<span class="NLM_cas:issn">2073-4409</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hutchinson-Gilford progeria syndrome (HGPS), a rare premature aging disorder that leads to death at an av. age of 14.7 years due to myocardial infarction or stroke, is caused by mutations in the LMNA gene.  Nearly 90% of HGPS cases carry the G608G mutation within exon 11 that generates a truncated prelamin A protein "progerin".  Progerin accumulates in HGPS cells and induces premature senescence at the cellular and organismal levels.  Children suffering from HGPS develop numerous clin. features that overlap with normal aging, including atherosclerosis, arthritis, hair loss and lipodystrophy.  To det. whether an aberrant signaling pathway might underliethedevelopmentofthesefourdiseases(atherosclerosis, arthritis, hairlossandlipodystrophy), we performed a text mining anal. of scientific literature and databases.  We found a total of 17 genes assocd. with all four pathologies, 14 of which were linked to the JAK1/2-STAT1/3 signaling pathway.  We report that the inhibition of the JAK-STAT pathway with baricitinib, a Food and Drug Administration-approved JAK1/2 inhibitor, restored cellular homeostasis, delayed senescence and decreased proinflammatory markers in HGPS cells.  Our ex vivo data using human cell models indicate that the overactivation of JAK-STAT signaling mediates premature senescence and that the inhibition of this pathway could show promise for the treatment of HGPS and age-related pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppgM8ThAvADbVg90H21EOLACvtfcHk0lgqwJAhUjguFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVygtbo%253D&md5=63739aa82503a5bc04e44c886b781779</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3390%2Fcells8101276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcells8101276%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DHenriques%26aufirst%3DG.%26aulast%3DDjabali%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520JAK-STAT%2520signaling%2520with%2520baricitinib%2520reduces%2520inflammation%2520and%2520improves%2520cellular%2520homeostasis%2520in%2520progeria%2520cells%26jtitle%3DCells%26date%3D2019%26volume%3D8%26spage%3D1276%26doi%3D10.3390%2Fcells8101276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span>FDA News
Release,  <i>Coronavirus (COVID-19) Update: FDA authorizes drug
combination for treatment of COVID-19</i>, November 19, <span class="NLM_year">2020</span>, <a href="https://www.fda.gov/" class="extLink">https://www.fda.gov/</a> (accessed 2020-11-26).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+News%0ARelease%2C+Coronavirus+%28COVID-19%29+Update%3A+FDA+authorizes+drug%0Acombination+for+treatment+of+COVID-19%2C+November+19%2C+2020%2C+https%3A%2F%2Fwww.fda.gov%2F+%28accessed+2020-11-26%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Update%253A%2520FDA%2520authorizes%2520drug%250Acombination%2520for%2520treatment%2520of%2520COVID-19%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haile, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyor, W. R.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.nbd.2016.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26851503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFyisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2016&pages=137-143&author=W.+B.+Haileauthor=C.+Gavegnanoauthor=S.+Taoauthor=Y.+Jiangauthor=R.+F.+Schinaziauthor=W.+R.+Tyor&title=The+Janus+kinase+inhibitor+ruxolitinib+reduces+HIV+replication+in+human+macrophages+and+ameliorates+HIV+encephalitis+in+a+murine+model&doi=10.1016%2Fj.nbd.2016.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model</span></div><div class="casAuthors">Haile, Woldeab B.; Gavegnano, Christina; Tao, Sijia; Jiang, Yong; Schinazi, Raymond F.; Tyor, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">Part_B</span>),
    <span class="NLM_cas:pages">137-143</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A hallmark of persistent HIV-1 infection in the central nervous system is increased activation of mononuclear phagocytes and surrounding astrogliosis, conferring persistent HIV-induced inflammation.  This inflammation is believed to result in neuronal dysfunction and the clin. manifestations of HIV-assocd. neurocognitive disorders (HAND).  The Jak/STAT pathway is activated in macrophages/myeloid cells upon HIV-1 infection, modulating many pro-inflammatory pathways that result in HAND, thereby representing an attractive cellular target.  Thus, the impact of ruxolitinib, a Janus Kinase (Jak) 1/2 inhibitor that is FDA approved for myelofibrosis and polycythemia vera, was assessed for its potential to inhibit HIV-1 replication in macrophages and HIV-induced activation in monocytes/macrophages in culture.  In addn., a murine model of HIV encephalitis (HIVE) was used to assess the impact of ruxolitinib on histopathol. features of HIVE, brain viral load, as well as its ability to penetrate the blood-brain-barrier (BBB).  Ruxolitinib was found to inhibit HIV-1 replication in macrophages, HIV-induced activation of monocytes (CD14/CD16) and macrophages (HLA-DR, CCR5, and CD163) without apparent toxicity.  In vivo, systemically administered ruxolitinib was detected in the brain during HIVE in SCID mice and markedly inhibited astrogliosis.  Together, these data indicate that ruxolitinib reduces HIV-induced activation and infiltration of monocytes/macrophages in vitro, reduces the replication of HIV in vitro, penetrates the BBB when systemically administered in mice and reduces astrogliosis in the brains of mice with HIVE.  These data suggest that ruxolitinib will be useful as a novel therapeutic to treat humans with HAND.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXOQeIdU_kbVg90H21EOLACvtfcHk0lhr6k75VdFHRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFyisrk%253D&md5=dbf6e2d9858d543e04ff66cef9d2c808</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaile%26aufirst%3DW.%2BB.%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DTyor%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Janus%2520kinase%2520inhibitor%2520ruxolitinib%2520reduces%2520HIV%2520replication%2520in%2520human%2520macrophages%2520and%2520ameliorates%2520HIV%2520encephalitis%2520in%2520a%2520murine%2520model%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2016%26volume%3D92%26spage%3D137%26epage%3D143%26doi%3D10.1016%2Fj.nbd.2016.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La
Rosee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrke, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochhaus, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birndt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fellhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Rosee, P.</span></span> <span> </span><span class="NLM_article-title">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1815</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0891-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41375-020-0891-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32518419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=1805-1815&author=F.+La%0ARoseeauthor=H.+C.+Bremerauthor=I.+Gehrkeauthor=A.+Kehrauthor=A.+Hochhausauthor=S.+Birndtauthor=M.+Fellhauerauthor=M.+Henkesauthor=B.+Kumleauthor=S.+G.+Russoauthor=P.+La+Rosee&title=The+Janus+kinase+1%2F2+inhibitor+ruxolitinib+in+COVID-19+with+severe+systemic+hyperinflammation&doi=10.1038%2Fs41375-020-0891-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation</span></div><div class="casAuthors">La Rosee, F.; Bremer, H. C.; Gehrke, I.; Kehr, A.; Hochhaus, A.; Birndt, S.; Fellhauer, M.; Henkes, M.; Kumle, B.; Russo, S. G.; La Rosee, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1805-1815</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure.  These patients present with progressive hyperinflammation governed by proinflammatory cytokines.  An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation.  Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux).  Patients were treated with efficacy/toxicity guided step up dosing up to 14 days.  Retrospective anal. of CIS redn. and clin. outcome was performed.  Out of 105 patients treated between March 30th and Apr. 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg.  A total of 12/14 patients achieved significant redn. of CIS by ≥25% on day 7 with sustained clin. improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity.  Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure.  A multicenter phase-II clin. trial has been initiated (NCT04338958).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnLEoRYA18u7Vg90H21EOLACvtfcHk0lhr6k75VdFHRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFelsL7K&md5=801ce3cc74a405a334ca0d380aa53333</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0891-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0891-0%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRosee%26aufirst%3DF.%26aulast%3DBremer%26aufirst%3DH.%2BC.%26aulast%3DGehrke%26aufirst%3DI.%26aulast%3DKehr%26aufirst%3DA.%26aulast%3DHochhaus%26aufirst%3DA.%26aulast%3DBirndt%26aufirst%3DS.%26aulast%3DFellhauer%26aufirst%3DM.%26aulast%3DHenkes%26aufirst%3DM.%26aulast%3DKumle%26aufirst%3DB.%26aulast%3DRusso%26aufirst%3DS.%2BG.%26aulast%3DLa%2BRosee%26aufirst%3DP.%26atitle%3DThe%2520Janus%2520kinase%25201%252F2%2520inhibitor%2520ruxolitinib%2520in%2520COVID-19%2520with%2520severe%2520systemic%2520hyperinflammation%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D1805%26epage%3D1815%26doi%3D10.1038%2Fs41375-020-0891-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2020.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaci.2020.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32470486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2020&pages=137-146&author=Y.+Caoauthor=J.+Weiauthor=L.+Zouauthor=T.+Jiangauthor=G.+Wangauthor=L.+Chenauthor=L.+Huangauthor=F.+Mengauthor=L.+Huangauthor=N.+Wangauthor=X.+Zhouauthor=H.+Luoauthor=Z.+Maoauthor=X.+Chenauthor=J.+Xieauthor=J.+Liuauthor=H.+Chengauthor=J.+Zhaoauthor=G.+Huangauthor=W.+Wangauthor=J.+Zhou&title=Ruxolitinib+in+treatment+of+severe+coronavirus+disease+2019+%28COVID-19%29%3A+A+multicenter%2C+single-blind%2C+randomized+controlled+trial&doi=10.1016%2Fj.jaci.2020.05.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial</span></div><div class="casAuthors">Cao, Yang; Wei, Jia; Zou, Liang; Jiang, Tiebin; Wang, Gaoxiang; Chen, Liting; Huang, Liang; Meng, Fankai; Huang, Lifang; Wang, Na; Zhou, Xiaoxi; Luo, Hui; Mao, Zekai; Chen, Xing; Xie, Jungang; Liu, Jing; Cheng, Hui; Zhao, Jianping; Huang, Gang; Wang, Wei; Zhou, Jianfeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-146.e3</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Accumulating evidence proposed Janus-assocd. kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation.  This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019.  We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019.  Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus std.-of-care treatment (22 patients) or placebo based on std.-of-care treatment (21 patients).  After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study.  Treatment with ruxolitinib plus std.-of-care was not assocd. with significantly accelerated clin. improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clin. improvement.  Eighteen (90%) patients from the ruxolitinib group showed computed tomog. improvement at day 14 compared with 13 (61.9%) patients from the control group (P =.0495).  Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group.  Ruxolitinib was well tolerated with low toxicities and no new safety signals.  Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group.  Although no statistical difference was obsd., ruxolitinib recipients had a numerically faster clin. improvement.  Significant chest computed tomog. improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsWKI4tj6YcLVg90H21EOLACvtfcHk0lhr6k75VdFHRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlaisbnJ&md5=b758d7ebcb2a43a00d91009ad4787240</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2020.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2020.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DH.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DRuxolitinib%2520in%2520treatment%2520of%2520severe%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%253A%2520A%2520multicenter%252C%2520single-blind%252C%2520randomized%2520controlled%2520trial%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2020%26volume%3D146%26spage%3D137%26epage%3D146%26doi%3D10.1016%2Fj.jaci.2020.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capochiani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frediani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iervasi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolicchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuccaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertaggia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nasso, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccioni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolletta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conticini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozzetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchia, M.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib rapidly reduces acute respiratory distress syndrome in covid-19 disease. Analysis of data collection from RESPIRE protocol</span>. <i>Front. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">466</span>, <span class="refDoi"> DOI: 10.3389/fmed.2020.00466</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffmed.2020.00466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB38bgvFymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=466&author=E.+Capochianiauthor=B.+Fredianiauthor=G.+Iervasiauthor=A.+Paolicchiauthor=S.+Saniauthor=P.+Roncucciauthor=A.+Cuccaroauthor=F.+Franchiauthor=F.+Simonettiauthor=D.+Carraraauthor=I.+Bertaggiaauthor=D.+Nassoauthor=R.+Riccioniauthor=S.+Scollettaauthor=S.+Valenteauthor=E.+Conticiniauthor=A.+Gozzettiauthor=M.+Bocchia&title=Ruxolitinib+rapidly+reduces+acute+respiratory+distress+syndrome+in+covid-19+disease.+Analysis+of+data+collection+from+RESPIRE+protocol&doi=10.3389%2Ffmed.2020.00466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol</span></div><div class="casAuthors">Capochiani Enrico; Cuccaro Annarosa; Simonetti Federico; Bertaggia Ilaria; Nasso Daniela; Riccioni Rossella; Frediani Bruno; Conticini Edoardo; Iervasi Giorgio; Paolicchi Aldo; Sani Spartaco; Roncucci Paolo; Franchi Federico; Scolletta Sabino; Carrara Davide; Valente Serafina; Gozzetti Alessandro; Bocchia Monica</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">466</span>
        ISSN:<span class="NLM_cas:issn">2296-858X</span>.
    </div><div class="casAbstract">Background: The Coronavirus disease (COVID-19) pandemic is causing millions of infections and hundreds of thousands of deaths worldwide.  Cumulative clinical and laboratory evidence suggest that a subset of patients with severe COVID-19 may develop a cytokine storm syndrome during the course of the disease, with severe respiratory impairment requiring ventilatory support.  One field of research nowadays is to identify and treat viral-induced hyperinflammation with drugs used in other clinical conditions characterized by an hyperinflammation status.  These drugs might help to reduce COVID19 mortality.  Methods: Ruxolitinib, a JAK1 and JAK2 inhibitor, has been successfully used to treat severe immune-mediated diseases, such as graft vs. host disease and Hemophagocytic lymphohistiocytosis.  We used ruxolitinib in 18 patients with clinically progressive COVID-19 related acute respiratory distress syndrome, with a primary endpoint to rapidly reduce the degree of respiratory impairment and as a secondary endpoint to rapidly restore the PaO2/FiO2 ratio, as an evaluation of clinical status, and monitoring of drug related Adverse Events.  Parameters of inflammation responses and organ functions were assessed and monitored.  The treatment plan was ruxolitinib 20 mg bid for the first 48 h and subsequent two-step de-escalation at 10 mg bid and 5 mg bid for a maximum of 14 days of treatment.  Results: Our data collection shows a rapid clinical response with no evolution from non-invasive ventilation to mechanical ventilation in 16/18 patients and no response in two patients (overall response rate-ORR 89%).  Already after 48 h of ruxolitinib treatment 16/18 patients showed evident clinical improvement, and after 7 days of treatment 11/18 patients showed fully recovered respiratory function (pO2 > 98% in spontaneous breathing), 4/18 patients had minimal oxygen requirement (2-4 L/m), 1/18 patient showed stable disease, and 2/18 patient showed progressive disease.  After 14 days, 16/18 patients showed complete recovery of respiratory function (ORR 89%).  Compliance to ruxolitinib planned treatment was 100% and no serious adverse event was recorded.  In our case series of 18 critically ill patients with COVID-19 and ARDS, administration of ruxolitinib resulted in a clinical improvement that concurred to modify the standard course of disease.  Ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in COVID-19 related ARDS.  RESPIRE Study (Ruxolitinib for the treatment of acute rESPIratory distREss syndrome, ClinicalTrials.gov Identifier: NCT04361903).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfIW9Qi75uwYNpW7w2tapOfW6udTcc2ebh0KktSPx3nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bgvFymtA%253D%253D&md5=69c99afcd5fa34a1d449bbba4267461c</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3389%2Ffmed.2020.00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffmed.2020.00466%26sid%3Dliteratum%253Aachs%26aulast%3DCapochiani%26aufirst%3DE.%26aulast%3DFrediani%26aufirst%3DB.%26aulast%3DIervasi%26aufirst%3DG.%26aulast%3DPaolicchi%26aufirst%3DA.%26aulast%3DSani%26aufirst%3DS.%26aulast%3DRoncucci%26aufirst%3DP.%26aulast%3DCuccaro%26aufirst%3DA.%26aulast%3DFranchi%26aufirst%3DF.%26aulast%3DSimonetti%26aufirst%3DF.%26aulast%3DCarrara%26aufirst%3DD.%26aulast%3DBertaggia%26aufirst%3DI.%26aulast%3DNasso%26aufirst%3DD.%26aulast%3DRiccioni%26aufirst%3DR.%26aulast%3DScolletta%26aufirst%3DS.%26aulast%3DValente%26aufirst%3DS.%26aulast%3DConticini%26aufirst%3DE.%26aulast%3DGozzetti%26aufirst%3DA.%26aulast%3DBocchia%26aufirst%3DM.%26atitle%3DRuxolitinib%2520rapidly%2520reduces%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520covid-19%2520disease.%2520Analysis%2520of%2520data%2520collection%2520from%2520RESPIRE%2520protocol%26jtitle%3DFront.%2520Med.%26date%3D2020%26volume%3D7%26spage%3D466%26doi%3D10.3389%2Ffmed.2020.00466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Detorio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planelles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1128/AAC.02496-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02496-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24419350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1977-1986&author=C.+Gavegnanoauthor=M.+Detorioauthor=C.+Monteroauthor=A.+Bosqueauthor=V.+Planellesauthor=R.+F.+Schinazi&title=Ruxolitinib+and+tofacitinib+are+potent+and+selective+inhibitors+of+HIV-1+replication+and+virus+reactivation+in+vitro&doi=10.1128%2FAAC.02496-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro</span></div><div class="casAuthors">Gavegnano, Christina; Detorio, Mervi; Montero, Catherine; Bosque, Alberto; Planelles, Vicente; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1977-1986, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The JAK-STAT pathway is activated in both macrophages and lymphocytes upon human immunodeficiency virus type 1 (HIV-1) infection and thus represents an attractive cellular target to achieve HIV suppression and reduced inflammation, which may impact virus sanctuaries.  Ruxolitinib and tofacitinib are JAK1/2 inhibitors that are FDA approved for rheumatoid arthritis and myelofibrosis, resp., but their therapeutic application for treatment of HIV infection was unexplored.  Both drugs demonstrated submicromolar inhibition of infection with HIV-1, HIV-2, and a simian-human immunodeficiency virus, RT-SHIV, across primary human or rhesus macaque lymphocytes and macrophages, with no apparent significant cytotoxicity at 2 to 3 logs above the median effective antiviral concn.  Combination of tofacitinib and ruxolitinib increased the efficacy by 53- to 161-fold vs. that obsd. for monotherapy, resp., and each drug applied alone to primary human lymphocytes displayed similar efficacy against HIV-1 contg. various polymerase substitutions.  Both drugs inhibited virus replication in lymphocytes stimulated with phytohemagglutinin (PHA) plus interleukin-2 (IL-2), but not PHA alone, and inhibited reactivation of latent HIV-1 at low-micromolar concns. across the J-Lat T cell latency model and in primary human central memory lymphocytes.  Thus, targeted inhibition of JAK provided a selective, potent, and novel mechanism to inhibit HIV-1 replication in lymphocytes and macrophages, replication of drug-resistant HIV-1, and reactivation of latent HIV-1 and has the potential to reset the immunol. milieu in HIV-infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3eFMp64h4bVg90H21EOLACvtfcHk0liUaOQ7Tl-ROw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVSltr8%253D&md5=85566414304fc2f381e99bca472b8691</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FAAC.02496-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02496-13%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DDetorio%26aufirst%3DM.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DBosque%26aufirst%3DA.%26aulast%3DPlanelles%26aufirst%3DV.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DRuxolitinib%2520and%2520tofacitinib%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520HIV-1%2520replication%2520and%2520virus%2520reactivation%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1977%26epage%3D1986%26doi%3D10.1128%2FAAC.02496-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Tofacitinib
in SARS-COV2 pneumonia</i> (NCT04332042);  <i>tofacitinib
plus hydroxycloroquine vs hydroxycloroquine in patients with COVID-19
interstitial pneumonia</i> (NCT04390061);  <i>tofacitinib
in hospitalized patients with COVID-19 pneumonia</i> (NCT04469114);  <i>tofacitinib for treatment of moderate COVID-19</i> (NCT04415151), <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Tofacitinib%0Ain+SARS-COV2+pneumonia+%28NCT04332042%29%3B+tofacitinib%0Aplus+hydroxycloroquine+vs+hydroxycloroquine+in+patients+with+COVID-19%0Ainterstitial+pneumonia+%28NCT04390061%29%3B+tofacitinib%0Ain+hospitalized+patients+with+COVID-19+pneumonia+%28NCT04469114%29%3B+tofacitinib+for+treatment+of+moderate+COVID-19+%28NCT04415151%29%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DTofacitinib%250Ain%2520SARS-COV2%2520pneumonia%26jtitle%3Dtofacitinib%250Aplus%2520hydroxycloroquine%2520vs%2520hydroxycloroquine%2520in%2520patients%2520with%2520COVID-19%250Ainterstitial%2520pneumonia%26jtitle%3Dtofacitinib%250Ain%2520hospitalized%2520patients%2520with%2520COVID-19%2520pneumonia%26jtitle%3Dtofacitinib%2520for%2520treatment%2520of%2520moderate%2520COVID-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span>; <span class="NLM_string-name">Schinazi, R. F.</span></span> <i>Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections</i>. U.S. Patent <span class="NLM_patent">10022378 B2</span>, May 15, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Gavegnano&author=R.+F.+Schinazi&title=Antiviral+JAK+inhibitors+useful+in+treating+or+preventing+retroviral+and+other+viral+infections"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26jtitle%3DAntiviral%2520JAK%2520inhibitors%2520useful%2520in%2520treating%2520or%2520preventing%2520retroviral%2520and%2520other%2520viral%2520infections%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedmak, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, A. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span>. <i>Intervirology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1159/000053979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1159%2F000053979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2000&pages=412-418&author=W.+J.+Waldmanauthor=D.+A.+Knightauthor=L.+Blinderauthor=J.+Shenauthor=N.+S.+Lurainauthor=D.+M.+Millerauthor=D.+D.+Sedmakauthor=J.+W.+Williamsauthor=A.+S.+Chong&title=Inhibition+of+cytomegalovirus+in+vitro+and+in+vivo+by+the+experimental+immunosuppressive+agent+leflunomide&doi=10.1159%2F000053979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide</span></div><div class="casAuthors">Waldman, W. James; Knight, Deborah A.; Blinder, Leonard; Shen, JiKun; Lurain, Nell S.; Miller, Daniel M.; Sedmak, Daniel D.; Williams, James W.; Chong, Anita S.-F.</div><div class="citationInfo"><span class="NLM_cas:title">Intervirology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">412-418</span>CODEN:
                <span class="NLM_cas:coden">IVRYAK</span>;
        ISSN:<span class="NLM_cas:issn">0300-5526</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Despite progress in antiviral chemotherapy, cytomegalovirus (CMV) remains a major cause of morbidity and mortality among pharmacol. immunosuppressed transplant recipients, frequently engaging the clinician in a struggle to balance graft preservation with control of CMV disease.  Leflunomide, an inhibitor of protein kinase activity and pyrimidine synthesis, is an exptl. immunosuppressive agent effective against acute and chronic rejection in animal models.  Herein we summarize our recent studies demonstrating that leflunomide inhibits the prodn. of multiple clin. CMV isolates (including multi-drug-resistant virus) in both human fibroblasts and endothelial cells.  In contrast to all other anti-CMV drugs currently in use, leflunomide does not inhibit viral DNA synthesis, but rather appears to interfere with virion assembly.  Finally, preliminary studies in a rat model suggest that this agent reduces viral load in vivo.  These findings imply that leflunomide, an effective immunosuppressive agent, shows potential to concurrently attenuate a major complication of immunosuppression, CMV disease, by a novel mechanism of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolSzgyco_QqrVg90H21EOLACvtfcHk0lhGoh-zZLxluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKisLk%253D&md5=e2fa6f422349ef0f74d13194a944c239</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1159%2F000053979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000053979%26sid%3Dliteratum%253Aachs%26aulast%3DWaldman%26aufirst%3DW.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DBlinder%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLurain%26aufirst%3DN.%2BS.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DSedmak%26aufirst%3DD.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DChong%26aufirst%3DA.%2BS.%26atitle%3DInhibition%2520of%2520cytomegalovirus%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520the%2520experimental%2520immunosuppressive%2520agent%2520leflunomide%26jtitle%3DIntervirology%26date%3D2000%26volume%3D42%26spage%3D412%26epage%3D418%26doi%3D10.1159%2F000053979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadambi, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thistlewaite, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfinkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwood, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meehan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josephson, M. A.</span></span> <span> </span><span class="NLM_article-title">Leflunomide for polyomavirus type BK nephropathy</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1056/NEJM200503173521125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1056%2FNEJM200503173521125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15784677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit1yhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=1157-1158&author=J.+W.+Williamsauthor=B.+Javaidauthor=P.+V.+Kadambiauthor=D.+Gillenauthor=R.+Harlandauthor=J.+R.+Thistlewaiteauthor=M.+Garfinkelauthor=P.+Fosterauthor=W.+Atwoodauthor=J.+M.+Millisauthor=S.+M.+Meehanauthor=M.+A.+Josephson&title=Leflunomide+for+polyomavirus+type+BK+nephropathy&doi=10.1056%2FNEJM200503173521125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Leflunomide for polyomavirus type BK nephropathy</span></div><div class="casAuthors">Williams, James W.; Javaid, Basit; Kadambi, Predeep V.; Gillen, Daniel; Harland, Robert; Thistlewaite, J. Richard; Garfinkel, Marc; Foster, Preston; Atwood, Walter; Millis, J. Michael; Meehan, Shane M.; Josephson, Michelle A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1157-1158</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4PplEiwJ6LVg90H21EOLACvtfcHk0lhGoh-zZLxluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit1yhur4%253D&md5=bcbfe6cac3b6ad7f1755eceb2fe94280</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1056%2FNEJM200503173521125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200503173521125%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DJ.%2BW.%26aulast%3DJavaid%26aufirst%3DB.%26aulast%3DKadambi%26aufirst%3DP.%2BV.%26aulast%3DGillen%26aufirst%3DD.%26aulast%3DHarland%26aufirst%3DR.%26aulast%3DThistlewaite%26aufirst%3DJ.%2BR.%26aulast%3DGarfinkel%26aufirst%3DM.%26aulast%3DFoster%26aufirst%3DP.%26aulast%3DAtwood%26aufirst%3DW.%26aulast%3DMillis%26aufirst%3DJ.%2BM.%26aulast%3DMeehan%26aufirst%3DS.%2BM.%26aulast%3DJosephson%26aufirst%3DM.%2BA.%26atitle%3DLeflunomide%2520for%2520polyomavirus%2520type%2520BK%2520nephropathy%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D1157%26epage%3D1158%26doi%3D10.1056%2FNEJM200503173521125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, H. G.</span></span> <span> </span><span class="NLM_article-title">Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation</span>. <i>Pediatr. Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">E50</span>– <span class="NLM_lpage">E54</span>, <span class="refDoi"> DOI: 10.1111/petr.12029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fpetr.12029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23210794" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2013&pages=E50-E54&author=Y.+H.+Jungauthor=K.+C.+Moonauthor=J.+W.+Haauthor=S.+J.+Kimauthor=I.+S.+Haauthor=H.+I.+Cheongauthor=H.+G.+Kang&title=Leflunomide+therapy+for+BK+virus+allograft+nephropathy+after+pediatric+kidney+transplantation&doi=10.1111%2Fpetr.12029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1111%2Fpetr.12029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpetr.12029%26sid%3Dliteratum%253Aachs%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DMoon%26aufirst%3DK.%2BC.%26aulast%3DHa%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DHa%26aufirst%3DI.%2BS.%26aulast%3DCheong%26aufirst%3DH.%2BI.%26aulast%3DKang%26aufirst%3DH.%2BG.%26atitle%3DLeflunomide%2520therapy%2520for%2520BK%2520virus%2520allograft%2520nephropathy%2520after%2520pediatric%2520kidney%2520transplantation%26jtitle%3DPediatr.%2520Transplant.%26date%3D2013%26volume%3D17%26spage%3DE50%26epage%3DE54%26doi%3D10.1111%2Fpetr.12029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prinz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">10132</span>– <span class="NLM_lpage">10145</span>, <span class="refDoi"> DOI: 10.1096/fj.201902793RR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1096%2Ffj.201902793RR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32598086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Gnu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=10132-10145&author=J.+Wangauthor=J.+Sunauthor=J.+Huauthor=C.+Wangauthor=R.+A.+Prinzauthor=D.+Pengauthor=X.+Liuauthor=X.+Xu&title=A77+1726%2C+the+active+metabolite+of+the+anti-rheumatoid+arthritis+drug+leflunomide%2C+inhibits+influenza+A+virus+replication+in+vitro+and+in+vivo+by+inhibiting+the+activity+of+Janus+kinases&doi=10.1096%2Ffj.201902793RR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases</span></div><div class="casAuthors">Wang, Jiongjiong; Sun, Jing; Hu, Jiao; Wang, Chengming; Prinz, Richard A.; Peng, Daxin; Liu, Xiufan; Xu, Xiulong</div><div class="citationInfo"><span class="NLM_cas:title">FASEB Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">10132-10145</span>CODEN:
                <span class="NLM_cas:coden">FAJOEC</span>;
        ISSN:<span class="NLM_cas:issn">1530-6860</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The newly reassorted IAV subtypes from zoonotic reservoirs respond poorly to current vaccines and antiviral therapy.  There is an unmet need in developing novel antiviral drugs for better control of IAV infection.  The cellular factors that are crucial for virus replication have been sought as novel mol. targets for antiviral therapy.  Recent studies have shown that Janus kinases (JAK), JAK1, and JAK2, play an important role in IAV replication.  Leflunomide is an anti-inflammatory drug primarily used for treating rheumatoid arthritis (RA).  Prior studies suggest that A77 1726, the active metabolite of leflunomide, inhibits the activity of JAK1 and JAK3.  Our current study aims to det. if A77 1726 can function as a JAK inhibitor to control IAV infection.  Here, we report that A77 1726 inhibited the replication of three IAV subtypes(H5N1, H1N1, H9N2)in three cell types (chicken embryonic fibroblasts, A549, and MDCK).  A77 1726 inhibited JAK1, JAK2, and STAT3 tyrosine phosphorylation.  Similar observations were made with Ruxolitinib (Rux), a JAK-specific inhibitor.  JAK2 overexpression enhanced H5N1 virus replication and compromised the antiviral activity of A77 1726.  Leflunomide inhibited virus replication in the lungs of IAV-infected mice, alleviated their body wt. loss, and prolonged their survival.  Our study demonstrates for the first time the ability of A77 1726 to inhibit JAK2 activity and suggests that inhibition of JAK activity contributes to its antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRh9AnI4C2i7Vg90H21EOLACvtfcHk0lgxxFZNtefyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Gnu7zO&md5=274979fb4412e68c2805196c6bc0aee7</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1096%2Ffj.201902793RR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.201902793RR%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DPrinz%26aufirst%3DR.%2BA.%26aulast%3DPeng%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DA77%25201726%252C%2520the%2520active%2520metabolite%2520of%2520the%2520anti-rheumatoid%2520arthritis%2520drug%2520leflunomide%252C%2520inhibits%2520influenza%2520A%2520virus%2520replication%2520in%2520vitro%2520and%2520in%2520vivo%2520by%2520inhibiting%2520the%2520activity%2520of%2520Janus%2520kinases%26jtitle%3DFASEB%2520J.%26date%3D2020%26volume%3D34%26spage%3D10132%26epage%3D10145%26doi%3D10.1096%2Ffj.201902793RR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sepulveda, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damonte, E. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of A771726, the active metabolite of leflunomide, against Junin virus</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1002/jmv.25024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fjmv.25024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29315647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslertb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=819-827&author=C.+S.+Sepulvedaauthor=C.+C.+Garciaauthor=E.+B.+Damonte&title=Antiviral+activity+of+A771726%2C+the+active+metabolite+of+leflunomide%2C+against+Junin+virus&doi=10.1002%2Fjmv.25024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of A771726, the active metabolite of leflunomide, against Junin virus</span></div><div class="casAuthors">Sepulveda, Claudia S.; Garcia, Cybele C.; Damonte, Elsa B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">819-827</span>CODEN:
                <span class="NLM_cas:coden">JMVIDB</span>;
        ISSN:<span class="NLM_cas:issn">0146-6615</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the effect of A771726, the active metabolite of leflunomide, (CONICET-UBA), Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad against the infection with Junin virus (JUNV), agent of Argentine hemorrhagic fever (AHF).  The treatment with non-cytotoxic concns. of A771726 of Vero and A549 cells infected with JUNV inhibited virus replication in a dose-dependent manner, as detd. by virus yield redn. assay.  The antiviral effectiveness of A771726 was not importantly affected by the multiplicity of infection and the virus strain.  Moreover, the combination of A771726 and ribavirin had a significantly more potent antiviral activity than each single drug treatment.  Mechanistic studies showed that the main action of A771726 is exerted before 6 h of JUNV infection.  Accordingly, inhibition of viral RNA synthesis was detected in treated infected cells by real time RT-PCR.  The exogenous addn. of uridine or orotic acid produced a partial reversal of the inhibitory effect of A771726 on infective virus prodn. whereas a total reversion was detected on JUNV RNA synthesis, probably by restoration of the enzymic activity of dihydroorotate dehydrogenase (DHODH) and the intracellular pyrimidine pools.  In conclusion, these results suggest that the antiviral target would be viral RNA synthesis through pyrimidine depletion, but any other effect of the compd. on JUNV infection cannot be excluded.  This study opens the possibility of the therapeutic application of a wide spectrum host-targeted compd. alone or in combination with ribavirin to combat AHF as well as other human pathogenic arena viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKcSOjtURN5bVg90H21EOLACvtfcHk0lgxxFZNtefyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslertb4%253D&md5=c54bf5daa9659353503eb8d009616e7d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1002%2Fjmv.25024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.25024%26sid%3Dliteratum%253Aachs%26aulast%3DSepulveda%26aufirst%3DC.%2BS.%26aulast%3DGarcia%26aufirst%3DC.%2BC.%26aulast%3DDamonte%26aufirst%3DE.%2BB.%26atitle%3DAntiviral%2520activity%2520of%2520A771726%252C%2520the%2520active%2520metabolite%2520of%2520leflunomide%252C%2520against%2520Junin%2520virus%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D2018%26volume%3D90%26spage%3D819%26epage%3D827%26doi%3D10.1002%2Fjmv.25024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liacini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seamone, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muruve, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tibbles, L. A.</span></span> <span> </span><span class="NLM_article-title">Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection</span>. <i>Transplantation</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1097/TP.0b013e3182007be2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1097%2FTP.0b013e3182007be2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21079551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGrtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2010&pages=1450-1457&author=A.+Liaciniauthor=M.+E.+Seamoneauthor=D.+A.+Muruveauthor=L.+A.+Tibbles&title=Anti-BK+virus+mechanisms+of+sirolimus+and+leflunomide+alone+and+in+combination%3A+toward+a+new+therapy+for+BK+virus+infection&doi=10.1097%2FTP.0b013e3182007be2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection</span></div><div class="casAuthors">Liacini, Abdelhamid; Seamone, Mark E.; Muruve, Daniel A.; Tibbles, Lee Anne</div><div class="citationInfo"><span class="NLM_cas:title">Transplantation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1450-1457</span>CODEN:
                <span class="NLM_cas:coden">TRPLAU</span>;
        ISSN:<span class="NLM_cas:issn">0041-1337</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Human BK polyomavirus is the causative agent of BK nephropathy which is now the leading cause of early renal graft loss.  Although no randomized clin. trials have supported this therapy, redn. of immunosuppressive drugs is the current BK nephropathy treatment.  We hypothesized that inhibition of the intracellular protein kinase pathways activated by BK virus may be a more effective therapeutic strategy than redn. of immunosuppression.  Four days after infection of renal epithelial cells lines CCD1103, CCD1105 and human primary tubular epithelial cells with BK virus, we found increased phosphorylation of 3'-phosphoinositide-dependent kinase-1 (PDK-1), the protein kinase Akt (Akt), mammalian target of rapamycin (mTOR), and 70 kDa ribosomal protein S6 kinase (p70S6K).  To inhibit this pathway, we used sirolimus, which repressed p70S6K phosphorylation and reduced BK virus large T antigen expression in a dose-dependent manner.  We then used the tyrosine kinase inhibitor leflunomide (using the active metabolite A77 1726), which decreased PDK1 and Akt phosphorylation and inhibited BK virus genome replication and early gene expression.  The combination of sirolimus and leflunomide inhibited BK virus genome replication, large T antigen expression, PDK1, Akt, mammalian target of rapamycin, and p70S6K phosphorylation.  On the basis of these results, we suggest that inhibition of protein kinase pathways with a combination of sirolimus and leflunomide may be an effective therapy for BK virus reactivation.  Because both sirolimus and leflunomide possess immunosuppressive activity, combination therapy may reduce BK pathogenesis while maintaining appropriate transplant immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtBRM8dTYrxbVg90H21EOLACvtfcHk0lgxxFZNtefyIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGrtrnO&md5=ae9aa5e1c961a5ebe3351e578bb9e7ec</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1097%2FTP.0b013e3182007be2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FTP.0b013e3182007be2%26sid%3Dliteratum%253Aachs%26aulast%3DLiacini%26aufirst%3DA.%26aulast%3DSeamone%26aufirst%3DM.%2BE.%26aulast%3DMuruve%26aufirst%3DD.%2BA.%26aulast%3DTibbles%26aufirst%3DL.%2BA.%26atitle%3DAnti-BK%2520virus%2520mechanisms%2520of%2520sirolimus%2520and%2520leflunomide%2520alone%2520and%2520in%2520combination%253A%2520toward%2520a%2520new%2520therapy%2520for%2520BK%2520virus%2520infection%26jtitle%3DTransplantation%26date%3D2010%26volume%3D90%26spage%3D1450%26epage%3D1457%26doi%3D10.1097%2FTP.0b013e3182007be2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, D.</span></span> <span> </span><span class="NLM_article-title">Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy</span>. <i>Nephrology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1111/nep.12948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fnep.12948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28247521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVOksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=326-329&author=J.+Jawauthor=P.+Hillauthor=D.+Goodman&title=Combination+of+Leflunomide+and+Everolimus+for+treatment+of+BK+virus+nephropathy&doi=10.1111%2Fnep.12948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of Leflunomide and Everolimus for treatment of BK virus nephropathy</span></div><div class="casAuthors">Jaw, Juli; Hill, Prue; Goodman, David</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326-329</span>CODEN:
                <span class="NLM_cas:coden">NEPHF2</span>;
        ISSN:<span class="NLM_cas:issn">1320-5358</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BK nephropathy (BKN) is a common cause of graft dysfunction following kidney transplantation.  Minimization of immunosuppressive therapy remains the first line of therapy, but this may lead to rejection and graft loss.  In some cases, despite lowering immunosuppression, BK infection can persist, leading to chronic damage and kidney failure.  Currently, there is no specific anti-BK viral therapy.  Recent in vitro expts. have demonstrated a redn. in BK viral replication when infected cells are treated with the combination of Leflunomide and Everolimus.  This study aims to explore the effect of this drugs combination on viral clearance and graft function in patients with persistent disease despite redn. in immunosuppression.  We treated three patients with combination Leflunomide and Everolimus.  Data on medical history, biochem. parameters and viral loads were collected.  Significant improvement in viral loads was obsd. in two cases with resoln. of viremia in another (Table 1).  Two recipients had preserved allograft function.  The remaining graft was lost because of combination of obstruction and BKN.  No adverse reactions such as bone marrow toxicity were obsd.  Combination of Leflunomide and Everolimus is safe and should be considered as a rescue therapy in treatment of BKN, esp. in those who fail to clear this infection despite redn. of immunosuppressive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9HcDHiE52SbVg90H21EOLACvtfcHk0lgjJgU3CLnuww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVOksb0%253D&md5=95aec43e62f5617065f3fd070c4cae4a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fnep.12948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnep.12948%26sid%3Dliteratum%253Aachs%26aulast%3DJaw%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DP.%26aulast%3DGoodman%26aufirst%3DD.%26atitle%3DCombination%2520of%2520Leflunomide%2520and%2520Everolimus%2520for%2520treatment%2520of%2520BK%2520virus%2520nephropathy%26jtitle%3DNephrology%26date%3D2017%26volume%3D22%26spage%3D326%26epage%3D329%26doi%3D10.1111%2Fnep.12948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of leflunomide for refractory COVID-19: An open-label controlled study</span>. <i>MedRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.29.20114223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.05.29.20114223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=Q.+Wangauthor=H.+Guoauthor=Y.+Liauthor=X.+Jianauthor=X.+Houauthor=N.+Zhongauthor=J.+Feiauthor=D.+Suauthor=Z.+Bianauthor=Y.+Zhangauthor=Y.+Huauthor=Y.+Sunauthor=X.+Yuauthor=Y.+Liauthor=B.+Jiangauthor=Y.+Liauthor=F.+Qinauthor=Y.+Wuauthor=Y.+Gaoauthor=Z.+Hu&title=Efficacy+and+safety+of+leflunomide+for+refractory+COVID-19%3A+An+open-label+controlled+study&doi=10.1101%2F2020.05.29.20114223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1101%2F2020.05.29.20114223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.29.20114223%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJian%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DFei%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DBian%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DZ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520leflunomide%2520for%2520refractory%2520COVID-19%253A%2520An%2520open-label%2520controlled%2520study%26jtitle%3DMedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.29.20114223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">NIH U.S. National
Library of Medicine</span>.  <i>Leflunomide
in Mild COVID-19 Patients</i>, NCT04361214, University of Chicago, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National%0ALibrary+of+Medicine.+Leflunomide%0Ain+Mild+COVID-19+Patients%2C+NCT04361214%2C+University+of+Chicago%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DLeflunomide%250Ain%2520Mild%2520COVID-19%2520Patients" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roschewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionakis, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roswarski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monticelli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roshon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrzesinski, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarakas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, W. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Bruton tyrosine kinase in patients with severe COVID-19</span>. <i>Sci. Immunol</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">eabd0110</span>, <span class="refDoi"> DOI: 10.1126/sciimmunol.abd0110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fsciimmunol.abd0110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32503877" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=eabd0110&author=M.+Roschewskiauthor=M.+S.+Lionakisauthor=J.+P.+Sharmanauthor=J.+Roswarskiauthor=A.+Goyauthor=M.+A.+Monticelliauthor=M.+Roshonauthor=S.+H.+Wrzesinskiauthor=J.+V.+Desaiauthor=M.+A.+Zarakasauthor=J.+Collenauthor=K.+Roseauthor=A.+Hamdyauthor=R.+Izumiauthor=G.+W.+Wrightauthor=K.+K.+Chungauthor=J.+Baselgaauthor=L.+M.+Staudtauthor=W.+H.+Wilson&title=Inhibition+of+Bruton+tyrosine+kinase+in+patients+with+severe+COVID-19&doi=10.1126%2Fsciimmunol.abd0110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1126%2Fsciimmunol.abd0110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciimmunol.abd0110%26sid%3Dliteratum%253Aachs%26aulast%3DRoschewski%26aufirst%3DM.%26aulast%3DLionakis%26aufirst%3DM.%2BS.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DRoswarski%26aufirst%3DJ.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DMonticelli%26aufirst%3DM.%2BA.%26aulast%3DRoshon%26aufirst%3DM.%26aulast%3DWrzesinski%26aufirst%3DS.%2BH.%26aulast%3DDesai%26aufirst%3DJ.%2BV.%26aulast%3DZarakas%26aufirst%3DM.%2BA.%26aulast%3DCollen%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DK.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DWright%26aufirst%3DG.%2BW.%26aulast%3DChung%26aufirst%3DK.%2BK.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26atitle%3DInhibition%2520of%2520Bruton%2520tyrosine%2520kinase%2520in%2520patients%2520with%2520severe%2520COVID-19%26jtitle%3DSci.%2520Immunol%26date%3D2020%26volume%3D5%26spage%3Deabd0110%26doi%3D10.1126%2Fsciimmunol.abd0110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeker, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shadman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mato, A. R.</span></span> <span> </span><span class="NLM_article-title">BTK inhibitors in cancer patients with COVID-19: ″The winner will be the one who controls that chaos″ (napoleon bonaparte)</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3514</span>– <span class="NLM_lpage">3516</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-20-1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-20-1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32345646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKrtrjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=3514-3516&author=E.+A.+Chongauthor=L.+E.+Roekerauthor=M.+Shadmanauthor=M.+S.+Davidsauthor=S.+J.+Schusterauthor=A.+R.+Mato&title=BTK+inhibitors+in+cancer+patients+with+COVID-19%3A+%E2%80%B3The+winner+will+be+the+one+who+controls+that+chaos%E2%80%B3+%28napoleon+bonaparte%29&doi=10.1158%2F1078-0432.CCR-20-1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">BTK inhibitors in cancer patients with COVID-19: "the winner will be the one who controls that chaos" (Napoleon Bonaparte)</span></div><div class="casAuthors">Chong, Elise A.; Roeker, Lindsey E.; Shadman, Mazyar; Davids, Matthew S.; Schuster, Stephen J.; Mato, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3514-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  As the SARS-CoV-2 (COVID-19) pandemic spreads and the no. of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID-19-affected patients grows, the authors must consider the pros and cons of BTKi discontinuation for the authors' patients.  In favor of BTKi continuation, BTK plays an active role in macrophage polarization.  By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state assocd. with COVID-19.  In favor of BTKi discontinuation, the authors note a potentially increased risk of secondary infections and impaired humoral immunity.  The authors hypothesize that the potential benefit of blunting a hyperinflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption.  On the basis of this, the authors suggest continuing BTKi in patients with COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNi9sKn8QYnLVg90H21EOLACvtfcHk0lhX6VjQ-yJg6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKrtrjF&md5=ae51304398c87b4c35d5e1038eb65b97</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-20-1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-20-1427%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DE.%2BA.%26aulast%3DRoeker%26aufirst%3DL.%2BE.%26aulast%3DShadman%26aufirst%3DM.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMato%26aufirst%3DA.%2BR.%26atitle%3DBTK%2520inhibitors%2520in%2520cancer%2520patients%2520with%2520COVID-19%253A%2520%25E2%2580%25B3The%2520winner%2520will%2520be%2520the%2520one%2520who%2520controls%2520that%2520chaos%25E2%2580%25B3%2520%2528napoleon%2520bonaparte%2529%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D3514%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-20-1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skarbnik, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumerai, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrera, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span> <span> </span><span class="NLM_article-title">The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1182/blood.2020006288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood.2020006288" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32302379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1SjtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2020&pages=1912-1915&author=S.+P.+Treonauthor=J.+J.+Castilloauthor=A.+P.+Skarbnikauthor=J.+D.+Soumeraiauthor=I.+M.+Ghobrialauthor=M.+L.+Guerreraauthor=K.+Meidauthor=G.+Yang&title=The+BTK+inhibitor+ibrutinib+may+protect+against+pulmonary+injury+in+COVID-19-infected+patients&doi=10.1182%2Fblood.2020006288"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients</span></div><div class="casAuthors">Treon, Steven P.; Castillo, Jorge J.; Skarbnik, Alan P.; Soumerai, Jacob D.; Ghobrial, Irene M.; Guerrera, Maria Luisa; Meid, Kirsten; Yang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1912-1915</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-vs.-host disease (cGVHD).  The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model.  Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients.  We care for 600 to 800 Waldenstrom macroglobulinemia (WM) patients each year, ~ 300 of whom are on a BTK inhibitor.  We identified 6 patients receiving ibrutinib for WM who were diagnosed with COVID-19; these patients consented to the use of their data.  Their clin. characteristics appear in Table 1.  Their median age was 66 years, and 5 were on the recommended treatment dose of 420 mg/d; the sixth patient was on a reduced dose of 140 mg/d because of arthralgias.  For all patients, the median time on ibrutinib was 52 mo.  Their median time with COVID-19-related symptoms prior to diagnostic testing was 5 days, and the median time since diagnosis of COVID-19 was 22 days.  All 6 patients experienced cough and fever as prodromal symptoms.  The 5 patients on ibrutinib, 420 mg/d, did not experience dyspnea and did not require hospitalization.  Their course was marked by steady improvement, and resoln. or near resoln. of COVID-19-related symptoms during the follow-up period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9ANuw-HJegbVg90H21EOLACvtfcHk0lhX6VjQ-yJg6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1SjtbzF&md5=702770337b78a2c6f22d1f22080695e5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1182%2Fblood.2020006288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2020006288%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DSkarbnik%26aufirst%3DA.%2BP.%26aulast%3DSoumerai%26aufirst%3DJ.%2BD.%26aulast%3DGhobrial%26aufirst%3DI.%2BM.%26aulast%3DGuerrera%26aufirst%3DM.%2BL.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DG.%26atitle%3DThe%2520BTK%2520inhibitor%2520ibrutinib%2520may%2520protect%2520against%2520pulmonary%2520injury%2520in%2520COVID-19-infected%2520patients%26jtitle%3DBlood%26date%3D2020%26volume%3D135%26spage%3D1912%26epage%3D1915%26doi%3D10.1182%2Fblood.2020006288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greff, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencze, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szantai-Kis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baska, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyuris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelemenics, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szathmary, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minarovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span> <span> </span><span class="NLM_article-title">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.2174/092986711794839188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+Nemethauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Szantai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathmaryauthor=J.+Minarovitsauthor=G.+Keriauthor=L.+Orfi&title=Novel%2C+selective+CDK9+inhibitors+for+the+treatment+of+HIV+infection&doi=10.2174%2F092986711794839188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0li5b6YSgpu2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSzantai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathmary%26aufirst%3DZ.%26aulast%3DMinarovits%26aufirst%3DJ.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520selective%2520CDK9%2520inhibitors%2520for%2520the%2520treatment%2520of%2520HIV%2520infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358%26doi%3D10.2174%2F092986711794839188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mothe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez-Arias, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Cell cycle control and HIV-1 susceptibility are linked by cdk6-dependent cdk2 phosphorylation of samhd1 in myeloid and lymphoid cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">1988</span>– <span class="NLM_lpage">1997</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1400873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1400873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25015816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2014&pages=1988-1997&author=E.+Paulsauthor=A.+Ruizauthor=R.+Badiaauthor=M.+Permanyerauthor=A.+Gubernauthor=E.+Riveira-Mu%C3%B1ozauthor=J.+Torres-Torronterasauthor=M.+%C3%81lvarezauthor=B.+Motheauthor=C.+Branderauthor=M.+Crespoauthor=L.+Men%C3%A9ndez-Ariasauthor=B.+Clotetauthor=O.+T.+Kepplerauthor=R.+Mart%C3%ADauthor=F.+Posasauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Cell+cycle+control+and+HIV-1+susceptibility+are+linked+by+cdk6-dependent+cdk2+phosphorylation+of+samhd1+in+myeloid+and+lymphoid+cells&doi=10.4049%2Fjimmunol.1400873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Cycle Control and HIV-1 Susceptibility Are Linked by CDK6-Dependent CDK2 Phosphorylation of SAMHD1 in Myeloid and Lymphoid Cells</span></div><div class="casAuthors">Pauls, Eduardo; Ruiz, Alba; Badia, Roger; Permanyer, Marc; Gubern, Albert; Riveira-Munoz, Eva; Torres-Torronteras, Javier; Alvarez, Mar; Mothe, Beatriz; Brander, Christian; Crespo, Manel; Menendez-Arias, Luis; Clotet, Bonaventura; Keppler, Oliver T.; Marti, Ramon; Posas, Francesc; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1988-1997</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Proliferating cells are preferentially susceptible to infection by retroviruses.  Sterile α motif and HD domain-contg. protein-1 (SAMHD1) is a recently described deoxynucleotide phosphohydrolase controlling the size of the intracellular deoxynucleotide triphosphate (dNTP) pool, a limiting factor for retroviral reverse transcription in noncycling cells.  Proliferating (Ki67+) primary CD4+ T cells or macrophages express a phosphorylated form of SAMHD1 that corresponds with susceptibility to infection in cell culture.  We identified cyclin-dependent kinase (CDK) 6 as an upstream regulator of CDK2 controlling SAMHD1 phosphorylation in primary T cells and macrophages susceptible to infection by HIV-1.  In turn, CDK2 was strongly linked to cell cycle progression and coordinated SAMHD1 phosphorylation and inactivation.  CDK inhibitors specifically blocked HIV-1 infection at the reverse transcription step in a SAMHD1-dependent manner, reducing the intracellular dNTP pool.  Our findings identify a direct relationship between control of the cell cycle by CDK6 and SAMHD1 activity, which is important for replication of lentiviruses, as well as other viruses whose replication may be regulated by intracellular dNTP availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-LI-z2ggFCbVg90H21EOLACvtfcHk0li5b6YSgpu2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Kju7%252FM&md5=5c1c895a20f64ad71e0578ea2fca74bf</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1400873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1400873%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DGubern%26aufirst%3DA.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3D%25C3%2581lvarez%26aufirst%3DM.%26aulast%3DMothe%26aufirst%3DB.%26aulast%3DBrander%26aufirst%3DC.%26aulast%3DCrespo%26aufirst%3DM.%26aulast%3DMen%25C3%25A9ndez-Arias%26aufirst%3DL.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DKeppler%26aufirst%3DO.%2BT.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPosas%26aufirst%3DF.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DCell%2520cycle%2520control%2520and%2520HIV-1%2520susceptibility%2520are%2520linked%2520by%2520cdk6-dependent%2520cdk2%2520phosphorylation%2520of%2520samhd1%2520in%2520myeloid%2520and%2520lymphoid%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2014%26volume%3D193%26spage%3D1988%26epage%3D1997%26doi%3D10.4049%2Fjimmunol.1400873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durand, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roizman, B.</span></span> <span> </span><span class="NLM_article-title">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">10591</span>– <span class="NLM_lpage">10599</span>, <span class="refDoi"> DOI: 10.1128/JVI.01242-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01242-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18753202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=10591-10599&author=L.+O.+Durandauthor=B.+Roizman&title=Role+of+cdk9+in+the+optimization+of+expression+of+the+genes+regulated+by+ICP22+of+herpes+simplex+virus+1&doi=10.1128%2FJVI.01242-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1</span></div><div class="casAuthors">Durand, Lizette Olga; Roizman, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">10591-10599</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">ICP22 is a multi-functional herpes simplex virus 1 (HSV-1) regulatory protein that regulates the accumulation of a subset of late (γ2) proteins exemplified by UL38, UL41, and US11.  ICP22 binds the cyclin-dependent kinase 9 (cdk9) but not cdk7, and this complex in conjunction with viral protein kinases phosphorylates the carboxyl terminus of RNA polymerase II (Pol II) in vitro.  The primary function of cdk9 and its partners, the cyclin T variants, is in the elongation of RNA transcripts, although functions related to the initiation and processing of transcripts have also been reported.  We report two series of expts. designed to probe the role of cdk9 in infected cells.  In the first, infected cells were treated with 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB), a specific inhibitor of cdk9.  In cells treated with DRB, the major effect was in the accumulation of viral RNAs and proteins regulated by ICP22.  The accumulation of α, β, or γ proteins not regulated by ICP22 was not affected by the drug.  The results obtained with DRB were duplicated in cells transfected with small interfering RNA (siRNA) targeting cdk9 mRNAs.  Interestingly, DRB and siRNA reduced the levels of ICP22 but not those of other α gene products.  In addn., cdk9 and ICP22 appeared to colocalize with RNA Pol II in wild-type-virus-infected cells but not in ΔUL13-infected cells.  We conclude that cdk9 plays a crit. role in the optimization of expression of genes regulated by ICP22 and that one function of cdk9 in HSV-1-infected cells may be to bring ICP22 into the RNA Pol II transcriptional complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXb1W_R979rVg90H21EOLACvtfcHk0li5b6YSgpu2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWitbbF&md5=7a494e43fe778e3ad849facc21b13143</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1128%2FJVI.01242-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01242-08%26sid%3Dliteratum%253Aachs%26aulast%3DDurand%26aufirst%3DL.%2BO.%26aulast%3DRoizman%26aufirst%3DB.%26atitle%3DRole%2520of%2520cdk9%2520in%2520the%2520optimization%2520of%2520expression%2520of%2520the%2520genes%2520regulated%2520by%2520ICP22%2520of%2520herpes%2520simplex%2520virus%25201%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D10591%26epage%3D10599%26doi%3D10.1128%2FJVI.01242-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhillon, S.</span></span> <span> </span><span class="NLM_article-title">Palbociclib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1007/s40265-015-0379-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs40265-015-0379-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25792301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=543-551&author=S.+Dhillon&title=Palbociclib%3A+first+global+approval&doi=10.1007%2Fs40265-015-0379-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib: First Global Approval</span></div><div class="casAuthors">Dhillon, Sohita</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-551</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Palbociclib (Ibrance) is an oral, reversible, selective, small-mol. inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6 developed by Pfizer for the treatment of cancer.  CDKs are important modulators of cell cycle entry and progression in response to growth signals, and inhibition of these kinases with palbociclib could enhance the activity of other anticancer drugs in tolerable regimens.  Palbociclib, in combination with letrozole, was recently approved in the US for the first-line treatment of advanced breast cancer.  Phase III development is underway worldwide investigating its use as first-line treatment in advanced breast cancer, as well as treatment of recurrent or advanced breast cancer and high-risk, early-stage breast cancer.  A phase II trial is underway in the USA for non-small cell lung cancer under a US National Cancer Institute-funded research collaboration, and several phase I and II investigations are being conducted for various other solid tumor types and haematol. malignancies.  This article summarizes the milestones in the development of palbociclib leading to this first approval for use in postmenopausal women with estrogen-pos., human epidermal growth factor receptor (HER) 2-neg. advanced breast cancer as initial endocrine-based therapy for their metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_I2Tzeff7_7Vg90H21EOLACvtfcHk0lit4r4GkSXeYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCrsrs%253D&md5=cd4f6d1160c06397c51e4b30222cb3d4</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0379-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0379-9%26sid%3Dliteratum%253Aachs%26aulast%3DDhillon%26aufirst%3DS.%26atitle%3DPalbociclib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D543%26epage%3D551%26doi%3D10.1007%2Fs40265-015-0379-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1097/QAD.0000000000000399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1097%2FQAD.0000000000000399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25036183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2213-2222&author=E.+Paulsauthor=R.+Badiaauthor=J.+Torres-Torronterasauthor=A.+Ruizauthor=M.+Permanyerauthor=E.+Riveira-Mu%C3%B1ozauthor=B.+Clotetauthor=R.+Martiauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Palbociclib%2C+a+selective+inhibitor+of+cyclin-dependent+kinase4%2F6%2C+blocks+HIV-1+reverse+transcription+through+the+control+of+sterile+%CE%B1+motif+and+HD+domain-containing+protein-1+%28SAMHD1%29+activity&doi=10.1097%2FQAD.0000000000000399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span></div><div class="casAuthors">Pauls, Eduardo; Badia, Roger; Torres-Torronteras, Javier; Ruiz, Alba; Permanyer, Marc; Riveira-Munoz, Eva; Clotet, Bonaventura; Marti, Ramon; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2213-2222</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Sterile α motif and HD domain-contg. protein-1 (SAMHD1) inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides.  SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation.  However, the exact mechanism of SAMHD1 regulation in primary cells is unclear.  We explore the effect of palbociclib, a CDK6 inhibitor, in HIV-1 replication.  Methods: Human primary monocytes were differentiated into macrophages with monocyte-colony stimulating factor and CD4 T lymphocytes stimulated with phytohaemagglutinin (PHA)/interleukin-2.  Cells were treated with palbociclib and then infected with a Green fluorescent protein-expressing HIV-1 or R5 HIV-1 BaL.  Viral DNA was measured by quant. PCR and infection assessed by flow cytometry.  Deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation.  HIV-1 replication was blocked by AT7519 (66.4±3.8%; n=4), roscovitine (47.3±3.9%; n=4) and purvalanol A (55.7±15.7%; n=4) at subtoxic concns.  Palbociclib, a potent and selective CDK6 inhibitor, blocked SAMHD1 phosphorylation, intracellular dNTP levels, HIV-1 reverse transcription and HIV-1 replication in primary macrophages and CD4 T lymphocytes.  Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160.  The antiviral effect was lost when SAMHD1 was degraded by Vpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect.  Conclusions: Our results indicate that SAMHD1-mediated HIV-1 restriction is controlled by CDK as previously suggested but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation.  Our study provides a new signaling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnbJDONasm7Vg90H21EOLACvtfcHk0lit4r4GkSXeYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM&md5=68935096ca65c2f15a2b24423c006302</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2FQAD.0000000000000399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0000000000000399%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DMarti%26aufirst%3DR.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DPalbociclib%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase4%252F6%252C%2520blocks%2520HIV-1%2520reverse%2520transcription%2520through%2520the%2520control%2520of%2520sterile%2520%25CE%25B1%2520motif%2520and%2520HD%2520domain-containing%2520protein-1%2520%2528SAMHD1%2529%2520activity%26jtitle%3DAIDS%26date%3D2014%26volume%3D28%26spage%3D2213%26epage%3D2222%26doi%3D10.1097%2FQAD.0000000000000399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile α motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0lit4r4GkSXeYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeiser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrlova, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiss, F.</span></span> <span> </span><span class="NLM_article-title">Trametinib (GSK1120212)</span>. <i>Recent Results Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-91442-8_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2F978-3-319-91442-8_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30069762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVSgtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=91-100&author=R.+Zeiserauthor=H.+Andrlovaauthor=F.+Meiss&title=Trametinib+%28GSK1120212%29&doi=10.1007%2F978-3-319-91442-8_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Trametinib (GSK1120212)</span></div><div class="casAuthors">Zeiser, Robert; Andrlova, Hana; Meiss, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Recent Results in Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">Small Molecules in Oncology</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">RRCRBU</span>;
        ISSN:<span class="NLM_cas:issn">2197-6767</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MEK MAPK/ERK kinase) signaling pathways play a crit. role in the regulation of diverse cellular activities, including survival, differentiation, proliferation, motility, and angiogenesis.  Therefore, MEK inhibition was recognized as a promising target for antineo-plastic therapy.  Trametinib (GSK1120212), an oral MEK inhibitor which is selective for MEK1 and MEK2, has been approved by the FDA for the treatment of metastatic melanoma in a combination with a BRAF inhibitor.  In this overview, preclin. and clin. data for trametinib are presented including mechanisms based on in vitro studies as well as findings from different clin. studies.  The future clin. trial in different solid tumor entities will define the therapeutic role of this targeted therapy approach, possibly as a combination with other targeted therapies such as BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7cKn7vicfELVg90H21EOLACvtfcHk0lhia2Shj76xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVSgtrjP&md5=c9255082da16be6f208cfb3e8334a74f</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-91442-8_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-91442-8_7%26sid%3Dliteratum%253Aachs%26aulast%3DZeiser%26aufirst%3DR.%26aulast%3DAndrlova%26aufirst%3DH.%26aulast%3DMeiss%26aufirst%3DF.%26atitle%3DTrametinib%2520%2528GSK1120212%2529%26jtitle%3DRecent%2520Results%2520Cancer%2520Res.%26date%3D2018%26volume%3D211%26spage%3D91%26epage%3D100%26doi%3D10.1007%2F978-3-319-91442-8_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schräder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29990517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmsFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=80-92&author=T.+Schr%C3%A4derauthor=S.+E.+Dudekauthor=A.+Schreiberauthor=C.+Ehrhardtauthor=O.+Planzauthor=S.+Ludwig&title=The+clinically+approved+MEK+inhibitor+Trametinib+efficiently+blocks+influenza+A+virus+propagation+and+cytokine+expression&doi=10.1016%2Fj.antiviral.2018.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression</span></div><div class="casAuthors">Schrader Tobias; Ehrhardt Christina; Dudek Sabine E; Schreiber Andre; Planz Oliver; Ludwig Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Influenza A virus (IAV) infections are still a major global threat for humans, especially for the risk groups of young children and the elderly.  Annual epidemics and sporadically occurring pandemics highlight the necessity of effective antivirals that can limit viral replication.  The currently licensed antiviral drugs target viral factors and are prone to provoke viral resistance.  In infected host cells IAV induces various cellular signaling cascades.  The Raf/MEK/ERK signaling cascade is indispensable for IAV replication because it triggers the nuclear export of newly assembled viral ribonucleoproteins (vRNPs).  Inhibition of this cascade limits viral replication.  Thus, next to their potential in anti-tumor therapy, inhibitors targeting the Raf/MEK/ERK signaling cascade came into focus as potential antiviral drugs.  The first licensed MEK inhibitor Trametinib (GSK-1120212) is used for treatment of malignant melanoma, being highly selective and having a promising side effect profile.  Since Trametinib may be qualified for a repurposing approach that would significantly shorten development time for an anti-flu use, we evaluated its antiviral potency and mode of action.  In this study, we describe that Trametinib efficiently blocks replication of different IAV subtypes in vitro and in vivo.  The broad antiviral activity against various IAV strains was due to its ability to interfere with export of progeny vRNPs from the nucleus.  The compound also limited hyper-expression of several cytokines.  Thus, we show for the first time that a clinically approved MEK inhibitor acts as a potent anti-influenza agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMPUw-TFMkJp6t8nS6Nc3fW6udTcc2ea-XnVoVtKqg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmsFOrsA%253D%253D&md5=5857631999e5b7b65ac64ab8d3767182</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchr%25C3%25A4der%26aufirst%3DT.%26aulast%3DDudek%26aufirst%3DS.%2BE.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DThe%2520clinically%2520approved%2520MEK%2520inhibitor%2520Trametinib%2520efficiently%2520blocks%2520influenza%2520A%2520virus%2520propagation%2520and%2520cytokine%2520expression%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D157%26spage%3D80%26epage%3D92%26doi%3D10.1016%2Fj.antiviral.2018.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haasbach, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmayer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2013.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2013.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23523553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntlSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=319-324&author=E.+Haasbachauthor=C.+Hartmayerauthor=O.+Planz&title=Combination+of+MEK+inhibitors+and+oseltamivir+leads+to+synergistic+antiviral+effects+after+influenza+A+virus+infection+in+vitro&doi=10.1016%2Fj.antiviral.2013.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro</span></div><div class="casAuthors">Haasbach, Emanuel; Hartmayer, Carmen; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-324</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">MEK inhibitors are very potent and promising compds. in cancer therapy.  Earlier investigations have demonstrated that they also possess antiviral properties against influenza virus.  This is due to the fact that activation of the Raf/MEK/ERK signaling pathway is a prerequisite for influenza virus replication.  As an alternative to vaccination, antiviral therapy is a means to control influenza.  The appearance of influenza virus strains that are resistant to current treatment options demonstrates the need for new antiviral strategies.  The aim of the presented study was to investigate whether the combination of MEK inhibitors with oseltamivir, an inhibitor of viral neuraminidase activity, would result in a synergistic antiviral effect against pandemic influenza A/Regensburg/D6/2009 (H1N1pdm09) virus.  Here we show that 4 different MEK inhibitors, PD-0325901, AZD-6244, AZD-8330, and RDEA-119 that are orally available and at least in a phase I clin. trial against cancer demonstrate antiviral activity as single agents or in combination with oseltamivir.  Combination treatment increased the antiviral activity of oseltamivir significantly and resulted in a synergistic antiviral effect as detd. by the Chou-Talalay method.  Taken together, the results demonstrate increased antiviral activity of oseltamivir after combination with MEK inhibitors.  These data are promising for further preclin. in vitro and in vivo investigations on the way to developing new antiviral regimens against influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA5--RW746VLVg90H21EOLACvtfcHk0lhia2Shj76xyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntlSmtbs%253D&md5=9723a5424927948bb7f18904f34a56b4</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2013.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2013.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DHaasbach%26aufirst%3DE.%26aulast%3DHartmayer%26aufirst%3DC.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DCombination%2520of%2520MEK%2520inhibitors%2520and%2520oseltamivir%2520leads%2520to%2520synergistic%2520antiviral%2520effects%2520after%2520influenza%2520A%2520virus%2520infection%2520in%2520vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2013%26volume%3D98%26spage%3D319%26epage%3D324%26doi%3D10.1016%2Fj.antiviral.2013.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koon, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krown, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapisuwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboulafia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudek, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dezube, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS malignancy consortium protocol 042</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">402</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.48.6365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1200%2FJCO.2012.48.6365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24378417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXls1Wiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=402-408&author=H.+B.+Koonauthor=S.+E.+Krownauthor=J.+Y.+Leeauthor=K.+Hondaauthor=S.+Rapisuwonauthor=Z.+Wangauthor=D.+Aboulafiaauthor=E.+G.+Reidauthor=M.+A.+Rudekauthor=B.+J.+Dezubeauthor=A.+Noy&title=Phase+II+trial+of+imatinib+in+AIDS-associated+Kaposi%E2%80%99s+sarcoma%3A+AIDS+malignancy+consortium+protocol+042&doi=10.1200%2FJCO.2012.48.6365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS malignancy consortium protocol 042</span></div><div class="casAuthors">Koon, Henry B.; Krown, Susan E.; Lee, Jeannette Y.; Honda, Kord; Rapisuwon, Suthee; Wang, Zhenghe; Aboulafia, David; Reid, Erin G.; Rudek, Michelle A.; Dezube, Bruce J.; Noy, Ariela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">402-408</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8).  Activation of the c-kit and platelet-derived growth factor (PDGF) receptors by autocrine/paracrine mechanisms follows endothelial cell KSHV infection.  In a pilot study, imatinib, a c-kit/PDGF-receptor inhibitor, induced partial regression of AIDS-assocd. KS (AIDS-KS) in five of 10 patients.  Patients and Methods This multicenter phase II study was designed to est. the response rate to imatinib in AIDS-KS.  Secondary objectives included investigation of predictors of response and imatinib pharmacokinetics in patients on antiretrovirals.  Patients received imatinib 400 mg/day by mouth for up to 12 mo with dose escalation up to 600 mg/day at 3 mo if their disease was stable.  Results Thirty patients were treated at 12 AIDS Malignancy Consortium sites.  Ten patients (33.3%) achieved partial response, six (20%) had stable disease, and seven (23.3%) exhibited KS progression.  Nine patients completed 52 wk of imatinib therapy.  The median treatment duration was 22.5 wk.  Only five patients (16.7%) discontinued therapy owing to adverse events.  Antiretroviral regimens did not significantly alter imatinib metab.  Activating mutations in PDGF-R and c-kit were not found at baseline or at disease progression.  We found no correlation with response with changes in any of the candidate cytokines.  Conclusion Imatinib has activity in AIDS-KS.  Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity.  Thirty percent of patients showed long-term clin. benefit and remained on imatinib for the entire year.  These results suggest imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1h992cqFsm7Vg90H21EOLACvtfcHk0ljgu1WDgVYZjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXls1Wiu7s%253D&md5=a58c653acc5f45e76011a6942934c172</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.6365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.6365%26sid%3Dliteratum%253Aachs%26aulast%3DKoon%26aufirst%3DH.%2BB.%26aulast%3DKrown%26aufirst%3DS.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DHonda%26aufirst%3DK.%26aulast%3DRapisuwon%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DAboulafia%26aufirst%3DD.%26aulast%3DReid%26aufirst%3DE.%2BG.%26aulast%3DRudek%26aufirst%3DM.%2BA.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DNoy%26aufirst%3DA.%26atitle%3DPhase%2520II%2520trial%2520of%2520imatinib%2520in%2520AIDS-associated%2520Kaposi%25E2%2580%2599s%2520sarcoma%253A%2520AIDS%2520malignancy%2520consortium%2520protocol%2520042%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D402%26epage%3D408%26doi%3D10.1200%2FJCO.2012.48.6365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egeblad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kempen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1006/bbrc.2001.4302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1006%2Fbbrc.2001.4302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11178955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFemsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2001&pages=25-31&author=M.+Egebladauthor=O.+H.+Mortensenauthor=L.+C.+van+Kempenauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=BIBX1382BS%2C+but+not+AG1478+or+PD153035%2C+inhibits+the+ErbB+kinases+at+different+concentrations+in+intact+cells&doi=10.1006%2Fbbrc.2001.4302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">BIBX1382BS, but Not AG1478 or PD153035, Inhibits the ErbB Kinases at Different Concentrations in Intact Cells</span></div><div class="casAuthors">Egeblad, Mikala; Mortensen, Ole H.; van Kempen, Leon C. L. T.; Jaattela, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The activation of ErbB tyrosine kinase receptors (ErbB1, -2, -3, and -4) by ligand-induced homo- or heterodimerization regulates cell growth, death, and differentiation.  AG1478 and PD153035 (also know as AG1517) have been adopted as specific ErbB1 inhibitors based on their high specificity for ErbB1 as compared to ErbB2 in in vitro kinase assays.  The authors compared their ability to inhibit ErbB receptor signaling in intact cells to that of a novel ErbB receptor kinase inhibitor, BIBX1382BS.  Neither AG1478 nor PD153035 displayed any specificity for ErbB1-mediated signaling induced by transforming growth factor α (TGF-α) as compared to signaling initiated through the other ErbB kinases.  In contrast, BIBX1382BS was more potent at inhibiting signaling induced by TGF-α than that induced by neuregulin1-β1 or anti-ErbB2 agonist antibodies.  Interestingly, this compd. blocked antibody-induced ErbB4 homodimer activation at even lower concns. than ErbB1-triggered signaling.  Thus, BIBX1382BS, but not AG1478 and PD153035, can be employed to differentiate between the ErbB kinases in intact cells when used at appropriate concns.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT-5Grd1YMP7Vg90H21EOLACvtfcHk0ljgu1WDgVYZjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFemsL0%253D&md5=a93b3d75bf3ef5dac851f284cd7cb39f</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2001.4302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2001.4302%26sid%3Dliteratum%253Aachs%26aulast%3DEgeblad%26aufirst%3DM.%26aulast%3DMortensen%26aufirst%3DO.%2BH.%26aulast%3Dvan%2BKempen%26aufirst%3DL.%2BC.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DBIBX1382BS%252C%2520but%2520not%2520AG1478%2520or%2520PD153035%252C%2520inhibits%2520the%2520ErbB%2520kinases%2520at%2520different%2520concentrations%2520in%2520intact%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D281%26spage%3D25%26epage%3D31%26doi%3D10.1006%2Fbbrc.2001.4302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spengler, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albariño, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava-Ranjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2015.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25986249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXos1eltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2015&pages=40-47&author=E.+L.+Mohrauthor=L.+K.+McMullanauthor=M.+K.+Loauthor=J.+R.+Spenglerauthor=%C3%89.+Bergeronauthor=C.+G.+Albari%C3%B1oauthor=P.+Shrivastava-Ranjanauthor=C.+F.+Chiangauthor=S.+T.+Nicholauthor=C.+F.+Spiropoulouauthor=M.+Flint&title=Inhibitors+of+cellular+kinases+with+broad-spectrum+antiviral+activity+for+hemorrhagic+fever+viruses&doi=10.1016%2Fj.antiviral.2015.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cellular kinases with broad-spectrum antiviral activity for hemorrhagic fever viruses</span></div><div class="casAuthors">Mohr, Emma L.; McMullan, Laura K.; Lo, Michael K.; Spengler, Jessica R.; Bergeron, Eric; Albarino, Cesar G.; Shrivastava-Ranjan, Punya; Chiang, Cheng-Feng; Nichol, Stuart T.; Spiropoulou, Christina F.; Flint, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-47</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Host cell kinases are important for the replication of a no. of hemorrhagic fever viruses.  We tested a panel of kinase inhibitors for their ability to block the replication of multiple hemorrhagic fever viruses.  OSU-03012 inhibited the replication of Lassa, Ebola, Marburg and Nipah viruses, whereas BIBX 1382 dihydrochloride inhibited Lassa, Ebola and Marburg viruses.  BIBX 1382 blocked both Lassa and Ebola virus glycoprotein-dependent cell entry.  These compds. may be used as tools to understand conserved virus-host interactions, and implicate host cell kinases that may be targets for broad spectrum therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMf48R5EzygbVg90H21EOLACvtfcHk0ljgu1WDgVYZjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXos1eltrk%253D&md5=8475f940789e99dff0ecb80bbd248b24</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DMohr%26aufirst%3DE.%2BL.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DSpengler%26aufirst%3DJ.%2BR.%26aulast%3DBergeron%26aufirst%3D%25C3%2589.%26aulast%3DAlbari%25C3%25B1o%26aufirst%3DC.%2BG.%26aulast%3DShrivastava-Ranjan%26aufirst%3DP.%26aulast%3DChiang%26aufirst%3DC.%2BF.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DFlint%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520cellular%2520kinases%2520with%2520broad-spectrum%2520antiviral%2520activity%2520for%2520hemorrhagic%2520fever%2520viruses%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D120%26spage%3D40%26epage%3D47%26doi%3D10.1016%2Fj.antiviral.2015.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span> <span> </span><span class="NLM_article-title">Canertinib pfizer</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=14730468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFOgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=58-63&author=C.+M.+Galmarini&title=Canertinib+pfizer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Canertinib (Pfizer)</span></div><div class="casAuthors">Galmarini, Carlos Maria</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-63</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review. Canertinib, a water-sol., orally available analog of PD-169414, is an epidermal growth factor tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.  This article describes the synthesis and structure-activity relations of the compd., its preclin. development, metab. and pharmacokinetics, toxicity, clin. development, and side effects and contraindications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB89fHpFtThrVg90H21EOLACvtfcHk0lj-Zht5i1BoNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFOgsL4%253D&md5=16edbe74a518e9eb2143a02ab48af1ec</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26atitle%3DCanertinib%2520pfizer%26jtitle%3DIDrugs%26date%3D2004%26volume%3D7%26spage%3D58%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reche, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morehead, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damon, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinherz, E. L.</span></span> <span> </span><span class="NLM_article-title">Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">379</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1172/JCI200523220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI200523220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15690085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=379-387&author=H.+Yangauthor=S.+K.+Kimauthor=M.+Kimauthor=P.+A.+Recheauthor=T.+J.+Moreheadauthor=I.+K.+Damonauthor=R.+M.+Welshauthor=E.+L.+Reinherz&title=Antiviral+chemotherapy+facilitates+control+of+poxvirus+infections+through+inhibition+of+cellular+signal+transduction&doi=10.1172%2FJCI200523220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction</span></div><div class="casAuthors">Yang, Hailin; Kim, Sung-Kwon; Kim, Mikyung; Reche, Pedro A.; Morehead, Tiara J.; Damon, Inger K.; Welsh, Raymond M.; Reinherz, Ellis L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">379-387</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">The EGF-like domain of smallpox growth factor (SPGF) targets human ErbB-1, inducing tyrosine phosphorylation of certain host cellular substrates via activation of the receptor's kinase domain and thereby facilitating viral replication.  Given these findings, low mol. wt. org. inhibitors of ErbB-1 kinases might function as antiviral agents against smallpox.  Here the authors show that CI-1033 and related 4-anilinoquinazolines inhibit SPGF-induced human cellular DNA synthesis, protein tyrosine kinase activation, and c-Cbl assocn. with ErbB-1 and resultant internalization.  Infection of monkey kidney BSC-40 and VERO-E6 cells in vitro by variola strain Solaimen is blocked by CI-1033, primarily at the level of secondary viral spreading.  In an in vivo lethal vaccinia virus pneumonia model, CI-1033 alone promotes survival of animals, augments systemic T cell immunity and, in conjunction with a single dose of anti-L1R intracellular mature virus particle-specific mAb, fosters virtually complete viral clearance of the lungs of infected mice by the eighth day after infection.  Collectively, these findings show that chem. inhibitors of host-signaling pathways exploited by viral pathogens may represent potent antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWVtv6p3y8lrVg90H21EOLACvtfcHk0lj-Zht5i1BoNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjsb0%253D&md5=c1b511e39b6762c0db4ccc081e0bf850</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1172%2FJCI200523220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI200523220%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DReche%26aufirst%3DP.%2BA.%26aulast%3DMorehead%26aufirst%3DT.%2BJ.%26aulast%3DDamon%26aufirst%3DI.%2BK.%26aulast%3DWelsh%26aufirst%3DR.%2BM.%26aulast%3DReinherz%26aufirst%3DE.%2BL.%26atitle%3DAntiviral%2520chemotherapy%2520facilitates%2520control%2520of%2520poxvirus%2520infections%2520through%2520inhibition%2520of%2520cellular%2520signal%2520transduction%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D379%26epage%3D387%26doi%3D10.1172%2FJCI200523220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cargill, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della
Corte, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardnell, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-20-0414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1541-7786.MCR-20-0414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=33172976" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=K.+Ramkumarauthor=C.+A.+Stewartauthor=K.+R.+Cargillauthor=C.+M.+Della%0ACorteauthor=Q.+Wangauthor=L.+Shenauthor=L.+Diaoauthor=R.+J.+Cardnellauthor=D.+H.+Pengauthor=B.+L.+Rodriguezauthor=Y.+H.+Fanauthor=J.+V.+Heymachauthor=J.+Wangauthor=C.+M.+Gayauthor=D.+L.+Gibbonsauthor=L.+A.+Byers&title=AXL+inhibition+induces+DNA+damage+and+replication+stress+in+non-small+cell+lung+cancer+cells+and+promotes+sensitivity+to+ATR+inhibitors&doi=10.1158%2F1541-7786.MCR-20-0414"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-20-0414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-20-0414%26sid%3Dliteratum%253Aachs%26aulast%3DRamkumar%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DC.%2BA.%26aulast%3DCargill%26aufirst%3DK.%2BR.%26aulast%3DDella%2BCorte%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DPeng%26aufirst%3DD.%2BH.%26aulast%3DRodriguez%26aufirst%3DB.%2BL.%26aulast%3DFan%26aufirst%3DY.%2BH.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DAXL%2520inhibition%2520induces%2520DNA%2520damage%2520and%2520replication%2520stress%2520in%2520non-small%2520cell%2520lung%2520cancer%2520cells%2520and%2520promotes%2520sensitivity%2520to%2520ATR%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F1541-7786.MCR-20-0414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strange, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiyarom, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourhabibi
Zarandi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadri-Ardekani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, S.</span></span> <span> </span><span class="NLM_article-title">Axl promotes zika virus entry and modulates the antiviral state of human sertoli cells</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e01372-19</span>, <span class="refDoi"> DOI: 10.1128/mBio.01372-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FmBio.01372-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31311882" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=e01372-19&author=D.+P.+Strangeauthor=B.+Jiyaromauthor=N.+Pourhabibi%0AZarandiauthor=X.+Xieauthor=C.+Bakerauthor=H.+Sadri-Ardekaniauthor=P.+Y.+Shiauthor=S.+Verma&title=Axl+promotes+zika+virus+entry+and+modulates+the+antiviral+state+of+human+sertoli+cells&doi=10.1128%2FmBio.01372-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1128%2FmBio.01372-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.01372-19%26sid%3Dliteratum%253Aachs%26aulast%3DStrange%26aufirst%3DD.%2BP.%26aulast%3DJiyarom%26aufirst%3DB.%26aulast%3DPourhabibi%2BZarandi%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBaker%26aufirst%3DC.%26aulast%3DSadri-Ardekani%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DP.%2BY.%26aulast%3DVerma%26aufirst%3DS.%26atitle%3DAxl%2520promotes%2520zika%2520virus%2520entry%2520and%2520modulates%2520the%2520antiviral%2520state%2520of%2520human%2520sertoli%2520cells%26jtitle%3DmBio%26date%3D2019%26volume%3D10%26spage%3De01372-19%26doi%3D10.1128%2FmBio.01372-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Soyza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phekoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarvey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar-Hari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sykes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">Accord Collaborators. ACCORD: A multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of covid-19 in hospitalised patients: A structured summary of a study protocol for a randomised controlled trial</span>. <i>Trials</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">691</span>, <span class="refDoi"> DOI: 10.1186/s13063-020-04584-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13063-020-04584-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32736596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFaisrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=691&author=T.+Wilkinsonauthor=R.+Dixonauthor=C.+Pageauthor=M.+Carrollauthor=G.+Griffithsauthor=L.+P.+Hoauthor=A.+De+Soyzaauthor=T.+Feltonauthor=K.+E.+Lewisauthor=K.+Phekooauthor=J.+D.+Chalmersauthor=A.+Gordonauthor=L.+McGarveyauthor=J.+Dohertyauthor=R.+C.+Readauthor=M.+Shankar-Hariauthor=N.+Martinez-Alierauthor=M.+O%E2%80%99Kellyauthor=G.+Duncanauthor=R.+Wallesauthor=J.+Sykesauthor=C.+Summersauthor=D.+Singh&title=Accord+Collaborators.+ACCORD%3A+A+multicentre%2C+seamless%2C+phase+2+adaptive+randomisation+platform+study+to+assess+the+efficacy+and+safety+of+multiple+candidate+agents+for+the+treatment+of+covid-19+in+hospitalised+patients%3A+A+structured+summary+of+a+study+protocol+for+a+randomised+controlled+trial&doi=10.1186%2Fs13063-020-04584-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial</span></div><div class="casAuthors">Wilkinson, Tom; Dixon, Rupert; Page, Clive; Carroll, Miles; Griffiths, Gareth; Ho, Ling-Pei; De Soyza, Anthony; Felton, Timothy; Lewis, Keir E.; Phekoo, Karen; Chalmers, James D.; Gordon, Anthony; McGarvey, Lorcan; Doherty, Jillian; Read, Robert C.; Shankar-Hari, Manu; Martinez-Alier, Nuria; O'Kelly, Michael; Duncan, Graeme; Walles, Roelize; Sykes, James; Summers, Charlotte; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Trials</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">691</span>CODEN:
                <span class="NLM_cas:coden">TRIACW</span>;
        ISSN:<span class="NLM_cas:issn">1745-6215</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">In Stage 1 we will evaluate the safety and efficacy of candidate agents as add-on therapies to std. of care (SoC) in patients hospitalized with COVID-19 in a screening stage.  Stage 2 is to confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalized with COVID-19 in an expansion stage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEl0Zg6TU-5rVg90H21EOLACvtfcHk0liMt3XBLCwTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFaisrrP&md5=5ceb30e9e8319c31831d2987f4a68172</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1186%2Fs13063-020-04584-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13063-020-04584-9%26sid%3Dliteratum%253Aachs%26aulast%3DWilkinson%26aufirst%3DT.%26aulast%3DDixon%26aufirst%3DR.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DHo%26aufirst%3DL.%2BP.%26aulast%3DDe%2BSoyza%26aufirst%3DA.%26aulast%3DFelton%26aufirst%3DT.%26aulast%3DLewis%26aufirst%3DK.%2BE.%26aulast%3DPhekoo%26aufirst%3DK.%26aulast%3DChalmers%26aufirst%3DJ.%2BD.%26aulast%3DGordon%26aufirst%3DA.%26aulast%3DMcGarvey%26aufirst%3DL.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DRead%26aufirst%3DR.%2BC.%26aulast%3DShankar-Hari%26aufirst%3DM.%26aulast%3DMartinez-Alier%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Kelly%26aufirst%3DM.%26aulast%3DDuncan%26aufirst%3DG.%26aulast%3DWalles%26aufirst%3DR.%26aulast%3DSykes%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DAccord%2520Collaborators.%2520ACCORD%253A%2520A%2520multicentre%252C%2520seamless%252C%2520phase%25202%2520adaptive%2520randomisation%2520platform%2520study%2520to%2520assess%2520the%2520efficacy%2520and%2520safety%2520of%2520multiple%2520candidate%2520agents%2520for%2520the%2520treatment%2520of%2520covid-19%2520in%2520hospitalised%2520patients%253A%2520A%2520structured%2520summary%2520of%2520a%2520study%2520protocol%2520for%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DTrials%26date%3D2020%26volume%3D21%26spage%3D691%26doi%3D10.1186%2Fs13063-020-04584-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Encinar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, J. A.</span></span> <span> </span><span class="NLM_article-title">Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2’-O-methylation of viral RNA</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">525</span>, <span class="refDoi"> DOI: 10.3390/v12050525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv12050525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2gtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=525&author=J.+A.+Encinarauthor=J.+A.+Menendez&title=Potential+drugs+targeting+early+innate+immune+evasion+of+SARS-coronavirus+2+via+2%E2%80%99-O-methylation+of+viral+RNA&doi=10.3390%2Fv12050525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2'-O-methylation of viral RNA</span></div><div class="casAuthors">Encinar, Jose Antonio; Menendez, Javier A.</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">525</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 respiratory disease pandemic utilizes unique 2'-O-methyltransferase (2'-O-MTase) capping machinery to camouflage its RNA from innate immune recognition.  The nsp16 catalytic subunit of the 2'-O-MTase is unusual in its requirement for a stimulatory subunit (nsp10) to catalyze the ribose 2'-O-methylation of the viral RNA cap.  Here we provide a computational basis for drug repositioning or de novo drug development based on three differential traits of the intermol. interactions of the SARS-CoV-2-specific nsp16/nsp10 heterodimer, namely: (1) the S-adenosyl-L-methionine-binding pocket of nsp16, (2) the unique "activating surface" between nsp16 and nsp10, and (3) the RNA-binding groove of nsp16.  We employed ≈9000 U.S. Food and Drug Administration (FDA)-approved investigational and exptl. drugs from the DrugBank repository for docking virtual screening.  After mol. dynamics calcns. of the stability of the binding modes of high-scoring nsp16/nsp10-drug complexes, we considered their pharmacol. overlapping with functional modules of the virus-host interactome that is relevant to the viral lifecycle, and to the clin. features of COVID-19.  Some of the predicted drugs (e.g., tegobuvir, sonidegib, siramesine, antrafenine, bemcentinib, itacitinib, or phthalocyanine) might be suitable for repurposing to pharmacol. reactivate innate immune restriction and antagonism of SARS-CoV-2 RNAs lacking 2'-O-methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0mO1fQpoAxrVg90H21EOLACvtfcHk0liMt3XBLCwTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2gtbzM&md5=48d6a5c7ce6aef4e099bd9e6256d2952</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.3390%2Fv12050525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv12050525%26sid%3Dliteratum%253Aachs%26aulast%3DEncinar%26aufirst%3DJ.%2BA.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DPotential%2520drugs%2520targeting%2520early%2520innate%2520immune%2520evasion%2520of%2520SARS-coronavirus%25202%2520via%25202%25E2%2580%2599-O-methylation%2520of%2520viral%2520RNA%26jtitle%3DViruses%26date%3D2020%26volume%3D12%26spage%3D525%26doi%3D10.3390%2Fv12050525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi"> DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+middle+east+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0liMt3XBLCwTcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520middle%2520east%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nabavi, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtemariam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berindan-Neagoe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cismaru, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasekhian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagheri, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabavi, S. M.</span></span> <span> </span><span class="NLM_article-title">Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2</span>. <i>Arch. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.5114/aoms.2020.94504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.5114%2Faoms.2020.94504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32399097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlWqsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=519-521&author=S.+F.+Nabaviauthor=S.+Habtemariamauthor=E.+Clementiauthor=I.+Berindan-Neagoeauthor=C.+A.+Cismaruauthor=M.+Rasekhianauthor=M.+Banachauthor=M.+Izadiauthor=M.+Bagheriauthor=M.+S.+Bagheriauthor=S.+M.+Nabavi&title=Lessons+learned+from+SARS-CoV+and+MERS-CoV%3A+FDA-approved+Abelson+tyrosine-protein+kinase+2+inhibitors+may+help+us+combat+SARS-CoV-2&doi=10.5114%2Faoms.2020.94504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2</span></div><div class="casAuthors">Nabavi, Seyed Fazel; Habtemariam, Solomon; Clementi, Emilio; Berindan-Neagoe, Ioana; Cismaru, Cosmin Andrei; Rasekhian, Mahsa; Banach, Maciej; Izadi, Morteza; Bagheri, Mahdi; Bagheri, Mohammad Sadegh; Nabavi, Seyed Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Medical Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">519-521</span>CODEN:
                <span class="NLM_cas:coden">AMSRDQ</span>;
        ISSN:<span class="NLM_cas:issn">1896-9151</span>.
    
            (<span class="NLM_cas:orgname">Termedia sp. z o.o.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZzKZM7zwe7Vg90H21EOLACvtfcHk0liWmYTL7Z5Vfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlWqsrzO&md5=78aabe527a681c3e4232446e06f4e5c9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.5114%2Faoms.2020.94504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5114%252Faoms.2020.94504%26sid%3Dliteratum%253Aachs%26aulast%3DNabavi%26aufirst%3DS.%2BF.%26aulast%3DHabtemariam%26aufirst%3DS.%26aulast%3DClementi%26aufirst%3DE.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26aulast%3DCismaru%26aufirst%3DC.%2BA.%26aulast%3DRasekhian%26aufirst%3DM.%26aulast%3DBanach%26aufirst%3DM.%26aulast%3DIzadi%26aufirst%3DM.%26aulast%3DBagheri%26aufirst%3DM.%26aulast%3DBagheri%26aufirst%3DM.%2BS.%26aulast%3DNabavi%26aufirst%3DS.%2BM.%26atitle%3DLessons%2520learned%2520from%2520SARS-CoV%2520and%2520MERS-CoV%253A%2520FDA-approved%2520Abelson%2520tyrosine-protein%2520kinase%25202%2520inhibitors%2520may%2520help%2520us%2520combat%2520SARS-CoV-2%26jtitle%3DArch.%2520Med.%2520Sci.%26date%3D2020%26volume%3D16%26spage%3D519%26epage%3D521%26doi%3D10.5114%2Faoms.2020.94504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabzevari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farsaci, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J. W.</span></span> <span> </span><span class="NLM_article-title">Distinct effects of saracatinib on memory CD8+ T cell differentiation</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">4323</span>– <span class="NLM_lpage">4333</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1101439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1101439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22450814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVKis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2012&pages=4323-4333&author=S.+Takaiauthor=H.+Sabzevariauthor=B.+Farsaciauthor=J.+Schlomauthor=J.+W.+Greiner&title=Distinct+effects+of+saracatinib+on+memory+CD8%2B+T+cell+differentiation&doi=10.4049%2Fjimmunol.1101439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation</span></div><div class="casAuthors">Takai, Shinji; Sabzevari, Helen; Farsaci, Benedetto; Schlom, Jeffrey; Greiner, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4323-4333</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Immunol. memory involving CD8+ T cells is a hallmark of an adaptive Ag-specific immune response and constitutes a crit. component of protective immunity.  Designing approaches that enhance long-term T cell memory would, for the most part, fortify vaccines and enhance host protection against infectious diseases and, perhaps, cancer immunotherapy.  A better understanding of the cellular programs involved in the Ag-specific T cell response has led to new approaches that target the magnitude and quality of the memory T cell response.  In this article, we show that T cells from TCR transgenic mice for the nucleoprotein of influenza virus NP68 exhibit the distinct phases-priming, expansion, contraction, and memory-of an Ag-specific T cell response when exposed in vitro to the cognate peptide.  Saracatinib, a specific inhibitor of Src family kinases, administered at low doses during the expansion or contraction phases, increased CD62Lhigh/CD44high central memory CD8+ T cells and IFN-γ prodn. but suppressed immunity when added during the priming phase.  These effects by saracatinib were not accompanied by the expected decline of Src family kinases but were accompanied by Akt-mammalian target of rapamycin suppression and/or mediated via another pathway.  Increased central memory cells by saracatinib were recapitulated in mice using a poxvirus-based influenza vaccine, thus underscoring the importance of dose and timing of the inhibitor in the context of memory T cell differentiation.  Finally, vaccine plus saracatinib treatment showed better protection against tumor challenge.  The immune-potentiating effects on CD8+ T cells by a low dose of saracatinib might afford better protection from pathogens or cancer when combined with vaccine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0R8mdTuUVi7Vg90H21EOLACvtfcHk0liWmYTL7Z5Vfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVKis7c%253D&md5=d7a00d74cb4bc6fb075f4b1ad3c2ae27</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1101439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1101439%26sid%3Dliteratum%253Aachs%26aulast%3DTakai%26aufirst%3DS.%26aulast%3DSabzevari%26aufirst%3DH.%26aulast%3DFarsaci%26aufirst%3DB.%26aulast%3DSchlom%26aufirst%3DJ.%26aulast%3DGreiner%26aufirst%3DJ.%2BW.%26atitle%3DDistinct%2520effects%2520of%2520saracatinib%2520on%2520memory%2520CD8%252B%2520T%2520cell%2520differentiation%26jtitle%3DJ.%2520Immunol.%26date%3D2012%26volume%3D188%26spage%3D4323%26epage%3D4333%26doi%3D10.4049%2Fjimmunol.1101439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e44</span>, <span class="refDoi"> DOI: 10.1038/bcj.2011.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fbcj.2011.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22829080" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=e44&author=S.+Hartauthor=K.+C.+Gohauthor=V.+Novotny-Diermayrauthor=Y.+C.+Tanauthor=B.+Madanauthor=C.+Amaliniauthor=L.+C.+Ongauthor=B.+Khengauthor=A.+Cheongauthor=J.+Zhouauthor=W.+J.+Chngauthor=J.+M.+Wood&title=Pacritinib+%28SB1518%29%2C+a+JAK2%2FFLT3+inhibitor+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1038%2Fbcj.2011.43"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2011.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2011.43%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DS.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DMadan%26aufirst%3DB.%26aulast%3DAmalini%26aufirst%3DC.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DKheng%26aufirst%3DB.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DPacritinib%2520%2528SB1518%2529%252C%2520a%2520JAK2%252FFLT3%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2011%26volume%3D1%26spage%3De44%26doi%3D10.1038%2Fbcj.2011.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>PRE-VENT
study in hospitalized patients with severe COVID-19 with or without
cancer</i>, NCT04404361, CTI BioPharma, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+PRE-VENT%0Astudy+in+hospitalized+patients+with+severe+COVID-19+with+or+without%0Acancer%2C+NCT04404361%2C+CTI+BioPharma%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DPRE-VENT%250Astudy%2520in%2520hospitalized%2520patients%2520with%2520severe%2520COVID-19%2520with%2520or%2520without%250Acancer" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persky, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">2997</span>– <span class="NLM_lpage">3005</span>, <span class="refDoi"> DOI: 10.1002/ijc.26324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fijc.26324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21796626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=2997-3005&author=W.+Qiauthor=X.+Liuauthor=L.+S.+Cookeauthor=D.+O.+Perskyauthor=T.+P.+Millerauthor=M.+Squiresauthor=D.+Mahadevan&title=AT9283%2C+a+novel+aurora+kinase+inhibitor%2C+suppresses+tumor+growth+in+aggressive+B-cell+lymphomas&doi=10.1002%2Fijc.26324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas</span></div><div class="casAuthors">Qi, Wenqing; Liu, Xiaobing; Cooke, Laurence S.; Persky, Daniel O.; Miller, Thomas P.; Squires, Matthew; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2997-3005</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Aurora kinases are oncogenic serine/threonine kinases that play key roles in regulating the mitotic phase of the eukaryotic cell cycle.  Auroras are overexpressed in numerous tumors including B-cell non-Hodgkin's lymphomas and are validated oncol. targets.  AT9283, a pan-aurora inhibitor inhibited growth and survival of multiple solid tumors in vitro and in vivo.  In this study, we demonstrated that AT9283 had potent activity against Aurora B in a variety of aggressive B-(non-Hodgkin lymphoma) B-NHL cell lines.  Cells treated with AT9283 exhibited endoreduplication confirming the mechanism of action of an Aurora B inhibitor.  Also, treatment of B-NHL cell lines with AT9283 induced apoptosis in a dose and time dependent manner and inhibited cell proliferation with an IC50 < 1 μM.  It is well known that inhibition of auroras (A or B) synergistically enhances the effects of microtubule targeting agents such as taxanes and vinca alkaloids to induce antiproliferation and apoptosis.  We evaluated whether AT9283 in combination with docetaxel is more efficient in inducing apoptosis than AT9283 or docetaxel alone.  At very low doses (5 nM) apoptosis was doubled in the combination (23%) compared to AT9283 or docetaxel alone (10%).  A mouse xenograft model of mantle cell lymphoma demonstrated that AT9283 at 15 mg/kg and docetaxel (10 mg/kg) alone had modest anti-tumor activity.  However, AT9283 at 20 mg/kg and AT9283 (15 or 20 mg/kg) plus docetaxel (10 mg/kg) demonstrated a statistically significant tumor growth inhibition and enhanced survival.  Together, our results suggest that AT9283 plus docetaxel may represent a novel therapeutic strategy in B-cell NHL and warrant early phase clin. trial evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZrGCnYS1skLVg90H21EOLACvtfcHk0lj2nZQ2nAqHAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyru77P&md5=97924eef001b0646fffe26b56ef4ad1b</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1002%2Fijc.26324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26324%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCooke%26aufirst%3DL.%2BS.%26aulast%3DPersky%26aufirst%3DD.%2BO.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DAT9283%252C%2520a%2520novel%2520aurora%2520kinase%2520inhibitor%252C%2520suppresses%2520tumor%2520growth%2520in%2520aggressive%2520B-cell%2520lymphomas%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D2997%26epage%3D3005%26doi%3D10.1002%2Fijc.26324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Aiuto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrion, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokuburra, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurdak, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yolken, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinchington, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloom, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimgaonkar, V. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of three cell-based drug screening platforms for HSV-1 infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28342892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsV2jtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=136-140&author=L.+D%E2%80%99Aiutoauthor=K.+Williamsonauthor=P.+Dimitrionauthor=J.+McNultyauthor=C.+E.+Brownauthor=C.+B.+Dokuburraauthor=A.+J.+Nielsenauthor=W.+J.+Linauthor=P.+Piazzaauthor=M.+E.+Schurdakauthor=J.+Woodauthor=R.+H.+Yolkenauthor=P.+R.+Kinchingtonauthor=D.+C.+Bloomauthor=V.+L.+Nimgaonkar&title=Comparison+of+three+cell-based+drug+screening+platforms+for+HSV-1+infection&doi=10.1016%2Fj.antiviral.2017.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of three cell-based drug screening platforms for HSV-1 infection</span></div><div class="casAuthors">D'Aiuto, Leonardo; Williamson, Kelly; Dimitrion, Peter; McNulty, James; Brown, Carla E.; Dokuburra, Chanti Babu; Nielsen, Alexander J.; Lin, Wen Jing; Piazza, Paolo; Schurdak, Mark E.; Wood, Joel; Yolken, Robert H.; Kinchington, Paul R.; Bloom, David C.; Nimgaonkar, Vishwajit L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">136-140</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acyclovir (ACV) and its derivs. have been highly effective for treating recurrent, lytic infections with Herpes Simplex Virus, type 1 (HSV-1), but searches for addnl. antiviral drugs are motivated by recent reports of resistance to ACV, particularly among immunocompromised patients.  In addn., the relative neurotoxicity of ACV and its inability to prevent neurol. sequelae among HSV-1 encephalitis survivors compel searches for new drugs to treat HSV-1 infections of the central nervous system (CNS).  Primary drug screens for neurotropic viruses like HSV-1 typically utilize non-neuronal cell lines, but they may miss drugs that have neuron specific antiviral effects.  Therefore, we compared the effects of a panel of conventional and novel anti-herpetic compds. in monkey epithelial (Vero) cells, human induced pluripotent stem cells (hiPSCs)-derived neural progenitor cells (NPCs) and hiPSC-derived neurons (N = 73 drugs).  While the profiles of activity for the majority of the drugs were similar in all three tissues, Vero cells were less likely than NPCs to identify drugs with substantial inhibitory activity in hiPSC-derived neurons.  We discuss the relative merits of each cell type for antiviral drug screens against neuronal infections with HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI5Pecgdd87LVg90H21EOLACvtfcHk0lj2nZQ2nAqHAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsV2jtLc%253D&md5=bbea0d9c8ea4c33dad8fc482d62088e0</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Aiuto%26aufirst%3DL.%26aulast%3DWilliamson%26aufirst%3DK.%26aulast%3DDimitrion%26aufirst%3DP.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DC.%2BE.%26aulast%3DDokuburra%26aufirst%3DC.%2BB.%26aulast%3DNielsen%26aufirst%3DA.%2BJ.%26aulast%3DLin%26aufirst%3DW.%2BJ.%26aulast%3DPiazza%26aufirst%3DP.%26aulast%3DSchurdak%26aufirst%3DM.%2BE.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DYolken%26aufirst%3DR.%2BH.%26aulast%3DKinchington%26aufirst%3DP.%2BR.%26aulast%3DBloom%26aufirst%3DD.%2BC.%26aulast%3DNimgaonkar%26aufirst%3DV.%2BL.%26atitle%3DComparison%2520of%2520three%2520cell-based%2520drug%2520screening%2520platforms%2520for%2520HSV-1%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D142%26spage%3D136%26epage%3D140%26doi%3D10.1016%2Fj.antiviral.2017.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. A.</span></span> <span> </span><span class="NLM_article-title">Filgotinib, a JAK1 inhibitor, for treatment-resistant rheumatoid arthritis</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.1001/jama.2019.9056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1001%2Fjama.2019.9056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31334773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvgt1CnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2019&pages=309-311&author=J.+A.+Singh&title=Filgotinib%2C+a+JAK1+inhibitor%2C+for+treatment-resistant+rheumatoid+arthritis&doi=10.1001%2Fjama.2019.9056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis</span></div><div class="casAuthors">Singh Jasvinder A; Singh Jasvinder A; Singh Jasvinder A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-311</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_PfUXIyzcJXwOGIfWJ7-GfW6udTcc2eYv7Y7-P17JObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvgt1CnsQ%253D%253D&md5=fc8f96d49b28c96593bac1d649e10a47</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1001%2Fjama.2019.9056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2019.9056%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%2BA.%26atitle%3DFilgotinib%252C%2520a%2520JAK1%2520inhibitor%252C%2520for%2520treatment-resistant%2520rheumatoid%2520arthritis%26jtitle%3DJAMA%26date%3D2019%26volume%3D322%26spage%3D309%26epage%3D311%26doi%3D10.1001%2Fjama.2019.9056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenike, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarella, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. C.</span></span> <span> </span><span class="NLM_article-title">Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">4969</span>– <span class="NLM_lpage">4984</span>, <span class="refDoi"> DOI: 10.1172/JCI137371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI137371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32573496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVejsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2020&pages=4969-4984&author=Y.+J.+Yehauthor=K.+M.+Jenikeauthor=R.+M.+Calviauthor=J.+Chiarellaauthor=R.+Hohauthor=S.+G.+Deeksauthor=Y.+C.+Ho&title=Filgotinib+suppresses+HIV-1-driven+gene+transcription+by+inhibiting+HIV-1+splicing+and+T+cell+activation&doi=10.1172%2FJCI137371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation</span></div><div class="casAuthors">Yeh, Yang-Hui Jimmy; Jenike, Katharine M.; Calvi, Rachela M.; Chiarella, Jennifer; Hoh, Rebecca; Deeks, Steven G.; Ho, Ya-Chi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4969-4984</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">1558-8238</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Despite effective antiretroviral therapy, HIV-1-infected cells continue to produce viral antigens and induce chronic immune exhaustion.  We propose to identify HIV-1-suppressing agents that can inhibit HIV-1 reactivation and reduce HIV-1-induced immune activation.  Using a newly developed dual-reporter system and a high-throughput drug screen, we identified FDA-approved drugs that can suppress HIV-1 reactivation in both cell line models and CD4+ T cells from virally suppressed HIV-1-infected individuals.  We identified 11 cellular pathways required for HIV-1 reactivation as druggable targets.  Using differential expression anal., gene set enrichment anal., and exon-intron landscape anal., we examd. the impact of drug treatment on the cellular environment at a genome-wide level.  We identified what we believe to be a new function of a JAK inhibitor, filgotinib, that suppresses HIV-1 splicing.  First, filgotinib preferentially suppresses spliced HIV-1 RNA transcription.  Second, filgotinib suppresses HIV-1-driven aberrant cancer-related gene expression at the integration site.  Third, we found that filgotinib suppresses HIV-1 transcription by inhibiting T cell activation and by modulating RNA splicing.  Finally, we found that filgotinib treatment reduces the proliferation of HIV-1-infected cells.  Overall, the combination of a drug screen and transcriptome anal. provides systematic understanding of cellular targets required for HIV-1 reactivation and drug candidates that may reduce HIV-1-related immune activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKVirccEf0HLVg90H21EOLACvtfcHk0lj8JTN6FYQ20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVejsbnI&md5=976532f9a28d0910ab5ed80f8b646eaa</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1172%2FJCI137371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI137371%26sid%3Dliteratum%253Aachs%26aulast%3DYeh%26aufirst%3DY.%2BJ.%26aulast%3DJenike%26aufirst%3DK.%2BM.%26aulast%3DCalvi%26aufirst%3DR.%2BM.%26aulast%3DChiarella%26aufirst%3DJ.%26aulast%3DHoh%26aufirst%3DR.%26aulast%3DDeeks%26aufirst%3DS.%2BG.%26aulast%3DHo%26aufirst%3DY.%2BC.%26atitle%3DFilgotinib%2520suppresses%2520HIV-1-driven%2520gene%2520transcription%2520by%2520inhibiting%2520HIV-1%2520splicing%2520and%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2020%26volume%3D130%26spage%3D4969%26epage%3D4984%26doi%3D10.1172%2FJCI137371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, J.</span></span> <span> </span><span class="NLM_article-title">Identification of repurposal drugs and adverse drug reactions for various courses of coronavirus disease 2019 (COVID-19) based on single-cell rna sequencing data</span>. <i>arXiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">arXiv:2005.07856</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=arXiv%3A2005.07856&author=K.+Guoauthor=Z.+Wangauthor=P.+Gaoauthor=Q.+Puauthor=M.+Wuauthor=C.+Huangauthor=J.+Hur&title=Identification+of+repurposal+drugs+and+adverse+drug+reactions+for+various+courses+of+coronavirus+disease+2019+%28COVID-19%29+based+on+single-cell+rna+sequencing+data"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DPu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DHur%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520repurposal%2520drugs%2520and%2520adverse%2520drug%2520reactions%2520for%2520various%2520courses%2520of%2520coronavirus%2520disease%25202019%2520%2528COVID-19%2529%2520based%2520on%2520single-cell%2520rna%2520sequencing%2520data%26jtitle%3DarXiv%26date%3D2020%26spage%3DarXiv%253A2005.07856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">FLT3 inhibitors in acute myeloid leukemia</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">133</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0675-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13045-018-0675-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30514344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFaisrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=133&author=M.+Wuauthor=C.+Liauthor=X.+Zhu&title=FLT3+inhibitors+in+acute+myeloid+leukemia&doi=10.1186%2Fs13045-018-0675-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors in acute myeloid leukemia</span></div><div class="casAuthors">Wu, Mei; Li, Chuntuan; Zhu, Xiongpeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML).  FLT3 inhibitors have been in active clin. development.  Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML.  In this review, we summarized the preclin. and clin. studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101.  New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopXLTxxmAs07Vg90H21EOLACvtfcHk0lj8JTN6FYQ20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFaisrrF&md5=f7de5205add8f1f94c531d44a6b1ba16</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0675-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0675-4%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DFLT3%2520inhibitors%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D133%26doi%3D10.1186%2Fs13045-018-0675-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Adamo, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2638</span>– <span class="NLM_lpage">2647</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-11-3203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22374332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsFeisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2638-2647&author=J.+J.+Lukeauthor=D.+R.+D%E2%80%99Adamoauthor=M.+A.+Dicksonauthor=M.+L.+Keohanauthor=R.+D.+Carvajalauthor=R.+G.+Makiauthor=E.+de+Stanchinaauthor=E.+Musiauthor=S.+Singerauthor=G.+K.+Schwartz&title=The+cyclin-dependent+kinase+inhibitor+flavopiridol+potentiates+doxorubicin+efficacy+in+advanced+sarcomas%3A+preclinical+investigations+and+results+of+a+phase+I+dose-escalation+clinical+trial&doi=10.1158%2F1078-0432.CCR-11-3203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial</span></div><div class="casAuthors">Luke, Jason J.; D'Adamo, David R.; Dickson, Mark A.; Keohan, Mary Louise; Carvajal, Richard D.; Maki, Robert G.; de Stanchina, Elisa; Musi, Elgilda; Singer, Samuel; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2638-2647</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Dysregulated cyclin-dependent kinases are important to the growth of some sarcomas.  Flavopiridol is a pan-CDK inhibitor that has been shown to potentiate chemotherapy.  As such, we explored the potentiation of doxorubicin by flavopiridol in sarcoma, in vitro and in vivo, and conducted a phase I trial of flavopiridol with doxorubicin in patients with advanced sarcomas.  Exptl. Design: Sarcoma cell lines and xenografts were treated with flavopiridol alone and in combination with doxorubicin.  In the phase I study, doxorubicin and flavopiridol were administered on two flavopiridol schedules; a 1-h bolus and split dosing as a 30-min bolus followed by a 4-h infusion.  RESULTS: Preclinically, flavopiridol potentiated doxorubicin.  In vivo, doxorubicin administered 1 h before flavopiridol was more active than doxorubicin alone.  Clin., 31 patients were enrolled on protocol and flavopiridol was escalated to target dose in two schedules (90 mg/m2 bolus; 50 mg/m2 bolus + 40 mg/m2 infusion) both in combination with doxorubicin (60 mg/m2).  Dose-limiting toxicities were neutropenia, leukopenia, and febrile neutropenia but no max. tolerated dose was defined.  Flavopiridol pharmacokinetics showed increasing Cmax with increasing dose.  Response Evaluation Criteria in Solid Tumors (RECIST) responses included two partial responses, however, stable disease was seen in 16 patients.  Of 12 evaluable patients with progressive well- and dedifferentiated liposarcoma, eight had stable disease greater than 12 wk.  CONCLUSIONS: The sequential combination of doxorubicin followed by flavopiridol is well tolerated on both schedules.  Disease control was obsd. in well- and dedifferentiated liposarcoma specifically, a disease in which CDK4 is known to be amplified.  Clin Cancer Res; 18(9); 2638-47.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFrDRUWsiTA7Vg90H21EOLACvtfcHk0lj8JTN6FYQ20g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsFeisLw%253D&md5=e001bd1f9f9146ad388734a6d7416e7f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3203%26sid%3Dliteratum%253Aachs%26aulast%3DLuke%26aufirst%3DJ.%2BJ.%26aulast%3DD%25E2%2580%2599Adamo%26aufirst%3DD.%2BR.%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DKeohan%26aufirst%3DM.%2BL.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DMusi%26aufirst%3DE.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DThe%2520cyclin-dependent%2520kinase%2520inhibitor%2520flavopiridol%2520potentiates%2520doxorubicin%2520efficacy%2520in%2520advanced%2520sarcomas%253A%2520preclinical%2520investigations%2520and%2520results%2520of%2520a%2520phase%2520I%2520dose-escalation%2520clinical%2520trial%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D2638%26epage%3D2647%26doi%3D10.1158%2F1078-0432.CCR-11-3203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>– <span class="NLM_lpage">28348</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.+H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0lieJvyX7_T4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.%2BH.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Criscitiello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span> <span> </span><span class="NLM_article-title">Dinaciclib for the treatment of breast cancer</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1312</span>, <span class="refDoi"> DOI: 10.1517/13543784.2014.948152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1517%2F13543784.2014.948152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25107301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlansr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=1305-1312&author=C.+Criscitielloauthor=G.+Vialeauthor=A.+Espositoauthor=G.+Curigliano&title=Dinaciclib+for+the+treatment+of+breast+cancer&doi=10.1517%2F13543784.2014.948152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">for the treatment of breast cancer</span></div><div class="casAuthors">Criscitiello, Carmen; Viale, Giulia; Esposito, Angela; Curigliano, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1305-1312</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncol. due to their key role in controlling gene transcription and cell cycle progression. (MK-7965, formerly SCH727965) is a relatively novel CDK 1/2/5/9 inhibitor that has shown promising results in preclin. studies and an acceptable safety profile in Phase I clin. trials.  It is currently under clin. evaluation for the treatment of hematol. and solid malignancies, including breast cancer.  Areas covered: This review summarizes the current understanding of CDK's role in physiol. and cancer, and the therapeutic value of blocking their pathways in breast cancer.  Particularly, the article reviews the preclin. and clin. data for dinaciclib in its use for the treatment of breast cancer.  Expert opinion: A better understanding of the mol. mechanisms underlying cell cycle dysregulation in cancer is needed in order to develop novel CDK inhibitors.  Addnl., further efforts are needed to identify potential biomarkers of dinaciclib efficacy, which could allow a better selection of patients enrolled in clin. trials.  Moreover, combination therapies with dinaciclib or other CDK and chemotherapy, endocrine therapy or targeted therapies might be further evaluated in breast cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFvTeT7jtBW7Vg90H21EOLACvtfcHk0lieJvyX7_T4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlansr3N&md5=7fb3eea033dba57830aa9afa6876f4c2</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.948152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.948152%26sid%3Dliteratum%253Aachs%26aulast%3DCriscitiello%26aufirst%3DC.%26aulast%3DViale%26aufirst%3DG.%26aulast%3DEsposito%26aufirst%3DA.%26aulast%3DCurigliano%26aufirst%3DG.%26atitle%3DDinaciclib%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D1305%26epage%3D1312%26doi%3D10.1517%2F13543784.2014.948152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldoss, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, A. K.</span></span> <span> </span><span class="NLM_article-title">Seliciclib in malignancies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1957</span>– <span class="NLM_lpage">1965</span>, <span class="refDoi"> DOI: 10.1517/13543780903418445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1517%2F13543780903418445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19938906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOhtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2009&pages=1957-1965&author=I.+T.+Aldossauthor=T.+Tashiauthor=A.+K.+Ganti&title=Seliciclib+in+malignancies&doi=10.1517%2F13543780903418445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Seliciclib in malignancies</span></div><div class="casAuthors">Aldoss, Ibrahim T.; Tashi, Tsewang; Ganti, Apar Kishor</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1957-1965</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Cyclins and cyclin-dependent kinases (CDK) form a key part of the regulatory proteins that govern the cell cycle.  Aberrancy in their function can lead to uncontrolled growth and proliferation of the cells which forms the basis of many human diseases, esp. cancers.  Seliciclib (CYC202, R-roscovitine) is a second-generation CDK inhibitor that competes for ATP binding sites on these kinases, reducing tumor growth and inducing cell death.  It is a direct inhibitor of cyclin E/CDK2 and also has inhibitory effects on cyclin H/CDK7 and cyclin T/CDK9.  Seliciclib leads to growth arrest and apoptosis of cell lines through activation of the p53 gene, inhibition of RNA processing and blockage of the RNA polymerase II-dependent transcription, and redn. of anti-apoptotic proteins.  Seliciclib has good oral bioavailability, although its absorption is slowed by food.  It is distributed rapidly to the body tissues and metabolized rapidly to a carboxylated deriv. that is excreted by the kidneys.  The major adverse effects of seliciclib are electrolyte disturbances (hypokalemia, hyponatremia), gastrointestinal side effects (nausea, emesis, anorexia), fatigue, transient hyperglycemia, elevation of liver enzymes and reversible elevation of serum creatinine.  At present, it is in Phase II trials for non-small cell lung cancer and nasopharyngeal carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4qaWdA4zynrVg90H21EOLACvtfcHk0lieJvyX7_T4lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOhtrbO&md5=73e7949fca2fa087f93f0d028449269c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1517%2F13543780903418445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543780903418445%26sid%3Dliteratum%253Aachs%26aulast%3DAldoss%26aufirst%3DI.%2BT.%26aulast%3DTashi%26aufirst%3DT.%26aulast%3DGanti%26aufirst%3DA.%2BK.%26atitle%3DSeliciclib%2520in%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D18%26spage%3D1957%26epage%3D1965%26doi%3D10.1517%2F13543780903418445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>Opaganib,
a sphingosine kinase-2 (sk2) inhibitor in covid-19 pneumonia</i>, NCT04467840, RedHill Biopharma Limited, <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+Opaganib%2C%0Aa+sphingosine+kinase-2+%28sk2%29+inhibitor+in+covid-19+pneumonia%2C+NCT04467840%2C+RedHill+Biopharma+Limited%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DOpaganib%252C%250Aa%2520sphingosine%2520kinase-2%2520%2528sk2%2529%2520inhibitor%2520in%2520covid-19%2520pneumonia" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de La Fuente, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nekhai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gianella-Borradori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pumfery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of CYC202 in HIV-1-infected cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">3029</span>– <span class="NLM_lpage">3042</span>, <span class="refDoi"> DOI: 10.1074/jbc.M406435200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.M406435200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15531588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2005&pages=3029-3042&author=E.+Agbottahauthor=C.+de+La+Fuenteauthor=S.+Nekhaiauthor=A.+Barnettauthor=A.+Gianella-Borradoriauthor=A.+Pumferyauthor=F.+Kashanchi&title=Antiviral+activity+of+CYC202+in+HIV-1-infected+cells&doi=10.1074%2Fjbc.M406435200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of CYC202 in HIV-1-infected Cells</span></div><div class="casAuthors">Agbottah, Emmanuel; de La Fuente, Cynthia; Nekhai, Sergie; Barnett, Anna; Gianella-Borradori, Athos; Pumfery, Anne; Kashanchi, Fatah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">3029-3042</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">There are currently 40 million individuals in the world infected with human immunodeficiency virus (HIV).  The introduction of highly active antiretroviral therapy (HAART) has led to a significant redn. in AIDS-related morbidity and mortality.  Unfortunately, up to 25% of patients discontinue their initial HAART regimen.  Current HIV-1 inhibitors target the fusion of the virus to the cell and two viral proteins, reverse transcriptase and protease.  Here, we examd. whether other targets, such as an activated transcription factor, could be targeted to block HIV-1 replication.  We specifically asked whether we could target a cellular kinase needed for HIV-1 transcription using CYC202 (R-roscovitine), a pharmacol. cyclin-dependent kinase inhibitor.  We targeted the cdk2-cyclin E complex in HIV-1-infected cells because both cdk2 and cyclin E are nonessential during mammalian development and are likely replaced by other kinases.  We found that CYC202 effectively inhibits wild type and resistant HIV-1 mutants in T-cells, monocytes, and peripheral blood mononuclear cells at a low IC50 and sensitizes these cells to enhanced apoptosis resulting in a dramatic drop in viral titers.  Interestingly, the effect of CYC202 is independent of cell cycle stage and more specific for the cdk2-cyclin E complex.  Finally, we show that cdk2-cyclin E is loaded onto the HIV-1 genome in vivo and that CYC202 is able to inhibit the uploading of this cdk-cyclin complex onto HIV-1 DNA.  Therefore, targeting cellular enzymes necessary for HIV-1 transcription, which are not needed for cell survival, is a compelling strategy to inhibit wild type and mutant HIV-1 strains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVxunqZ3T3lLVg90H21EOLACvtfcHk0lgqWjjbLDXYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12itg%253D%253D&md5=af4003d6df64a8d3773940ab69a15d77</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M406435200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M406435200%26sid%3Dliteratum%253Aachs%26aulast%3DAgbottah%26aufirst%3DE.%26aulast%3Dde%2BLa%2BFuente%26aufirst%3DC.%26aulast%3DNekhai%26aufirst%3DS.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DGianella-Borradori%26aufirst%3DA.%26aulast%3DPumfery%26aufirst%3DA.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DAntiviral%2520activity%2520of%2520CYC202%2520in%2520HIV-1-infected%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2005%26volume%3D280%26spage%3D3029%26epage%3D3042%26doi%3D10.1074%2Fjbc.M406435200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinchington, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. F.</span></span> <span> </span><span class="NLM_article-title">Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">2853</span>– <span class="NLM_lpage">2862</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.6.2853-2862.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.78.6.2853-2862.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=14990704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitlSntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=2853-2862&author=S.+L.+Taylorauthor=P.+R.+Kinchingtonauthor=A.+Brooksauthor=J.+F.+Moffat&title=Roscovitine%2C+a+cyclin-dependent+kinase+inhibitor%2C+prevents+replication+of+varicella-zoster+virus&doi=10.1128%2FJVI.78.6.2853-2862.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus</span></div><div class="casAuthors">Taylor, Shannon L.; Kinchington, Paul R.; Brooks, Andrew; Moffat, Jennifer F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2853-2862</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Understanding the interactions between varicella-zoster virus (VZV) and host cells can be addressed by using small mol. inhibitors of cellular enzymes.  Roscovitine (Rosco) is a purine deriv. that inhibits cyclindependent kinase 1 (cdk1), cdk2, cdk5, cdk7, and cdk9, which are key regulators of the cell cycle and transcription.  Herpesviruses are known to interact with cell cycle proteins; thus, the antiviral effects of Rosco on VZV growth were evaluated.  In a plaque redn. assay, 25 μM Rosco prevented VZV replication, and the antiviral effect was reversible for at least up to 24 h posttreatment.  Rosco also reduced expression of the major transactivator, IE62, over 48 h.  Confocal microscopy studies indicated that Rosco caused the immediate-early proteins ORF4 and IE62 to abnormally localize in infected cells and prevented cell-cell spread of VZV over 48 h.  Rosco was found to inhibit VZV DNA synthesis as measured by real-time PCR, and this technique was used to est. the 50% effective concn. (EC50) of 14 μM.  This value was close to the EC50 est. of 12 μM detd. from plaque redn. assays.  At 25 μM, Rosco was not cytotoxic over 48 h in a neutral red uptake assay, and proliferation was slowed as the cells accumulated in a G2-like state.  These results demonstrate the importance of cdk's in VZV replication and suggest that cdk inhibitors could serve as useful VZV antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjl83l5YV547Vg90H21EOLACvtfcHk0lgEi-0lsPcoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitlSntLo%253D&md5=f03716ff4cc2afc925ddc10c87a2a8bd</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.6.2853-2862.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.6.2853-2862.2004%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BL.%26aulast%3DKinchington%26aufirst%3DP.%2BR.%26aulast%3DBrooks%26aufirst%3DA.%26aulast%3DMoffat%26aufirst%3DJ.%2BF.%26atitle%3DRoscovitine%252C%2520a%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520prevents%2520replication%2520of%2520varicella-zoster%2520virus%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D2853%26epage%3D2862%26doi%3D10.1128%2FJVI.78.6.2853-2862.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>526</i></span>,  <span class="NLM_fpage">1143</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2020.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbrc.2020.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32327257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2020&pages=1143-1149&author=Q.+Huangauthor=Y.+Zhongauthor=J.+Liauthor=Y.+Yeauthor=W.+Wuauthor=L.+Chenauthor=M.+Fengauthor=J.+Yangauthor=S.+Liu&title=Kinase+inhibitor+roscovitine+as+a+PB2+cap-binding+inhibitor+against+influenza+a+virus+replication&doi=10.1016%2Fj.bbrc.2020.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication</span></div><div class="casAuthors">Huang, Qi; Zhong, Yingyuan; Li, Jingyan; Ye, Yilu; Wu, Wenjiao; Chen, Lizhu; Feng, Mingkai; Yang, Jie; Liu, Shuwen</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1143-1149</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study, we examd. the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clin. trials, on influenza A viruses (IAVs) and its antiviral mechanism.  The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC50 value of 3.35 ± 0.39, 7.01 ± 1.84 and 5.99 ± 1.89μM, resp.  Moreover, roscovitine suppressed the gene transcription and genome replication steps in the viral life cycle.  Further mechanistic studies indicated that roscovitine reduced viral polymerase activity and bound specifically to the viral PB2cap protein by fluorescence polarization assay (FP) and surface plasmon resonance (SPR).  Therefore, we believed roscovitine, as a PB2cap inhibitor, was a prospective antiviral agent to be developed as therapeutic treatment against influenza A virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv4xhVjCGNgbVg90H21EOLACvtfcHk0lgEi-0lsPcoIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeiu70%253D&md5=663e0a6a4109d3fc00f6cc56a249ac92</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2020.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2020.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26atitle%3DKinase%2520inhibitor%2520roscovitine%2520as%2520a%2520PB2%2520cap-binding%2520inhibitor%2520against%2520influenza%2520a%2520virus%2520replication%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2020%26volume%3D526%26spage%3D1143%26epage%3D1149%26doi%3D10.1016%2Fj.bbrc.2020.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamrakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, D. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus ul122–123 and ul37 immediate-early transcripts and at later times for virus production</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">11219</span>– <span class="NLM_lpage">11232</span>, <span class="refDoi"> DOI: 10.1128/JVI.78.20.11219-11232.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.78.20.11219-11232.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15452241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlKis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2004&pages=11219-11232&author=V.+Sanchezauthor=A.+K.+McElroyauthor=J.+Yenauthor=S.+Tamrakarauthor=C.+L.+Clarkauthor=R.+A.+Schwartzauthor=D.+H.+Spector&title=Cyclin-dependent+kinase+activity+is+required+at+early+times+for+accurate+processing+and+accumulation+of+the+human+cytomegalovirus+ul122%E2%80%93123+and+ul37+immediate-early+transcripts+and+at+later+times+for+virus+production&doi=10.1128%2FJVI.78.20.11219-11232.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production</span></div><div class="casAuthors">Sanchez, Veronica; McElroy, Anita K.; Yen, Judy; Tamrakar, Sama; Clark, Charles L.; Schwartz, Rachel A.; Spector, Deborah H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11219-11232</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human cytomegalovirus (HCMV) infection leads to dysregulation of multiple cell cycle-regulatory proteins.  In this study, we examd. the effects of inhibition of cyclin-dependent kinase (cdk) activity on viral replication.  With the drug Roscovitine, a specific inhibitor of cyclin-dependent kinases 1, 2, 5, 7, and 9, we have shown that during the first 6 h of infection, cyclin-dependent kinase-dependent events occurred that included the regulated processing and accumulation of the immediate-early (IE) UL122-123 transcripts and UL36-37 transcripts.  Altered processing of UL122-123 led to a loss of IE1-72 and an increase in IE2-86.  The ratio of spliced to unspliced UL37 transcripts also changed.  These effects did not require de novo protein synthesis or degrdn. of proteins by the proteasome.  Addn. of Roscovitine at the beginning of the infection was also assocd. with inhibition of expression of selected viral early gene products, viral DNA replication, and late viral gene expression.  When Roscovitine was added after the first 6 h of infection, the effects on IE gene expression were no longer obsd. and viral replication proceeded through the late phase, but viral titers were reduced.  The redn. in viral titer was obsd. even when Roscovitine was first added at 48 h postinfection, indicating that cyclin-dependent kinase activity is required at both IE and late times.  Flavopiridol, another specific inhibitor of cyclin-dependent kinases, had similar effects on IE and early gene expression.  These results underscore the importance of accurate RNA processing and reiterate the significant role of cell cycle-regulatory factors in HCMV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoErcDAXG9aarVg90H21EOLACvtfcHk0liBhlR1r4o6dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlKis70%253D&md5=1af7de712f5b08ef39b60dafce06ac9f</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1128%2FJVI.78.20.11219-11232.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.78.20.11219-11232.2004%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DV.%26aulast%3DMcElroy%26aufirst%3DA.%2BK.%26aulast%3DYen%26aufirst%3DJ.%26aulast%3DTamrakar%26aufirst%3DS.%26aulast%3DClark%26aufirst%3DC.%2BL.%26aulast%3DSchwartz%26aufirst%3DR.%2BA.%26aulast%3DSpector%26aufirst%3DD.%2BH.%26atitle%3DCyclin-dependent%2520kinase%2520activity%2520is%2520required%2520at%2520early%2520times%2520for%2520accurate%2520processing%2520and%2520accumulation%2520of%2520the%2520human%2520cytomegalovirus%2520ul122%25E2%2580%2593123%2520and%2520ul37%2520immediate-early%2520transcripts%2520and%2520at%2520later%2520times%2520for%2520virus%2520production%26jtitle%3DJ.%2520Virol.%26date%3D2004%26volume%3D78%26spage%3D11219%26epage%3D11232%26doi%3D10.1128%2FJVI.78.20.11219-11232.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresnahan, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldogh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1006/viro.1997.8489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1006%2Fviro.1997.8489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=9168886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1997&pages=239-247&author=W.+A.+Bresnahanauthor=I.+Boldoghauthor=P.+Chiauthor=E.+A.+Thompsonauthor=T.+Albrecht&title=Inhibition+of+cellular+Cdk2+activity+blocks+human+cytomegalovirus+replication&doi=10.1006%2Fviro.1997.8489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span></div><div class="casAuthors">Bresnahan, Wade A.; Boldough, Istvan; Chi, Ping; Thompson, E. Aubrey; Albrecht, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Human cytomegalovirus is a herpesvirus that induces numerous cellular processes upon infection.  Among these are activation of cyclin-dependent kinase 2, which regulates cell cycle progression in G1 and S phase.  We report here that inhibition of cellular Cdk2 activity blocks HCMV replication.  Inhibition of Cdk2 activity by roscovitine inhibits HCMV DNA synthesis, prodn. of infectious progeny, and late antigen expression in infected cells in a dose-dependent manner.  HCMV replication is also inhibited by the expression of a Cdk2 dominant neg. mutant, whereas expression of wild-type Cdk2 has no effect on viral replication.  These data indicate that activation of cellular Cdk2 is necessary for HCMV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3AKL3CzS17Vg90H21EOLACvtfcHk0limo8hDYQ_CuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D&md5=ae27d67b0473636f85e5a292eb5db347</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1006%2Fviro.1997.8489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1997.8489%26sid%3Dliteratum%253Aachs%26aulast%3DBresnahan%26aufirst%3DW.%2BA.%26aulast%3DBoldogh%26aufirst%3DI.%26aulast%3DChi%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26aulast%3DAlbrecht%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cellular%2520Cdk2%2520activity%2520blocks%2520human%2520cytomegalovirus%2520replication%26jtitle%3DVirology%26date%3D1997%26volume%3D231%26spage%3D239%26epage%3D247%26doi%3D10.1006%2Fviro.1997.8489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1172/JCI73805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1172%2FJCI73805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25003190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3479-3488&author=M.+Yamamotoauthor=H.+Onogiauthor=I.+Kiiauthor=S.+Yoshidaauthor=K.+Iidaauthor=H.+Sakaiauthor=M.+Abeauthor=T.+Tsubotaauthor=N.+Itoauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+prevents+replication+of+multiple+DNA+viruses&doi=10.1172%2FJCI73805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span></div><div class="casAuthors">Yamamoto, Makoto; Onogi, Hiroshi; Kii, Isao; Yoshida, Suguru; Iida, Kei; Sakai, Hiroyuki; Abe, Minako; Tsubota, Toshiaki; Ito, Nobutoshi; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3479-3488</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk.  Here, we explored the use of compds. that inhibit or interfere with the action of essential host factors to prevent virus replication.  In particular, we focused on the cyclin-dependent kinase 9 (CDK9) inhibitor, FIT-039, which suppressed replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.  Specifically, FIT-039 inhibited replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells, and topical application of FIT-039 ointment suppressed skin legion formation in a murine HSV-1 infection model.  FIT-039 did not affect cell cycle progression or cellular proliferation in host cells.  Compared with the general CDK inhibitor flavopiridol, transcriptome analyses of FIT-039-treated cells revealed that FIT-039 specifically inhibited CDK9.  Given at concns. above the inhibitory concn., FIT-039 did not have a cytotoxic effect on mammalian cells.  Importantly, administration of FIT-039 ameliorated the severity of skin lesion formation in mice infected with an acydovir-resistant HSV-1, without noticeable adverse effects.  Together, these data indicate that FIT-039 has potential as an antiviral agent for clin. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_l0ZnQV7lWLVg90H21EOLACvtfcHk0limo8hDYQ_CuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I&md5=f5e7516ba1e29c56f33530b2cd2f6811</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1172%2FJCI73805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI73805%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DTsubota%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520prevents%2520replication%2520of%2520multiple%2520DNA%2520viruses%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D3479%26epage%3D3488%26doi%3D10.1172%2FJCI73805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama-Dobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriishi, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27515132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=156-164&author=T.+Tanakaauthor=K.+Okuyama-Dobashiauthor=S.+Murakamiauthor=W.+Chenauthor=T.+Okamotoauthor=K.+Uedaauthor=T.+Hosoyaauthor=Y.+Matsuuraauthor=A.+Ryoauthor=Y.+Tanakaauthor=M.+Hagiwaraauthor=K.+Moriishi&title=Inhibitory+effect+of+CDK9+inhibitor+FIT-039+on+hepatitis+B+virus+propagation&doi=10.1016%2Fj.antiviral.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span></div><div class="casAuthors">Tanaka, Tomohisa; Okuyama-Dobashi, Kaori; Murakami, Shuko; Chen, Wenjia; Okamoto, Toru; Ueda, Keiji; Hosoya, Takamitsu; Matsuura, Yoshiharu; Ryo, Akihide; Tanaka, Yasuhito; Hagiwara, Masatoshi; Moriishi, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current therapies for hepatitis B virus (HBV) cannot completely eliminate the HBV genome because of the stable population of covalently closed circular DNA (cccDNA) and so on.  FIT-039, which is a cyclin-dependent kinase (CDK) 9 inhibitor, is known to suppress the replication of several DNA viruses including HSV, HPV and human adenovirus.  In this study, we investigated the antiviral effect of FIT-039 on HBV infection.  HepG2 cells expressing human sodium taurocholate cotransporting polypeptide (HepG2/NTCP cells) were infected with HBV in the presence of FIT-039.  FIT-039 dose-dependently reduced intracellular viral RNA, nucleocapsid-assocd. viral DNA, and supernatant viral antigens without cytotoxicity in the infected cells (IC50 = 0.33 μM, CC50 > 50 μM).  The antiviral activity of FIT-039 was prominent at an early phase of viral infection, although the compd. did not inhibit preS1-binding to HepG2/NTCP cells.  FIT-039 reduced cccDNA in HBV-replicating or HBV-infected cells.  Furthermore, the antiviral activity of entecavir was significantly enhanced by the combination with FIT-039 in the chimeric mice having human hepatocytes infected with HBV.  None of the mice had significant drug-related body wt. or serum human-albumin concn. changes.  These data suggest that CDK9 inhibitor FIT-039 is a promising antiviral candidate for HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWi-qx6kiD2rVg90H21EOLACvtfcHk0liPljuSj4DQug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL&md5=1ab41f68b2a0645ce4d1031798e281d0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOkuyama-Dobashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DMoriishi%26aufirst%3DK.%26atitle%3DInhibitory%2520effect%2520of%2520CDK9%2520inhibitor%2520FIT-039%2520on%2520hepatitis%2520B%2520virus%2520propagation%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D133%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.antiviral.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ajiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 suppresses viral oncogenes e6 and e7 and has a therapeutic effect on Hpv-induced neoplasia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4518</span>– <span class="NLM_lpage">4528</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-3119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-17-3119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29712686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjt1ejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4518-4528&author=M.+Ajiroauthor=H.+Sakaiauthor=H.+Onogiauthor=M.+Yamamotoauthor=E.+Sumiauthor=T.+Sawadaauthor=T.+Nomuraauthor=K.+Kabashimaauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+suppresses+viral+oncogenes+e6+and+e7+and+has+a+therapeutic+effect+on+Hpv-induced+neoplasia&doi=10.1158%2F1078-0432.CCR-17-3119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 suppresses viral oncogenes E6 and E7 and has a therapeutic effect on HPV-induced neoplasia</span></div><div class="casAuthors">Ajiro, Masahiko; Sakai, Hiroyuki; Onogi, Hiroshi; Yamamoto, Makoto; Sumi, Eriko; Sawada, Teruo; Nomura, Takashi; Kabashima, Kenji; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4518-4528</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide.  The purpose of this study is to assess the therapeutic effect of the newly developed cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on cervical neoplasia induced by human papillomavirus (HPV) infection.  Exptl. Design: We examd. FIT-039 for its effect on HPV gene expression in HPV+ cervical cancer cells.  Primary keratinocytes monolayer and organotypic raft culture models were used to evaluate HPV viral replication and cervical intraepithelial neoplasia (CIN) phenotypes.  Preclin. pharmacokinetics and toxicity tests for FIT-039 were also conducted.  Finally, the anti-HPV effect of FIT-039 was further examd. in vivo, using HPV+ cervical cancer xenografts.  Results: FIT-039 inhibits HPV replication and expression of E6 and E7 viral oncogenes, restoring tumor suppressors p53 and pRb in HPV+ cervical cancer cells.  The therapeutic effect of FIT-039 was demonstrated in CIN model of an organotypic raft culture, where FIT-039 suppressed HPV18-induced dysplasia/hyperproliferation with redn. in viral load.  FIT-039 also repressed growth of HPV16+, but not HPV- cervical cancer xenografts without any significant adverse effects.  Safety and pharmacokinetics of FIT-039 were confirmed for systemic and topical routes.  Conclusions: The CDK9 inhibitor FIT-039 showed potent anti-HPV activity without significant toxicity in preclin. studies.  Thus, FIT-039 is expected to be a novel therapeutic for CIN to prevent cervical cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaMGDFeOIC7bVg90H21EOLACvtfcHk0liVPSGUfVC8rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjt1ejt7s%253D&md5=b352ae15eefe61c3480c6c619c249060</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-3119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-3119%26sid%3Dliteratum%253Aachs%26aulast%3DAjiro%26aufirst%3DM.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DSumi%26aufirst%3DE.%26aulast%3DSawada%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DKabashima%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520suppresses%2520viral%2520oncogenes%2520e6%2520and%2520e7%2520and%2520has%2520a%2520therapeutic%2520effect%2520on%2520Hpv-induced%2520neoplasia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4518%26epage%3D4528%26doi%3D10.1158%2F1078-0432.CCR-17-3119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egawa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toichi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uozumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabashima, K.</span></span> <span> </span><span class="NLM_article-title">The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial</span>. <i>Trials</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">489</span>, <span class="refDoi"> DOI: 10.1186/s13063-019-3570-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13063-019-3570-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31399147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=489&author=T.+Nomuraauthor=E.+Sumiauthor=G.+Egawaauthor=S.+Nakajimaauthor=E.+Toichiauthor=R.+Uozumiauthor=H.+Tadaauthor=T.+Nakagawaauthor=M.+Hagiwaraauthor=K.+Kabashima&title=The+efficacy+of+a+cyclin+dependent+kinase+9+%28CDK9%29+inhibitor%2C+FIT039%2C+on+verruca+vulgaris%3A+study+protocol+for+a+randomized+controlled+trial&doi=10.1186%2Fs13063-019-3570-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial</span></div><div class="casAuthors">Nomura Takashi; Egawa Gyohei; Nakajima Saeko; Kabashima Kenji; Sumi Eriko; Uozumi Ryuji; Tada Harue; Toichi Eiko; Nakagawa Takayuki; Hagiwara Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Trials</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">489</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Human papilloma viruses (HPVs) infect squamous epithelial cells and form verrucous lesions, or warts.  Besides the psychosocial problems caused by the disfiguring warts, a subset of HPVs can be the primary etiologic agent for malignancies such as cervical cancer.  However, there is no curative antiviral therapy for HPV infection.  We recently found that the viral RNA transcription of DNA viruses requires cyclin dependent kinase 9 (CDK9) in the host cells, and that FIT039, a specific inhibitor of CDK9, suppressed the proliferation of DNA viruses such as herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, human cytomegalovirus, hepatitis virus B, and HPVs.  Here, we describe a protocol to evaluate the safety and antiviral effect of FIT039 on common warts in human skin.  METHODS AND DESIGN:  A multi-institutional, single-blind, placebo-controlled randomized phase I/II clinical trial was designed to evaluate the safety and efficacy of FIT039 on common warts on the extremities.  A total of 44 adults with a primary diagnosis of verruca vulgaris on the extremities without serious comorbidities will be randomized into either the intervention group with an FIT039-releasing transdermal patch or a control group for a duration of 14 days.  Outcomes will be assessed at baseline and postintervention.  Participants will be further assessed at 2 months follow-up.  The primary endpoint for efficacy is the resolution of the warts.  The safety endpoint is the incidence of adverse events and adverse drug reactions.  The secondary endpoints are changes in the dimensions of the wart, the cross-sectional area of the wart, and the number of clots within the area of the wart.  DISCUSSION:  This study is the first to assess the efficacy of FIT039 and will contribute to the development of antiviral agents that can cure refractory common warts in immunocompromised patients.  TRIAL REGISTRATION:  UMIN Clinical Trials, UMIN000029695 .  Registered on 1 November 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGFM6SumS6DFHFYivNCdPRfW6udTcc2ea0wkF0MaWJEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvms1enug%253D%253D&md5=b5d65de2c1048cf410ee94eb0015d91b</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1186%2Fs13063-019-3570-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13063-019-3570-6%26sid%3Dliteratum%253Aachs%26aulast%3DNomura%26aufirst%3DT.%26aulast%3DSumi%26aufirst%3DE.%26aulast%3DEgawa%26aufirst%3DG.%26aulast%3DNakajima%26aufirst%3DS.%26aulast%3DToichi%26aufirst%3DE.%26aulast%3DUozumi%26aufirst%3DR.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DNakagawa%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DKabashima%26aufirst%3DK.%26atitle%3DThe%2520efficacy%2520of%2520a%2520cyclin%2520dependent%2520kinase%25209%2520%2528CDK9%2529%2520inhibitor%252C%2520FIT039%252C%2520on%2520verruca%2520vulgaris%253A%2520study%2520protocol%2520for%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DTrials%26date%3D2019%26volume%3D20%26spage%3D489%26doi%3D10.1186%2Fs13063-019-3570-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo</span>. <i>BMC Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">217</span>, <span class="refDoi"> DOI: 10.1186/s12879-017-2305-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs12879-017-2305-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28320320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFags73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=217&author=J.+Houauthor=Z.+Zhangauthor=Q.+Huangauthor=J.+Yanauthor=X.+Zhangauthor=X.+Yuauthor=G.+Tanauthor=C.+Zhengauthor=F.+Xuauthor=S.+He&title=Antiviral+activity+of+PHA767491+against+human+herpes+simplex+virus+in+vitro+and+in+vivo&doi=10.1186%2Fs12879-017-2305-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo</span></div><div class="casAuthors">Hou, Jue; Zhang, Zili; Huang, Qiang; Yan, Jun; Zhang, Xiaohu; Yu, Xiaoliang; Tan, Guihua; Zheng, Chunfu; Xu, Feng; He, Sudan</div><div class="citationInfo"><span class="NLM_cas:title">BMC Infectious Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">217/1-217/9</span>CODEN:
                <span class="NLM_cas:coden">BIDMBJ</span>;
        ISSN:<span class="NLM_cas:issn">1471-2334</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Herpes simplex virus (HSV) is a common human pathogen that causes a variety of diseases, including oral-labial, genital lesions and life-threatening encephalitis.  The antiviral nucleoside analogs such as acyclovir are currently used in anti-HSV therapies; however, clin. overuse of these drugs has led to the emergence of drug-resistant viral strains.  Hence, there is an urgent need to develop new anti-HSV agents.  Methods: To identify novel anti-HSV-1 compds., we screened the LOPAC small scale library of 1280 bioactive compds. to identify inhibitors of HSV-1-induced necroptosis.  Further expts. including western blot anal., Q-PCR anal. and immunohistochem. were performed to explore the antiviral mechanism of the compds.  Results: Here, we identified PHA767491 as a new inhibitor of HSV.  PHA767491 potently blocked the proliferation of HSV in cells, as well as HSV induced cell death.  Further, we found that PHA767491 strongly inhibited HSV infection post viral entry.  Moreover, PHA767491 reduced the expression of viral genes required for DNA synthesis including UL30/42 DNA polymerase and UL5/8/52 helicase-primase complex.  The essential immediate early (IE) genes such as ICP4 and ICP27 are crit. for the expression of the early and late genes.  Of note, PHA767491 inhibited the expression of all IE genes of both HSV-1 and HSV-2.  Importantly, PHA767491 reduced viral titers in the tissues from the mice infected with HSV-1.  Consistently, immunohistochem. anal. showed that PHA767491 dramatically attenuated expression of viral protein gB in the livers.  Conclusions: Taken together, PHA767491 has potent anti-HSV activity by inhibiting viral replication both in vitro and in mouse model.  Thus, PHA767491 could be a promising agent for the development of new anti-HSV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kctOsqvqqLVg90H21EOLACvtfcHk0lin1kmxWUVMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFags73O&md5=b58b795a9b799dde25b63f01ff7a5a58</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1186%2Fs12879-017-2305-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12879-017-2305-0%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DS.%26atitle%3DAntiviral%2520activity%2520of%2520PHA767491%2520against%2520human%2520herpes%2520simplex%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBMC%2520Infect.%2520Dis.%26date%3D2017%26volume%3D17%26spage%3D217%26doi%3D10.1186%2Fs12879-017-2305-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haasbach, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.03.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.03.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28377100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvFWrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2017&pages=178-184&author=E.+Haasbachauthor=C.+M%C3%BCllerauthor=C.+Ehrhardtauthor=A.+Schreiberauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=The+MEK-inhibitor+CI-1040+displays+a+broad+anti-influenza+virus+activity+in+vitro+and+provides+a+prolonged+treatment+window+compared+to+standard+of+care+in+vivo&doi=10.1016%2Fj.antiviral.2017.03.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo</span></div><div class="casAuthors">Haasbach, Emanuel; Mueller, Christin; Ehrhardt, Christina; Schreiber, Andre; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178-184</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza viruses (IV) continue to pose an imminent threat to human welfare.  Yearly re-occurring seasonal epidemic outbreaks and pandemics with high mortality can occur.  Besides vaccination against a limited no. of viral strains only a few antiviral drugs are available, which are losing their effectiveness as more and more IV strains become resistant.  Thus, new antiviral approaches that omit IV resistance are urgently needed.  Here, the dependency on the cellular Raf/MEK/ERK signaling pathway for IV replication opens a new perspective.  In consequence, we studied the antiviral potential of the MEK inhibitor Cl-1040 (PD184352).  We show that Cl-1040 significantly reduces virus titers in vitro via retention of viral RNP complexes in the cell nucleus.  Furthermore, Cl-1040 is effective against a broad range of IV strains, including highly pathogenic avian IV, as well as against a Tamiflu-resistant IV strain. Using a mouse model, we demonstrate that Cl-1040 can reduce IV lung titers in vivo. Importantly, the treatment window for Cl-1040 expands up to 48 h post infection when Tamiflu treatment has no effect.  In conclusion, Cl-1040 offers an interesting perspective for anti-IV approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz9V8putsbXLVg90H21EOLACvtfcHk0lin1kmxWUVMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvFWrurc%253D&md5=f4025799c292f98eb4eea6f9765a77bc</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.03.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.03.024%26sid%3Dliteratum%253Aachs%26aulast%3DHaasbach%26aufirst%3DE.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DThe%2520MEK-inhibitor%2520CI-1040%2520displays%2520a%2520broad%2520anti-influenza%2520virus%2520activity%2520in%2520vitro%2520and%2520provides%2520a%2520prolonged%2520treatment%2520window%2520compared%2520to%2520standard%2520of%2520care%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D142%26spage%3D178%26epage%3D184%26doi%3D10.1016%2Fj.antiviral.2017.03.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Heier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quernheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104806</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2020.104806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32304723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104806&author=M.+Laureauthor=H.+Hamzaauthor=J.+Koch-Heierauthor=M.+Quernheimauthor=C.+M%C3%BCllerauthor=A.+Schreiberauthor=G.+M%C3%BCllerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+efficacy+against+influenza+virus+and+pharmacokinetic+analysis+of+a+novel+MEK-inhibitor%2C+ATR-002%2C+in+cell+culture+and+in+the+mouse+model&doi=10.1016%2Fj.antiviral.2020.104806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span></div><div class="casAuthors">Laure, Martin; Hamza, Hazem; Koch-Heier, Julia; Quernheim, Martin; Mueller, Christin; Schreiber, Andre; Mueller, Gerhard; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104806</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiviral therapies against influenza are required, esp. for high-risk patients, severe influenza and in case of highly pathogenic influenza virus (IV) strains.  This may be overcome by targeting host cell factors that are required for IV propagation.  IV induces a variety of host cell signaling cascades, such as the Raf/MEK/ERK kinase pathway.  MEK-inhibitors block the activation of the pathway on the bottleneck of the signaling cascade leading to impaired virus propagation.  In the present study, we aimed to compare the antiviral potency and bioavailability of the MEK-inhibitor CI-1040 vs. its major active metabolite ATR-002, in vitro as well as in the mouse model.  In cell culture assays, an approx. 10-fold higher concn. of ATR-002 is required to generate the same antiviral activity as for CI-1040.  Interestingly, we obsd. that considerably lower concns. of ATR-002 were required to achieve a redn. of the viral load in vivo.  Pharmacokinetic studies with ATR-002 and CI-1040 in mice have found the Cmax and AUC to be far higher for ATR-002 than for CI-1040.  Our results thereby demonstrate the in vivo superiority of the active metabolite ATR-002 over CI-1040 as an antiviral agent despite its weaker cell membrane permeability.  Therefore, ATR-002 is an attractive candidate for development as an efficient antiviral agent, esp. given the fact that a treatment based on cellular pathway inhibition would be far less likely to lead to viral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCdKB75g1RNbVg90H21EOLACvtfcHk0lin1kmxWUVMMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D&md5=9d7774956ebbe323b85b719653716ef4</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104806%26sid%3Dliteratum%253Aachs%26aulast%3DLaure%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DH.%26aulast%3DKoch-Heier%26aufirst%3DJ.%26aulast%3DQuernheim%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520efficacy%2520against%2520influenza%2520virus%2520and%2520pharmacokinetic%2520analysis%2520of%2520a%2520novel%2520MEK-inhibitor%252C%2520ATR-002%252C%2520in%2520cell%2520culture%2520and%2520in%2520the%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104806%26doi%3D10.1016%2Fj.antiviral.2020.104806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bimbo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denisova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkilä, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaasalainen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirvonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakkola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, H. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">6884</span>– <span class="NLM_lpage">6893</span>, <span class="refDoi"> DOI: 10.1021/nn402062f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/nn402062f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOqu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=6884-6893&author=L.+M.+Bimboauthor=O.+V.+Denisovaauthor=E.+M%C3%A4kil%C3%A4author=M.+Kaasalainenauthor=J.+K.+De+Brabanderauthor=J.+Hirvonenauthor=J.+Salonenauthor=L.+Kakkolaauthor=D.+Kainovauthor=H.+A.+Santos&title=Inhibition+of+influenza+A+virus+infection+in+vitro+by+saliphenylhalamide-loaded+porous+silicon+nanoparticles&doi=10.1021%2Fnn402062f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Influenza A Virus Infection in Vitro by Saliphenylhalamide-Loaded Porous Silicon Nanoparticles</span></div><div class="casAuthors">Bimbo, Luis M.; Denisova, Oxana V.; Makila, Ermei; Kaasalainen, Martti; De Brabander, Jef K.; Hirvonen, Jouni; Salonen, Jarno; Kakkola, Laura; Kainov, Denis; Santos, Helder A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Nano</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6884-6893</span>CODEN:
                <span class="NLM_cas:coden">ANCAC3</span>;
        ISSN:<span class="NLM_cas:issn">1936-0851</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Influenza A viruses (IAVs) cause recurrent epidemics in humans, with serious threat of lethal worldwide pandemics.  The occurrence of antiviral-resistant virus strains and the emergence of highly pathogenic influenza viruses have triggered an urgent need to develop new anti-IAV treatments.  One compd. found to inhibit IAV, and other virus infections, is saliphenylhalamide (SaliPhe).  SaliPhe targets host vacuolar-ATPase and inhibits acidification of endosomes, a process needed for productive virus infection.  The major obstacle for the further development of SaliPhe as antiviral drug has been its poor soly.  Here, we investigated the possibility to increase SaliPhe soly. by loading the compd. in thermally hydrocarbonized porous silicon (THCPSi) nanoparticles.  SaliPhe-loaded nanoparticles were further investigated for the ability to inhibit influenza A infection in human retinal pigment epithelium and Madin-Darby canine kidney cells, and we show that upon release from THCPSi, SaliPhe inhibited IAV infection in vitro and reduced the amt. of progeny virus in IAV-infected cells.  Overall, the PSi-based nanosystem exhibited increased dissoln. of the investigated anti-IAV drug SaliPhe and displayed excellent in vitro stability, low cytotoxicity, and remarkable redn. of viral load in the absence of org. solvents.  This proof-of-principle study indicates that PSi nanoparticles could be used for efficient delivery of antivirals to infected cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0XrUI2NFPO7Vg90H21EOLACvtfcHk0lgXX8wqTk74cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOqu77N&md5=16612b7ec5369e80370940a9bedb0059</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Fnn402062f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fnn402062f%26sid%3Dliteratum%253Aachs%26aulast%3DBimbo%26aufirst%3DL.%2BM.%26aulast%3DDenisova%26aufirst%3DO.%2BV.%26aulast%3DM%25C3%25A4kil%25C3%25A4%26aufirst%3DE.%26aulast%3DKaasalainen%26aufirst%3DM.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DHirvonen%26aufirst%3DJ.%26aulast%3DSalonen%26aufirst%3DJ.%26aulast%3DKakkola%26aufirst%3DL.%26aulast%3DKainov%26aufirst%3DD.%26aulast%3DSantos%26aufirst%3DH.%2BA.%26atitle%3DInhibition%2520of%2520influenza%2520A%2520virus%2520infection%2520in%2520vitro%2520by%2520saliphenylhalamide-loaded%2520porous%2520silicon%2520nanoparticles%26jtitle%3DACS%2520Nano%26date%3D2013%26volume%3D7%26spage%3D6884%26epage%3D6893%26doi%3D10.1021%2Fnn402062f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Denisova, O. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Söderholm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Schantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bychkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vashchinkina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desloovere, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tynell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikonen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theisen, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyman, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matikainen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallioniemi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julkunen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saelens, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkhusha, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kainov, D. E.</span></span> <span> </span><span class="NLM_article-title">Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3689</span>– <span class="NLM_lpage">3696</span>, <span class="refDoi"> DOI: 10.1128/AAC.02798-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.02798-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24752266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3689-3696&author=O.+V.+Denisovaauthor=S.+S%C3%B6derholmauthor=S.+Virtanenauthor=C.+Von+Schantzauthor=D.+Bychkovauthor=E.+Vashchinkinaauthor=J.+Desloovereauthor=J.+Tynellauthor=N.+Ikonenauthor=L.+L.+Theisenauthor=T.+A.+Nymanauthor=S.+Matikainenauthor=O.+Kallioniemiauthor=I.+Julkunenauthor=C.+P.+Mullerauthor=X.+Saelensauthor=V.+V.+Verkhushaauthor=D.+E.+Kainov&title=Akt+inhibitor+MK2206+prevents+influenza+pH1N1+virus+infection+in+vitro&doi=10.1128%2FAAC.02798-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro</span></div><div class="casAuthors">Denisova, Oxana V.; Soderholm, Sandra; Virtanen, Salla; Von Schantz, Carina; Bychkov, Dmitrii; Vashchinkina, Elena; Desloovere, Jens; Tynell, Janne; Ikonen, Niina; Theisen, Linda L.; Nyman, Tuula A.; Matikainen, Sampsa; Kallioniemi, Olli; Julkunen, Ilkka; Muller, Claude P.; Saelens, Xavier; Verkhusha, Vladislav V.; Kainov, Denis E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3689-3696, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The influenza pH1N1 virus caused a global flu pandemic in 2009 and continues manifestation as a seasonal virus.  Better understanding of the virus-host cell interaction could result in development of better prevention and treatment options.  Here we show that the Akt inhibitor MK2206 blocks influenza pH1N1 virus infection in vitro.  In particular, at noncytotoxic concns., MK2206 alters Akt signaling and inhibits endocytic uptake of the virus.  Interestingly, MK2206 is unable to inhibit H3N2, H7N9, and H5N1 viruses, indicating that pH1N1 evolved specific requirements for efficient infection.  Thus, Akt signaling could be exploited further for development of better therapeutics against pH1N1 virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0gFAt6524vbVg90H21EOLACvtfcHk0lgXX8wqTk74cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7jJ&md5=dd78e965b377f1f1748089b78c367297</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FAAC.02798-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02798-13%26sid%3Dliteratum%253Aachs%26aulast%3DDenisova%26aufirst%3DO.%2BV.%26aulast%3DS%25C3%25B6derholm%26aufirst%3DS.%26aulast%3DVirtanen%26aufirst%3DS.%26aulast%3DVon%2BSchantz%26aufirst%3DC.%26aulast%3DBychkov%26aufirst%3DD.%26aulast%3DVashchinkina%26aufirst%3DE.%26aulast%3DDesloovere%26aufirst%3DJ.%26aulast%3DTynell%26aufirst%3DJ.%26aulast%3DIkonen%26aufirst%3DN.%26aulast%3DTheisen%26aufirst%3DL.%2BL.%26aulast%3DNyman%26aufirst%3DT.%2BA.%26aulast%3DMatikainen%26aufirst%3DS.%26aulast%3DKallioniemi%26aufirst%3DO.%26aulast%3DJulkunen%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DC.%2BP.%26aulast%3DSaelens%26aufirst%3DX.%26aulast%3DVerkhusha%26aufirst%3DV.%2BV.%26aulast%3DKainov%26aufirst%3DD.%2BE.%26atitle%3DAkt%2520inhibitor%2520MK2206%2520prevents%2520influenza%2520pH1N1%2520virus%2520infection%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3689%26epage%3D3696%26doi%3D10.1128%2FAAC.02798-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haddach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwaebe, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffaele, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui-Jain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darjania, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proffitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macalino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bliesath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryckman, D. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of CX-6258. A potent, selective, and orally efficacious pan-PIM kinases inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1021/ml200259q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200259q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1OjurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=135-139&author=M.+Haddachauthor=J.+Michauxauthor=M.+K.+Schwaebeauthor=F.+Pierreauthor=S.+E.+O%E2%80%99Brienauthor=C.+Borsanauthor=J.+Tranauthor=N.+Raffaeleauthor=S.+Ravulaauthor=D.+Dryginauthor=A.+Siddiqui-Jainauthor=L.+Darjaniaauthor=R.+Stansfieldauthor=C.+Proffittauthor=D.+Macalinoauthor=N.+Streinerauthor=J.+Bliesathauthor=M.+Omoriauthor=J.+P.+Whittenauthor=K.+Anderesauthor=W.+G.+Riceauthor=D.+M.+Ryckman&title=Discovery+of+CX-6258.+A+potent%2C+selective%2C+and+orally+efficacious+pan-PIM+kinases+inhibitor&doi=10.1021%2Fml200259q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor</span></div><div class="casAuthors">Haddach, Mustapha; Michaux, Jerome; Schwaebe, Michael K.; Pierre, Fabrice; O'Brien, Sean E.; Borsan, Cosmin; Tran, Joe; Raffaele, Nicholas; Ravula, Suchitra; Drygin, Denis; Siddiqui-Jain, Adam; Darjania, Levan; Stansfield, Ryan; Proffitt, Chris; Macalino, Diwata; Streiner, Nicole; Bliesath, Joshua; Omori, May; Whitten, Jeffrey P.; Anderes, Kenna; Rice, William G.; Ryckman, David M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-139</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationship anal. in a series of 3-(5-((2-oxoindolin-3-ylidene)methyl)furan-2-yl)amides identified I, a pan-Pim kinases inhibitor with excellent biochem. potency and kinase selectivity.  I exhibited in vitro synergy with chemotherapeutics and robust in vivo efficacy in two Pim kinases driven tumor models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5-aB3Tu-gDrVg90H21EOLACvtfcHk0lgcJGbPhhcJtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1OjurjP&md5=a8c9dc11c9d192d1276e3c05161a40cb</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fml200259q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200259q%26sid%3Dliteratum%253Aachs%26aulast%3DHaddach%26aufirst%3DM.%26aulast%3DMichaux%26aufirst%3DJ.%26aulast%3DSchwaebe%26aufirst%3DM.%2BK.%26aulast%3DPierre%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BE.%26aulast%3DBorsan%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DJ.%26aulast%3DRaffaele%26aufirst%3DN.%26aulast%3DRavula%26aufirst%3DS.%26aulast%3DDrygin%26aufirst%3DD.%26aulast%3DSiddiqui-Jain%26aufirst%3DA.%26aulast%3DDarjania%26aufirst%3DL.%26aulast%3DStansfield%26aufirst%3DR.%26aulast%3DProffitt%26aufirst%3DC.%26aulast%3DMacalino%26aufirst%3DD.%26aulast%3DStreiner%26aufirst%3DN.%26aulast%3DBliesath%26aufirst%3DJ.%26aulast%3DOmori%26aufirst%3DM.%26aulast%3DWhitten%26aufirst%3DJ.%2BP.%26aulast%3DAnderes%26aufirst%3DK.%26aulast%3DRice%26aufirst%3DW.%2BG.%26aulast%3DRyckman%26aufirst%3DD.%2BM.%26atitle%3DDiscovery%2520of%2520CX-6258.%2520A%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520pan-PIM%2520kinases%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D135%26epage%3D139%26doi%3D10.1021%2Fml200259q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M. L.</span></span> <span> </span><span class="NLM_article-title">Pim1 impacts enterovirus A71 replication and represents a potential target in antiviral therapy</span>. <i>iScience</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/j.isci.2019.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.isci.2019.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31476618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCnt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=715-727&author=F.+Zhouauthor=Q.+Wanauthor=J.+Luauthor=Y.+Chenauthor=G.+Luauthor=M.+L.+He&title=Pim1+impacts+enterovirus+A71+replication+and+represents+a+potential+target+in+antiviral+therapy&doi=10.1016%2Fj.isci.2019.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Pim1 Impacts Enterovirus A71 Replication and Represents a Potential Target in Antiviral Therapy</span></div><div class="casAuthors">Zhou, Fanghang; Wan, Qianya; Lu, Jing; Chen, Ying; Lu, Gui; He, Ming-Liang</div><div class="citationInfo"><span class="NLM_cas:title">iScience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">715-727</span>CODEN:
                <span class="NLM_cas:coden">ISCICE</span>;
        ISSN:<span class="NLM_cas:issn">2589-0042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Enterovirus A71 (EV-A71) infection causes hand-foot-and-mouth disease (HFMD) and fatal neurol. diseases, and there are no effective treatments.  Host factors play key roles in establishing viral infection and detg. the disease progression and outcome of antiviral therapies.  In this study, we found that the expression of Pim1 was significantly upregulated in EV-A71 infection.  Ectopic expression or silencing of Pim1 promoted or inhibited EV-A71 replication through two distinct mechanisms.  Pim1 enhanced viral IRES activity by increasing viral 2A protease-mediated eIF4G cleavage and blocked AUF1, a suppressor of IRES, translocation from the nucleus to cytosol.  More importantly, we discovered that Pim1 inhibitors (SGI-1776, AZD-1208, and CX-6258) reduced EV-A71 reprodn.  Particularly, CX-6258 remarkably reduced EV-A71 reprodn. more than 1,000 times, providing a potential therapeutic agent for EV-A71 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPKRxeFryZj7Vg90H21EOLACvtfcHk0lgcJGbPhhcJtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCnt7bN&md5=2e7d7a4025e39099af92fc3095f90cf5</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.isci.2019.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.isci.2019.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DWan%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DHe%26aufirst%3DM.%2BL.%26atitle%3DPim1%2520impacts%2520enterovirus%2520A71%2520replication%2520and%2520represents%2520a%2520potential%2520target%2520in%2520antiviral%2520therapy%26jtitle%3DiScience%26date%3D2019%26volume%3D19%26spage%3D715%26epage%3D727%26doi%3D10.1016%2Fj.isci.2019.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Recum-Knepper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Frandsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yángüez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soonthornvacharin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanda, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Identification of Polo-like kinases as potential novel drug targets for influenza A virus</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">8629</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-08942-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fs41598-017-08942-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28819179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC1cfpsVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=8629&author=M.+O.+Pohlauthor=J.+von+Recum-Knepperauthor=A.+Rodriguez-Frandsenauthor=C.+Lanzauthor=E.+Y%C3%A1ng%C3%BCezauthor=S.+Soonthornvacharinauthor=T.+Wolffauthor=S.+K.+Chandaauthor=S.+Stertz&title=Identification+of+Polo-like+kinases+as+potential+novel+drug+targets+for+influenza+A+virus&doi=10.1038%2Fs41598-017-08942-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Polo-like kinases as potential novel drug targets for influenza A virus</span></div><div class="casAuthors">Pohl Marie O; Lanz Caroline; Yanguez Emilio; Stertz Silke; Pohl Marie O; Lanz Caroline; von Recum-Knepper Jessica; Rodriguez-Frandsen Ariel; Soonthornvacharin Stephen; Chanda Sumit K; Wolff Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8629</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In recent years genome-wide RNAi screens have revealed hundreds of cellular factors required for influenza virus infections in human cells.  The long-term goal is to establish some of them as drug targets for the development of the next generation of antivirals against influenza.  We found that several members of the polo-like kinases (PLK), a family of serine/threonine kinases with well-known roles in cell cycle regulation, were identified as hits in four different RNAi screens and we therefore studied their potential as drug target for influenza.  We show that knockdown of PLK1, PLK3, and PLK4, as well as inhibition of PLK kinase activity by four different compounds, leads to reduced influenza virus replication, and we map the requirement of PLK activity to early stages of the viral replication cycle.  We also tested the impact of the PLK inhibitor BI2536 on influenza virus replication in a human lung tissue culture model and observed strong inhibition of virus replication with no measurable toxicity.  This study establishes the PLKs as potential drug targets for influenza and contributes to a more detailed understanding of the intricate interactions between influenza viruses and their host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiV1UTYqDlf1f1XRtfYM0dfW6udTcc2ebRxVu97kfcjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfpsVKrsQ%253D%253D&md5=72b66e333c4bf7f57dcb8793b7c70f93</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-08942-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-08942-7%26sid%3Dliteratum%253Aachs%26aulast%3DPohl%26aufirst%3DM.%2BO.%26aulast%3Dvon%2BRecum-Knepper%26aufirst%3DJ.%26aulast%3DRodriguez-Frandsen%26aufirst%3DA.%26aulast%3DLanz%26aufirst%3DC.%26aulast%3DY%25C3%25A1ng%25C3%25BCez%26aufirst%3DE.%26aulast%3DSoonthornvacharin%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DChanda%26aufirst%3DS.%2BK.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520Polo-like%2520kinases%2520as%2520potential%2520novel%2520drug%2520targets%2520for%2520influenza%2520A%2520virus%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D8629%26doi%3D10.1038%2Fs41598-017-08942-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Torre, J. C.</span></span> <span> </span><span class="NLM_article-title">The PI3K/Akt pathway contributes to arenavirus budding</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">4578</span>– <span class="NLM_lpage">4585</span>, <span class="refDoi"> DOI: 10.1128/JVI.06604-11</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.06604-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22345463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsVCgtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=4578-4585&author=S.+Urataauthor=N.+Ngoauthor=J.+C.+de+la+Torre&title=The+PI3K%2FAkt+pathway+contributes+to+arenavirus+budding&doi=10.1128%2FJVI.06604-11"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K/Akt pathway contributes to arenavirus budding</span></div><div class="casAuthors">Urata, Shuzo; Ngo, Nhi; Carlos de la Torre, Juan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4578-4585</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Several arenaviruses, chiefly Lassa virus (LASV), cause hemorrhagic fever (HF) disease in humans and pose a significant public health concern in regions where they are endemic.  On the other hand, evidence indicates that the globally distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a neglected human pathogen.  The phosphatidylinositol 3-kinase (PI3K)/Akt pathway participates in many cellular processes, including cell survival and differentiation, and also has been shown to play important roles in different steps of the life cycles of a variety of viruses.  Here we report that the inhibition of the PI3K/Akt pathway inhibited budding and to a lesser extent RNA synthesis, but not cell entry, of LCMV.  Accordingly, BEZ-235, a PI3K inhibitor currently in cancer clin. trials, inhibited LCMV multiplication in cultured cells.  These findings, together with those previously reported for Junin virus (JUNV), indicate that targeting the PI3K/Akt pathway could represent a novel antiviral strategy to combat human-pathogenic arenaviruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZhC88x3storVg90H21EOLACvtfcHk0lgfpUuyraK1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsVCgtr0%253D&md5=298878f4dd1ed84f7175f85a8673aada</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1128%2FJVI.06604-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.06604-11%26sid%3Dliteratum%253Aachs%26aulast%3DUrata%26aufirst%3DS.%26aulast%3DNgo%26aufirst%3DN.%26aulast%3Dde%2Bla%2BTorre%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520PI3K%252FAkt%2520pathway%2520contributes%2520to%2520arenavirus%2520budding%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D4578%26epage%3D4585%26doi%3D10.1128%2FJVI.06604-11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruckman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herns, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durden, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, S. A.</span></span> <span> </span><span class="NLM_article-title">Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">5808</span>– <span class="NLM_lpage">5820</span>, <span class="refDoi"> DOI: 10.1074/jbc.RA118.002353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.RA118.002353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29475942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFSqu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=5808-5820&author=G.+R.+Campbellauthor=R.+S.+Bruckmanauthor=S.+D.+Hernsauthor=S.+Joshiauthor=D.+L.+Durdenauthor=S.+A.+Spector&title=Induction+of+autophagy+by+PI3K%2FMTOR+and+PI3K%2FMTOR%2FBRD4+inhibitors+suppresses+HIV-1+replication&doi=10.1074%2Fjbc.RA118.002353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication</span></div><div class="casAuthors">Campbell, Grant R.; Bruckman, Rachel S.; Herns, Shayna D.; Joshi, Shweta; Durden, Donald L.; Spector, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5808-5820</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In this study, we investigated the effects of the dual phosphatidylinositol 3-kinase/mechanistic target of rapamycin (PI3K/MTOR) inhibitor dactolisib (NVP-BEZ235), the PI3K/MTOR/bromodomain-contg. protein 4 (BRD4) inhibitor SF2523, and the bromodomain and extra terminal domain inhibitor JQ1 on the productive infection of primary macrophages with human immunodeficiency type-1 (HIV).  These inhibitors did not alter the initial susceptibility of macrophages to HIV infection.  However, dactolisib, JQ1, and SF2523 all decreased HIV replication in macrophages in a dose-dependent manner via degrdn. of intracellular HIV through autophagy.  Macrophages treated with dactolisib, JQ1, or SF2523 displayed an increase in LC3B lipidation combined with SQSTM1 degrdn. without inducing increased cell death.  LC3B-II levels were further increased in the presence of pepstatin A suggesting that these inhibitors induce autophagic flux.  RNA interference for ATG5 and ATG7 and pharmacol. inhibitors of autophagosome-lysosome fusion and of lysosomal hydrolases all blocked the inhibition of HIV.  Thus, we demonstrate that the mechanism of PI3K/MTOR and PI3K/MTOR/BRD4 inhibitor suppression of HIV requires the formation of autophagosomes, as well as their subsequent maturation into autolysosomes.  These data provide further evidence in support of a role for autophagy in the control of HIV infection and open new avenues for the use of this class of drugs in HIV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8-D9wUfaylbVg90H21EOLACvtfcHk0lgfpUuyraK1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFSqu74%253D&md5=06a414ed7a31e34ed7cfd9bb28b48fdd</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA118.002353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA118.002353%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DG.%2BR.%26aulast%3DBruckman%26aufirst%3DR.%2BS.%26aulast%3DHerns%26aufirst%3DS.%2BD.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26aulast%3DSpector%26aufirst%3DS.%2BA.%26atitle%3DInduction%2520of%2520autophagy%2520by%2520PI3K%252FMTOR%2520and%2520PI3K%252FMTOR%252FBRD4%2520inhibitors%2520suppresses%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D5808%26epage%3D5820%26doi%3D10.1074%2Fjbc.RA118.002353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Britten, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett-Mayer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogretmen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentz, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisendine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maines, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. B.</span></span> <span> </span><span class="NLM_article-title">A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4642</span>– <span class="NLM_lpage">4650</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-2363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F1078-0432.CCR-16-2363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28420720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4642-4650&author=C.+D.+Brittenauthor=E.+Garrett-Mayerauthor=S.+H.+Chinauthor=K.+Shiraiauthor=B.+Ogretmenauthor=T.+A.+Bentzauthor=A.+Brisendineauthor=K.+Andertonauthor=S.+L.+Cusackauthor=L.+W.+Mainesauthor=Y.+Zhuangauthor=C.+D.+Smithauthor=M.+B.+Thomas&title=A+phase+I+study+of+ABC294640%2C+a+first-in-class+sphingosine+kinase-2+inhibitor%2C+in+patients+with+advanced+solid+tumors&doi=10.1158%2F1078-0432.CCR-16-2363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Britten, Carolyn D.; Garrett-Mayer, Elizabeth; Chin, Steven H.; Shirai, Keisuke; Ogretmen, Besim; Bentz, Tricia A.; Brisendine, Alan; Anderton, Kate; Cusack, Susan L.; Maines, Lynn W.; Zhuang, Yan; Smith, Charles D.; Thomas, Melanie B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4642-4650</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Sphingosine kinases (SK1 and SK2) regulate tumor growth by generating the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P).  This phase I study investigated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABC294640, a first-in-class orally available inhibitor of SK2.  Exptl. Design: Escalating doses of ABC294640 were administered orally to patients with advanced solid tumors in sequential cohorts at the following dose levels: 250 mg qd, 250 mg bid, 500 mg bid, and 750 mg bid, continuously in cycles of 28 days.  Serial blood samples were obtained to measure ABC294640 concns. and sphingolipid profiles.  Results: Twenty-two patients were enrolled, and 21 received ABC294640.  The most common drug-related toxicities were nausea, vomiting, and fatigue.  Among the 4 patients at 750 mg bid, one had dose-limiting grade 3 nausea and vomiting, and 2 were unable to complete cycle 1 due to diverse drug-related toxicities.  The 500 mg bid dose level was established as the recommended phase II dose.  ABC294640 administration resulted in decreases in S1P levels over the first 12 h, with return to baseline at 24 h.  The best response was a partial response in a patient with cholangiocarcinoma at 250 mg qd, and stable disease was obsd. in 6 patients with various solid tumors across dose levels.  Conclusions: At 500 mg bid, ABC294640 is well tolerated and achieves biol. relevant plasma concns.  Changes in plasma sphingolipid levels may provide a useful pharmacodynamic biomarker for ABC294640.  Clin Cancer Res; 23(16); 4642-50. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqccHLDVdNAnrVg90H21EOLACvtfcHk0lgfpUuyraK1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCmu7rF&md5=036326983052de4e17377dee55052098</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-2363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-2363%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DGarrett-Mayer%26aufirst%3DE.%26aulast%3DChin%26aufirst%3DS.%2BH.%26aulast%3DShirai%26aufirst%3DK.%26aulast%3DOgretmen%26aufirst%3DB.%26aulast%3DBentz%26aufirst%3DT.%2BA.%26aulast%3DBrisendine%26aufirst%3DA.%26aulast%3DAnderton%26aufirst%3DK.%26aulast%3DCusack%26aufirst%3DS.%2BL.%26aulast%3DMaines%26aufirst%3DL.%2BW.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26aulast%3DThomas%26aufirst%3DM.%2BB.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520ABC294640%252C%2520a%2520first-in-class%2520sphingosine%2520kinase-2%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4642%26epage%3D4650%26doi%3D10.1158%2F1078-0432.CCR-16-2363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeBlanc, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughran, T. P.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1111/bjh.16530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1111%2Fbjh.16530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32124438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFaqtL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=405-417&author=F.+R.+LeBlancauthor=J.+M.+Pearsonauthor=S.+F.+Tanauthor=H.+Cheonauthor=J.+C.+Xingauthor=W.+Duntonauthor=D.+J.+Feithauthor=T.+P.+Loughran&title=Sphingosine+kinase-2+is+overexpressed+in+large+granular+lymphocyte+leukaemia+and+promotes+survival+through+Mcl-1&doi=10.1111%2Fbjh.16530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1</span></div><div class="casAuthors">LeBlanc, Francis R.; Pearson, Jennifer M.; Tan, Su-Fern; Cheon, HeeJin; Xing, Jeffrey C.; Dunton, Wendy; Feith, David J.; Loughran, Thomas P., Jr</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">405-417</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sphingolipid metab. is increasingly recognized as a therapeutic target in cancer due to its regulation of cell proliferation and apoptosis.  The sphingolipid rheostat is proposed to control cell fate through maintaining balance between pro-apoptotic and pro-survival sphingolipids.  This balance is regulated by metabolising enzymes involved in sphingolipid prodn.  One such enzyme, sphingosine kinase-2 (SPHK2), produces pro-survival sphingosine 1-phosphate (S1P) by phosphorylation of pro-apoptotic sphingosine.  Elevated SPHK2 has been found in multiple cancer types and contributes to cell survival, chemotherapeutic resistance and apoptosis resistance.  We have previously shown elevation of S1P in large granular lymphocyte (LGL) leukemia serum and cells isolated from patients.  Here, we examd. SPHK2 expression in LGL leukemia and found SPHK2 mRNA and protein upregulation in a majority of LGL leukemia patient samples.  Knockdown of SPHK2 with siRNA in LGL leukemia cell lines decreased proliferation.  Addnl., the use of ABC294640 or K145, both SPHK2-specific inhibitors, decreased viability of LGL leukemia cell lines.  ABC294640 selectively induced apoptosis in LGL cell lines and freshly isolated LGL leukemia patient cells compared to normal controls.  Mechanistically, SPHK2 inhibition downregulated pro-survival myeloid cell leukemia-1 (Mcl-1) protein through proteasomal degrdn.  Targeting of SPHK2 therefore provides a novel therapeutic approach for the treatment of LGL leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5UKhTZsBXlrVg90H21EOLACvtfcHk0lgfpUuyraK1mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFaqtL3J&md5=4cf5aef2342b639b2d9af4cee8f9c596</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1111%2Fbjh.16530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.16530%26sid%3Dliteratum%253Aachs%26aulast%3DLeBlanc%26aufirst%3DF.%2BR.%26aulast%3DPearson%26aufirst%3DJ.%2BM.%26aulast%3DTan%26aufirst%3DS.%2BF.%26aulast%3DCheon%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DJ.%2BC.%26aulast%3DDunton%26aufirst%3DW.%26aulast%3DFeith%26aufirst%3DD.%2BJ.%26aulast%3DLoughran%26aufirst%3DT.%2BP.%26atitle%3DSphingosine%2520kinase-2%2520is%2520overexpressed%2520in%2520large%2520granular%2520lymphocyte%2520leukaemia%2520and%2520promotes%2520survival%2520through%2520Mcl-1%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2020%26volume%3D190%26spage%3D405%26epage%3D417%26doi%3D10.1111%2Fbjh.16530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studstill, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahm, B.</span></span> <span> </span><span class="NLM_article-title">Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30125617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyrs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=171-177&author=C.+Xiaauthor=Y.+J.+Seoauthor=C.+J.+Studstillauthor=M.+Vijayanauthor=J.+J.+Wolfauthor=B.+Hahm&title=Transient+inhibition+of+sphingosine+kinases+confers+protection+to+influenza+A+virus+infected+mice&doi=10.1016%2Fj.antiviral.2018.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice</span></div><div class="casAuthors">Xia, Chuan; Seo, Young-Jin; Studstill, Caleb J.; Vijayan, Madhuvanthi; Wolf, Jennifer J.; Hahm, Bumsuk</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">171-177</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza continues to pose a threat to public health by causing illness and mortality in humans.  Discovering host factors that regulate influenza virus propagation is vital for the development of novel drugs.  We have previously reported that sphingosine kinase (SphK) 1 promotes influenza A virus (IAV) replication in vitro.  Here we demonstrate that the other isoform of SphK, SphK2 promotes the replication of influenza A virus (IAV) in cultured cells, and temporary inhibition of SphK1 or SphK2 enhances the host defense against influenza in mice.  IAV infection led to an increased expression and phosphorylation of SphK2 in host cells.  Furthermore, pharmacol. inhibition or siRNA-based knockdown of SphK2 attenuated IAV replication in vitro.  Notably, oral administration of an SphK2-specific inhibitor substantially improved the viability of mice following IAV infection.  In addn., the local instillation of an SphK1-specific inhibitor or an inhibitor that globally blocks SphK1 and SphK2 provided protection to IAV-infected mice.  Collectively, our results indicate that both SphK1 and SphK2 function as proviral factors during IAV infection in vivo.  Therefore, SphK1 and SphK2 represent potential host targets for therapeutics against influenza.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGortAJwhk2uhbVg90H21EOLACvtfcHk0lh6EUROz4eyUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyrs7zN&md5=917faf2ff203854730479084e4db5808</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DC.%26aulast%3DSeo%26aufirst%3DY.%2BJ.%26aulast%3DStudstill%26aufirst%3DC.%2BJ.%26aulast%3DVijayan%26aufirst%3DM.%26aulast%3DWolf%26aufirst%3DJ.%2BJ.%26aulast%3DHahm%26aufirst%3DB.%26atitle%3DTransient%2520inhibition%2520of%2520sphingosine%2520kinases%2520confers%2520protection%2520to%2520influenza%2520A%2520virus%2520infected%2520mice%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D158%26spage%3D171%26epage%3D177%26doi%3D10.1016%2Fj.antiviral.2018.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krausz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlag, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lufkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kuijk, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodde, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedquist, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tak, P. P.</span></span> <span> </span><span class="NLM_article-title">Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1750</span>– <span class="NLM_lpage">1755</span>, <span class="refDoi"> DOI: 10.1002/art.34339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fart.34339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=22170479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=1750-1755&author=S.+Krauszauthor=M.+J.+Boumansauthor=D.+M.+Gerlagauthor=J.+Lufkinauthor=A.+W.+van+Kuijkauthor=A.+Bakkerauthor=M.+de+Boerauthor=B.+M.+Loddeauthor=K.+A.+Reedquistauthor=E.+W.+Jacobsonauthor=M.+O%E2%80%99Mearaauthor=P.+P.+Tak&title=Brief+report%3A+a+phase+IIa%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+apilimod+mesylate%2C+an+interleukin-12%2Finterleukin-23+inhibitor%2C+in+patients+with+rheumatoid+arthritis&doi=10.1002%2Fart.34339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis</span></div><div class="casAuthors">Krausz, Sarah; Boumans, Maria J. H.; Gerlag, Danielle M.; Lufkin, Joelle; van Kuijk, Arno W. R.; Bakker, Alian; de Boer, Maarten; Lodde, Beatrijs M.; Reedquist, Kris A.; Jacobson, Eric W.; O'Meara, Michael; Tak, Paul P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1750-1755</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin-12 (IL-12)/IL-23 inhibitor, in patients with rheumatoid arthritis (RA).  Methods : We performed a phase IIa, randomized, double-blind, placebo-controlled proof-of-concept study of apilimod, in combination with methotrexate, in 29 patients with active RA (3:1 ratio of apilimod-treated to placebo-treated patients) in 3 stages.  Patients received apilimod 100 mg/day or placebo for 4 wk (stage 1) or 8 wk (stage 2).  In stage 3, patients received apilimod 100 mg twice a day or placebo for 8 wk, with an optional extension of 4 wk.  Clin. response (Disease Activity Score in 28 joints [DAS28] and American College of Rheumatol. [ACR] criteria) was assessed throughout; synovial tissue samples collected at baseline and on day 29 (stages 1 and 2) or day 57 (stage 3) were stained for cellular markers and cytokines for immunohistochem. anal.  Results : While only mild adverse events were obsd. in stages 1 and 2, in stage 3, all patients experienced headache and/or nausea.  Among apilimod-treated patients (100 mg/day), there was a small, but significant, redn. in the DAS28 on day 29 and day 57 compared with baseline.  ACR20 response was reached in only 6% of patients on day 29 and 25% of patients on day 57, similar to the percentage of responders in the placebo group.  Increasing the dosage (100 mg twice a day) did not improve clin. efficacy.  Consistent with clin. results, apilimod did not have an effect on expression of synovial biomarkers.  Of importance, we also did not observe an effect of apilimod on synovial IL-12 and IL-23 expression.  Conclusion : Our results do not support the notion that IL-12/IL-23 inhibition by apilimod is able to induce robust clin. improvement in RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDSYFKciwGeLVg90H21EOLACvtfcHk0lh6EUROz4eyUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOltL0%253D&md5=962eb0fb499e40cc7de36f41adfef49f</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fart.34339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.34339%26sid%3Dliteratum%253Aachs%26aulast%3DKrausz%26aufirst%3DS.%26aulast%3DBoumans%26aufirst%3DM.%2BJ.%26aulast%3DGerlag%26aufirst%3DD.%2BM.%26aulast%3DLufkin%26aufirst%3DJ.%26aulast%3Dvan%2BKuijk%26aufirst%3DA.%2BW.%26aulast%3DBakker%26aufirst%3DA.%26aulast%3Dde%2BBoer%26aufirst%3DM.%26aulast%3DLodde%26aufirst%3DB.%2BM.%26aulast%3DReedquist%26aufirst%3DK.%2BA.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%26aulast%3DTak%26aufirst%3DP.%2BP.%26atitle%3DBrief%2520report%253A%2520a%2520phase%2520IIa%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520apilimod%2520mesylate%252C%2520an%2520interleukin-12%252Finterleukin-23%2520inhibitor%252C%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D1750%26epage%3D1755%26doi%3D10.1002%2Fart.34339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbloom, S.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease</span>. <i>Inflamm Bowel Dis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/ibd.21159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1002%2Fibd.21159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19918967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1209-1218&author=B.+E.+Sandsauthor=E.+W.+Jacobsonauthor=T.+Sylwestrowiczauthor=Z.+Younesauthor=G.+Drydenauthor=R.+Fedorakauthor=S.+Greenbloom&title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+oral+interleukin-12%2F23+inhibitor+apilimod+mesylate+for+treatment+of+active+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease</span></div><div class="casAuthors">Sands Bruce E; Jacobson Eric W; Sylwestrowicz Thomas; Younes Ziad; Dryden Gerald; Fedorak Richard; Greenbloom Susan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1209-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD).  We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD.  METHODS:  We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450).  Patients were stratified according to C-reactive protein (CRP) levels and corticosteroid use and were randomly assigned to receive placebo or apilimod mesylate 50 mg daily or 100 mg daily.  The study was divided into an induction phase (43 days) and a maintenance phase (125 days).  The primary analysis involved a comparison of the proportion of patients experiencing clinical response, defined as at least a 100-point decrease in CDAI score from baseline at day 29.  Data on adverse events were also collected.  RESULTS:  In all, 220 of the planned 282 patients were enrolled when the Data Monitoring Committee determined that the drug was not efficacious as a treatment and closed enrollment.  A clinical response was experienced by 18 patients (24.7%) in the 50-mg daily (QD) group (n = 73) and 19 patients (25.7%) in the 100 mg QD group (n = 74), as compared with 21 patients (28.8%) in the placebo group (n = 73) on day 29 (P = 0.71 for each comparison).  No significant adverse safety signal was observed.  CONCLUSIONS:  Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKP1Ngip31hrrIbt-tGZmxfW6udTcc2eZHg1qMBKnBtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D&md5=4e87fe88e4b06cb7a47d7554a6597a4a</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fibd.21159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21159%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DDryden%26aufirst%3DG.%26aulast%3DFedorak%26aufirst%3DR.%26aulast%3DGreenbloom%26aufirst%3DS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520oral%2520interleukin-12%252F23%2520inhibitor%2520apilimod%2520mesylate%2520for%2520treatment%2520of%2520active%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm%2520Bowel%2520Dis%26date%3D2010%26volume%3D16%26spage%3D1209%26epage%3D1218%26doi%3D10.1002%2Fibd.21159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar-Roman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Camilli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span> <span> </span><span class="NLM_article-title">PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=23890009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=912-921&author=X.+Caiauthor=Y.+Xuauthor=A.+K.+Cheungauthor=R.+C.+Tomlinsonauthor=A.+Alcazar-Romanauthor=L.+Murphyauthor=A.+Billichauthor=B.+Zhangauthor=Y.+Fengauthor=M.+Klumppauthor=J.+M.+Rondeauauthor=A.+N.+Fazalauthor=C.+J.+Wilsonauthor=V.+Myerauthor=G.+Jobertyauthor=T.+Bouwmeesterauthor=M.+A.+Labowauthor=P.+M.+Finanauthor=J.+A.+Porterauthor=H.+L.+Ploeghauthor=D.+Bairdauthor=P.+De+Camilliauthor=J.+A.+Tallaricoauthor=Q.+Huang&title=PIKfyve%2C+a+class+III+PI+kinase%2C+is+the+target+of+the+small+molecular+IL-12%2FIL-23+inhibitor+apilimod+and+a+player+in+Toll-like+receptor+signaling&doi=10.1016%2Fj.chembiol.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling</span></div><div class="casAuthors">Cai, Xinming; Xu, Yongyao; Cheung, Atwood K.; Tomlinson, Ronald C.; Alcazar-Roman, Abel; Murphy, Leon; Billich, Andreas; Zhang, Bailin; Feng, Yan; Klumpp, Martin; Rondeau, Jean-Michel; Fazal, Aleem N.; Wilson, Christopher J.; Myer, Vic; Joberty, Gerard; Bouwmeester, Tewis; Labow, Mark A.; Finan, Peter M.; Porter, Jeffrey A.; Ploegh, Hidde L.; Baird, Daniel; De Camilli, Pietro; Tallarico, John A.; Huang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">912-921</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) signaling is a key component of innate immunity.  Aberrant TLR activation leads to immune disorders via dysregulation of cytokine prodn., such as IL-12/IL-23.  Herein, we identify and characterize PIKfyve, a lipid kinase, as a crit. player in TLR signaling using apilimod as an affinity tool.  Apilimod is a potent small mol. inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clin. trials for patients with Crohn's disease or rheumatoid arthritis.  Using a chem. genetic approach, we show that it binds to PIKfyve and blocks its phosphotransferase activity, leading to selective inhibition of IL-12/IL-23p40.  Pharmacol. or genetic inactivation of PIKfyve is necessary and sufficient for suppression of IL-12/IL-23p40 expression.  Thus, we have uncovered a phosphoinositide-mediated regulatory mechanism that controls TLR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpALdejwmIR_rVg90H21EOLACvtfcHk0lhqtnDVp4g3EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE&md5=9b296c00beb17b95ec9a17c1750a1862</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCheung%26aufirst%3DA.%2BK.%26aulast%3DTomlinson%26aufirst%3DR.%2BC.%26aulast%3DAlcazar-Roman%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DKlumpp%26aufirst%3DM.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DFazal%26aufirst%3DA.%2BN.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%2BA.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DBaird%26aufirst%3DD.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DPIKfyve%252C%2520a%2520class%2520III%2520PI%2520kinase%252C%2520is%2520the%2520target%2520of%2520the%2520small%2520molecular%2520IL-12%252FIL-23%2520inhibitor%2520apilimod%2520and%2520a%2520player%2520in%2520Toll-like%2520receptor%2520signaling%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D912%26epage%3D921%26doi%3D10.1016%2Fj.chembiol.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0005540</span>, <span class="refDoi"> DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=e0005540&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0lhqtnDVp4g3EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26spage%3De0005540%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warkentin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salambanga, F. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobasa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, M.</span></span> <span> </span><span class="NLM_article-title">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2017.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virol.2017.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29031163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=17-28&author=S.+Qiuauthor=A.+Leungauthor=Y.+Boauthor=R.+A.+Kozakauthor=S.+P.+Anandauthor=C.+Warkentinauthor=F.+D.+R.+Salambangaauthor=J.+Cuiauthor=G.+Kobingerauthor=D.+Kobasaauthor=M.+C%C3%B4t%C3%A9&title=Ebola+virus+requires+phosphatidylinositol+%283%2C5%29+bisphosphate+production+for+efficient+viral+entry&doi=10.1016%2Fj.virol.2017.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span></div><div class="casAuthors">Qiu, Shirley; Leung, Anders; Bo, Yuxia; Kozak, Robert A.; Anand, Sai Priya; Warkentin, Corina; Salambanga, Fabiola D. R.; Cui, Jennifer; Kobinger, Gary; Kobasa, Darwyn; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For entry, Ebola virus (EBOV) requires the interaction of its viral glycoprotein with the cellular protein Niemann-Pick C1 (NPC1) which resides in late endosomes and lysosomes.  How EBOV is trafficked and delivered to NPC1 and whether this is pos. regulated during entry remain unclear.  Here, we show that the PIKfyve-ArPIKfyve-Sac3 cellular complex, which is involved in the metab. of phosphatidylinositol (3,5) bisphosphate (PtdIns(3,5)P2), is crit. for EBOV infection.  Although the expression of all subunits of the complex was required for efficient entry, PIKfyve kinase activity was specifically crit. for entry by all pathogenic filoviruses.  Inhibition of PIKfyve prevented colocalization of EBOV with NPC1 and led to virus accumulation in intracellular vesicles with characteristics of early endosomes.  Importantly, genetically-encoded phosphoinositide probes revealed an increase in PtdIns(3,5)P2-pos. vesicles in cells during EBOV entry.  Taken together, our studies suggest that EBOV requires PtdIns(3,5)P2 prodn. in cells to promote efficient delivery to NPC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBj4bGDkDZELVg90H21EOLACvtfcHk0lg-IoYOIKTPVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI&md5=1a0bed541a6186ca937abcc2cabc4bb6</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2017.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2017.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAnand%26aufirst%3DS.%2BP.%26aulast%3DWarkentin%26aufirst%3DC.%26aulast%3DSalambanga%26aufirst%3DF.%2BD.%2BR.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DKobinger%26aufirst%3DG.%26aulast%3DKobasa%26aufirst%3DD.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.%26atitle%3DEbola%2520virus%2520requires%2520phosphatidylinositol%2520%25283%252C5%2529%2520bisphosphate%2520production%2520for%2520efficient%2520viral%2520entry%26jtitle%3DVirology%26date%3D2018%26volume%3D513%26spage%3D17%26epage%3D28%26doi%3D10.1016%2Fj.virol.2017.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">NIH U.S. National Library of Medicine</span>.  <i>A
study of
LAM-002A for the prevention of progression of COVID-19</i>, NCT04446377,
AI Therapeutics, Inc., <a href="https://www.clinicaltrials.gov/" class="extLink">https://www.clinicaltrials.gov/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NIH+U.S.+National+Library+of+Medicine.+A%0Astudy+of%0ALAM-002A+for+the+prevention+of+progression+of+COVID-19%2C+NCT04446377%2C%0AAI+Therapeutics%2C+Inc.%2C+https%3A%2F%2Fwww.clinicaltrials.gov%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DA%250Astudy%2520of%250ALAM-002A%2520for%2520the%2520prevention%2520of%2520progression%2520of%2520COVID-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlauf, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cureton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">20803</span>– <span class="NLM_lpage">20813</span>, <span class="refDoi"> DOI: 10.1073/pnas.2007837117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1073%2Fpnas.2007837117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32764148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=20803-20813&author=Y.-L.+Kangauthor=Y.-Y.+Chouauthor=P.+W.+Rothlaufauthor=Z.+Liuauthor=T.+K.+Sohauthor=D.+Curetonauthor=J.+B.+Caseauthor=R.+E.+Chenauthor=M.+S.+Diamondauthor=S.+P.+J.+Whelanauthor=T.+Kirchhausen&title=Inhibition+of+PIKfyve+kinase+prevents+infection+by+Zaire+ebolavirus+and+SARS-CoV-2&doi=10.1073%2Fpnas.2007837117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span></div><div class="casAuthors">Kang, Yuan-Lin; Chou, Yi-ying; Rothlauf, Paul W.; Liu, Zhuoming; Soh, Timothy K.; Cureton, David; Case, James Brett; Chen, Rita E.; Diamond, Michael S.; Whelan, Sean P. J.; Kirchhausen, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20803-20813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Virus entry is a multistep process.  It initiates when the virus attaches to the host cell and ends when the viral contents reach the cytosol.  Genetically unrelated viruses can subvert analogous subcellular mechanisms and use similar trafficking pathways for successful entry.  Antiviral strategies targeting early steps of infection are therefore appealing, particularly when the probability for successful interference through a common step is highest.  We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) contg. the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small-mol. inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.  We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.  These results define tools for studying the intracellular trafficking of pathogens elicited by inhibition of PIKfyve kinase and suggest the potential for targeting this kinase in developing small-mol. antivirals against SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYcbVh--KCN7Vg90H21EOLACvtfcHk0lg-IoYOIKTPVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP&md5=a7e1b43b16edffb6dabc91258b88ab7c</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2007837117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2007837117%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.-L.%26aulast%3DChou%26aufirst%3DY.-Y.%26aulast%3DRothlauf%26aufirst%3DP.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSoh%26aufirst%3DT.%2BK.%26aulast%3DCureton%26aufirst%3DD.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DR.%2BE.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DWhelan%26aufirst%3DS.%2BP.%2BJ.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520PIKfyve%2520kinase%2520prevents%2520infection%2520by%2520Zaire%2520ebolavirus%2520and%2520SARS-CoV-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D20803%26epage%3D20813%26doi%3D10.1073%2Fpnas.2007837117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulp, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4309</span>– <span class="NLM_lpage">4318</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-4063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1158%2F0008-5472.CAN-03-4063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15205346" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkvFWlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4309-4318&author=J.+Zhuauthor=J.+W.+Huangauthor=P.+H.+Tsengauthor=Y.+T.+Yangauthor=J.+Fowbleauthor=C.+W.+Shiauauthor=Y.+J.+Shawauthor=S.+K.+Kulpauthor=C.+S.+Chen&title=From+the+cyclooxygenase-2+inhibitor+celecoxib+to+a+novel+class+of+3-phosphoinositide-dependent+protein+kinase-1+inhibitors&doi=10.1158%2F0008-5472.CAN-03-4063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors</span></div><div class="casAuthors">Zhu, Jiuxiang; Huang, Jui-Wen; Tseng, Ping-Hui; Yang, Ya-Ting; Fowble, Joseph; Shiau, Chung-Wai; Shaw, Yeng-Jeng; Kulp, Samuel K.; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4309-4318</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The blockade of Akt activation through the inhibition of 3-phosphoinositide-dependent kinase-1 (PDK-1) represents a major signaling mechanism whereby celecoxib mediates apoptosis.  Celecoxib, however, is a weak PDK-1 inhibitor (IC50, 48 μM), requiring at least 30 μM to exhibit discernable effects on the growth of tumor cells in vitro.  Here, we report the structure-based optimization of celecoxib to develop PDK-1 inhibitors with greater potency in enzyme inhibition and growth inhibition.  Kinetics of PDK-1 inhibition by celecoxib with respect to ATP suggest that celecoxib derivs. inhibit PDK-1 by competing with ATP for binding, a mechanism reminiscent to that of many kinase inhibitors.  Structure-activity anal. together with mol. modeling was used to generate compds. that were tested for their potency in inhibiting PDK-1 kinase activity and in inducing apoptosis in PC-3 prostate cancer cells.  Docking of potent compds. into the ATP-binding site of PDK-1 was performed for lead optimization, leading to two compds., OSU-03012 and OSU-03013, with IC50 values in PDK-1 inhibition and apoptosis induction in the low μM range.  Exposure of PC-3 cells to these agents led to Akt dephosphorylation and inhibition of p70 S6 kinase activity.  Moreover, overexpression of constitutively active forms of PDK-1 and Akt partially protected OSU-03012-induced apoptosis.  Screening in a panel of 60 cell lines and more extensive testing in PC-3 cells indicated that the mean concn. for total growth inhibition was ∼3 μM for both agents.  Considering the conserved role of PDK-1/Akt signaling in promoting tumorigenesis, these celecoxib analogs are of translational relevance for cancer prevention and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKrSQXLNmChLVg90H21EOLACvtfcHk0lg-IoYOIKTPVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkvFWlsbg%253D&md5=41dd9332d38a19283709719a7e3cb574</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-4063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-4063%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%2BW.%26aulast%3DTseng%26aufirst%3DP.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DFowble%26aufirst%3DJ.%26aulast%3DShiau%26aufirst%3DC.%2BW.%26aulast%3DShaw%26aufirst%3DY.%2BJ.%26aulast%3DKulp%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DFrom%2520the%2520cyclooxygenase-2%2520inhibitor%2520celecoxib%2520to%2520a%2520novel%2520class%2520of%25203-phosphoinositide-dependent%2520protein%2520kinase-1%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4309%26epage%3D4318%26doi%3D10.1158%2F0008-5472.CAN-03-4063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chik, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tee, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span> <span> </span><span class="NLM_article-title">The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30326204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGhsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2018&pages=38-47&author=J.+F.+Chanauthor=Z.+Zhuauthor=H.+Chuauthor=S.+Yuanauthor=K.+K.+Chikauthor=C.+C.+Chanauthor=V.+K.+Poonauthor=C.+C.+Yipauthor=X.+Zhangauthor=J.+O.+Tsangauthor=Z.+Zouauthor=K.+M.+Teeauthor=H.+Shuaiauthor=G.+Luauthor=K.+Y.+Yuen&title=The+celecoxib+derivative+kinase+inhibitor+AR-12+%28OSU-03012%29+inhibits+Zika+virus+via+down-regulation+of+the+PI3K%2FAkt+pathway+and+protects+Zika+virus-infected+A129+mice%3A+A+host-targeting+treatment+strategy&doi=10.1016%2Fj.antiviral.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy</span></div><div class="casAuthors">Chan, Jasper Fuk-Woo; Zhu, Zheng; Chu, Hin; Yuan, Shuofeng; Chik, Kenn Ka-Heng; Chan, Chris Chung-Sing; Poon, Vincent Kwok-Man; Yip, Cyril Chik-Yan; Zhang, Xi; Tsang, Jessica Oi-Ling; Zou, Zijiao; Tee, Kah-Meng; Shuai, Huiping; Lu, Gang; Yuen, Kwok-Yung</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Zika virus (ZIKV) is a human-pathogenic flavivirus that has recently emerged as a global public health threat.  ZIKV infection may be assocd. with congenital malformations in infected fetuses and severe neurol. and systemic complications in infected adults.  There are currently limited treatment options for ZIKV infection.  AR-12 (OSU-03012) is a celecoxib deriv. cellular kinase inhibitor that has broad-spectrum antiviral activities.  In this study, we investigated the antiviral activity and mechanism of AR-12 against ZIKV.  We evaluated the in vitro anti-ZIKV activity of AR-12, using cell protection and virus yield redn. assays, in multiple clin. relevant cell lines, and the in vivo treatment effects of AR-12 in a lethal mouse model using type I interferon receptor-deficient A129 mice.  AR-12 inhibited ZIKV strains belonging to both the African and Asian/American lineages in Huh-7 and/or neuronal cells.  AR12 IC50 against ZIKV was consistently <2 μM in these cells.  ZIKV-infected A129 mice treated with i.p. or orally administered AR-12 had significantly higher survival rate (50.0%-83.3% vs 0%, P < 0.05), less body wt. loss, and lower blood and tissue ZIKV RNA loads than untreated control A129 mice.  These anti-ZIKV effects were likely the results of down-regulation of the PI3K/Akt pathway by AR-12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Ds4v9pBb07Vg90H21EOLACvtfcHk0ljxlNw4wApjLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGhsL%252FO&md5=05baf975452e24ce11ac163b47937a97</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DChik%26aufirst%3DK.%2BK.%26aulast%3DChan%26aufirst%3DC.%2BC.%26aulast%3DPoon%26aufirst%3DV.%2BK.%26aulast%3DYip%26aufirst%3DC.%2BC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTsang%26aufirst%3DJ.%2BO.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DTee%26aufirst%3DK.%2BM.%26aulast%3DShuai%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26atitle%3DThe%2520celecoxib%2520derivative%2520kinase%2520inhibitor%2520AR-12%2520%2528OSU-03012%2529%2520inhibits%2520Zika%2520virus%2520via%2520down-regulation%2520of%2520the%2520PI3K%252FAkt%2520pathway%2520and%2520protects%2520Zika%2520virus-infected%2520A129%2520mice%253A%2520A%2520host-targeting%2520treatment%2520strategy%26jtitle%3DAntiviral%2520Res.%26date%3D2018%26volume%3D160%26spage%3D38%26epage%3D47%26doi%3D10.1016%2Fj.antiviral.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koselny, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halterman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fothergill, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiederhold, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cushion, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rappelye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krysan, D. J.</span></span> <span> </span><span class="NLM_article-title">The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7115</span>– <span class="NLM_lpage">7127</span>, <span class="refDoi"> DOI: 10.1128/AAC.01061-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.01061-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27645246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=7115-7127&author=K.+Koselnyauthor=J.+Greenauthor=L.+DiDoneauthor=J.+P.+Haltermanauthor=A.+W.+Fothergillauthor=N.+P.+Wiederholdauthor=T.+F.+Pattersonauthor=M.+T.+Cushionauthor=C.+Rappelyeauthor=M.+Wellingtonauthor=D.+J.+Krysan&title=The+celecoxib+derivative+AR-12+has+broad-spectrum+antifungal+activity+in+vitro+and+improves+the+activity+of+fluconazole+in+a+murine+model+of+cryptococcosis&doi=10.1128%2FAAC.01061-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">The celecoxib derivative AR-12 has broad-spectrum antifungal activity in vitro and improves the activity of fluconazole in a murine model of cryptococcosis</span></div><div class="casAuthors">Koselny, Kristy; Green, Julianne; Di Done, Louis; Halterman, Justin P.; Fothergill, Annette W.; Wiederhold, Nathan P.; Patterson, Thomas F.; Cushion, Melanie T.; Rappelye, Chad; Wellington, Melanie; Krysan, Damian J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">7115-7127</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Only one new class of antifungal drugs has been introduced into clin. practice in the last 30 years, and thus the identification of small mols. with novel mechanisms of action is an important goal of current anti-infective research.  Here, we describe the characterization of the spectrum of in vitro activity and in vivo activity of AR-12, a celecoxib deriv. which has been tested in a phase I clin. trial as an anticancer agent.  AR-12 inhibits fungal acetyl CoA (acetyl-CoA) synthetase in vitro and is fungicidal at concns. similar to those achieved in human plasma.  AR-12 has a broad spectrum of activity, including activity against yeasts (e.g., Candida albicans, non-albicans Candida spp., Cryptococcus neoformans), molds (e.g., Fusarium, Mucor), and dimorphic fungi (Blastomyces, Histoplasma, and Coccidioides) with MICs of 2 to 4 μg/mL.  AR-12 is also active against azole- and echinocandin-resistant Candida isolates, and subinhibitory AR-12 concns. increase the susceptibility of fluconazole- and echinocandin-resistant Candida isolates.  Finally, AR-12 also increases the activity of fluconazole in a murine model of cryptococcosis.  Taken together, these data indicate that AR-12 represents a promising class of small mols. with broad-spectrum antifungal activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkQ4IgzvpGPLVg90H21EOLACvtfcHk0ljxlNw4wApjLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWjsLc%253D&md5=2e9f2e77742e265c5cfbb4f43bb63b2f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1128%2FAAC.01061-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01061-16%26sid%3Dliteratum%253Aachs%26aulast%3DKoselny%26aufirst%3DK.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DDiDone%26aufirst%3DL.%26aulast%3DHalterman%26aufirst%3DJ.%2BP.%26aulast%3DFothergill%26aufirst%3DA.%2BW.%26aulast%3DWiederhold%26aufirst%3DN.%2BP.%26aulast%3DPatterson%26aufirst%3DT.%2BF.%26aulast%3DCushion%26aufirst%3DM.%2BT.%26aulast%3DRappelye%26aufirst%3DC.%26aulast%3DWellington%26aufirst%3DM.%26aulast%3DKrysan%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520celecoxib%2520derivative%2520AR-12%2520has%2520broad-spectrum%2520antifungal%2520activity%2520in%2520vitro%2520and%2520improves%2520the%2520activity%2520of%2520fluconazole%2520in%2520a%2520murine%2520model%2520of%2520cryptococcosis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D7115%26epage%3D7127%26doi%3D10.1128%2FAAC.01061-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibuya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, Y.</span></span> <span> </span><span class="NLM_article-title">Genistein, a specific inhibitor of tyrosine-specific protein kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>262</i></span>,  <span class="NLM_fpage">5592</span>– <span class="NLM_lpage">5595</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)45614-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0021-9258%2818%2945614-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=3106339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaL2sXktF2rurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=262&publication_year=1987&pages=5592-5595&author=T.+Akiyamaauthor=J.+Ishidaauthor=S.+Nakagawaauthor=H.+Ogawaraauthor=S.+Watanabeauthor=N.+Itohauthor=M.+Shibuyaauthor=Y.+Fukami&title=Genistein%2C+a+specific+inhibitor+of+tyrosine-specific+protein+kinases&doi=10.1016%2FS0021-9258%2818%2945614-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein, a specific inhibitor of tyrosine-specific protein kinases</span></div><div class="casAuthors">Akiyama, Tetsu; Ishida, Junko; Nakagawa, Suguru; Ogawara, Hiroshi; Watanabe, Shunichi; Itoh, Noriki; Shibuya, Masabumi; Fukami, Yasuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">262</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5592-5</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Tyrosine-specific protein kinase activity of the EGF receptor, pp60v-src, and pp110gag-fes was inhibited in vitro by an isoflavone, genistein.  The inhibition was competitive with respect to ATP and noncompetitive to a phosphate acceptor, histone H2B.  By contrast, genistein scarcely inhibited the enzyme activities of serine- and threonine-specific protein kinases, such as cAMP-dependent protein kinase, phosphorylase kinase, and the Ca2+/phospholipid-dependent enzyme protein kinase C.  When the effect of genistein on the phosphorylation of the EGF receptor was examd. in cultured A431 cells, EGF-stimulated serine, threonine, and tyrosine phosphorylation was decreased.  Phosphoamino acid anal. of total cell proteins revealed that genistein inhibited EGF-stimulated increase in phosphotyrosine level in A431 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNrl4yNfRolrVg90H21EOLACvtfcHk0lj_tZy4NOuYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktF2rurk%253D&md5=a5166857ec7cf5aaf80118fcca1f254a</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2945614-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252945614-1%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DNakagawa%26aufirst%3DS.%26aulast%3DOgawara%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DS.%26aulast%3DItoh%26aufirst%3DN.%26aulast%3DShibuya%26aufirst%3DM.%26aulast%3DFukami%26aufirst%3DY.%26atitle%3DGenistein%252C%2520a%2520specific%2520inhibitor%2520of%2520tyrosine-specific%2520protein%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1987%26volume%3D262%26spage%3D5592%26epage%3D5595%26doi%3D10.1016%2FS0021-9258%2818%2945614-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damm, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelkmans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartenbeck, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezzacasa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzchalia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helenius, A.</span></span> <span> </span><span class="NLM_article-title">Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">488</span>, <span class="refDoi"> DOI: 10.1083/jcb.200407113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1083%2Fjcb.200407113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15668298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2005&pages=477-488&author=E.+M.+Dammauthor=L.+Pelkmansauthor=J.+Kartenbeckauthor=A.+Mezzacasaauthor=T.+Kurzchaliaauthor=A.+Helenius&title=Clathrin-+and+caveolin-1-independent+endocytosis%3A+entry+of+simian+virus+40+into+cells+devoid+of+caveolae&doi=10.1083%2Fjcb.200407113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Clathrin- and caveolin-1-independent endocytosis: Entry of simian virus 40 into cells devoid of caveolae</span></div><div class="casAuthors">Damm, Eva-Maria; Pelkmans, Lucas; Kartenbeck, Juergen; Mezzacasa, Anna; Kurzchalia, Teymuras; Helenius, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-488</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Simian Virus 40 (SV40) has been shown to enter host cells by caveolar endocytosis followed by transport via caveosomes to the endoplasmic reticulum (ER).  Using a caveolin-1 (cav-1)-deficient cell line (human hepatoma 7) and embryonic fibroblasts from a cav-1 knockout mouse, we found that in the absence of caveolae, but also in wild-type embryonic fibroblasts, the virus exploits an alternative, cav-1-independent pathway.  Internalization was rapid (t1/2 = 20 min) and cholesterol- and tyrosine kinase- dependent but independent of clathrin, dynamin II, and ARF6.  The viruses were internalized in small, tight-fitting vesicles and transported to membrane-bounded, pH-neutral organelles similar to caveosomes but devoid of cav-1 and -2.  The viruses were next transferred by microtubule-dependent vesicular transport to the ER, a step that was required for infectivity.  Our results revealed the existence of a virus-activated endocytic pathway from the plasma membrane to the ER that involves neither clathrin nor caveolae and that can be activated also in the presence of cav-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGr1Y1-7CiqLVg90H21EOLACvtfcHk0lj_tZy4NOuYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWktbw%253D&md5=07724bccee68642067ef720e8e66f4ef</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200407113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200407113%26sid%3Dliteratum%253Aachs%26aulast%3DDamm%26aufirst%3DE.%2BM.%26aulast%3DPelkmans%26aufirst%3DL.%26aulast%3DKartenbeck%26aufirst%3DJ.%26aulast%3DMezzacasa%26aufirst%3DA.%26aulast%3DKurzchalia%26aufirst%3DT.%26aulast%3DHelenius%26aufirst%3DA.%26atitle%3DClathrin-%2520and%2520caveolin-1-independent%2520endocytosis%253A%2520entry%2520of%2520simian%2520virus%252040%2520into%2520cells%2520devoid%2520of%2520caveolae%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2005%26volume%3D168%26spage%3D477%26epage%3D488%26doi%3D10.1083%2Fjcb.200407113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stantchev, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, C. C.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2006.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2006.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17030448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2007&pages=178-189&author=T.+S.+Stantchevauthor=I.+Markovicauthor=W.+G.+Telfordauthor=K.+A.+Clouseauthor=C.+C.+Broder&title=The+tyrosine+kinase+inhibitor+genistein+blocks+HIV-1+infection+in+primary+human+macrophages&doi=10.1016%2Fj.virusres.2006.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span></div><div class="casAuthors">Stantchev, Tzanko S.; Markovic, Ingrid; Telford, William G.; Clouse, Kathleen A.; Broder, Christopher C.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Binding of HIV-1 envelope glycoprotein (Env) to its cellular receptors elicits a variety of signaling events, including the activation of select tyrosine kinases.  To evaluate the potential role of such signaling, we examd. the effects of the tyrosine kinase inhibitor, genistein, on HIV-1 entry and infection of human macrophages using a variety of assays.  Without altering cell viability, cell surface expression of CD4 and CCR5 or their abilities to interact with Env, genistein inhibited infection of macrophages by reporter gene-encoding, β-lactamase contg., or wild type virions, as well as Env-mediated cell-fusion.  The observation that genistein blocked virus infection if applied before, during or immediately after the infection period, but not 24 h later; coupled with a more pronounced inhibition of infection in the reporter gene assays as compared to both β-lactamase and p24 particle entry assays, imply that genistein exerts its inhibitory effects on both entry and early post-entry steps.  These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as addnl. opportunities for the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOAvO4kSxB7Vg90H21EOLACvtfcHk0lj_tZy4NOuYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D&md5=310c85933553074029e094e7d3a1bdb8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2006.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2006.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DStantchev%26aufirst%3DT.%2BS.%26aulast%3DMarkovic%26aufirst%3DI.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26aulast%3DClouse%26aufirst%3DK.%2BA.%26aulast%3DBroder%26aufirst%3DC.%2BC.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520genistein%2520blocks%2520HIV-1%2520infection%2520in%2520primary%2520human%2520macrophages%26jtitle%3DVirus%2520Res.%26date%3D2007%26volume%3D123%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.virusres.2006.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1007/BF01309554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2FBF01309554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=8397505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1993&pages=451-461&author=Y.+Yuraauthor=H.+Yoshidaauthor=M.+Sato&title=Inhibition+of+herpes+simplex+virus+replication+by+genistein%2C+an+inhibitor+of+protein-tyrosine+kinase&doi=10.1007%2FBF01309554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span></div><div class="casAuthors">Yura, Y.; Yoshida, H.; Sato, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">451-61</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    </div><div class="casAbstract">Genistein, an inhibitor of protein-tyrosine kinase, inhibited the replication of herpes simplex virus type 1 (HSV-1) at genistein concns. of more than 25 μM, whereas the related compds., which do not inhibit protein-tyrosine kinases, did not affect the replication of HSV-1.  In the presence of genistein, the phosphorylation of tyrosine residues in specific viral polypeptides was markedly reduced.  These results indicate that the phosphorylation of tyrosine residues in viral polypeptides may be essential for the replication of HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPTvlkqS9JUbVg90H21EOLACvtfcHk0lj_tZy4NOuYsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D&md5=ddabba9625d89206daf303e7f4739274</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1007%2FBF01309554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01309554%26sid%3Dliteratum%253Aachs%26aulast%3DYura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520replication%2520by%2520genistein%252C%2520an%2520inhibitor%2520of%2520protein-tyrosine%2520kinase%26jtitle%3DArch.%2520Virol.%26date%3D1993%26volume%3D132%26spage%3D451%26epage%3D461%26doi%3D10.1007%2FBF01309554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowick, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. F.</span></span> <span> </span><span class="NLM_article-title">Genistein treatment of cells inhibits arenavirus infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2007.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17961732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=153-156&author=E.+M.+Velaauthor=G.+C.+Bowickauthor=N.+K.+Herzogauthor=J.+F.+Aronson&title=Genistein+treatment+of+cells+inhibits+arenavirus+infection&doi=10.1016%2Fj.antiviral.2007.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein treatment of cells inhibits arenavirus infection</span></div><div class="casAuthors">Vela, Eric M.; Bowick, Gavin C.; Herzog, Norbert K.; Aronson, Judith F.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arenaviridae is a family of enveloped viruses some of which are capable of causing hemorrhagic fever syndromes in humans.  In this report, we demonstrate that treatment of host cells with the tyrosine kinase inhibitor genistein inhibits infection of cells with the New World arenavirus Pichinde (PICV).  The greatest degree of inhibition was obsd. in pre-treated target cells, but modest inhibition of infection was also seen when drug was added to cultures up to 48 h after infection.  We show that PICV-induced phosphorylation of the activating transcription factor-2 protein (ATF-2) and cAMP response element binding protein (CREB) is inhibited following genistein treatment.  Lastly, genistein treatment also inhibited transduction of cells with pseudotyped retrovirus particles expressing envelope proteins of the Old World arenavirus Lassa virus.  These results demonstrate that kinase activity is required for arenavirus infection and that therapeutics designed to inhibit kinase activity should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxt-7U7F05bVg90H21EOLACvtfcHk0liprGqho5zDTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D&md5=ed23a98d1235f071148053c4620f5594</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DE.%2BM.%26aulast%3DBowick%26aufirst%3DG.%2BC.%26aulast%3DHerzog%26aufirst%3DN.%2BK.%26aulast%3DAronson%26aufirst%3DJ.%2BF.%26atitle%3DGenistein%2520treatment%2520of%2520cells%2520inhibits%2520arenavirus%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.antiviral.2007.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LeCher, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diep, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, J. K.</span></span> <span> </span><span class="NLM_article-title">Genistein has antiviral activity against herpes B virus and acts synergistically with antiviral treatments to reduce effective dose</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">499</span>, <span class="refDoi"> DOI: 10.3390/v11060499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fv11060499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=499&author=J.+C.+LeCherauthor=N.+Diepauthor=P.+W.+Krugauthor=J.+K.+Hilliard&title=Genistein+has+antiviral+activity+against+herpes+B+virus+and+acts+synergistically+with+antiviral+treatments+to+reduce+effective+dose&doi=10.3390%2Fv11060499"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.3390%2Fv11060499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11060499%26sid%3Dliteratum%253Aachs%26aulast%3DLeCher%26aufirst%3DJ.%2BC.%26aulast%3DDiep%26aufirst%3DN.%26aulast%3DKrug%26aufirst%3DP.%2BW.%26aulast%3DHilliard%26aufirst%3DJ.%2BK.%26atitle%3DGenistein%2520has%2520antiviral%2520activity%2520against%2520herpes%2520B%2520virus%2520and%2520acts%2520synergistically%2520with%2520antiviral%2520treatments%2520to%2520reduce%2520effective%2520dose%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D499%26doi%3D10.3390%2Fv11060499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan-Jacob, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okram, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendrich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vajpai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzesiek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daley, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmuth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>463</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/nature08675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fnature08675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20072125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=501-506&author=J.+Zhangauthor=F.+J.+Adrianauthor=W.+Jahnkeauthor=S.+W.+Cowan-Jacobauthor=A.+G.+Liauthor=R.+E.+Iacobauthor=T.+Simauthor=J.+Powersauthor=C.+Dierksauthor=F.+Sunauthor=G.+R.+Guoauthor=Q.+Dingauthor=B.+Okramauthor=Y.+Choiauthor=A.+Wojciechowskiauthor=X.+Dengauthor=G.+Liuauthor=G.+Fendrichauthor=A.+Straussauthor=N.+Vajpaiauthor=S.+Grzesiekauthor=T.+Tuntlandauthor=Y.+Liuauthor=B.+Bursulayaauthor=M.+Azamauthor=P.+W.+Manleyauthor=J.+R.+Engenauthor=G.+Q.+Daleyauthor=M.+Warmuthauthor=N.+S.+Gray&title=Targeting+Bcr-Abl+by+combining+allosteric+with+ATP-binding-site+inhibitors&doi=10.1038%2Fnature08675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</span></div><div class="casAuthors">Zhang, Jianming; Adrian, Francisco J.; Jahnke, Wolfgang; Cowan-Jacob, Sandra W.; Li, Allen G.; Iacob, Roxana E.; Sim, Taebo; Powers, John; Dierks, Christine; Sun, Fangxian; Guo, Gui-Rong; Ding, Qiang; Okram, Barun; Choi, Yongmun; Wojciechowski, Amy; Deng, Xianming; Liu, Guoxun; Fendrich, Gabriele; Strauss, Andre; Vajpai, Navratna; Grzesiek, Stephan; Tuntland, Tove; Liu, Yi; Bursulaya, Badry; Azam, Mohammad; Manley, Paul W.; Engen, John R.; Daley, George Q.; Warmuth, Markus; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">501-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In an effort to find new pharmacol. modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of GNF-2, a selective allosteric Bcr-Abl inhibitor.  Here, using soln. NMR, X-ray crystallog., mutagenesis and hydrogen exchange mass spectrometry, we show that GNF-2 binds to the myristate-binding site of Abl, leading to changes in the structural dynamics of the ATP-binding site.  GNF-5, an analog of GNF-2 with improved pharmacokinetic properties, when used in combination with the ATP-competitive inhibitors imatinib or nilotinib, suppressed the emergence of resistance mutations in vitro, displayed additive inhibitory activity in biochem. and cellular assays against T315I mutant human Bcr-Abl and displayed in vivo efficacy against this recalcitrant mutant in a murine bone-marrow transplantation model.  These results show that therapeutically relevant inhibition of Bcr-Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUtkKFuTQx1LVg90H21EOLACvtfcHk0liprGqho5zDTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlCnuw%253D%253D&md5=46c122384fa004d27865c77f4a9165b7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1038%2Fnature08675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08675%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DJahnke%26aufirst%3DW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DA.%2BG.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DDierks%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DG.%2BR.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DOkram%26aufirst%3DB.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DStrauss%26aufirst%3DA.%26aulast%3DVajpai%26aufirst%3DN.%26aulast%3DGrzesiek%26aufirst%3DS.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Bcr-Abl%2520by%2520combining%2520allosteric%2520with%2520ATP-binding-site%2520inhibitors%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D501%26epage%3D506%26doi%3D10.1038%2Fnature08675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potisopon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann Chu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">GNF-2 inhibits dengue virus by targeting abl kinases and the viral e protein</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.chembiol.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27105280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=443-452&author=M.+J.+Clarkauthor=C.+Miduturuauthor=A.+G.+Schmidtauthor=X.+Zhuauthor=J.+D.+Pittsauthor=J.+Wangauthor=S.+Potisoponauthor=J.+Zhangauthor=A.+Wojciechowskiauthor=J.+J.+Hann+Chuauthor=N.+S.+Grayauthor=P.+L.+Yang&title=GNF-2+inhibits+dengue+virus+by+targeting+abl+kinases+and+the+viral+e+protein&doi=10.1016%2Fj.chembiol.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein</span></div><div class="casAuthors">Clark, Margaret J.; Miduturu, Chandra; Schmidt, Aaron G.; Zhu, Xuling; Pitts, Jared D.; Wang, Jinhua; Potisopon, Supanee; Zhang, Jianming; Wojciechowski, Amy; Chu, Justin Jang Hann; Gray, Nathanael S.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-452</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus.  Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yielded drugs that have advanced to the clinic.  Here, we show that the allosteric Abl kinase inhibitor GNF-2 interferes with dengue virus replication via activity mediated by cellular Abl kinases but addnl. blocks viral entry via an Abl-independent mechanism.  To characterize this newly discovered antiviral activity, we developed disubstituted pyrimidines that block dengue virus entry with structure-activity relationships distinct from those driving kinase inhibition.  We demonstrate that biotin- and fluorophore-conjugated derivs. of GNF-2 interact with the dengue glycoprotein, E, in the pre-fusion conformation that exists on the virion surface, and that this interaction inhibits viral entry.  This study establishes GNF-2 as an antiviral compd. with polypharmacol. activity and provides "lead" compds. for further optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-_Dumc6V_A7Vg90H21EOLACvtfcHk0ljxM2ZvhGcQGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D&md5=d5bd0ad159a7df03b992ecb96a7d231f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPitts%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPotisopon%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DHann%2BChu%26aufirst%3DJ.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DGNF-2%2520inhibits%2520dengue%2520virus%2520by%2520targeting%2520abl%2520kinases%2520and%2520the%2520viral%2520e%2520protein%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D443%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rausch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackett, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinbren, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeder, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyne, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, S.</span></span> <span> </span><span class="NLM_article-title">Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against zika virus</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.celrep.2016.12.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28099856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Chs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=804-815&author=K.+Rauschauthor=B.+A.+Hackettauthor=N.+L.+Weinbrenauthor=S.+M.+Reederauthor=Y.+Sadovskyauthor=C.+A.+Hunterauthor=D.+C.+Schultzauthor=C.+B.+Coyneauthor=S.+Cherry&title=Screening+bioactives+reveals+nanchangmycin+as+a+broad+spectrum+antiviral+active+against+zika+virus&doi=10.1016%2Fj.celrep.2016.12.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Screening Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against Zika Virus</span></div><div class="casAuthors">Rausch, Keiko; Hackett, Brent A.; Weinbren, Nathan L.; Reeder, Sophia M.; Sadovsky, Yoel; Hunter, Christopher A.; Schultz, David C.; Coyne, Carolyn B.; Cherry, Sara</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">804-815</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Zika virus is an emerging arthropod-borne flavivirus for which there are no vaccines or specific therapeutics.  We screened a library of 2,000 bioactive compds. for their ability to block Zika virus infection in three distinct cell types with two different strains of Zika virus.  Using a microscopy-based assay, we validated 38 drugs that inhibited Zika virus infection, including FDA-approved nucleoside analogs.  Cells expressing high levels of the attachment factor AXL can be protected from infection with receptor tyrosine kinase inhibitors, while placental-derived cells that lack AXL expression are insensitive to this inhibition.  Importantly, we identified nanchangmycin as a potent inhibitor of Zika virus entry across all cell types tested, including physiol. relevant primary cells.  Nanchangmycin also was active against other medically relevant viruses, including West Nile, dengue, and chikungunya viruses that use a similar route of entry.  This study provides a resource of small mols. to study Zika virus pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYuIFZmaMBHLVg90H21EOLACvtfcHk0ljxM2ZvhGcQGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Chs7g%253D&md5=6f64daa643f3c4dd4f98a090e1e3e056</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DRausch%26aufirst%3DK.%26aulast%3DHackett%26aufirst%3DB.%2BA.%26aulast%3DWeinbren%26aufirst%3DN.%2BL.%26aulast%3DReeder%26aufirst%3DS.%2BM.%26aulast%3DSadovsky%26aufirst%3DY.%26aulast%3DHunter%26aufirst%3DC.%2BA.%26aulast%3DSchultz%26aufirst%3DD.%2BC.%26aulast%3DCoyne%26aufirst%3DC.%2BB.%26aulast%3DCherry%26aufirst%3DS.%26atitle%3DScreening%2520bioactives%2520reveals%2520nanchangmycin%2520as%2520a%2520broad%2520spectrum%2520antiviral%2520active%2520against%2520zika%2520virus%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D804%26epage%3D815%26doi%3D10.1016%2Fj.celrep.2016.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaTerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnapp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rieder, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. M.</span></span> <span> </span><span class="NLM_article-title">The small molecule hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1083/jcb.200208092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1083%2Fjcb.200208092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12707311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjtl2isb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2003&pages=281-294&author=S.+Haufauthor=R.+W.+Coleauthor=S.+LaTerraauthor=C.+Zimmerauthor=G.+Schnappauthor=R.+Walterauthor=A.+Heckelauthor=J.+van+Meelauthor=C.+L.+Riederauthor=J.+M.+Peters&title=The+small+molecule+hesperadin+reveals+a+role+for+Aurora+B+in+correcting+kinetochore-microtubule+attachment+and+in+maintaining+the+spindle+assembly+checkpoint&doi=10.1083%2Fjcb.200208092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint</span></div><div class="casAuthors">Hauf, Silke; Cole, Richard W.; LaTerra, Sabrina; Zimmer, Christine; Schnapp, Gisela; Walter, Rainer; Heckel, Armin; van Meel, Jacques; Rieder, Conly L.; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">281-294</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The proper segregation of sister chromatids in mitosis depends on bipolar attachment of all chromosomes to the mitotic spindle.  We have identified the small mol. Hesperadin as an inhibitor of chromosome alignment and segregation.  Our data imply that Hesperadin causes this phenotype by inhibiting the function of the mitotic kinase Aurora B.  Mammalian cells treated with Hesperadin enter anaphase in the presence of numerous monooriented chromosomes, many of which may have both sister kinetochores attached to one spindle pole (syntelic attachment).  Hesperadin also causes cells arrested by taxol or monastrol to enter anaphase within <1 h, whereas cells in nocodazole stay arrested for 3-5 h.  Together, our data suggest that Aurora B is required to generate unattached kinetochores on monooriented chromosomes, which in turn could promote bipolar attachment as well as maintain checkpoint signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG-9s78ZbJorVg90H21EOLACvtfcHk0ljxM2ZvhGcQGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjtl2isb8%253D&md5=a79851e7d015a1530340a38e86b1943f</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200208092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200208092%26sid%3Dliteratum%253Aachs%26aulast%3DHauf%26aufirst%3DS.%26aulast%3DCole%26aufirst%3DR.%2BW.%26aulast%3DLaTerra%26aufirst%3DS.%26aulast%3DZimmer%26aufirst%3DC.%26aulast%3DSchnapp%26aufirst%3DG.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3Dvan%2BMeel%26aufirst%3DJ.%26aulast%3DRieder%26aufirst%3DC.%2BL.%26aulast%3DPeters%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520small%2520molecule%2520hesperadin%2520reveals%2520a%2520role%2520for%2520Aurora%2520B%2520in%2520correcting%2520kinetochore-microtubule%2520attachment%2520and%2520in%2520maintaining%2520the%2520spindle%2520assembly%2520checkpoint%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2003%26volume%3D161%26spage%3D281%26epage%3D294%26doi%3D10.1083%2Fjcb.200208092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musharrafieh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1929</span>, <span class="refDoi"> DOI: 10.3390/ijms18091929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3390%2Fijms18091929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOlsrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1929&author=Y.+Huauthor=J.+Zhangauthor=R.+Musharrafiehauthor=R.+Hauauthor=C.+Maauthor=J.+Wang&title=Chemical+genomics+approach+leads+to+the+identification+of+hesperadin%2C+an+aurora+B+kinase+inhibitor%2C+as+a+broad-spectrum+influenza+antiviral&doi=10.3390%2Fijms18091929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genomics approach leads to the identification of hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral</span></div><div class="casAuthors">Hu, Yanmei; Zhang, Jiantao; Musharrafieh, Rami; Hau, Raymond; Ma, Chunlong; Wang, Jun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1929/1-1929/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Influenza viruses are respiratory pathogens that are responsible for annual influenza epidemics and sporadic influenza pandemics.  Oseltamivir (Tamiflu) is currently the only FDAapproved oral drug that is available for the prevention and treatment of influenza virus infection.  However, its narrow therapeutic window, coupled with the increasing incidence of drug resistance, calls for the next generation of influenza antivirals.  In this study, we discovered hesperadin, an aurora B kinase inhibitor, as a broad-spectrum influenza antiviral through forward chem. genomics screening.  Hesperadin inhibits multiple human clin. isolates of influenza A and B viruses with single to submicromolar efficacy, including oseltamivir-resistant strains.  Mechanistic studies revealed that hesperadin inhibits the early stage of viral replication by delaying the nuclear entry of viral ribonucleoprotein complex, thereby inhibiting viral RNA transcription and translation as well as viral protein synthesis.  Moreover, a combination of hesperadin with oseltamivir shows synergistic antiviral activity, therefore hesperadin can be used either alone to treat infections by oseltamivir-resistant influenza viruses or used in combination with oseltamivir to delay resistance evolution among oseltamivir-sensitive strains.  In summary, the discovery of hesperadin as a broad-spectrum influenza antiviral offers an alternative to combat future influenza epidemics and pandemics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwxC84q0qSarVg90H21EOLACvtfcHk0lgTI9j5LJ4kfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOlsrzJ&md5=06792c248e23e339c22a3f0be405ef2f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.3390%2Fijms18091929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18091929%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMusharrafieh%26aufirst%3DR.%26aulast%3DHau%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DChemical%2520genomics%2520approach%2520leads%2520to%2520the%2520identification%2520of%2520hesperadin%252C%2520an%2520aurora%2520B%2520kinase%2520inhibitor%252C%2520as%2520a%2520broad-spectrum%2520influenza%2520antiviral%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1929%26doi%3D10.3390%2Fijms18091929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication</span>. <i>J. Virol</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2827</span>, <span class="refDoi"> DOI: 10.1128/JVI.01969-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.01969-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21209112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=2818-2827&author=N.+Kumarauthor=Y.+Liangauthor=T.+G.+Parslowauthor=Y.+Liang&title=Receptor+tyrosine+kinase+inhibitors+block+multiple+steps+of+influenza+a+virus+replication&doi=10.1128%2FJVI.01969-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span></div><div class="casAuthors">Kumar, Naveen; Liang, Yuhong; Parslow, Tristram G.; Liang, Yuying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2818-2827</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host signaling pathways play important roles in the replication of influenza virus, but their functional effects remain to be characterized at the mol. level.  Here we identify two receptor tyrosine kinase inhibitors (RTKIs) of the tyrphostin class that exhibit robust antiviral activity against influenza A virus replication in cultured cells.  One of these (AG879) is a selective inhibitor of the nerve growth factor receptor and human epidermal growth factor receptor 2 (TrkA/HER2) signaling; the other, tyrphostin A9 (A9), inhibits the platelet-derived growth factor receptor (PDGFR) pathway.  We find that each inhibits at least three postentry steps of the influenza virus life cycle: AG879 and A9 both strongly inhibit the synthesis of all three influenza virus RNA species, block Crm1-dependent nuclear export, and also prevent the release of viral particles through a pathway that is modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).  Tests of short hairpin RNA (shRNA) knockdown and addnl. small-mol. inhibitors confirmed that interventions targeting TrkA can suppress influenza virus replication.  Our study suggests that host cell receptor tyrosine kinase signaling is required for maximal influenza virus RNA synthesis, viral ribonucleoprotein (vRNP) nuclear export, and virus release and that specific RTKIs hold promise as novel anti-influenza virus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDOKlH_iMWLVg90H21EOLACvtfcHk0lgTI9j5LJ4kfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM&md5=5b0e29955db6cd71e6d371db771138d0</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1128%2FJVI.01969-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01969-10%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DParslow%26aufirst%3DT.%2BG.%26aulast%3DLiang%26aufirst%3DY.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520multiple%2520steps%2520of%2520influenza%2520a%2520virus%2520replication%26jtitle%3DJ.%2520Virol%26date%3D2011%26volume%3D85%26spage%3D2818%26epage%3D2827%26doi%3D10.1128%2FJVI.01969-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">104651</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31751591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2020&pages=104651&author=W.+Dongauthor=W.+Xieauthor=Y.+Liuauthor=B.+Suiauthor=H.+Zhangauthor=L.+Liuauthor=Y.+Tanauthor=X.+Tongauthor=Z.+F.+Fuauthor=P.+Yinauthor=L.+Fangauthor=G.+Peng&title=Receptor+tyrosine+kinase+inhibitors+block+proliferation+of+TGEV+mainly+through+p38+mitogen-activated+protein+kinase+pathways&doi=10.1016%2Fj.antiviral.2019.104651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Dong, Wanyu; Xie, Wenting; Liu, Yunbo; Sui, Baokun; Zhang, Hao; Liu, Liran; Tan, Yubei; Tong, Xiaohan; Fu, Zhen F.; Yin, Ping; Fang, Liurong; Peng, Guiqing</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104651</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available.  Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays.  Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV) and feline infectious peritonitis virus (FIPV).  We further performed a comparative phosphoproteomic anal. to investigate the mechanism of action of A9 against TGEV infection in vitro.  We specifically identified p38 and JNK1, which are the downstream mols. of receptor tyrosine kinases (RTKs) required for efficient TGEV replication, as A9 targets through plaque assays, qRT-PCR and Western blotting assays. p38 and JNK1 inhibitors and RNA interference further showed that the inhibitory activity of A9 against TGEV infection was mainly mediated by the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  All these findings indicated that the RTKI A9 directly inhibits TGEV replication and that its inhibitory activity against TGEV replication mainly occurs by targeting p38, which provides vital clues to the design of novel drugs against CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnYnZ9MxD37Vg90H21EOLACvtfcHk0lgTI9j5LJ4kfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO&md5=d0b78e75caf0d2932528e2ff6706d961</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104651%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DG.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520proliferation%2520of%2520TGEV%2520mainly%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D173%26spage%3D104651%26doi%3D10.1016%2Fj.antiviral.2019.104651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakisaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chutiwitoonchai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.05.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbrc.2014.05.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24858693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslaitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2014&pages=49-54&author=Y.+Sasakiauthor=M.+Kakisakaauthor=N.+Chutiwitoonchaiauthor=S.+Tajimaauthor=H.+Hikonoauthor=T.+Saitoauthor=Y.+Aida&title=Identification+of+a+novel+multiple+kinase+inhibitor+with+potent+antiviral+activity+against+influenza+virus+by+reducing+viral+polymerase+activity&doi=10.1016%2Fj.bbrc.2014.05.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel multiple kinase inhibitor with potent antiviral activity against influenza virus by reducing viral polymerase activity</span></div><div class="casAuthors">Sasaki, Yutaka; Kakisaka, Michinori; Chutiwitoonchai, Nopporn; Tajima, Shigeru; Hikono, Hirokazu; Saito, Takehiko; Aida, Yoko</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Neuraminidase inhibitors are the only currently available influenza treatment, although resistant viruses to these drugs have already been reported.  Thus, new antiviral drugs with novel mechanisms of action are urgently required.  In this study, we identified a novel antiviral compd., WV970, through cell-based screening of a 50,000 compd. library and subsequent lead optimization.  This compd. exhibited potent antiviral activity with nanomolar IC50 values against both influenza A and B viruses but not non-influenza RNA viruses.  Time-of-addn. and indirect immunofluorescence assays indicated that WV970 acted at an early stage of the influenza life cycle, but likely after nuclear entry of viral ribonucleoprotein (vRNP).  Further analyses of viral RNA expression and viral polymerase activity indicated that WV970 inhibited vRNP-mediated viral genome replication and transcription.  Finally, structure-based virtual screening and comprehensive human kinome screening were used to demonstrate that WV970 acts as a multiple kinase inhibitor, many of which are assocd. with influenza virus replication.  Collectively, these results strongly suggest that WV970 is a promising anti-influenza drug candidate and that several kinases assocd. with viral replication are promising drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVOZMxWNbCLVg90H21EOLACvtfcHk0liKmY0euQEgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslaitbk%253D&md5=e8cc148a987f9dcddc59e2bbf43b045e</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.05.058%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DKakisaka%26aufirst%3DM.%26aulast%3DChutiwitoonchai%26aufirst%3DN.%26aulast%3DTajima%26aufirst%3DS.%26aulast%3DHikono%26aufirst%3DH.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DAida%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520a%2520novel%2520multiple%2520kinase%2520inhibitor%2520with%2520potent%2520antiviral%2520activity%2520against%2520influenza%2520virus%2520by%2520reducing%2520viral%2520polymerase%2520activity%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2014%26volume%3D450%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.bbrc.2014.05.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunte, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wali, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koetsier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostjukova, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilimnik, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyatkin, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelnikova, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, H. K.</span></span> <span> </span><span class="NLM_article-title">Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">3497</span>– <span class="NLM_lpage">3502</span>, <span class="refDoi"> DOI: 10.1016/j.febslet.2005.05.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.febslet.2005.05.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15961079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2005&pages=3497-3502&author=D.+P.+Kunteauthor=R.+K.+Waliauthor=J.+L.+Koetsierauthor=J.+Hartauthor=M.+N.+Kostjukovaauthor=A.+Y.+Kilimnikauthor=I.+G.+Pyatkinauthor=S.+R.+Strelnikovaauthor=H.+K.+Roy&title=Down-regulation+of+the+tumor+suppressor+gene+C-terminal+Src+kinase%3A+an+early+event+during+premalignant+colonic+epithelial+hyperproliferation&doi=10.1016%2Fj.febslet.2005.05.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Down-regulation of the tumor suppressor gene C-terminal Src kinase: An early event during premalignant colonic epithelial hyperproliferation</span></div><div class="casAuthors">Kunte, Dhananjay P.; Wali, Ramesh K.; Koetsier, Jennifer L.; Hart, John; Kostjukova, Maria N.; Kilimnik, Anna Y.; Pyatkin, Ilia G.; Strelnikova, Svetlana R.; Roy, Hemant K.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3497-3502</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyperproliferation of the premalignant epithelium is crit. for colonic carcinogenesis; however the mechanisms remain largely unexplored.  We report herein that prior to occurrence of neoplastic lesions in the azoxymethane-rat model of colon carcinogenesis; the tumor suppressor gene C-terminal Src kinase (Csk) was down-regulated with a concomitant increase in Src activity.  Furthermore, pharmacol. or genetic (RNA interference) inhibition of Csk resulted in increased proliferation in colon cancer cell lines through the mitogen-activated protein kinase dependent pathway.  Thus, we demonstrate, for the first time, that Csk suppression is an important early event in colorectal cancer pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFkbrFw5VpbVg90H21EOLACvtfcHk0liKmY0euQEgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWrtrs%253D&md5=8bba93e1ce1da827af8fb57622242dad</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.febslet.2005.05.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.febslet.2005.05.030%26sid%3Dliteratum%253Aachs%26aulast%3DKunte%26aufirst%3DD.%2BP.%26aulast%3DWali%26aufirst%3DR.%2BK.%26aulast%3DKoetsier%26aufirst%3DJ.%2BL.%26aulast%3DHart%26aufirst%3DJ.%26aulast%3DKostjukova%26aufirst%3DM.%2BN.%26aulast%3DKilimnik%26aufirst%3DA.%2BY.%26aulast%3DPyatkin%26aufirst%3DI.%2BG.%26aulast%3DStrelnikova%26aufirst%3DS.%2BR.%26aulast%3DRoy%26aufirst%3DH.%2BK.%26atitle%3DDown-regulation%2520of%2520the%2520tumor%2520suppressor%2520gene%2520C-terminal%2520Src%2520kinase%253A%2520an%2520early%2520event%2520during%2520premalignant%2520colonic%2520epithelial%2520hyperproliferation%26jtitle%3DFEBS%2520Lett.%26date%3D2005%26volume%3D579%26spage%3D3497%26epage%3D3502%26doi%3D10.1016%2Fj.febslet.2005.05.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medigeshi, G. R.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30490</span>, <span class="refDoi"> DOI: 10.1038/srep30490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Fsrep30490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=27457684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=30490&author=R.+Kumarauthor=T.+Agrawalauthor=N.+A.+Khanauthor=Y.+Nakayamaauthor=G.+R.+Medigeshi&title=Identification+and+characterization+of+the+role+of+c-terminal+Src+kinase+in+dengue+virus+replication&doi=10.1038%2Fsrep30490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of the role of c-terminal Src kinase in dengue virus replication</span></div><div class="casAuthors">Kumar, Rinki; Agrawal, Tanvi; Khan, Naseem Ahmed; Nakayama, Yuji; Medigeshi, Guruprasad R.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30490</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We screened a siRNA library targeting human tyrosine kinases in Huh-7 cells and identified c-terminal Src kinase (Csk) as one of the kinases involved in dengue virus replication.  Knock-down of Csk expression by siRNAs or inhibition of Csk by an inhibitor reduced dengue virus RNA levels but did not affect viral entry.  Csk partially colocalized with viral replication compartments.  Dengue infection was drastically reduced in cells lacking the three ubiquitous src family kinases, Src, Fyn and Yes.  Csk knock-down in these cells failed to block dengue virus replication suggesting that the effect of Csk is via regulation of Src family kinases.  Csk was found to be hyper-phosphorylated during dengue infection and inhibition of protein kinase A led to a block in Csk phosphorylation and dengue virus replication.  Overexpression studies suggest an important role for the kinase and SH3 domains in this process.  Our results identified a novel role for Csk as a host tyrosine kinase involved in dengue virus replication and provide further insights into the role of host factors in dengue replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVlEp-nx5hb7Vg90H21EOLACvtfcHk0liKmY0euQEgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gu7%252FJ&md5=91a61fd24e54e8517cd5bd07bf27bb74</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1038%2Fsrep30490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep30490%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DAgrawal%26aufirst%3DT.%26aulast%3DKhan%26aufirst%3DN.%2BA.%26aulast%3DNakayama%26aufirst%3DY.%26aulast%3DMedigeshi%26aufirst%3DG.%2BR.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520the%2520role%2520of%2520c-terminal%2520Src%2520kinase%2520in%2520dengue%2520virus%2520replication%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D30490%26doi%3D10.1038%2Fsrep30490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strang, B. L.</span></span> <span> </span><span class="NLM_article-title">RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2017.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2017.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28501424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVCqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2017&pages=21-26&author=B.+L.+Strang&title=RO0504985+is+an+inhibitor+of+CMGC+kinase+proteins+and+has+anti-human+cytomegalovirus+activity&doi=10.1016%2Fj.antiviral.2017.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">RO0504985 is an inhibitor of CMGC kinase proteins and has anti-human cytomegalovirus activity</span></div><div class="casAuthors">Strang, Blair L.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Public-private partnerships allow many previously unavailable compds. to be screened for antiviral activity.  Here a screening method was used to identify an oxindole compd., RO0504985, from a Roche kinase inhibitor library that inhibited human cytomegalovirus (HCMV) protein prodn.  RO0504985 was previously described as an inhibitor of cyclin-dependent kinase 2 (CDK2).  However, using kinase selectivity assays it was found that RO0504985 was an inhibitor of several CMGC group kinase proteins, including CDK2.  Using virus yield redn. assays it was obsd. that RO0504985 inhibited replication of different HCMV strains at low micromolar concns.  Western blotting was used to investigate how RO0504985 inhibited HCMV replication.  Treatment of HCMV infected cells with RO0504985 inhibited prodn. of the immediate early viral IE2 proteins and the late viral protein pp28.  Thus, RO0504985 inhibited HCMV replication by preventing prodn. of specific HCMV proteins necessary for virus replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo519ED6ixmbVg90H21EOLACvtfcHk0liKmY0euQEgqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVCqurs%253D&md5=9758b92eed458cc7743842d50b228f3f</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2017.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2017.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DStrang%26aufirst%3DB.%2BL.%26atitle%3DRO0504985%2520is%2520an%2520inhibitor%2520of%2520CMGC%2520kinase%2520proteins%2520and%2520has%2520anti-human%2520cytomegalovirus%2520activity%26jtitle%3DAntiviral%2520Res.%26date%3D2017%26volume%3D144%26spage%3D21%26epage%3D26%26doi%3D10.1016%2Fj.antiviral.2017.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavalli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volety, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">BX795 demonstrates potent antiviral benefits against herpes simplex virus-1 infection of human cell lines</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">104814</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104814</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2020.104814" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32380150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOjurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=104814&author=A.+Iqbalauthor=R.+Suryawanshiauthor=T.+Yadavalliauthor=I.+Voletyauthor=D.+Shukla&title=BX795+demonstrates+potent+antiviral+benefits+against+herpes+simplex+virus-1+infection+of+human+cell+lines&doi=10.1016%2Fj.antiviral.2020.104814"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines</span></div><div class="casAuthors">Iqbal, Aqsa; Suryawanshi, Rahul; Yadavalli, Tejabhiram; Volety, Ipsita; Shukla, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104814</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herpes simplex virus-1 (HSV-1) infection is known to cause skin blisters, keratitis as well as deadly cases of encephalitis in some situations.  Only a few therapeutic modalities are available for this globally prevalent infection.  Very recently, a small mol. BX795 was identified as an inhibitor of HSV-1 protein synthesis in an ocular model of infection.  In order to demonstrate its broader antiviral benefits, this study was aimed at evaluating the antiviral efficacy, mode-of-action, and toxicity of BX795 against HSV-1 infection of three human cell lines: HeLa, HEK, and HCE.  Several different assays, including cell survival anal., imaging, plaque anal., Immunoblotting, and qRT-PCR, were performed.  In all cases, BX795 demonstrated low toxicity at therapeutic concn. and showed strong antiviral benefits.  Quite interestingly, cell line-dependent differences in the mechanism of antiviral action and cytokine response to infection were seen upon BX795 treatment.  Taken together, our results suggest that BX795 may exert its antiviral benefits via cell-line specific mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXJfeQoc1x97Vg90H21EOLACvtfcHk0lisItfcoloulw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOjurrK&md5=27947db17288ceec13c1cf5f92eb0284</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104814%26sid%3Dliteratum%253Aachs%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DSuryawanshi%26aufirst%3DR.%26aulast%3DYadavalli%26aufirst%3DT.%26aulast%3DVolety%26aufirst%3DI.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DBX795%2520demonstrates%2520potent%2520antiviral%2520benefits%2520against%2520herpes%2520simplex%2520virus-1%2520infection%2520of%2520human%2520cell%2520lines%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D180%26spage%3D104814%26doi%3D10.1016%2Fj.antiviral.2020.104814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavalli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qatanani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volety, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koganti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo activity, tolerability, and mechanism of action of BX795 as an antiviral against herpes simplex virus 2 genital infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">e00245-20</span>, <span class="refDoi"> DOI: 10.1128/AAC.00245-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.00245-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32601167" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&pages=e00245-20&author=J.+Hopkinsauthor=T.+Yadavalliauthor=R.+Suryawanshiauthor=F.+Qatananiauthor=I.+Voletyauthor=R.+Kogantiauthor=A.+Iqbalauthor=D.+Shukla&title=In+vitro+and+in+vivo+activity%2C+tolerability%2C+and+mechanism+of+action+of+BX795+as+an+antiviral+against+herpes+simplex+virus+2+genital+infection&doi=10.1128%2FAAC.00245-20"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1128%2FAAC.00245-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00245-20%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DJ.%26aulast%3DYadavalli%26aufirst%3DT.%26aulast%3DSuryawanshi%26aufirst%3DR.%26aulast%3DQatanani%26aufirst%3DF.%26aulast%3DVolety%26aufirst%3DI.%26aulast%3DKoganti%26aufirst%3DR.%26aulast%3DIqbal%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520activity%252C%2520tolerability%252C%2520and%2520mechanism%2520of%2520action%2520of%2520BX795%2520as%2520an%2520antiviral%2520against%2520herpes%2520simplex%2520virus%25202%2520genital%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26spage%3De00245-20%26doi%3D10.1128%2FAAC.00245-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elbahesh, H.</span></span> <span> </span><span class="NLM_article-title">Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2019.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virol.2019.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31176924" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFensLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2019&pages=54-63&author=S.+Bergmannauthor=H.+Elbahesh&title=Targeting+the+proviral+host+kinase%2C+FAK%2C+limits+influenza+a+virus+pathogenesis+and+NFkB-regulated+pro-inflammatory+responses&doi=10.1016%2Fj.virol.2019.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the proviral host kinase, FAK, limits influenza A virus pathogenesis and NFκB-regulated pro-inflammatory responses</span></div><div class="casAuthors">Bergmann, Silke; Elbahesh, Husni</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54-63</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infections result in ∼500,000 global deaths annually.  Host kinases link multiple signaling pathways at various stages of infection and are attractive therapeutic target.  Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, regulates several cellular processes including NFκB and antiviral responses.  We investigated how FAK kinase activity regulates IAV pathogenesis.  Using a severe infection model, we infected IAV-susceptible DBA/2 J mice with a LD of H1N1 IAV.  We obsd. reduced viral load and pro-inflammatory cytokines, delayed mortality, and increased survival in FAK inhibitor (Y15) treated mice.  In vitro IAV-induced NFκB-promoter activity was reduced by Y15 or a dominant neg. kinase-dead FAK mutant (FAK-KD) independently of the viral immune modulator, NS1.  Finally, we obsd. reduced IAV-induced nuclear localization of NFkB in FAK-KD expressing cells.  Our data suggest a novel mechanism where IAV hijacks FAK to promote viral replication and limit its ability to contribute to innate immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJjWpvNXcU7bVg90H21EOLACvtfcHk0lisItfcoloulw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFensLrE&md5=1cdb026d95d30541bc34a640b204e437</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2019.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DBergmann%26aufirst%3DS.%26aulast%3DElbahesh%26aufirst%3DH.%26atitle%3DTargeting%2520the%2520proviral%2520host%2520kinase%252C%2520FAK%252C%2520limits%2520influenza%2520a%2520virus%2520pathogenesis%2520and%2520NFkB-regulated%2520pro-inflammatory%2520responses%26jtitle%3DVirology%26date%3D2019%26volume%3D534%26spage%3D54%26epage%3D63%26doi%3D10.1016%2Fj.virol.2019.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knockaert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malim, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7882</span>, <span class="refDoi"> DOI: 10.1128/JVI.76.15.7874-7882.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.76.15.7874-7882.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=12097601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD38XltlKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=7874-7882&author=L.+M.+Schangauthor=A.+Bantlyauthor=M.+Knockaertauthor=F.+Shaheenauthor=L.+Meijerauthor=M.+H.+Malimauthor=N.+S.+Grayauthor=P.+A.+Schaffer&title=Pharmacological+cyclin-dependent+kinase+inhibitors+inhibit+replication+of+wild-type+and+drug-resistant+strains+of+herpes+simplex+virus+and+human+immunodeficiency+virus+type+1+by+targeting+cellular%2C+not+viral%2C+proteins&doi=10.1128%2FJVI.76.15.7874-7882.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins</span></div><div class="casAuthors">Schang, Luis M.; Bantly, Andrew; Knockaert, Marie; Shaheen, Farida; Meijer, Laurent; Malim, Michael H.; Gray, Nathanael S.; Schaffer, Priscilla A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7874-7882</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Pharmacol. cyclin-dependent kinase (cdk) inhibitors (PCIs) block replication of several viruses, including herpes simplex virus type 1 (HSV-1) and human immunodeficiency virus type 1 (HIV-1).  Yet, these antiviral effects could result from inhibition of either cellular cdks or viral enzymes.  For example, in addn. to cellular cdks, PCIs could inhibit any of the herpesvirus-encoded kinases, DNA replication proteins, or proteins involved in nucleotide metab.  To address this issue, we asked whether purine-derived PCIs (P-PCIs) inhibit HSV and HIV-1 replication by targeting cellular or viral proteins.  P-PCIs inhibited replication of HSV-1 and -2 and HIV-1, which require cellular cdks to replicate, but not vaccinia virus or lymphocytic choriomeningitis virus, which are not known to require cdks to replicate.  P-PCIs also inhibited strains of HSV-1 and HIV-1 that are resistant to conventional antiviral drugs, which target viral proteins.  In addn., the anti-HSV effects of P-PCIs and a conventional antiherpesvirus drug, acyclovir, were additive, demonstrating that the two drugs act by distinct mechanisms.  Lastly, the spectrum of proteins that bound to P-PCIs in exts. of mock- and HSV-infected cells was the same.  Based on these observations, we conclude that P-PCIs inhibit virus replication by targeting cellular, not viral, proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlu88p4K_ArVg90H21EOLACvtfcHk0lisItfcoloulw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltlKqsbY%253D&md5=ef81912af20cae0a92208b81dc7405de</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1128%2FJVI.76.15.7874-7882.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.76.15.7874-7882.2002%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26aulast%3DBantly%26aufirst%3DA.%26aulast%3DKnockaert%26aufirst%3DM.%26aulast%3DShaheen%26aufirst%3DF.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DMalim%26aufirst%3DM.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSchaffer%26aufirst%3DP.%2BA.%26atitle%3DPharmacological%2520cyclin-dependent%2520kinase%2520inhibitors%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520drug-resistant%2520strains%2520of%2520herpes%2520simplex%2520virus%2520and%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520targeting%2520cellular%252C%2520not%2520viral%252C%2520proteins%26jtitle%3DJ.%2520Virol.%26date%3D2002%26volume%3D76%26spage%3D7874%26epage%3D7882%26doi%3D10.1128%2FJVI.76.15.7874-7882.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2eZM2EFz244qxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisenfelder, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. L.</span></span> <span> </span><span class="NLM_article-title">Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis</span>. <i>Biochim. Biophys. Acta, Proteins Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1697</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.bbapap.2003.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bbapap.2003.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15023363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1697&publication_year=2004&pages=225-231&author=J.+F.+Moffatauthor=M.+A.+McMichaelauthor=S.+A.+Leisenfelderauthor=S.+L.+Taylor&title=Viral+and+cellular+kinases+are+potential+antiviral+targets+and+have+a+central+role+in+varicella+zoster+virus+pathogenesis&doi=10.1016%2Fj.bbapap.2003.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis</span></div><div class="casAuthors">Moffat, Jennifer F.; McMichael, Michelle A.; Leisenfelder, Stacey A.; Taylor, Shannon L.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1697</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Herpesviruses utilize viral and cellular kinases for replication, and these mediate essential functions that are important for viral pathogenesis.  Elucidating the roles of kinases in herpesvirus infections may highlight virus-host interactions that are possible targets for kinase inhibitors with antiviral activity.  Varicella zoster virus (VZV) encodes two kinases that phosphorylate viral proteins involved in regulation, assembly, and virulence.  VZV infection also induces the activity of host cell cyclin-dependent kinases (cdk4 and cdk2) in nondividing cells, causing a dysregulation of the cell cycle.  Roscovitine and purvalanol, kinase inhibitors that target cdks, prevent VZV replication at concns. with few cytotoxic effects.  Cdk inhibitors therefore have potential as antivirals that may extend to a broad range of viruses and have the added advantage that resistance does not arise easily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWqyA-ur1aprVg90H21EOLACvtfcHk0ljgs3EcSZUjrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitFKlsLs%253D&md5=5fe3d869f6987f54e5bd81700503074e</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2003.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2003.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DMoffat%26aufirst%3DJ.%2BF.%26aulast%3DMcMichael%26aufirst%3DM.%2BA.%26aulast%3DLeisenfelder%26aufirst%3DS.%2BA.%26aulast%3DTaylor%26aufirst%3DS.%2BL.%26atitle%3DViral%2520and%2520cellular%2520kinases%2520are%2520potential%2520antiviral%2520targets%2520and%2520have%2520a%2520central%2520role%2520in%2520varicella%2520zoster%2520virus%2520pathogenesis%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2004%26volume%3D1697%26spage%3D225%26epage%3D231%26doi%3D10.1016%2Fj.bbapap.2003.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutterer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milbradt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeittrager, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zischinsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, M.</span></span> <span> </span><span class="NLM_article-title">A novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1128/AAC.04534-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FAAC.04534-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25624324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=2062-2071&author=C.+Huttererauthor=J.+Eickhoffauthor=J.+Milbradtauthor=K.+Kornauthor=I.+Zeittragerauthor=H.+Bahsiauthor=S.+Wagnerauthor=G.+Zischinskyauthor=A.+Wolfauthor=C.+Degenhartauthor=A.+Ungerauthor=M.+Baumannauthor=B.+Kleblauthor=M.+Marschall&title=A+novel+CDK7+inhibitor+of+the+pyrazolotriazine+class+exerts+broad-spectrum+antiviral+activity+at+nanomolar+concentrations&doi=10.1128%2FAAC.04534-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span></div><div class="casAuthors">Hutterer Corina; Milbradt Jens; Korn Klaus; Zeittrager Isabel; Bahsi Hanife; Wagner Sabrina; Marschall Manfred; Eickhoff Jan; Zischinsky Gunther; Wolf Alexander; Degenhart Carsten; Unger Anke; Baumann Matthias; Klebl Bert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2062-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases represent central and multifunctional regulators of a balanced virus-host interaction.  Cyclin-dependent protein kinase 7 (CDK7) plays crucial regulatory roles in cell cycle and transcription, both connected with the replication of many viruses.  Previously, we developed a CDK7 inhibitor, LDC4297, that inhibits CDK7 in vitro in the nano-picomolar range.  Novel data from a kinome-wide evaluation (>330 kinases profiled in vitro) demonstrate a kinase selectivity.  Importantly, we provide first evidence for the antiviral potential of the CDK7 inhibitor LDC4297, i.e., in exerting a block of the replication of human cytomegalovirus (HCMV) in primary human fibroblasts at nanomolar concentrations (50% effective concentration, 24.5 ± 1.3 nM).  As a unique feature compared to approved antiherpesviral drugs, inhibition occurred already at the immediate-early level of HCMV gene expression.  The mode of antiviral action was considered multifaceted since CDK7-regulated cellular factors that are supportive of HCMV replication were substantially affected by the inhibitors.  An effect of LDC4297 was identified in the interference with HCMV-driven inactivation of retinoblastoma protein (Rb), a regulatory step generally considered a hallmark of herpesviral replication.  In line with this finding, a broad inhibitory activity of the drug could be demonstrated against a selection of human and animal herpesviruses and adenoviruses, whereas other viruses only showed intermediate drug sensitivity.  Summarized, the CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFOdfST00W0BcfW6udTcc2eZM2EFz244qxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D&md5=57c36db4aa7415d9023016868151ba3f</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1128%2FAAC.04534-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04534-14%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMilbradt%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DK.%26aulast%3DZeittrager%26aufirst%3DI.%26aulast%3DBahsi%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DZischinsky%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DDegenhart%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMarschall%26aufirst%3DM.%26atitle%3DA%2520novel%2520CDK7%2520inhibitor%2520of%2520the%2520pyrazolotriazine%2520class%2520exerts%2520broad-spectrum%2520antiviral%2520activity%2520at%2520nanomolar%2520concentrations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D2062%26epage%3D2071%26doi%3D10.1128%2FAAC.04534-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">4871</span>– <span class="NLM_lpage">4877</span>, <span class="refDoi"> DOI: 10.1128/JVI.75.10.4871-4877.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1128%2FJVI.75.10.4871-4877.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11312358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD3M3it1ensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2001&pages=4871-4877&author=O.+Planzauthor=S.+Pleschkaauthor=S.+Ludwig&title=MEK-specific+inhibitor+U0126+blocks+spread+of+Borna+disease+virus+in+cultured+cells&doi=10.1128%2FJVI.75.10.4871-4877.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">MEK-specific inhibitor U0126 blocks spread of Borna disease virus in cultured cells</span></div><div class="casAuthors">Planz O; Pleschka S; Ludwig S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4871-7</span>
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Borna disease virus (BDV) is a highly neurotropic virus that causes Borna disease, a virus-induced immune-mediated encephalomyelitis, in a variety of warm-blooded animals.  Recent studies reported that BDV can be detected in patients with psychiatric disorders.  BDV is noncytopathic, replicates in the nucleus of infected cells, and spreads intraaxonally in vivo.  Upon infection of susceptible cultured cells, virus can be detected in foci.  Little is known about the cellular components required for BDV replication.  Here, we show that the cellular Raf/MEK/ERK signaling cascade is activated upon infection with BDV.  In the presence of the MEK-specific inhibitor U0126, cells get infected with BDV; however, there is a block in virus spread to neighboring cells.  The effect of the inhibitor on virus spread was still observed when the compound was added 2 h postinfection but not if treatment was initiated as late as 4 h after infection.  Our results provide new insights into the BDV-host cell interaction and show that virus infection can be controlled with drugs interfering with a cellular signaling pathway.  Since concentrations of the MEK inhibitor required to block BDV focus formation are not toxic for the host cells, our finding may be important with respect to antiviral drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbDfTsMtEqSHy-c-E1v-fmfW6udTcc2eb-pHHurMWiJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M3it1ensg%253D%253D&md5=71a4536e48840bf1a13302f744b36696</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1128%2FJVI.75.10.4871-4877.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.75.10.4871-4877.2001%26sid%3Dliteratum%253Aachs%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DMEK-specific%2520inhibitor%2520U0126%2520blocks%2520spread%2520of%2520Borna%2520disease%2520virus%2520in%2520cultured%2520cells%26jtitle%3DJ.%2520Virol.%26date%3D2001%26volume%3D75%26spage%3D4871%26epage%3D4877%26doi%3D10.1128%2FJVI.75.10.4871-4877.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span> <span> </span><span class="NLM_article-title">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(04)00108-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0014-5793%2804%2900108-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=15013748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2004&pages=37-43&author=S.+Ludwigauthor=T.+Wolffauthor=C.+Ehrhardtauthor=W.+J.+Wurzerauthor=J.+Reinhardtauthor=O.+Planzauthor=S.+Pleschka&title=MEK+inhibition+impairs+influenza+B+virus+propagation+without+emergence+of+resistant+variants&doi=10.1016%2FS0014-5793%2804%2900108-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span></div><div class="casAuthors">Ludwig, Stephan; Wolff, Thorsten; Ehrhardt, Christina; Wurzer, Walter Jurgen; Reinhardt, Jens; Planz, Oliver; Pleschka, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Influenza A and B viruses are still a major worldwide threat.  We demonstrate that influenza B virus infection induces signaling via the Raf/MEK/ERK cascade, a process required for efficient virus prodn.  Expression of dominant-neg. Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers.  MEK inhibition appears to interfere with a distinct viral nuclear export process.  Most importantly, no resistant virus variants emerged in the presence of U0126 demonstrating that influenza viruses cannot easily adapt to the missing cellular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH2SOtrmGyrbVg90H21EOLACvtfcHk0lheXbrMUFSiiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D&md5=30a70331cb39e18f1db14f415063ba91</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2804%2900108-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252804%252900108-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DWurzer%26aufirst%3DW.%2BJ.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26atitle%3DMEK%2520inhibition%2520impairs%2520influenza%2520B%2520virus%2520propagation%2520without%2520emergence%2520of%2520resistant%2520variants%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D561%26spage%3D37%26epage%3D43%26doi%3D10.1016%2FS0014-5793%2804%2900108-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Droebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21854809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2011&pages=195-203&author=K.+Droebnerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+activity+of+the+MEK-inhibitor+U0126+against+pandemic+H1N1v+and+highly+pathogenic+avian+influenza+virus+in+vitro+and+in+vivo&doi=10.1016%2Fj.antiviral.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span></div><div class="casAuthors">Droebner, Karoline; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of the 2009 H1N1 pandemic swine influenza A virus is a good example of how this viral infection can impact health systems around the world in a very short time.  The continuous zoonotic circulation and reassortment potential of influenza A viruses (IAV) in nature represents an enormous public health threat to humans.  Beside vaccination antivirals are needed to efficiently control spreading of the disease.  In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v = variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.  U0126 showed antiviral activity in cell culture against all tested IAV strains including oseltamivir resistant variants.  Furthermore, we were able to demonstrate that treatment of mice with U0126 via the aerosol route led to (i) inhibition of MEK activation in the lung (ii) redn. of progeny IAV titers compared to untreated controls (iii) protection of IAV infected mice against a 100× lethal viral challenge.  Moreover, no adverse effects of U0126 were found in cell culture or in the mouse.  Thus, we conclude that U0126, by inhibiting the cellular target MEK, has an antiviral potential not only in vitro in cell culture, but also in vivo in the mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6szZdpUCJ_bVg90H21EOLACvtfcHk0lheXbrMUFSiiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI&md5=2818e18e307a3cda653b302d30857638</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDroebner%26aufirst%3DK.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520activity%2520of%2520the%2520MEK-inhibitor%2520U0126%2520against%2520pandemic%2520H1N1v%2520and%2520highly%2520pathogenic%2520avian%2520influenza%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D92%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.antiviral.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castilla, V.</span></span> <span> </span><span class="NLM_article-title">Raf/MEK/ERK pathway activation is required for Junín virus replication</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">799</span>– <span class="NLM_lpage">805</span>, <span class="refDoi"> DOI: 10.1099/vir.0.061242-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2Fvir.0.061242-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24421112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyms7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2014&pages=799-805&author=M.+E.+Rodr%C3%ADguezauthor=J.+E.+Brunettiauthor=M.+B.+Wachsmanauthor=L.+A.+Scolaroauthor=V.+Castilla&title=Raf%2FMEK%2FERK+pathway+activation+is+required+for+Jun%C3%ADn+virus+replication&doi=10.1099%2Fvir.0.061242-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Raf/MEK/ERK pathway activation is required for Junin virus replication</span></div><div class="casAuthors">Rodriguez, Maria Eugenia; Brunetti, Jesus Emanuel; Wachsman, Monica Beatriz; Scolaro, Luis Alberto; Castilla, Viviana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">799-805</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">In the present work we investigated the importance of the Raf/MEK/ERK signalling pathway in the multiplication of the arenavirus Junin (JUNV) in monkey and human cell cultures.  We established that JUNV induces a biphasic activation of ERK and we proved that a specific inhibitor of the ERK pathway, U0126, impairs viral replication.  Furthermore, U0126 exerted inhibitory action against the arenaviruses Tacaribe and Pichinde.  Moreover, treatment with known ERK activators such as phorbol 12-myristate 13-acetate and serum increased viral yields whereas ERK silencing by small interfering RNAs caused the inhibition of viral multiplication.  Therefore, activation of the Raf/MEK/ERK signalling pathway is required to ensure efficient JUNV replication and may constitute a host target for the development of novel effective therapeutic strategies to deal with arenavirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4QqvKAiMrerVg90H21EOLACvtfcHk0liRMHVvC507gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyms7rM&md5=8be371d05a5c15534f003376291e76fc</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.061242-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.061242-0%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DM.%2BE.%26aulast%3DBrunetti%26aufirst%3DJ.%2BE.%26aulast%3DWachsman%26aufirst%3DM.%2BB.%26aulast%3DScolaro%26aufirst%3DL.%2BA.%26aulast%3DCastilla%26aufirst%3DV.%26atitle%3DRaf%252FMEK%252FERK%2520pathway%2520activation%2520is%2520required%2520for%2520Jun%25C3%25ADn%2520virus%2520replication%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2014%26volume%3D95%26spage%3D799%26epage%3D805%26doi%3D10.1099%2Fvir.0.061242-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albarnaz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Oliveira, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palhares, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casteluber, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Souza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacca, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroon, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonjardim, C. A.</span></span> <span> </span><span class="NLM_article-title">MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2014.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2014.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=25241249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFylu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=82-92&author=J.+D.+Albarnazauthor=L.+C.+De+Oliveiraauthor=A.+A.+Torresauthor=R.+M.+Palharesauthor=M.+C.+Casteluberauthor=C.+M.+Rodriguesauthor=P.+L.+Cardozoauthor=A.+M.+De+Souzaauthor=C.+C.+Paccaauthor=P.+C.+Ferreiraauthor=E.+G.+Kroonauthor=M.+L.+Nogueiraauthor=C.+A.+Bonjardim&title=MEK%2FERK+activation+plays+a+decisive+role+in+yellow+fever+virus+replication%3A+implication+as+an+antiviral+therapeutic+target&doi=10.1016%2Fj.antiviral.2014.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">MEK/ERK activation plays a decisive role in yellow fever virus replication: Implication as an antiviral therapeutic target</span></div><div class="casAuthors">Albarnaz, Jonas D.; De Oliveira, Leonardo C.; Torres, Alice A.; Palhares, Rafael M.; Casteluber, Marisa C.; Rodrigues, Claudiney M.; Cardozo, Pablo L.; De Souza, Aryadina M. R.; Pacca, Carolina C.; Ferreira, Paulo C. P.; Kroon, Erna G.; Nogueira, Mauricio L.; Bonjardim, Claudio A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-92</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Exploiting the inhibition of host signaling pathways aiming for discovery of potential antiflaviviral compds. is clearly a beneficial strategy for the control of life-threatening diseases caused by flaviviruses.  Here we describe the antiviral activity of the MEK1/2 inhibitor U0126 against Yellow fever virus 17D vaccine strain (YFV-17D).  Infection of VERO cells with YFV-17D stimulates ERK1/2 phosphorylation early during infection.  Pharmacol. inhibition of MEK1/2 through U0126 treatment of VERO cells blockades not only the YFV-stimulated ERK1/2 phosphorylation, but also inhibits YFV replication by ∼99%.  U0126 was also effective against dengue virus (DENV-2 and -3) and Saint-Louis encephalitis virus (SLEV).  Levels of NS4AB, as detected by immunofluorescence, are diminished upon treatment with the inhibitor, as well as the characteristic endoplasmic reticulum membrane invagination stimulated during the infection.  Though not protective, treatment of YFV-infected, adult BALB/c mice with U0126 resulted in significant redn. of virus titers in brains.  Collectively, our data suggest the potential targeting of the MEK1/2 kinase as a therapeutic tool against diseases caused by flaviviruses such as yellow fever, adverse events assocd. with yellow fever vaccination and dengue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOhqYp9UV497Vg90H21EOLACvtfcHk0liRMHVvC507gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFylu77N&md5=ea466efa138d26eb89b490b23d2b8792</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlbarnaz%26aufirst%3DJ.%2BD.%26aulast%3DDe%2BOliveira%26aufirst%3DL.%2BC.%26aulast%3DTorres%26aufirst%3DA.%2BA.%26aulast%3DPalhares%26aufirst%3DR.%2BM.%26aulast%3DCasteluber%26aufirst%3DM.%2BC.%26aulast%3DRodrigues%26aufirst%3DC.%2BM.%26aulast%3DCardozo%26aufirst%3DP.%2BL.%26aulast%3DDe%2BSouza%26aufirst%3DA.%2BM.%26aulast%3DPacca%26aufirst%3DC.%2BC.%26aulast%3DFerreira%26aufirst%3DP.%2BC.%26aulast%3DKroon%26aufirst%3DE.%2BG.%26aulast%3DNogueira%26aufirst%3DM.%2BL.%26aulast%3DBonjardim%26aufirst%3DC.%2BA.%26atitle%3DMEK%252FERK%2520activation%2520plays%2520a%2520decisive%2520role%2520in%2520yellow%2520fever%2520virus%2520replication%253A%2520implication%2520as%2520an%2520antiviral%2520therapeutic%2520target%26jtitle%3DAntiviral%2520Res.%26date%3D2014%26volume%3D111%26spage%3D82%26epage%3D92%26doi%3D10.1016%2Fj.antiviral.2014.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saminathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivasharanappa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umeshappa, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunathareddy, G. B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model</span>. <i>Microb. Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.micpath.2017.09.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.micpath.2017.09.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=28939254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGntbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2017&pages=38-49&author=V.+Manjunathaauthor=K.+P.+Singhauthor=M.+Saminathanauthor=R.+Singhauthor=N.+Shivasharanappaauthor=C.+S.+Umeshappaauthor=K.+Dhamaauthor=G.+B.+Manjunathareddy&title=Inhibition+of+MEK-ERK1%2F2-MAP+kinase+signalling+pathway+reduces+rabies+virus+induced+pathologies+in+mouse+model&doi=10.1016%2Fj.micpath.2017.09.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of MEK-ERK1/2-MAP kinase signalling pathway reduces rabies virus induced pathologies in mouse model</span></div><div class="casAuthors">Manjunatha, Venkataravanappa; Singh, Karam Pal; Saminathan, Mani; Singh, Rajendra; Shivasharanappa, Nayakwadi; Umeshappa, Channakeshava Sokke; Dhama, Kuldeep; Manjunathareddy, Gundallahalli Bayyappa</div><div class="citationInfo"><span class="NLM_cas:title">Microbial Pathogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-49</span>CODEN:
                <span class="NLM_cas:coden">MIPAEV</span>;
        ISSN:<span class="NLM_cas:issn">0882-4010</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The extracellular signal-regulated kinase (ERK) pathway has been shown to regulate pathogenesis of many viral infections, but its role during rabies virus (RV) infection in vivo is not clear.  In the present study, we investigated the potential role of MEK-ERK1/2 signalling pathway in the pathogenesis of rabies in mouse model and its regulatory effects on pro-inflammatory cytokines and other mediators of immunity, and kinetics of immune cells.  Mice were infected with 25 LD50 of challenge virus std. (CVS) strain of RV by intracerebral (i.c.) inoculation and were treated i.c. with U0126 (specific inhibitor of MEK1/2) at 10 μM/mouse at 0, 2, 4 and 6 days post-infection.  Treatment with U0126 resulted in delayed disease development and clin. signs, increased survival time with lesser mortality than untreated mice.  The better survival of inhibitor-treated and RV infected mice was pos. correlated with reduced viral load and reduced viral spread in the brain as quantified by real-time PCR, direct fluorescent antibody test and immunohistochem.  CVS-infected/mock-treated mice developed severe histopathol. lesions with increased Fluoro-Jade B pos. degenerating neurons in brain, which were assocd. with higher levels of serum nitric oxide, iNOS, TNF-α, and CXCL10 mRNA.  Also CVS-infected/U0126-treated mice revealed significant decrease in caspase 3 but increase in Bcl-2 mRNA levels and less TUNEL pos. apoptotic cells.  CVS-infected/U0126-treated group also showed significant increase in CD4+, CD8+ T lymphocytes and NK cells in blood and spleen possibly due to less apoptosis of these cells.  In conclusion, these data suggest that MEK-ERK1/2 signalling pathway play crit. role in the pathogenesis of RV infection in vivo and opens up new avenues of therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq3QpjKTwJj7Vg90H21EOLACvtfcHk0liRMHVvC507gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGntbjM&md5=0be81b1f8e34f6be6d74cc7c5d366599</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.micpath.2017.09.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.micpath.2017.09.044%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DV.%26aulast%3DSingh%26aufirst%3DK.%2BP.%26aulast%3DSaminathan%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DShivasharanappa%26aufirst%3DN.%26aulast%3DUmeshappa%26aufirst%3DC.%2BS.%26aulast%3DDhama%26aufirst%3DK.%26aulast%3DManjunathareddy%26aufirst%3DG.%2BB.%26atitle%3DInhibition%2520of%2520MEK-ERK1%252F2-MAP%2520kinase%2520signalling%2520pathway%2520reduces%2520rabies%2520virus%2520induced%2520pathologies%2520in%2520mouse%2520model%26jtitle%3DMicrob.%2520Pathog.%26date%3D2017%26volume%3D112%26spage%3D38%26epage%3D49%26doi%3D10.1016%2Fj.micpath.2017.09.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, H.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span>. <i>J. Funct. Foods</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.jff.2017.11.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jff.2017.11.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2018&pages=219-228&author=S.+Kangauthor=M.+J.+Songauthor=H.+Min&title=Antiviral+activity+of+ginsenoside+Rg3+isomers+against+gammaherpesvirus+through+inhibition+of+p38-+and+JNK-associated+pathways&doi=10.1016%2Fj.jff.2017.11.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of ginsenoside Rg3 isomers against gammaherpesvirus through inhibition of p38- and JNK-associated pathways</span></div><div class="casAuthors">Kang, Soowon; Song, Moon Jung; Min, Hyeyoung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Functional Foods</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JFFOAX</span>;
        ISSN:<span class="NLM_cas:issn">1756-4646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Natural compds. from functional foods targeting viruses are considered to have important role for regulating virus-related diseases.  Ginsenoside Rg3 is one of the active pharmaceutical components found in Panax ginseng C.  A. Meyer which is widely used as a functional food in East Asia.  In our present study, we have characterized the antiviral activities of the ginsenoside Rg3 isomers, 20(R)- and 20(S)-ginsenoside Rg3, against murine gammaherpesvirus 68 (MHV-68), a mouse model of human gammaherpesvirus which can cause various malignancies including cancer.  We found that both 20(R)- and 20(S)-ginsenoside Rg3 inhibited lytic replication and viral proliferation of MHV-68, although 20(S)-ginsenoside Rg3 was more effective than 20(R)-ginsenoside Rg3.  Furthermore, ginsenoside Rg3 isomers efficiently repressed chem.-induced lytic replication of human gammaherpesviruses in EBV-pos. BC-3 and KSHV-pos. Raji cell lines.  Finally, our data showed that ginsenoside Rg3 isomers suppressed the p38 and/or the JNK-assocd. MAPK signaling pathways, thereby inhibiting viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_oaZOyBy4jLVg90H21EOLACvtfcHk0lgxcpRloEzong"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVeitrrM&md5=10a34e872f4bf9805190044b8f8eec71</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.jff.2017.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jff.2017.11.011%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DM.%2BJ.%26aulast%3DMin%26aufirst%3DH.%26atitle%3DAntiviral%2520activity%2520of%2520ginsenoside%2520Rg3%2520isomers%2520against%2520gammaherpesvirus%2520through%2520inhibition%2520of%2520p38-%2520and%2520JNK-associated%2520pathways%26jtitle%3DJ.%2520Funct.%2520Foods%26date%3D2018%26volume%3D40%26spage%3D219%26epage%3D228%26doi%3D10.1016%2Fj.jff.2017.11.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Root, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wills, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNair, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Entry of influenza viruses into cells is inhibited by a highly specific protein kinase c inhibitor</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">2697</span>– <span class="NLM_lpage">2705</span>, <span class="refDoi"> DOI: 10.1099/0022-1317-81-11-2697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1099%2F0022-1317-81-11-2697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=11038382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvFWgurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2000&pages=2697-2705&author=C.+N.+Rootauthor=E.+G.+Willsauthor=L.+L.+McNairauthor=G.+R.+Whittaker&title=Entry+of+influenza+viruses+into+cells+is+inhibited+by+a+highly+specific+protein+kinase+c+inhibitor&doi=10.1099%2F0022-1317-81-11-2697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor</span></div><div class="casAuthors">Root, Christiana N.; Wills, Elizabeth G.; McNair, LaShonn L.; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2697-2705</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Following binding to cell surface sialic acid, entry of influenza viruses into cells is mediated by endocytosis.  Productive entry of influenza virus requires the low-pH environment of the late endosome for fusion and release of the virus into the cytoplasm and transport of the virus genome into the nucleus.  We investigated novel mechanisms to inhibit influenza virus infection using highly specific inhibitors of protein kinase C.  We found that one inhibitor, bisindolylmaleimide I, prevented replication of influenza A virus in a dose-dependent manner when added at the time of infection, but had little specific effect when added 2 h after infection had commenced.  Virus yields dropped by more than 3 log units in the presence of micromolar levels of bisindolylmaleimide I.  Influenza B virus replication was also inhibited by bisindolylmaleimide at micromolar concns.  We carried out expts. to det. the point in infection that was blocked by bisindolylmaleimide I, and detd. that entry of viral ribonucleoproteins (vRNPs) into the nucleus was prevented.  Upon drug washout vRNP nuclear entry resumed, showing that bisindolylmaleimide I is reversible.  Bisindolylmaleimide I did not affect virus binding and was apparently not acting as a weak base, because its effects were independent of the pH of the external growth medium.  These expts. show that bisindolylmaleimide I blocks replication of different types of influenza virus in a dose-dependent and reversible manner, and that virus entry into the cell is inhibited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGqK6tlaJrrVg90H21EOLACvtfcHk0lgxcpRloEzong"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvFWgurY%253D&md5=3f37c83d7f771e05f8e926429de56603</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1099%2F0022-1317-81-11-2697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252F0022-1317-81-11-2697%26sid%3Dliteratum%253Aachs%26aulast%3DRoot%26aufirst%3DC.%2BN.%26aulast%3DWills%26aufirst%3DE.%2BG.%26aulast%3DMcNair%26aufirst%3DL.%2BL.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DEntry%2520of%2520influenza%2520viruses%2520into%2520cells%2520is%2520inhibited%2520by%2520a%2520highly%2520specific%2520protein%2520kinase%2520c%2520inhibitor%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2000%26volume%3D81%26spage%3D2697%26epage%3D2705%26doi%3D10.1099%2F0022-1317-81-11-2697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis c agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3410</span>, <span class="refDoi"> DOI: 10.1021/jm501759m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501759m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3393-3410&author=S.+Kovackovaauthor=L.+Changauthor=E.+Bekermanauthor=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Chaikuadauthor=C.+Herovenauthor=M.+%C5%A0%C3%A1laauthor=S.+De+Jongheauthor=S.+Knappauthor=S.+Einavauthor=P.+Herdewijn&title=Selective+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+as+anti-hepatitis+c+agents&doi=10.1021%2Fjm501759m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents</span></div><div class="casAuthors">Kovackova, Sona; Chang, Lei; Bekerman, Elena; Neveu, Gregory; Barouch-Bentov, Rina; Chaikuad, Apirat; Heroven, Christina; Sala, Michal; De Jonghe, Steven; Knapp, Stefan; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3393-3410</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin G assocd. kinase (GAK) emerged as a promising drug target for the treatment of viral infections.  However, no potent and selective GAK inhibitors have been reported in the literature to date.  This paper describes the discovery of isothiazolo[5,4-b]pyridines as selective GAK inhibitors, with the most potent congeners displaying low nanomolar binding affinity for GAK.  Cocrystn. expts. revealed that these compds. behaved as classic type I ATP-competitive kinase inhibitors.  In addn., the authors have demonstrated that these compds. exhibit a potent activity against hepatitis C virus (HCV) by inhibiting two temporally distinct steps in the HCV life cycle (i.e., viral entry and assembly).  Hence, these GAK inhibitors represent chem. probes to study GAK function in different disease areas where GAK has been implicated (including viral infection, cancer, and Parkinson's disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjwEtUi0av7Vg90H21EOLACvtfcHk0lgxcpRloEzong"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D&md5=ed7f93eb3d49f6c7265dd2c0da880b43</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Fjm501759m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501759m%26sid%3Dliteratum%253Aachs%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DSelective%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520as%2520anti-hepatitis%2520c%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3393%26epage%3D3410%26doi%3D10.1021%2Fjm501759m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure-activity relationship studies and antiviral activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1666</span>– <span class="NLM_lpage">1672</span>, <span class="refDoi"> DOI: 10.1039/C5MD00229J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1039%2FC5MD00229J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=26925208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12mu7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1666-1672&author=J.+Liauthor=S.+Kovackovaauthor=S.+Puauthor=J.+Rozenskiauthor=S.+De+Jongheauthor=S.+Einavauthor=P.+Herdewijn&title=Isothiazolo%5B4%2C3-b%5Dpyridines+as+inhibitors+of+cyclin+G+associated+kinase%3A+synthesis%2C+structure-activity+relationship+studies+and+antiviral+activity&doi=10.1039%2FC5MD00229J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure-activity relationship studies and antiviral activity</span></div><div class="casAuthors">Li, Jiahong; Kovackova, Sona; Pu, Szuyuan; Rozenski, Jef; De Jonghe, Steven; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1666-1672</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Isothiazolo[4,3-b]pyridines were known to be endowed with potent affinity for cyclin G assocd. kinase (GAK).  Structure-activity relationship studied by broadening the structural variety at position 3 of the isothiazolo[4,3-b]pyridine scaffold.  The most potent GAK ligands (displaying Kd values of less than 100 nM) within this series carry an alkoxy group at position 3 of the central scaffold.  Unfortunately, these ligands display only modest antiviral activity against the hepatitis C virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTXoI1_7VbSrVg90H21EOLACvtfcHk0lg5mgis9chK8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12mu7vM&md5=d9232d534cf6597819798e33b9b8cc0c</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1039%2FC5MD00229J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00229J%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DIsothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%253A%2520synthesis%252C%2520structure-activity%2520relationship%2520studies%2520and%2520antiviral%2520activity%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1666%26epage%3D1672%26doi%3D10.1039%2FC5MD00229J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of isothiazolo[4,3- b]pyridine-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6178</span>– <span class="NLM_lpage">6192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6178-6192&author=S.+Y.+Puauthor=R.+Woutersauthor=S.+Schorauthor=J.+Rozenskiauthor=R.+Barouch-Bentovauthor=L.+I.+Prugarauthor=C.+M.+O%E2%80%99Brienauthor=J.+M.+Brannanauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+De+Jongheauthor=S.+Einav&title=Optimization+of+isothiazolo%5B4%2C3-+b%5Dpyridine-based+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+with+broad-spectrum+antiviral+activity&doi=10.1021%2Facs.jmedchem.8b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Isothiazolo[4,3-b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">Pu, Szu-Yuan; Wouters, Randy; Schor, Stanford; Rozenski, Jef; Barouch-Bentov, Rina; Prugar, Laura I.; O'Brien, Cecilia M.; Brannan, Jennifer M.; Dye, John M.; Herdewijn, Piet; De Jonghe, Steven; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6178-6192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue and other emerging viral infections.  We reported that cyclin G-assocd. kinase (GAK), a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle.  We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity.  Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity.  These compds. demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses.  Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compds.  These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDe8aVxkBtKLVg90H21EOLACvtfcHk0lg5mgis9chK8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP&md5=fe33e256835ea01c5e1932c3ccea7eac</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00613%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BM.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520isothiazolo%255B4%252C3-%2520b%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6178%26epage%3D6192%26doi%3D10.1021%2Facs.jmedchem.8b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115188</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.bmc.2019.115188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31757682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115188&author=B.+Martinez-Gualdaauthor=S.+Y.+Puauthor=M.+Froeyenauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Structure-activity+relationship+study+of+the+pyridine+moiety+of+isothiazolo%5B4%2C3-b%5Dpyridines+as+antiviral+agents+targeting+cyclin+G-associated+kinase&doi=10.1016%2Fj.bmc.2019.115188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Pu, Szu-Yuan; Froeyen, Mathy; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115188</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 3,6-disubstituted isothiazolo[4,3-b]pyridines as potent and selective cyclin G-assocd. kinase (GAK) inhibitors with promising antiviral activity was reported.  In this manuscript, the structure-activity relationship study was expanded to synthesis of isothiazolo[4,3-b]pyridines with modifications of the pyridine moiety.  This effort led to the discovery of an isothiazolo[4,3-b]pyridine deriv. with a 3,4-dimethoxyphenyl residue at position 5 that displayed low nanomolar GAK binding affinity and antiviral activity against dengue virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqu1a3iqS1i7Vg90H21EOLACvtfcHk0lg5mgis9chK8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM&md5=cf709736ad37cfcda6e2310a243c55d4</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115188%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520the%2520pyridine%2520moiety%2520of%2520isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520antiviral%2520agents%2520targeting%2520cyclin%2520G-associated%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115188%26doi%3D10.1016%2Fj.bmc.2019.115188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3, 5-disubstituted-pyrrolo [2, 3-b] pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.-Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.-J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C+5-disubstituted-pyrrolo+%5B2%2C+3-b%5D+pyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0lgj0L9_mU0rGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.-Y.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.-J.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C%25205-disubstituted-pyrrolo%2520%255B2%252C%25203-b%255D%2520pyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, G. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, B. Y.</span></span> <span> </span><span class="NLM_article-title">Aurora kinase A promotes hepatitis B virus replication and expression</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">104572</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.104572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31376425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsL3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2019&pages=104572&author=G.+U.+Jeongauthor=B.+Y.+Ahn&title=Aurora+kinase+A+promotes+hepatitis+B+virus+replication+and+expression&doi=10.1016%2Fj.antiviral.2019.104572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora kinase A promotes hepatitis B virus replication and expression</span></div><div class="casAuthors">Jeong, Gi Uk; Ahn, Byung-Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104572</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cellular protein kinases play crit. roles in various steps of the hepatitis B virus life cycle.  We found that viral replication in infected or transfected hepatoma cell was markedly inhibited by treatment with A-443654, a specific inhibitor of Akt.  The antiviral mechanism of the drug mainly depended on the downregulation of Aurora A, a protein kinase that plays an essential role in mitosis but has not been implicated in the viral life cycle.  Our data indicated that Aurora kinase A enhances viral replication and expression independently of its kinase activity required for mitotic function.  Our findings suggest that mitotic kinases, considered to be an attractive target of antitumor agents, also provide a novel target for the development of antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHCW4eApXK7Vg90H21EOLACvtfcHk0lgj0L9_mU0rGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsL3N&md5=150d43535f9213a117af884cd600c1dd</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104572%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DG.%2BU.%26aulast%3DAhn%26aufirst%3DB.%2BY.%26atitle%3DAurora%2520kinase%2520A%2520promotes%2520hepatitis%2520B%2520virus%2520replication%2520and%2520expression%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D170%26spage%3D104572%26doi%3D10.1016%2Fj.antiviral.2019.104572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lama, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blondel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagaudrière-Gesbert, C.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies virus cycle</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.antiviral.2019.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31071352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVers7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2019&pages=51-60&author=Z.+Lamaauthor=Y.+Gaudinauthor=D.+Blondelauthor=C.+Lagaudri%C3%A8re-Gesbert&title=Kinase+inhibitors+tyrphostin+9+and+rottlerin+block+early+steps+of+rabies+virus+cycle&doi=10.1016%2Fj.antiviral.2019.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors tyrphostin 9 and rottlerin block early steps of rabies virus cycle</span></div><div class="casAuthors">Lama, Zoe; Gaudin, Yves; Blondel, Danielle; Lagaudriere-Gesbert, Cecile</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Rabies virus (RABV) is a neurotropic virus that causes fatal encephalitis in humans and animals and still kills up to 59,000 people worldwide every year.  To date, only preventive or post-exposure vaccination protects against the disease but therapeutics are missing.  After screening a library of 80 kinases inhibitors, we identified two compds. as potent inhibitors of RABV infection: tyrphostin 9 and rottlerin.  Mechanism of action studies show that both inhibitors interfere with an early step of viral cycle and can prevent viral replication.  In presence of tyrphostin 9, the viral entry through endocytosis is disturbed leading to improper delivery of viral particles in cytoplasm, whereas rottlerin is inhibiting the transcription, most likely by decreasing intracellular ATP concn., and therefore the replication of the viral genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDmpE09EIyCrVg90H21EOLACvtfcHk0lgj0L9_mU0rGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVers7nE&md5=b477b4d4dc4ab9a1e7fe34d3beff3f99</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DLama%26aufirst%3DZ.%26aulast%3DGaudin%26aufirst%3DY.%26aulast%3DBlondel%26aufirst%3DD.%26aulast%3DLagaudri%25C3%25A8re-Gesbert%26aufirst%3DC.%26atitle%3DKinase%2520inhibitors%2520tyrphostin%25209%2520and%2520rottlerin%2520block%2520early%2520steps%2520of%2520rabies%2520virus%2520cycle%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D168%26spage%3D51%26epage%3D60%26doi%3D10.1016%2Fj.antiviral.2019.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simanjuntak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. S.</span></span> <span> </span><span class="NLM_article-title">Benzenesulfonamide derivatives as calcium/calmodulin-dependent protein kinase inhibitors and antiviral agents against dengue and zika virus infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1313-1327&author=W.+C.+Chenauthor=Y.+Simanjuntakauthor=L.+W.+Chuauthor=Y.+H.+Pingauthor=Y.+L.+Leeauthor=Y.+L.+Linauthor=W.+S.+Li&title=Benzenesulfonamide+derivatives+as+calcium%2Fcalmodulin-dependent+protein+kinase+inhibitors+and+antiviral+agents+against+dengue+and+zika+virus+infections&doi=10.1021%2Facs.jmedchem.9b01779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections</span></div><div class="casAuthors">Chen, Wei-Chia; Simanjuntak, Yogy; Chu, Li-Wei; Ping, Yueh-Hsin; Lee, Yi-Ling; Lin, Yi-Ling; Li, Wen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1313-1327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging and resurging mosquito-borne flaviviruses are an important public health challenge.  The increased prevalence of dengue virus (DENV) infection has had a significant socioeconomic impact on epidemic countries.  The recent outbreak of Zika virus (ZIKV) has created an international public health emergency because ZIKV infection has been linked to congenital defects and Guillain-Barr´e syndrome.  To develop potentially prophylactic antiviral drugs for combating these acute infectious diseases, we have targeted the host calcium/calmodulin-dependent kinase II (CaMKII) for inhibition.  By using CaMKII structure-guided inhibitor design, we generated four families of benzenesulfonamide (BSA) derivs. for SAR anal.  Among these substances, N-(4-cycloheptyl-4-oxobutyl)-4-methoxy-N-phenylbenzenesulfonamide (9) showed superior properties as a lead CaMKII inhibitor and antiviral agent.  BSA 9 inhibited CaMKII activity with an IC50 value of 0.79 μM and displayed EC50 values of 1.52 μM and 1.91 μM against DENV and ZIKV infections of human neuronal BE(2)C cells, resp.  Notably, 9 significantly reduced the viremia level and increased animal survival time in mouse-challenge models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPIVcnOOQM9LVg90H21EOLACvtfcHk0lg2CSmZBZKaLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D&md5=4222b9a25616a59243c22bfd57b223e7</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01779%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DSimanjuntak%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DL.%2BW.%26aulast%3DPing%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DY.%2BL.%26aulast%3DLin%26aufirst%3DY.%2BL.%26aulast%3DLi%26aufirst%3DW.%2BS.%26atitle%3DBenzenesulfonamide%2520derivatives%2520as%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520antiviral%2520agents%2520against%2520dengue%2520and%2520zika%2520virus%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1313%26epage%3D1327%26doi%3D10.1021%2Facs.jmedchem.9b01779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkheil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span> <span> </span><span class="NLM_article-title">PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3375</span>– <span class="NLM_lpage">3384</span>, <span class="refDoi"> DOI: 10.1093/jac/dky327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1093%2Fjac%2Fdky327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30219827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlChsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2018&pages=3375-3384&author=L.+Delangauthor=C.+Harakauthor=M.+Benkheilauthor=H.+Khanauthor=P.+Leyssenauthor=M.+Andrewsauthor=V.+Lohmannauthor=J.+Neyts&title=PI4KIII+inhibitor+enviroxime+impedes+the+replication+of+the+hepatitis+C+virus+by+inhibiting+PI3+kinases&doi=10.1093%2Fjac%2Fdky327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases</span></div><div class="casAuthors">Delang, Leen; Harak, Christian; Benkheil, Mohammed; Khan, Hayat; Leyssen, Pieter; Andrews, Martin; Lohmann, Volker; Neyts, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3375-3384</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">1460-2091</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Many pos.-stranded RNA viruses, including HCV, drastically remodel intracellular membranes to generate specialized environments for RNA replication.  Phosphatidylinositol 4-kinase III (PI4KIII)α plays an essential role in the formation of HCV replication complexes and has therefore been explored as a potential drug target.  Here, the authors characterized the anti-HCV activity of the PI4KIII inhibitors enviroxime and BF738735 and elucidated their mechanism of action.  Methods: Antiviral assays were performed using HCV subgenomic replicons and infectious HCV.  Enviroxime- and BF738735-resistant HCV replicons were generated by long-term culture with increasing compd. concns.  Intracellular localization of phosphatidylinositol 4-phosphate (PI4P) lipids was analyzed by confocal microscopy.  Results: HCV subgenomic replicons resistant to either enviroxime or BF738735 proved cross-resistant and carried mutations in the NS3, NS4B and NS5A genes.  Knockdown of PI4KIIIβ by small interfering RNA (siRNA) did not affect the replication of the HCV subgenomic replicon in this study.  Furthermore, the compds. did not affect PI4P lipid levels at the replication complexes nor the phosphorylation status of NS5A, activities attributed to PI4KIIIα.  Interestingly, the broad-spectrum phosphoinositide 3-kinase (PI3K) inhibitor LY294002 proved to be 10-fold less effective against the resistant replicons.  In addn., enviroxime and BF738735 inhibited several PI3Ks in enzymic assays.  Conclusions: Contrary to assumptions, the data indicate that PI4KIIIα and PI4KIIIβ are not the main targets for the anti-HCV activity of enviroxime and BF738735.  Instead, the authors demonstrated that both mols. impede HCV replication at least partially by an inhibitory effect on PI3Ks.  Moreover, HCV is able to bypass PI3K inhibition by acquiring mutations in its genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWRZRxsOCf-bVg90H21EOLACvtfcHk0lg2CSmZBZKaLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlChsr0%253D&md5=fc2f79b4735519f87682bccdd43acb63</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdky327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdky327%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DHarak%26aufirst%3DC.%26aulast%3DBenkheil%26aufirst%3DM.%26aulast%3DKhan%26aufirst%3DH.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DAndrews%26aufirst%3DM.%26aulast%3DLohmann%26aufirst%3DV.%26aulast%3DNeyts%26aufirst%3DJ.%26atitle%3DPI4KIII%2520inhibitor%2520enviroxime%2520impedes%2520the%2520replication%2520of%2520the%2520hepatitis%2520C%2520virus%2520by%2520inhibiting%2520PI3%2520kinases%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2018%26volume%3D73%26spage%3D3375%26epage%3D3384%26doi%3D10.1093%2Fjac%2Fdky327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3 kinase-AKT pathway controls cellular entry of ebola virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e1000141</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1000141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1000141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=18769720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=e1000141&author=M.+F.+Saeedauthor=A.+A.+Kolokoltsovauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Phosphoinositide-3+kinase-AKT+pathway+controls+cellular+entry+of+ebola+virus&doi=10.1371%2Fjournal.ppat.1000141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span></div><div class="casAuthors">Saeed Mohammad F; Kolokoltsov Andrey A; Freiberg Alexander N; Holbrook Michael R; Davey Robert A</div><div class="citationInfo"><span class="NLM_cas:title">PLoS pathogens</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1000141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide-3 kinase (PI3K) pathway regulates diverse cellular activities related to cell growth, migration, survival, and vesicular trafficking.  It is known that Ebola virus requires endocytosis to establish an infection.  However, the cellular signals that mediate this uptake were unknown for Ebola virus as well as many other viruses.  Here, the involvement of PI3K in Ebola virus entry was studied.  A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of Zaire Ebola virus (ZEBOV).  Inhibitors of PI3K and Akt significantly reduced infection by ZEBOV at an early step during the replication cycle.  Furthermore, phosphorylation of Akt-1 was induced shortly after exposure of cells to radiation-inactivated ZEBOV, indicating that the virus actively induces the PI3K pathway and that replication was not required for this induction.  Subsequent use of pseudotyped Ebola virus and/or Ebola virus-like particles, in a novel virus entry assay, provided evidence that activity of PI3K/Akt is required at the virus entry step.  Class 1A PI3Ks appear to play a predominant role in regulating ZEBOV entry, and Rac1 is a key downstream effector in this regulatory cascade.  Confocal imaging of fluorescently labeled ZEBOV indicated that inhibition of PI3K, Akt, or Rac1 disrupted normal uptake of virus particles into cells and resulted in aberrant accumulation of virus into a cytosolic compartment that was non-permissive for membrane fusion.  We conclude that PI3K-mediated signaling plays an important role in regulating vesicular trafficking of ZEBOV necessary for cell entry.  Disruption of this signaling leads to inappropriate trafficking within the cell and a block in steps leading to membrane fusion.  These findings extend our current understanding of Ebola virus entry mechanism and may help in devising useful new strategies for treatment of Ebola virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVYOnEFnn8xZVVjGoY74BafW6udTcc2eaS48rDk1zyqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D&md5=337fa485785e2a091d392f6ff1dcc1a4</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000141%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide-3%2520kinase-AKT%2520pathway%2520controls%2520cellular%2520entry%2520of%2520ebola%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26spage%3De1000141%26doi%3D10.1371%2Fjournal.ppat.1000141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pisonero-Vaquero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Mediavilla, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorquera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majano, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jover, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Gallego, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Campos, S.</span></span> <span> </span><span class="NLM_article-title">Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1038/labinvest.2013.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1038%2Flabinvest.2013.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24492281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2014&pages=262-274&author=S.+Pisonero-Vaqueroauthor=M.+V.+Garc%C3%ADa-Mediavillaauthor=F.+Jorqueraauthor=P.+L.+Majanoauthor=M.+Benetauthor=R.+Joverauthor=J.+Gonz%C3%A1lez-Gallegoauthor=S.+S%C3%A1nchez-Campos&title=Modulation+of+PI3K-LXR%CE%B1-dependent+lipogenesis+mediated+by+oxidative%2Fnitrosative+stress+contributes+to+inhibition+of+HCV+replication+by+quercetin&doi=10.1038%2Flabinvest.2013.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of PI3K-LXRα-dependent lipogenesis mediated by oxidative/nitrosative stress contributes to inhibition of HCV replication by quercetin</span></div><div class="casAuthors">Pisonero-Vaquero, Sandra; Garcia-Mediavilla, Maria V.; Jorquera, Francisco; Majano, Pedro L.; Benet, Marta; Jover, Ramiro; Gonzalez-Gallego, Javier; Sanchez-Campos, Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">262-274</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is exptl. evidence that some antioxidant flavonoids show therapeutic potential in the treatment of hepatitis C through inhibition of hepatitis C virus (HCV) replication.  We examd. the effect of treatment with the flavonols quercetin and kaempferol, the flavanone taxifolin and the flavone apigenin on HCV replication efficiency in an in vitro model.  While all flavonoids studied were able to reduce viral replication at very low concns. (ranging from 0.1 to 5 μM), quercetin appeared to be the most effective inhibitor of HCV replication, showing a marked anti-HCV activity in replicon-contg. cells when combined with interferon (IFN)α.  The contribution of oxidative/nitrosative stress and lipogenesis modulation to inhibition of HCV replication by quercetin was also examd.  As expected, quercetin decreased HCV-induced reactive oxygen and nitrogen species (ROS/RNS) generation and lipoperoxidn. in replicating cells.  Quercetin also inhibited liver X receptor (LXR)α-induced lipid accumulation in LXRα-overexpressing and replicon-contg. Huh7 cells.  The mechanism underlying the LXRα-dependent lipogenesis modulatory effect of quercetin in HCV-replicating cells seems to involve phosphatidylinositol 3-kinase (PI3K)/AKT pathway inactivation.  Thus, inhibition of the PI3K pathway by LY294002 attenuated LXRα upregulation and HCV replication mediated by lipid accumulation, showing an additive effect when combined with quercetin.  Inactivation of the PI3K pathway by quercetin may contribute to the repression of LXRα-dependent lipogenesis and to the inhibition of viral replication induced by the flavonol.  Combined, our data suggest that oxidative/nitrosative stress blockage and subsequent modulation of PI3K-LXRα-mediated lipogenesis might contribute to the inhibitory effect of quercetin on HCV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJq5yDphNBrbVg90H21EOLACvtfcHk0lhDE0nEtJos6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFals78%253D&md5=37339fa28d0ec07ead34883327f0b4ec</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1038%2Flabinvest.2013.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Flabinvest.2013.156%26sid%3Dliteratum%253Aachs%26aulast%3DPisonero-Vaquero%26aufirst%3DS.%26aulast%3DGarc%25C3%25ADa-Mediavilla%26aufirst%3DM.%2BV.%26aulast%3DJorquera%26aufirst%3DF.%26aulast%3DMajano%26aufirst%3DP.%2BL.%26aulast%3DBenet%26aufirst%3DM.%26aulast%3DJover%26aufirst%3DR.%26aulast%3DGonz%25C3%25A1lez-Gallego%26aufirst%3DJ.%26aulast%3DS%25C3%25A1nchez-Campos%26aufirst%3DS.%26atitle%3DModulation%2520of%2520PI3K-LXR%25CE%25B1-dependent%2520lipogenesis%2520mediated%2520by%2520oxidative%252Fnitrosative%2520stress%2520contributes%2520to%2520inhibition%2520of%2520HCV%2520replication%2520by%2520quercetin%26jtitle%3DLab.%2520Invest.%26date%3D2014%26volume%3D94%26spage%3D262%26epage%3D274%26doi%3D10.1038%2Flabinvest.2013.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linero, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, L. A.</span></span> <span> </span><span class="NLM_article-title">Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junín virus replication in vitro</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2009.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.virusres.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19595723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsr%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2009&pages=166-170&author=F.+N.+Lineroauthor=L.+A.+Scolaro&title=Participation+of+the+phosphatidylinositol+3-kinase%2FAkt+pathway+in+Jun%C3%ADn+virus+replication+in+vitro&doi=10.1016%2Fj.virusres.2009.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junin virus replication in vitro</span></div><div class="casAuthors">Linero, F. N.; Scolaro, L. A.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">166-170</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The authors show that infection of cell cultures with the arenavirus Junin (JUNV), agent of the argentine hemorrhagic fever, leads to the activation of PI3K/Akt signalling pathway.  Phosphorylation of Akt occurs early during JUNV infection of Vero cells and is blocked by the PI3K inhibitor, Ly294002.  Infection of cells with UV-irradiated JUNV redeemed the pattern of stimulation obsd. for infectious virus indicating that an early stage of multiplication cycle would be enough to trigger activation.  Treatment of cells with chlorpromazine abrogated phosphorylation of Akt upon JUNV infection suggesting virus internalization as responsible for activation.  Inhibition of Akt phosphorylation by Ly294002 impaired viral protein synthesis and expression leading to a reduced infectious virus yield without blocking the onset of persistent stage of infection.  This impairment is linked to a reduced amt. of virus bound to cells probably due to a blockage on the recycling of transferrin cell-receptor, employed by the virus to adsorb to the cell surface.  Early Akt activation was also obsd. in BHK-21 and A549 JUNV infected cells suggesting an important role of PI3K/Akt signalling in JUNV multiplication in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodcaY729bbdLVg90H21EOLACvtfcHk0lhDE0nEtJos6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtV2qsr%252FK&md5=436b56d4d6f8c239cea2ecec81f5252b</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DLinero%26aufirst%3DF.%2BN.%26aulast%3DScolaro%26aufirst%3DL.%2BA.%26atitle%3DParticipation%2520of%2520the%2520phosphatidylinositol%25203-kinase%252FAkt%2520pathway%2520in%2520Jun%25C3%25ADn%2520virus%2520replication%2520in%2520vitro%26jtitle%3DVirus%2520Res.%26date%3D2009%26volume%3D145%26spage%3D166%26epage%3D170%26doi%3D10.1016%2Fj.virusres.2009.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Hanlon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyva-Grado, V. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sourisseau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, M. L.</span></span> <span> </span><span class="NLM_article-title">An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1793</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.9b00230</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.9b00230" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1779-1793&author=R.+O%E2%80%99Hanlonauthor=V.+H.+Leyva-Gradoauthor=M.+Sourisseauauthor=M.+J.+Evansauthor=M.+L.+Shaw&title=An+influenza+virus+entry+inhibitor+targets+class+II+PI3+kinase+and+synergizes+with+oseltamivir&doi=10.1021%2Facsinfecdis.9b00230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">An Influenza Virus Entry Inhibitor Targets Class II PI3 Kinase and Synergizes with Oseltamivir</span></div><div class="casAuthors">O'Hanlon, Ryan; Leyva-Grado, Victor H.; Sourisseau, Marion; Evans, Matthew J.; Shaw, Megan L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1779-1793</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two classes of antivirals targeting the viral neuraminidase (NA) and endonuclease are currently the only clin. useful drugs for the treatment of influenza.  However, resistance to both antivirals has been obsd. in clin. isolates, and there was widespread resistance to oseltamivir (an NA inhibitor) among H1N1 viruses prior to 2009.  This potential for resistance and lack of diversity for antiviral targets highlights the need for new influenza antivirals with a higher barrier to resistance.  In this study, we identified an antiviral compd., M85, that targets host kinases, epidermal growth factor receptor (EGFR), and phosphoinositide 3 class II β (PIK3C2β) and is not susceptible to resistance by viral mutations.  M85 blocks endocytosis of influenza viruses and inhibits a broad-spectrum of viruses with minimal cytotoxicity.  In vitro, we found that combinations of M85 and oseltamivir have strong synergism.  In the mouse model for influenza, treatment with the combination therapy was more protective against a lethal viral challenge than oseltamivir alone, indicating that development of M85 could lead to combination therapies for influenza.  Finally, through this discovery of M85 and its antiviral mechanism, we present the first description of PIK3C2β as a necessary host factor for influenza virus entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zpIDqdoe5bVg90H21EOLACvtfcHk0lhDE0nEtJos6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensrrI&md5=04c3472d6f3bb26c5a7aaa39a9a38ae9</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.9b00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.9b00230%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hanlon%26aufirst%3DR.%26aulast%3DLeyva-Grado%26aufirst%3DV.%2BH.%26aulast%3DSourisseau%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DM.%2BJ.%26aulast%3DShaw%26aufirst%3DM.%2BL.%26atitle%3DAn%2520influenza%2520virus%2520entry%2520inhibitor%2520targets%2520class%2520II%2520PI3%2520kinase%2520and%2520synergizes%2520with%2520oseltamivir%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D1779%26epage%3D1793%26doi%3D10.1021%2Facsinfecdis.9b00230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mejdrová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalupská, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kögler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plačková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumlová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hřebabecký, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procházková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejmek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertlíková-Kaiserová, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencka, R.</span></span> <span> </span><span class="NLM_article-title">Highly selective phosphatidylinositol 4-kinase IIIΒ inhibitors and structural insight into their mode of action</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3767</span>– <span class="NLM_lpage">3793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslOit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3767-3793&author=I.+Mejdrov%C3%A1author=D.+Chalupsk%C3%A1author=M.+K%C3%B6glerauthor=M.+%C5%A0%C3%A1laauthor=P.+Pla%C4%8Dkov%C3%A1author=A.+Baumlov%C3%A1author=H.+H%C5%99ebabeck%C3%BDauthor=E.+Proch%C3%A1zkov%C3%A1author=M.+Dejmekauthor=R.+Guillonauthor=D.+Struninauthor=J.+Weberauthor=G.+Leeauthor=G.+Birkusauthor=H.+Mertl%C3%ADkov%C3%A1-Kaiserov%C3%A1author=E.+Bouraauthor=R.+Nencka&title=Highly+selective+phosphatidylinositol+4-kinase+III%CE%92+inhibitors+and+structural+insight+into+their+mode+of+action&doi=10.1021%2Facs.jmedchem.5b00499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Phosphatidylinositol 4-Kinase IIIβ Inhibitors and Structural Insight into Their Mode of Action</span></div><div class="casAuthors">Mejdrova, Ivana; Chalupska, Dominika; Kogler, Martin; Sala, Michal; Plackova, Pavla; Baumlova, Adriana; Hrebabecky, Hubert; Prochazkova, Eliska; Dejmek, Milan; Guillon, Remi; Strunin, Dmytro; Weber, Jan; Lee, Gary; Birkus, Gabriel; Mertlikova-Kaiserova, Helena; Boura, Evzen; Nencka, Radim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3767-3793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 4-kinase IIIβ is a cellular lipid kinase pivotal to pathogenesis of various RNA viruses.  These viruses hijack the enzyme to modify the structure of intracellular membranes and use them for the construction of functional replication machinery.  Selective inhibitors of this enzyme are potential broad-spectrum antiviral agents, as inhibition of this enzyme results in the arrest of replication of PI4K IIIβ-dependent viruses.  Herein, we report a detailed study of novel selective inhibitors of PI4K IIIβ, which exert antiviral activity against a panel of single-stranded pos.-sense RNA viruses.  Our crystallog. data show that the inhibitors occupy the binding site for the adenine ring of the ATP mol. and therefore prevent the phosphorylation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojwEoKXCJFnbVg90H21EOLACvtfcHk0lioAHhdGvP93g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslOit7k%253D&md5=0f1e2c86236783ded33bfe529fafe5f1</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00499%26sid%3Dliteratum%253Aachs%26aulast%3DMejdrov%25C3%25A1%26aufirst%3DI.%26aulast%3DChalupsk%25C3%25A1%26aufirst%3DD.%26aulast%3DK%25C3%25B6gler%26aufirst%3DM.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DPla%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DBaumlov%25C3%25A1%26aufirst%3DA.%26aulast%3DH%25C5%2599ebabeck%25C3%25BD%26aufirst%3DH.%26aulast%3DProch%25C3%25A1zkov%25C3%25A1%26aufirst%3DE.%26aulast%3DDejmek%26aufirst%3DM.%26aulast%3DGuillon%26aufirst%3DR.%26aulast%3DStrunin%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DMertl%25C3%25ADkov%25C3%25A1-Kaiserov%25C3%25A1%26aufirst%3DH.%26aulast%3DBoura%26aufirst%3DE.%26aulast%3DNencka%26aufirst%3DR.%26atitle%3DHighly%2520selective%2520phosphatidylinositol%25204-kinase%2520III%25CE%2592%2520inhibitors%2520and%2520structural%2520insight%2520into%2520their%2520mode%2520of%2520action%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3767%26epage%3D3793%26doi%3D10.1021%2Facs.jmedchem.5b00499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mejdrová, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalupská, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plačková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šála, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klíma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumlová, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hřebabecký, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Procházková, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejmek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strunin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matoušová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertlíková-Kaiserová, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencka, R.</span></span> <span> </span><span class="NLM_article-title">Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIΒ (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01465</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01465" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGitbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=100-118&author=I.+Mejdrov%C3%A1author=D.+Chalupsk%C3%A1author=P.+Pla%C4%8Dkov%C3%A1author=C.+M%C3%BCllerauthor=M.+%C5%A0%C3%A1laauthor=M.+Kl%C3%ADmaauthor=A.+Baumlov%C3%A1author=H.+H%C5%99ebabeck%C3%BDauthor=E.+Proch%C3%A1zkov%C3%A1author=M.+Dejmekauthor=D.+Struninauthor=J.+Weberauthor=G.+Leeauthor=M.+Matou%C5%A1ov%C3%A1author=H.+Mertl%C3%ADkov%C3%A1-Kaiserov%C3%A1author=J.+Ziebuhrauthor=G.+Birkusauthor=E.+Bouraauthor=R.+Nencka&title=Rational+design+of+novel+highly+potent+and+selective+phosphatidylinositol+4-kinase+III%CE%92+%28PI4KB%29+inhibitors+as+broad-spectrum+antiviral+agents+and+tools+for+chemical+biology&doi=10.1021%2Facs.jmedchem.6b01465"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIβ (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology</span></div><div class="casAuthors">Mejdrova, Ivana; Chalupska, Dominika; Plackova, Pavla; Muller, Christin; Sala, Michal; Klima, Martin; Baumlova, Adriana; Hrebabecky, Hubert; Prochazkova, Eliska; Dejmek, Milan; Strunin, Dmytro; Weber, Jan; Lee, Gary; Matousova, Marika; Mertlikova-Kaiserova, Helena; Ziebuhr, John; Birkus, Gabriel; Boura, Evzen; Nencka, Radim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">100-118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphatidylinositol 4-kinase IIIβ (PI4KB) is indispensable for the replication of various pos.-sense single stranded RNA viruses, which hijack this cellular enzyme to remodel intracellular membranes of infected cells to set up the functional replication machinery.  Therefore, the inhibition of this PI4K isoform leads to the arrest of viral replication.  Here, the authors report on the synthesis of novel PI4KB inhibitors, which were rationally designed based on two distinct structural types of inhibitors that bind in the ATP binding side of PI4KB.  These "hybrids" not only excel in outstanding inhibitory activity but also show high selectivity to PI4KB compared to other kinases.  Thus, these compds. exert selective nanomolar or even subnanomolar activity against PI4KB as well as profound antiviral effect against hepatitis C virus, human rhinovirus, and coxsackievirus B3.  The authors' crystallog. anal. unveiled the exact position of the side chains and explains their extensive contribution to the inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoG7GOmo2xaL7Vg90H21EOLACvtfcHk0lioAHhdGvP93g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGitbbM&md5=d0cc3a744b59313677b10454012c495b</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01465%26sid%3Dliteratum%253Aachs%26aulast%3DMejdrov%25C3%25A1%26aufirst%3DI.%26aulast%3DChalupsk%25C3%25A1%26aufirst%3DD.%26aulast%3DPla%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3D%25C5%25A0%25C3%25A1la%26aufirst%3DM.%26aulast%3DKl%25C3%25ADma%26aufirst%3DM.%26aulast%3DBaumlov%25C3%25A1%26aufirst%3DA.%26aulast%3DH%25C5%2599ebabeck%25C3%25BD%26aufirst%3DH.%26aulast%3DProch%25C3%25A1zkov%25C3%25A1%26aufirst%3DE.%26aulast%3DDejmek%26aufirst%3DM.%26aulast%3DStrunin%26aufirst%3DD.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DMatou%25C5%25A1ov%25C3%25A1%26aufirst%3DM.%26aulast%3DMertl%25C3%25ADkov%25C3%25A1-Kaiserov%25C3%25A1%26aufirst%3DH.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DBoura%26aufirst%3DE.%26aulast%3DNencka%26aufirst%3DR.%26atitle%3DRational%2520design%2520of%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphatidylinositol%25204-kinase%2520III%25CE%2592%2520%2528PI4KB%2529%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520agents%2520and%2520tools%2520for%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D100%26epage%3D118%26doi%3D10.1021%2Facs.jmedchem.6b01465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grafen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chithelen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleuser, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyersdorf, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider-Schaulies, J.</span></span> <span> </span><span class="NLM_article-title">Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro</span>. <i>Front. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">218</span>, <span class="refDoi"> DOI: 10.3389/fcell.2019.00218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3389%2Ffcell.2019.00218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31632969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3MnpvFSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=218&author=A.+Grafenauthor=F.+Schumacherauthor=J.+Chithelenauthor=B.+Kleuserauthor=N.+Beyersdorfauthor=J.+Schneider-Schaulies&title=Use+of+acid+ceramidase+and+sphingosine+kinase+inhibitors+as+antiviral+compounds+against+measles+virus+infection+of+lymphocytes+in+vitro&doi=10.3389%2Ffcell.2019.00218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Acid Ceramidase and Sphingosine Kinase Inhibitors as Antiviral Compounds Against Measles Virus Infection of Lymphocytes in vitro</span></div><div class="casAuthors">Grafen Anika; Chithelen Janice; Beyersdorf Niklas; Schneider-Schaulies Jurgen; Schumacher Fabian; Kleuser Burkhard; Schumacher Fabian</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in cell and developmental biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">218</span>
        ISSN:<span class="NLM_cas:issn">2296-634X</span>.
    </div><div class="casAbstract">As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses.  Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication.  Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90%) in PBL and 70-80% in BJAB cells.  Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides.  SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells.  Furthermore, we found that MV infection of lymphocytes induced a transient (0.5-6 h) increase in S1P, which was prevented by SKI-II.  Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells.  As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism.  In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication.  Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL.  Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5BYysmWirH-Lt9HypzAgQfW6udTcc2eZrwG5VdCXNVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnpvFSmsQ%253D%253D&md5=5d4eceb052e8201acd32b5c17bd00f61</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.3389%2Ffcell.2019.00218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffcell.2019.00218%26sid%3Dliteratum%253Aachs%26aulast%3DGrafen%26aufirst%3DA.%26aulast%3DSchumacher%26aufirst%3DF.%26aulast%3DChithelen%26aufirst%3DJ.%26aulast%3DKleuser%26aufirst%3DB.%26aulast%3DBeyersdorf%26aufirst%3DN.%26aulast%3DSchneider-Schaulies%26aufirst%3DJ.%26atitle%3DUse%2520of%2520acid%2520ceramidase%2520and%2520sphingosine%2520kinase%2520inhibitors%2520as%2520antiviral%2520compounds%2520against%2520measles%2520virus%2520infection%2520of%2520lymphocytes%2520in%2520vitro%26jtitle%3DFront.%2520Cell%2520Dev.%2520Biol.%26date%3D2019%26volume%3D7%26spage%3D218%26doi%3D10.3389%2Ffcell.2019.00218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, D. W.</span></span> <span> </span><span class="NLM_article-title">Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2020.06.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.tips.2020.06.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32580895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=531-543&author=W.+Luoauthor=Y.+X.+Liauthor=L.+J.+Jiangauthor=Q.+Chenauthor=T.+Wangauthor=D.+W.+Ye&title=Targeting+JAK-STAT+signaling+to+control+cytokine+release+syndrome+in+COVID-19&doi=10.1016%2Fj.tips.2020.06.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19</span></div><div class="casAuthors">Luo, Wei; Li, Yi-Xin; Jiang, Li-Jun; Chen, Qian; Wang, Tao; Ye, Da-Wei</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">531-543</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recent advances in the pathophysiol. understanding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe coronavirus disease 2019 (COVID-19) might experience cytokine release syndrome (CRS), characterized by increased interleukin (IL)-6, IL-2, IL-7, IL-10, etc.  Therefore, the treatment of cytokine storm has been proposed as a crit. part of rescuing severe COVID-19.  Several of the cytokines involved in COVID-19 employ a distinct intracellular signaling pathway mediated by Janus kinases (JAKs).  JAK inhibition, therefore, presents an attractive therapeutic strategy for CRS, which is a common cause of adverse clin. outcomes in COVID-19.  Below, we review the possibilities and challenges of targeting the pathway in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8D2HH09CZ3LVg90H21EOLACvtfcHk0ljn-nyeiomLcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtF2lsLbF&md5=4812456ab95bfb61bef7bb78f13b8229</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2020.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2020.06.007%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DL.%2BJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYe%26aufirst%3DD.%2BW.%26atitle%3DTargeting%2520JAK-STAT%2520signaling%2520to%2520control%2520cytokine%2520release%2520syndrome%2520in%2520COVID-19%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2020%26volume%3D41%26spage%3D531%26epage%3D543%26doi%3D10.1016%2Fj.tips.2020.06.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span> <span> </span><span class="NLM_article-title">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30183-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930183-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31986264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=497-506&author=C.+Huangauthor=Y.+Wangauthor=X.+Liauthor=L.+Renauthor=J.+Zhaoauthor=Y.+Huauthor=L.+Zhangauthor=G.+Fanauthor=J.+Xuauthor=X.+Guauthor=Z.+Chengauthor=T.+Yuauthor=J.+Xiaauthor=Y.+Weiauthor=W.+Wuauthor=X.+Xieauthor=W.+Yinauthor=H.+Liauthor=M.+Liuauthor=Y.+Xiaoauthor=H.+Gaoauthor=L.+Guoauthor=J.+Xieauthor=G.+Wangauthor=R.+Jiangauthor=Z.+Gaoauthor=Q.+Jinauthor=J.+Wangauthor=B.+Cao&title=Clinical+features+of+patients+infected+with+2019+novel+coronavirus+in+Wuhan%2C+China&doi=10.1016%2FS0140-6736%2820%2930183-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</span></div><div class="casAuthors">Huang, Chaolin; Wang, Yeming; Li, Xingwang; Ren, Lili; Zhao, Jianping; Hu, Yi; Zhang, Li; Fan, Guohui; Xu, Jiuyang; Gu, Xiaoying; Cheng, Zhenshun; Yu, Ting; Xia, Jiaan; Wei, Yuan; Wu, Wenjuan; Xie, Xuelei; Yin, Wen; Li, Hui; Liu, Min; Xiao, Yan; Gao, Hong; Guo, Li; Xie, Jungang; Wang, Guangfa; Jiang, Rongmeng; Gao, Zhancheng; Jin, Qi; Wang, Jianwei; Cao, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV).  We report the epidemiol., clin., lab., and radiol. characteristics and treatment and clin. outcomes of these patients.  All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan.  We prospectively collected and analyzed data on patients with lab.-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing.  Data were obtained with standardised data collection forms shared by the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records.  Researchers also directly communicated with patients or their families to ascertain epidemiol. and symptom data.  Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.  By Jan 2, 2020, 41 admitted hospital patients had been identified as having lab.-confirmed 2019-nCoV infection.  Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]).  Median age was 49·0 years (IQR 41·0-58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market.  One family cluster was found.  Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum prodn. (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38).  Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0-13·0]).  26 (63%) Of 41 patients had lymphopenia.  All 41 patients had pneumonia with abnormal findings on chest CT.  Complications included acute respiratory distress syndrome (12 [29%]), RNAemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died.  Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα.  The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was assocd. with ICU admission and high mortality.  Major gaps in our knowledge of the origin, epidemiol., duration of human transmission, and clin. spectrum of disease need fulfilment by future studies.  Ministry of Science and Technol., Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technol. Commission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VbprmL3SvLVg90H21EOLACvtfcHk0ljn-nyeiomLcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Kqu7c%253D&md5=b279b965c1054d99e60f673859c03b49</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930183-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930183-5%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DB.%26atitle%3DClinical%2520features%2520of%2520patients%2520infected%2520with%25202019%2520novel%2520coronavirus%2520in%2520Wuhan%252C%2520China%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D497%26epage%3D506%26doi%3D10.1016%2FS0140-6736%2820%2930183-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damsky, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, B.</span></span> <span> </span><span class="NLM_article-title">The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">e223</span>– <span class="NLM_lpage">e226</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2020.03.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaad.2020.03.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32278797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFyrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2020&pages=e223-e226&author=D.+Petersonauthor=W.+Damskyauthor=B.+King&title=The+use+of+Janus+kinase+inhibitors+in+the+time+of+severe+acute+respiratory+syndrome+coronavirus+2+%28SARS-CoV-2%29&doi=10.1016%2Fj.jaad.2020.03.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</span></div><div class="casAuthors">Peterson, Danielle; Damsky, William; King, Brett</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e223-e226</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The rates of infections, including upper respiratory infection, nasopharyngitis, and influenza, are only mildly increased in the Janus kinase inhibitor-treated group than in the placebo group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg8yia9ReS_rVg90H21EOLACvtfcHk0ljn-nyeiomLcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFyrt7s%253D&md5=31825b69099e79685654661ed72ebf3c</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2020.03.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2020.03.099%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DD.%26aulast%3DDamsky%26aufirst%3DW.%26aulast%3DKing%26aufirst%3DB.%26atitle%3DThe%2520use%2520of%2520Janus%2520kinase%2520inhibitors%2520in%2520the%2520time%2520of%2520severe%2520acute%2520respiratory%2520syndrome%2520coronavirus%25202%2520%2528SARS-CoV-2%2529%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D82%26spage%3De223%26epage%3De226%26doi%3D10.1016%2Fj.jaad.2020.03.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotfi-Emran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thielen, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Techar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tignanelli, C. J.</span></span> <span> </span><span class="NLM_article-title">Immunomodulation in COVID-19</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">546</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(20)30226-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS2213-2600%2820%2930226-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32380023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=544-546&author=N.+E.+Ingrahamauthor=S.+Lotfi-Emranauthor=B.+K.+Thielenauthor=K.+Techarauthor=R.+S.+Morrisauthor=S.+G.+Holtanauthor=R.+A.+Dudleyauthor=C.+J.+Tignanelli&title=Immunomodulation+in+COVID-19&doi=10.1016%2FS2213-2600%2820%2930226-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulation in COVID-19</span></div><div class="casAuthors">Ingraham, Nicholas E.; Lotfi-Emran, Sahar; Thielen, Beth K.; Techar, Kristina; Morris, Rachel S.; Holtan, Shernan G.; Dudley, R. Adams; Tignanelli, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">544-546</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite unprecedented social isolation and restrictions resulting in widespread economic decline.  More than 3.2 million people have been infected and more than 230,000 of them have died.  To date, no treatments have been definitively shown to be effective; however, a multipronged approach to mitigate transmission, morbidity, and mortality is ongoing.  While upstream prevention strategies such as vaccination are ideal, these strategies are unlikely to be available in time to address current clin. need.  Instead, fast-tracking of drug development and repurposing of approved drugs has facilitated and expedited clin. trials that might hasten effective therapeutics.  Many of these drugs act, at least in part, to directly limit viral replication.  By contrast, the use of interleukin-6 (IL-6) inhibition might have benefits by controlling the pathol. immune response to the virus.  Here, we expand on the theor. basis of IL-6 inhibition and propose potential benefits from other immunomodulators that could, in theory, prove more efficacious.  While IL-6 inhibition attenuates key aspects of the cytokine cascade, we posit other immune targets of inhibition to be considered and their potential to be more efficacious in the setting of COVID-19, specifically IL-1 inhibitors and Janus kinase (JAK) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5vsPO8PNStLVg90H21EOLACvtfcHk0liGecIEbsePIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1Wgt7o%253D&md5=f46765c8f803136d15684c23ab0c73bb</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2820%2930226-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252820%252930226-5%26sid%3Dliteratum%253Aachs%26aulast%3DIngraham%26aufirst%3DN.%2BE.%26aulast%3DLotfi-Emran%26aufirst%3DS.%26aulast%3DThielen%26aufirst%3DB.%2BK.%26aulast%3DTechar%26aufirst%3DK.%26aulast%3DMorris%26aufirst%3DR.%2BS.%26aulast%3DHoltan%26aufirst%3DS.%2BG.%26aulast%3DDudley%26aufirst%3DR.%2BA.%26aulast%3DTignanelli%26aufirst%3DC.%2BJ.%26atitle%3DImmunomodulation%2520in%2520COVID-19%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2020%26volume%3D8%26spage%3D544%26epage%3D546%26doi%3D10.1016%2FS2213-2600%2820%2930226-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAuley, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manson, J. J.</span></span> <span> </span><span class="NLM_article-title">COVID-19: consider cytokine storm syndromes and immunosuppression</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30628-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930628-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32192578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFCjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1033-1034&author=P.+Mehtaauthor=D.+F.+McAuleyauthor=M.+Brownauthor=E.+Sanchezauthor=R.+S.+Tattersallauthor=J.+J.+Manson&title=COVID-19%3A+consider+cytokine+storm+syndromes+and+immunosuppression&doi=10.1016%2FS0140-6736%2820%2930628-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19: consider cytokine storm syndromes and immunosuppression</span></div><div class="casAuthors">Mehta, Puja; McAuley, Daniel F.; Brown, Michael; Sanchez, Emilie; Tattersall, Rachel S.; Manson, Jessica J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10229</span>),
    <span class="NLM_cas:pages">1033-1034</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">All patients with severe COVID-19 should be screened for hyper-inflammation using lab. trends (e.g. increasing ferritin, decreasing platelet counts, or erythrocyte sedimentation rate) and the HScore to identify the subgroup of patients for whom immunosuppression could improve mortality.  Therapeutic options include steroids, i.v. Ig, selective cytokine blockade (e.g. anakinra or tocilizumab) and JAK kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmddXCLdaAZLVg90H21EOLACvtfcHk0liGecIEbsePIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFCjsb8%253D&md5=bd1ede3e6234aafcecf0547a3d768bfb</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930628-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930628-0%26sid%3Dliteratum%253Aachs%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DMcAuley%26aufirst%3DD.%2BF.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSanchez%26aufirst%3DE.%26aulast%3DTattersall%26aufirst%3DR.%2BS.%26aulast%3DManson%26aufirst%3DJ.%2BJ.%26atitle%3DCOVID-19%253A%2520consider%2520cytokine%2520storm%2520syndromes%2520and%2520immunosuppression%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1033%26epage%3D1034%26doi%3D10.1016%2FS0140-6736%2820%2930628-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbrocini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patruno, C.</span></span> <span> </span><span class="NLM_article-title">Reply: Potential role of Janus kinase inhibitors in COVID-19</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">e65</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2020.04.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jaad.2020.04.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32339701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsFCns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2020&pages=e65&author=M.+Napolitanoauthor=G.+Fabbrociniauthor=C.+Patruno&title=Reply%3A+Potential+role+of+Janus+kinase+inhibitors+in+COVID-19&doi=10.1016%2Fj.jaad.2020.04.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Reply: Potential role of Janus kinase inhibitors in COVID-19</span></div><div class="casAuthors">Napolitano, Maddalena; Fabbrocini, Gabriella; Patruno, Cataldo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e65</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We read with interest the letter ofPeterson et al1 about the use of Janus kinase (JAK)inhibitors in the time of severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2).  The authors reported that discontinuation of JAK inhibitors in th esetting of the initial infection, such as with SARSCoV-2, maybe beneficial given the role of JAK-signal transducer and activator of transcription (STAT) dependent type I (α/β) and type II (γ) interferons in antiviral immunity.  However, data in the literature regarding the possible use of JAK inhibitors in COVID 19 patients is growing.  All of these preclin. data seem to suggest that treatment with both baricitinib and upatacitinib should not be stopped during the COVID-19 pandemic.  Obviously, a careful assessment is mandatory for each individual patient reporting any adverse effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-2YX4Z-s-O7Vg90H21EOLACvtfcHk0liGecIEbsePIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsFCns7s%253D&md5=4abc528aaa7ee6fe277e035161652a1a</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2020.04.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2020.04.098%26sid%3Dliteratum%253Aachs%26aulast%3DNapolitano%26aufirst%3DM.%26aulast%3DFabbrocini%26aufirst%3DG.%26aulast%3DPatruno%26aufirst%3DC.%26atitle%3DReply%253A%2520Potential%2520role%2520of%2520Janus%2520kinase%2520inhibitors%2520in%2520COVID-19%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2020%26volume%3D83%26spage%3De65%26doi%3D10.1016%2Fj.jaad.2020.04.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seif, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aazami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoshmirsafa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohsenzadegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pornour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, D.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition as a new treatment strategy for patients with COVID-19</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">475</span>, <span class="refDoi"> DOI: 10.1159/000508247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1159%2F000508247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32392562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=467-475&author=F.+Seifauthor=H.+Aazamiauthor=M.+Khoshmirsafaauthor=M.+Kamaliauthor=M.+Mohsenzadeganauthor=M.+Pornourauthor=D.+Mansouri&title=JAK+inhibition+as+a+new+treatment+strategy+for+patients+with+COVID-19&doi=10.1159%2F000508247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">JAK Inhibition as a New Treatment Strategy for Patients with COVID-19</span></div><div class="casAuthors">Seif, Farhad; Aazami, Hossein; Khoshmirsafa, Majid; Kamali, Monireh; Mohsenzadegan, Monireh; Pornour, Majid; Mansouri, Davood</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-475</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world.  Understanding the Immunopathogenesis of COVID-19 is essential for interrupting viral infectivity and preventing aberrant immune responses before a vaccine can be developed.  In this review, we provide the latest insights into the roles of angiotensin-converting enzyme II (ACE2) and Ang II receptor-1 (AT1-R) in this disease.  Novel therapeutic strategies, including recombinant ACE2, ACE inhibitors, AT1-R blockers, and Ang 1-7 peptides, may prevent or reduce viruses-induced pulmonary, cardiac, and renal injuries.  However, more studies are needed to clarify the efficacy of these therapeutics.  Furthermore, considering the common role of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in AT1-R expressed on peripheral tissues and cytokine receptors on the surface of immune cells, potential targeting of this pathway using JAK inhibitors (JAKinibs) is suggested as a promising approach in patients with COVID-19 who are admitted to hospitals.  In addn. to antiviral therapy, potential ACE2- and AT1-R-inhibiting strategies, and other supportive care, we suggest other potential JAKinibs and novel anti-inflammatory combination therapies that affect the JAK-STAT pathway in patients with COVID-19.  Since the combination of MTX and baricitinib leads to outstanding clin. outcomes, the addn. of baricitinib to MTX might be a potential strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeDIB1cKJRLVg90H21EOLACvtfcHk0lg3W8MLQYC55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WjsrfL&md5=dc9d52d82a5d090166752a684d100942</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1159%2F000508247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000508247%26sid%3Dliteratum%253Aachs%26aulast%3DSeif%26aufirst%3DF.%26aulast%3DAazami%26aufirst%3DH.%26aulast%3DKhoshmirsafa%26aufirst%3DM.%26aulast%3DKamali%26aufirst%3DM.%26aulast%3DMohsenzadegan%26aufirst%3DM.%26aulast%3DPornour%26aufirst%3DM.%26aulast%3DMansouri%26aufirst%3DD.%26atitle%3DJAK%2520inhibition%2520as%2520a%2520new%2520treatment%2520strategy%2520for%2520patients%2520with%2520COVID-19%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2020%26volume%3D181%26spage%3D467%26epage%3D475%26doi%3D10.1159%2F000508247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Convertino, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdiserra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappello, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focosi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blandizzi, C.</span></span> <span> </span><span class="NLM_article-title">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span>. <i>Crit Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>, <span class="refDoi"> DOI: 10.1186/s13054-020-03020-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13054-020-03020-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32527304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=331&author=I.+Convertinoauthor=M.+Tuccoriauthor=S.+Ferraroauthor=G.+Valdiserraauthor=E.+Cappelloauthor=D.+Focosiauthor=C.+Blandizzi&title=Exploring+pharmacological+approaches+for+managing+cytokine+storm+associated+with+pneumonia+and+acute+respiratory+distress+syndrome+in+COVID-19+patients&doi=10.1186%2Fs13054-020-03020-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients</span></div><div class="casAuthors">Convertino Irma; Tuccori Marco; Ferraro Sara; Valdiserra Giulia; Cappello Emiliano; Blandizzi Corrado; Tuccori Marco; Blandizzi Corrado; Focosi Daniele</div><div class="citationInfo"><span class="NLM_cas:title">Critical care (London, England)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">331</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sars-CoV-2 complications include pneumonia and acute respiratory distress syndrome (ARDS), which require intensive care unit admission.  These conditions have rapidly overwhelmed healthcare systems, with detrimental effects on the quality of care and increased mortality.  Social isolation strategies have been implemented worldwide with the aim of reducing hospital pressure.  Among therapeutic strategies, the use of immunomodulating drugs, to improve prognosis, seems promising.  Particularly, since pneumonia and ARDS are associated with a cytokine storm, drugs belonging to therapeutic classes as anti-IL-6, anti-TNF, and JAK inhibitors are currently studied.  In this article, we discuss the potential advantages of the most promising pharmacological approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrt2z806QLEuxsqfvU0ziafW6udTcc2ebgoEmzeFLMg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38roslykuw%253D%253D&md5=338f561d1c6796524ffedbcd9b6f8df3</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1186%2Fs13054-020-03020-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13054-020-03020-3%26sid%3Dliteratum%253Aachs%26aulast%3DConvertino%26aufirst%3DI.%26aulast%3DTuccori%26aufirst%3DM.%26aulast%3DFerraro%26aufirst%3DS.%26aulast%3DValdiserra%26aufirst%3DG.%26aulast%3DCappello%26aufirst%3DE.%26aulast%3DFocosi%26aufirst%3DD.%26aulast%3DBlandizzi%26aufirst%3DC.%26atitle%3DExploring%2520pharmacological%2520approaches%2520for%2520managing%2520cytokine%2520storm%2520associated%2520with%2520pneumonia%2520and%2520acute%2520respiratory%2520distress%2520syndrome%2520in%2520COVID-19%2520patients%26jtitle%3DCrit%2520Care%26date%3D2020%26volume%3D24%26spage%3D331%26doi%3D10.1186%2Fs13054-020-03020-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Supekova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezacki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlapbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, P. G.</span></span> <span> </span><span class="NLM_article-title">Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1074/jbc.M703988200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1074%2Fjbc.M703988200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=17951261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=29-36&author=L.+Supekovaauthor=F.+Supekauthor=J.+Leeauthor=S.+Chenauthor=N.+Grayauthor=J.+P.+Pezackiauthor=A.+Schlapbachauthor=P.+G.+Schultz&title=Identification+of+human+kinases+involved+in+hepatitis+C+virus+replication+by+small+interference+RNA+library+screening&doi=10.1074%2Fjbc.M703988200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human kinases involved in Hepatitis C virus replication by small interference RNA library screening</span></div><div class="casAuthors">Supekova, Lubica; Supek, Frantisek; Lee, Jongkook; Chen, Shawn; Gray, Nathanael; Pezacki, John P.; Schlapbach, Achim; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-36</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The propagation of the hepatitis C virus (HCV) is a complex process that requires both host and viral proteins.  To facilitate identification of host cell factors that are required for HCV replication, we screened a panel of small interference RNAs that preferentially target human protein kinases using an HCV replicon expressing the firefly luciferase gene as a genetic reporter.  Small interference RNAs specific for three human kinases, Csk, Jak1, and Vrk1, were identified that reproducibly reduce viral RNA and viral protein levels in HCV replicon-bearing cells.  Treatment of replicon cells with a small mol. inhibitor of Csk also resulted in a significant redn. in HCV RNA and proteins, further supporting a role for Csk in HCV replication.  The effects of siRNAs targeting eight kinases known to be neg. regulated by Csk were then examd.; knock down of one of these kinases, Fyn, resulted in up-regulation of the HCV replicon, suggesting that Csk mediates its effect on HCV replication through Fyn.  This conclusion was further corroborated by demonstration that replicon cells treated with Csk inhibitor contained lower levels of the phosphorylated form of Fyn than control cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2twHkVKI2sLVg90H21EOLACvtfcHk0lg3W8MLQYC55A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOksA%253D%253D&md5=a78cc4bfc82aeb94e0f3a7cdf7641200</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703988200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703988200%26sid%3Dliteratum%253Aachs%26aulast%3DSupekova%26aufirst%3DL.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DPezacki%26aufirst%3DJ.%2BP.%26aulast%3DSchlapbach%26aufirst%3DA.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DIdentification%2520of%2520human%2520kinases%2520involved%2520in%2520hepatitis%2520C%2520virus%2520replication%2520by%2520small%2520interference%2520RNA%2520library%2520screening%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D29%26epage%3D36%26doi%3D10.1074%2Fjbc.M703988200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span> <span> </span><span class="NLM_article-title">Interaction of hepatitis C virus core protein with janus kinase is required for efficient production of infectious viruses</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2013.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4062%2Fbiomolther.2013.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=97-106&author=C.+Lee&title=Interaction+of+hepatitis+C+virus+core+protein+with+janus+kinase+is+required+for+efficient+production+of+infectious+viruses&doi=10.4062%2Fbiomolther.2013.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of hepatits C virus core protein with Janus kinase is required for efficient production of infectious viruses</span></div><div class="casAuthors">Lee, Choongho</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">Chronic hepatitis C virus (HCV) infection is responsible for the development of liver cirrhosis and hepatocellular carcinoma.  HCV core protein plays not only a structural role in the virion morphogenesis by encapsidating a virus RNA genome but also a nonstructural role in HCV-induced pathogenesis by blocking innate immunity.  Esp., it has been shown to regulate JAK-STAT signaling pathway through its direct interaction with Janus kinase (JAK) via its proline-rich JAK-binding motif (79PGYPWP84).  However, little is known about the physiol. significance of this HCV core-JAK assocn. in the context of the virus life cycle.  In order to gain an insight, a mutant HCV genome (J6/JFH1-79A82A) was constructed to express the mutant core with a defective JAK-binding motif (79AGYAWP84) using an HCV genotype 2a infectious clone (J6/JFH1).  When this mutant HCV genome was introduced into hepatocarcinoma cells, it was found to be severely impaired in its ability to produce infectious viruses in spite of its robust RNA genome replication.  Taken together, all these results suggest an essential requirement of HCV core-JAK protein interaction for efficient prodn. of infectious viruses and the potential of using core-JAK blockers as a new anti-HCV therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB6PBOORRDBbVg90H21EOLACvtfcHk0liQnWwgTjduaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt12ks7c%253D&md5=01b53d8d5f7d333ae663f7b21e29f509</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2013.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2013.007%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26atitle%3DInteraction%2520of%2520hepatitis%2520C%2520virus%2520core%2520protein%2520with%2520janus%2520kinase%2520is%2520required%2520for%2520efficient%2520production%2520of%2520infectious%2520viruses%26jtitle%3DBiomol.%2520Ther.%26date%3D2013%26volume%3D21%26spage%3D97%26epage%3D106%26doi%3D10.4062%2Fbiomolther.2013.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gavegnano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehm, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuy, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulpa, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marconi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routy, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbagh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sékaly, R. P.</span></span> <span> </span><span class="NLM_article-title">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">e1006740</span>, <span class="refDoi"> DOI: 10.1371/journal.ppat.1006740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1371%2Fjournal.ppat.1006740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=29267399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=e1006740&author=C.+Gavegnanoauthor=J.+H.+Brehmauthor=F.+P.+Dupuyauthor=A.+Tallaauthor=S.+P.+Ribeiroauthor=D.+A.+Kulpaauthor=C.+Cameronauthor=S.+Santosauthor=S.+J.+Hurwitzauthor=V.+C.+Marconiauthor=J.+P.+Routyauthor=L.+Sabbaghauthor=R.+F.+Schinaziauthor=R.+P.+S%C3%A9kaly&title=Novel+mechanisms+to+inhibit+HIV+reservoir+seeding+using+Jak+inhibitors&doi=10.1371%2Fjournal.ppat.1006740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors</span></div><div class="casAuthors">Gavegnano, Christina; Brehm, Jessica H.; Dupuy, Franck P.; Talla, Aarthi; Ribeiro, Susan Pereira; Kulpa, Deanna A.; Cameron, Cheryl; Santos, Stephanie; Hurwitz, Selwyn J.; Marconi, Vincent C.; Routy, Jean-Pierre; Sabbagh, Laurent; Schinazi, Raymond F.; Sekaly, Rafick Pierre</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e1006740/1-e1006740/30</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Despite advances in the treatment of HIV infection with ART, elucidating strategies to overcome HIV persistence, including blockade of viral reservoir establishment, maintenance, and expansion, remains a challenge.  T cell homeostasis is a major driver of HIV persistence.  Cytokines involved in regulating homeostasis of memory T cells, the major hub of the HIV reservoir, trigger the Jak-STAT pathway.  We evaluated the ability of tofacitinib and ruxolitinib, two FDA-approved Jak inhibitors, to block seeding and maintenance of the HIV reservoir in vitro.  We provide direct demonstration for involvement of the Jak-STAT pathway in HIV persistence in vivo, ex vivo, and in vitro; pSTAT5 strongly correlates with increased levels of integrated viral DNA in vivo, and in vitro Jak inhibitors reduce the frequency of CD4+ T cells harboring integrated HIV DNA.  We show that Jak inhibitors block viral prodn. from infected cells, inhibit γ-C receptor cytokine (IL-15)-induced viral reactivation from latent stores thereby preventing transmission of infectious particles to bystander activated T cells.  These results show that dysregulation of the Jak-STAT pathway is assocd. with viral persistence in vivo, and that Jak inhibitors target key events downstream of γ-C cytokine (IL-2, IL-7 and IL-15) ligation to their receptors, impacting the magnitude of the HIV reservoir in all memory CD4 T cell subsets in vitro and ex vivo.  Jak inhibitors represent a therapeutic modality to prevent key events of T cell activation that regulate HIV persistence and together, specific, potent blockade of these events may be integrated to future curative strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUxFHplJKULVg90H21EOLACvtfcHk0liQnWwgTjduaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFalsr7N&md5=b311dec0f2c603fcf337df2b3b2a1e56</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006740%26sid%3Dliteratum%253Aachs%26aulast%3DGavegnano%26aufirst%3DC.%26aulast%3DBrehm%26aufirst%3DJ.%2BH.%26aulast%3DDupuy%26aufirst%3DF.%2BP.%26aulast%3DTalla%26aufirst%3DA.%26aulast%3DRibeiro%26aufirst%3DS.%2BP.%26aulast%3DKulpa%26aufirst%3DD.%2BA.%26aulast%3DCameron%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DS.%26aulast%3DHurwitz%26aufirst%3DS.%2BJ.%26aulast%3DMarconi%26aufirst%3DV.%2BC.%26aulast%3DRouty%26aufirst%3DJ.%2BP.%26aulast%3DSabbagh%26aufirst%3DL.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DS%25C3%25A9kaly%26aufirst%3DR.%2BP.%26atitle%3DNovel%2520mechanisms%2520to%2520inhibit%2520HIV%2520reservoir%2520seeding%2520using%2520Jak%2520inhibitors%26jtitle%3DPLoS%2520Pathog.%26date%3D2017%26volume%3D13%26spage%3De1006740%26doi%3D10.1371%2Fjournal.ppat.1006740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">e30</span>– <span class="NLM_lpage">e31</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=e30-e31&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0liQnWwgTjduaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3De30%26epage%3De31%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Nievas, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falcone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommerauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiadoni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virdis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monzani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizos, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forfori, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avendano Cespedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrozzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lena, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Jurado, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerenza, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesira, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldevilla Bernardo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendez, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranitsaris, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farcomeni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pistello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres Pretel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon-Talero, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Molina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felce, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizami, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miklosi, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menichetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abizanda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span> <span> </span><span class="NLM_article-title">JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality</span>. <i>Sci. Adv.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">eabe4724</span>, <span class="refDoi"> DOI: 10.1126/sciadv.abe4724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1126%2Fsciadv.abe4724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=33187978" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2021&pages=eabe4724&author=J.+Stebbingauthor=G.+Sanchez+Nievasauthor=M.+Falconeauthor=S.+Youhannaauthor=P.+Richardsonauthor=S.+Ottavianiauthor=J.+X.+Shenauthor=C.+Sommerauerauthor=G.+Tiseoauthor=L.+Ghiadoniauthor=A.+Virdisauthor=F.+Monzaniauthor=L.+R.+Rizosauthor=F.+Forforiauthor=A.+Avendano+Cespedesauthor=S.+De+Marcoauthor=L.+Carrozziauthor=F.+Lenaauthor=P.+M.+Sanchez-Juradoauthor=L.+G.+Lacerenzaauthor=N.+Cesiraauthor=D.+Caldevilla+Bernardoauthor=A.+Perrellaauthor=L.+Niccoliauthor=L.+S.+Mendezauthor=D.+Matarreseauthor=D.+Golettiauthor=Y.-J.+Tanauthor=V.+Monteilauthor=G.+Dranitsarisauthor=F.+Cantiniauthor=A.+Farcomeniauthor=S.+Duttaauthor=S.+K.+Burleyauthor=H.+Zhangauthor=M.+Pistelloauthor=W.+Liauthor=M.+M.+Romeroauthor=F.+Andres+Pretelauthor=R.+S.+Simon-Taleroauthor=R.+Garcia-Molinaauthor=C.+Kutterauthor=J.+H.+Felceauthor=Z.+F.+Nizamiauthor=A.+G.+Miklosiauthor=J.+M.+Penningerauthor=F.+Menichettiauthor=A.+Mirazimiauthor=P.+Abizandaauthor=V.+M.+Lauschke&title=JAK+inhibition+reduces+SARS-CoV-2+liver+infectivity+and+modulates+inflammatory+responses+to+reduce+morbidity+and+mortality&doi=10.1126%2Fsciadv.abe4724"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1126%2Fsciadv.abe4724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fsciadv.abe4724%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DSanchez%2BNievas%26aufirst%3DG.%26aulast%3DFalcone%26aufirst%3DM.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DJ.%2BX.%26aulast%3DSommerauer%26aufirst%3DC.%26aulast%3DTiseo%26aufirst%3DG.%26aulast%3DGhiadoni%26aufirst%3DL.%26aulast%3DVirdis%26aufirst%3DA.%26aulast%3DMonzani%26aufirst%3DF.%26aulast%3DRizos%26aufirst%3DL.%2BR.%26aulast%3DForfori%26aufirst%3DF.%26aulast%3DAvendano%2BCespedes%26aufirst%3DA.%26aulast%3DDe%2BMarco%26aufirst%3DS.%26aulast%3DCarrozzi%26aufirst%3DL.%26aulast%3DLena%26aufirst%3DF.%26aulast%3DSanchez-Jurado%26aufirst%3DP.%2BM.%26aulast%3DLacerenza%26aufirst%3DL.%2BG.%26aulast%3DCesira%26aufirst%3DN.%26aulast%3DCaldevilla%2BBernardo%26aufirst%3DD.%26aulast%3DPerrella%26aufirst%3DA.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMendez%26aufirst%3DL.%2BS.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DGoletti%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DDranitsaris%26aufirst%3DG.%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DFarcomeni%26aufirst%3DA.%26aulast%3DDutta%26aufirst%3DS.%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPistello%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRomero%26aufirst%3DM.%2BM.%26aulast%3DAndres%2BPretel%26aufirst%3DF.%26aulast%3DSimon-Talero%26aufirst%3DR.%2BS.%26aulast%3DGarcia-Molina%26aufirst%3DR.%26aulast%3DKutter%26aufirst%3DC.%26aulast%3DFelce%26aufirst%3DJ.%2BH.%26aulast%3DNizami%26aufirst%3DZ.%2BF.%26aulast%3DMiklosi%26aufirst%3DA.%2BG.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DMenichetti%26aufirst%3DF.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DAbizanda%26aufirst%3DP.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26atitle%3DJAK%2520inhibition%2520reduces%2520SARS-CoV-2%2520liver%2520infectivity%2520and%2520modulates%2520inflammatory%2520responses%2520to%2520reduce%2520morbidity%2520and%2520mortality%26jtitle%3DSci.%2520Adv.%26date%3D2021%26volume%3D7%26spage%3Deabe4724%26doi%3D10.1126%2Fsciadv.abe4724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veeravalli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madgula, L. M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Critical assessment of pharmacokinetic drug–drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1007/s40264-020-00938-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1007%2Fs40264-020-00938-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32367507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXos1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2020&pages=711-725&author=V.+Veeravalliauthor=R.+P.+Dashauthor=J.+A.+Thomasauthor=R.+J.+Babuauthor=L.+M.+V.+Madgulaauthor=N.+R.+Srinivas&title=Critical+assessment+of+pharmacokinetic+drug%E2%80%93drug+interaction+potential+of+tofacitinib%2C+baricitinib+and+upadacitinib%2C+the+three+approved+janus+kinase+inhibitors+for+rheumatoid+arthritis+treatment&doi=10.1007%2Fs40264-020-00938-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment</span></div><div class="casAuthors">Veeravalli, Vijayabhaskar; Dash, Ranjeet P.; Thomas, Jennifer A.; Babu, R. Jayachandra; Madgula, Lakshmi Mohan Vamsi; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-725</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: The introduction of novel, small-mol. Janus kinase inhibitors namely tofacitinib, baricitinib and upadacitinib has provided an alternative treatment option for patients with rheumatoid arthritis outside of traditional drugs and expensive biologics.  This review aimed to critically assess the drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib and provide a balanced perspective for choosing the most appropriate Janus kinase inhibitor based on the needs of patients with rheumatoid arthritis including co-medications and renal/hepatic impairment status.  Based on the crit. assessment, all three approved Janus kinase inhibitors generally provide a favorable opportunity for co-prescription with a plethora of drugs.  While cytochrome P 450 3A4-related inhibition or induction altered the exposures (area under the curve) of tofacitinib and upadacitinib, it did not impact the exposure of baricitinib.  Transporter drug-drug interaction studies revealed that the disposition of baricitinib was altered with certain transporter inhibitors as compared with either tofacitinib or upadacitinib.  Adjustment of tofacitinib or baricitinib dosages but not that of upadacitinib is required with the progression of renal impairment from a mild to a severe condition.  While the dosage of tofacitinib needs to be adjusted for patients with moderate hepatic impairment status, it is not the case for either baricitinib or upadacitinib.  Assessment of the drug-drug interaction potential suggests that tofacitinib, baricitinib and upadacitinib generally show a favorable disposition with no perpetrator activity; however, as victim drugs, they show subtle pharmacokinetic differences that may be considered during polypharmacy.  Moreover, careful choice of the three drugs could be made in patients with rheumatoid arthritis with varying degrees of renal/hepatic impairments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKv0ESe477rVg90H21EOLACvtfcHk0ljXxlkVOvCPVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXos1SnsLc%253D&md5=a4e4054c400620cf07cdd5a3a6d2651d</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1007%2Fs40264-020-00938-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40264-020-00938-z%26sid%3Dliteratum%253Aachs%26aulast%3DVeeravalli%26aufirst%3DV.%26aulast%3DDash%26aufirst%3DR.%2BP.%26aulast%3DThomas%26aufirst%3DJ.%2BA.%26aulast%3DBabu%26aufirst%3DR.%2BJ.%26aulast%3DMadgula%26aufirst%3DL.%2BM.%2BV.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DCritical%2520assessment%2520of%2520pharmacokinetic%2520drug%25E2%2580%2593drug%2520interaction%2520potential%2520of%2520tofacitinib%252C%2520baricitinib%2520and%2520upadacitinib%252C%2520the%2520three%2520approved%2520janus%2520kinase%2520inhibitors%2520for%2520rheumatoid%2520arthritis%2520treatment%26jtitle%3DDrug%2520Saf.%26date%3D2020%26volume%3D43%26spage%3D711%26epage%3D725%26doi%3D10.1007%2Fs40264-020-00938-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyslop, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddle Camp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winthrop, K. L.</span></span> <span> </span><span class="NLM_article-title">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.3899/jrheum.171361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.3899%2Fjrheum.171361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30219772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2019&pages=7-18&author=J.+S.+Smolenauthor=M.+C.+Genoveseauthor=T.+Takeuchiauthor=D.+L.+Hyslopauthor=W.+L.+Maciasauthor=T.+Rooneyauthor=L.+Chenauthor=C.+L.+Dicksonauthor=J.+Riddle+Campauthor=T.+E.+Cardilloauthor=T.+Ishiiauthor=K.+L.+Winthrop&title=Safety+profile+of+baricitinib+in+patients+with+active+rheumatoid+arthritis+with+over+2+years+median+time+in+treatment&doi=10.3899%2Fjrheum.171361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span></div><div class="casAuthors">Smolen, Josef S.; Genovese, Mark C.; Takeuchi, Tsutomu; Hyslop, David L.; Macias, William L.; Rooney, Terence; Chen, Lei; Dickson, Christina L.; Camp, Jennifer Riddle; Cardillo, Tracy E.; Ishii, Taeko; Winthrop, Kevin L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-18</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">1499-2752</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective.  Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA).  We evaluated baricitinib's safety profile through 288 wk (up to Sept. 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].  The "all-bari-RA" group included patients who received any baricitinib dose.  Placebo comparison was based on the 6 studies with 4 mg and placebo up to Week 24 ("placebo-4 mg" dataset).  Dose response assessment was based on 4 studies with 2 mg and 4 mg including LTE data ("2 mg-4 mg - extended").  The uncommon events description used the non-controlled all-bari-RA.  There were 3492 patients who received baricitinib for 6637 total patient-years (PY) of exposure (median 2.1 yrs, max. 5.5 yrs).  No differences in rates of death, adverse events leading to drug discontinuation, malignancies, major adverse cardiovascular event (MACE), or serious infections were seen for 4 mg vs. placebo or for 4 mg vs. 2 mg.  Infections including herpes zoster were significantly more frequent for 4 mg vs. placebo.  Deep vein thrombosis/pulmonary embolism were reported with 4 mg but not placebo [all-bari-RA incidence rate (IR) 0.5/100 PY]; the IR did not differ between doses (0.5 vs 0.6/100 PY, 2 mg vs 4 mg, resp.) or compared to published RA rates.  All-bari-RA had 6 cases of lymphoma (IR 0.09/100 PY), 3 gastrointestinal perforations (0.05/100 PY), 10 cases of tuberculosis (all in endemic areas; 0.15/100 PY), and 22 all-cause deaths (0.33/100 PY).  IR for malignancies (0.8/100 PY) and MACE (0.5/100 PY) were low and did not increase with prolonged exposure.  Conclusion.  In this integrated anal. of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.  Trial registration nos.: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGtLt3TTbQXrVg90H21EOLACvtfcHk0ljXxlkVOvCPVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2rtLjL&md5=65e80ff8290c092f167e04f6505ca261</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.171361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.171361%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DHyslop%26aufirst%3DD.%2BL.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DRooney%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDickson%26aufirst%3DC.%2BL.%26aulast%3DRiddle%2BCamp%26aufirst%3DJ.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DWinthrop%26aufirst%3DK.%2BL.%26atitle%3DSafety%2520profile%2520of%2520baricitinib%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520over%25202%2520years%2520median%2520time%2520in%2520treatment%26jtitle%3DJ.%2520Rheumatol.%26date%3D2019%26volume%3D46%26spage%3D7%26epage%3D18%26doi%3D10.3899%2Fjrheum.171361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicastri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobbione, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span> <span> </span><span class="NLM_article-title">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.jinf.2020.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jinf.2020.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32333918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=318-356&author=F.+Cantiniauthor=L.+Niccoliauthor=D.+Matarreseauthor=E.+Nicastriauthor=P.+Stobbioneauthor=D.+Goletti&title=Baricitinib+therapy+in+COVID-19%3A+A+pilot+study+on+safety+and+clinical+impact&doi=10.1016%2Fj.jinf.2020.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span></div><div class="casAuthors">Cantini, Fabrizio; Niccoli, Laura; Matarrese, Daniela; Nicastri, Emanuele; Stobbione, Paolo; Goletti, Delia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-356</span>CODEN:
                <span class="NLM_cas:coden">JINFD2</span>;
        ISSN:<span class="NLM_cas:issn">1532-2742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preliminary results on 12 patients with moderate COVID-19 pneumonia confirmed the safety of baricitinib therapy in a clin. context.  In the baricitinib-treated group, all clin. characteristics and respiratory function parameters improved both at wk 1 and 2 compared to baseline.  C-reactive protein values significantly decreased in the same timeframes.  No infections, cardiovascular, and hematol. adverse events occurred after a 2 wk treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0f8W8UmI8rVg90H21EOLACvtfcHk0ljE9SAMJ_J4rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO&md5=d47bb194919c10f50d24312f137ec88d</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1016%2Fj.jinf.2020.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinf.2020.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DNicastri%26aufirst%3DE.%26aulast%3DStobbione%26aufirst%3DP.%26aulast%3DGoletti%26aufirst%3DD.%26atitle%3DBaricitinib%2520therapy%2520in%2520COVID-19%253A%2520A%2520pilot%2520study%2520on%2520safety%2520and%2520clinical%2520impact%26jtitle%3DJ.%2520Infect.%26date%3D2020%26volume%3D81%26spage%3D318%26epage%3D356%26doi%3D10.1016%2Fj.jinf.2020.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0ljE9SAMJ_J4rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0liyyhHUIjZ0UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span> <span> </span><span class="NLM_article-title">Inflammation research association-15th international conference advances in asthma and COPD and other inflammatory diseases</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">865</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=19051144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=863-865&author=K.+Walker&title=Inflammation+research+association-15th+international+conference+advances+in+asthma+and+COPD+and+other+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation Research Association--15th international conference advances in asthma and COPD and other inflammatory diseases</span></div><div class="casAuthors">Walker Karen</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs : the investigational drugs journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">863-5</span>
        ISSN:<span class="NLM_cas:issn">1369-7056</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgMoQJbY8mfRBrI9DTGjC0fW6udTcc2eb9fYVZQf39q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjot1Ghug%253D%253D&md5=45aa68e772177ff24bf3fd91cfd0557b</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DK.%26atitle%3DInflammation%2520research%2520association-15th%2520international%2520conference%2520advances%2520in%2520asthma%2520and%2520COPD%2520and%2520other%2520inflammatory%2520diseases%26jtitle%3DIDrugs%26date%3D2008%26volume%3D11%26spage%3D863%26epage%3D865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenzveig, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of INCB018424, a selective JAK2 inhibitor for the treatment of myeloproliferative disorders</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3538</span>, <span class="refDoi"> DOI: 10.1182/blood.V110.11.3538.3538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1182%2Fblood.V110.11.3538.3538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=3538&author=J.+Fridmanauthor=R.+Nussenzveigauthor=P.+Liuauthor=J.+Rodgersauthor=T.+Burnauthor=P.+Haleyauthor=P.+Scherleauthor=R.+Newtonauthor=G.+Hollisauthor=S.+Friedmanauthor=S.+Verstovsekauthor=K.+Vaddi&title=Discovery+and+preclinical+characterization+of+INCB018424%2C+a+selective+JAK2+inhibitor+for+the+treatment+of+myeloproliferative+disorders&doi=10.1182%2Fblood.V110.11.3538.3538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1182%2Fblood.V110.11.3538.3538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V110.11.3538.3538%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DNussenzveig%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DFriedman%26aufirst%3DS.%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%2520INCB018424%252C%2520a%2520selective%2520JAK2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D3538%26doi%3D10.1182%2Fblood.V110.11.3538.3538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shilling, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedza, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeever, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvanitis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galya, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2023</span>– <span class="NLM_lpage">2031</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.033787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fdmd.110.033787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=20699411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=2023-2031&author=A.+D.+Shillingauthor=F.+M.+Nedzaauthor=T.+Emmauthor=S.+Diamondauthor=E.+McKeeverauthor=N.+Punwaniauthor=W.+Williamsauthor=A.+Arvanitisauthor=L.+G.+Galyaauthor=M.+Liauthor=S.+Shepardauthor=J.+Rodgersauthor=T.-Y.+Yueauthor=S.+Yeleswaram&title=Metabolism%2C+excretion%2C+and+pharmacokinetics+of+%5B14C%5D+INCB018424%2C+a+selective+Janus+tyrosine+kinase+1%2F2+inhibitor%2C+in+humans&doi=10.1124%2Fdmd.110.033787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans</span></div><div class="casAuthors">Shilling, Adam D.; Nedza, Frank M.; Emm, Thomas; Diamond, Sharon; McKeever, Edward; Punwani, Naresh; Williams, William; Arvanitis, Argyrios; Galya, Laurine G.; Li, Mei; Shepard, Stacey; Rodgers, James; Yue, Tai-Yuen; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2023-2031</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The metab., excretion, and pharmacokinetics of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (INCB018424), a potent, selective inhibitor of Janus tyrosine kinase 1/2 and the first investigational drug of its class in phase III studies for the treatment of myelofibrosis, were investigated in healthy human subjects given a single oral 25-mg dose of [14C]INCB018424 as an oral soln.  INCB018424 and total radio-activity were absorbed rapidly (mean time to reach the maximal drug concn. <1 h), declining in a monophasic or biphasic fashion (mean t1/2 of 2.32 and 5.81 h, resp.).  Recovery of administered radioactivity was fairly rapid (>70% within 24 h post-dose) with 74 and 22% recovered in urine and feces, resp.  Parent compd. was the predominant entity in the circulation, representing 58 to 74% of the total radioactivity up to 6 h postdose, indicating that the overall circulating metabolite burden was low (<50% of parent).  Two metabolite peaks in plasma (M18 and a peak contg. M16/M27, both hydroxylations on the cyclopentyl moiety) were identified as major (30 and 14% of parent based on area under the curve from 0 to 24 h).  The exposures of other circulating INCB018424-related peaks were <10% of parent, consisting of mono- and dihydroxylated metabolites.  The profiles in urine and feces consisted of hydroxyl and oxo metabolites and subsequent glucuronide conjugates with parent drug accounting for <1% of the excreted dose, strongly suggesting that after an oral dose, INCB018424 was >95% absorbed.  In healthy subjects administered daily oral doses of unlabeled INCB018424, there were minimal differences in parent and metabolite concns. between day 1 and day 10, indicating a lack of accumulation of parent or metabolites between single and multiple dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVzg3TxNAT7Vg90H21EOLACvtfcHk0liyyhHUIjZ0UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVWqurvI&md5=4d3e77d36b51f557e2825d90a4ad9696</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033787%26sid%3Dliteratum%253Aachs%26aulast%3DShilling%26aufirst%3DA.%2BD.%26aulast%3DNedza%26aufirst%3DF.%2BM.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DMcKeever%26aufirst%3DE.%26aulast%3DPunwani%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DArvanitis%26aufirst%3DA.%26aulast%3DGalya%26aufirst%3DL.%2BG.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DYue%26aufirst%3DT.-Y.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DMetabolism%252C%2520excretion%252C%2520and%2520pharmacokinetics%2520of%2520%255B14C%255D%2520INCB018424%252C%2520a%2520selective%2520Janus%2520tyrosine%2520kinase%25201%252F2%2520inhibitor%252C%2520in%2520humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D2023%26epage%3D2031%26doi%3D10.1124%2Fdmd.110.033787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punwani, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1644</span>– <span class="NLM_lpage">1654</span>, <span class="refDoi"> DOI: 10.1177/0091270010389469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1177%2F0091270010389469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=21257798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Gks7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=1644-1654&author=J.+G.+Shiauthor=X.+Chenauthor=R.+F.+McGeeauthor=R.+R.+Landmanauthor=T.+Emmauthor=Y.+Loauthor=P.+A.+Scherleauthor=N.+G.+Punwaniauthor=W.+V.+Williamsauthor=S.+Yeleswaram&title=The+pharmacokinetics%2C+pharmacodynamics%2C+and+safety+of+orally+dosed+INCB018424+phosphate+in+healthy+volunteers&doi=10.1177%2F0091270010389469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers</span></div><div class="casAuthors">Shi, Jack G.; Chen, Xuejun; McGee, Ryan F.; Landman, Robert R.; Emm, Thomas; Lo, Yvonne; Scherle, Peggy A.; Punwani, Naresh G.; Williams, William V.; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1644-1654</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">INCB018424 phosphate, a potent inhibitor of JAK enzymes with selectivity for JAK1&2, is in development for the treatment of myelofibrosis (MF).  The oral dose pharmacokinetics, pharmacodynamics, safety, and tolerability of INCB018424 were evaluated in healthy volunteers in 2 double-blind, randomized, and placebo-controlled studies.  The first study evaluated single ascending doses of 5 to 200 mg INCB018424 and the effect of food, whereas the second study evaluated multiple ascending doses, including both once- and twice-daily dosing for 10 days.  As a Biopharma-ceutical Classification System class I drug, INCB018424 exhibited good oral bioavailability and dose-proportional systemic exposures.  INCB018424 showed low oral dose clearance and a small vol. of distribution, with an approx. 3-h plasma half-life and insignificant accumulation following repeat dosing.  A high-fat meal reduced INCB018424 Cmax by 24% but had little effect on INCB018424 AUC.  INCB018424 was cleared primarily by metab. with negligible renal excretion.  The pharmacodynamics of INCB018424, evaluated by the inhibition of phosphorylated STAT3 following cytokine stimulation in whole blood, showed good correlation with INCB018424 plasma concns.  INCB018424 was generally safe and well tolerated, with 25 mg bid and 100 mg qd established as the max. tolerated doses in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9sAcu1yiNf7Vg90H21EOLACvtfcHk0liiwq3P8aiA2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Gks7%252FJ&md5=b400dc074ce6a7ffd45b716ba145995e</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1177%2F0091270010389469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010389469%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%2BG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DMcGee%26aufirst%3DR.%2BF.%26aulast%3DLandman%26aufirst%3DR.%2BR.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DPunwani%26aufirst%3DN.%2BG.%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DThe%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520and%2520safety%2520of%2520orally%2520dosed%2520INCB018424%2520phosphate%2520in%2520healthy%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D51%26spage%3D1644%26epage%3D1654%26doi%3D10.1177%2F0091270010389469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van+Rompaeyauthor=R.+Galienauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+M.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0liiwq3P8aiA2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortmann, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckerman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, P. C.</span></span> <span> </span><span class="NLM_article-title">Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">183</span>, <span class="refDoi"> DOI: 10.1186/s13075-019-1964-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13075-019-1964-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=31375130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvkt1GitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=183&author=I.+B.+McInnesauthor=N.+L.+Byersauthor=R.+E.+Higgsauthor=J.+Leeauthor=W.+L.+Maciasauthor=S.+Naauthor=R.+A.+Ortmannauthor=G.+Rochaauthor=T.+P.+Rooneyauthor=T.+Wehrmanauthor=X.+Zhangauthor=S.+H.+Zuckermanauthor=P.+C.+Taylor&title=Comparison+of+baricitinib%2C+upadacitinib%2C+and+tofacitinib+mediated+regulation+of+cytokine+signaling+in+human+leukocyte+subpopulations&doi=10.1186%2Fs13075-019-1964-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations</span></div><div class="casAuthors">McInnes Iain B; Byers Nicole L; Higgs Richard E; Lee Jonathan; Macias William L; Na Songqing; Ortmann Robert A; Rocha Guilherme; Rooney Terence P; Zhang Xin; Zuckerman Steven H; Wehrman Thomas; Taylor Peter C</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the cellular level.  METHODS:  Peripheral blood mononuclear cells from healthy donors were incubated with different JAKis, levels of phosphorylated signal transducer and activator of transcription (pSTAT) were measured following cytokine stimulation, and half maximum inhibitory concentration (IC50) values were calculated in phenotypically gated leukocyte subpopulations.  Therapeutic dose relevance of the in vitro analysis was assessed using calculated mean concentration-time profiles over 24 h obtained from JAKi-treated subjects.  Time above IC50 and average daily percent inhibition of pSTAT formation were calculated for each JAKi, cytokine, and cell type.  RESULTS:  Distinct JAKis displayed different in vitro pharmacologic profiles.  For example, tofacitinib and upadacitinib were the most potent inhibitors of the JAK1/3-dependent cytokines tested (interleukin [IL]-2, IL-4, IL-15, and IL-21) with lower IC50 values and increased time above IC50 translating to a greater overall inhibition of STAT signaling during the dosing interval.  All JAKis tested inhibited JAK1/2-dependent cytokines (e.g., IL-6 and interferon [IFN]-γ), the JAK1/tyrosine kinase 2 (TYK2)-dependent cytokines IL-10 and IFN-α, the JAK2/2-dependent cytokines IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), and the JAK2/TYK2-dependent cytokine granulocyte colony-stimulating factor (G-CSF), but often to significantly differing degrees.  CONCLUSIONS:  Different JAKis modulated distinct cytokine pathways to varying degrees, and no agent potently or continuously inhibited an individual cytokine signaling pathway throughout the dosing interval.  Notably, baricitinib inhibited JAK1/3 signaling to a lesser extent than upadacitinib and tofacitinib, while upadacitinib, baricitinib, and tofacitinib inhibited the signaling of JAK2/2-dependent cytokines, including GM-CSF and IL-3, as well as the signaling of the JAK2/TYK2-dependent cytokine G-CSF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXxM4ksZxDYUNHe_gFldTbfW6udTcc2eZqBC5dJdlssLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvkt1GitQ%253D%253D&md5=cd8854ced4361fefab9972a1e19a5d0d</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1964-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1964-1%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3DNa%26aufirst%3DS.%26aulast%3DOrtmann%26aufirst%3DR.%2BA.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DWehrman%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZuckerman%26aufirst%3DS.%2BH.%26aulast%3DTaylor%26aufirst%3DP.%2BC.%26atitle%3DComparison%2520of%2520baricitinib%252C%2520upadacitinib%252C%2520and%2520tofacitinib%2520mediated%2520regulation%2520of%2520cytokine%2520signaling%2520in%2520human%2520leukocyte%2520subpopulations%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D183%26doi%3D10.1186%2Fs13075-019-1964-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+clinical+translation+of+tofacitinib%2C+a+Janus+kinase+inhibitor%2C+in+rheumatoid+arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lgJOQ5Mq5q5HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520clinical%2520translation%2520of%2520tofacitinib%252C%2520a%2520Janus%2520kinase%2520inhibitor%252C%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wollenhaupt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mojcik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strengholt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazariciu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">89</span>, <span class="refDoi"> DOI: 10.1186/s13075-019-1866-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1186%2Fs13075-019-1866-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=30953540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=89&author=J.+Wollenhauptauthor=E.-B.+Leeauthor=J.+R.+Curtisauthor=J.+Silverfieldauthor=K.+Terryauthor=K.+Somaauthor=C.+Mojcikauthor=R.+DeMasiauthor=S.+Strengholtauthor=K.+Kwokauthor=I.+Lazariciuauthor=L.+Wangauthor=S.+Cohen&title=Safety+and+efficacy+of+tofacitinib+for+up+to+9.5+years+in+the+treatment+of+rheumatoid+arthritis%3A+final+results+of+a+global%2C+open-label%2C+long-term+extension+study&doi=10.1186%2Fs13075-019-1866-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span></div><div class="casAuthors">Wollenhaupt Jurgen; Lee Eun-Bong; Curtis Jeffrey R; Silverfield Joel; Terry Ketti; Wang Lisy; Soma Koshika; Mojcik Chris; Kwok Kenneth; DeMasi Ryan; Strengholt Sander; Lazariciu Irina; Cohen Stanley</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis research & therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Final data are presented for the ORAL Sequel long-term extension (LTE) study evaluating the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) for up to 9.5 years in patients with rheumatoid arthritis (RA).  METHODS:  Eligible patients had previously completed a phase 1, 2, or 3 qualifying index study of tofacitinib and received open-label tofacitinib 5 mg or 10 mg BID.  Stable background therapy, including csDMARDs, was continued; adjustments to tofacitinib or background therapy were permitted at investigators' discretion.  Assignment to dose groups (5 mg or 10 mg BID) was based on patients' average total daily dose.  The primary objective was to determine the long-term safety and tolerability of tofacitinib 5 mg and 10 mg BID; the key secondary objective was to evaluate the long-term persistence of efficacy.  RESULTS:  Between February 5, 2007, and November 30, 2016, 4481 patients were enrolled.  Total tofacitinib exposure was 16,291 patient-years.  Safety data are reported up to month 114 for all tofacitinib; efficacy data are reported up to month 96 for tofacitinib 5 mg BID and month 72 for 10 mg BID (with low patient numbers limiting interpretation beyond these time points).  Overall, 52% of patients discontinued (24% due to adverse events [AEs] and 4% due to insufficient clinical response); the safety profile remained consistent with that observed in prior phase 1, 2, 3, or LTE studies.  The incidence rate (IR; number of patients with events per 100 patient-years) for AEs leading to discontinuation was 6.8.  For all-cause AEs of special interest, IRs were 3.4 for herpes zoster, 2.4 for serious infections, 0.8 for malignancies excluding non-melanoma skin cancer, 0.4 for major adverse cardiovascular events, and 0.3 for all-cause mortality.  Clinically meaningful improvements in the signs and symptoms of RA and physical functioning, which were observed in the index studies, were maintained.  CONCLUSIONS:  Tofacitinib 5 mg and 10 mg BID demonstrated a consistent safety profile (as monotherapy or combination therapy) and sustained efficacy in this open-label LTE study of patients with RA.  Safety data are reported up to 9.5 years, and efficacy data up to 8 years, based on adequate patient numbers to support conclusions.  TRIAL REGISTRATION:  NCT00413699 , funded by Pfizer Inc (date of trial registration: December 20, 2006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQry7CBP_Rh3thwrmtH4OBfW6udTcc2eY4NhaVRr5aNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FitlWquw%253D%253D&md5=15c33765e0ca5ffa5772fe872ede2a8a</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1186%2Fs13075-019-1866-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-019-1866-2%26sid%3Dliteratum%253Aachs%26aulast%3DWollenhaupt%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.-B.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26aulast%3DSilverfield%26aufirst%3DJ.%26aulast%3DTerry%26aufirst%3DK.%26aulast%3DSoma%26aufirst%3DK.%26aulast%3DMojcik%26aufirst%3DC.%26aulast%3DDeMasi%26aufirst%3DR.%26aulast%3DStrengholt%26aufirst%3DS.%26aulast%3DKwok%26aufirst%3DK.%26aulast%3DLazariciu%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DS.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520tofacitinib%2520for%2520up%2520to%25209.5%2520years%2520in%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%253A%2520final%2520results%2520of%2520a%2520global%252C%2520open-label%252C%2520long-term%2520extension%2520study%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2019%26volume%3D21%26spage%3D89%26doi%3D10.1186%2Fs13075-019-1866-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charles-Schoeman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolcott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanik, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. R.</span></span> <span> </span><span class="NLM_article-title">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1400</span>– <span class="NLM_lpage">1413</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-216761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1136%2Fannrheumdis-2019-216761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32759265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2020&pages=1400-1413&author=P.+Measeauthor=C.+Charles-Schoemanauthor=S.+Cohenauthor=L.+Fallonauthor=J.+Woolcottauthor=H.+Yunauthor=J.+Kremerauthor=J.+Greenbergauthor=W.+Malleyauthor=A.+Onofreiauthor=K.+S.+Kanikauthor=D.+Grahamauthor=C.+Wangauthor=C.+Connellauthor=H.+Valdezauthor=M.+Haubenauthor=E.+Hungauthor=A.+Madsenauthor=T.+V.+Jonesauthor=J.+R.+Curtis&title=Incidence+of+venous+and+arterial+thromboembolic+events+reported+in+the+tofacitinib+rheumatoid+arthritis%2C+psoriasis+and+psoriatic+arthritis+development+programmes+and+from+real-world+data&doi=10.1136%2Fannrheumdis-2019-216761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data</span></div><div class="casAuthors">Mease, Philip; Charles-Schoeman, Christina; Cohen, Stanley; Fallon, Lara; Woolcott, John; Yun, Huifeng; Kremer, Joel; Greenberg, Jeffrey; Malley, Wendi; Onofrei, Alina; Kanik, Keith S.; Graham, Daniela; Wang, Cunshan; Connell, Carol; Valdez, Hernan; Hauben, Manfred; Hung, Eric; Madsen, Ann; Jones, Thomas V.; Curtis, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1400-1413</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO).  Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily vs. those receiving tumor necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib.  Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programs and observational studies.  Data from an ad hoc safety anal. of Study A3921133 are reported sep within.  Methods This post-hoc anal. used data from sep tofacitinib RA, PsO and PsA programs.  Incidence rates (IRs; patients with events per 100 patient-years exposure) were calcd. for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors.  Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analyzed.  Results 12 410 tofacitinib-treated patients from the development programs (RA: n = 7964; PsO: n = 3663; PsA: n = 783) were included.  IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts av. tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectivley, were: DVT (0.17 (0.09-0.27) and 0.15 (0.09-0.22)); PE (0.12 (0.06-0.22) and 0.13 (0.08-0.21)); ATE (0.32 (0.22-0.46) and 0.38 (0.28-0.49)).  IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors.  IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naive/biol. disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs obsd. among the corresponding patients in the tofacitinib development program.  No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.  Conclusions DVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programs were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments.  As expected, IRs of thromboembolic events were elevated in patients with vs without baseline cardiovascular or VTE risk factors, and were broadly consistent with those obsd. in the Study A3921133 ad hoc safety anal. data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32-0.87)), vs patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA program (0.24 (0.13-0.41)).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXpWehht-WfbVg90H21EOLACvtfcHk0liwfZJDiNiueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisF2nu7vN&md5=dc3bb7d3c470a51e397502b1f5a31d28</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-216761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-216761%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%26aulast%3DCharles-Schoeman%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DFallon%26aufirst%3DL.%26aulast%3DWoolcott%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DH.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DGreenberg%26aufirst%3DJ.%26aulast%3DMalley%26aufirst%3DW.%26aulast%3DOnofrei%26aufirst%3DA.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DGraham%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DConnell%26aufirst%3DC.%26aulast%3DValdez%26aufirst%3DH.%26aulast%3DHauben%26aufirst%3DM.%26aulast%3DHung%26aufirst%3DE.%26aulast%3DMadsen%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DT.%2BV.%26aulast%3DCurtis%26aufirst%3DJ.%2BR.%26atitle%3DIncidence%2520of%2520venous%2520and%2520arterial%2520thromboembolic%2520events%2520reported%2520in%2520the%2520tofacitinib%2520rheumatoid%2520arthritis%252C%2520psoriasis%2520and%2520psoriatic%2520arthritis%2520development%2520programmes%2520and%2520from%2520real-world%2520data%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2020%26volume%3D79%26spage%3D1400%26epage%3D1413%26doi%3D10.1136%2Fannrheumdis-2019-216761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. O.</span></span> <span> </span><span class="NLM_article-title">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span>. <i>J. Microbiol Immunol Infect</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">370</span>, <span class="refDoi"> DOI: 10.1016/j.jmii.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1016%2Fj.jmii.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32205092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2020&pages=368-370&author=D.+Wuauthor=X.+O.+Yang&title=TH17+responses+in+cytokine+storm+of+COVID-19%3A+An+emerging+target+of+JAK2+inhibitor+Fedratinib&doi=10.1016%2Fj.jmii.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit239R"><div class="casContent"><span class="casTitleNuber">239</span><div class="casTitle"><span class="NLM_cas:atitle">TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</span></div><div class="casAuthors">Wu, Dandan; Yang, Xuexian O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Microbiology, Immunology and Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-370</span>CODEN:
                <span class="NLM_cas:coden">JMIIFG</span>;
        ISSN:<span class="NLM_cas:issn">1995-9133</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Taiwan LLC</span>)
        </div><div class="casAbstract">COVID-19 emerges as a pandemic disease with high mortality.  Development of effective prevention and treatment is an urgent need.  We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUfWxGcfQbVg90H21EOLACvtfcHk0liwfZJDiNiueQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsFalurc%253D&md5=bab4a2496a1381dd062fbaf5349baf57</span></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1016%2Fj.jmii.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmii.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DX.%2BO.%26atitle%3DTH17%2520responses%2520in%2520cytokine%2520storm%2520of%2520COVID-19%253A%2520An%2520emerging%2520target%2520of%2520JAK2%2520inhibitor%2520Fedratinib%26jtitle%3DJ.%2520Microbiol%2520Immunol%2520Infect%26date%3D2020%26volume%3D53%26spage%3D368%26epage%3D370%26doi%3D10.1016%2Fj.jmii.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebaza, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanchieri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slade, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, C. S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, L.</span></span> <span> </span><span class="NLM_article-title">Janus kinase-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: A systematic review and meta-analysis</span>. <i>medRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.08.10.20172189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=10.1101%2F2020.08.10.20172189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;key=32817985" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Walzauthor=A.+J.+Cohenauthor=A.+P.+Rebazaauthor=J.+Vanchieriauthor=M.+D.+Sladeauthor=C.+S.+D.+Cruzauthor=L.+Sharma&title=Janus+kinase-inhibitor+and+type+I+interferon+ability+to+produce+favorable+clinical+outcomes+in+COVID-19+patients%3A+A+systematic+review+and+meta-analysis&doi=10.1101%2F2020.08.10.20172189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1101%2F2020.08.10.20172189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.08.10.20172189%26sid%3Dliteratum%253Aachs%26aulast%3DWalz%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DA.%2BJ.%26aulast%3DRebaza%26aufirst%3DA.%2BP.%26aulast%3DVanchieri%26aufirst%3DJ.%26aulast%3DSlade%26aufirst%3DM.%2BD.%26aulast%3DCruz%26aufirst%3DC.%2BS.%2BD.%26aulast%3DSharma%26aufirst%3DL.%26atitle%3DJanus%2520kinase-inhibitor%2520and%2520type%2520I%2520interferon%2520ability%2520to%2520produce%2520favorable%2520clinical%2520outcomes%2520in%2520COVID-19%2520patients%253A%2520A%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DmedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.08.10.20172189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i20"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01467">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06457"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01467?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01467</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical structures of JAK inhibitor clinical candidates and in vitro antiviral activity and cellular cytotoxicity of kinase inhibitors (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01467/suppl_file/jm0c01467_si_001.pdf">jm0c01467_si_001.pdf (284.26 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01467&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01467%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01467" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c5cc089c3cd6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
